ࡱ> . bjbj &J 4"((k(k(G*G*G*[*[*[*8*L9E[* ~^?YYYY&7\ zG*CW.CCk(k(YY L#4#4#4C#k(VYG*Y#4C#4#4 h)DYk0[**NdT,\;2\ DD\G* CC#4CCCCC/3CCCCCCC\CCCCCCCCC( 1':  The Interface Formulary For Adults An introduction The purpose of the formulary is to promote rational, safe and cost-effective prescribing and to help promote seamless care at the primary-secondary care interface. This formulary has been developed by the Formulary Working Group, which has medical and pharmaceutical representation from Heart of England NHS Foundation Trust, Birmingham Cross City CCG, Solihull CCG and South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group. Prescribers can nominate a preparation for consideration by the Formulary Working Group via Solihull CCG Head of Medicines and Prescribing  HYPERLINK "mailto:Kate.arnold@nhs.net" Kate.arnold@nhs.net Birmingham Cross City CCG Interface Pharmacist  HYPERLINK "mailto:Rakhi.aggarwal@nhs.net" Rakhi.aggarwal@nhs.net HEFT Formulary Team Interface Prescribing Manager  HYPERLINK "mailto:Carolevans2@nhs.net" Carolevans2@nhs.net or  HYPERLINK "mailto:formulary@heartofengland.nhs.uk" formulary@heartofengland.nhs.uk The content of the formulary reflects nationally recognised evidence or consensus opinion at the time of compilation. Evidence or opinion may change over time and it is the responsibility of the prescriber to ensure that new evidence or national guidelines are taken into account in their prescribing. The individual prescriber remains responsible for the patients care and the prescription written. The formulary will be updated to reflect additions, removals or other changes approximately every 3 months. Any changes will be documented from page 3 for easy reference. The Traffic Light System The medicines included in the formulary have been classified using a traffic light system. Green These preparations are prescribable within primary and secondary care and are considered first line Yellow These preparations are prescribable within primary and secondary care and are considered as either second line or they are restricted in some other way e.g. the use may be unlicensed/off label. Where a restriction applies, it is stated in the additional information section. Double Yellow These preparations are prescribable within primary and secondary care and however their use is further restricted. Restrictions are stated in the additional information section. In addition to the restrictions, medicines in this column may require an ESCA (Effective Shared Care Agreement) or a RICaD (Rationale for Initiation, Continuation and Discontinuation)to be completed before prescribing can be undertaken in Primary care. ESCAs and RICaDs are developed via collaboration between the Formulary Working Group and the relevant specialists. Red These drugs are for specialist use only. They should not be prescribed in primary care unless by a GP with special interest Funding in Primary Care Inclusion within the green, yellow or double yellow columns implies that funding from primary care prescribing budgets has been agreed, provided prescribing lies within any stated restrictions (e.g. within documented shared care agreements) Additional Information Where , or is shown, this indicates a greater cost when compared to similar medicines used for identical indications. Some preparations have been assessed by the Formulary Working Group as suitable for prescribing in primary care following Specialist initiation Preparation deemed appropriate for the patient by the specialist, for which the patient receives an initial prescription from the specialist. Specialist recommendation Preparation deemed appropriate for the patient by the specialist. The specialist provides the GP with a formal letter in support of the recommendation. Provision of a HEFT pink recommendation slip alone is not acceptable. Links The formulary has many links to online resources throughout the document; these can be accessed by either clicking on the link OR clicking on the link whilst holding down your control (ctrl) key. Searches You can search for text by selecting Find from the Formulary menu in the menu bar above and typing what you want to search for This formulary should be used in conjunction with the BNF and additional prescribing information should be obtained from the Summary of Product Characteristics. Recent Changes to the formulary This section details the outcome of applications made to the Formulary Working Group (FWG) over an approximate rolling two year period. DateConsiderationOutcomeApril 2011Logynon APPENDIX for women already established on Logynon or who wish to return to Logynin following a break from OCP New Patients should not be offered Logynin April 2011PravastatinMOVED now YELLOW was previously Double yellowApril 2011SaxagliptinYELLOW - Saxagliptin is the first gliptin to have gained a licence for the management of type 2 diabetes in patients with moderate to severe renal impairment,April 2011VildagliptinMOVED TO APPENDIX existing patients onlyMay 2011TapentadolDECLINED It is not appropriate for primary care to initiate tapentadol. Switching therapy to tapentadol is not straightforward The level of detail in studies is not sufficient to assess the comparative use of laxatives across the treatment arms, making it difficult to assess the overall balance of pain relief and adverse effects, and any additional costs associated with laxative prescribing GPs have experience of using oxycodone (originating in Palliative care) and are familiar with its pros and consMay 2011Midodrine (unlicensed)RED For initiation and maintenance in secondary care only. GPs must not be asked to prescribe midodrineMay 2011Elleste and Evorel rangeGreen - Approved as 1st line options for women when started by HEFT immediately post hysterectomy. May 2011DapsoneDouble Yellow with ESCAJune 2011Nuvaring APPENDIX for women already established on Nuvaring or who wish to return to Nuvaring following a break from OCP. New patients should not be offered Nuvaring June 2011Qlaira APPENDIX for women already established on Qlaira or who wish to return to Qlaira following a break from OCP New Patients should not be offered QlairaJune 2011DanazolRED Hereditary angioedema - off label as an unlicensed indication Double yellow specialist recommendation -Severe pain and tenderness in benign fibrocystic breast disease not responding to other treatment . DateConsiderationOutcomeJune 2011StanozololRED Hereditary angioedema - this is an unlicensed product. GPs must not be asked to prescribe this productJune 2011Aluminium acetate 13% ear dropsRED Unlicensed product for use by ENT only. GPs must not be asked to prescribe this product.June 2011TauroLock 500 RED This is a CE marked medical device. For use in home TPN patients only, GPs must not be asked to prescribe this productJune 2011Trichloroacetic acid 90%RED Dermatology directorate only for the treatment of xanthelasmaJune 2011Emla creamGreenJune 2011Ametop gelGreen June 2011ClomipramineAPPENDIX Existing patients onlyJune 2011AcamprosateDouble Yellow Specialist initiation June 2011Testosterone undecanoate capsulesDouble Yellow specialist initiation. Dr Dyers team onlyJune 2011FlutamideDouble yellow with ESCAJune 2011Otovent balloonsDouble Yellow Spec recommendationJune 2011LacosamideDouble yellow Specialist initiation and stabilization with ESCAJune 2011Hyoscine patchYellowJune 2011Hyoscine hydrobromide tabletsYellowJune 2011 Roflumilast DECLINED SMC = The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC. MTRAC = can not be recommended for prescribing because of inadequate evidence of efficacy and /or safety.June 2011Sodium hyaluronate DECLINED 1.4.4.2 NICE CG 59 intra-articular injections of hyaluranon injections are not recommended for the treatment of osteoarthritis.June 2011Combodart DECLINED The Interface Formulary places finasteride as the first line treatment. The Interface Formulary rarely includes combination oral products. Combodart is less cost effective than using first line treatment and tamsulosin as separate agents. June 2011Capsaicin 8% patch RED For prescribing to a maximum of 10 patients by the Pain Team only for use strictly in accordance with licence.June 2011Romiplostim RED For use in Oncology and Haematology strictly in accordance with NICE TA 221June 2011CorticorelinRED For use as a diagnostic agentJuly 2011TapentadolDECLINED The level of detail in studies is not sufficient to assess the comparative use of laxatives across the treatment arms, making it difficult to assess the overall balance of pain relief and adverse effects, and any additional costs associated with laxative prescribing DateConsiderationOutcomeJuly 2011 IndacaterolDECLINED - Available evidence proves non inferiority only, Long term patient follow up data is not good.The quicker onset of action of indacaterol is not thought to be advantageous as this is a maintenance therapy. There is a narrow licence for indacaterol as COPD only. FWG aim to keep the formulary simple. To this end having multiple options in each drug class is not desirable.July 2011Sativex DECLINED - The balance of evidence between benefits and side effects does not support its introduction to the formulary. MTRAC verdict = cannot be recommended for prescribing because of inadequate evidence for efficacy and/or safety. SMC = Not RecommendedJuly 2011Fesoterodine  DECLINED - The side effects of fesoterodine fumarate are similar to those of other related medicines; it is as effective and costs the same as Tolterodine.The patent on Tolterodine will shortly expire. Continued use of Tolterodine after this point will offer a cost saving.July 2011LacosamideDouble Yellow Specialist recommendation (Usually from UHB)August 2011Phlexy-Vits sachetsRED - To be used for adult patients, in accordance with NICE CG 32 and HEFT Guidelines for the Prevention & Management of Refeeding Syndrome (March 2008) on the recommendation of HEFT Clinical Nutrition teamAugust 2011Artesunate RED - Treatment of severe falciparium malaria, an alternative to i/v quinine.September 2011RivaroxabanRED - Prophylaxis of VTE following total knee or hip replacement as per NICE TA 170. As GPs should not be asked to prescribe, sufficient medication to complete the full course of treatment is to be supplied at discharge. September 2011DabigatranRED - Prophylaxis of VTE following total knee or hip replacement as per NICE TA 157. As GPs should not be asked to prescribe, sufficient medication to complete the full course of treatment is to be supplied at discharge. September 2011DiazoxideDOUBLE YELLOW Treatment of chronic intractable hypoglycemiaOctober 2011Dexamethasone intravitreal implantRED For the treatment of macular oedema secondary to retinal vein occlusion as per NICE TAG 229 only. October 2011GolimumabRED - As per NICE guidelines within licence and for those patients identified as suitable below. Patients receiving warfarin (and in particular requiring maintenance of a higher INR) that are prone to bruising an bleeding, patients required to travel for periods greater than 2 weeks at a time, patients with a genuine fear of injections.DateConsiderationOutcomeOctober 2011DexrazoxaneRED To be used in strict accordance with HEFT protocols for suspected anthracycline extravasation. It must only be used as per licence and must be prescribed in the same way as any other cytotoxic drug. Only one pack per Trust will be stocked at any one time. FWG must be notified of every occasion that it is used and provided with a summary of the event from the discovery of the potential/actual extravasation due to anthracycline administration, to the eventual outcome for the patient. November 2011AbataceptRED For use within licence in accordance with NICE TA 195 November 2011Fosfomycin infusionRED - to treat severe respiratory infections due to multiresistant gram negative organism especially Pseudomonas aeruginosa in CF patients. All prescribing must de bone via HEFT. GPs must not be asked to prescribe this medication.November 2011Lignocaine, adrenaline and tetracaine Gel (LAT Gel) RED - for use in A & E as recommended in the Association of paediatric anaesthetists Good practice in post operative and procedural pain guidelines. November 2011 Nevirapine Prolonged releaseRED - For use within licence only. All prescribing to remain the responsibility of HEFT. The formulary status of nevirapine prolonged release will be reviewed in December 2012 when generic alternatives may be available. December 2011RanolazineDouble Yellow with a RICaD - for use as per NICE guidance within licence. The use of ranolazine will be audited in 6 months timeDecember 2011ScheriproctGreen Replaces Xyloproct January 2012LMX 4 gelRED For use in PaediatricsFebruary 2012Ethylenediaminetetraacetic Acid (EDTA) 0.37% dropsRED For use in Ophthalmology only for chelation of calcium deposited on corneal surface (Band keratopathy) as per Moorfields Handbook. This is an unlicensed product.February 2012LinagliptinYellow - All for use as per licence and in line with NICE guidance. Saxagliptin to move to the appendix for continued use in patients established on therapyDateConsiderationOutcomeFebruary 2012 Testosterone 2% gel (Tostran 10mg metered application 60g multidose dispenser)Green For use within licence only February 2012Fluticasone furoate nasal spray (Avamys)Yellow For use within licence. This preparation replaces fluticasone propionate (Flixonase and Nasofan) which will move to the appendix for use in existing patients only. February 2012Hyaluronidase 1,500 unitsRED For use in ophthalmologyMarch 2012Aquadeks liquid/softgels and chewable tablets Declined - This is a multivitamin preparation specifically formulated for cystic fibrosis patients This is an unlicensed product in the UK and would be classified as a special if prescribed in Primary Care. The cost of specials in Primary care is largely unregulated and much work is underway to reduce its financial burden to the local health economy. FWG could not add Aquadeks to the formulary as it is inappropriate for prescribing in Primary care (Unlicensed) and impractical for HEFT to maintain the prescribing responsibility as would be required by a red classification.March 2012Moviprep orange/ lemon flavoured sachetsRED - For use in line with licence. Prescribing by HEFT staff only. March 2012Optison (Protein-type A injectable microspheres suspension)RED - For use within cardiology directorate only under the direct supervision of suitably trained medical staff March 2012Dovobet GelGREEN for use within licence for scalp and body useApril 2012VSL#3 SachetsDouble Yellow with the support of a RICaD. The initial prescription MUST be provided by HEFT. Prescribing data will be audited to ensure that clinicians are complying with formulary restrictions and to determine the continued appropriateness of VSL#3 position on the formularyApril 2012Indacaterol maleate ( Onbrez Breezhaler )DECLINED The evidence provided failed to add anything to what has already been considered in the 2 previous submissions . Indacaterol will not be considered again by FWG unless there is NICE guidance and or NEW evidence. DateConsiderationOutcomeApril 2012Temocillin (Negaban)RED - For use within licence on recommendation of ID or Microbiology only. Temocillin must only be prescribed by HEFT cliniciansApril 2012Fultium D3Green - Each capsule of Fultium D3 contains colecalciferol 800IU, which is equivalent to 20 microgram vitamin D3.April 2012RifaximinPENDING awaiting input from the Directorate Manager May 2012BoceprevirRED - For use within licence and in direct concordance with NICE TAG 253May 2012TelaprevirRED - For use within licence and in direct concordance with NICE TAG 252May 2012Dabigatran etexilate (for the treatment of AF)Double Yellow - For use within licence for AF and within the scope of NICE TAG 249. The Birmingham and Solihull NHS Cluster has developed guidance and patient discussion aids etc to support the implementation of TAG 249. The initial prescription for dabigatran must be provided by a clinician who routinely initiates warfarin. This may be the GP (in some instances) but more frequently will be a secondary care specialist. In these circumstances on-going prescribing will be the undertaken by the GP with the aid of a RICaD May 2012Rifapentine ( Priftin )RED - Treatment of latent TB in specific circumstances where directly observed therapy (DOTS) is needed on the recommendation of a TB consultant only. (Unlicensed medicine)May 2012Exenatide MR injectin ( Bydureon )DOUBLE YELLOW For use within license and as per HEFT GLP-1 flow chart. Specialist initiation with support of RICaD ongoing treatment can be prescribed by GP.June 2012 Ferric Carboxy maltoside (Ferinject)PENDING awaiting combined input from Gastroenterology and Renal directoratesJune 2012RespeRate DECLINED The quality of evidence for the Medical Device, RespeRate is poor therefore it will not be added to the Interface FormularyJune 2012Nicorette quickmist single mouth sprayGREEN for use within licence and with the support of local Stop Smoking ServicesJune 2012Nicotinell patches GREEN for use within licence and with the support of local Stop Smoking ServicesJune 2012Nicorette inhalator 10mgGREEN for use within licence and with the support of local Stop Smoking ServicesJuly 2012Indacaterol inhalerPENDING awaiting the publication of new evidencePhlexy-vits RED - For patients at risk of re-feeding syndrome who are unable to tolerate or swallow Forceval capsules or who are enterally fed. For post bariatric surgery patients (that as a result of complications or delays in progression from liquid diet require a soluble vitamin supplement beyond 10 days and possibly for the duration of the inpatient stay.DateConsiderationOutcomeJuly 2012Ciclosporin ESCA s are no longer required for this preparation. August 2012Ulipristal acetate (Esmya)DOUBLE YELLOW For use within licence for the pre-operative treatment of fibroids. HEFT to supply initial prescription with an ESCA, GPs will prescribe for the remaining 2 months of treatment.August 2012LofexidineRED for use as per licence as part of the SAFE projectSeptember 2012Grazax RED for use within licence to treat adults meeting the Directorates criteria for treatment. Al prescribing will remain the responsibility of HEFT clinicians. Sept ember 2012 Rivaroxaban for AF DOUBLE YELLOW For use within licence for AF and within the scope of NICE TAG 256 The Birmingham and Solihull NHS Cluster has developed guidance and patient discussion aids etc to support the implementation of TAG. The initial prescription for rivaroxaban must be provided by a clinician who routinely initiates warfarin. This may be the GP (in some instances) but more frequently will be a secondary care specialist. In these circumstances on-going prescribing will be the undertaken by the GP with the aid of a RICaDOctober 2012Rivaroxaban for DVTDOUBLE YELLOW For use within licence as per NICE TAG 261 in line with approved HEFT pathwayOctober 2012Bicalutamide ESCA s are no longer required for this preparationNovember 2012IcatibantRED- For use in line with licence by Immunology Department. Patients that have had more than 1 attack (requiring treatment with icatibant/C1 inh) in a 12 month period may be offered icatibant for self administrationNovember 2012C1-esterase inhibitor (Cinryze)RED - For use in line with licence by immunology department.November 2012PalonosetronRED - For use as a single dose prior to chemotherapy in secondary care only November 2012Peristeen anal irrigationDOUBLE YELLOW - For initiation, assessment and stabilization in secondary care under the expert guidance of the colorectal team before transferring ongoing prescribing responsibility to GP December 2012TicagrelorDOUBLE YELLOW with a RICaD- In line with TA 236DateConsiderationOutcomeDecember 2012RotigotineMOVED from RED to DOUBLE YELLOW WITH RICaD - In patients who cannot swallow or their gut is not working. Patients with poor overnight control of PD. Rotigotine can be considered after CR L dopa preparations and long half life oral DAs (e.g. ropinirole and pramipexole) Patients with erratic motor control during the daytime despite using oral long acting DAs, e.g. ropinirole or pramipexole either as standard TDS regimes or once daily SR preparations. In this setting rotigotine patch can be useful before considering sc apomorphine infusion of enteral duodopa infusion. The latter two treatment options are much more invasive and expensive. Patients intolerant of current first line DAs (ropinirole and pramipexole) should be considered for rotigotine before abandoning the DA class of drugs. December 2012ColesevelamDECLINED - Colesevelam is more costly than existing treatment options. In the absence of any head to head trial, the application was declined December 2012FidaxomicinRED - for patients with first relapse of C-diff and requiring concomitant antibiotic therapy. Restricted to Infectious Diseases, Microbiology Consultants only. December 2012Mucous clearing device ( Flutter )RED - To be prescribed and supplied by Secondary Care for appropriate patients. GPs must not be asked to prescribe this item. Patients may purchase this OTC, however the cost is likely to be in the region of 70.December 2012 Glycopyrronium inhaler (%Seebri Breezhaler ) YELLOW - For use in line with licence and MTRAC recommendations. The addition of glycopyrronium to the formulary prompted a review of section 3.1.2. No further applications for medications in this section will be considered for a minimum of 12 months (unless NICE approved). The Respiratory Directorate is aware of this and the implications for other products such as aclidinium inhaler. December 2012 (revised Feb 2013)Flutiform % (Fluticasone propionate/formoterol fumarate aerosol inhaler) GREEN = Moved from YELLOW - For use in clinically appropriate situations. FWG acknowledge that this may include off label use of Flutiform in COPD patientsFebruary 2013ApixabanRED In line with NICE TA 275February 2013Denosumab (Xgeva)RED In line with NICE TA 265DateConsiderationOutcomeFebruary 2013Bivalirudin RED In line with NICE TA 230February 2013RetigabineRED In line with NICE TA 232February 2013Tapentadol ( for neuropathic pain)DECLINED insufficient evidence to consider adding to the formulary at the present timeFebruary 2013Trospium XLYELLOW in line with draft NICE guidance. Solifenacin will be moved to the appendix as this does not currently feature in the draft NICE guidance. This decision will be reviewed once a TA is published.February 2013Loteprednol Etabonate 0.5% Eye Drops, suspensionRED to replace rimexolone. February 2013Sevikar DECLINED - This is a combination product which includes olmesartan, which is non-formulary The Interface Formulary for Adults has a preference to avoid combination products unless there is an overwhelming advantage. FWG did not judge there to be such an advantage in this instanceFebruary 2013FampridineDECLINED UHB declined the addition of the drug onto the formulary due to the limited trial data available at present and the marginal efficacy of the drug. FWG support this decision and fampridine will not be added to the interface formulary for adultsFebruary 2013Collagenase Clostridium histolyticum injection (Xiapex) RED Restricted to use as an alternative to limited fasciectomy in adult patients with Dupuytrens contracture of moderate severity (as defined by the British Society for Surgery of the Hand (BSSH), with a palpable cord and up to two affected joints per hand, who are suitable for limited fasciectomy, but for whom percutaneous needle fasciotomy is not considered a suitable treatment option. And in line with Procedures of Limited Clinical Value commissioning policy. This states treatment of moderate to severe is appropriate where patients meet either of the following criteria: moderate metacarpo-phalangeal joint contracture (greater than 30 degrees ).any proximal inter-phalangeal joint contracture. First web contracture The above eligibility criteria is in line with the BSSH - The British Society for Surgery of the Hand - Evidence for Surgical Treatment Dupuytrens Disease.  HYPERLINK "http://www.bssh.ac.uk/education/guidelines/dd_guidelines.pdf" http://www.bssh.ac.uk/education/guidelines/dd_guidelines.pdf DateConsiderationOutcomeFebruary InsumanAPPENDIX EXISTING PATIENTS ONLY. NOT FOR INITIATIONMarch 2013The Interface Formulary for Adults has been updated to include hyperlinks to active NICE TAs. If the TA is applicable to an area of practice represented in the local health economy and specific preparations are recommended within it; these preparations are also listed in the formulary. April 2013Actikerall (0.5% fluorouracil, 10% salicylic acid solution)GREEN As an alternative to 5% fluorouracil cream for patients that have a layer of thick hyperkeratotic skin over the actinic keratosis lesions. April 2013Desunin ( Colcalcifeol 800 IU)GREEN May 2013Fumaric estersRED - (unlicensed)- For use in Dermatology Directorate only.May 2013Fostair GREEN Moved from yellow to green in line with local COPD diagnosis and management guidelinesMay 2013Gelaspan RED May 2013GeloplasmaREDMay 2013DimeticoneGREEN replaces permethrin which is active against head lice but the formulations and licensed methods of application of the current products make them unsuitable for the treatment of head lice.May 2013QuinagolideDOUBLE YELLOW for specialist initiation May 2013DronedaroneRED (previously double yellow): The EMA states in Questions and answers on the review of Multaq (dronedarone) Outcome of a procedure under Article 20 of Regulation (EC) No 726/2004: Treatment with Multaq should only be started and monitored by a specialist. Therefore FWG agree that dronedarone will be re-classified as a RED drug.June 2013Ferrinject (feric carboxymaltose)RED For use in the renal department onlyJune 2013Forceval SolubleRED - Forceval soluble (replaces Phlexy-vits) prevention of re-feeding syndrome as per HEFT guidelines on recommendation of clinical nutrition team. Also post bariatric surgery patients (that as a result of complications or delays in progression from liquid diet cannot tolerate vitamin supplementation tablets/capsules form and will need a soluble vitamin supplement beyond 10 days and possibly for the duration of their in-patient stay).June 2013PhlexyvitsREMOVED from the formulary and replaced with Forceval solubleJune 2013Capsaicin creamYELLOW moved from red to yellow in line with UHB formularyJune 2013Proflavine creamRED Theatres onlyJune 2013DehydroepiandosteroneRED Endocrinology onlyJune 2013RifaximinRED (Via specialized commissioning PbR included) - Gastroenterology Directorate only for recurrent hepatic encephalopathy despite lactulose and optimal medical management. June 2013PropanthelineDOUBLE YELLOW specialist initiation via Dermatology for hyperhydrosisDateConsiderationOutcomeJuly 2013DapagliflozinYellow. For use in line with NICE TA 288.July 2013Degludec 100 units/ml cartridge and pre-filled penRED: For initiation and maintenance by HEFT diabetologists only in line with licence. Review in March.GPs are not to be asked to take over prescribing of degludec.July 2013Hydrocortisone M/R tabletsDeclined: FWG did not support the theory that once daily administration of hydrocortisone offered any benefit in promoting compliance in the treatment of this life threatening condition July 2013Lixisenatide (Lyxumia )DOUBLE YELLOW: Specialist initiation with RICaD for use in the same circumstances as those applicable to liraglutide in NICE TA 203.July 2013Mirabegron (Betmiga ) YELLOW: For use within license as per NICE TA 290July 2013Oxycodone slow releaseRED: For use within HEFT for approximately 48 hours post operatively to facilitate EROS only. Not for prescribing in Primary care.July 2013Scar reduction preparations (all topical preparations used solely for the treatment/reduction of keloid scars)DECLINED: Cochrane review states Trials evaluating silicon gel sheeting as a treatment for hypertrophic and keloid scarring are of poor quality and highly susceptible to  HYPERLINK "http://summaries.cochrane.org/lexicon/9" \l "bias" \o "Any factor, recognised or not, that distorts the findings of a study." bias. There is weak evidence of a benefit of silicon gel sheeting as a prevention for abnormal scarring in high  HYPERLINK "http://summaries.cochrane.org/lexicon/9" \l "risk" \o "A way of expressing the chance of an event taking place, expressed as the number of events divided by the total number of observations or people. It can be stated as the chances of falling were one in four (1/4 = 25%). This measure is good no matter the incidence of events ie common or infrequent." risk individuals but the poor quality of  HYPERLINK "http://summaries.cochrane.org/lexicon/9" \l "research" \o "The term research means different things to different people, but is essentially about finding out new knowledge that could lead to changes to treatments, policies or care. The definition used by the Department of Health is: \The attempt to derive generalisable new knowledge by addressing clearly defined questions with systematic and rigorous methods.\ " research means a great deal of uncertainty prevails. July 2013Sodium Hyaluronate Viscoelastic (CIMA OCU+1.4% (OcuPlus )RED: For use in ophthalmology only.July 2013Ingenol mebutate ( Picato )YELLOW: for use when poor compliance with other preparations of longer treatment periods is expected to be poor.September 2013St Marks Powder ( pre-made)RED: for use in HEFT onlySeptember 2013St Marks recipe and information leafletYELLOW: for specialist recommendation for appropriate patients to mix their own St Marks powder at home.September 2013Conestat Alpha ( Ruconest )RED: NHSE commissioned medicine. For use by HEFT Immunologists onlySeptember 2013Lisdexamphetamine (Elvanse )RED: For use within license by Dr Rabb and his teamSeptember 2013Dymistsa nasal spray ( azelastine hydrochloride and fluticasone propionate)DECLINED: Dymista costs approximately 19. This is approximately 4 more that the constituent parts cost. Most patients are managed on beclometasone and loratadine this costs less than 5 FWG declined the application as there is insufficient evidence to support its use in preference to existing, cost effective alternatives. DateConsiderationOutcomeSeptember 2013Balanced crystalloid solution (Plasma-Lyte 148 (pH 7.4)RED: Critical care onlySeptember 2013Darifenacin ( Emselex )YELLOW: in line with CG 171September 2013Ocriplasmin ( Jetrea )RED: For use in line with NICE TA 297November 2013Ferrinject (feric carboxymaltose)RED: For use in Haematology and Gastro departments (already available to Renal)November 2013Locust bean gum oral contrast mediaRED: for short bowel MRINovember 2013Indigo Carmine diagnostic stainRED: for use in Endoscopy onlyNovember 2013MegesterolYELLOW: Unintentionally omitted from formulary previously November 2013Flixonase Nasules YELLOW: To treat nasal polyps (unintentionally omitted from formulary previously). November 2013EltrombopagRED: as per NICE TA 293 Gastro Intestinal System Dyspepsia and gastro-oesophageal reflux disease Notes on class Liquid preparations are generally more effective than solid dosage forms Antacids commonly interact with other drugs, particularly enteric coated drugs Magnesium salts can be laxative whilst aluminium salts tend to constipate Alginate preps should only be used for reflux -they are relatively poor neutralizers and have a relatively high electrolyte content Efficacy may be reduced in patients with very low levels of gastric acid production (e.g. due to PPI) GreenYellowDouble YellowRedAntacidsMagnesium trisilicate mixtureCo-magaldrox suspension A When a lower sodium content is requiredAntacid and oxetacaine specialist only, post head and neck radiotherapyAlginatesPeptac for reflux only (same components as Gaviscon )Gaviscon Advance B - for reflux only (primary care only)Gastrocote - When a lower sodium content is required Additional informationDrug specific notesA BCombination of aluminium and magnesium salts may reduce GI side effects Gaviscon liquid (not Advance ) is now only available as an OTC preparation and should not be prescribed () HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG017quickrefguide.pdf"NICE CG 17: Managing dyspepsia in adults HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_proven_du_gu_or_nsaid_associated_ulcer" Prodigy: Dyspepsia with ulcer; HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_proven_gastro_oesophageal_reflux_disease"Prodigy: Dyspepsia GORD;  HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_proven_non_ulcer_dyspepsia" Prodigy: Dyspepsia without ulcer  HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_symptoms_uninvestigated_by_endoscopy" Prodigy: Dyspepsia symptoms;  HYPERLINK "http://www.prodigy.nhs.uk/nonsteroidal_anti_inflammatory_drugs_nsaids" Prodigy: NSAIDsPCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Antispasmodics and other drugs altering gut motility Notes on class Antimuscarinics tend to have more side effects than the other antispasmodics Other antispasmodics directly relax intestinal smooth muscle and are therefore useful in IBD and diverticular disease; there are no serious side effects GreenYellowDouble YellowRedAntimuscarinicsHyoscine butylbromide injection (Buscopan ) - For treatment of excessive bronchial secretions in end of life carePropantheline specialist initiation for hyperhyrosis Hyoscine butylbromide tablets (for ureteric colic)Dicycloverine Hyoscine butylbromide tablets (dysmenorrhoea, and palliative care)Other antispasmodicsMebeverineAlverine citrate (for dysmenorrhoea)Peppermint B.P. water Peppermint oil capsulesMotility stimulants (Section 4.6 BNF)Metoclopramide ADomperidone (when metoclopramide is inappropriate) Additional informationDrug specific notesANot effective in postoperative nausea and vomiting and not 1st choice in patients under 20 years of age.  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/irritable_bowel_syndrome" Prodigy: Irritable Bowel SyndromePCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm" Ulcer Healing Drugs Notes on class Treatment doses are rarely needed for longer than two months (NICE) and should be stepped down Avoid prescribing treatment doses on repeat prescriptions Consider step down from PPI to H2 antagonist to ensure cost effective prescribing For gastro-protection with NSAID, omeprazole is recommended GreenYellowDouble YellowRed1.3.1 H2 antagonistsRanitidine DCimetidine A1.3.4 Prostoglandin analoguesMisoprostol Obs and Gynae (off-label) 1.3.5 Proton Pump InhibitorsOmeprazole capsules ELansoprazole FasTabs B Omeprazole injection FLansoprazole capsulesEOmeprazole MUPS C Sucralfate specialists in oncology , gastroenterology and haematology Additional informationDrug specific notesA B C D E FDo not use effervescent preparations. Avoid when patient taking phenytoin, warfarin or theophylline Patients with naso-gastric tube, who are dysphagic or nil by mouth only. Paediatrics only Do not use effervescent preparations Tablet preparations are considerably more expensive than capsule formulations Reserved for gastroenterologists, GI surgeons, critical care and oncology HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=CG017"NICE CG 17: Managing dyspepsia in adults HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_proven_du_gu_or_nsaid_associated_ulcer" Prodigy: Dyspepsia with ulcer; HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_proven_gastro_oesophageal_reflux_disease"Prodigy: Dyspepsia GORD;  HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_proven_non_ulcer_dyspepsia" Prodigy: Dyspepsia without ulcer  HYPERLINK "http://www.prodigy.nhs.uk/dyspepsia_symptoms_uninvestigated_by_endoscopy" Prodigy: Dyspepsia symptoms;  HYPERLINK "http://www.prodigy.nhs.uk/nonsteroidal_anti_inflammatory_drugs_nsaids" Prodigy: NSAIDsPCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Acute diarrhoea Notes on class First line treatment for acute diarrhoea is rehydration therapy Antibiotics are rarely indicated for the treatment of infective diarrhoea as it is usually viral in the UK GreenYellowDouble YellowRedOral rehydration saltsSpecialist recommendationCo-phenotrope BLoperamide ASt Marks powder D recipe and patient information leafletSt Marks pre-made powder C (unlicensed)Codeine phosphate Additional informationDrug specific notesA B C DAlso available as OTC Do NOT prescribe loperamide where C.diff infection is a potential diagnosis GU medicine patients only Available as a special from BCM specials 0800 952 1010 Patients requiring St Marks solution when not an inpatient at HEFT will be provided with a patient information leaflet to include instructions on how to make the powder at home. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  PCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  1.5 Chronic Bowel Disorder Notes on class Differential diagnosis includes irritable bowel syndrome, malabsorption syndromes, ulcerative colitis, Crohns disease, diverticular disease and pseudomembranous colitis. Patients receiving aminosalicylates should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever and malaise that occur during treatment. A blood count should be performed and the drug stopped immediately if there is any suspicion of a blood dyscrasia.  GreenYellowDouble YellowRed (as per NICE TAs)Consultant initiationAzathioprine - ESCAAdalimumabSulfasalazine A Ciclosporin (cyclosporin) Infliximab Mesalazine B Methotrexate - ESCA Oral 1st choicePentasa 2nd choice Asacol 3rd choiceMezavant XL C Rectal1st choicesuppositories2nd choiceEnemasPrednisolone tablets & suppositoriesBalsalazide (specialist recommendation)Hydrocortisone foam enemaBudesonide capsulesPrednisolone foam enema Mercaptopurine ESCAPrednisolone retention enema Additional informationDrug specific notesA B CMany patients intolerant. Stains contact lenses. EC more expensive than standard tablets Should be prescribed by brand For use within licensed indications where compliance is an issue. Patients that are stable on effective prescriptions should not be changed to this preparation. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA040"NICE TA 40 Infliximab in Crohns disease HYPERLINK "http://guidance.nice.org.uk/TA140"NICE TA 140 Ulcerative colitis (subacute manifestations) - infliximab HYPERLINK "http://www.nice.org.uk/nicemedia/live/12104/42745/42745.PDF"NICE TA 163 Infliximab for acute exacerbations of ulcerative colitis HYPERLINK "http://guidance.nice.org.uk/TA187"NICE TA 187 Crohn's disease - infliximab and adalimumab  HYPERLINK "http://guidance.nice.org.uk/TA199"NICE 199 Psoriatic arthritis - etanercept, infliximab and adalimumab  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/irritable_bowel_syndrome" Prodigy: Irritable Bowel Syndrome  HYPERLINK "http://www.prodigy.nhs.uk/diverticular_disease_and_diverticulitis" Prodigy: Diverticular diseasePCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  1.6 Laxatives Notes on class Patients taking bulk forming laxatives should by advised to increase fluid intake Stimulant laxatives are unsuitable for long-term use. They can precipitate onset of an atonic non-functioning colon and significant electrolyte imbalance. However extended use may be justified to counter the constipating effects of other drugs (e.g. opioids, anticholinergics) Tolerance to osmotic laxatives may develop with prolonged use. Avoid stimulant laxatives in intestinal obstruction Use bulk and fluids first before using osmotic laxativesGreenYellowDouble YellowRed1.6.1. Bulk forming laxativesIspaghula sachets A 1.6.2. Stimulant laxativesGlycerin suppositoriesBisacodylSodium picosulfate (Dulcolax )SennaCo-danthramer (palliative care) Docusate sodium B1.6.3. Faecal softeners Arachis oil enema D Liquid Paraffin Palliative Care Team recommendation only for patients with bowel obstruction Green YellowDouble YellowRed1.6.4. Osmotic laxativesSodium citrate enema Macrogol powders (Laxido/Movicol ) E  Phosphate enema Lactulose (hepatic encephalopathy and paediatrics only) C1.6.4. Bowel cleansersSodium picosulfate (sodium picosulphate) Picolax Klean-Prep Fleet Phospho-soda Moviprep  Green YellowDouble YellowRed1.6.7 5HT4-receptor agonistsPrucalopride - With a RICaD -as per NICE TA 211 Additional informationDrug specific notesA B C D ECombination Ispaghula/senna combinations will be changed on admission to secondary care Slower onset 1-2 days Avoid prn dosing Contraindicated in peanut allergy Movicol is recommended for use in faecal impaction, chronic idiopathic constipation and opioid induced constipation, not controlled by 1st line treatments individually or in combination HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/constipation" Prodigy: Constipation HYPERLINK "http://guidance.nice.org.uk/TA211"NICE TA 211 Constipation (women) - prucalopride PCT information HYPERLINK "http://www.drugtariff.co.uk/"  SCT & HEFT laxative policy HYPERLINK "mailto:carolevans2@nhs.net?subject=Request%20for%20document:%20Laxative%20guidance"Request a copy from HEFT HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  Local preparations for anal and rectal disorders Notes on class Soothing agents should be considered first line and are freely available OTC Products containing corticosteroids may cause atrophy if use is prolonged: some products are available OTC Tolerance to osmotic laxatives may develop with prolonged use. Avoid stimulant laxatives in intestinal obstruction Use bulk and fluids first before using osmotics GreenYellowDouble YellowRed1.7.1 Soothing preparationsAnusol 1.7.2 Compound preparationsAnusol-HC Uniroid-HC B Scheriproct 1.7.3 Rectal scleroscantsOily phenol1.7.4. Treatment of anal fissureGTN 0.4% ointment Rectogesic Diltiazem 2% cream A (unlicensed) Specialist initiation Additional informationDrug specific notesA BRecommendation of colorectal surgeons for chronic anal fissure for patients unable to tolerate or with contra indications to GTN. Unlicensed formulations are generally made by Specials manufacturing units at considerable cost (usually above 70 per tube) and have only a four week shelf life Uniroid-HC formulation is the same as that of Proctosedyl  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/anal_fissure" Prodigy: Anal fissurePCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Stoma Care Drugs affecting intestinal secretions GreenYellowDouble YellowRedSpecialist initiationUrsodeoxycholic acid for cholestasis of pregnancy (off label)Pancreatin formulations Colestyramine (cholestyramine) Ursodeoxycholic acid - for use in gastroenterology and cystic fibrosis patients onlyMiscellaneous GreenYellowDouble YellowRedOctreotide off label Specialist initiation in palliative careVSL#3 Sachets RICaDAOctreotide off label use Gastroenterologists and GI surgeonsPeristeen anal irrigation specialist initiation, assessment and stabilisationTerlipressin off label use gastroenterologists and palliative carePhlexy-vits B Locust bean Gum (Carobel) MRI oral contrast agentIndigo carmine - Endoscopy Additional informationDrug specific notesA BFor the maintenance of remission of ileoanal pouchitis only in adults. For patients at risk of re-feeding syndrome who are unable to tolerate or swallow Forceval capsules or who are enterally fed. For post bariatric surgery patients (that as a result of complications or delays in progression from liquid diet require a soluble vitamin supplement beyond 10 days and possibly for the duration of the inpatient stay. PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Cardiovascular system 2.1 Positive Inotropic Drugs Notes on classPositive inotropic drugs increase the force of contraction of the myocardium. GreenYellowDouble YellowRed2.1.1 Cardiac GlycosidesDigoxin ADigibind2.1.2 Phosphodiesterase InhibitiorsEnoximone B Additional informationDrug specific notesA BIndicated in supraventricular arrhythmias (e.g. A.F) and heart failure. Levels can be useful to assess toxicity, but need taking at least 6 hours post dose, best to give at night. In A.F. pulse rate at rest is best guide to dose Enoximone exerts most of its effect on the myocardium. Sustained haemodynamic benefit has been observed after administration, but there is no evidence of any beneficial effect on survival.  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf"NICE clinical guideline 5: Chronic Heart Failure HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance HYPERLINK "http://www.prodigy.nhs.uk/heart_failure"Prodigy: Heart Failure  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topics HYPERLINK "http://www.npc.co.uk/MeReC_Briefings/2001/briefing_no_15.pdf"MEREC: Diagnosis and drug treatment of heart failure (2001)PCT informationHYPERLINK "http://www.nice.org.uk/guidance/index.jsp?action=download&o=29136"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Diuretics Notes on classNotes on class Thiazide type diuretics are first line treatments for hypertension in the majority of cases Act within 1-2 hours of oral administration and most have duration of 12-24 hours Administer early in the day to avoid interference with sleep Diuretics aggravate gout GreenYellowDouble YellowRed2.2.1 Thiazides and related diureticsBendroflumethiazide (bendrofluazide) A Indapamide AIndapamide M/R Chlortalidone Metolazone Specialist recommendation (unlicensed)2.2.2 Loop diureticsFurosemide (Frusemide) B Bumetanide B 2.2.3 Potassium-sparing diureticsAmiloride C2.2.3 Aldosterone antagonistsSpironolactone DEplerenone RICaD In line with NICE CG 48 E2.2.4 Potassium-sparing diuretics with other diureticsCo-amilofruse2.2.5 Osmotic diureticsMannitol (cerebral oedema, glaucoma)2.2.6 Carbonic anhydrase inhibitors2.2.7 0smotic diuretics Acetazolamide Ophthalmology and ITU Additional informationDrug specific notesA B C D E2.5mg dose (higher doses not indicated in hypertension) Most patients do not develop hypokalaemia. Suggest check potassium level one month after initiation and annually thereafter. (MeReC 10/94) Monitor potassium level. Indicated in pulmonary oedema. Need large doses in renal failure Caution with ACE inhibitors. A weak diuretic. Retains potassium Useful in liver cirrhosis and congestive heart failure usually with loop diuretic. Monitor potassium levels carefully For initiation in secondary care during the immediate post MI period in direct concordance with NICE CG48. Primary Care may continue prescribing under a RICaD and transfer suitable patients to spironolactone (in accordance with its licence) after 6 months treatment. Eplerenone may be used in place of spironolactone in extremis HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf"NICE CG 05 Chronic Heart Failure HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdf"NICE CG 34 Hypertension HYPERLINK "http://www.nice.org.uk/CG48"NICE CG48 Secondary prevention in primary and secondary care  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/hypertension" Prodigy: Hypertension ;  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topics PCT informationCombination diuretics should be avoided unless compliance is an issue.  HYPERLINK "http://www.drugtariff.co.uk/"  2.3 Anti-arrhythmics Notes on classAnti-arrhythmics are generally initiated in hospital GreenYellowDouble YellowRedSpecialist initiationSpecialist initiationAdenosine Amiodarone ALidocaine hydrochloride (lignocaine hydrochloride)FlecainideDronedarone B NICE TA 197DisopyramidePropafenone hydrochlorideProcainamide hydrochlorideQuinidine (unlicensed)Mexiletine hydrochloride Additional informationDrug specific notesA BLFTs and TFTs need baseline and 6 monthly monitoring. Observe for other side effects e.g. micro corneal deposits, photosensitivity and lung disorders For use within the parameters of the NICE TAG 197, the option to use dronedarone should be exercised only for the following groups of patients: patients with both left ventricular hypertrophy and hypertension (requiring antihypertensive medication from two different classes), who do not have structural heart disease. patients meeting the NICE criteria who have thyroid disease and who would otherwise require amiodarone The EMA states in Questions and answers on the review of Multaq (dronedarone) Outcome of a procedure under Article 20 of Regulation (EC) No 726/2004: Treatment with Multaq should only be started and monitored by a specialist. Therefore dronedarone is classified as a RED drug. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA197"NICE TA 197 Atrial fibrillation - dronedarone  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topicsPCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Beta blockers Notes on classBeta blockers are not recommended for initiation as first line therapy for patients with hypertension Significant morbidity and mortality benefits have been demonstrated with beta blockers post MI and for licenced beta blockers in CHF Beta blockers also retain an important role in the management of angina Beta blockers tend to be less effective (as monotherapy) in black patients due to suppressed renin-angiotensin system Reduce dose gradually if beta blocker is to be stopped  GreenYellowDouble YellowRedAtenolol ALabetalol (specialist initiation in pregnancy)EsmololPropranolol BNebivolol specialist recommendation for hypertension in those with concomitant LVD or with co-morbidity of CADLabetolol injectionMetoprololSotalol (arrhythmia) Specialist initiationTimolol -Specialist initiation post MICarvedilol for heart failure. Specialist initiation or initiation by GP following approved local protocolBisoprolol (heart failure Specialist initiation or initiation by GP following approved local protocol) C  Additional informationDrug specific notesA B C Hypertension up to 50mg, 100mg may be justified in angina LA preparations has a restricted use verdict from MTRAC and should be initiated by GPwSI in HF (or on the recommendation of specialist cardiac nurses under local protocol) or by consultants and subsequently managed in primary care. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "previous%20versions"NICE CG 34 Hypertension HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf"NICE CG 5 Chronic Heart Failure  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" Bisoprolol has a restricted use verdict from MTRAC and should be initiated by GPwSI in HF (or on the recommendation of specialist cardiac nurses under local protocol) or by consultants and subsequently managed in primary care.  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topics ;  HYPERLINK "http://www.prodigy.nhs.uk/hypertension" Prodigy: HypertensionPCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  2.5 Hypertension and heart failure Notes on classVasodilators are very potent drugs, especially when used in combination with a beta blocker and a thiazide ACE inhibitors are indicated for all grades of heart failure and post MI with systolic LVD/HF ACE inhibitors/ARBs may be less effective in black patients due to suppressed renin-angiotensin system ACE/ARBs require renal function tests before and after initiation (and at dose changes) ARBs should only be used where ACE induced cough is a problem and other hypertensives are poorly tolerated. In clinical trials incidence of cough with ACE was only 4-6% greater than in placebo arm. In HF cough may indicate worsening pulmonary oedema. ACE/ARBs are foetotoxic There is no evidence of any specific agent offering advantages use most cost effective choice GreenYellowDouble YellowRed2.5.1 VasodilatorsSpecialist recommendation Sodium nitroprusside (hypertensive crisis)Hydralazine tabletsDiazoxide injection MinoxidilHydralazine 2.5.2 Centrally acting antihypertensivesMethyldopa specialist recommendation in pregnancyClonidine Moxonidine specialist recommendationGreenYellowDouble YellowRed2.5.3 Adrenergic neurone blockersGuanethidine2.5.4 Alpha blockersDoxazosin A BPhenoxybenzamine specialist initiationDoxazosin M/R - for patients for whom there is no alternative antihypertensive and for whom the hypotensive adverse effects are intolerablePhentolamine mesilate2.5.5.1 ACE inhibitorsRamipril C capsules Perindopril erbumine D LisinoprilEnalapril 2.5.5.2 Angiotensin Receptor Blockers Irbesartan if micro/macro albuminuria in T2DMValsartan FLosartan G Candesartan E2.5.5.3 Renin InhibitorsAliskiren H RICaD2.5.6 Ganglion blocking drugsTrimetaphan camsilate2.5.7 Tyrosine hydroxylase inhibitorsMetirosineAdditional informationDrug specific notesA B C D E F G HAlpha blockers are usually fourth/fifth line unless there is co-existing benign prostatic hypertrophy Doxazosin may induce first dose hypotension Ramipril has a solid evidence base and should be considered first line Perindopril has no evidence of superiority over other ACEs. Candesartan is only ARB licensed for heart failure; first line choice Valsartan is licensed for use in LVF/LVSD post MI Losartan is licensed in diabetic nephropathy and heart failure (Irbesartan is licensed for renal disease with hypertension) For treatment of hypertension in step four of the ACD algorithm in patients with BP >140/90 despite previous treatment with 3 or more antihypertensive agents. A RICaD is required for prescribing in primary care. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf"NICE CG 05 Chronic Heart Failure HYPERLINK "previous%20versions"NICE CG 34 Hypertension  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other  HYPERLINK "http://www.prodigy.nhs.uk/hypertension" Prodigy: Hypertension ;  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topics  HYPERLINK "http://www.npc.nhs.uk/MeReC_Bulletins/2002Volumes/vol13no6.pdf" MEREC 2002: Place of ARBs in therapy2.6 Nitrates, calcium-channel blockers & potassium-channel activators Notes on classNItrates Glyceryl trinitrate sprays are more cost effective for infrequent users, patches are expensive and need to be removed overnight Calcium channel blockers There are important differences between diltiazem and verapamil and dihydropyridine calcium channel blockers Prescribe nifedipine and diltiazem sustained release preparations by brand (for bioavailability reasons). Once a brand is selected, exclusive use should be maintained. Use diltiazem cautiously with beta blockers Sudden withdrawal can exacerbate angina GreenYellowDouble YellowRed2.6.1 NitratesGlyceryl Trinitrate (Spray / tablets SL)Glyceryl trinitrate patches for pts unable to take/tolerate oral/sublingual preparationsGTN injectionIsosorbide mononitrate tablets S/R AIsosorbide dinitrate injection Glyceryl trinitrate buccal tablets2.6.2 Calcium channel blockersNifedipine SR CFelodipineNifedipine capsules off label Palliative Care Team recommendation for tenesmusNimodipineAmlodipine maleate B DVerapamil Diltiazem oral preparations2.6.3 Potassium channel activatorsNicorandilIvabradine specialist recommendation for anginaIvabradine specialist initiation and RICaD for heart failure- NICE TA 267Ranolazine RICaD 2.6.4 Peripheral vasodilatorsTemazolineNaftidrofuryl oxalateAdditional informationDrug specific notesA B C DIsosorbide mononitrate may be given as twice a day asymmetric dosing or once daily sustained release. Isosorbide XL / MR preparations should be prescribed by brand Prescribe as amlodipine or amlodipine maleate Nifedipine prescribed as Adalat is generally more expensive Agent of choice where CCB indicated for hypertension in patient with HF HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdf"NICE CG 34 Hypertension HYPERLINK "http://guidance.nice.org.uk/TA223"NICE TA 223 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate HYPERLINK "http://guidance.nice.org.uk/TA267"NICE TA 267 Chronic heart failure - ivabradine HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/hypertension" Prodigy: Hypertension ;  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topicsPCT informationIn Primary Care, either GTN sprays or S/L tablets should be used. Use Monomil tablets as first choice. If another brand has been chosen by the practice, there is no need to change HYPERLINK "http://www.drugtariff.co.uk/" Preferred brands Felodipine Diltiazem Nifedipine Cardioplen Angitil/Slozem od: Adipine LA, Coracten XL, bd: Adipine SR, Coracten SR  Sympathomimetics GreenYellowDouble YellowRedDobutamine, dopamine, ephedrine, metaraminol (named patient) phenylephrine, noradrenaline, adrenaline/epinephrineUnlicensed GreenYellowDouble YellowRedMidodrine Unlicensed Endocrinology onlyAnticoagulants & Protamine GreenYellowDouble YellowRed2.8.1 Parenteral anticoagulantsEnoxaparinA (specialist initiation) ESCA EpoprostenolDanaparoidFondaparinuxHeparin (specialist initiation)Tinzaparin (within licence for renal dialysis patients only)2.8.2 Oral anticoagulantsWarfarinPhenindione (specialist initiation)Rivaroxaban NICE TA170 VTE prophylaxis onlyDabigatran with a RICaD NICE TA 249 Dabigatran NICE TA 157 VTE prophylaxis onlyRivaroxaban with a RICaD NICE TA 261 and TA 256 Protamine sulphateApixaban - NICE TA 245 and NICE TA 275Bivalirudin NICE TA 230Rivaroxaban TA 287 Temporary Formulary position 2.8.3 ProtaminesProtamine sulfate GreenYellowDouble YellowRed(medical device)TauroLock TauroLock - HEP 500  Additional informationDrug specific notesAESCA available for the treatment of and prevention of Venous Thromboembolism in general medical patients. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA157"NICE TA 157 Venous thromboembolism - dabigatran  HYPERLINK "http://guidance.nice.org.uk/TA170"NICE TA 170 Venous thromboembolism - rivaroxaban HYPERLINK "http://guidance.nice.org.uk/TA230"NICE TA 230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin HYPERLINK "http://guidance.nice.org.uk/TA245"NICE TA 245 Venous thromboembolism - apixaban (hip and knee surgery)  HYPERLINK "http://guidance.nice.org.uk/TA249"NICE TA 249 Atrial fibrillation - dabigatran etexilate HYPERLINK "http://guidance.nice.org.uk/TA256"NICE TA 256 Atrial fibrillation (stroke prevention) - rivaroxaban HYPERLINK "http://guidance.nice.org.uk/TA261"NICE TA 261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban HYPERLINK "http://guidance.nice.org.uk/TA275"NICE TA 275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban HYPERLINK "http://publications.nice.org.uk/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism-ta287"NICE TA 287 Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism   HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/atrial_fibrillation" Prodigy: Atrial fibrillation ;  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topics  HYPERLINK "http://www.npc.nhs.uk/MeReC_Bulletins/2001Volumes/pdfs/vol12no5.pdf" MEREC 2001: Atrial Fibrillation in Primary CarePCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Antiplatelet drugs GreenYellowDouble YellowRed as per NICE TAsAspirin dispersible AClopidogrel C Prasugrel Specialist initiation RICaD DTirofiban Dipyridamole MR BTicagrelor Specialist initiation RICaD - NICE TA 236AbciximabAsasantin Retard B CEptifibatide E -  Additional informationDrug specific notesA B C D EIn acute severe dyspepsia dont forget to counsel pc dosing, If pc dosing fails, try aspirin plus omeprazole before clopidogrel Dipyridamole indicated in combination with aspirin for 2 years post Occlusive (neurological) Vascular Event, then revert to aspirin Clopidogrel indicated as monotherapy if patient has a documented hypersensitivity to aspirin or has severe acute dyspepsia associated with aspirin. Combination therapy with aspirin post ACS, PCI or CABG for maximum 12 months, then revert to aspirin. There are no proven benefits to using enteric coated aspirin For specialist initiation with a RICaD in patients who suffer a stent thrombosis receive stent angioplasty following STEMI (for patients under 75, weighing more than 60kg and never having had a stoke) Prasugrel is not available for any other indication 1)Prevention of early myocardial infarction in patients with unstable angina or non-ST segment elevation myocardial infarction and with last episode of chest pain within 24 hours (use under specialist supervision) this is a licensed indication 2) an adjunct to primary PCI for patients with STEMI (this is an unlicensed indication) HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA047"NICE TA 47 Acute coronary syndromes - eptifibatide and tirofiban HYPERLINK "http://guidance.nice.org.uk/TA80"NICE TA 80 Acute coronary syndromes - clopidogrel HYPERLINK "http://guidance.nice.org.uk/TA182"NICE TA 182 Acute coronary syndrome - prasugrel HYPERLINK "http://guidance.nice.org.uk/TA210"NICE TA 210 Vascular disease - clopidogrel and dipyridamole HYPERLINK "http://guidance.nice.org.uk/TA236"NICE TA 236 Acute coronary syndromes - ticagrelor HYPERLINK "http://www.nice.org.uk/nicemedia/live/12949/47924/47924.pdf"NICE CG 94 unstable angina and NSTEMI HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance Guidance on  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" clopidogrel, dipyridamole.  HYPERLINK "http://www.prodigy.nhs.uk/aspirin_for_prevention_of_cardiovascular_events" Prodigy: Aspirin for the prevention of CV events ;  HYPERLINK "http://www.prodigy.nhs.uk/transient_ischaemic_attack_not_in_atrial_fibrillation" Prodigy: TIA (not in AF) ;  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topicsPCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Fibrinolytic Drugs Notes on class GreenYellowDouble YellowRedAlteplaseReteplase Streptokinase Urokinase (off licence)Tenectoplase Anti- Fibrinolytic Drugs & Haemostatics Notes on class GreenYellowDouble YellowRedTranexamic acid (oral)Tranexamic acid injection EtamsylateFactor VII Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA52"NICE TA 52 - Myocardial infarction - thrombolysis (alteplase, reteplase, streptokinase and tenecteplase) HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA084"NICE TA 84 (withdrawn) Sepsis (severe) - drotrecogin HYPERLINK "http://publications.nice.org.uk/alteplase-for-treating-acute-ischaemic-stroke-review-of-technology-appraisal-guidance-122-ta264"NICE TA 264 alteplase for treating acute ischaemic stroke HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Lipid-regulating drugs Notes on classCurrent National Service Framework guidance recommends treating cholesterol to a target of 5mmol/litre or a 30% reduction from baseline, whichever is greater NICE guidance (Jan 2006) recommends considering primary prevention statin treatment for all patients with a 10year CVD risk of 20% or greater GreenYellowDouble YellowRedSimvastatin AAtorvastatin Ezetimibe B NICE TA 132BezafibrateColestyramine (cholestyramine) Rosuvastatin (specialist initiation lipid clinic only)Fenofibrate Fluvastatin (specialist recommendation in renal patients only)Omacor as second line agent in hypertriglyceridemia or secondary prevention in post MI patients intolerant of oily fish.Tredaptive M/R specialist recommendation onlyNicotinic acidPravastatin Additional informationDrug specific notesA B Evidence base suggests 40mg starting dose When prescribed in accordance with NICE TA 132 Clinical Guidelines. Specialist initiation when used as monotherapy. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA94"NICE TA 94 Cardiovascular disease - statins HYPERLINK "http://guidance.nice.org.uk/TA132"NICE TA 132 Hypercholesterolaemia - ezetimibe  HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG48QuickRefGuide.pdf" NICE CG 48: MI - Secondary Prevention  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular" Prodigy: All cardiovascular topics ;  HYPERLINK "http://www.prodigy.nhs.uk/hyperlipidaemia" Prodigy: Hyperlipidaemia  HYPERLINK "http://www.npc.nhs.uk/MeReC_Briefings/2002/briefing_no_19.pdf" MEREC: Lifestyle measures to reduce CV risk  HYPERLINK "http://www.npc.nhs.uk/MeReC_Briefings/2004/briefing_no_28.pdf" MEREC: Update on statins PCT informationSimvastatin 40mg should be used in preference to atorvastatin 10mg HYPERLINK "http://www.drugtariff.co.uk/" Local sclerosants Notes on class GreenYellowDouble YellowRedSodium tetradecyl sulphateEthanolamine oleate  Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Miscellaneous GreenYellowDouble YellowRedOptison for use within cardiology directorate only under direct supervision of suitably trained staff Respiratory System Bronchodilators Beta adrenoceptor agonists Notes on classNICE guidance: All inhalers should be prescribed as MDI / MDI plus spacer unless co-ordination / compliance is a problem. Spacer devices now available as AeroChamber adult (blue) with or without mask, infant (orange) or child (yellow). GSK have announced the re-introduction of the Volumatic device from February 06 following Committee on Human Medicines (formerly CSM) advice that AeroChamber is not suitable for GSK inhalers (Ventolin, Becotide, Serevent, Flixotide, Seretide) Avoid use of dry powder formulations if MDIs are suitable (diskhalers, accuhalers etc) Long Acting beta Agonists (LABAs) should be trialled for four weeks and withdrawn if no benefit observed Committee on Human Medicines (formerly CSM) has issued a reminder that in asthma, LABAs should only be used in conjunction with inhaled corticosteroids Salbutamol: High doses in severe asthma does warrant regular checking of Us & Es, especially if prescribed with theophylline GreenYellowDouble YellowRed3.1.1.1 Adrenoceptor agonistsShort actingSalbutamol Terbutaline Salbutamol (nebulised) ALong actingSalmeterol Formoterol (eformoterol) BAdditional informationDrug specific notesA BSecondary care and emergency use in primary care. Regular use in primary care on recommendation of specialist. Salbutamol and spacer should be used before resorting to nebuliser Available as dry powder turbohaler. New MDI formulation requires refrigeration HYPERLINK "http://www.nice.nhs.uk/guidance/index.jsp?action=byTopic&o=7308&set=true"NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA10"NICE TA 10 (Asthma - children under 5 - inhaler devices) HYPERLINK "http://guidance.nice.org.uk/TA38"NICE TA 38 (Asthma - older children - inhaler devices) HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance   HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/63/index.html" SIGN Guideline No. 63: British Guideline on the Management of Asthma;  HYPERLINK "http://www.prodigy.nhs.uk/asthma" Prodigy: Asthma ;  HYPERLINK "http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_disease" Prodigy: COPD ; HYPERLINK "http://www.npc.co.uk/MeReC_Briefings/2006/copb_briefing_no_33.pdf"MEREC: Management of COPDPCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  3.1.2 Antimuscarinic bronchodilators Notes on classNICE guidance: All inhalers should be prescribed as MDI / MDI plus spacer unless co-ordination / compliance is a problem. Spacer devices now available as AeroChamber adult (blue) with or without mask, infant (orange) or child (yellow). GSK have announced the re-introduction of the Volumatic device from February 06 following Committee on Human Medicines (formerly CSM) advice that AeroChamber is not suitable for GSK inhalers (Ventolin, Becotide, Serevent, Flixotide, Seretide) GreenYellowDouble YellowRedShort actingIpratropium Glycopyrronium BIpratropium (nebulised) A Long actingTiotropium C Additional informationDrug specific notesA B CSecondary care and emergency use in primary care. Regular use in primary care on recommendation of specialist As per licence and MTRAC recommendations Safety concerns have been expressed around the Respimat device. HYPERLINK "http://www.nelm.nhs.uk/en/NeLM-Area/News/2012---October/08/Systematic-review-and-meta-analysis-questions-safety-of-tiotropium-Respimat-inhaler-in-COPD/"NELM Systematic review and meta analysis questions safety of tiotropium Respimat inhaler in COPD  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.nice.org.uk/page.aspx?o=cg012" Clinical guideline 12: Chronic Obstructive Pulmonary Disease HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance   HYPERLINK "http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_disease" Prodigy: COPD ;  HYPERLINK "http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf" MEREC: Management of COPD HYPERLINK "http://www.keele.ac.uk/media/keeleuniversity/fachealth/fachealthsop/mtrac/documents/summary/Glycopyrronium%20SUM%20final%20(1).pdf"MTRAC summary Glycopyrronium PCT informationLaunch of CFC free formulations does not require change to prescription HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff   HYPERLINK "http://www.drugtariff.co.uk/"  Theophylline Notes on classXanthines have a narrow therapeutic index so measuring plasma levels is recommended. Theophylline levels may rise when patient stops smoking, Modified release products should be prescribed by brand Xanthine naive patients should be initiated on theophylline GreenYellowDouble YellowRedTheophylline AAminophylline B  Additional informationDrug specific notesA BAt appropriate stage of relevant guideline. At appropriate stage of relevant guideline.  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/page.aspx?o=cg012"NICE CG 12: Chronic Obstructive Pulmonary Disease HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance ;  HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/63/index.html" SIGN Guideline No. 63: British Guideline on the Management of Asthma;  HYPERLINK "http://www.prodigy.nhs.uk/asthma" Prodigy: Asthma ;  HYPERLINK "http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_disease" Prodigy: COPD ;  HYPERLINK "http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf" MEREC: Management of COPDPCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Compound bronchodilators Notes on class GreenYellowDouble YellowRedCombivent A Additional informationDrug specific notesANebuliser solution only available HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/page.aspx?o=cg012"NICE CG 12: Chronic Obstructive Pulmonary Disease HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance ;  HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/63/index.html" SIGN Guideline No. 63: British Guideline on the Management of Asthma  HYPERLINK "http://www.prodigy.nhs.uk/asthma" Prodigy: Asthma ;  HYPERLINK "http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_disease" Prodigy: COPD ;  HYPERLINK "http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf" MEREC: Management of COPDPCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Peak flow meters, inhaler devices and nebulisers Notes on classPeak flow meters were changed in 2004 to European standards. The older peak flow meters should be used with older charts as the old and new scales are not equivalent  GreenYellowDouble YellowRedPeak flow metersSpacers Corticosteroids Notes on classAs with bronchodilators, MDIs should be used first line in conjunction with a spacer. Spacers should be used for all inhaled steroids, especially high dose steroids (above 800 micrograms) AeroChamber Spacer devices: adult (blue) with or without mask, infant (orange) or child (yellow). Not suitable for GSK inhalers (Ventolin, Becotide, Serevent, Flixotide, Seretide) use Volumatic. Not suitable for Bricanyl/Pulmicort Oral hygiene should be emphasised to reduce risk of oral thrush Committee on Human Medicines (formerly CSM) Guidance for high dose fluticasone  HYPERLINK "http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007455&ssTargetNodeId=368" Current problems in pharmacovigilance August 2001 High dose fluticasone and on HYPERLINK "http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007451&ssTargetNodeId=368" risk of adrenal suppression in children Oct 2002 Committee on Human Medicines (formerly CSM) guidance that LABA should only be used in conjunction with an inhaled steroid  HYPERLINK "http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2025447" MHRA updates on LABAs in asthma CFC free beclometasone preparations are not interchangeable and should be prescribed by brand (MHRA August 2006)  GreenYellowDouble YellowRedBeclometasone (beclomethasone) Fluticasone Budesonide 3.2.1.1.Combination Corticosteroid Inhalers if compliance is a problemFlutiform BSymbicort Fostair Low dose Seretide High dose Seretide AAdditional informationDrug specific notesA B 250 micrograms and above: Specialist recommendation if to treat asthma For use in clinically appropriate situations. Formulary working group acknowledge that this may include off label use of Flutiform in COPD patients. Patients stable on other therapies should not be switched to Flutiform on the basis of formulary category alone. However it is appropriate to consider Flutiform at an asthmas review and or step up or step down. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/page.aspx?o=cg012"NICE CG 12: Chronic Obstructive Pulmonary Disease HYPERLINK "http://publications.nice.org.uk/inhaled-corticosteroids-for-the-treatment-of-chronic-asthma-in-children-under-the-age-of-12-years-ta131"NICE TA 131 Inhaled corticosteroids for the treatment of chronic asthma in children under 12 years HYPERLINK "http://guidance.nice.org.uk/TA138"NICE TA 138 Asthma (in adults) - corticosteroids (TA138) HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance   HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/63/index.html" SIGN Guideline No. 63: British Guideline on the Management of Asthma  HYPERLINK "http://www.prodigy.nhs.uk/asthma" Prodigy: Asthma ;  HYPERLINK "http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_disease" Prodigy: COPD ;  HYPERLINK "http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf" MEREC: Management of COPD Cromoglicate, related therapy and leukotriene receptor antagonists Notes on class GreenYellowDouble YellowRedMontelukast A Zafirlukast (off label in GU medicine)Zafirlukast  Additional informationDrug specific notesAFor addition to therapy only at appropriate step HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA244"NICE TA 244 Chronic obstructive pulmonary disease - roflumilast  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/63/index.html" SIGN Guideline No. 63: British Guideline on the Management of Asthma;  HYPERLINK "http://www.prodigy.nhs.uk/asthma" Prodigy: Asthma ; PCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Antihistamines, hyposensitisation and allergic emergencies Notes on class GreenYellowDouble YellowRed3.4.1 AntihistiminesNon-sedating antihistaminesLoratadineFexofenadine Cetirizine Sedating antihistiminesChlorphenamine (chlorpheniramine) Alimemazine (trimeprazine) Hydroxyzine APromethazine B 3.4.2 HyposensitisationPharmalgen ( treatment of Bee & wasp allergy)Grass & tree pollen extractsGrazax DOmalizumab NICE TA 2783.4.3 Allergic emergenciesAdrenaline injections (Jext and Epipen)Icatibant C For the treatment of hereditary angio-oedema patientsC1 esterase inhibitor ( Cinryze and Berinert)Conestat alpha (Ruconest) (Via specialized commissioning)Additional informationDrug specific notesA B C DFor pruritus For hyperemesis Patients that have had more than 1 attack (requiring treatment with icatibant/C1 inh) in a 12 month period may be offered icatibant for self administration For use as per licence in adult patients meeting the Directorate criteria for treatment  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://publications.nice.org.uk/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-ta278"NICE TA 278 Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201)  HYPERLINK "http://guidance.nice.org.uk/TA246"NICE TA 246 Venom anaphylaxis - immunotherapy pharmalgen Respiratory stimulants and pulmonary surfactants GreenYellowDouble YellowRed3.5.1 Respiratory stimulantsCaffeine (unlicensed) A Doxapram3.5.2 Pulmonary surfactantsPoractant alpha Additional informationDrug specific notesANeonates only unlicensed use HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Oxygen GreenYellowDouble YellowRedOxygen Mucolytics GreenYellowDouble YellowRedCarbocisteine A specialist recommendationDornase alfa Patients established on therapy prior to 31/3/13 will continue to receive treatment under an ESCA Dornase alfa Patients starting therapy on 1/04/13 or later will receive treatment at HEFT (via specialised commissioningAcetylcysteine sachets off label use specialist recommendation for the treatment of distal intestinal obstruction syndrome in cystic fibrosisAcetylcysteine other off label useErdosteine. Respiratory Directorate only. For inpatients and TTO only. Not for GP prescribing. Devices GreenYellowDouble YellowRedFlutter Mucous clearing device Additional informationDrug specific notesA HYPERLINK "http://www.nice.org.uk/page.aspx?o=cg012"NICE CG 12: Chronic Obstructive Pulmonary Disease  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/page.aspx?o=cg012"NICE CG 12: Chronic Obstructive Pulmonary Disease  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT information HYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Aromatic inhalations GreenYellowDouble YellowRedMenthol & eucalyptus  Cough preparations Notes on class GreenYellowDouble YellowRedSimple linctusPholcodine linctus limited roleMethadone linctus 2mg/5ml A Palliative care only Systemic nasal decongestants GreenYellowDouble YellowRed Antifibrotics GreenYellowDouble YellowRedPirfenidone NICE TA 282 (via specialised commissioning) Miscellaneous GreenYellowDouble YellowRedNebusal (Sodium chloride 7% nebuliser solution) for CF patientsInhaled mannitol Additional informationDrug specific notesASpecialists in palliative care only HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA266"NICE TA 266 Cystic fibrosis - mannitol dry powder for inhalation  HYPERLINK "http://publications.nice.org.uk/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis-ta282"NICE TA 282 Pirfenidone for treating idiopathic pulmonary fibrosis   HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff  Pseudoephedrine (Drugs of limited Clinical Value) is of limited use; available OTC HYPERLINK "http://www.drugtariff.co.uk/"  Central Nervous System Hypnotics and Anxiolytics Notes Committee on Human Medicines (formerly CSM) Benzodiazepines are indicated for the short term relief (two to four weeks only) of anxiety that is severe, disabling or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness. The use of benzodiazepines to treat short-term mild anxiety is inappropriate and unsuitable. Benzodiazepines should be used to treat insomnia only when it is severe, disabling, or subjecting the individual to extreme distress. Z-drugs should be used for a maximum of two to four weeks in line with their product licence and are not superior to benzodiazepinesGeneral notes No hypnotic is licensed for more than 28 days use Prescribers should routinely provide information on promotion of good sleep habits (sleep hygiene) Link to Prodigy PIL  HYPERLINK "http://www.cks.library.nhs.uk/patient_information_leaflet/insomnia/prevention" Prevention of insomnia GreenYellowDouble YellowRedHypnoticsTemazepamZolpidem NICE TA 77Chloral hydrate syrup - paediatricsZopiclone - NICE TA 77Triclofos - PaediatricsPromethazine for hyperemesis Zaleplon NICE TA 77AnxiolyticsDiazepam AChlordiazepoxide BLorazepam injectionLorazepamDiazepam injectionAdditional informationDrug specific notesA B Not recommended due to long duration of action compared to temazepam For alcohol withdrawal HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA051"NICE TA 51 Depression and anxiety - computerised cognitive behavioural therapy; HYPERLINK "http://guidance.nice.org.uk/TA77"NICE TA 77 -Insomnia newer hypnotic drugs HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/hypnotic_or_anxiolytic_dependence" Prodigy: Hypnotic and anxiolytic dependence ;  HYPERLINK "http://www.prodigy.nhs.uk/insomnia" Prodigy: InsomniaDrugs used in psychoses and related disorders Notes on classThe Committee on Human Medicines (formerly The Committee on the Safety of Medicines) has advised that: Risperidone or olanzapine should not be used for the treatment of behavioural symptoms of dementia Use of risperidone for the management of acute psychotic conditions in elderly patients who also have dementia should be limited to the short-term and should be under specialist advice (olanzapine is not licensed for management of acute psychoses) Prescribers should consider carefully the risk of cerebrovascular events before treating any patient with a previous history of stroke or TIA. Consideration should also be given to other risk factors for cerebrovascular disease including hypertension, diabetes, current smoking and AF Increased risk of cerebrovascular events when antipsychotics used to treat behavioural or psychotic symptoms of dementia. See NICE Clinical Guideline The NICE Clinical guideline on Dementia states that antipsychotics should only be considered for patients with severe non-cognitive symptoms (psychosis &/or agitated behaviour causing significant distress), after very careful assessment of risks and benefits. The dose must be carefully titrated, and use should under close supervision on a time-limited basis with changes in target symptoms regularly assessed and recorded.  HYPERLINK "http://guidance.nice.org.uk/cg42/niceguidance/word/English" CG42 Dementia: NICE guideline (Word) see section 1.7.2 p34 Furthermore, the CHM notes that although there is currently insufficient evidence to include other antipsychotics in these recommendations, prescribers should bear in mind that a risk of stroke cannot be excluded, pending the availability of further evidence. Patients with dementia who are currently treated with an atypical antipsychotic drug should have their treatment reviewed. GreenYellowDouble YellowRed4.2.1 Antipsychotic drugsChlorpromazine BOlanzapine C -Consultant initiationAripiprazole -Consultant recommendation Clozapine (Mental Health Trust)HaloperidolRisperidone - Consultant initiationAmisulpride -Consultant recommendationQuetiapine -Consultant recommendation GreenYellowDouble YellowRed4.2.2Consultant initiationZuclopenthixolFlupentixol (flupenthixol)Fluphenazine4.2.3 Antimanic drugsLithium A Valproate acid (BSMHFT) Additional informationDrug specific notesA B CMust state brand as different formulations / salts are not interchangeable Not for use in the management of agitation in dementia or delirium Oro-dispersible can be considered for compliance issues HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=CG001"NICE CG 1 Clinical Guidance on Schizophrenia; HYPERLINK "http://www.nice.org.uk/nicemedia/live/10990/30191/30191.pdf"NICE CG 38 bipolar disorder HYPERLINK "http://www.nice.org.uk/nicemedia/live/11786/43610/43610.pd"NICE CG 82 schizophrenia HYPERLINK "http://guidance.nice.org.uk/cg42/niceguidance/word/English"NICE CG42 Dementia HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA066"NICE TA 66 Bipolar disorder - newer drugs HYPERLINK "http://guidance.nice.org.uk/TA213"NICE TA 213 Schizophrenia - aripiprazole HYPERLINK "http://publications.nice.org.uk/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder-ta292"NICE TA 292 Bipolar disorder- adolescents - aripiprazole  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance Olanzapine and Risperidone initiation in secondary care GPs can continue prescribing Olanzapine for bipolar disorder - initiation in secondary care. GPs can continue prescribing Lithium ESCA is being developed by B&S MHT  HYPERLINK "http://www.prodigy.nhs.uk/schizophrenia" Prodigy: SchizophreniaPCT informationBirmingham and Solihull Mental Health Trust guidelines on antipsychotics (HYPERLINK "http://nww.pctnet.wmids.nhs.uk/z_internet_hob/schz_guidelines/default.htm"http://nww.pctnet.wmids.nhs.uk/z_internet_hob/schz_guidelines/default.htm) HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Antidepressants Notes on classAll of the SSRI antidepressants are of similar efficacy to one another and slightly better than placebo SSRI antidepressants are not licensed for under 18s GreenYellowDouble YellowRedSSRIsFluoxetineCitalopramSertraline ATricyclics AmitriptylineLofepramineOther AntidepressantsMirtazapine Duloxetine within licence as per NICE CG96 for diabetic peripheral neuropathic painVenlafaxine Additional informationDrug specific notesAHas most evidence in cardiovascular disease  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/topic/behavioural"NICE guidance on mental health and behavioural conditions HYPERLINK "http://www.nice.org.uk/CG96"NICE CG 96 Neuropathic pain pharmacological management  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/depression" Prodigy: Depression PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  CNS Stimulants and other Drugs used for attention deficit hyperactivity disorder Notes on class GreenYellowDouble YellowRedMethylphenidate ESCADexamfetamine (dexamphetamine)Atomoxetine ESCA AModafinil for narcolepy ESCA BModafinil ( as a consequence of sleep apnoea) CLisdexamphetamine Additional informationDrug specific notesA The MHRA has announced that it is investigating the risks and benefits of atomoxetine (for ADHD), following research that has identified a possible increase in suicidal thoughts and behaviour in children treated with the drug. In the mean time the MHRA advises that children taking the drug should be monitored for signs of depression, suicidal thoughts or behaviour, and referred for appropriate treatment if necessary. Patients (and carers) should be advised to watch for relevant behaviours. Children who are taking atomoxetine who are feeling well should not be concerned and there is no need to stop it as the benefits will outweigh the risks for most children.B CFor treatment of narcolepsy only. Patients who are stable and being treated with modafinil for excessive daytime sleepiness (in relation to sleep apnea) may continue treatment under the ESCA. Following a Safety and Effectiveness review by the EMEA Modafinil for the treatment of excessive daytime sleepiness as a consequence of sleep apnoea has been moved to the red section of the formulary. NEWLY diagnosed patients requiring treatment with modafinil will receive all of their medication from HEFT and GPs will not be asked to prescribe. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA098"NICE TA 98 Attention deficit hyperactivity disorder (ADHD) HYPERLINK "http://guidance.nice.org.uk/TA139"NICE TA 139 Sleep apnoea - continuous positive airway pressure (CPAP) HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance Guidance available for both atomoxetine and methylphenidate  HYPERLINK "http://www.prodigy.nhs.uk/attention_deficit_disorder_methylphenidate_nice_guidance" Prodigy: ADHD PCT informationESCAs for both methylphenidate and atomoxetine are available. HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs used in obesity Notes on classDrugs in this class are subject to inclusion criteria based on patients current physical condition and progress with unassisted weight loss prior to commencing medication. Refer to BNF  HYPERLINK "http://www.bnf.org/bnf/bnf/current/3381.htm" 4.5 Drugs used in the treatment of obesity: British National Formulary  GreenYellowDouble YellowRedOrlistat  Additional informationDrug specific notesRimonabant The European Medicines Agency (EMEA) recommended the suspension of the marketing authorisation for Acomplia (rimonabant) from Sanofi-Aventis. The EMEAs Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be suspended across the European Union (EU). HYPERLINK "http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf"EMEA information regarding rimonabant HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/CG43/?c=296726"NICE CG 43 Obesity  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/obesity" Prodigy: Obesity PCT informationPractices should have a prescribing protocol in place HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs used in nausea and vomiting GreenYellowDouble YellowRedBetahistineHyoscine hydrobromide Ondansetron (Hyperemesis / paeds)CinnarizineHyoscine hydrobromide patchGranisetron CyclizineLevomepromazine (Palliative Care)ProchlorperazineAprepitant (Emend ) BMetoclopramide ADroperidol injection CDomperidonePalonosetron  Additional informationDrug specific notesA B CNot effective in postoperative nausea and vomiting and not 1st choice in patients under 20 years of age For use as per Pan Birmingham Cancer Network guidelines Reserved for those patients in whom other agents have failed to control PONV or are otherwise unsuitable for treatment with other agents HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.birminghamcancer.nhs.uk/viewdoc.ashx?id=AvuZW0tU2WZREqlW%2FRuzLg%3D%3D"PBCN Anti Emetic Guidelines for Adults receiving chemotherapy PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Analgesics Notes on classWhere ever possible, avoid the use of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine / dihydrocdeine are deemed products less suitable for prescribing in the BNF Co-codamol 8/500 is similar in efficacy to paracetamol and should be avoided Most drugs in section 4.7.2 are subject to the Misuse of Drugs Act. Handwriting exemptions have recently been lifted to allow computer generated scripts. These prescriptions still require all of the previous details. Patients name and address Name of preparation. The form and where appropriate the strength of the preparation The total quantity of the preparation or the number of dose units in both words and figures The dose  GreenYellowDouble YellowRed4.7.1 Non-opioid anlgesicsParacetamolCo-codamol 30/500 *Paracetamol injection DCo-codamol 30/500 *effervescent (high sodium content) Paracetamol soluble (high sodium content)4.7.2 Opioid analgesicsMorphine saltsBuprenorphine 200 microgram S/L tablets Hydromorphone (palliative care recommendation only)Papaveretum Codeine phosphateFentanyl patch A Oxycodone - usually on palliative care recommendationMeptazinol obstetric pain and renal colic only Diamorphine saltsTramadol CBPethidine Sublingual fentanyl Palliative Pain Team Recommendation only - for the management of breakthrough pain in adults using opioid therapy for chronic cancer pain & who are unsuitable for other short acting opioids4.7.2 Opioid analgesics continuedDihydrocodeine Methadone liquid - Palliative Care Team recommendation onlyTranstec patches prescribing restricted to Dr Meystre - during end of life care onlyFentanyl lozenge Palliative Care Team recommendation onlyOxycodone MR 48 hours treatment post operatively to facilitate EROS only4.7.3 Neuropathic painAmitriptyline (off label use)Carbamazepine trigeminal neuralgia onlyPregabalin specialist initiation and stablilisationCapsaicin 8% patch - 10 patients only via Pain TeamGabapentin Clonazepam (off-label) palliative care only4.7.4 Antimigraine drugs4.7.4.1 Migraine treatmentSumatriptan Rizatriptan Migraleve pinkSumatriptan injection A Naratriptan (Primary Care only)Zolmitriptan (Primary Care only)4.7.4.2 Migraine prophylaxisPropranolol (section 2.4)Pizotifen Amitriptyline  Additional informationDrug specific notesA B C D *These products should only be used if oral treatments are not effective Post operatively or Pain Team advice only. Not to be used in conjunction with other regular opiates. Combination products containing tramadol are NON-FORMULARY For use in patients that are unable to tolerate oral paracetamol and have established IV access. Paracetamol injection is a more cost effective option than paracetamol suppository Caution in elderly patients (over 69) HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_alphabet/p" Prodigy: Palliative Care series ;  HYPERLINK "http://www.prodigy.nhs.uk/migraine" Prodigy: Migraine ;  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/musculoskeletal" Prodigy: Musculoskeletal problemsPCT informationMigraleve yellow tablets are co-codamol 8/500 and should be avoided alone or as part of Migraleve duo packs. Refer to palliative care dose conversion charts for equivalent dosings and formulations HYPERLINK "http://www.drugtariff.co.uk/"  4.8 Antiepileptics 4.8.1 Control of epilepsy Notes on classAnti epileptic medications are prone to interactions; check with BNF GreenYellowDouble YellowRedSpecialist recommendationRetigabine NICE TA 232CarbamazepineClonazepam Primidone (also for essential tremor section 4.9.3)Sodium valproateLamotrigineZonisamide ESCA Diazepam rectal (section 4.1.2)GabapentinLacosamide ESCA LevetiracetamPhenytoin capsulesTopiramatePhenobarbitoneVigabatrin Additional informationDrug specific notes Phenytoin capsules cost 3p per 100mg phenytoin tablets cost 2.22 per 100mg  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://publications.nice.org.uk/the-epilepsies-the-diagnosis-and-management-of-the-epilepsies-in-adults-and-children-in-primary-and-cg137"NICE CG 137- Diagnosis and management of the epilepsies in adults and children in primary and secondary care  HYPERLINK "http://guidance.nice.org.uk/TA232"NICE TA 232 Epilepsy (partial) - retigabine (adjuvant) HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance HYPERLINK "http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007475&ssTargetNodeId=368"CSM statement regarding vigabatrin Phenobarbital (phenobarbitone) and primidone, whilst still used in primary care are rarely initiated 4.8.2 Drugs used in status epilepticus GreenYellow Double YellowRedDiazepam rectal tubesMidazolam buccal liquid (unlicensed) Paediatric patients onlyDiazepam injection (diazemuls)Paraldehyde (unlicensed)Lorazepam injectionPhenytoin sodium injectionPhenobarbital sodium injection 4.9 Drugs used in parkinsonism and related disorders 4.9.1 Dopaminergic drugs used in parkinsonism GreenYellowDouble YellowRedSelegilineCo-beneldopa (modified release)Specialist initiation Co-beneldopa Co-careldopa (modified release)Entacapone ESCA - ACo-careldopa Apomorphine (consultant initiation)Stalevo ESCA - APramipexole ESCA - ARopinirole ESCA - ARasagiline ESCAAmantadineBromocriptineRotigotine patches B 4.9.2 Antimuscarinic drugs used in parkinsonism GreenYellowDouble Yellow Red Specialist initiation in Parkinsons diseaseProcyclidine (for drug induced parkinsonism/dystonia)Benzatropine (benztropine)OrphenadrineTrihexyphenidyl (benzhexol)Procyclidine (Parkinsons disease) Additional informationDrug specific notesAB C ESCA required if prescribed in primary care For use within licence in these specific circumstances In patients who cannot swallow or their gut is not working. Patients with poor overnight control of PD. Rotigotine can be considered after CR L dopa preparations and long half life oral DAs (e.g. ropinirole and pramipexole) Patients with erratic motor control during the daytime despite using oral long acting DAs, e.g. ropinirole or pramipexole either as standard TDS regimes or once daily SR preparations. In this setting rotigotine patch can be useful before considering sc apomorphine infusion of enteral duodopa infusion. The latter two treatment options are much more invasive and expensive. Patients intolerant of current first line DAs (ropinirole and pramipexole) should be considered for rotigotine before abandoning the DA class of drugs. NICE state that newer drugs should be used in patients refractory to treatment with older AEDs or for whom older drugs are contraindicated. Combination therapy should be used only when monotherapy has failed. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://publications.nice.org.uk/the-epilepsies-the-diagnosis-and-management-of-the-epilepsies-in-adults-and-children-in-primary-and-cg137"NICE CG 137 Diagnosis and management of epilepsy in adults and children  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance HYPERLINK "http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2030729"CSM statement regarding pergolide HYPERLINK "http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007453&ssTargetNodeId=368"CSM statement regarding fibrotic reactions with pergolide and other ergot-derived dopamine receptor agonists4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders GreenYellowDouble Yellow Red PrimidoneHaloperidolRiluzole ESCA NICE TA 20Botulinum A toxinPropranololPiracetamTetrabenazine Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA20"NICE TA 20 Motor neurone disease - riluzole HYPERLINK "http://guidance.nice.org.uk/TA260"NICE TA 260 Migraine (chronic) - botulinum toxin type A HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  4.10 Drugs used in substance dependence GreenYellowDouble Yellow Red Nicotine replacement therapy (Patch considered first line) BupropionMethadone mixture 1mg/ml A on advice of substance misuse team only (NICE TA 114)Lofexidine - for use within licence as part of the SAFE projectVarenicline when NRT inappropriate or has failed. One 12 week cycle onlyBuprenorphine- On advice of substance misuse team only (NICE TA 114)Naltrexone substance misuse team onlyAcamprosate Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA20"NICE TA 20 (Motor neurone disease - riluzole) HYPERLINK "http://www.nice.org.uk/nicemedia/live/11925/41664/41664.pdf"NICE PH 10 Smoking cessation services HYPERLINK "http://guidance.nice.org.uk/TA114"NICE TA 114 Drug misuse - methadone and buprenorphine HYPERLINK "http://guidance.nice.org.uk/TA115"NICE TA 115 Drug misuse - naltrexone  HYPERLINK "http://guidance.nice.org.uk/TA123"NICE TA 123 Smoking cessation - varenicline HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  4.11 Drugs for dementia Notes on class GreenYellowDouble YellowRed As per NICE TAsDonepezilGalantamineRivastigmineMemantine Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA217"NICE TA 217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationPatients living within the Birmingham and Solihull areas are treated by the Birmingham and Solihull Mental Health Trust with all prescribing undertaken by the Mental Health Trust.  NotesPrescribe an antibiotic only when there is likely to be a clear clinical benefit i.e. clinical indication of infection. Apply lower threshold for antibiotics in immunocompromised or those with multiple morbidities. Collect cultures where appropriate. A dose and duration for adults is suggested, but may need modification for age, weight or renal function. In severe or recurrent cases consider a larger dose or longer course. Please refer to BNF for further dosing and interaction information (e.g. interaction between macrolides and statins) if needed and please check for hypersensitivity Paediatric doses stated in BNFc may be found at Appendix 1. Refer to the BNF and BNFc for further dosing information. Consider a no, or delayed, antibiotic strategy for acute self-limiting upper respiratory tract infections. Avoid broad spectrum antibiotics (co-amoxiclav, 2nd and 3rd generation cephalosporins, quinolones) if possible as they increase risk of Clostridium difficile, MRSA (both not as much a concern for children) and UTIs caused by multi-drug-resistant organisms. Limit prescribing over the telephone to exceptional cases. In pregnancy AVOID tetracyclines, aminoglycosides, quinolones, and high dose metronidazole. Short term use of nitrofurantoin is unlikely to cause problems to the foetus; nor is trimethoprim unless poor dietary folate intake or taking another folate antagonist e.g. antiepileptic. Clarithromycin is an acceptable alternative in those who are unable to tolerate erythromycin because of side effects. Avoid widespread use of topical antibiotics, especially those agents also available as systemic preparations e.g. fusidic acid. Where a best guess therapy has failed or special circumstances exist, microbiological advice can be obtained from 0121 424 2000 and ask for the duty microbiologist on call. Send appropriate specimens wherever indicated. The content of the formulary reflects evidence or consensus opinion at the time of compilation. Evidence or opinion may change over time and it is the responsibility of the prescriber to ensure that new evidence or national guidelines are taken into account in their prescribing. The individual prescriber remains responsible for the patients care and the prescription written. There are useful resources on antibiotics including patient information leaflets, antibiotic posters, training programmes on antibiotics available at the following website  HYPERLINK "http://www.rcgp.org.uk/TARGETantibiotics" TARGET antibiotics resources 5 Infections Guidance for the Management of Infection in Primary Care Index of sections Click on the link below: HYPERLINK \l "Meningitis" Meningitis,  HYPERLINK \l "Emergency_treatment_for_CAP_in_adults" Emergency treatment for CAP in adults  HYPERLINK \l "URTI" Upper respiratory tract infections  HYPERLINK \l "Common_cold" Common cold, HYPERLINK \l "Influenza"Influenza, HYPERLINK \l "Acute_sore_throat"Acute sore throat, HYPERLINK \l "AOM"Acute Otitis Media,  HYPERLINK \l "Acute_Otitis_Externa" Acute Otitis Externa, HYPERLINK \l "Sinusitis"Rhinosinusitis,  HYPERLINK \l "LRTI" Lower respiratory tract infections  HYPERLINK \l "Acute_bronchitis" Acute cough bronchitis,  HYPERLINK \l "Acute_exac_COPD" Acute exacerbation of COPD,  HYPERLINK \l "CAP" Community Acquired Pneumonia  HYPERLINK \l "UTI" Urinary Tract Infections  HYPERLINK \l "Uncomp_UTI" Uncomplicated UTI in men and non-pregnant women, HYPERLINK \l "Acute_prostatitis"Acute Prostatitis,  HYPERLINK \l "UTI_preg_and_men" UTI in pregnancy, HYPERLINK \l "UTI_children"UTI in Children,  HYPERLINK \l "Acute_pyeloneph" Acute pyelonephritis,  HYPERLINK \l "Recurr_UTI" Recurrent UTI in non pregnant women  HYPERLINK \l "GI" Gastro-intestinal tract infections  HYPERLINK \l "H_pylori" Oral candidiasis,  HYPERLINK \l "H_pylori" H. pylori,  HYPERLINK \l "Gastroenteritis" Clostridium difficile, HYPERLINK \l "Gastroenteritis"Infectious diarrhoea, HYPERLINK \l "Infectious_diarrhoea"Travellers Diarrhoea,  HYPERLINK \l "Threadworm" Threadworm  HYPERLINK \l "Genital_tract" Genital Tract Infections HYPERLINK \l "Chlamydia"Chlamydia, HYPERLINK \l "VC"Vaginal candidiasis, HYPERLINK \l "BV"Bacterial vaginosis, ,  HYPERLINK \l "Trichomoniasis" Trichomoniasis,  HYPERLINK \l "PID" PID,  HYPERLINK \l "Skin_soft_tissue" Skin/Soft Tissue infections  HYPERLINK \l "Impetigo" Impetigo,  HYPERLINK \l "Eczema" Eczema,  HYPERLINK \l "Cellulitis" Cellulitis, HYPERLINK \l "MRSA"MRSA, HYPERLINK \l "_MRSA"PVL,  HYPERLINK \l "Leg_Ulcers" Leg Ulcers,  HYPERLINK \l "Leg_Ulcers" Diabetic Leg Ulcer,  HYPERLINK \l "Conjunctivitis" Conjunctivitis,  HYPERLINK \l "Scabies" Scabies,  HYPERLINK \l "Fungal_nail" Fungal nail infection,  HYPERLINK \l "Fungal_skin" Fungal skin infection,  HYPERLINK \l "Acne" Acne,  HYPERLINK \l "Chickenpox_and_shingles" Chicken pox & shingles  HYPERLINK \l "DENTAL" Dental infections IllnessCommentsFirst LineSecond LineMENINGITISSuspected meningococcal disease HYPERLINK "http://www.hpa.org.uk/infections/topics_az/meningo/menu.htm"HPA HYPERLINK "http://www.hpa.org.uk/cdph/issues/CDPHVol5/no3/Meningococcal_Guidelines.pdf" Transfer all patients to hospital immediately. If time before admission, and non-blanching rash give either IV benzylpenicillin or cefotaxime unless definite history of hypersensitivity. i.e. history of difficult breathing, collapse, loss of consciousness, or rash. If history of anaphylaxis with penicillins or cephalosporins, seek urgent advice from on-call microbiologist via BHH switchboard 0121 424 2000.IV# Benzylpenicillin Children <1 yr: 300 mg Children 1 - 9 yr: 600 mg Other: 1200 mg IV# Cefotaxime > 12yrs 1g < 12 yrs 50mg/kg (max 1g) # Give IM if vein cannot be foundPrevention of secondary case of meningitis: Only prescribe following advice from a Public Health Doctor 0121 352 5345 or 5349. Out of hours contact duty microbiologist via Heartlands switchboard 0121 424 2000. EMERGENCY TREATMENT FOR COMMUNITY ACQUIRED PNEUMONIA IN ADULTSCommunity acquired pneumoniaUse CRB65 score to help guide and review: Each scores 1: New Confusion (AMT<8); Respiratory rate >30/min; BP systolic <90 or diastolic d" 60 Age > 65 years Score 3-4: urgent hospital admission If delayed admission (> 6 hours) / life threatening Unless history of hypersensitivity&! IM or iv Benzylpenicillin 1200 mg OR IM or iv Cefotaxime 1g OR Amoxicillin 1000mg by mouth &! See under meningitis above UPPER RESPIRATORY TRACT INFECTIONS: Common Cold  HYPERLINK "http://cks.nice.org.uk/common-cold" Common cold - NICE CKS  Symptomatic treatmentInfluenza HYPERLINK "http://www.hpa.org.uk/infections/topics_az/influenza/seasonal/pdfs/Treatmentflowchart.pdf"HPA Influenza  HYPERLINK "http://guidance.nice.org.uk/TA158" NICE TA 158 Influenza prophylaxis Annual vaccination is essential for all those at risk of influenza. See DoH Guidance for definition of at risk groups and vaccination schedule including pandemic influenza vaccination where appropriate Treat at risk patients only when influenza is circulating in the community as confirmed by the DoH, within 48 hours of onset. Offer post-exposure prophylaxis only in line with NICE During epidemic follow HPA or equivalent national/local guidance.  Treatment Oseltamivir 75mg BD for 5 days * *Adult dose for children see BNFc Prophylaxis Oseltamivir 75mg OD for 10 days * *Adult dose for children see BNFc  If there is resistance to oseltamivir or if pregnant Treatment Zanamivir 10mg BD (2 inhalations by diskhaler) for 5 days* *Adult dose for children see BNFc Prophylaxis Zanamivir 10mg OD (2 inhalations by diskhaler) for 10 days* *Adult dose for children see BNFc Acute Sore Throat  HYPERLINK "http://cks.nice.org.uk/sore-throat-acute" Sore throat - acute - NICE CKS  HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/117/index.html" SIGN Guideline 117 (2010)  HYPERLINK "http://guidance.nice.org.uk/CG69" NICE CG69 (2008) The majority of sore throats are viral; most patients do not benefit from antibiotics. 90% of acute sore throats will resolve in 7 days without antibiotics and pain is only reduced by 16 hours Antibiotics to prevent Quinsy NNT>4000 Antibiotics to prevent Otitis media NNT 200 Use HYPERLINK \l "Centor"Clinical Prediction Rule to estimate likelihood of Group A beta haemolytic Streptococcus If Centor score 3 or 4 (fever, no cough, lymphadenopathy, tonsillar exudate), consider 2-3 day delayed, or immediate antibiotics. If the patient reconsults then a swab should be takenSymptomatic treatment If antibiotics indicated, consider delayed prescription, held in the practice as per original study Phenoxymethylpenicillin 500mg QDS for 10 days * (Syrup has unpleasant taste  use tablets wherever possible) OR (if allergic to penicillin) Clarithromycin 500mg BD for 5 days * (for child, consider erythromycin) * Adult doses  for children see HYPERLINK \l "APPENDIX1"Appendix 1   Little P, Williamson I, Warner G et al. (1997) Open randomised trial of prescribing strategies in managing sore throat. BMJ 314: 722-7 Acute Otitis Media  HYPERLINK "http://cks.nice.org.uk/otitis-media-acute" Otitis media - acute - NICE CKS Children Evidence suggests that slightly more children will be pain free at 2 days if they take ibuprofen TDS than if given paracetamol TDS. However, use of ibuprofen may be associated with a slightly higher risk ofmild nausea, vomiting or abdominal pain Avoid antibiotics as 60% are better in 24 hours without; they only reduce pain at 2 days (NNT 15) and do not prevent deafness Consider 2 or 3 day-delayed or immediate antibiotics for pain relief if: <2yrs with bilateral AOM NNT4 All ages with otorrhoea NNT3 Antibiotics to prevent Mastoiditis NNT > 4000 Macrolides are not the drug of choice against Haemophilus.If no vomiting or temp <38.5oC optimise analgesia with paracetamol or ibuprofen. Consider delayed prescription, held in practice as per original study. If antibiotics indicated: Amoxicillin 500mg TDS for 5 days* OR (if allergic to penicillin) For children Erythromycin Doses see HYPERLINK \l "APPENDIX1"Appendix 1 For adults Clarithromycin 500mg BD for 5 days* * Adult doses for children see HYPERLINK \l "APPENDIX1"Appendix 1 Acute Otitis externa  HYPERLINK "http://cks.nice.org.uk/otitis-externa" Otitis externa - NICE CKSFirst use aural toilet (if available) and analgesia. Cure rates similar at 7 days for topical acetic acid or antibiotic +/- steroid If cellulitis or disease extending outside aural canal, start oral antibiotics and refer. (see  HYPERLINK \l "Cellulitis" cellulitis ) In children with grommets, topical treatment should be used with care. In the immunocompromised or (older) diabetic patient where Pseudomonas aeruginosa is identified in an ear swab, malignant otitis externa must be considered. This invasive infection is associated with severe pain. Immediate referral to the ENT surgeon is necessary. Acetic acid 2% (Earcalm ear spray is available to the public): 1 spray TDS to affected ear(s) for 7 days. After topical treatment has been applied, the patient must lie with the ear up for at least 10 minutes to enable maximum contact with the lining of the ear. Dexamethasone 0.1%, neomycin sulphate 3250 units/mL, glacial acetic acid 2%. (Otomize) 1 spray TDS to affected ear(s) for 7days. Rhinosinusitis acute or chronic  HYPERLINK "http://cks.nice.org.uk/sinusitis" Sinusitis - NICE CKSAvoid antibiotics as 80% resolve in 14 days without, and they only offer marginal benefit after 7 days NNT 15 Reserve antibiotics for severe symptoms +/or >10 days Use adequate analgesia Consider 7-day delayed or immediate antibiotic when purulent nasal discharge NNT 8  Do not prescribe OR Amoxicillin 500mg TDS for 7 days (Adult dose for children see HYPERLINK \l "APPENDIX1"Appendix 1) OR Doxycycline 200mg stat, then 100mg daily (7 day course) (Adult dose. Not for use in children under 12 years or in pregnancy or lactation.) Seek expert advice for child allergic to penicillin. For persistent symptoms: Co-amoxiclav 625mg tds for 7 days  IllnessCommentsFirst LineSecond Line LOWER RESPIRATORY TRACT INFECTIONSDo NOT use quinolone (ciprofloxacin, ofloxacin) first line due to poor pneumococcal activity. Reserve all quinolones for proven resistant organisms Acute cough, bronchitis  HYPERLINK "http://cks.nice.org.uk/chest-infections-adult" Chest infections - adult - NICE CKS  HYPERLINK "http://guidance.nice.org.uk/CG69" NICE CG69 (2008) Antibiotics have little benefit if no co-morbidity Symptom resolution may take 3 weeks Consider 7day delayed antibiotic with symptomatic advice/leaflet Consider immediate antibiotics if > 80yr and ONE of: hospitalisation in past year, oral steroids, diabetic, congestive heart failure OR> 65yrs with 2 of above  Do not prescribe OR Amoxicillin 500mg TDS for 5 days * OR (if allergic to penicillin) Clarithromycin 500mg BD for 5 days * For child, consider erythromycin * Adult doses for children see HYPERLINK \l "APPENDIX1"Appendix 1  Doxycycline 200mg stat then 100mg OD. 5 day course. (Adult dose. Not for use in children under 12 years or in pregnancy or lactation.) Acute exacerbation of COPD Adults only  HYPERLINK "http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease" Chronic obstructive pulmonary disease - NICE CKS  HYPERLINK "http://www.nice.org.uk/CG101" NICE COPD guidelines CG 101  Antibiotics are not indicated in the absence of purulent sputum, unless consolidation on chest radiograph or clinical signs of pneumonia Treat exacerbations promptly with antibiotics if purulent sputum and increased shortness of breath and/or increased sputum volume Risk factors for antibiotic resistant organisms include co-morbid disease, severe COPD, frequent exacerbations, antibiotics in last 3 months Amoxicillin 500mg TDS for 5 days OR Doxycycline 200mg stat then 100mg OD for 5 days (not for use in pregnancy or lactation) In penicillin allergy: Clarithromycin 500mg BD for 5 days 3rd line if clinical failure to other antibiotics/resistance risk factors: Co-amoxiclav 625mg TDS for 5 days Community-acquired pneumonia: ADULTs Treatment in the community  HYPERLINK "http://cks.nice.org.uk/chest-infections-adult" Chest infections - adult - NICE CKS HYPERLINK "http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Pneumonia/Guidelines/CAPGuideline-full.pdf"BTS CAP Guidelines Updated 2009 Use CRB65 score to help guide and review: Each scores 1: New Confusion (AMT<8); Respiratory rate >30/min; BP systolic <90 or diastolic d" 60; Age > 65 years Score 0: suitable for home treatment; Score 1-2: hospital assessment or admission Score 3-4: urgent hospital admission Give immediate IM Benzylpenicillin or amoxicillin 1g orally if delayed admission (> 6 hours) / life threatening Mycoplasma infection is rare in over 65s IF CRB65 = 0 : Amoxicillin 500mg TDS for 7 days OR Clarithromycin 500mg BD for 7 days OR Doxycycline 200mg stat/100mg OD for 7 days (Adults only. Not for use in pregnancy or lactation.) If CRB65 = 1 & AT HOME Amoxicillin 500mg TDS AND clarithromycin 500mg BD for 7 10 days OR Doxycycline alone 200mg stat/100mg OD for 710 days  Community- acquired pneumonia CHILDREN Treatment in the community HYPERLINK "http://cks.nice.org.uk/cough-acute-with-chest-signs-in-children"CAP children - NICE CKSCRB65 scoring system not appropriate HYPERLINK "http://cks.nice.org.uk/cough-acute-with-chest-signs-in-children" \l "!scenariorecommendation:6"CKS risk assessment tool For children who are managed at home advise carers to: Control fever and maintain hydration with  HYPERLINK "http://www.cks.nhs.uk/cough_acute_with_chest_signs_in_children/management/detailed_answers/self_care_advice" self-care measures. Check on the child regularly, including through the night, and seek medical advice if the child deteriorates or the carers are unable to cope. Arrange a review of the child and refer for hospital assessment if: The child deteriorates on treatment. The child does not improve after 48hours of treatment. For child well enough to be treated in the community Child under 5 years of age Amoxicillin 1 month <1 year: 125mg TDS 1 - <5 years: 250mg TDS All for 5 - 7 days OR (if allergic to penicillin) Erythromycin ethylsuccinate SF suspension 1 month - < 2years: 250mg QDS for 7 days > 2 years: 500mg QDS for 7 days Child >5 years of age Amoxicillin > 5 years: 500mg TDS for 5 7 days OR if allergic to penicillin OR during known Mycoplasma outbreak Erythromycin ethylsuccinate SF suspension > 2 years: 500mg QDS for 7 days  Ref: NHS Clinical Knowledge summary  HYPERLINK "http://www.cks.nhs.uk/cough_acute_with_chest_signs_in_children" \l "-300872" NHS Clinical Knowledge Summaries - Clinical topic - Cough - acute with chest signs in children Accessed 04.11.10 IllnessCommentsFirst LineSecond LineURINARY TRACT INFECTIONS People >65yrs: do not treat asymptomatic bacteriuria; it is common but is not associated with increased morbidity Catheter in situ: antibiotics will not eradicate asymptomatic bacteriuria; only treat if systemically unwell or pyelonephritis likely Do not use prophylactic antibiotics for catheter changes unless history of catheter-change associated UTI Please do not use ciprofloxacin unless no other option availableUncomplicated UTI in men and non-pregnant adult females (i.e. no fever or flank pain) HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947404720"HPA UTI quick reference guide HYPERLINK "http://www.hpa.org.uk/infections/topics_az/esbl/default.htm"ESBLs  HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-lower-women" Urinary tract infection (lower) - women - NICE CKS  HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-lower-men" Urinary tract infection (lower) - men - NICE CKSHYPERLINK "http://nww.solihullccg.nhs.uk/index.php/infection"Uncomplicated lower UTI in non pregnant women (Birmingham and Solihull August 2012) Women with severe/e" 3 symptoms: treat Women with mild/ d"2 symptoms: use dipstick to guide treatment. Men: send pre-treatment MSU OR if symptoms mild/non-specific, use  ve nitrite and leucocytes to exclude UTI  Trimethoprim 200mg BD or Nitrofurantoin 100mg m/r BD Women for 3 days Men for 7 daysCommunity multi-resistant E. coli with Extended-spectrum Beta-lactamase (ESBL) enzymes are increasing so perform culture in all treatment failures. ESBLs may be sensitive to nitrofurantoin. Seek specialist advice. Acute prostatitis  HYPERLINK "http://www.bashh.org/guidelines" BASHH Guidelines  HYPERLINK "http://cks.nice.org.uk/prostatitis-acute" Prostatitis - acute - NICE CKS Consider referral for GUM opinion Send MSU for culture and start antibiotics 4 weeks treatment may prevent chronic infection Quinolones achieve higher prostate levelsCiprofloxacin 500mg BD for 28 days Trimethoprim 200mg bd for 28 daysUTI in pregnancy HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947404720"HPA UTI quick reference guide HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-lower-women" \l "!scenariorecommendation:13"UTI in pregnancy - NICE CKS  Send pre-treatment MSU for culture & sensitivity and commence empirical antibiotics. In pregnancy, short term use of trimethoprim or nitrofurantoin is unlikely to cause problems to the foetus Avoid trimethoprim if low folate status or on folate antagonist (eg antiepileptic or proguanil)  Cefalexin 500mg TDS for 7 days  Nitrofurantoin 100mg m/r BD for 7 days OR Trimethoprim 200mg (off label) BD for 7 days Give folic acid if first trimester  UTI in Children  HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-children" Urinary tract infection - children - NICE CKS HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG54quickrefguide.pdf"NICE CG54 Urinary tract infection in children: diagnosis, treatment and long-term management: Quick reference guide See pp 8 & 9  HYPERLINK "http://www.nice.org.uk/nicemedia/live/11010/30524/30524.pdf" NICE CG 47 Feverish Illness in Children  Children <3mths: refer urgently for assessment Child >3mths: assess and manage in line with NICE 54 and 47. Start antibiotic treatment, unless high risk of serious illness in child < 3 years of age, then refer urgently. If suspect upper UTI seek specialist advice  Co-amoxiclav < 1 year Consult BNFc 1 6 years 5ml of 125/31mg suspension TDS 6 12 years 5ml of 250/62mg suspension TDS >12 years 1 x 250/125mg tablet TDS All doses are for 3 days  Cefalexin in divided doses 3mths - 1 yr 125mg BD 1-5 yrs 125mg TDS 5-12 yrs 250mg TDS > 12 years 500mg TDS All doses are for 3 days Acute pyelonephritis (adults)  HYPERLINK "http://cks.nice.org.uk/pyelonephritis-acute" Pyelonephritis - acute - NICE CKS If admission not required, send MSU for culture & sensitivities and start antibiotics. If no response to treatment within 24 hours admit. Co-amoxiclav 625mg TDS for 14 days OR For patients with penicillin allergy Ciprofloxacin 500mg BD for 7 days Recurrent UTI in non- pregnant women >3 UTIs/year Consider STIs Emphasise good fluid intake, and post-coital micturition. Cranberry products OR Post-coital OR standby antibiotics may reduce recurrence Post coital prophylaxis is as effective as prophylaxis taken nightly. Nightly prophylaxis: reduces UTIs but adverse effects Review every 3 months.  Nitrofurantoin 50- 100mg OR Trimethoprim 100mg BOTH: stat post coital (off-label) OR OD at night IllnessCommentsFirst LineSecond LineGASTRO-INTESTINAL TRACT INFECTIONSOral candidiasis  HYPERLINK "http://cks.nice.org.uk/candida-oral" Candida - oral - NICE CKSAntifungal agents absorbed from the gastrointestinal tract prevent oral candidiasis in patients receiving treatment for cancerMiconazole oral gel Apply QDS for 7 days (continue for 48 hours after symptoms resolve)Fluconazole 50mg OD for 7 days Eradication of H.pylori HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG017quickrefguide.pdf"NICE CG17 Dyspepsia: Quick reference guide HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947419406"HPA QRG Diagnosis of H.pylori in dyspepsia HYPERLINK "http://cks.nice.org.uk/dyspepsia-unidentified-cause"Dyspepsia unidentified cause - NICE CKS HYPERLINK "http://cks.nice.org.uk/dyspepsia-proven-peptic-ulcer" \l "!scenariorecommendation:3"H pylori NICE CKS Managing symptomatic relapse DU: Duodenal ulcer GU: Gastric ulcer NUD: Non ulcer dyspepsia GORD: Gastro oesophageal reflux disease Eradication beneficial in DU, GU, and low grade MALToma, For NUD, the NNT is 14 for symptomatic relief Consider test & treat in persistent uninvestigated dyspepsia Do not offer eradication in GORD it is not effective Do not use clarithromycin or metronidazole if used in the past year for any infection. DU/GU relapse retest for H. pylori if symptomatic using breath test OR consider endoscopy for culture & susceptibility NUD- Do not retest, treat as functional dyspepsia offer PPI or H2RA PPI (cheapest) Full dose BD AND Clarithromycin 250mg BD AND Metronidazole 400mg BD all for 7 days or PPI (cheapest) Full dose BD AND Clarithromycin 500mg BD AND Amoxicillin 1g BD all for 7 days  PPI (cheapest) Full dose BD AND Bismuthate (De-nol tab) 120mg QDS AND 2 unused antibiotics: Amoxicillin 1g BD Metronidazole 400mg TDS Tetracycline 500mg QDS Relapse or MALToma 14 daysClostridium difficile  HYPERLINK "http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ClostridiumDifficile/Guidelines/" HPA Stop unnecessary antibiotics and/or PPIs and/or laxatives 70% respond to Metronidazole in 5 days; 92% in 14 days If severe symptoms or signs (below) or for relapses seek specialist advice. Admit if severe: T >38.5; WCC >15, rising creatinine or signs/symptoms of severe colitis1st / 2nd episodes Metronidazole 400mg TDS for 14 days 3rd episode / severe Seek specialist adviceInfectious diarrhoea  HYPERLINK "http://cks.nice.org.uk/gastroenteritis" Gastroenteritis - NICE CKSRefer previously healthy children with acute painful or bloody diarrhoea to exclude E. coli 0157 infection. Antibiotic therapy not indicated unless systemically unwell. If systemically unwell and campylobacter suspected (e.g. undercooked meat and abdominal pain), consider clarithromycin 500mg BD for 57days if treated early. Beware of haemolytic uraemic syndrome (HUS) following VTEC 0157 which is increased with antibioticsTravellers Diarrhoea  HYPERLINK "http://cks.nice.org.uk/diarrhoea-prevention-and-advice-for-travellers" Diarrhoea - prevention and advice for travellers - NICE CKSOnly consider standby antibiotics for remote areas or people at high-risk of severe illness with travellers diarrhoea If stand-by treatment appropriate give: ciprofloxacin 500mg BD x 3 days This would be a private prescription If quinolone resistance high (e.g. South Asia): consider bismuth subsalicylate (PeptoBismol) 2 tablets QDS as prophylaxis or 2 days treatment (bought OTC from pharmacy)  IllnessCommentsFirst LineSecond LineThreadworms  HYPERLINK "http://cks.nice.org.uk/threadworm" Threadworm - NICE CKS HYPERLINK "http://bnfc.org/bnfc/bnfc/current/4057.htm"BNF for Children: 5.5.1 Drugs for threadworms Treat household contacts at the same time PLUS Advise on hygiene measures for 2 weeks (hand hygiene, pants at night, morning shower) PLUS Wash sleepwear, bed linen, dust and vacuum on day one BNFc 2013 states that mebendazole is the drug of choice in children > 6 months. Reinfection is common and a second dose may be required after 2 weeks. Use under the age of 2 years is off-label Adult and child > 6 months Mebendazole 100mg stat (Off label if < 2 years) Infant < 6 months Six weeks hygiene Other wormsSeek advice from ID specialistTreatment to be prescribed by ID specialist (not GP). IllnessCommentsFirst LineSecond LineGENITAL TRACT INFECTIONSSTI screening People with risk factors should be screened for chlamydia, gonorrhoea, HIV, syphilis. Refer individual and partners to GUM service. Risk factors: no condom use, recent (<12mth) or frequent change of sexual partner, symptomatic partner.Chlamydia trachomatis HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/109/index.html"SIGN HYPERLINK "http://www.bashh.org/guidelines"BASHH HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947417467"HPA  HYPERLINK "http://cks.nice.org.uk/chlamydia-uncomplicated-genital" Chlamydia - uncomplicated genital - NICE CKSIdeally, refer all patients with positive result to open access GUM service for treatment, contact screening and investigation for further STIs. Pregnancy or breastfeeding: Azithromycin is the most effective option Due to lower cure rate in pregnancy, test for cure 6 weeks after treatment Azithromycin 1g stat 1 hour before or 2 hours after food Pregnant or breastfeeding: Azithromycin 1g stat (off-label use) OR Erythromycin 500mg QDS for 7 days OR Amoxicillin 500mg TDS for 7 daysDoxycycline 100mg BD for 7 days (not for use in pregnancy or lactation)For suspected epididymitis in men For all age groups, send a urine sample for Chlamydia and GC PCR, need to specifically request BOTH of these tests. First-catch urine, 5-10 mL, should be collected into a RED top sterile container, at least 1 hour (preferably 2), after the last micturition. For patients with urethral discharge, confirmed N.gonorrhoea or Chlamydia refer to GUM clinic Need for urgent scrotal U/S should be made on an individual patient basis. Cefixime 200mg STAT + ofloxacin 400mg bd for 14 days Beta-lactam allergy: monotherapy with ofloxacin 400 mg bd for 14 days  Vaginal candidiasis  HYPERLINK "http://www.bashh.org/guidelines" Guidelines - BASHH  HYPERLINK "http://cks.nice.org.uk/candida-female-genital" Candida - female genital - NICE CKS HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846"HPA Management of abnormal vaginal discharge All topical and oral azoles give 75% cure In pregnancy avoid oral azole - use intravaginal for 7 daysClotrimazole 10% 5g vaginal cream stat OR Clotrimazole 500mg pessary stat OR Fluconazole 150mg orally stat Pregnancy: Clotrimazole 100mg pessary at night x 6 nights Miconazole 2% cream 5g intravaginally BD x 7 daysBacterial vaginosis HYPERLINK "http://www.bashh.org/guidelines"BASHH  HYPERLINK "http://cks.nice.org.uk/bacterial-vaginosis" Bacterial vaginosis - NICE CKS HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846"HPA Management of abnormal vaginal discharge  Oral metronidazole (MTZ) is as effective as topical but cheaper Less relapse with 7 day than 2g stat at 4 weeks Pregnant/breast feeding: avoid 2g stat Treating partner(s) does not reduce relapse Metronidazole 400mg BD for 7 days or 2g stat  Metronidazole 0.75% vaginal gel 5g applicatorful at night x 5 nights OR Clindamycin 2% cream 5g applicator full at night for 7 days  Trichomoniasis HYPERLINK "http://www.bashh.org/guidelines"BASHH HYPERLINK "http://cks.nice.org.uk/trichomoniasis"Trichomoniasis - NICE CKS HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846"HPA Management of abnormal vaginal discharge Ideally, refer all patients to open access GUM service for treatment, contact screening and investigation for further STIs. Metronidazole 400mg BD for 5 - 7 days OR Metronidazole 2g in a single dose (Avoid single dose regimen in pregnancy or breastfeeding) OR Clotrimazole 100mg pessary at night for 6 nights (Gives symptomatic relief - not cure).Pelvic Inflammatory Disease (PID) HYPERLINK "http://www.bashh.org/guidelines"BASHH HYPERLINK "http://www.rcog.org.uk/womens-health/guidelines"RCOG HYPERLINK "http://cks.nice.org.uk/pelvic-inflammatory-disease"pelvic-inflammatory-disease - NICE CKS Refer woman and contacts to GUM clinic. Essential to test for Chlamydia and N. gonorrhoeae. 28% of gonorrhoea isolates now resistant to quinolones. If gonorrhoea likely (partner has it, severe symptoms, sex abroad) avoid ofloxacin regimen Admit in pregnancy or lactation as primary care antibiotic regimens are not suitableMetronidazole 400mg BD for 14 days PLUS Ofloxacin 400mg BD for 14 days OR if high risk of GC Cefixime 400mg stat PLUS Metronidazole 400mg BD for 14 days PLUS Doxycycline 100mg BD for 14 days  IllnessCommentsFirst LineSecond LineSKIN/SOFT TISSUE INFECTIONSImpetigo  HYPERLINK "http://cks.nice.org.uk/impetigo" Impetigo - NICE CKS As resistance is increasing reserve topical antibiotics for very localised lesions only. For extensive, severe, or bullous impetigo, use oral antibiotics Reserve Mupirocin for MRSA. Flucloxacillin (suspension has unpleasant taste use capsules wherever possible.) 500mg QDS for 7 days * OR (if allergic to penicillin) Clarithromycin 250 500mg BD for 7 days * (for child, consider erythromycin) * Adult doses for children see HYPERLINK \l "APPENDIX1"Appendix 1  Fusidic acid topically TDS for 5 days OR Mupirocin topically TDS for 5 days (for MRSA only) Eczema  HYPERLINK "http://cks.nice.org.uk/eczema-atopic" Eczema - atopic - NICE CKS  Using antibiotics does not improve healing. In absence of visible signs of infection, use of antibiotics (alone or with steroids) encourages resistance. No evidence for use of combined topical antibiotics and steroids. In presence of visible signs of infection use treatment as in impetigo. Visible signs of infection Cellulitis, spreading necrosis Markedly increasing exudate Increasing pain and swelling at eczema sites Cellulitis  HYPERLINK "http://cks.nice.org.uk/cellulitis-acute" Cellulitis - acute - NICE CKS If febrile and ill, consider referral to Home iv service Solihull CCG protocols available at HYPERLINK "http://nww.solihullccg.nhs.uk/index.php/clinical-pathways-solis/cat_view/4-solis/53-clinical-pathways/92-iv-therapy-and-cellulitis"IV therapy and cellulitis Tel: 0121 746 4499 (Solihull Community IV therapy team) or admit for IV treatment If afebrile and otherwise healthy, other than cellulitis, use flucloxacillin alone Discuss with microbiologist where river or sea water exposure Stop clindamycin if diarrhoea occurs Flucloxacillin 500mg 1g QDS * Treatment generally 7 days but if slow response continue for a further 7 days Suspension has unpleasant taste use capsules wherever possible OR (if allergic to penicillin) Clarithromycin 500mg BD * (for child, consider erythromycin) Or Clindamycin 450mg QDS Treatment generally 7 days but if slow response continue for a further 7 days In facial cellulitis Co-amoxiclav 500/125mg TDS * Treatment generally 7 days but if slow response continue for a further 7 days In periorbital cellulitis Admit *Adult doses for children see HYPERLINK \l "APPENDIX1"Appendix 1  MRSA HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947336805"HPA MRSA quick reference guide. For MRSA screening and suppression, see HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947336805"HPA MRSA quick reference guide. For active MRSA infection: Use antibiotic sensitivities to guide treatment, seek advice from microbiologist For queries on colonisation, contact Infection Prevention team Solihull tel 0121 713 8886 If active infection confirmed, antibiotic treatment guided by sensitivities, seek specialist advice. If tetracycline sensitive MRSA strain: Doxycycline 100mg BD for 7 days If severe infection or no response to monotherapy after 48 hours, seek advice from microbiologist PVL HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1242630044068"HPA QRGPanton-Valentine Leukocidin (PVL) is a toxin produced by 2% of S. aureus. Can rarely cause severe invasive infections in healthy people. Send swabs if recurrent boils/abscesses. At risk: close contact in communities or sport; poor hygiene 1CLeg Ulcers HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947348323"HPA QRG  HYPERLINK "http://cks.nice.org.uk/leg-ulcer-venous" Leg ulcer - venous - NICE CKS Diabetic Leg Ulcer Ulcers always colonised. Antibiotics do not improve healing unless active infection. Active infection if cellulitis/increased pain/pyrexia/purulent exudate/odour. If active infection, send pre-treatment swab Review antibiotics after culture results If active infection: Flucloxacillin 500mg QDS OR Clarithromycin 500mg BD for 7 days but if slow response continue for further 7 daysNot all diabetic ulcers should be considered infected. A simple ulcer with exudates does not on its own merit antimicrobial therapy Not infected no cellulitis, no signs of inflammation Mild infection superficial cellulitis <2cm, 2 of the following symptoms of inflammation around ulcer erythema, pain, warmth, induration, Moderate infection cellulitis >2cm, signs of inflammation around ulcer PLUS lymphangitic streaking +/or localised dry gangrene +/or deep tissue involvementRefer for specialist opinion if severe infection Not infected no antibiotics Mild infection Flucloxacillin 1g qds Moderate infection Co-amoxiclav 625mg TDS for 7 days and review (adult dose) Bites Animal Bite  HYPERLINK "http://cks.nice.org.uk/bites-human-and-animal" Bites - human and animal - NICE CKS Human BiteSurgical toilet most important. Assess tetanus and rabies risk. Antibiotic prophylaxis should be given for cat bite/puncture wound; bite involving hand, foot, face, joint, tendon, ligament; immunocompromised, diabetics, elderly, asplenic, cirrhotic Antibiotic prophylaxis is advised. Assess tetanus and HIV/Hep B & C risk discuss with virologist as a matter of urgencyProphylaxis or treatment: Co-amoxiclav 375-625mg TDS for 7 days* OR (If penicillin allergic) Cat/dog/human bite Metronidazole 200-400mg TDS for 7 days* PLUS Doxycycline 100mg BD for 7 days (not for use in pregnancy or lactation) OR Human bite Metronidazole 200 400mg TDS for 7 days * PLUS Clarithromycin 250 500mg BD for 7 days* (for child, consider erythromycin) In all cases review at 24&48 hours * Adult doses for children see HYPERLINK \l "APPENDIX1"Appendix 1  Conjunctivitis  HYPERLINK "http://cks.nice.org.uk/conjunctivitis-infective" Conjunctivitis - infective - NICE CKS  Most bacterial infections are unilateral and self-limiting 65% resolve on placebo by day five. If a sore throat is also present then it is probably a virus and so antibiotics are not indicated. In newborn consider gonococcus, chlamydial or herpetic conjunctivitis - Send bacterial AND viral eye swabs and take history of vaginal discharge or lesions from mother. Infant will require systemic treatment refer to paediatrics and ophthalmology for assessment and treatment Refer mother and partner(s) to GUM for assessment and treatment  Consider delayed prescription If severe: Chloramphenicol 0.5% drops 2 hourly for 2 days then reducing to every four hours whilst awake.. AND Chloramphenicol eye 1% ointment at night. Continue for 48 hours after resolution Scabies  HYPERLINK "http://cks.nice.org.uk/scabies" Scabies - NICE CKS Treat whole body from ear/chin downwards and under nails. If under 2yrs/elderly include scalp & face. Treat all household and sexual contacts within 24h.  Permethrin 5% cream. If allergy: malathion 0.5% aqueous liquid Use TWO applications one week apart Dermatophyte infection - nail  HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726" HPA Fungal Skin and Nail Infections  HYPERLINK "http://cks.nice.org.uk/fungal-nail-infection" http://cks.nice.org.uk/fungal-nail-infection  Take nail clippings: Start therapy only if infection is confirmed by laboratory. Terbinafine is more effective than azoles For infections with yeasts and non-dermatophyte moulds use itraconazole. Liver reactions rare with oral antifungals For children seek specialist advice Terbinafine 250mg OD. 6-12 weeks for fingers and 3-6 months for toes. (adult dose) Itraconazole (Adult dose) 200mg BD for first 7 days of 28 day cycle. Two cycles for fingers. Three cycles for toes.  Superficial only: Amorolfine 5% nail lacquer once or twice weekly.(adult dose) 6 months for fingers and 12 months for toes.Dermatophyte infection of the skin  HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726" HPA Fungal Skin and Nail Infections  HYPERLINK "http://cks.nice.org.uk/fungal-skin-infection-body-and-groin" Fungal skin infection - body and groin - NICE CKS  HYPERLINK "http://cks.nice.org.uk/fungal-skin-infection-foot" Fungal skin infection - foot - NICE CKS  HYPERLINK "http://cks.nice.org.uk/fungal-skin-infection-scalp" Fungal skin infection - scalp - NICE CKSTerbinafine is fungicidal thus shorter treatment time required than with fungistatic imidazoles If candida possible use imidazole If intractable: Take skin scrapings for culture. If infection confirmed, use oral terbinafine/itraconazole Discuss scalp infections with dermatology specialist.Topical terbinafine BD x 1 2 weeks OR (athletes foot only): Topical undecanoates (Mycota) BD for 1 -2 weeks after healing (i.e. for 4-6 weeks)Topical imidazole BD for 1 2 weeks after healing (i..e. for 4 6 weeks) Acne HYPERLINK "http://cks.nice.org.uk/acne-vulgaris" \l "!prescribinginfosub:21"CKS - Acne vulgaris Topical treatments for acne should be used first line (see section 13.6.1 of interface formulary) Co-cyprindiol contains an anti-androgen. It is no more effective than a broad spectrum antibacterial but is useful in women who also wish to receive oral contraception. Oral antibiotics should be reserved for acne if topical treatment is not adequately effective or if it is inappropriate. Minocycline is associated with increased rates of adverse effects compared to other tetracyclines and has no clear evidence of being more effective or better toleratedTopical treatments for acne if not effective or inappropriate Oxytetracycline 500mg bd (not for use in pregnancy or lactation)Doxycycline 100mg od (not for use in pregnancy or lactation) OR Lymecycline 408mg od (not for use in pregnancy or lactation) Third line (reserved for patients not responding to other antibiotics specialist recommendation only) Minocycline MR 100mg od (not for use in pregnancy or lactation)  Varicella zoster/ Chicken pox & Herpes zoster/ Shingles  HYPERLINK "http://cks.nice.org.uk/chickenpox" Chickenpox - NICE CKS  HYPERLINK "http://cks.nice.org.uk/shingles" Shingles - NICE CKS  If pregnant or immunocompromised or neonate: seek urgent specialist advice. Chicken pox: Clinical value of antivirals minimal unless adult with severe pain or dense/oral rash or on steroids or secondary household case or smoker AND treatment started <24h of onset of rash consider aciclovir Shingles: Treat if active ophthalmic, or Ramsay Hunt syndrome, or eczema OR over 50 years and within 72 hrs of onset of rash (post herpetic neuralgia rare if < 50 years)  Where indicated: Aciclovir 800mg five times a day for 7 days * Emphasise importance of compliance with regimen * Adult doses for children see HYPERLINK \l "APPENDIX1"Appendix 1  In exceptional cases only Valaciclovir 1g TDS* OR Famciclovir 250mg TDS* Both for 7 days NOTE: Ten to twenty times cost of aciclovir only use if serious compliance problems in shingles * Adult doses  IllnessCommentsFirst lineSecond line DENTAL INFECTIONS derived from the Scottish Dental Clinical Effectiveness Programme 2011 HYPERLINK "http://www.sdcep.org.uk/index.aspx?o=2334"SDCEP Guidelines This guidance is not designed to be a definitive guide to oral conditions. It is for GPs for the management of acute oral conditions pending being seen by a dentist or dental specialist. GPs should not routinely be involved in dental treatment and, if possible, advice should be sought from the patients dentist, who should have an answer-phone message with details of how to access treatment out-of-hours, or NHS Direct on 0845 4657Mucosal ulceration and inflammation (simple gingivitis)Temporary pain and swelling relief can be attained with saline mouthwash Use antiseptic mouthwash: If more severe & pain limits oral hygiene to treat or prevent secondary infection. The primary cause for mucosal ulceration or inflammation (aphthous ulcers, oral lichen planus, herpes simplex infection, oral cancer) needs to be evaluated and treated.Simple saline mouthwash - tsp salt dissolved in glass warm water Always spit out after use. Use until lesions resolve or less pain allows oral hygieneChlorhexidine 0.12-0.2% (Do not use within 30 mins of toothpaste) - Rinse mouth for 1 minute BD with 5 ml diluted with 5-10 ml water. Hydrogen peroxide 6% (spit out after use) Rinse mouth for 2 mins TDS with 15ml diluted in glass warm water Always spit out after use. Use until lesions resolve or less pain allows oral hygiene Acute necrotising ulcerative gingivitis Commence metronidazole and refer to dentist for scaling and oral hygiene advice Use in combination with antiseptic mouthwash if pain limits oral hygiene Metronidazole 400mg TDS for 3 days Chlorhexidine or hydrogen peroxide (see above dosing in mucosal ulceration). Until oral hygiene possible PericoronitisRefer to dentist for irrigation & debridement. If persistent swelling or systemic symptoms use metronidazole. Use antiseptic mouthwash if pain and trismus limit oral hygieneAmoxicillin 500mg TDS for 3 days Metronidazole 400mg TDS for 3 days Chlorhexidine or hydrogen peroxide see above dosing in mucosal ulceration Until oral hygiene possible Dental abscess Regular analgesia should be first option until a dentist can be seen for urgent drainage, as repeated courses of antibiotics for abscess are not appropriate; Repeated antibiotics alone, without drainage are ineffective in preventing spread of infection. Antibiotics are recommended if there are signs of severe infection, systemic symptoms or high risk of complications. Severe odontogenic infections; defined as cellulitis plus signs of sepsis, difficulty in swallowing, impending airway obstruction, Ludwigs angina. Refer urgently for admission to protect airway, achieve surgical drainage and IV antibiotics The empirical use of cephalosporins, co-amoxiclav, clarithromycin, and clindamycin do not offer any advantage for most dental patients and should only be used if no response to first line drugs when referral is the preferred option.If pus drain by incision, tooth extraction or via root canal. Send pus for microbiology. If spreading infection (lymph node involvement, or systemic signs ie fever or malaise) ADD metronidazole8-10C Amoxicillin 500mg TDS Up to 5 days review at 3d True penicillin allergy: Clarithromycin 500 mg BD Up to 5 days review at 3 days  Severe infection add Metronidazole 400mg TDS  Additional informationCT informationHYPERLINK "http://www.ppa.org.uk/ppa/edt_intro.htm"Drug Tariff References:HYPERLINK "http://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListName/Page/1197637041219"Health Protection Agency: Management of Infection - Guidance for Primary Care HYPERLINK "http://www.bnf.org/bnf/"BNF 64 (Sept 2012) HYPERLINK "http://bnfc.org/bnfc/index.htm"BNF for Children 2013Development GroupDr D Pillay, Dr K Nye, Dr K Struthers, Microbiology, HEFT Dr S Welch, Dept of Paediatrics, HEFT Karen Ennis, Mark Dasgupta, NHS BEN; Kate Arnold, SCT Update May 2013 Dr D Pillay, Rakhi Aggarwal, Bethan Knight, Shahzad Razaq Consultation Dr D Pillay, Dr K Nye, Microbiology, HEFT, & HEFT Antimicrobial committee Dr S Hackett, Dr S Welch, Dept of Paediatrics, HEFT Dr Jenny Short, Consultant ID Physician, HEFT Dr Husam Osman, Consultant Virologist, HEFT ApprovalTrust Antimicrobial Committee, Formulary Working Group, Solihull CCG Drug and Therapeutics Committee; BCCCCG Medicines Management Group APPENDIX 1 Doses for childrenDrugBNFc 2012-13 dosesNotesPhenoxymethylpenicillin 1 month - 1yr 62.5mg QDS 1-6 yrs 125mg QDS 6-12 yrs 250mg QDS >12 yrs 500mg QDS (1g QDS in severe infection) May be increased to 12.5mg/Kg QDS in severe infectionSyrup has unpleasant taste use tablets wherever possible Amoxicillin 1 month - 1 yrs 62.5mg TDS 1- 5yrs 125mg TDS 5 - 18yrs 250mg TDS Dose doubled in community acquired pneumonia or other severe infection.Dose also doubled in salmonellosis or Lyme disease (not featured in this guideline) Flucloxacillin1 month - 2 yrs 62.5 - 125mg QDS 2-10 yrs 125 - 250mg QDS >10yrs 250 - 500mg QDS Suspension has unpleasant taste use capsules where possibleCo-amoxiclav< 1 year Consult BNFc 1 6 years 5ml of 125/31mg suspension TDS 6 12 years 5ml of 250/62mg suspension TDS >12 years 1 x 250/125mg tablet TDS Dose doubled in severe infectionCefalexin1m - 1 yr 125mg BD 1-5 yrs 125mg TDS 5-12 yrs 250mg TDS > 12 years 500mg BD TDS (increased to 1 1.5g 3-4 times daily for severe infection)Erythromycin1m 2yr 125mg QDS 2 8 yr 250mg QDS >8 yr 250 500mg QDS Dose doubled in severe infectionTotal daily dose may be given in two divided dosesClarithromycinChild 1m 12 years dose by bodyweight Body-weight < 8kg 7.5mg/Kg BD Body-weight 8 11 Kg 62.5mg BD Body-weight 12 19Kg 125mg BD Body-weight 20 29Kg 187.5mg BD Body-weight 30 40Kg 250mg BD 12+ years 250mg BD (may be doubled in severe infections for max 14 days)Trimethoprim6 weeks 6 months 25mg BD 6m 6 years 50mg BD 6 12 years 100mg BD 12+ years 200mg BDNitrofurantoin3m 12 years 750 microgram/Kg QDS 12+ 50mg QDS; may be increased up to 100mg QDS in severe chronic recurrent infectionsMetronidazoleConsult BNFcAciclovir Chickenpox and herpes zoster infection Other indications see cBNF1m - 2 years: 200mg QDS for 5 days 2-6 years: 400mg QDS for 5 days 6-12 years: 800mg QDS for 5 days 12+ (Adult dose) 800mg FIVE times daily for 7 days APPENDIX 2 Clinical Prediction rules for Group A beta haemolytic streptococcus in tonsillitisCentor Criteria Ref: Centor RM et al. Med Decision Making 1981; 1 : 239 246 HYPERLINK \l "Sore_throat"Back to acute sore throatAssess History of fever Absence of cough Swollen tender anterior cervical lymph nodes Tonsillar Exudate If none of the above likelihood of GABHS < 3% If 3 of 4 criteria present likelihood of GABHS ca 40% McIsaac Clinical Prediction Rule Ref: McIsaac WJ et al, JAMA 2004; 291:1587-1595 HYPERLINK \l "Sore_throat"Back to acute sore throatAssess and score Temperature > 38 C = 1 point Absence of cough = 1 point Swollen tender anterior cervical lymph nodes = 1 point Tonsillar swelling or exudate = 1 point Age 3 14 years = 1 point 15 44 years = 0 point 45 years or older = subtract 1 point Score Risk of GABHS 0 or <0 1-2.5% 1 5-10% 2 11-17% 3 28-35% 4 51-53%  Infections (secondary care specific) This chapter is under development. Currently only medicines that are specifically subject to a positive NICE TA appear. GreenYellowDouble YellowRed as per NICE TAs5.1.9 Antituberculosis All antituberculosis preparations are classified as RED and should be prescribed by HEFT5.3.1 HIV InfectionTenofovir disoproxilLamivudine5.3.3 Viral hepatitis 5.3.3.1 Chronic hepatitis BEntecavirAdefovir dipivoxil5.3.3.2 Chronic hepatitis cTelaprevir Boceprevir 5.3.5 Respiratory syncytial virus PalivizumabRibavirin Additional information HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA75"NICE TA 75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon HYPERLINK "http://guidance.nice.org.uk/TA96"NICE TA 096 Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a HYPERLINK "http://guidance.nice.org.uk/TA106"NICE TA 106 Hepatitis C - peginterferon alfa and ribavirin  HYPERLINK "http://guidance.nice.org.uk/TA153"NICE TA 153 Hepatitis B - entecavir HYPERLINK "http://guidance.nice.org.uk/TA154"NICE TA 154 Hepatitis B - telbivudine HYPERLINK "http://publications.nice.org.uk/tenofovir-disoproxil-for-the-treatment-of-chronic-hepatitis-b-ta173"NICE TA 173 tenofovir disoproxil - chronic hepatitis B HYPERLINK "http://guidance.nice.org.uk/TA200"NICE TA 200 Hepatitis C - peginterferon alfa and ribavirin  HYPERLINK "http://guidance.nice.org.uk/TA252"NICE TA 252 Hepatitis C (genotype 1) - telaprevir HYPERLINK "http://guidance.nice.org.uk/TA253"NICE TA 253 Hepatitis C (genotype 1) - boceprevir HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT information Endocrine Sytem Drugs used in diabetes Notes on classInsulins Recent discontinuations include Pork Actrapid, Pork Mixtard, Human Monotard, Human Insulatard, Humulin I Devices (syringe/pen/pre-filled pen) should be chosen to suit patient Oral antidiabetics UKPDS study demonstrates compelling evidence for the use of metformin as first line therapy Sulphonylureas are second line therapy Glitazones are indicated in patients unable to tolerate a metformin/sulphonylureas combination or if either element is contra indicated (NICE 2003)  GreenYellowDouble YellowRed6.1.1 Insulins6.1.1.1 Short Acting InsulinsSoluble insulin (e.g. Actrapid Humulin S )Insulin aspartInsulin glulisineInsulin lispro6.1.1.2 Intermediate & Long Acting InsulinsInsulin glargine NICE TA 53Lixisenatide E (Lyxumia )- specialist initiation RICaDDeguldec HEFT diabetologists onlyInsulin detemirNovomix 30 Humalog Mix 6.1.2 Oral antidiabetics6.1.2.1 SulphonylureasGliclazide Glibenclamide A 6.1.2.2 BiguanidesMetformin Metformin M/R C ONLY for patients intolerant of slowly titrated standard release metformin6.1.2.3 Other antidiabeticsRosiglitazone B - Specialist recommendation in line with NICEExenatide D - Specialist Initiation with RICaDPioglitazone -Specialist recommendation - in line with NICELiraglutide Specialist Initiation with RICaD. Maximum formulary dose 1.2mg per day as per NICE TA 203.Nateglinide- Specialist recommendation in line with NICEExenatide M/R injection. Specialist initiation with RICaD NICE TA 248Repaglinide- Specialist recommendation in line with NICEDapagliflozin in line with NICE TA 288 Sitagliptin linagliptin6.1.3 KetoacidosisIV fluidsSoluble insulin6.1.4 HypoglycaemiaGlucagonGlucose 50 %Diazoxide6.1.6 DiagnosticsRefer to local guidelinesAdditional informationDrug specific notesA B C D E Longer acting; avoid in elderly Patients admitted on combination (Avandamet ) will be supplied metformin and rosiglitazone whilst in hospital Prescribing of Metformin M/R is expected to be in the region of 5% of the total of oral diabetic drugs. Medicines Management in Primary and Secondary care will monitor this. For use within licence, following specialist initiation as per NICE guidance. A RICaD must be provided to GPs if they are asked to take over prescribing. HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG87QuickRefGuide.pdf"(NICE CG87 relating to exenatide) Specialist initiation for use in the same circumstances as those applicable to liraglutide in NICE TA 203. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA53"NICE TA 53 Diabetes (types 1 and 2) - long acting insulin analogues  HYPERLINK "http://guidance.nice.org.uk/TA60"NICE TA 60 - Patient education models HYPERLINK "http://guidance.nice.org.uk/CG66"NICE CG 66 Type 2 diabetes HYPERLINK "http://publications.nice.org.uk/type-2-diabetes-cg87"NICE CG 87 Type 2 diabetes - newer agents HYPERLINK "http://guidance.nice.org.uk/TA151"NICE TA 151 Diabetes - insulin pump therapy HYPERLINK "http://guidance.nice.org.uk/TA203"NICE TA 203 Diabetes (type 2) - liraglutide HYPERLINK "http://guidance.nice.org.uk/TA248"NICE TA 248 Diabetes (type 2) - exenatide (prolonged release) HYPERLINK "http://publications.nice.org.uk/dapagliflozin-in-combination-therapy-for-treating-type-2-diabetes-ta288"NICE TA 288 Dapagliflozin in combination therapy for treating type 2 diabetes   HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.npc.nhs.uk/MeReC_Briefings/briefing2003.htm" MEREC: Blood glucose management in type 2 diabetes ;  HYPERLINK "http://www.npc.nhs.uk/MeReC_Briefings/2003/briefing_no_26.pdf" MEREC: Managing CV risk in diabetes  HYPERLINK "http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/endocrine_and_metabolic" Prodigy: Diabetes management seriesPCT informationInsulin Pumps are subject to a commissioning approval HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Thyroid & antithyroid drugs Notes on classCarbimazole is associated with rare cases of neutropenia and agranulocytosis due to bone marrow suppression Patients should be advised to report symptoms suggestive of infection, especially sore throat Blood cell count should be performed if clinical evidence of infection Carbimazole should be stopped if clinical/lab evidence of neutropenia GreenYellowDouble YellowRed6.2.1 Thyroid HormonesLevothyroxine ALiothyronine6.2.2 AntithyroidCarbimazole BPropylthiouracil BAqueous iodine Additional informationDrug specific notesA BStart at 25 micrograms in elderly or in cardiac states and increas by 25 micrograms every 4-6 weeks Regular thyroid function tests required HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/hyperthyroidism" Prodigy: Hyperthyroidism ;  HYPERLINK "http://www.prodigy.nhs.uk/hypothyroidism" Prodigy: HypothyroidismPCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Corticosteroids Notes on classIn Addisons Disease or following adrenalectomy, physiological replacement is achieved with hydrocortisone supplements with fludrocortisone to augment mineralocorticoid effect Glucocorticoid equivalent Prednisolone 5mg a" dexamethasone 750 microgram a" hydrocortisone 20mg a" methylprednisolone 4mg a" triamcinolone 4mg If an equivalent of >7.5mg prednisolone daily long term (>3 months) assess for osteoporosis risk In asthma a two week acute course of 40mg daily of prednisolone or equivalent or less does not need stepping down HYPERLINK "http://www.bnf.org/bnf/bnf/current/100138.htm"BNF - withdrawal of corticosteroids GreenYellowDouble YellowRed6.3.1 Replacement TherapyFludrocortisone6.3.2 GlucocorticoidsHydrocortisoneBetamethasone - parenteralPrednisoloneDexamethasoneMethylprednisolone - parenteralTriamcinolone - parenteral Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Sex hormones Female sex hormones Notes on classNotes on class Heart of England NHS Foundation Trust will usually commence women on a product from the Elleste or Evorel range immediately following hysterectomy. HRT no longer recommended as first choice for prevention of osteoporosis (MHRA) HRT beneficial in quality of life vs risk balance, however, lowest effective dose used for shortest time possible, evaluate every 12 months (Committee on Human Medicines (formerly CSM) <50 yrs do not use for first line treatment of osteoporosis <50 yrs used as first line for premature menopausal symptoms > 50 HRT second line treatment should be considered HRT increases risk of venous thromboembolism, stroke and endometrial and breast cancer  HYPERLINK "http://www.bnf.org/bnf/bnf/current/100039.htm" Hormone replacement therapy: British National Formulary Evidence suggests transdermal oestrogens do not produce the same degree of favourable alterations of lipoprotein cholesterol levels as oral oestrogens. However, oral therapy can raise triglyceride levels. Transdermal therapy may be appropriate in patients with hypertension, gall bladder disease, hypertriglyceridaemia, oral intoleranceGreenYellowDouble YellowRed6.4.1.1 Oestrogens and HRTOral Combination ProductsPrempak C APremique cycleElleste-Duet Femoston Oral Oestrogen OnlyConjugated oestrogens (Premarin )Estradiol (Elleste-Solo ) Period-Free Combination (Estradiol/Norethisterone) (B)Premique Premique low dose Femoston-Conti Kliovance  Transdermal Oestrogen Only When oral therapy inappropriateEstradot when oral therapy inappropriateEvorel - when oral therapy inappropriateFemSeven - when oral therapy inappropriateTransdermal CombinationWhen oral therapy inappropriateEvra - Double yellow for women for whom neither an oral preparation nor a long acting reversible contraceptive technology is appropriateEvorel Sequi- when oral therapy inappropriateEvorel Conti when oral therapy inappropriateOtherTiboloneRaloxifene D6.4.1.2 ProgestogensNorethisterone CUlipristal acetate ( Esmya ) ESCA EMirena - intra-uterine systemDuphaston HRT Heart of England NHS Foundation Trust will usually commence women on a product from the Elleste or Evorel range immediately following hysterectomy. Additional informationDrug specific notesA B C D EStart with one month to ensure patient suitability, discussion of risks vs benefits essential Suitable for post menopausal, non-hysterectomised women who have not had natural period for at least one year Tranexamic acid is the first line treatment for menorrhagia, progestogens relatively ineffective, still useful to delay menses (start 3 days before period due) Raloxifene is indicated as second line for secondary prevention of osteoporotic fractures For use as per licence for pre-operative treatment of fibroids. HEFT to supply first month and ESCA and the GP to provide the further 2 months supply.  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA087"NICE TA 087 Osteoporosis - secondary prevention (bisphosphonates, raloxifene and teriparatide)  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Male sex hormones GreenYellowDouble YellowRedFinasteride ADutasteride when finasteride has failed or is contraindicatedTestosterone undecanoate capsules specialist recommendation onlyTestosterone implants BNebido injectionCyproterone acetateTestosterone 2% gel (Tostran 10mg metered application 60g multidose dispenser) Additional informationDrug specific notesA BOnly effective in men with enlarged prostates >40ml; useful in benign prostatic hyperplasia if alpha blockers not tolerated Transdermal formulations not currently on formulary HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/" Hypothalamic and pituitary hormones and anti-oestrogens GreenYellowDouble Yellow as per NICE TAsRed6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogensAnti-oestrogensClomifene citrate (clomiphene)Anterior Pituitary HormonesSomatropinTetracosactide (tetracosactrin)Chorionic gonadotrophin (human chorionic gonadotrophin HCG) Human menopausal gonadotrophinsHypothalmic HormonesGonadorelin ( gonadatrophin releasing hormone GnRH, LH-RH)Protirelin (thyrotrophin-releasing hormone TRH)Corticorelin diagnostic use only6.5.2 Posterior pituitary hormones and antagonistsPosterior pituitary hormonesDesmopressinArgipressin (synthetic vasopressin)TerlipressinAntidiuretic Hormone AntagonistsDemeclocycline (unlicensed)Tolvaptan AAdditional informationDrug specific notesATEMPORARILY added to the red section of the formulary. It will be available only to consultants specialising in either diabetes and endocrinology, renal medicine and biochemistry.Tolvaptan will be available for 5 inpatients or for a period of 6 months (whichever is sooner). Dr Shakher will appraise FWG of the effects it had on the patients treated. FWG will then review the position of tolvaptan on the formulary. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA64"NICE TA 064 - Growth hormone deficiency in adults -somatropin HYPERLINK "http://www.nice.org.uk/nicemedia/live/12992/48724/48724.pdf"NICE TA 188 Growth hormone deficiency in children - somatropinDrugs affecting bone metabolism Notes on classNICE Guidance specifies alendronic acid/risedronate as first line for secondary prevention of fractures People at risk of osteoporosis need to maintain an adequate intake of calcium and vitamin D; vitamin D dosage should be 800iu per day GreenYellowDouble YellowRedAlendronic acid A C Risedronate A Ibandronic acid 50mg ESCADisodium pamidronateEtidronate A Sodium clodronate ESCA (HaematologyZoledronic acid (Aclasta and Zometa ) - D Strontium ranelate B Teriparatide Denosumab (Prolia) NICE TA 204Denosumab (Xgeva ) NICE TA 265 Additional informationDrug specific notesA B C DTablets must be taken on rising, swallowed whole with a full glass of water, 30 minutes before food. Patient must remain upright for 30 minutes post dose For treatment of postmenopausal osteoporosis for women who can not tolerate or comply with bisphosphonate therapy Available generically and should be used first line where appropriate Zometa For the treatment of Pagets bone disease in patients for whom the use of a bisphosphonate is appropriate OR Aclasta The treatment of osteoporosis in post-menopausal women at increased risk of fractures who are unsuitable for or unable to tolerate oral treatment options for osteoporosis. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA087"NICE TA 087 Osteoporosis - secondary prevention (bisphosphonates, raloxifene and teriparatide) HYPERLINK "http://guidance.nice.org.uk/TA160"NICE TA 160 Osteoporosis - primary prevention HYPERLINK "http://guidance.nice.org.uk/TA204"NICE TA 204 Osteoporotic fractures - denosumab  HYPERLINK "http://guidance.nice.org.uk/TA265"NICE TA 265 Bone metastases from solid tumours - denosumab HYPERLINK "http://guidance.nice.org.uk/TA161"NICE TA 161 Osteoporosis - secondary prevention including strontium ranelate  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.prodigy.nhs.uk/osteoporosis_treatment_and_prevention_of_fragility_fractures" Prodigy: Osteoporosis: Treatment and prevention of fragility fracturesPCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Other endocrine drugs GreenYellowDouble YellowRed6.7.1 Bromocriptine and Other Dopaminergic DrugsCabergoline (specialist recommendation)Quinagolide specialist initiation6.7.2 Drugs affecting gonadotrophinsBuserelin (Suprefact) Goserelin (Zoladex ) - for endometreosis or breast cancer Goserelin - for assisted conception Danazol specialist recommendation benign fibrocystic breast diseaseDanazol hereditary angiodema (off label)Leuprorelin (Prostap) Buserelin- for assisted conception 6.7.3 Metyrapone and trilostaneTrilostane (specialist initiation)6.7.4 SomatomedinsMecasermin (Increlex) Specialist paediatricians only for named patients only GreenYellowDouble YellowRedUnlicensedStanozolol hereditary angiodemaDehydroepiandosterone Endocrinology only Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance Cabergoline, is appropriate for Primary Care prescribing after confirmation of hyperprolactinaemia by specialist Obstetrics, gynaecology and urinary-tract disorders Drugs used in obstetrics Notes on class GreenYellowDouble YellowRed7.1.1 Prostaglandins and oxytocicsCarboprostDinoprostoneErgometrine maleateOxytocinSyntometrineMisoprostol (off label)7.1.1.1 Ductus arteriosusIndometacin (indomethacin) Indocid PDA Alprostadil7.1.2 MifepristoneMifepristone7.1.3 MyometrialAtosibanSalbutamolAdditional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://publications.nice.org.uk/induction-of-labour-cg70"NICE CG 70 induction of labour CG70 Treatment of vaginal and vulval conditions Notes on class GreenYellowDouble YellowRed7.2.1 Preparations for vaginal atrophyEstradiol (Vagifem vaginal tablets and Estring )Estriol (Ovestin and Ortho-Gynest 7.2.2 Vaginal and vulval infections Clotrimazole ADalacin Econazole pessariesMiconazoleZidoval Nystatin pessaries (unlicensed)Amphotericin in KY jelly (unlicensed)Amphotericin + flucytosine in KY jelly (unlicensed)Boric acid pessaries (unlicensed) Additional informationDrug specific notesA All formulations HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Contraceptives Notes on classThere is an increased risk of venous thromboembolic disease (particularly during the first year) in users of oral contraceptives but this risk is considerably smaller than that associated with pregnancy (about 60 cases of venous thromboembolic disease per 100000 pregnancies). In all cases the risk of venous thromboembolism increases with age and in the presence of other risk factors for venous thromboembolism (e.g. obesity). The risk of venous thromboembolism with transdermal patches is not yet known. The incidence of venous thromboembolism in healthy, non-pregnant women who are not taking an oral contraceptive is about 5 cases per 100000 women per year. For those using combined oral contraceptives containing second-generation progestogens e.g. levonorgestrel, this incidence is about 15 per 100000 women per year of use. Some studies have reported a greater risk of venous thromboembolism in women using preparations containing the third-generation progestogens desogestrel and gestodene; the incidence in these women is about 25 per 100000 women per year of use.7.3.1 Combined hormonal contraceptivesGreenYellowDouble YellowRedLow dose preparationsLoestrin 20 (norethisterone acetate 1mg ethinyloestradiol 20 micrograms)Mercilon (desogestrel 150 micrograms, ethinyloestradiol 20 micrograms)Femodette (gestodene 75 micrograms, ethinyloestradiol 20 micrograms)Standard Dose PreparationsMicrogynon 30 (ethinyloestradiol 30 micrograms, levonorgestrel 150 micrograms)Marvelon (ethinyloestradiol 30 micrograms, desogesterol 150 micrograms) AFemodene (gestodene 75 micrograms, ethinyloestradiol 30 micrograms) A Cilest (norgestimate 250 micrograms ethinyloestradiol 35 micrograms) ALoestrin 30 (norethisterone acetate 1.5mg, ethinylestradiol 30micrograms) 7.3.2 Progestogen only contraceptives 7.3.2.1 Oral Progestogen-only contraceptivesMicronor (norethisterone 350micrograms)Femulen (etynodiol diacetate 500 micrograms) for heavy bleedingCerazette (desogestrel 75 micrograms) -for younger women, previous ectopic pregnancy or >70kg Noriday (norethisterone 350 micrograms) - for older women or whilst breast feedingNorgeston (levonorgestrel 30 micrograms) 7.3.2.2 Parenteral Progesterone only Preparations Etonogestrel implant 68mg (Implanon )  Medroxyprogesterone acetate 150mg 7.3.2.3 Intra-uterine progesteroneMirena (releasing 20 micrograms levonorgestrel in 24 hours) 7.3.5 Emergency Hormonal ContraceptionLevonorgestrel 1.5mgUlipristal acetate (EllaOne) B Additional informationDrug specific notesA BThe progestogens desogestrel, drospirenone, and gestodene (in combination with ethinylestradiol) may be considered for women who have side-effects (such as acne, headache, depression, weight gain, breast symptoms, and breakthrough bleeding) with other progestogens. However, women should be advised that desogestrel and gestodene have also been associated with an increased risk of venous thromboembolism As an option for women who have has unprotected intercourse between 72 and 120 hours previously who do not wish the fitting of a copper-bearing intrauterine device or for whom it is not possible to fit a copper-bearing intrauterine device. Women presenting within 72 hours of unprotected intercourse who do not wish the fitting of a copper-bearing intrauterine device should be offered levonelle.  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=CG030"NICE CG 30 The effective and appropriate use of long-acting reversible contraceptionPCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs for genito-urinary disorders GreenYellowDouble YellowRed7.4.1 Drugs for urinary retentionTamsulosin AAlfuzosin (specialist initiation) BAlfuzosin (off-label) to ease passing of renal stonesDistigmine bromideAlfuzosin MR specialist initiation7.4.2 Drugs for urinary frequency, enuresis and incontinenceOxybutyninOxybutynin XL Oxybutynin patches (Kentera) specialist recommendationAmitriptyline (off-label)TolteridineTolteridine XL Imipramine (off-label)Trospium XLDesmopressin (off-label)Mirabegron (Betmiga ) Darifenacin 7.4.3 Drugs used in urological painRefer to BNF for preps7.4.4 Bladder instillations and urological surgeryChlorhexidinexe "Chlorhexidine"Cystistat Dimethyl sulphoxidexe "Dimethyl sulphoxide"Uracyst Glycinexe "Glycine"Sodium chloridexe "Sodium Chloride"Sodium citrate solutionxe "Sodium Citrate Solution"7.4.5 Drugs for erectile dysfunction DSildenafil DPapaverine DTadalafil CDAlprostadil Additional informationDrug specific notesA B C DFlomaxtra was launched at the patent expiry of its predecessor Flomax. Prescribers are advised to prescribe tamsulosin capsules For two to three days post catheterisation and one day post removal Tadalafil daily dosing is considered appropriate for men experiencing sexual activity on two or more occasions per week who have previously responded to on demand PDE5I treatment. Not prescribable at SHH or BHH. Now available as a generic preparation HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://webarchive.nationalarchives.gov.uk/20130107105354/http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012086.pdf"Health Service Circular 1999/148 treatment of impotence HYPERLINK "C:\\Documents and Settings\\emis2000\\Local Settings\\Temporary Internet Files\\Content.IE5\\IYFS8QJU\\NICE TA 290 - overactive bladder - Mirabegron"NICE TA 290 - overactive bladder - Mirabegron HYPERLINK "http://publications.nice.org.uk/urinary-incontinence-cg171"NICE CG171 Urinary incontinence  Malignant disease and immunosuppression Cytotoxic drugs Notes on classNotes on class The chemotherapy of cancer is complex and should be confined to specialists in oncology/haematology. All chemotherapy drugs cause side-effects and a balance has to be struck between likely benefit and acceptable toxicity 8.1 Cytotoxic drugs Double YellowRedDexrazoxane for suspected anthracycline extravasation. Use as per HEFT policyCalcium folinate (folinic acid/calcium leucovorin) Double YellowRed as per NICE TAs where they exist (or via other specific formal agreement e.g. IFR)8.1.1 Alkylating drugsCyclophosphamide(oral) ESCABendamustineCyclophosphamide 8.1.2 Cytotoxic metabolitesPegylated liposomal doxorubicin hydrochloride8.1.3 AntimetabolitesMethotrexate ESCAGemcitabine Fludarabine Capecitabine Tegafur with uracil PemetrexedFluorouracil Azacitidine Double YellowRed as per NICE TAs where they exist (or via other specific formal agreement e.g. IFR)8.1.4 Vinca alkaloids and etoposideVinorelbine 8.1.5 Other neoplastic drugsBevacizumab Off label use only for DMO CBortezomib CetuximabCisplatinDasatinibDocetaxel ErlotinibGefitinib Imatinib IpilimumabIrinotecanLapatinibHydroxycarbamide ESCA - for myeloproliferative disordersNilotinibOxaliplatin Paclitaxel PazopanibSunitinibTemozolomide TopotecanTrabectedinTrastuzumab Vemurafenib Additional information HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA23"NICE TA 023 Brain Cancer - temozolomide  HYPERLINK "http://guidance.nice.org.uk/TA25"NICE TA 025 - Pancreatic cancer - gemcitabine HYPERLINK "http://guidance.nice.org.uk/TA29"NICE TA 029 - Leukaemia (lymphocytic) - fludarabine HYPERLINK "http://guidance.nice.org.uk/TA34"NICE TA 034 Breast cancer - trastuzumab HYPERLINK "http://publications.nice.org.uk/guidance-on-the-use-of-paclitaxel-in-the-treatment-of-ovarian-cancer-ta55"NICE TA 055 Ovarian Cancer - paclitaxel HYPERLINK "http://guidance.nice.org.uk/TA61"NICE TA 061 - colorectal cancer - capecitabine and tegafur uracil HYPERLINK "http://guidance.nice.org.uk/TA70"NICE TA 070 -Leukaemia (chronic myeloid) - imatinib HYPERLINK "http://guidance.nice.org.uk/TA86"NICE TA 086 - Gastrointestinal stromal tumours - imatinib  HYPERLINK "http://guidance.nice.org.uk/TA91"NICE TA 091 - Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan HYPERLINK "http://guidance.nice.org.uk/TA99"NICE TA 99 Renal transplantation - immunosuppressive regimens for children and adolescents HYPERLINK "http://guidance.nice.org.uk/TA100"NICE TA 100 Colon cancer (adjuvant) - capecitabine and oxaliplatin  HYPERLINK "http://guidance.nice.org.uk/TA101"NICE TA 101 Prostate cancer (hormone-refractory) - docetaxel HYPERLINK "http://guidance.nice.org.uk/TA107"NICE TA 107 Breast cancer (early) - trastuzumab HYPERLINK "http://guidance.nice.org.uk/TA108"NICE TA 108 Breast cancer (early) - paclitaxel HYPERLINK "http://guidance.nice.org.uk/TA109"NICE TA 109 Breast cancer (early) - docetaxel HYPERLINK "http://guidance.nice.org.uk/TA116"NICE TA 116 Breast cancer - gemcitabine  HYPERLINK "http://guidance.nice.org.uk/TA118"NICE TA 118 coloectal cancer (metastatic) - bevacizumab and cetuximab (partially updated by TA242) HYPERLINK "http://guidance.nice.org.uk/TA119"NICE TA 119 Leukaemia (lymphocytic) - fludarabine  HYPERLINK "http://guidance.nice.org.uk/TA121"NICE TA 121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (Glioma is not treated at HEFT, but patients would be suitably referred) HYPERLINK "http://guidance.nice.org.uk/TA124"NICE TA 124 Lung cancer (non-small-cell) - pemetrexed HYPERLINK "http://guidance.nice.org.uk/TA129"NICE TA 129 Multiple myeloma - bortezomib  HYPERLINK "http://guidance.nice.org.uk/TA135"NICE TA 135 Mesothelioma - pemetrexed disodium HYPERLINK "http://guidance.nice.org.uk/TA145"NICE TA 145 Head and neck cancer - cetuximab HYPERLINK "http://guidance.nice.org.uk/TA162"NICE TA 162 Lung cancer (non-small-cell) - erlotinib HYPERLINK "http://guidance.nice.org.uk/TA169"NICE TA 169 Renal cell carcinoma (advanced/metastatic) - sunitinib HYPERLINK "http://guidance.nice.org.uk/TA172"NICE TA 172 Head and neck cancer (squamous cell carcinoma) - cetuximab HYPERLINK "http://guidance.nice.org.uk/TA176"NICE TA 176 Colorectal cancer (first line) - cetuximab HYPERLINK "http://guidance.nice.org.uk/TA178"NICE TA 178 bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma HYPERLINK "previous%20versions"NICE TA 179 Gastrointestinal stromal tumours - sunitinib HYPERLINK "http://guidance.nice.org.uk/TA181"NICE TA 181 Lung cancer (non-small-cell, first line treatment) - pemetrexed HYPERLINK "http://guidance.nice.org.uk/TA183"NICE TA 183 Cervical cancer (recurrent) - topotecan HYPERLINK "previous%20versions"NICE TA 184 Lung cancer (small-cell) - topotecan HYPERLINK "http://guidance.nice.org.uk/TA185"NICE TA 185 Soft tissue sarcoma - trabectedin HYPERLINK "http://guidance.nice.org.uk/TA189"NICE TA 189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) HYPERLINK "http://guidance.nice.org.uk/TA190"NICE TA 190 Lung cancer (non-small-cell) - pemetrexed (maintenance) HYPERLINK "http://guidance.nice.org.uk/TA191"NICE TA 191 Gastric cancer (advanced) - capecitabine HYPERLINK "http://guidance.nice.org.uk/TA192"NICE TA 192 Lung cancer (non-small-cell, first line) - gefitinib HYPERLINK "http://guidance.nice.org.uk/TA196"NICE TA 196 Gastrointestinal stromal tumours - imatinib (adjuvant) HYPERLINK "http://guidance.nice.org.uk/TA208"NICE TA 208 Gastric cancer (HER2-positive metastatic) - trastuzumab  HYPERLINK "http://guidance.nice.org.uk/TA209"NICE TA 209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib HYPERLINK "http://guidance.nice.org.uk/TA189"NICE TA 189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) HYPERLINK "http://guidance.nice.org.uk/TA190"NICE TA 190 Lung cancer (non-small-cell) - pemetrexed (maintenance) HYPERLINK "http://guidance.nice.org.uk/TA191"NICE TA 191 Gastric cancer (advanced) - capecitabine HYPERLINK "http://guidance.nice.org.uk/TA192"NICE TA 192 Lung cancer (non-small-cell, first line) - gefitinib HYPERLINK "http://guidance.nice.org.uk/TA193"NICE TA 193 Leukaemia (chronic lymphocytic, relapsed) - rituximab  NICE TA 196 Gastrointestinal stromal tumours - imatinib (adjuvant) HYPERLINK "http://guidance.nice.org.uk/TA208"NICE TA 208 Gastric cancer (HER2-positive metastatic) - trastuzumab HYPERLINK "http://guidance.nice.org.uk/TA209"NICE TA 209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib HYPERLINK "http://guidance.nice.org.uk/TA212"NICE TA 212 Colorectal cancer (metastatic) - bevacizumab HYPERLINK "http://guidance.nice.org.uk/TA214"NICE TA 214 Breast cancer - bevacizumab (in combination with a taxane) HYPERLINK "http://guidance.nice.org.uk/TA215"NICE TA 215 Renal cell carcinoma (first line metastatic) - pazopanib  HYPERLINK "http://guidance.nice.org.uk/TA216"NICE TA 216 Leukaemia (lymphocytic) - bendamustine HYPERLINK "http://guidance.nice.org.uk/TA218"NICE TA 218 Myelodysplastic syndromes - azacitidine HYPERLINK "http://guidance.nice.org.uk/TA219"NICE TA 219 Everolimus for the second-line treatment of advanced renal cell carcinoma HYPERLINK "http://guidance.nice.org.uk/TA222"NICE TA 222 Ovarian cancer (relapsed) - trabectedin HYPERLINK "http://guidance.nice.org.uk/TA227"NICE TA 227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) HYPERLINK "http://guidance.nice.org.uk/TA228"NICE TA 228 Multiple myeloma (first line) - bortezomib and thalidomide HYPERLINK "http://guidance.nice.org.uk/TA241"NICE TA 241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) HYPERLINK "http://guidance.nice.org.uk/TA242"NICE TA 242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) HYPERLINK "http://guidance.nice.org.uk/TA243"NICE TA 243 Follicular lymphoma - rituximab HYPERLINK "http://guidance.nice.org.uk/TA250"NICE TA 250 Breast cancer (advanced) - eribulin HYPERLINK "http://guidance.nice.org.uk/TA251"NICE TA 251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib  HYPERLINK "http://guidance.nice.org.uk/TA255"NICE TA 255 Prostate cancer - cabazitaxel HYPERLINK "http://guidance.nice.org.uk/TA257"NICE TA 257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) HYPERLINK "http://guidance.nice.org.uk/TA258"NICE TA 258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) HYPERLINK "http://guidance.nice.org.uk/TA263"NICE TA 263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer HYPERLINK "http://guidance.nice.org.uk/TA268"NICE TA 268 Melanoma (stage III or IV) - ipilimumab HYPERLINK "http://guidance.nice.org.uk/TA269"NICE TA 269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib HYPERLINK "http://publications.nice.org.uk/crizotinib-for-previously-treated-non-small-cell-lung-cancer-associated-with-an-anaplastic-lymphoma-ta296"NICE TA 296 previously treated non small cell lung cancer - crizotinib HYPERLINK "http://publications.nice.org.uk/everolimus-in-combination-with-exemestane-for-treating-advanced-her2-negative-ta295"NICE TA 295 negative appraisal everolimus in combination with exemestane for treating advanced her2 negative HYPERLINK "http://guidance.nice.org.uk/TA26"NICE CG 024 Lung cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine  HYPERLINK "http://www.nice.org.uk/nicemedia/live/11778/43308/43308.pdf"NICE CG 081 Advanced Breast Cancer HYPERLINK "http://guidance.nice.org.uk/CG131"NICE CG 131 Colorectal cancer HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationCFor the treatment of diabetic macular odema (only) in patients that have a) Failed laser treatment with gradual reduction of vision or b) Involvement of central macula by DME where laser is risky. Each patient may have up to three injections per affected eye as is clinically appropriate. This must be performed as a day case in theatre. NB Primary Care will not fund the drug cost or the day case fee (Sept 10) These drugs are excluded from PbR HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs affecting the immune response GreenYellowDouble Yellow as per NICE TAs where they existRed as per NICE TAs where they exist (or via other specific formal agreement e.g. IFR)8.2.1 Antiproliferative immunosuppressantsAzathioprineMycophenolate 8.2.2 Corticosteroids and other immunosuppressantsCiclosporinTacrolimus A Sirolimus 8.2.3 Rituximab & alemtuzumabRituximabAlemtuzumab8.2.4 Other immunomodulating drugsBCG Bladder instillationPeginterferon alfaThalidomide Mifamurtide Lenalidomide Interferon alfaInterferon betaInterferon gamma 8.2 continued Drugs affecting the immune response Additional informationDrug specific notesAThere are two formulations of tacrolimus which are not interchangeable Please prescribe by brand HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceRituximab for follicular NHL (March 2002) Rituximab for aggressive NHL (Sept 2003) HYPERLINK "http://guidance.nice.org.uk/TA32"NICE TA 032 - beta interferon and glatiramer acetate (not recommended MS)TA32) HYPERLINK "http://guidance.nice.org.uk/TA85"NICE TA 085 - Renal transplantation - immunosuppressive regimens (adults) (basiliximab, daclizumab are indicated in the acute period post operatively this is not applicable at HEFT as transplants are not undertaken) HYPERLINK "http://guidance.nice.org.uk/TA65"NICE TA 065 Non hodgkin's lymphoma HYPERLINK "http://guidance.nice.org.uk/TA99"NICE TA 099 - Renal transplantation - immunosuppressive regimens for children and adolescents HYPERLINK "http://guidance.nice.org.uk/TA106"NICE TA 106 Hepatitis C - peginterferon alfa and ribavirin  HYPERLINK "http://guidance.nice.org.uk/TA127"NICE TA 127 Multiple sclerosis - natalizumab (Multiple sclerosis is not a specialty represented at HEFT) HYPERLINK "http://guidance.nice.org.uk/TA137"NICE TA 137 Lymphoma (follicular non-Hodgkin's) - rituximab HYPERLINK "http://guidance.nice.org.uk/TA171"NICE TA 171 Multiple myeloma - lenalidomide HYPERLINK "http://guidance.nice.org.uk/TA174"NICE TA 174 Leukaemia (chronic lymphocytic, first line) - rituximab HYPERLINK "http://guidance.nice.org.uk/TA193"NICE TA 193 Leukaemia (chronic lymphocytic, relapsed) - rituximab  HYPERLINK "http://guidance.nice.org.uk/TA200"NICE TA 200 Hepatitis C - peginterferon alfa and ribavirin HYPERLINK "http://guidance.nice.org.uk/TA202"NICE TA 202 Chronic lymphocytic leukaemia - ofatumumab HYPERLINK "http://guidance.nice.org.uk/TA226"NICE TA 226 Lymphoma (follicular non-Hodgkin's) - rituximab HYPERLINK "http://guidance.nice.org.uk/TA228"NICE TA 228 Multiple myeloma (first line) - bortezomib and thalidomide HYPERLINK "previous%20versions"NICE TA 235 Osteosarcoma - mifamurtide HYPERLINK "http://guidance.nice.org.uk/TA243"NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma HYPERLINK "http://guidance.nice.org.uk/TA254"NICE TA 254 Multiple sclerosis (relapsing-remitting) - fingolimod (Multiple sclerosis is not a specialty represented at HEFT) HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Sex hormones and hormone antagonists for malignant disease GreenYellowDouble YellowRedOestrogensDiethylstilboestrol (Consultant Initiation)8.3.2 ProgestogensMedroxyprogesterone acetateMesgesterol 8.3.3 Androgens ( none used)8.3.4 Hormone antagonists8.3.4.1 Breast cancerGreenYellowDouble Yellow (as per NICE TAs where they exist)Red as per NICE TAs where they existTamoxifenAnastrozole ESCA Exemestane ESCA Letrozole ESCA 8.3.4.2 Prostrate cancer and gonadorelin analoguesCyproteroneGoserelin (First line parenteral)Bicalutamide Abiraterone Leuprorelin (Second line parenteral)Flutamide ESCA8.3.4.3 Somatostatin analoguesOctreotide A Lanreotide A Additional informationDrug specific notesAPalliative care use only off label use. Specialist prescribing through Cancer Network HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://guidance.nice.org.uk/TA112"NICE TA 112 Breast cancer (early) - hormonal treatments  HYPERLINK "http://guidance.nice.org.uk/TA239"NICE TA 239 Breast cancer (metastatic) - fulvestrant HYPERLINK "http://guidance.nice.org.uk/TA259"NICE TA 259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy) HYPERLINK "http://guidance.nice.org.uk/TA272"NICE TA 272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance MTRAC guidance (1998; archived) advises against prescribing either octreotide or lanreotide  9.Nutrition 9.1 Anaemias and some blood disorders GreenYellowDouble YellowRed9.1.1 Iron-deficiency anaemias9.1.1.1 Oral ironFerrous sulphateFerrous fumarate liquid (Fersamal )Sodium feredetate (Sytron ) for paediatricsFerrous gluconate if patient intolerant of sulphate Ferrous fumarate9.1.1.2 Parenteral ironIron dextran (CosmoFer )Iron sucrose ( Venofer )Iron isomaltoside (Monofer) B Feric carboxymaltose (Ferinject ) Gastro, Haematology and Renal only9.1.2 Drugs used in megaloblastic anaemiasHydroxocobalamin injection Cyanobalamin oral preparations, for dietary vitamin B12 deficiency. (Non- NHS prescribable in primary care unless endorsed SLS)Folic acid9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias *EpoetinDarbepoetin alfaDesferrioxamine mesilate (desferoxamine mesilate)DeferiproneDeferasirox AMicera Aranesp 9.1.4 Drugs used in platelet disordersAnagrelideRomiplostimEltrombopag - NICE TA 2939.1.5 G6PD deficiency for drugs to avoid or used with caution consult the BNF9.1.6 Drugs used in neutropeniaFilgrastimLenograstimPegfilgrastimAdditional informationDrug specific notes A BModified release preparations of iron are licensed for once daily dosage but have no therapeutic advantage and should not be used. Compound preparations there is no justification for the inclusion of other ingredients such as the B group of vitamins (except folic acid for pregnant women) For patients where desferrioxamine has proved inadequate or the patient cant tolerate or fails to respond to deferiprone To treat iron deficiency in pregnant women whose Hb falls below 10.5g/dl during the 2nd and 3rd trimester and post delivery patients who have failed to respond or tolerate standard oral treatment due to moderate or severe intolerance or poor absorption of oral preparations For high risk situations such as severe anaemia (Hb<7.0) post 36 weeks gestation or at an increased risk of bleeding e.g. placenta previa and patients who refuse blood transfusion where oral iron response would be too slow HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA48"NICE TA 48 - home versus hospital haemodialysis HYPERLINK "http://guidance.nice.org.uk/TA142"NICE TA 142 Anaemia (cancer-treatment induced) - erythropoietin (alfa and beta) and darbepoetin HYPERLINK "http://guidance.nice.org.uk/TA221"NICE TA 221 Thrombocytopenic purpura - romiplostim HYPERLINK "http://publications.nice.org.uk/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-ta293"NICE TA 293 - thrombocyctopenic pupura - eltrombopag  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT information* Patients treated at HEFT or UHB funding transferred to specialist. GPs should refer any request to prescribe back to the hospital Patients treated at BCH or other providers GP prescribing under ESCA HYPERLINK "http://www.drugtariff.co.uk/"  9.2.2Fluids and electrolytes GreenYellowDouble YellowRed9.2.1 Oral preparations for fluid and electrolyte imbalance9.2.1.1 Oral potassiumPotassium chloridePotassium removalCalcium Resonium Resonium A 9.2.1.2 Oral sodium and waterSodium chloride MR specialist recommendationSodium chloride 1mmol/l oral solutionOral rehydration salts (ORS)9.2.1.3 Oral bicarbonateSodium bicarbonate9.2.2 Parenteral preparations for fluid and electrolyte imbalance9.2.2.1 Electrolytes and waterSodium chlorideSodium chloride/glucose infusionGlucoseHartmanns solutionWater for injectionsPotassium chloride infusionsSodium bicarbonate9.2.2.2 Plasma and plasma substitutesDextran 40 Dextran 70 Gelofusine Etherified starch Volulyte Voluven (if Volulyte unavailable)Gelaspan Geloplasma  Additional information HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA74"NICE TA 74 - Trauma Fluid replacement therapy  9.3 Intravenous nutrition Notes on classNotes on class All patients who require parenteral nutrition must be referred to the Parenteral Nutrition Team. For patients who require home care, arrangements for discharge must be made as early as possible. Basic regimes are stocked for emergencies but wherever possible treatment must be tailored to the needs of the patient. These regimens are required to be ordered specially and may take a few days to arrive. 9.4 Oral Nutrition- Sip Feeds Notes on classNotes on class The use of sip feeds should usually only be considered when food boosting dietary measures alone have failed to improve nutritional intake or status after 4 weeks. The community nutritional screening tool (below) should be used to identify patients who need food boosting dietary measures ACBS. In certain clinical conditions some foods may have the characteristics of drugs and ACBS advises as to the circumstances in which such foods may be regarded as drugs and so can be prescribed in the NHS. Prescriptions should be endorsed ACBS. Refer to appendix 7 in the BNF. The ACBS approved categories for prescribing sip feeds are; Shortbowel syndrome, Intractable malabsorption, Pre-operative preparation of patients who are malnourished, Proven inflammatory bowel disease, Total gastrectomy, Dysphagia and Disease related malnutrition (this can incorporate a range of conditions and is open to interpretation) Full details of the appropriate use of sip feeds can be found in the HYPERLINK "http://www.solihull-pct.nhs.uk/foi/policies_clinical.asp"SCT Guidelines for The Use of Sip Feeds  GreenYellowDouble YellowRedFood Boosting Dietary Measures (see below)Fortisip BottleScandishake MixFortisip MultifibreCalogenFortijuceFortisip Yogurt StyleFortisip Extra (Protein)Fortimel AForticreme AFortisip Fruit Dessert A Additional informationMain Aspects of Food Boosting Dietary Measures. See  HYPERLINK "http://www.solihull-pct.nhs.uk/foi/policies_clinical.asp" SCT Guidelines for The Use of Sip Feeds for further details Use at least one pint of full fat milk each day Little and often have nourishing snacks or drinks between meals and a snack supper before bed Enrich food and drinks such as cereals, milk puddings, canned fruit, potatoes, soups and vegetables with cream, butter, margarine, cheese, evaporated milk or sugar Drink more milk based drinks e.g. milky coffee, malted milk, hot chocolate and milkshakes Encourage full fat, high sugar varieties to provide more calories instead of low fat, low sugar products Food Boosters Leaflets are available from the Nutrition Support Service, Freshfields: (01564) 732803 and available on the SCT intranet from January 2009 This leaflet is not suitable for special diets e.g. people with diabetes or for people who require modified textures e.g. soft, pured or liquid foodsDrug specific notes The use of sip feeds needs regular monitoring and they should only be used for an appropriate amount of time. Initial prescription should be for one weeks supply and marked mixed flavours Solihull Care Trust has a contract via the HPC with Nutricia. A rebate is made on Nutricia products that are prescribed on an FP10 prescription. A Dessert like sip feeds should not be used on a regular basis. These may be appropriate for patients with swallowing difficulties. Patients should be encouraged to follow food boosting advice and have real desserts.  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/guidance/index.jsp?action=byID&o=10978"NICE GC 32 Nutrition Support in AdultsPCT informationHYPERLINK "http://www.solihull-pct.nhs.uk/foi/policies_clinical.asp"SCT Guidelines for The Use of Sip Feeds The guidelines are a result of collaboration between the Nutritional Support Service and Medicines Management. They include a nutritional screening tool which identifies patients at risk of malnutrition and then a course of action once this risk has been identified.  HYPERLINK "http://www.drugtariff.co.uk/"  See below for summary of the community nutritional screening tool and oral nutritional support flow chart. COMMUNITY NUTRITIONAL SCREENING TOOL Select one score from each Criterion then add together for total score Criterion 1: Visual Assessment of Body Weight- use body mass index (BMI) if height and weight are available) Criterion 2: Unintentional Weight LossCriterion 3: Problem with intake of Food and FluidsVisually, weight is acceptable (or BMI > 20) Score: 0 Visually, thin (or BMI 18.5 20) Score: 1 Visually, very thin (or BMI < 18.5) Score: 3 No weight loss Score: 0 36 kg within 12 months ( - 1 stone) Score: 2 > 6kg within 12 months ( > 1 stone) Score: 3 > 3kg within 3 months (> stone) Score: 3No problems Score: 0 Some problems with intake of food & fluids for > 3 days Score: 1 Severe problems with intake of food & fluid for > 3 days Score: 3 ScoreAction Required0No further action required 1-2Monitor weight where possible/repeat screening tool in 4 weeks 3+Patient potentially malnourished or at risk of malnutrition Food Boosting Dietary Measures required- refer to Food Booster Leaflet See Oral Nutritional Support Flow Chart below ORAL NUTRITIONAL SUPPORT FLOW CHART                     9.5 Minerals GreenYellowDouble YellowRed9.5.1 Calcium and magnesium9.5.1.1 Calcium supplementsAdcal-D3 preparationsCalcium Sandoz specialist recommendation (paeds) for children on milk-free diets or for endocrine/renal use post parathyroidectomyCalcium gluconate injectionCalcium chloride injection9.5.1.2 Hypercalcaemia and hypercalciuriaCinacalcet renal directorate NICE TA 117 9.5.1.3 MagnesiumMagnesium glycerophosphate (unlicensed) specialist initiation and stabilisationMagnesium sulphate injection9.5.2 Phosphorus9.5.1.2 Phosphorus supplementsPotassium acid phosphateJoulies phosphate solution - paediatricsPhosphate-Sandoz Addiphos 9.5.2.2 Phosphate-binding agents Aluminium hydroxide specialist recommendationPatients established on therapy prior to 31/3/13 will continue to receive treatment under an ESCA Patients starting therapy on 1/04/13 or later will receive treatment at HEF (via specialised commissioning)Calcium salts specialist recommendationSevelamer ESCA Sevelamer Osvaren - specialist recommendationLanthanum ESCA Lanthanum 9.5.3 Fluoride9.5.4 ZincZinc sulphate Additional information HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA117"NICE TA 117 Hyperparathyroidism - cinacalcet  9.6 Vitamins GreenYellowDouble YellowRed9.6.1 Vitamin AVitamins A & D specialist recommendation Vitamin A drops paediatric directorate only (unlicensed)9.6.2 Vitamin B groupThiaminePabrinex injectionPyridoxineNicotinamide - unlicensedVitamin B Compound StrongVigranon B 9.6.3 Vitamin CAscorbic acid9.6.4 Vitamin DCalcichew D3 Forte Colecalciferol drops specialist recommendationParicalcitol renal directorateCalcichew D3 AlfacalcidolVitamin D (colecalciferol) 800 units (Fultium and Desunin )9.6.5 Vitamin EAlpha tocopheryl acetate capsules CF patients onlyVitamin E suspension9.6.6 Vitamin KMenadiol sodium phosphatePhytomenadione 9.6.7 Multivitamin preparationson recommendation of gastroenterologist or dieticianForceval soluble prevention of re-feeding syndrome as per HEFT guidelines on recommendation of clinical nutrition team. Also post bariatric surgery patients (that as a result of complications or delays in progression from liquid diet cannot tolerate vitamin supplementation tablets/capsules form and will need a soluble vitamin supplement beyond 10 days and possibly for the duration of their in-patient stay). Vitamin A.B,C and D dropsKetovite MultivitaminsForceval 9.7 Bitters and tonics GreenYellowDouble YellowRed 9.8 Drugs used in metabolic disorders Notes on classNotes on class BNF may be consulted for a list of drugs unsafe for use in acute porphyrias GreenYellowDouble YellowRed9.8.1 Drugs used in metabolic disordersPenicillamine For Wilsons disease (with ESCA)ArginineCarnitine for canite deficiency (paediatric directorate only)Mercaptamine (cysteamine) Sodium phenylbutyrateSodium benzoate9.8.2 Acute porphyriasHaem arginate Musculoskeletal and joint diseases Drugs used in rheumatic diseases and gout 10.1.1 Non Steroidal anti-inflammatory drugs Notes on classFor ALL NSAIDs use lowest dose of least toxic agent for shortest duration Assess GI, CV and renal risk, monitor regularly  HYPERLINK "http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2025040&ssTargetNodeId=221" Safety of selective and non-selective NSAIDs: MHRA Oct 06 GreenYellowDouble YellowRedIbuprofenDiclofenac B, CEtodolac DNaproxenCelecoxib ASulindac in renal impariment onlyMefenamic acid (for dysmenorrhoea)Meloxicam Indometacin (indomethacin)Aspirin B Additional informationDrug specific notesA B C DCelecoxib is associated with fewer GI effects over the shorter term. Contraindicated in CV disease See NICE CG 59 and CG 79 Gastro-intestinal discomfort or nausea, ulceration with occult bleeding common with anti-inflammatory doses There are no proven benefits to using enteric coated aspirin CV risk comparable with coxibs: see HYPERLINK "http://www.npc.co.uk/MeReC_Extra/2008/pdfs/MeReC_Extra_No30.pdf"MeReC_Extra_No30 See NICE CG 59 and CG 79 HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf"NICE CG 59 Osteoarthritis HYPERLINK "http://www.nice.org.uk/nicemedia/live/12131/43329/43329.pdf"NICE CG 79 Rheumatoid Arthritis HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationThere is poor outcome evidence for meloxicam. HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  10.1.2 Local corticosteroids Notes on class GreenYellowDouble YellowRedTriamcinolone acetonideMethylprednisolone acetateMethylprednisolone acetate with lidocaine (lignocaine) Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs which suppress the rheumatic disease process Notes on classEfaluzimab -Marketing authorisation was withdrawn by EMA after publication of TA103. GreenYellowDouble YellowRed as per NICE TAs where they exist Methotrexate ESCA A Adalimumab Ciclosporin ESCA Infliximab Penicillamine ESCA Etanercept Sulfasalazine ESCA Certolizumab Sodium aurothiomalate ESCATocilizumab (Rheumatology only)Leflunomide ESCA Golimumab Hydroxychloroquine Abatacept Azathioprine ESCA BRituximab Additional informationDrug specific notesA BShould only be prescribed as 2.5mg tablets (National Patient Safety Agency) ESCAs for Gastroenterological, rheumatological and dermatological conditions Azathioprine ESCA available for the treatment of patients with unresponsive chronically active Crohns disease, resistant or frequently relapsing cases of Crohns disease or Ulcerative colitis and as second-line treatment for fistulating Crohns disease and continued as maintenance (all unlicensed indications. However an established therapy in these conditions) and autoimmune hepatitis (licensed indication)  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA35"NICE TA 035 - Arthritis (juvenile idiopathic) - etanercept  HYPERLINK "http://guidance.nice.org.uk/TA130"NICE TA 130 Rheumatoid arthritis - adalimumab, etanercept and infliximab HYPERLINK "http://guidance.nice.org.uk/TA143"NICE TA 143 Ankylosing spondylitis - adalimumab, etanercept and infliximab HYPERLINK "http://guidance.nice.org.uk/TA186"NICE TA 186 Rheumatoid arthritis - certolizumab pegol HYPERLINK "http://publications.nice.org.uk/adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-ta195"NICE TA 195 adalimumab etanercept infliximab rituximab and abatacept for the treatment of rheumatoid athritis after the failure of a TNF inhibitor HYPERLINK "http://www.nice.org.uk/nicemedia/live/13110/50424/50424.pdf"NICE TA 199 Etanercept, infliximab and adalimumab for treatment of psoriatic arthritis HYPERLINK "http://guidance.nice.org.uk/TA220"NICE TA 220 Psoriatic arthritis - golimumab HYPERLINK "http://guidance.nice.org.uk/TA233"NICE TA 223 Ankylosing spondylitis - golimumab HYPERLINK "http://guidance.nice.org.uk/TA225"NICE TA 225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab HYPERLINK "http://publications.nice.org.uk/abatacept-for-treating-rheumatoid-arthritis-after-the-failure-of-conventional-disease-modifying-ta280"NICE TA 280 Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234)  HYPERLINK "http://guidance.nice.org.uk/TA238"NICE TA 238 Arthritis (juvenile idiopathic, systemic) - tocilizumab HYPERLINK "http://publications.nice.org.uk/tocilizumab-for-the-treatment-of-rheumatoid-arthritis-rapid-review-of-technology-appraisal-guidance-ta247"NICE TA 247 Tocilizumab for the treatment of rheumatoid arthritis  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationEnhanced services in place for monitoring HYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Gout and cytotoxic induced hyperuricaemia Notes on class GreenYellowDouble YellowRedAllopurinolFebuxostat - in line with NICE TA 164 Probenecid - prevention of nephrotoxicity associated with some anti-infective agentsColchicineRasburicase Onc and Haem Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA164"NICE TA 164 Hyperuricaemia - febuxostat HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs used in neuromuscular disorders Drugs which enhance neuromuscular transmission Notes on class GreenYellowDouble YellowRedPyridostigmine bromide (specialist recommendation)Edrophonium chloride (diagnostic)NeostigmineDistigmine Skeletal muscle relaxants GreenYellowDouble YellowRedBaclofenTizanidine specialist initiation and stabilisationDantroleneDiazepamQuinine sulphate Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  Drugs for the relief of soft tissue inflammation Enzymes GreenYellowDouble YellowRedCollagenase Clostridium (Xiapex) A Additional informationDrug specific notesARestricted to use as an alternative to limited fasciectomy in adult patients with Dupuytrens contracture of moderate severity (as defined by the British Society for Surgery of the Hand (BSSH), with a palpable cord and up to two affected joints per hand, who are suitable for limited fasciectomy, but for whom percutaneous needle fasciotomy is not considered a suitable treatment option. And in line with Procedures of Limited Clinical Value commissioning policy. This states treatment of moderate to severe is appropriate where patients meet either of the following criteria: moderate metacarpo-phalangeal joint contracture (greater than 30 degrees ). any proximal inter-phalangeal joint contracture. First web contracture The above eligibility criteria is in line with the BSSH - The British Society for Surgery of the Hand - Evidence for Surgical Treatment Dupuytren s Disease.  HYPERLINK "http://www.bssh.ac.uk/education/guidelines/dd_guidelines.pdf" http://www.bssh.ac.uk/education/guidelines/dd_guidelines.pdf  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Rubifacients and other topical antirheumatics GreenYellowDouble YellowRedAlgesal Ibuprofen gel ATransvasin creamCapsaicin cream Additional informationDrug specific notesATopical NSAIDs should be considered ahead of oral NSAIDs, COX-2 inhibitors. Be aware of systemic absorption.  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11926"NICE CG 59 Oesteoarthritis HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT information HYPERLINK "http://www.drugtariff.co.uk/"  Miscellaneous GreenYellowDouble YellowRed Eye Anti-infective eye preparations Notes on classPreservative free preparations are only indicated where there is demonstrable clinical need GreenYellowDouble YellowRed11.3.1 AntibacterialsChloramphenicol BFusidic Acid AGentamicin 0.3% drops- ophthalmologist recommendation when sensitivity confirmedCiprofloxacin for corneal ulcersCefuroxime 5% drops (unlicensed) Ophthalmologists onlyOfloxacin ophthalmologist initiationNeomycin sulphate 0.5% drops and ointment neonates onlyPenicillin 5000 units in 1ml eye drops (unlicensed) ophthalmologists only 11.3.2 Antifungals C11.3.3 AntiviralAciclovir (acyclovir) 3% eye ointment for herpes simplexTrifluorothymidine drops  Additional informationDrug specific notesA BUseful in staphylococcal infections Broad spectrum and treatment of choice for superficial eye infections HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Corticosteroids and other anti-inflammatory preparations Notes on classOcular corticosteroids are associated with serious long term adverse effects and their use should be under specialist supervision Prodigy recommend against GPs starting corticosteroids for ophthalmic conditions unless they have access to a slit lamp and the necessary expertise For some chronic conditions e.g. uveitis, patients may be required to use steroid eye drops in the longer term under the advice and continuing review of a specialist. Long-term use is not covered by the licences for these eye drops, so the risks and benefits should be carefully considered and discussed with the patient before use. There is no stated limit for steroid eye drop use (in terms of days/weeks), it would seem sensible to ensure all patients using a corticosteroid eye drop receive regular reviews regarding its use. Therapy started for acute conditions should be stopped once the course is completed. Therapy for chronic conditions should be under the advice and continuing review of a specialist. GreenYellowDouble YellowRed11.4.1 CorticosteroidsBetamethasone 0.1% drops B Short term only unless ophthalmologist recommendationMaxitrol drops and ointmentDexamethasone intravitreal implant NICE TAG 229Dexamethasone 0.1% drops Short term only unless ophthalmologist recommendationPrednisolone 0.5% drops ophthalmologists recommendationLoteprednol Etabonate 0.5% Eye DropsPrednisolone 1% drops ophthalmologist recommendationRimexolone drops ophthalmologist recommendation Fluorometholone drops Short term only - ophthalmologist only 11.4.2 Other anti-inflammatories Sodium cromoglicate (sodium cromoglycate) 2% dropsAntazoline sulphate (with xylometazoline) drops Olopatadine C  Additional informationDrug specific notesA B CBNF states that use of combination products is rarely justified SPCs state that after more prolonged treatment (over 6 to 8 weeks), the drops should be withdrawn slowly to avoid relapse. For children with severe allergic eye disease when compliance with the more frequent dosage schedule of the other agents is an issue and treatment with sodium nedocromil has failed HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA229"NICE TA 229 Macular oedema (retinal vein occlusion) - dexamethasone HYPERLINK "http://guidance.nice.org.uk/TA271"NICE TA 271 Diabetic macular oedema - fluocinolone acetonide intravitreal implantPCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Mydriatics and cycloplegics Notes on class GreenYellowDouble YellowRedAtropine sulphate 0.5% drops - Ophthalmologist recommendationPhenylephrine hydrochloride drops For clinic/practice use, not prescribableAtropine 1% ointment - Ophthalmologist recommendationTropicamide drops For clinic/practice use, not prescribable Cyclopentolate hydrochloride drops - Ophthalmologist recommendation Treatment of glaucoma Notes on classAll treatments for glaucoma should be hospital initiated GreenYellowDouble YellowRedBeta Blockers (A)Timolol drops Betaxolol dropsCarteolol drops DuoTrav Prostaglandin analoguesLatanoprost dropsTravaprost drops Xalacom drops Tafluprost preservative free drops B SympathomimeticsBrimonidine 0.5% dropsCarbonic anhydrase inhibitors and systemic drugsAcetazolamide oral Brinzolamide dropsDorzolamide 2% drops Cosopt - dropsMioticsPilocarpine drops and ophthalmic gel Additional informationDrug specific notesA BBeta blockers should not be used in patients with asthma or a history of obstructive airways disease unless no alternative treatment is available For use within licence for those patients requiring a preservative free preparationPCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/" Local anaesthetics Notes on classThese are obtainable for clinical practice; not prescribable GreenYellowDouble YellowRedFor clinic/practice use, not prescribableOxybuprocaine hydrochloride (benoxinate) dropsLignocaine and fluorescein dropsTetracaine hydrochloride drops (amethocaine hydrochloride)Proxymetacaine hydrochlorideProxymetacaine hydrochloride and fluorescein Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Miscellaneous ophthalmic preparations GreenYellowDouble YellowRed11.8.1 Preparations For Tear DeficiencyHypromellose dropsViscotears liquid gel single dose units for patients that can not tolerate preservativesAcetylcysteine 5% eye drops 5% eye drops (Euronac) Unlicensed AGelTears Celluvisc drops - for patients that can not tolerate preservativesSodium Hyaluronate Viscoelastic (CIMA OCU+1.4% (OcuPlus ) Lacri-Lube Artificial Tears drops for patients that can not tolerate preservativesSno Tears Sodium hyaluronate eye drops ophthalmologist initiation Simple eye ointment yellow soft paraffinSodium Chloride 0.9% drops11.8.2 Ocular Diagnostic and Perioperative PreparationsApraclonidine drops Ophthalmologist initiationFluorescein sodium drops For clinic/practice use, not prescribable Diclofenac sodium drops Ophthalmologist initiationRose Bengal drops For clinic/practice use, not prescribable Ketorolac trometamol Ophthalmologist initiationAcetylcholine chloride solution for intra-ocular irrigation Ophthalmologists onlyRanibizumab - NICE TA 155, TA 274 and TA 283 Ocriplasmin NICE TA 297Aflibercept NICE TA 294Additional informationDrug specific notesAUnlicensed product manufactured in France. It has a shelf life of 15 days once opened  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA68"NICE TA 068 Macular degeneration (age related) photodynamic therapy HYPERLINK "http://guidance.nice.org.uk/TA155"NICE TA 155 Macular degeneration (age-related) - ranibizumab and pegaptanib  HYPERLINK "http://guidance.nice.org.uk/TA274"NICE TA 274 Macular oedema (diabetic) - ranibizumab HYPERLINK "http://publications.nice.org.uk/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-ta283"NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion  HYPERLINK "http://publications.nice.org.uk/ocriplasmin-for-treating-vitreomacular-traction-ta297"NICE TA 297 treating vitreomacular traction - Ocriplasmin HYPERLINK "http://publications.nice.org.uk/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration-ta294"NICE TA 294 age realted macular odema - aflibercept Miscellanous GreenYellowDouble YellowRed5FU dropsBalanced salt solution Sodium chloride 5% dropsCiclosporin (cyclosporin)Mitomycin dropsEthylenediaminetetraacetic acid (EDTA) 0.37% dropsHyaluronidase 1500 units Ear, Nose and oropharynx Drugs acting on the ear Notes on classInflammatory reaction of skin, usually responds to gentle syringing or dry mopping. Most effective treatment is ribbon gauze soaked in corticosteroid eardrops. Exclude perforation before using topical amino glycosides (risk deafness). Committee on Human Medicines (formerly CSM ) warning: topical aminoglycosides are contraindicated in patients with tympanic perforation Products containing anti-bacterials should be used for up to a week to prevent fungal complications which require specialist treatment GreenYellowDouble YellowRed12.1.1 Otitis externaAnti-inflammatory preparationsSingle agent preparationsBetamethasone sodium phosphatePrednisolone sodium phosphate Predsol Compound preparationsBetamethasone sodium phosphate with neomycin (Vista-methasone N )Dexamethasone with neomycin and glacial acetic acid (Otomize ) Prednisolone with neomycin (Predsol N ) Hydrocortisone with gentamicin (Gentisone HC ) specialist receommendation. Not for use in tympanic perforationFlumetasone with clioquinol (Locorten-Vioform )Tri-Adcortyl OTIC specialist recommendationSofradex Anti-infective preparationsClotrimazole solutionCiprofloxacin 0.3% drops Specialist recommendation (off label of eye drops) Unlicensed Aluminium acetate 13% drops12.1.2 Otitis MediaRefer to antimicrobial formulary12.1.3 Removal of waxOlive oilSodium bicarbonate 5% ear drops GreenYellowDouble YellowRedUnlicenced (medical device)Otovent balloons specialist recommendation Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs acting on the nose GreenYellowDouble YellowRed12.2.1 Drugs used in nasal allergyBeclometasonexe "Beclomethasone" (beclomethasone) dipropionate nasal preparationsFluticasonexe "Fluticasone" furoate nasal spray(Avamys ) BFluticasone furoate nasal drops for use post operativelyBetamethasonexe "Betamethasone" sodium phosphate nasal preparationsFluticasonexe "Fluticasone" propionate (Flixonase naslules ) Nasal polypsBudesonide nasal sprayMometasone for use in Children only (Nasonex ) B12.2.2 Topical nasal decongestantsSodium chloride 0.9% dropsEphedrine hydrochloride 0.5% and 1% drops. C12.2.3 Anti infective nasal preparationsMupirocin 2% nasal ointment - (Bactroban) (A)Bismuth subnitrate and iodoform Chlorhexidinexe "Chlorhexidine" plus neomycin (Naseptin cream)12.2.4 Other nasalSodium chloride nasal drops Additional informationDrug specific notesA B CFor methicillin resistant strains No evidence to demonstrate superior efficacy over beclomethasone Short term use only efficacy limited HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Drugs acting on the oropharynx Notes on class GreenYellowDouble YellowRed12.3.1 Drugs for oral ulceration and inflammationCholine salicylate dental gelBenzydamine hydrochloride Orabase paste Adcortyl in Orabase 12.3.2 Oropharyngeal anti-infective drugsAmphotericin lozenges and suspensionMiconazole oral gelNystatin pastilles and suspension12.3.3 lozenges and spraysBenzydamine hydrochloride spray12.3.4 Mouthwashes, gargles and dentifricesChlorhexidine gluconate 0.2% as mouthwash12.3.5 Treatment of dry mouthGlandosane spray ASalivix pastilles AOral balance oral gel A Additional informationDrug specific notesA Endorse ACBS in primary care HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance HYPERLINK "http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON044014"MHRA alert ref Choline salicylate in under 16s PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Skin Emollients Notes on classShould be applied frequently as effects are short-lived. Preparations containing an antibacterial should be avoided unless infection is present or a frequent complication Generally the best emollient will have a high lipid content,, which is lowest in lotions, intermediate in creams and highest in ointments i.e. the greasier the emollient the better it is. However, it is important to remember that emollient choice for an individual patient involves consideration of patient preference, other ingredients (does it contain potential allergens) and cost. GreenYellowDouble YellowRed13.2.1 EmollientsAqueous creamOilatum cream Emulsifying ointmentDiprobase cream White soft paraffin Doublebase gel Yellow soft paraffinUnguentum M cream Liquid paraffin/ white soft paraffin 50/50Hydromol cream Hydromol ointment Cetraben emollient cream Hydrous ointment BP E45 cream (contains lanolin)Dermol 500 lotion (contains antimicrobials)Epaderm ointment (contains lanolin)Dermol 200 shower emollient (contains antimicrobials)Aquadrate cream (contains urea)Balneum Plus cream (contains urea) Calmurid cream (contains urea) Eucerin (contains urea)   13.2.1.1 Emollient Bath AdditivesOilatum emollient bath additive (contains wool fat)Dermol 600 (contains antimicrobials) Oilatum fragrance free (contains wool fat)Aveeno colloidal bath additive Cetraben bath additiveOilatum Plus bath additive Balneum bath oil Aveeno Bath oil Balneum Plus EmulsidermHydromol 13.2.2 Barrier preparationsZinc and castor oil ointment (contains peanut oil)Metanium ointment SprilonConotrane creamSudocrem cream - Paediatrics only Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Topical local anaesthetics and antipruritics Notes on class GreenYellowDouble YellowRedCalamine lotion do not use on insect stings Crotamiton cream (pruritis after scabies)Doxepin hydrochloride cream . (Caution possible systemic effects) Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Topical corticosteroids Notes on classTopical corticosteroids are contra-indicated in rosacea Notes: Apply once or twice daily. Max quantities per week for an adult: Face/Neck 15-30g Both legs 100g Both arms 30-60g Scalp 15-30g Both hands 15-30g Trunk 100g Groins 15-30g Formulation depends on lesion/site; cream is better for moist weepy lesions. Ointment useful for scaly, lichenfied areas. Occlusion increases absorption (+side effects) use only on thick skin in short term Patients receiving regular topical steroids should be reviewed regularly. GPs should ensure patients are told about potential side effects and are advised that this advice, together with frequency of usage is documented in patients notes.  GreenYellowDouble YellowRedMildHydrocortisone 0.5% and 1%Moderately potentClobetasone butyrate 0.05% (Eumovate )Haelan Tape Specialist recommendation Alclometasone cream and ointment (Modrasone ) Betamethasone 0.025% (Betnovate RD) PotentBetamethasone 0.1% (Betnovate )Beclometasone dipropionate (beclomethasone dipropionate) cream ointment and scalp applicationBetacap scalp applicationHydrocortisone butyrate cream, lipocream, ointment and scalp lotion Mometasone furoate cream, ointment and scalp lotion Diflucortolone valerate 0.1% oily cream Very potentClobetasol propionate (Dermovate ) cream ointment & scalp application (for short term treatment max 4 weeks)Diflucortolone valerate 0.3% oily cream (short term treatment of severe exacerbations only)  Additional informationDrug specific notesRequesting a topical steroid to be diluted is not recommended and is expensive. Prescribe a less potent steroid HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA81"NICE TA 81 - Atopic dermatitis - topical steroids  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  GreenYellowDouble YellowRedWith AntifungalDaktacort A (hydrocortisone 1%, miconazole nitrate 2%)Nystaform-HC cream ACanestenHC A (clotrimazole 1%, hydrocortisone 1%)Lotriderm cream C With antibacterialVioform-Hydrocortisone A E (clioquinol 3%, hydrocortisone 1%)Locoid C cream and ointment C Ebetamethasone 0.1%, clioquinol 3% C EFuciBet C E (betamethasone 0.1%, fusidic acid 2%)Other compound preparationsEurax -Hydrocortisone cream ACalmurid HC cream BWith antibacterial and antifungalTimodine A (nystatin 100,000u per g, hydrocortisone 0.5%, dimethicone 10%)Trimovate B (clobetasone butyrate 0.05%, nystatin 100,000u per g, oxytetracycline 3%)With salicylic acidDiprosalic B(betamethasone 0.05%, salicylic acid 3%)Additional informationDrug specific notesA B C D ESteroid potency mild Steroid potency moderately potent Steroid potency potent Steroid potency-very potent Visibly infected eczema should be treated with oral antibiotics. Topical antimicrobial/corticosteroid combinations have been shown to be no more effective than topical corticosteroid alone in treating either visibly infected or uninfected flare-ups HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://www.nice.nhs.uk/page.aspx?o=TA081"NICE TA 81 Atopic dermatitis topical steroids HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  HYPERLINK "http://www.cks.library.nhs.uk/eczema_atopic/in_depth/management_issues" Prodigy guidance on combined topical steroid/antibacterial preparations Preparations for Eczema and psoriasis GreenYellowDouble YellowRedCalcipotriol cream, ointment and scalp solution ACalcitriol ointment Acitretin Dermatologists and paediatricians onlyCoal Tar preparations (proprietary e.g. Exorex lotion & Polytar Emollient bath additive (contains peanut oil)Tazarotene gel Alitretinoin - Dermatologists only in line with HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/TA177Guidance.pdf"NICE TA 177 Dithrocream cream Tacalcitol (face and flexures) Micanol 3% cream Dovobet ointment A B 4 weeks therapy only. Specialist initiation. Maximum 15g per day or 100g per week Alphosyl HC cream (contains wool fat)Coal tar specials - (see Specials section) Sebco ointmentDovobet Gel for use on scalp and or body Zinc and salicylic acid paste  13.5.3 Drugs affecting the immune responseGreenYellowDouble YellowRedTacrolimus ointment Specialist recommendation Methotrexate specialist initiation and stabilisation, then suitable for GP prescribing with an ESCA Ustekinumab Dermatologists only in line with HYPERLINK "http://guidance.nice.org.uk/TA180/QuickRefGuide/pdf/English"NICE TA 180 Pimecrolimus cream Specialist recommendation Ciclosporin - specialist initiation and stabilisationInfliximab EtanerceptAdalimumab Additional informationDrug specific notesAMaximum 100g in one weekBUse for four weeks and then assess. Subsequent courses repeated after an interval of at least 4 weeks. Continuous use is not recommended due to the possibly of skin atrophy HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA82"NICE TA 082 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus NICE TA 103 - Psoriasis - efalizumab and etanercept HYPERLINK "http://guidance.nice.org.uk/TA134"NICE TA 134 Psoriasis - infliximab  HYPERLINK "http://guidance.nice.org.uk/TA146"NICE TA 146 Psoriasis - adalimumab HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/TA177Guidance.pdf"NICE TA 177 for the treatment of severe chronic hand eczema HYPERLINK "http://www.nice.org.uk/nicemedia/live/12235/45464/45464.pdf"NICE TA 180 Treatment of adults with moderate to severe psoriasis with ustekinumab HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Acne and rosacea 13.6.1 Topical preparations for acneGreenYellowDouble YellowRedAzelaic acid creamDalacin T ABenzoyl peroxideDuac 4% gel A Adapalene Avoid in pregnancyBenzamycin gel A Isotretinoin 0.05% gel Avoid in pregnancyNicotinamide 4% gelTretinoin preparations (Retin- A ) B Avoid in pregnancy 13.6.2 Oral preparations for acne (see also antimicrobial formulary for oral preparations)GreenYellowDouble YellowRedCo-cyprindiol (Dianette ) C Trimethoprim Specialist initiation off label use Clindamycin specialist initiationIsotretinoin- Dermatologists only. Contraindicated in pregnancyOxytetracyclineDoxycylineRifampicin specialist initiation Erythromycin LymecyclineMinocycline  Additional informationDrug specific notesA B CBNF No 51 Topical antibiotics are probably best reserved for patients who wish to avoid oral antibacterials or who cannot tolerate them To avoid antibiotic resistance: where possible use non-antibiotic antimicrobials such as benzoyl peroxide avoid concomitant treatment with different oral and topical antibiotics if a particular antibiotic is effective, use it for repeat courses if needed. (short intervening courses of a topical antibacterial such as benzoyl peroxide may eliminate any resistant propionibacteria) Useful for comedonal acne  HYPERLINK "http://www.bnf.org/bnf/bnf/current/19966.htm" CSM guidance on hormone treatment for acne HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance Prodigy guidance  HYPERLINK "http://www.cks.library.nhs.uk/Acne_vulgaris/In_depth/Background_information" Acne vulgarisPCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Preparations for warts and calluses GreenYellowDouble YellowRedSpecialist InitiationFormaldehyde solution 10%Glutaraldehyde 10% solutionImiquimod 5% creamSalicylic acid (Verrugon Occlusal Salactol )Podophyllotoxin ( Warticon and Warticon Fem )Silver nitrate applicators (40%,75% and 95%)  Sunscreens and camouflagers GreenYellowDouble YellowRed13.8.1 Sunscreen preparations Sunsense Ultra lotion Roc Total Sunblock - tinted cream for patients with vitiligoMethyl aminolevulinate cream (Metvix)Uvistat cream and ultrablock creamDiclofenac sodium 3% gel Specialist initiation A.Actikerall BFluorouracil 5% creamIngenol mebutate C13.8.2 CamouflagersVeil - for prescribing in primary care following specialist recommendation (contains wool fat)Dermablend - for prescribing in primary care following specialist recommendation Additional informationDrug specific notesA B CFor patient who have experienced an adverse effect to topical fluorouracil. (Maximum treatment period 90 days. Optimum effect seen 4 weeks after ceasing therapy) As an alternative to fluorouracil 5% cream for patients that have a layer of thick hyperkeratotic skin over the actinic keratosis lesions. Reserved for patients were there is a potential for poor compliance. HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/" 13.9 Shampoos and Other preparations for scalp and hair conditions GreenYellowDouble YellowRedAlphosyl 2 in 1 shampooCapasal shampoo - Selsun shampoo application Polytar plus liquidPolytar liquid (contains peanut oil)TGel shampooKetoconazole 2% shampoo - for seborrhoeic dermatitis and pityriasis versicolor. Primary care prescriptions must be endorsed SLSCeanel Concentrate shampooEflornithine13.10 Anti-infective skin Preparations GreenYellowDouble YellowRed13.10.1.1 Antibacterial preparations only used topicallyFusidic acid 2%Mupirocin 2% cream and ointment For MRSA.Polyfax ointment 13.10.1.2 Antibacterial preparations also used systemically Fusidic acid 2% cream and ointment (ointment contains wool fat)Metronidazole 0.75% gel (Rosex ) Acne rosacea Metronidazole 0.8% gel (Metrotop ) Malodorous tumours and skin ulcers Metronidazole 0.75% (Anabact ) - gel Malodorous tumours and skin ulcers13.10.2 Antifungal preparationsGreenYellowDouble YellowRedClotrimazoleAmorolfine cream and nail lacquer consultant initiation MiconazoleMonphytol paint consultant initiation Terbinafine cream Tioconazole nail solution Ketoconazole creamNystatin cream and ointment 13.10.3 Antiviral preparationsAciclovir 5% cream limited value unless started early13.10.4 Parasitical preparationsMalathionCarbarylDimeticone13.10.5 Preparations for minor cuts and abrasionsMagnesium sulphate pasteCollodion flexible BP not prescribable, to be applied by appropriately trained healthcare professional Dermabond not prescribable, to be applied by appropriately trained healthcare professionalProflavine cream Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Skin Cleansers and antiseptics GreenYellowDouble YellowRed13.11.1 SalineIrriclensSteripodsNormasol sachets13.11.2 ChlorhexidineHibitane Obstetric creamTisept solutionHibiscrub solution13.11.4 IodinePovidone iodine preparations13.11.5 PhenolicsAquasept For MRSA13.11.6 Astringents, oxidisers and dyesHydrogen peroxidePotassium permanganate solution tabletsCrystacide cream Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Antiperspirants GreenYellowDouble YellowRed13.12 AntiperspirantsAluminum salts Topical circulatory preparations GreenYellowDouble YellowRed13.14 Topical circulatory preparationsHeparinoid 0.3% cream Miscellaneous GreenYellowDouble YellowRedBotulinum A Toxin-Haemagglutinin complex For hyperhidrosis of axillae*Depigmenting (tretinoin Manchester Formula) cream Hydroquinone 2% and 4% creamDoxepin 5% creamTrichloroacetic acid 90%Fumaric esters Additional informationDrug specific notes*This is classified as a procedure of low clinical value. See link to Primary Care policy on PLCV below HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidanceHYPERLINK "http://guidance.nice.org.uk/TA260"NICE TA 260 Migraine (chronic) - botulinum toxin type A  HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  HYPERLINK "http://www.solihull.nhs.uk/getmedia/56316432-acb7-4a5c-8a2c-4f2742c70970/Procedures-of-Low-Clinical-Value-Policy-v1.2-Solihull-GP-version11052011(Matt-Formatted).aspx"PLCV Policy   Specials. CompoundsCompoundsCompoundsCompoundsDermovate cream 25% and propylene glycol 40% in Unguentum M Emulsifying ointment 25% in coconut oilSulphur 2% and salicylic acid 2% in Unguentum M Coal Tar preparations Coal Tar preparationsCoal Tar preparationsCoal Tar preparationsCoal tar solution 5% and Betnovate ointment 25% in Unguentum M Coal tar solution 3%, 5% and 6%in yellow soft paraffin Crude coal tar 1 to 10% in yellow soft paraffinDithranolDithranolDithranolDithranolDithranol 0.1%, 0.25%, 0.5% 1%, 2%, and 5% in yellow soft paraffin or zinc and salicylic acid pasteOtherOtherOtherOtherSalicylic acid 2%, 10% and 20% in white soft paraffinMenthol 1% in aqueous creamMetronidazole 2% in aqueous cream Heart of England NHS Foundation NHS Trust, Solihull Care Trust and Birmingham East and North Primary Care Trust agree that those specials included in the British Association of Dermatologists (BAD) preferred list of specials are all by default included in the Interface Formulary as an option for appropriate prescribing. HYPERLINK "http://www.bad.org.uk/Portals/_Bad/Specials/BAD%20Specials%20Booklet.pdf"BAD Preferred list of specials Vaccines and antisera This chapter is under development. Currently only medicines that are specifically subject to a positive NICE TA appear 14.5.3. GreenYellowDouble YellowRedANTI-D (Rh0) immunoglobulinAnti-D (Rh0) immunoglobulin Additional informationDrug specific notesHYPERLINK "http://guidance.nice.org.uk/TA156"NICE TA 156 Pregnancy (rhesus negative women) - routine anti-D  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  Anaesthesia 15.1.1 Intravenous anaesthetics GreenYellowDouble YellowRedBarbituratesThiopental sodiumOther intravenous anaestheticsEtomidateKetaminePropofol Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  15.1.2 Inhalational anaesthetics Notes on class  GreenYellowDouble YellowRedIsofluraneSevofluraneNitrous oxide Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  15.1.3 Antimuscarinic drugs Notes on class  GreenYellowDouble YellowRedHyoscine patchAtropine sulphateHyoscine hydrobromide Glycopyrronium bromide Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  15.1.4.Sedative and analgesic peri-operative drugs Notes on class Do not prescribe tramadol and codeine phosphate together GreenYellowDouble YellowRed15.1.4.1 Anxiolytics and neurolepticsDiazepamLorazepamMidazolamTemazepam15.1.4.2 Non-opioid analgesicsDiclofenac post operative useKetorolacParecoxibEtoralacTenoxicam15.1.4.3 Opioid analgesicsAlfentanilAlfentanil intensive care -High strength - Palliative Care Team recommendation during end of life care onlyAlfentanil nasal spray (unlicensed)- Palliative Care Team during end of life care for the relief of incident painFentanylRemifentanilMorphinePethidineTramadol 15.1.5 Neuromuscular blocking drugs Notes on class  GreenYellowDouble YellowRedNon-depolarising muscle relaxantsAtracuriumMivacuriumPancuroniumRocuroniumVecuroniumDepolarising muscle relaxantsSuxamethonium Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  15.1.6 Anticholinesterases used in anaesthesia GreenYellowDouble YellowRedEdrophonium chlorideNeostigmineSugammadex AAdditional informationDrug specific notesAFor use within the terms of its licence when Approved by a Consultant Anesthetist either at the time of the emergency or as soon as practical post emergency 2)Suxamethonium is contraindicated HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance  PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  15.1.7 Antagonists for central and respiratory depression Notes on class  GreenYellowDouble YellowRedFlumazenilNaloxone Additional informationDrug specific notes HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  15.1.8 Drugs for Malignant hyperthermia GreenYellowDouble YellowRedDantrolene sodium 15.2 Local anaesthesia Notes on class GreenYellowDouble YellowRedEmla creamLidocaine 5% patches - A specialist initiation. LidocaineAmetop creamBupivacaineLevobupivacainePrilocaineRopivacaineTetracaineArticaine hydrochlorideLAT gel (unlicensed product)LMX gel - paediatrics only Additional informationDrug specific notesA$%-.9HI  ȸȥ{d{d{d{N8{*h:hF5>*CJOJPJQJ^JaJ*h:h<5>*CJOJPJQJ^JaJ-h:h<5>*CJOJPJQJ\^JaJ-h:hN#5>*CJOJPJQJ\^JaJ$h:h.CJOJPJQJ^JaJ$h:hN#CJOJPJQJ^JaJh24CJ0aJhGYCJ0aJhN#CJ0aJh24h24>*CJ0aJh.CJ0aJjhGYUmHnHujhfUmHnHu9I h S # $ deIJhi $p^p`a$$a$gd$a$$a$$a$$a$gd9} $ a$gdGYgd. & 1 g h u  9 : P Q S X g i ðⰟÌÌ{kҌÌ{\h:h9}OJPJQJ^Jh:h9}5OJPJQJ^J h:hF0JOJPJQJ^J%jh:hFOJPJQJU^J h:hN0JOJPJQJ^J%jh:hNOJPJQJU^Jh:hFOJPJQJ^Jh:hF5OJPJQJ^Jh:hNOJPJQJ^Jh:hN#OJPJQJ^J"   ! " # $ J T _ ` h 'd}~ݽvvvcP9-h:hN#5>*CJOJPJQJ\^JaJ$h:hCJOJPJQJ^JaJ$h:hN#CJOJPJQJ^JaJh:hN#5OJPJQJ^J*h:hN#5OJPJQJ\^JmH sH "h:hN#5OJPJQJ\^Jh:hN#OJPJQJ^Jh:hNOJPJQJ^J h:h!BU0JOJPJQJ^Jh:h!BUOJPJQJ^J%jh:h!BUOJPJQJU^JJPZfjѸќхlхUUUAU'h:hN#>*CJOJPJQJ^JaJ-h:hF5>*CJOJPJQJ\^JaJ0 *h:hN#5>*CJOJPJQJ\^JaJ-h:hO*5>*CJOJPJQJ\^JaJ6h:hN#5>*B*CJOJPJQJ\^JaJphv<0 *h:hN#5>*CJOJPJQJ\^JaJ-h:hN#5>*CJOJPJQJ\^JaJ-h:hu5>*CJOJPJQJ\^JaJ 9ghivxuzѺѣѺs]GѺѺ]]*h:hO*>*CJOJPJQJ\^JaJ*h:hN#>*CJOJPJQJ\^JaJ'h:hN#>*CJOJPJQJ^JaJ6h:hN#5>*B*CJOJPJQJ\^JaJphl -h:h245>*CJOJPJQJ\^JaJ-h:hO*5>*CJOJPJQJ\^JaJ-h:hN#5>*CJOJPJQJ\^JaJ-h:h}L5>*CJOJPJQJ\^JaJ#%)*/9=f}ӼӥӥӼӎӎwdQ@!hO*hN#5>*CJ\^JaJ$ *hO*hN#5>*CJ\^JaJ$ *hO*h9}5>*CJ\^JaJ-h:h5>*CJOJPJQJ\^JaJ-h:hM5>*CJOJPJQJ\^JaJ-h:h9}5>*CJOJPJQJ\^JaJ-h:hO*5>*CJOJPJQJ\^JaJ-h:hN#5>*CJOJPJQJ\^JaJ*h:h9}>*CJOJPJQJ\^JaJi !":+,C=>!$a$ $@ ^@ `a$ $^`a$$a$$a$ $p^p`a$$p^p`a$gd9} !"9,B>ST_˽wggTFh:hN#>*OJQJ^J%h:hN#5>*CJOJQJ\^Jh:hN#>*CJOJQJaJ%h:hM5>*CJOJQJ\aJ%h:h:5>*CJOJQJ\aJh:hN#OJQJaJ%h:hN#5>*CJOJQJ\aJh:hN#OJQJ\aJ!hO*h:5>*CJ\^JaJhO*5>*CJ\^JaJ)h:hN#5>*CJOJQJ\^JaJ34UV\iɷ٤yqi]Q]HQHQh:>*CJaJhh>*CJaJhhN#>*CJaJhN#CJaJhN#CJ$aJh:5>*CJ\aJh9}5>*CJ\aJ%h:h9}5>*CJOJQJ\aJ%h:hN#5>*CJOJQJ\aJ"h:hN#5>*CJOJQJ^Jh:hN#56OJQJ^Jh:hN#OJQJ^Jh:h:OJQJmH sH h:hN#OJQJ3$ f$Ifa$gdgt 2$If^2gdgt $$Ifa$gdgt @ ^@ `$ T@ ^@ `a$$a$gd:$a$$a$ TU`klűűűraPBPhZB*OJQJ^Jph!hZhZB*OJQJ^Jph!hhZB*OJQJ^JphhhZOJQJ^J hZhZOJQJ^JmH sH hZOJQJ^Jh@hOJQJ^JhOJQJ^J&h (h5>*CJ^JaJnH tH hh5OJQJ^Jh h5OJQJ^J#h (h>*CJ^JaJnH tH hhM>*CJaJI=, 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& ``` t0>6    44 lapyt'TU`lQE4 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd!3lQE4 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd8+TUVamn45>lnR S ] e k ȴ֧ȴ֧ȴ֝ȴ֏ȴȴ֧ȴւȴւq h(ChOJQJ^JmH sH h(ChOJQJ^Jh!3hH*OJQJ^Jh}LOJQJ^Jh@hOJQJ^J&h (h5>*CJ^JaJnH tH hh5OJQJ^JhOJQJ^JhZB*OJQJ^Jph!hhZB*OJQJ^Jph,UVanQE4 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $IfgdZnQE4 2$If^2gd!3 $$Ifa$gd!3kdz$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd-9D8 $$Ifa$gd!3kdN$$IflFrAx=*7& t0>6    44 lapyt% & F/$Ifgd+=n $Ifgd!345>@4 $$Ifa$gd!3kd"$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd!3 2$If^2gd}L>W@4 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd  2$If^2gd!3QE4 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $IfgdKotD8 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $Ifgdl $Ifgd!3' R S ] @4 $$Ifa$gd!3kdr$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd!3 2$If^2gd!3] e :!;!6    44 lapyt% $Ifgd $Ifgd!3 2$If^2gd!3 7!8!:!;!*CJ^JaJnH tH h h5OJQJ^J#h (h>*CJ^JaJnH tH hh5OJQJ^Jh(Ch_OJQJ^JhOJQJ^Jh(ChOJQJ^J h(ChOJQJ^JmH sH h}LOJQJ^JmH sH "6    44 lapytm!!!!"e"QE4 2$If^2gd!3 $$Ifa$gd!3kd $$IflFrAx=*7& t0>6    44 lapyt% $Ifgd}Le"f"p"""^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd $$IflFrAx=*7& t0>6    44 lapyt%""#!#e#^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd $$IflFrAx=*7& t0>6    44 lapyt%e#f#p#{##^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd $$IflFrAx=*7& t0>6    44 lapyt%f#p##########$$!$9$~$$$$$$$$$C%D%N%d%e%o%%%%%%"&&&&&&&8'9':'D'P'M(N(O(Y(n((⽬쏈 h6aJh#h6B*aJphhOJQJ^JmH sH hgehOJQJ^JmH sH hgehOJQJ^JhyYOJQJ^Jhh5OJQJ^JhOJQJ^J&h (h5>*CJ^JaJnH tH 4#####^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kdh$$IflFrAx=*7& t0>6    44 lapyt%#####^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd<$$IflFrAx=*7& t0>6    44 lapyt%####$^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%$$!$C$~$^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%~$$$$$^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%$$$$$^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%$$$%C%^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd`$$IflFrAx=*7& t0>6    44 lapyt%C%D%N%]%d%^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd4$$IflFrAx=*7& t0>6    44 lapyt%d%e%o%%%^RA4 $Ifgd!3 2$If^2gd $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%%%%%&^RA4 $Ifgd!3 2$If^2gd!3 $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%&&&&&^RF5 2$If^2gd!3 1$$Ifa$gd< $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%&9':'D'P'QE9 1$$Ifa$gdYZ! $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $IfgdP'N(O(Y(m(n(QE9- 1$$Ifa$gdYZ! 1$$Ifa$gd# $$Ifa$gd!3kdX$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd!3(((((((1)7)8);)M)N)X)d)e)))))))***********ʻ짚ʎʎweWeʎh h5OJQJ^J#h (h>*CJ^JaJnH tH h_OJQJ^JhhOJQJ^Jh6B*aJphhZhZOJQJ^JhZh)hOJQJ^J h6aJh#h6B*aJph&h (h5>*CJ^JaJnH tH hh5OJQJ^JhOJQJ^Jh}LOJQJ^J n(((((QE9 1$$Ifa$gd_ $$Ifa$gd!3kd,$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd!3(M)N)X)e)QE9 1$$Ifa$gd# $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $IfgdZe)))))QE9 1$$Ifa$gd# $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd!3)*****QE $$Ifa$gdJkd$$IflFrAx=*7& t0>6    44 lapyt% #$If^#gd_****(kd|$$IflFrAx=*7& ``` t0>6    44 lapytl$ f$Ifa$gdJ 2$If^2gdJ***l,m,w,,=kdz$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd% 1$$Ifa$gd# $$Ifa$gd!3**%+'+U+V+++++k,l,m,w,, -i-j-p---------3.࿱p_ֱS_hyY6B*aJph h%hOJQJ^JmH sH hOJQJ]^JnH tH #h%hOJQJ]^JnH tH h6B*aJph&h (h5>*CJ^JaJnH tH hh5OJQJ^JhhOJQJ^Jh}LOJQJ^JhOJQJ^Jh%hOJQJ^J$h}h5B*OJQJ^JphT,----UI= 1$$Ifa$gd# $$Ifa$gd!3kdN$$IflFrAx=*7& t0>6    44 lapyt% $Ifgd%3.>.?.M.X........ / //*/0////000`0b0q0}00Լyj]PhgehOJQJ^Jh4?hOJQJ^Jh#h6B*aJphhlhhOJQJ^JhOJQJ^Jh6B*aJphhyY6B*aJph&h (h5>*CJ^JaJnH tH hh5OJQJ^JhyYOJQJ^Jh%hOJQJ^J h%hOJQJ^JmH sH hyYOJQJ^JmH sH -....C7+ 1$$Ifa$gd# $$Ifa$gd!3kd"$$IflFrAx=*7& t0>6    44 lapyt%#dK$-DIfM [$^#gd%. / //*/C7+ 1$$Ifa$gd# $$Ifa$gd!3kd$$IflFrAx=*7& t0>6    44 lapyt%#dK$-DIfM [$^#gd%*///00a0UI=4 $Ifgd 1$$Ifa$gd3 $$Ifa$gd3kd $$IflFrAx=*7& t0>6    44 lapyt% $Ifgdlha0b0q0}00Z1[1^RF=== $Ifgd:~ 1$$Ifa$gd3 $$Ifa$gd3kd!$$IflFrAx=*7& t0>6    44 lapyt30Y1[1\1k1v1|1R2T2U2d2n222222233D3E3F3G3T3^3334ȼȼȼuȼdVdh}LCJOJQJ^JaJ hhCJOJQJ^JaJh:OJQJ^JhOJQJ^JmH sH  h#h)hOJQJ^JmH sH  hlChOJQJ^JmH sH h#h)hOJQJ^Jh6B*aJph&h (h5>*CJ^JaJnH tH hgehOJQJ^JhOJQJ^Jh:~hOJQJ^J[1\1k1v11S2T2^RF=== $Ifgd:~ 1$$Ifa$gd3 $$Ifa$gd3kdr"$$IflFrAx=*7& t0>6    44 lapyt3T2U2d2n22^RF= $Ifgd:~ 1$$Ifa$gd3 $$Ifa$gd3kdF#$$IflFrAx=*7& t0>6    44 lapyt32222E3F3^RF== $Ifgd 1$$Ifa$gd3 $$Ifa$gd3kd$$$IflFrAx=*7& t0>6    44 lapyt3F3G3T3^34^RF9 -$If^gd: 1$$Ifa$gd3 $$Ifa$gd3kd$$$IflFrAx=*7& t0>6    44 lapyt3444444444h5o5666667 7,7-7;7E7N7O7⮢⮢tg]gNBNh6B*^Jphh4?h6B*^Jphh}LOJQJ^Jh4?hOJQJ^Jh4?h6B*aJphh}LCJOJQJ^JaJ hhCJOJQJ^JaJh6B*aJph&h (h5>*CJ^JaJnH tH h h5OJQJ^J#h (h>*CJ^JaJnH tH hgehOJQJ^J hh:CJOJQJ^JaJ44444^RA1$ f$Ifa$gdgt 2$If^2gdgt $$Ifa$gdgtkd%$$IflFrAx=*7& t0>6    44 lapyt344446I=1$ -$If^gd4 1$$Ifa$gd3 $$Ifa$gd3kd&$$IflFrAx=*7& ``` t0>6    44 lapyt6666+7,7^RF=0 -$If^gd4 $Ifgd4? 1$$Ifa$gd3 $$Ifa$gd3kd'$$IflFrAx=*7& t0>6    44 lapyt3,7-7;7O77778^RF;;; $Ifgd4?m$ 1$$Ifa$gd3 $$Ifa$gd3kdh($$IflFrAx=*7& t0>6    44 lapyt3O7]7687888F8y8{8888899999$9A9V9]9: :.:ïyoeTïJïh}LOJQJ^J!hHhB*OJQJ^JphhOJQJ^Jh)hOJQJ^JhHh5OJQJ^JhHhOJQJ^Jh4?h6B*^Jphh6B*^Jph&h (h5>*CJ^JaJnH tH hgehOJQJ^Jh4?hOJQJ^J'h4?hOJPJQJ^JmHnHuh4?hOJPJQJ^J7888F8{899^RF=2 $Ifgd4?m$ $IfgdH 1$$Ifa$gdH $$Ifa$gd3kd<)$$IflFrAx=*7& t0>6    44 lapyt399$9A999^RF== $IfgdH 1$$Ifa$gdH $$Ifa$gdHkd*$$IflFrAx=*7& t0>6    44 lapyt39: :.:9::UI=0 -$If^gdN* 1$$Ifa$gdH $$Ifa$gdHkd*$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd K.:8:9:|:::::::::::::ĵğ~mWDW5h6^JaJmHnHu%hCJOJQJ^JaJmHnHu+hhCJOJQJ^JaJmHnHu hh6B*^JaJph&h (h5>*CJ^JaJnH tH hgehOJQJ^J+hN*hCJOJQJ^JaJmHnHuh}LCJOJQJ\^JaJ#hN*hCJOJQJ\^JaJ+h"4h6B*^JaJmHnHphu%h6B*^JaJmHnHphu:::::^RF9 -$If^gd 1$$Ifa$gdH $$Ifa$gdHkd+$$IflFrAx=*7& t0>6    44 lapyt3::::; ; ;*;+;9;k;l;;;;;;;̸|̸k|UBU|U%hyYCJOJQJ^JaJmHnHu+h"4hCJOJQJ^JaJmHnHu h"4h6B*^JaJph%hCJOJQJ^JaJmHnHu+h"4h6B*^JaJmHnHphu%h6B*^JaJmHnHphu&h (h5>*CJ^JaJnH tH hgehOJQJ^J+hhCJOJQJ^JaJmHnHu hhCJOJQJ^JaJ::; ;*;^RF9 -$If^gd"4 1$$Ifa$gdH $$Ifa$gdkd,$$IflFrAx=*7& t0>6    44 lapyt3*;+;9;l;<\PD7 -$If^gd}L 1$$Ifa$gdH $$Ifa$gdHkd`-$$Ifl:FrAx=*7& t0>6    44 lapyt<);< <<<<<#<.</<K<R<r<<<<<ǺpbWbL=+#h (h>*CJ^JaJnH tH hOJQJ^JmHnHuhOJQJ\^Jh}LOJQJ\^Jh"4hOJQJ\^J+h"4h6B*^JaJmHnHphu%h6B*^JaJmHnHphu&h (h5>*CJ^JaJnH tH hgehOJQJ^JhHhOJQJ^J"hCJOJQJ^JaJmH sH "h}LCJOJQJ^JaJmH sH (h"4hCJOJQJ^JaJmH sH <<#</<s<t<<^RF;;; $Ifgd Km$ 1$$Ifa$gdH $$Ifa$gdHkd8.$$IflFrAx=*7& t0>6    44 lapyt3<<<<<^RA1$ f$Ifa$gdgt 2$If^2gdgt $$Ifa$gdgtkd /$$IflFrAx=*7& t0>6    44 lapyt3<<<<<J=K=b=i=p=q=r=====Z>[>\>j>ҾuҾdUFU4Ҿ#hhCJOJQJ\^JaJh}LCJOJQJ\^JaJhCJOJQJ\^JaJ hh6B*^JaJphh"4hOJQJ\^Jh}LOJQJ\^JhOJQJ\^J+hh6B*^JaJmHnHphuhh6B*^Jph&h (h5>*CJ^JaJnH tH hgehOJQJ^J#h (h>*CJ^JaJnH tH h h5OJQJ^J<<<<K=I==4 1$Ifgd $$Ifa$gdHkd/$$IflFrAx=*7& ``` t0>6    44 lapytK=o=p=q=r===SG> 1$Ifgd $$Ifa$gdHkd0$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd"4m$=[>\>j>>L@7 1$IfgdtMS $$Ifa$gdHkd1$$IflFrAx=*7& t0>6    44 lapyt3-#d$If^#gd Kj>>>>>>>>>H?U?\?I@@@*A+A,A7A?A}s}bTbF7hh6B*^JphhhOJQJ\^Jh}LOJQJ^JmH sH  hhOJQJ^JmH sH h}LOJQJ^JhhOJQJ^J(hhCJOJQJ^JaJmH sH &h (h5>*CJ^JaJnH tH hgehOJQJ^J#hhCJOJQJ\^JaJhCJOJQJ\^JaJ hh6B*^JaJphh6B*^JaJph>>>>>H?L@4 1$$Ifa$gd2 $$Ifa$gdHkd2$$IflFrAx=*7& t0>6    44 lapyt3-#d$If^#gdH??I@+A,A7AG; $$Ifa$gdHkdZ3$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd}L & F1$Ifgd]m$?A@AFAGA_A`A{AAAAAAAAAAA\BڹocTGT=hOJQJ^JhhB*^Jphhh6B*^Jphh6B*^Jph&h (h5>*CJ^JaJnH tH hgehOJQJ^J#hhCJOJQJ\^JaJh}LOJQJ^JhhOJQJ^J hh6B*^JaJphh6B*^JmH phsH $hh6B*^JmH phsH #hh6B*]^JaJph7A`AAAA7kd.4$$IflFrAx=*7& t0>6    44 lapyt3-#d$If^#gd $Ifgd 1$$Ifa$gd<)AAA]B^B_BjB=kd5$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd 1$$Ifa$gd2 $$Ifa$gdH\B]B^B_BjBvBBBBBBBBBCCCCDDDDDqq_I+hwShCJOJQJ\^JaJmH sH #hwShCJOJQJ\^JaJhh6B*^JphhhB*^JphhhOJQJ\^Jh}LOJQJ\^JhOJQJ\^JhT Hh6B*^Jph&h (h5>*CJ^JaJnH tH hgehOJQJ^JhhOJQJ^J!hSphB*OJQJ^JphjBvBBBBBBBL@ $$Ifa$gdHkd5$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd 1$IfgdB'C(CCCCDUI@ 1$Ifgd $$Ifa$gdHkd6$$IflFrAx=*7& t0>6    44 lapyt3 $IfgdDDDDDF: $$Ifa$gdgtkd~7$$IflFrAx=*7& t0>6    44 lapyt3 $IfgdwSm$ -$If^gdDDEEEE4EIEPEEEEEEE?F@FAFBFCFҾҾr`rIr;htMSh=OJQJ\^J,htMShB*H*OJQJ^JmH phsH #hB*OJQJ^JmH phsH )htMShB*OJQJ^JmH phsH htMSh6B*^Jphh}LOJQJ\^JhwShOJQJ\^JhwSh6B*^Jph&h (h5>*CJ^JaJnH tH hgehOJQJ^Jh h5OJQJ^J#h (h>*CJ^JaJnH tH DEEE(kdR8$$IflFrAx=*7& ``` t0>6    44 lapyt$ f$Ifa$gdgt 2$If^2gdgtEE4EEEEE9kdP9$$IflFrAx=*7& t0>6    44 lapyt3$#$If^#a$gdwS 1$Ifgd $$Ifa$gdHEBFCFNFXFFNB9 1$Ifgd $$Ifa$gdHkd$:$$IflFrAx=*7& t0>6    44 lapyt3$#$If^#a$gd=CFNFWFXFFFFFFFFFFFFFGGGGJGKGLGUGiGѿzl_U_lHzl_U_lHzhgehOJQJ^Jh}LOJQJ^JhwShOJQJ^JhwShOJQJ\^JhT Hh6B*^Jph&h (h5>*CJ^JaJnH tH hgeh=OJQJ^J)htMSh=B*OJQJ^JmH phsH #h=B*OJQJ^JmH phsH htMSh=6B*^Jphh=6B*^Jph&h (h=5>*CJ^JaJnH tH FFFFF^RI9$#$If^#a$gdwS 1$Ifgd $$Ifa$gdHkd:$$IflFrAx=*7& t0>6    44 lapyt3FFFGKG^RI9$#$If^#a$gdwS 1$Ifgd $$Ifa$gdHkd;$$IflFrAx=*7& t0>6    44 lapyt3KGLGUGGGGfHgH^RI@@@@ $IfgdwS 1$Ifgd $$Ifa$gdHkd<$$IflFrAx=*7& t0>6    44 lapyt3iGGGGGGGGGGeHfHgHIIIIIIIII"JκۭpaUaC#hwShOJQJ^JmHnHuh6B*^JphhwSh6B*^Jph&h (h5>*CJ^JaJnH tH hgehOJQJ^JhwShOJQJ\^JhwSh5OJQJ^JhwShzOJQJ^JhzOJQJ^Jh}LOJQJ^JhwShOJQJ^JhOJQJ^JhT Hh6B*^Jphhz6B*^JphgHHIIIIE9 $$Ifa$gdHkdt=$$IflFrAx=*7& t0>6    44 lapyt3$#$If^#a$gdwS $IfgdwSIIhJiJrJJ6KL@ $$Ifa$gdHkdH>$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd}L 1$Ifgd"JUJ\JgJhJiJqJrJJJJJJJ5K6K7K@KAKBKdzxndnZF:h:/6B*^Jph&h (h:/5>*CJ^JaJnH tH hOJQJ^Jh}LOJQJ^JhRNOJQJ^JhwSh6B*^JphhQZ6B*^JphhRN6B*^Jph&h (h5>*CJ^JaJnH tH &h (hRN5>*CJ^JaJnH tH hgehOJQJ^JhwShOJQJ^Jh}LOJQJ^JmHnHuhOJQJ^JmHnHu6K7KAKhKK^RI@ $IfgdwS 1$Ifgd $$Ifa$gdHkd?$$IflFrAx=*7& t0>6    44 lapyt3BKZKeKfKgKhKKKKKKKULVL`LLLLLLLLMMùهzm\N\m\= h#h)hOJQJ^JmH sH h}LOJQJ^JmH sH h#hQZOJQJ^JmH sH hgehQZOJQJ^JhQZhQZOJQJ^J hQZhQZOJQJ^JmH sH &h (hQZ5>*CJ^JaJnH tH hgehRNOJQJ^JhRNOJQJ^JhQZOJQJ^JhRN6B*^JphhQZ6B*^Jphh:/6B*^Jphh:/h:/6B*^JphKKKKUL^RI@ $IfgdQZ 1$Ifgd $$Ifa$gdHkd?$$IflFrAx=*7& t0>6    44 lapyt3ULVL`LLL^RI@ $IfgdQZ 1$IfgdQZ $$Ifa$gdHkd@$$IflFrAx=*7& t0>6    44 lapyt3LLLLRM^RI@ $Ifgd)h 1$IfgdQZ $$Ifa$gdHkdA$$IflFrAx=*7& t0>6    44 lapyt3MMRMSM]MxMMMMMMMNN N.N4NOOOԠyeYKAK4hgehOOJQJ^JhOOJQJ^JhOOJQJ^JmH sH hO6B*^Jph&h (hO5>*CJ^JaJnH tH hgehN:OJQJ^JhN:OJQJ^JmH sH hN:6B*^Jph&h (hN:5>*CJ^JaJnH tH hQZ6B*^Jph&h (hQZ5>*CJ^JaJnH tH hgehQZOJQJ^J h#hQZOJQJ^JmH sH h}LOJQJ^JmH sH RMSM]MxMM^RI@ $IfgdQZ 1$IfgdQZ $$Ifa$gdHkdlB$$IflFrAx=*7& t0>6    44 lapyt3MMMMN^RI@ $IfgdQZ 1$IfgdQZ $$Ifa$gdHkd@C$$IflFrAx=*7& t0>6    44 lapyt3NN N.NNO^RI<< & F2$Ifgd] 1$IfgdQZ $$Ifa$gdHkdD$$IflFrAx=*7& t0>6    44 lapyt3OOOOO^RA1$ f$Ifa$gd 2$If^2gd $$Ifa$gdkdD$$IflFrAx=*7& t0>6    44 lapyt3OOOOOOOOOPP!P@PGPPPPPQQ4Q5QEQNQcQjQQQRR%R4R;R*CJ^JaJnH tH hgeh-iOJQJ^Jh h-i5OJQJ^J#h (h-i>*CJ^JaJnH tH #OOOOOI=4+ $IfgdQZ 1$IfgdQZ $$Ifa$gdHkdE$$IflFrAx=*7& ``` t0>6    44 lapyt-iOOP!PP^RI@ $Ifgdz 1$Ifgdz $$Ifa$gdHkdF$$IflFrAx=*7& t0>6    44 lapyt3PPPP4Q^RI@ $Ifgdz 1$Ifgdz $$Ifa$gdHkdG$$IflFrAx=*7& t0>6    44 lapyt34Q5Q?QEQNQQ^RRI@ $Ifgd)h 1$Ifgdz $$Ifa$gd.akdbH$$IflFrAx=*7& t0>6    44 lapyt3QQQRRhRiR^RRI@@ $IfgdO 1$Ifgdz $$Ifa$gd.akd6I$$IflFrAx=*7& t0>6    44 lapyt3[RgRiRRRR SST T!T/TCTbTiTqT}TTTTTTTU UU$U+U/U0U:U־㦒xf㦒㦒YOYYh}LOJQJ^JhtMh-iOJQJ^J#h] h-i5OJQJ^JmH sH h}LOJQJ^JmH sH h-i6B*^Jph&h (h-i5>*CJ^JaJnH tH hgeh-iOJQJ^JhY)5OJQJ^JhwSh-i5OJQJ^Jh-iOJQJ^JhwSh-iOJQJ^Jh-iOJQJ^JmH sH h] h-i5OJQJ^JiRRR[S T!T)T/TUII $$Ifa$gd.akd J$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd</TCTTTTTTL@@ $$Ifa$gd.akdJ$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd+ 1$IfgdzTTTU UFUGUUI@77 $IfgdtM 1$Ifgdz $$Ifa$gd.akdK$$IflFrAx=*7& t0>6    44 lapyt3 $IfgdO:U;UFUGUUUUUVVVV.V5VOVPVQV_VlVrVVVVVVVW!WWWWWWWWWWκۑκκzmz\ h-i5>*CJ^JaJnH tH h#h-iOJQJ^Jhdc_h-iOJQJ^Jh}LOJQJ^J htMh-iOJQJ^JmH sH h-i6B*^JphhyY6B*^Jph&h (h-i5>*CJ^JaJnH tH hgeh-iOJQJ^Jh-iOJQJ^JmH sH htMh-iOJQJ^Jh-iOJQJ^J$GUUUUVPVUI@ 1$Ifgdz $$Ifa$gd.akdL$$IflFrAx=*7& t0>6    44 lapyt3 $IfgdtMPVQV_VlVVV^RI@7 $IfgdO $IfgdtM 1$Ifgdz $$Ifa$gd.akdZM$$IflFrAx=*7& t0>6    44 lapyt3VVVVWW^RI@@ $IfgdO 1$Ifgdz $$Ifa$gd.akd.N$$IflFrAx=*7& t0>6    44 lapyt3WWWWW^RI@ $IfgdO 1$Ifgdz $$Ifa$gd.akdO$$IflFrAx=*7& t0>6    44 lapyt3WWWXX^RA1$ f$Ifa$gd 2$If^2gd $$Ifa$gdkdO$$IflFrAx=*7& t0>6    44 lapyt3WWXX XX"X4XNXOXPXXXA[B[C[D[Ҿ{jUjKA5hgeh-i5\^Jhhh:5^Jh:h-i5^J(hhh-iCJOJQJ^JaJnH tH  hhh-iOJQJ^JnH tH !hhh-iB*OJQJ^Jphl hhh-iOJQJ^Jhhh-i5OJQJ^Jh-iOJQJ^Jh[h-iOJQJ^J&h[h-i5>*CJ^JaJnH tH hgeh-iOJQJ^Jh h-i5OJQJ^J#h (h-i>*CJ^JaJnH tH X XXX"XI==, 2$If^2gd $$Ifa$gdkdP$$IflFrAx=*7& ``` t0>6    44 lapyth"XPXX2YZB[C[ h$If^hgd: & F3$Ifgd] $IfgdhC[D[M[R[^[[[^RRA88 $Ifgdh 2$If^2gd $$Ifa$gdkdQ$$IflFrAx=*7& t0>6    44 lapyt3D[Q[R[[[[[[[\ \\\\\\\\]]]]]^v^^^^BaFaHaJadaaaaaaĸĥθĸΛΑ΀ĸobbh%(Zh-iOJQJ^J h[`5>*CJ^JaJnH tH !h1pth-iB*OJQJ^JphhTOJQJ^Jh}LOJQJ^J$h)h-i5B*OJQJ^Jphhgeh-i5\^Jh-iOJQJ^Jh[h-iOJQJ^J&h[h-i5>*CJ^JaJnH tH  h-i5>*CJ^JaJnH tH %[[[\\\^RA8/ $Ifgdh $Ifgd[ 2$If^2gd $$Ifa$gdkd|R$$IflFrAx=*7& t0>6    44 lapyt3\\\\,]-]]^RA888 $Ifgd[ 2$If^2gd $$Ifa$gd[kdPS$$IflFrAx=*7& t0>6    44 lapyt3]]]]:^^^^RAA88 $Ifgd[ 2$If^2gd[ $$Ifa$gd[kd$T$$IflFrAx=*7& t0>6    44 lapyt3^FaHaJaabUI8 2$If^2gdT $$Ifa$gd[kdT$$IflFrAx=*7& t0>6    44 lapyt3 $Ifgd[abbbb)bbbbbbbbbbbb*c+c0c>cFcGcVcccccccGdHdVd-e.e*CJ^JaJnH tH hgeh\U5\^Jh\UOJQJ^J h\U5>*CJ^JaJnH tH h:OJQJ^Jh-iOJQJ^J h-i5>*CJ^JaJnH tH hgeh-i5\^Jh[`OJQJ^Jh%(Zh-iOJQJ^Jh%(Zh-i5OJQJ^J#bbbbbQE4 2$If^2gd[ $$Ifa$gd[kdU$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd%(Zbbbb cQE4 2$If^2gdb $$Ifa$gdbkdV$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd: c*c+c0c>cQE4 2$If^2gd $$Ifa$gdkdtW$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gdb>cFcGcQcVc9-- $$Ifa$gd[kdHX$$IflFrAx=*7& ``` t0>6    44 lapyt-i$ f$Ifa$gdVccccccc@44 $$Ifa$gd[kdFY$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd%(Z 2$If^2gd[cccccc@4 $$Ifa$gd[kdZ$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd%(Z 2$If^2gd[cGdHdVdbd-eQE4 2$If^2gd[ $$Ifa$gd[kdZ$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd%(Z-e.e6    44 lapyt3*CJ^JaJnH tH hgeh\U5\^Jh\UOJQJ^J!hfh\UB*OJQJ^Jphhfh\UOJQJ^J h=h\UCJOJQJ^JaJh=h\UOJQJ^JeeeeeQE4 2$If^2gd $$Ifa$gd[kd\$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd%(Zeefff;/ $$Ifa$gd[kdj]$$IflFrAx=*7& t0>6    44 lapyt3 #$If^#gd- #d$If^gdffgggg@44 $$Ifa$gd[kd>^$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd| 2$If^2gd[gh#h$hiijkkklllll%m&m'm(m)m.m*CJ^JaJnH tH hgeh\U5\^J%h\Uh\U0JB*OJQJ^Jph!jh\Uh\UOJQJU^Jh\Uh\U5OJQJ^Jh\Uh\UOJQJ^Jh\Uh\UOJQJh\Uh\UnH tH  h\Uh\UOJQJ^JmH sH h\UOJQJ^Jh[h\U6OJQJ^J'h[h\U0JG6OJQJ^JmH sH g$h)hijkll'm(myy $Ifgd\U $Ifgd\U$ & F7 $If`a$gd1$ & F7 ,$If`,a$gd1$ & F6 $Ifa$gd1 & F8$Ifgd1 $IfgdqK 2$If^2gd[ (m)m.m6    44 lapyt3DmEmOmXmI=, 2$If^2gd[ $$Ifa$gd%Mkd_$$IflFrAx=*7& ``` t0>6    44 lapyt\UEmOmmmmnnnoZo_ooooooooo$p%p.ppppppppppqqqqqqqrrrrs٭r-h%Mh%MB*OJPJQJ^JmH phsH hEh%MOJQJ^JhEh-OJQJ^Jh-OJQJ^J h-5>*CJ^JaJnH tH hvVh\U5OJQJ^JhRMh\UOJQJ^Jhgeh\U5\^Jh\UOJQJ^J h\U5>*CJ^JaJnH tH *XmmmmmnQE8 -$If^-gd`LV $$Ifa$gd[kd`$$IflFrAx=*7& t0>6    44 lapyt3 -$If^-gd%(Znnnoovj]P -$If^-gdL\h -$If^-gd%(Z $$Ifa$gd[kda$$Ifl0rx=a7 t0>644 lapytooooo^REE -$If^-gdvV $$Ifa$gd[kdlb$$IflFrAx=*7& t0>6    44 lapytRMoooo$p^REE -$If^-gddW $$Ifa$gd[kd@c$$IflFrAx=*7& t0>6    44 lapytRM$p%p.p8pp^RE8 -$If^-gd_ -$If^-gddW $$Ifa$gd[kdd$$IflFrAx=*7& t0>6    44 lapytRMppppp^REE -$If^-gd_ $$Ifa$gd[kdd$$IflFrAx=*7& t0>6    44 lapytRMppppp^RE8 -$If^-gd%M -$If^-gddW $$Ifa$gd[kde$$IflFrAx=*7& t0>6    44 lapytRMppppq^RE8 -$If^-gdh -$If^-gddW $$Ifa$gd[kdf$$IflFrAx=*7& t0>6    44 lapytRMqqqqq^RE8 -$If^-gdh -$If^-gddW $$Ifa$gd[kddg$$IflFrAx=*7& t0>6    44 lapytRMqqqqrs^RE<. $7$8$H$Ifgd%M I$Ifgd%M -$If^-gddW $$Ifa$gd[kd8h$$IflFrAx=*7& t0>6    44 lapytRMsIsJsKsUsbscsdsisjsxssssstYt^t_tt|u}u~uuuuu*v+v5vZvµ£ˆzm_O_ˆˆˆh*soh\U5OJQJ\^Jh*soh\UOJQJ\^Jh*soh\UOJQJ^Jh*soh\U5OJQJ^Jhgeh\U5\^Jh\UOJQJ^JmHnHu#h(,h\UOJQJ^JmHnHuh(,h\UOJQJ^Jh\UOJQJ^J h\U5>*CJ^JaJnH tH hgeh-5\^Jh-OJQJ^Jh%Mh%MOJQJ^JsJsKsUsysQE8 -$If^-gd(, $$Ifa$gd[kd i$$IflFrAx=*7& t0>6    44 lapytRM -$If^-gd%MysssssQE8 -$If^-gd(, $$Ifa$gd[kdi$$IflFrAx=*7& t0>6    44 lapytRM -$If^-gdhs}u~uuuQE8 -$If^-gd(, $$Ifa$gd[kdj$$IflFrAx=*7& t0>6    44 lapytRM -$If^-gdKouuuuuQE8 -$If^-gd(, $$Ifa$gd[kdk$$IflFrAx=*7& t0>6    44 lapytRM -$If^-gdhu*v+v5vFvZvQE8 -$If^-gd(, $$Ifa$gd[kd\l$$IflFrAx=*7& t0>6    44 lapytRM -$If^-gdgxZv[vev{vv^RE8 -$If^-gdgx -$If^-gd(, $$Ifa$gd[kd0m$$IflFrAx=*7& t0>6    44 lapytRMZv[vevvvvvwwTwWwXwbwwwwwwwwxx!x"xWxxxxyeXKXyh*h*OJQJ^Jh*hW ?OJQJ^J&h*h*5>*CJ^JaJnH tH hgehW ?^JhW ?OJQJ^J&h*hW ?5>*CJ^JaJnH tH hgehW ?5\^JhhhW ?5OJQJ^J#hhhW ?>*CJ^JaJnH tH hxh\UOJQJ^Jh\UOJQJ^J h\U5>*CJ^JaJnH tH hgeh\U5\^JvvvvWw^RE8 -$If^-gd%M -$If^-gdx $$Ifa$gd[kdn$$IflFrAx=*7& t0>6    44 lapytRMWwXwbwpww^RE8 -$If^-gd -$If^-gdx $$Ifa$gd[kdn$$IflFrAx=*7& t0>6    44 lapytRMwwwww^RA1$ f$Ifa$gd/ 2$If^2gd/ $$Ifa$gd/kdo$$IflFrAx=*7& t0>6    44 lapytRMwwwwI=0 -$If^-gd/ $$Ifa$gd/kdp$$IflFrAx=*7& ``` t0>6    44 lapytW ?wxx"xWxxQE< $Ifgd* $$Ifa$gd/kd~q$$IflFrAx=*7& t0>6    44 lapytRM -$If^-gdW ?xxy!yy^RE< $Ifgd* -$If^-gdW ? $$Ifa$gd/kdRr$$IflFrAx=*7& t0>6    44 lapytRMxyyyyyyyyyyzzz'z2zzzzzzzzzzzλ~tt~g]gKg]#h{h{OJQJ^JmHnHuh{OJQJ^Jh{h{OJQJ^JhWaOJQJ^JhWah*OJQJ^JhWahWaOJQJ^J#hWahWaOJQJ^JmHnHu h{5>*CJ^JaJnH tH hgeh*^Jh*OJQJ^Jh*h*OJQJ^J&h*h*5>*CJ^JaJnH tH  h*5>*CJ^JaJnH tH yyyzz^RE< $IfgdWa -$If^-gdW ? $$Ifa$gd/kd&s$$IflFrAx=*7& t0>6    44 lapytRMzzzzz^RE< $IfgdF= -$If^-gd{ $$Ifa$gd/kds$$IflFrAx=*7& t0>6    44 lapytRMzz{{{^RE< $Ifgd{ -$If^-gd{ $$Ifa$gd/kdt$$IflFrAx=*7& t0>6    44 lapytRMzz{{{{{{{{|8|||L}M}Q}R}}}0156[\ CDEOouuuuuuuuulZ#h ~h ;=OJQJ^JmHnHuhgeh ;=^J1jh ;=h ;=OJQJU^JmH nH sH tH (h ;=h ;=OJQJ^JmH nH sH tH h ;=OJQJ^Jh ;=h ;=OJQJ^J h ;=5>*CJ^JaJnH tH h{h{5OJQJ^Jh{h{OJQJ^J h{5>*CJ^JaJnH tH hgeh{^J"{{{|D^RE: $9DIfgdF= -$If^-gd ;= $$Ifa$gd/kdu$$IflFrAx=*7& t0>6    44 lapytRMDEOo^RE8/ $IfgdF= -$If^-gdF= -$If^-gd ;= $$Ifa$gd/kdvv$$IflFrAx=*7& t0>6    44 lapytRMoՁցFGHWstǂ12@ȶwe[NEw[E4 hV5>*CJ^JaJnH tH hgeh+=*^Jh ~h+=*OJQJ^Jh+=*OJQJ^J#h ~h+=*OJQJ^JmHnHuh+=*OJQJ^JmHnHu h+=*5>*CJ^JaJnH tH h ~h ~OJQJ^J#h ~h ;=OJQJ^JmHnHu#h ~h ~OJQJ^JmHnHu h ;=5>*CJ^JaJnH tH  h ~5>*CJ^JaJnH tH hgeh ;=^Jh ~h ;=OJQJ^JցG^RE< $Ifgd+=* -$If^-gd ;= $$Ifa$gd ~kdJw$$IflFrAx=*7& t0>6    44 lapytRMGHWt^RE< $Ifgd+=* -$If^-gd ;= $$Ifa$gd ~kdx$$IflFrAx=*7& t0>6    44 lapytRMǂ1^RE< $Ifgd+=* -$If^-gd ;= $$Ifa$gd ~kdx$$IflFrAx=*7& t0>6    44 lapytRM12A^^RE< $Ifgd+=* -$If^-gd ;= $$Ifa$gd ~kdy$$IflFrAx=*7& t0>6    44 lapytRM@A]^ÃσЃakmǽǖDŽ{j`SLSChgehF=^J h%MhF=h%MhF=OJQJ^Jh%MOJQJ^J hF=5>*CJ^JaJnH tH hgehV^J#hVhVOJQJ^JmHnHuhVhVOJQJ^J hV5>*CJ^JaJnH tH hgeh+=*^Jh+=*OJQJ^JhVOJQJ^Jh+=*OJQJ^JmHnHuhVOJQJ^JmHnHu h+=*5>*CJ^JaJnH tH Ѓ^RE< $Ifgd+=* -$If^-gdV $$Ifa$gd ~kdz$$IflFrAx=*7& t0>6    44 lapytRMbm^RE/-hd$If^h`gdF= -$If^-gd%M $$Ifa$gd ~kdn{$$IflFrAx=*7& t0>6    44 lapytRMm̈́!" $Ifgd+=* $IfgdF=- & F9d$Ifgd1- & F:d$Ifgd1…ʅ^RA1$ f$Ifa$gd/ 2$If^2gd/ $$Ifa$gd/kdB|$$IflFrAx=*7& t0>6    44 lapytRM…ʅ˅څ+,:;FSTopq°ˆt`SI*CJ^JaJnH tH &hHhH5>*CJ^JaJnH tH hgehF=5\^JhF=hF=OJQJ^JhF=OJQJ^JmHnHu#hF=hF=OJQJ^JmHnHu&hF=hF=5>*CJ^JaJnH tH hgehF=^JhhhF=5OJQJ^J#hhhF=>*CJ^JaJnH tH ʅ˅څI=,, 2$If^2gd/ $$Ifa$gd/kd}$$IflFrAx=*7& ``` t0>6    44 lapytF=+,;9- $$Ifa$gd/kd~$$IflFrAx=*7&  t0>6    44 lapytF=$ f$Ifa$gd/;Tpq(kd$$IflFrAx=*7&  t0>6    44 lapytF=$ f$Ifa$gd/ 2$If^2gd/q͆چۆ܆ABPyz˾؞vdUdKBKBhgehb ^Jh=$OJQJ^Jhb OJQJ^JmHnHu#h(,hb OJQJ^JmHnHuh(,hb OJQJ^Jhb OJQJ^J hb 5>*CJ^JaJnH tH hgehF=5\^J&h ]h ]5>*CJ^JaJnH tH h ]hF=OJQJ^Jh ]h ]OJQJ^J&h ]hF=5>*CJ^JaJnH tH &h ]hH5>*CJ^JaJnH tH q$ f$Ifa$gd/ 2$If^2gd/ $$Ifa$gd/͆I=0 -$If^-gd/ $$Ifa$gdb kd$$IflFrAx=*7&  t0>6    44 lapytF=ABP<0 $$Ifa$gdb kd$$IflFrAx=*7&  t0>6    44 lapytF= -$If^-gd=$Pv/kd $$IflFrAx=*7&  t0>6    44 lapytF= -$If^-gd=$ -$If^-gd/܇݇އ23AˆÈڈۈ܈݈߈*ԸԸyh^UMEhN#CJaJh.sCJaJhgehW ^JhW OJQJ^J hW 5>*CJ^JaJnH tH hgeh-^Jh-OJQJ^Jh[_OJQJ^J h-5>*CJ^JaJnH tH  h[_5>*CJ^JaJnH tH hgeh=$^Jhgehb ^Jhb OJQJ^Jh=$OJQJ^J hb 5>*CJ^JaJnH tH  h=$5>*CJ^JaJnH tH ݇ -$If^-gd=$ -$If^-gd/ $$Ifa$gdb ݇އI=0 -$If^-gd/ $$Ifa$gdb kd $$IflFrAx=*7&  t0>6    44 lapytF=23<A<00 $$Ifa$gdb kd$$IflFrAx=*7&  t0>6    44 lapytF= -$If^-gdb AT/kd$$IflFrAx=*7&  t0>6    44 lapytF= -$If^-gd=$ -$If^-gd/Èۈ -$If^-gd=$ -$If^-gd/ $$Ifa$gdb ۈ܈݈ވI=0 -$If^-gd/ $$Ifa$gdb kd$$IflFrAx=*7&  t0>6    44 lapytF=ވ߈<,$@ K^@ `Ka$gdzkd$$IflFrAx=*7&  t0>6    44 lapytF= -$If^-gd=$*+:;׉#wwkd$$Ifl9R:  t 0644 lap $If & F 8 *+;H<LNwxz{|Ҍ2:ݍލߍ6ܸܸܸܕ܄xܕnh|OJQJ^JhN#0JOJQJ^J!jUhN#OJQJU^JjhN#OJQJU^JhN#CJaJhN#6OJQJ]^JhN#OJQJ]^JhN#B*OJQJ^JphhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^Jh!M5OJQJ\^J&$+9= $$Ifa$$Ifgkd$$Ifl9R: t0644 la=>G5/$Ifkd3$$Ifl\ A*99::g (04 lap(GHf$IfpkdV$$Ifl9:   04 lap e_$Ifkd$$Ifl\ A*99::g04 la<xyz$Ifpkdŋ$$Ifl9:   04 lap z{|e____$Ifkdr$$Ifl\ A*99::g04 laьec]$Ifkd4$$Ifl\ A*99::g04 laьҌ2$Ifwkd$$Ifl9R:  t 0644 lap bqkk$Ifkd$$IflF9|P* t06    44 la678`acdYZ[xy|}Տ֏׏?@Aabcdʹʜʋzi!jŕhN#OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^J!j֒hN#OJQJU^JhN#0JOJQJ^J!jבhN#OJQJU^JhN#OJQJ^Jh|0JOJQJ^JjhN#OJQJU^J!j6h|OJQJU^J)bccB~~~$Ifzkd7$$Ifl09|+ t0644 ladאؐېܐ/01@AST‘đőƑɑodQodDhN#5OJQJ\^J$jchN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jhoo0J5OJQJ^J$jhoo5OJQJU^Jhoo5OJQJ^Jjhoo5OJQJU^J!jۗhN#OJQJU^JhN#0JOJQJ^JjhN#OJQJU^J!jƖhN#OJQJU^JhN#OJQJ^JBCSő~~$Ifzkd$$Ifl09|+ t0644 laőƑǑɑys$If & F 8zkd$$Ifl09|+ t0644 laɑ./0ܓ#$fÔʔ˔ TVWoÕ-./<=ᾳ}qhN#0JOJQJ^J!j0hN#OJQJU^JjhN#OJQJU^JhN#B*CJaJphhN#H*OJQJ^JhOJQJ\^JhN#OJQJ\^JhN#B*OJQJ^JphhJOJQJ^JhN#OJQJ^JhN#5OJQJ\^JhN#CJaJ,`t0$If^`0$Ifwkd$$Ifl9R:  t 0644 lap   $$Ifa$gkdW$$Ifl9R: t0644 la/71$Ifkd$$Ifl\ A*{89 : (04 lap(/0ݓ$Ifnkd$$Ifl{88  04 lap  !"#gaaaa$Ifkd$$Ifl\ lA*{89 :04 la#$ghijgaaaa$Ifkd$$Ifl\ lA*{89 :04 lajkga$IfkdO$$Ifl\ lA*{89 :04 laʔ $Ifgd$Ifnkd$$Ifl{88  04 lap ʔ˔̔gaaaa$Ifkdġ$$Ifl\ A*{89 :04 la ga$Ifkd$$Ifl\ A*{89 :04 la STU$Ifnkd\$$Ifl{88  04 lap UVWnge_$Ifkd$$Ifl\ A*{89 :04 lano$IfwkdѤ$$Ifl9R:  t 0644 lap >?qkk$Ifkdz$$IflF9|P* t06    44 la?@ݖC~~$Ifzkd$$Ifl09|+ t0644 la=@A–ɖʖݖޖ ABTUԗ՗חٗ{n[$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jihN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^J CDTؗ~u $Ifgd=/$IfzkdR$$Ifl09|+ t0644 laؗٗڗۗܗzuuljd$If & F 8gd5  8gd5zkd$$Ifl09|+ t0644 laٗڗܗ/12hrstÙ̙ϙ6789پϴϛϑه|oddYh(H*OJQJ^Jha$H*OJQJ^Jha$6OJQJ]^Jha$OJQJ]^Jha$OJQJ^JhOJQJ^JhN#H*OJQJ^Jh(h(H*OJQJ^Jh(OJQJ^J!hN#5B*OJQJ\^JphhN#OJQJ^JhN#5OJQJ\^JhN#CJaJh5mH sH tHh5CJaJb0$Iftkd&$$Ifl9R:  t 0644 lap 0128?MQ $$Ifa$ekdʭ$$Ifl9R: t0644 laQRg71$IfkdO$$Ifl\ ){8D   (04 lap(ghu$If $Ifgd(nkdn$$Ifl{88   04 lap ga$Ifkd$$Ifl\ ){8D  04 laϙ $Ifgd$Ifnkdհ$$Ifl{88   04 lap ϙЙga$Ifkd~$$Ifl\ ){89  04 la !9y$If $Ifgd  $Ifgd(nkdJ$$Ifl{88   04 lap 9:QijgaXaa $Ifgd $Ifkd$$Ifl\ ){8D  04 la9:OP\`bef̚ijƹѮ󠓉~s~s~s~eTeHehN#0JOJQJ^J!jεhN#OJQJU^JjhN#OJQJU^Jh(H*OJQJ^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^JhN#>*B*CJaJphha$H*OJQJ^Jha$6OJQJ]^Jha$OJQJ]^Jha$OJQJ^Jh(h(H*OJQJ^Jh(OJQJ^Jha$5OJQJ\^J˚gb\$If$a$kd$$Ifl\ ){8D  04 la˚̚PЛh$Ifwkdo$$Ifl9R:  t 0644 lap hiqkk$Ifkd$$IflF9|P* t06    44 laefglmpq./23p!jhN#OJQJU^J!jhN#OJQJU^J!j)hN#OJQJU^JhN#0JOJQJ^J!j*hN#OJQJU^JhN#OJQJ^JhR0JOJQJ^J!jhROJQJU^JhROJQJ^JjhN#OJQJU^J%~~~$Ifzkd$$Ifl09|+ t0644 lapqr =>?KMwxz}ʹʨʘzmZPhOJQJ^J$jhN#5OJQJU^Jhoo0J5OJQJ^J$jݿhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!j.hN#OJQJU^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J {~~$Ifzkd=$$Ifl09|+ t0644 la{|}~vp$If  & F 8gdzkdI$$Ifl09|+ t0644 laNr¡áԡա֡סݡ(*;<@AYmoptvڹ乍tčghbahOOJQJ^JhOH*OJQJ^JhN#B*OJQJ^JphhH*OJQJ^JhN#OJQJ\^Jh+=*OJQJ\^Jh+=*H*OJQJ^JhOJQJ\^JhN#H*OJQJ^JhN#5OJQJ^JhN#OJQJ^JhN#5OJQJ\^J hhN#hN#CJaJ(O~~ 9$If]9wkd$$Ifl9:  t 0644 lap OPRX_mq $9$If]9a$9]9gkd$$Ifl9: t0644 laqr7- $9$If]9a$ 9$If]9kd$$Ifl\ A*99 U (04 lap(á)]PC 9$If]9gd 9$If]9gd+=*kdI$$Ifl\ A*99 U04 la 9$If]9)*<=>?g]]]] 9$If]9kd$$Ifl\ A*99 U04 la?@AXgaW 9$If]99]9kd$$Ifl\ A*99 U04 laXYmoprtvآ~~~~~~mX & F,  9$If]9gd+=n & F,9$If]9gd+=n 9$If]9wkd$$Ifl9R:  t 0644 lap עآ,Qpɣޣߣ,-01|}~ƼƼЮНЮЀЮo_jhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!j hN#OJQJU^JjhN#OJQJU^Jh+=*OJQJ^JhOJQJ^JhN#OJQJ^JhOOJQJ^JhbahOOJQJ^JhbahO6OJQJ^J آ,ߣ./IC$IfkdV$$IflF9|P* t06    44 la 9$If]9gd+=* 9$If]9  9$If]9gdO/0ͤϤ~p  9$If]9$Ifzkd$$Ifl09|+ t0644 laϤФR~~$IfzkdE$$Ifl09|+ t0644 la"$NOQUqNpʧ˧ѧyh]hh]hN#H*OJQJ^J!hN#5B*OJQJ\^JphhOJQJ^JhpOJQJ^JhN75OJQJ\^JhN#5OJQJ\^JhN#OJQJ^J$jhN#5OJQJU^Jhoo0J5OJQJ^JjhN#5OJQJU^J$jhN#5OJQJU^JhN#5OJQJ^J"RSTqr|$IfzkdQ$$Ifl09|+ t0644 la/O||$If^`tkd$$Ifl9R:  t 0644 lap OPRX_m $$Ifa$ekd$$Ifl9R: t0644 la71(1 $$Ifa$$Ifkd$$Ifl\ )9D   (04 lap(ͧ^XXO $Ifgdyu$Ifkd9$$Ifl\ )9D  04 la $IfgdN7gaaVa  9r $If$Ifkd$$Ifl\ )9D  04 la$&.58:;<>@IORTUVX[mquwxy٨15LƵӪӝӵƵӪӝӵƵӪӪӵƵӪӉƵӪӵ{hN#OJQJ^JmH sH &hN#OJQJ^JaJmH nH sH tH hN#6OJQJ]^JhN#H*OJQJ^J!hN#5B*OJQJ\^JphhN#5OJQJ\^JhN#OJQJ^J#hJhN#5OJQJ^JmH sH  hJhN#OJQJ^JmH sH 0#.89:b\\\\\\$Ifkd$$Ifl4;\ )9`D ` `04 laf4:;<=IRS<66666$Ifkd$$Ifl4ֈ )9 D`8   04 laf4STUVW[b6kd$$Ifl4,ֈ )9 D 8   04 laf4$Ifbuvwxy6kd($$Ifl4,ֈ )9 D 8   04 laf4$If0kdv$$Ifl4Yֈ )9 D8   04 laf4$$If$If$If٨<6606$If$Ifkd$$Ifl4ֈ )9 D8   04 laf423b\\\\$Ifkd$$Ifl4\ )9D  04 laf4345Qefb\\\\$Ifkd$$Ifl4\ )9D  04 laf4LMPQ_`dhĩJQݪު)*ŵޗtj\K\?\hN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^Jh}LOJQJ^JhN#H*OJQJ^Jh85>*CJ\aJh`W5>*CJ\aJ hJhN#OJQJ^JmH sH hN#5OJQJ\^Jhlhhlh5OJQJ\^JhlhOJQJ\^Jh) h<)sOJQJ\^JhN#OJQJ^JhuShuS5OJQJ^JhuSOJQJ^Jfghb\\Q\  9r $If$Ifkd$$Ifl4\ )9D  `04 laf4dbbbbbbbbbbkde$$Ifl4\ )9D   04 laf4 ©ĩ;ܪz $Ifgd}Lukd.$$Ifl9R:  t 044 lap $If ܪݪ+uvsmmdd[R[ $IfgdB[9 $Ifgd $Ifgd0*T$Ifkd$$IflF9|P* t0    44 la*+,`abMNOì宗j[A[3jhh>*B*OJQJU^Jphhh0JOJQJ^J3jChh>*B*OJQJU^Jph$hh>*B*OJQJ^Jph-jhh>*B*OJQJU^JphhhN#OJQJ^Jh)z'0JOJQJ^J'jhhh)z'OJQJU^Jh)z'OJQJ^J!jhhN#OJQJU^JhN#OJQJ^JìĬŬ-./stuvwοίk\A4*hN#OJQJ^JhhB[9OJQJ^J4hB[9hB[9>*B*OJQJ^JmH nH phsH tH hB[9hB[90JOJQJ^J3jhB[9hB[9>*B*OJQJU^Jph$hB[9hB[9>*B*OJQJ^Jph-jhB[9hB[9>*B*OJQJU^Jphhp>*B*OJQJ^Jphhh0JOJQJ^J-jhh>*B*OJQJU^Jph3jhh>*B*OJQJU^Jphvws  $Ifgd8$Ifykd$$Ifl09|+ t044 lawxíĭŭʭ˭έϭUVWxyz{|ˮ̮ͮ123}r_}$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^Jh8OJQJ^J!jhN#OJQJU^J!jGhN#OJQJU^JhN#0JOJQJ^J!jHhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J!o$Ifykd$$Ifl09|+ t044 la3?Aklnprs¯Яvұ %&\⺭}i[P[hN#H*OJQJ^JhN#OJQJ^JnH tH &hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH h:VOJQJ^JhN#CJaJhN#5OJQJ\^Jh85OJQJ\^JhN#OJQJ^J$jNhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jhoo0J5OJQJ^Jopqsvp$If 8^`ykd$$Ifl09|+ t044 la@vzzzzg 9r 0$If^`00$If^`0wkd$$Ifl9R:  t 0644 lap ͱѱ $$Ifa$gkd?$$Ifl9R: t0644 laѱұ5/$Ifkd$$Ifl\ ){8D   (06k4 lap( $Ifokd$$Ifl{88   06k4 lap  %f`$Ifkd$$Ifl\ ){8D  06k4 la%&=GHhv $Ifgd:V  $If$IfokdX$$Ifl{88   06k4 lap \dhiòIJŲز۲ܲݲ;<=y "$%Z[]^klno߼ߥh%& OJQJ^JhH*OJQJ^Jh:VOJQJ^Jh5OJQJ\^JhOJQJ^JhhlQOJQJ^JhN#5OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^JhN#OJQJ^JhyYOJQJ^J/hiof`V``  $If$Ifkd$$Ifl\ ){8D  06k4 laf````$Ifkd$$Ifl\ ){8D  06k4 laòIJf``$Ifkd$$Ifl\ ){8D  06k4 laIJŲƲ۲ܲݲ< $Ifgd 0o$IfokdG$$Ifl{88   06k4 lap <=ELZ^cTHHH $$Ifa$gd  $Ifgdkd$$Ifl\ ){8D  06k4 layt^_x2,$Ifkd$$Ifl\ A*{89 : (06k4 lap(yt8xy $Ifgd:V$Ifokd$$Ifl{88   06k4 lap ͳ f````$Ifkd$$Ifl\ ){8D  06k4 la !f`$Ifkd]$$Ifl\ ){8D  06k4 la!"#$%Z$Ifokd$$Ifl{88   06k4 lap Z[\]^kf````$Ifkd$$Ifl\ ){8D  06k4 laklmnof````$Ifkd$$Ifl\ ){8D  06k4 lac]]]]$IfkdL$$Ifl\ ){8D  06k4 laytҴӴԴմִ "6ʻʝʝtfYOhOJQJ^Jh5OJQJ\^JhN#>*B*CJaJphh:Vh85OJQJ\^Jh8OJQJ\^Jhh8OJQJ\^Jh8OJQJ^J&hh85H*OJQJ^JmH sH h85OJQJ^JmH sH #hh85OJQJ^JmH sH h85OJQJ\^Jh%& OJQJ^Jh%& 5OJQJ\^JcTHHH $$Ifa$gd,  $Ifgd,kd$$Ifl\ ){8D  06k4 laytӴ0*$Ifkd$$Ifl \ A*{89::: (06k4 lap(yt8ӴԴմִ{ $Ifgd:V$Iftkd$$Ifl{88  06k4 lap yt8 !KFF= $Ifgd$a$kd$$Ifl\ ){8D  06k4 lap(yt!"68:<>@||||||||||| $Ifgdzkd$$Ifl9R:  t 0644 lap yt 6@۶ܶݶ:;<ABEFnopwx·׷طٷڷܿܿܿܿ܂kX$h8h8>*B*OJQJ^Jph-jh8h8>*B*OJQJU^JphhOJQJ^J!jNhOJQJU^J!jhOJQJU^J!jhOJQJU^Jh0JOJQJ^J!jhOJQJU^JjhOJQJU^JhOJQJ^JhH*OJQJ^J nee $IfgdkdS$$IflF9|P* t06    44 laytٷ;xkb $Ifgd8  $Ifgd $Ifgd}kd$$Ifl09|+ t0644 layt 89LMwxzEFGSTοεyhy\yI<hoo0J5OJQJ^J$jlh5OJQJU^Jh0JOJQJ^J!j=hOJQJU^JjhOJQJU^J$jh5OJQJU^Jh5OJQJ^Jjh5OJQJU^JhOJQJ^Jh8h80JOJQJ^J-jh8h8>*B*OJQJU^Jph3jh8h8>*B*OJQJU^Jph;<LUxxx $Ifgd}kd$$Ifl09|+ t0644 laytUVXuo$If  & F 8}kd-$$Ifl09|+ t0644 laytTVXͺ>JhŻ  (/GHbvz{}Ʋ駚׏鄚קzozez׏ozh}LOJQJ^Jh(3H*OJQJ^Jh(3OJQJ^Jh0kOJQJ]^JhN#H*OJQJ^JhN#6OJQJ]^JhN#OJQJ]^J&hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^JhN#CJaJhN#5OJQJ\^JhOJQJ^J'Vͺy  9r $If$Iftkd$$Ifl9R:  t 0644 lap  $$Ifa$ekdw$$Ifl9R: t0644 la !=71$Ifkd$$Ifl\ ){8DHh  (04 lap(=>GHIJ$Ifnkd)$$Ifl{88   04 lap JKgga$Ifkd$$Ifl\ ){8DHh 04 laght$Ifnkd $$Ifl{88   04 lap g^XXX$If $Ifgd0kkdG $$Ifl\ ){8DHh 04 laga$Ifkd $$Ifl\ ){8DHh 04 laŻ$Ifnkd $$Ifl{88   04 lap Żƻga$Ifkd $$Ifl\ ){8DHh 04 la H $Ifgd}L$IfnkdT $$Ifl{88   04 lap HIJage_$Ifkd $$Ifl\ ){8DHh 04 laabvxyz{}zq $Ifgd8 $Ifgd(3$Ifukd$$Ifl9R:  t 044 lap MNнҽӽ !"/034оѾ׫o^!jhN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!j"hN#OJQJU^JjhN#OJQJU^JhuFOJQJ]^Jh8OJQJ^JhN#OJQJ^JhN#6OJQJ]^JhN#OJQJ]^JhuFOJQJ^Jh(3OJQJ^Jh}LOJQJ^J#12smm$Ifkdo$$IflF9|P* t0    44 la23оv  $If$Ifykd$$Ifl09|+ t044 la/0cdeqs׿NOnoʺ|ogZgooooooRghuFCJaJh8h8mH sH tHhN#CJaJhN#5OJQJ\^J$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jXhN#OJQJU^J /$Ifykd)$$Ifl09|+ t044 la׿ؿ޿zuzllll $$Ifa$gd8  & F 8ykd2$$Ifl09|+ t044 la N71111$Ifkd$$Ifl\ ){8D   (04 lap(NOPlmngaaaa$Ifkd$$Ifl\ ){8D  04 lanopgaaaa$Ifkd$$Ifl\ ){8D  04 lagaaaaa$Ifkdj$$Ifl\ ){8D  04 la gULLLL $$Ifa$ 8^`gdb kd($$Ifl\ ){8D  04 laeruz{|_`abcnopstuɹ⚌ue[V[KuhyuH*OJQJ^J hN:5hN:OJQJ^JhuFhr!H*OJQJ\^Jhr!OJQJ^Jhr!5OJQJ\^JhuV'hN#OJQJ\^JhuV'huV'OJQJ\^J!hhuV'5H*OJQJ\^JhhuV'5OJQJ\^JhuV'OJQJ\^Jhr!huV'OJQJ\^JhN#OJQJ^JhN#5OJQJ\^J h8h8e|5,&&$If $$Ifa$kd$$Ifl\ )9f   (04 lap(|__VMG$If $IfgduV' $$Ifa$kd $$Ifl\ )9f  04 la$If_`abcte\VMD $Ifgdb $Ifgdr!$If $$Ifa$kd$$Ifl\ )9f  04 latuvwxe\VMD $Ifgdb $Ifgdr!$If $$Ifa$kd$$Ifl\ )9f  04 lauvwxH[²̥vi__ODhuF5OJQJ^JjhuF5OJQJU^JhyuOJQJ^JhOehOeOJQJ^JhOehOeOJQJ^JaJhN:H*OJQJ^JhuFH*OJQJ^JhuFOJQJ^JhuF5OJQJ\^JhuFh=$H*OJQJ\^Jh=$OJQJ^Jh=$5OJQJ\^JhuFhb H*OJQJ\^Jhb OJQJ^Jhb 5OJQJ\^Je\VMD $Ifgd=$ $Ifgdr!$If $$Ifa$kdO$$Ifl\ )9f  04 lae\ $Ifgd kd$$Ifl\ )9f  04 la[}tttbYY} $Ifgd8xx$7$8$H$IfgdOe $IfgdN: $Ifgd xkd$$Ifl9R:  t 044 lap yt  Anee $Ifgd kd $$IflF9|P* t0    44 laytOe=>@BCv'MNOZ[\]^v56rŲݨ~~s~~e~s~~s~W~jhN#OJQJU^JhN#B*OJQJ^JphhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^JhN#CJaJhuFhuFmH sH huFOJQJ^J$j"huF5OJQJU^JhuF5OJQJ^Jhoo0J5OJQJ^JjhuF5OJQJU^J$jNOcʺ|rj]]]]]RRhN#H*OJQJ^JhN#5OJQJ\^JhN#CJaJh|`OJQJ^J$j 2hN#5OJQJU^Jhoo0J5OJQJ^J$j+1hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!j/hN#OJQJU^J ~~$Ifzkd0$$Ifl09|+ t0644 lazkd2$$Ifl09|+ t0644 la$vpffff & F$Ifzkdk3$$Ifl;:  t 0644 lap yt[|E$If  & F 8gd+=n $$Ifa$jkd4$$Ifl;: t0644 layt[|E,&$Ifkd4$$IfTl\k+<: (0t64 la=p(yt[|ET>?Pbc$Ifxkd5$$IfTl<:   0t64 la=p yt[|ETcdt]WNWW $Ifgd}L$Ifkd6$$IfTl\k+<:0t64 la=yt[|ETcd!"#$'EXY[hm>?@顓zhN#OJQJ\^Jh}"h|`H*OJQJ^Jh|`h|`5OJQJ^Jh|`OJQJ^JhN#OJQJ^JnH tH  hJhN#OJQJ^JmH sH hN#H*OJQJ^Jh}LOJQJ^Jh8OJQJ^JhN#OJQJ^JhN#5OJQJ\^J)]W$IfkdF7$$IfTl\k+<:0t64 la=yt[|ETu  9r $If$Ifxkd8$$IfTl<:   0t64 la=p yt[|ET]WLWW  9r $If$Ifkd8$$IfTl\k+<:0t64 la=yt[|ET]W$Ifkd9$$IfTl\k+<:0t64 la=yt[|ET#$%&u  9r $If$Ifxkd?:$$IfTl<:   0t64 la=p yt[|ET&'EFGH]WQQQ$If$Ifkd:$$IfTl\k+<:0t64 la=yt[|ETHIZ[)##$Ifkd;$$IfTl4\k+<: (0t64 la=f4p(yt[|ET[Kkd<$$IfTl4\k+<:0t64 la=f4yt[|ET $Ifgd}"$If{uuu$If  9r $Ifxkd=$$IfTl<:   0t64 la=p yt[|ET]W$Ifkdd>$$IfTl\k+<:0t64 la=yt[|ETu  9r $If$Ifxkd"?$$IfTl<:   0t64 la=p yt[|ET:]W$Ifkd?$$IfTl\k+<:0t64 la=yt[|ET:;<=>?u  9r $If$Ifxkd@$$IfTl<:   0t64 la=p yt[|ET?@Y]R  9r $Ifkd^A$$IfTl\k+<:0t64 la=yt[|ET@Y]=J\%ķĄyoeoeo[oeoMjhN#OJQJU^Jh}LOJQJ^Jh|`OJQJ^Jh}"OJQJ^Jh}"H*OJQJ^JhN#H*OJQJ^JhaHOJQJ^J hJhaHOJQJ^JmH sH h|`5OJQJ\^JhaH5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH hN#5OJQJ\^J&hJhN#5OJQJ\^JmH sH YZ[\]l}}}rr  9r $If$If{kdB$$IfTl4<:  0t64 la=f4p yt[|ET]WWWWWL  9r $If$IfkdB$$IfTl\k+<:0t64 la=yt[|ET]W$IfkdC$$IfTl\k+<:0t64 la=yt[|ET{{{{{{{{{{{{{$If~kd]D$$IfTl<:  t 0t644 la=p yt[|ET(6q[kdE$$IfTlF/<: t0t6    44 la=yt[|ET $Ifgd|`$If%&'4567|}~ 012opqrsʼsb!j)JhN#OJQJU^J!jHh|`OJQJU^J!jGh|`OJQJU^Jh|`0JOJQJ^J!jFh|`OJQJU^Jh|`OJQJ^Jjh|`OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jEhN#OJQJU^J$qr}wne $Ifgd|` $IfgdJV%$IfkdzI$$IfTl0<:   t0t644 la=yt[|ETDEF[\_`56`acefgʹʨʞʎpdS!hN#5B*OJQJ\^JphhN#B*CJaJph$jPNhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhJV%OJQJ^J!jLhN#OJQJU^J!jKhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!j(KhN#OJQJU^J5d}www$IfkdM$$IfTl0<:   t0t644 la=yt[|ETdefg}~}{qljd$Ifgd}" 0^`0kdN$$IfTl0<:   t0t644 la=yt[|ETgh}+,-abmno{~+?AEۺ۰ۛۺh[H*OJQJ^Jh}LOJQJ^Jh.OJQJ^Jh-H*OJQJ^Jh-OJQJ^JhN#H*OJQJ^Jh[5OJQJ^JhN#5OJQJ^JhN#OJQJ^Jh}"hN#5OJQJ^JhN#5OJQJ\^J2 & F$IftkdO$$Ifl9R:  t 0644 lap  $$Ifa$ekdNP$$Ifl9R: t0644 la5/&/ $$Ifa$$IfkdP$$Ifl\ B*|8:::: (04 lap( -.a\OF $Ifgd- h$If^hgd-kdQ$$Ifl4\ B*|8::::04 laf4$Ifabcnob\V\E< $Ifgd-"$If^"`gd-$If$IfkdR$$Ifl4\ B*|8::::04 laf4b\V\\$If$IfkdNS$$Ifl4\ B*|8::::04 laf4b\V\\$If$IfkdT$$Ifl4\ B*|8::::04 laf4b\V\\$If$IfkdT$$Ifl4\ B*|8::::04 laf4b\S\\ $Ifgd}L$Ifkd|U$$Ifl4\ B*|8::::04 laf4b\\\\$Ifkd6V$$Ifl4\ B*|8::::04 laf4*b`Z$IfkdV$$Ifl4\ B*|8::::04 laf4*+?ABCEo qdd & F.$Ifgd+=n"$If^"`gd[$IfwkdW$$Ifl9R:  t 0644 lap ox}~ !npdM-jhgehge>*B*OJQJU^JphhN#0JOJQJ^J!j YhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh-h-OJQJ^J-h-h-B*OJPJQJ^JmH phsH hEh-OJQJ^Jh[OJQJ^JnH tH  hQh[OJQJ^JnH tH hQh[OJQJ^Jh[OJQJ^J!nQQKB $Ifgdge$IfkdSX$$IflF9|P* t06    44 la $Ifgd- $7$8$H$Ifgd- I$Ifgd- !OPQRSEFGij|ӼwkZkIk!j]hN#OJQJU^J!jV\hN#OJQJU^JhN#0JOJQJ^J!jW[hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jhgeh}"OJQJ^Jhgehge0JOJQJ^J-jhgehge>*B*OJQJU^Jph3jYhgehge>*B*OJQJU^Jph$hgehge>*B*OJQJ^JphQRk~~$IfzkdZ$$Ifl09|+ t0644 lakl|~t h$If^h$Ifzkd^$$Ifl09|+ t0644 la|}FG !"𨗆~qf[ffqqPhN#H*OJQJ^Jh}LOJQJ\^JhN#OJQJ\^JhN#5OJQJ\^JhN#CJaJ!h25B*OJQJ\^Jph!hN#5B*OJQJ\^JphhN#OJQJ^J$jq_hN#5OJQJU^Jhoo0J5OJQJ^J$j^hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jzzzzpnh$If  & F 8 0^`0zkd`$$Ifl09|+ t0644 layG & F$Iftkd`$$Ifl9R:  t 0644 lap  $$Ifa$ekd`a$$Ifl9R: t0644 la"QR5/$/  9r $If$Ifkda$$Ifl\ B*|8:::: (04 lap("QZ[ghi(*+,SW0348?Wknpqr圊uugh25OJQJ\]^Jh7OJQJ^Jh2H*OJQJ^J#hJh2H*OJQJ^JmH sH hN#H*OJQJ^Jh2OJQJ^J#hJhN#H*OJQJ^JmH sH h(H*OJQJ^Jh(OJQJ^JhN#5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH 'RZ[i_T  9r $Ifkdb$$Ifl\ B*|8::::04 la$If()*e_T__  9r $If$Ifkdc$$Ifl\ B*|8::::04 la*+,STUe_T__  9r $If$Ifkd8d$$Ifl\ B*|8::::04 laUVWe_T__  9r $If$Ifkdd$$Ifl\ B*|8::::04 la456e_T__  9r $If$Ifkde$$Ifl\ B*|8::::04 la6789:;<=>?Vecccccccc]$Ifkd*f$$Ifl\ B*|8::::04 la VWkmqryyyy $Ifgd8$Ifwkdf$$Ifl9R:  t 0644 lap "qkkkk$Ifkdyg$$IflF9|P* t06    44 la !"#hij *+vp!jlhN#OJQJU^J!jkhN#OJQJU^J!jjh2OJQJU^Jh20JOJQJ^J!jihOJQJU^Jh2OJQJ^JhN#0JOJQJ^J!j/hhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J(*\(~~~$Ifzkdk$$Ifl09|+ t0644 lavwx\]&'9:mno{}ʼʫʚʊl_L$j{qhN#5OJQJU^Jhoo0J5OJQJ^J$jphN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!j[ohN#OJQJU^J!jZnhN#OJQJU^JhN#5OJQJ\]^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jmmhN#OJQJU^J()9~t h$If^h$Ifzkdp$$Ifl09|+ t0644 la{2`abv,-;<?^ż毢uguZh85OJQJ\^Jh2OJQJ^JmH sH  hJhaHOJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ^Jh`LV5OJQJ\^JhN#5OJQJ\^JhN#5\^JhN#CJaJh`WCJaJ!hN#5B*OJQJ\^JphhN#OJQJ^JjhN#5OJQJU^J!zhb$If 8^`gd2 0^`0zkd&r$$Ifl09|+ t0644 laKhc{ & F$Iftkdr$$Ifl9R:  t 0644 lap  $$Ifa$ekdjs$$Ifl9R: t0644 la 2,$Ifkds$$Ifl\ B*$:::: (04 lap(yt245`} $$Ifa$$Ifskd u$$Ifl$::  04 lap yt2`abvwb\Q\\  9r $If$Ifkdu$$Ifl\ B*$::::04 layt2b\Q\\  9r $If$Ifkdwv$$Ifl\ B*$::::04 layt2b\$Ifkd1w$$Ifl\ B*$::::04 layt2x  9r $Ifgd2$Ifskdw$$IflF$::  04 lap yt2-<=>b\NN\\  9r $Ifgd2$Ifkdx$$IflF\ B*$::::04 layt2>?ELZ^bVVVV $$Ifa$gd kdXy$$IflF\ B*$::::04 layt2^_/)$Ifkdz$$Ifl4\ B*$:::: (~04 laf4p(~yt2^_p()cdeμαzzoμhN#H*OJQJ^J#hJh(H*OJQJ^JmH sH  hJh(OJQJ^JmH sH &hJhN#5OJQJ\^JmH sH hN#OJQJ\^J#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^JhN#5OJQJ\^Jh8OJQJ^J)$Ifvkd3{$$Ifl4$::  04 laf4p yt2_Y$Ifkd{$$Ifl4\ B*$::::04 laf4yt2p~xo~ $IfgdaH$If  9r $Ifvkd|$$Ifl4$::   04 laf4p yt2bW  9r $Ifkde}$$Ifl\ B*$::::04 layt2~xr~$If$If  9r $Ifvkd~$$Ifl4$::   04 laf4p yt2bWQQW$If  9r $Ifkd~$$Ifl\ B*$::::04 layt2bWQQW$If  9r $Ifkd$$Ifl\ B*$::::04 layt2(bW  9r $IfkdL$$Ifl\ B*$::::04 layt2()Yefg}rll$If  9r $If  9r $Ifvkd$$Ifl4$::   04 laf4p yt2eghqrvxy봟zzkYzzz#h8h85OJQJ^JmH sH h8H*OJQJ^JmH sH &hJhN#5OJQJ\^JmH sH  h (hN#CJ^JaJnH tH )h (hN#5>*CJH*^JaJnH tH &h (hN#5>*CJ^JaJnH tH #hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#CJaJghuvwx_TTNN$If  9r $Ifkd$$Ifl4\ B*$::::04 laf4yt2xy_VPEE  9r $If$If $$Ifa$kd$$Ifl4\ B*$::::04 laf4yt2_T  9r $Ifkd?$$Ifl4\ B*$::::04 laf4yt2~~~~  9r $Ifvkd$$Ifl4$::  04 laf4p yt2/$  9r $Ifkd$$Ifl4\ B*$:::: (04 laf4p(yt2~~~~  9r $Ifvkdم$$Ifl4$::  04 laf4p yt2/$  9r $Ifkd$$Ifl4\ B*$:::: (04 laf4p(yt2 +~~~~  9r $Ifvkd$$Ifl4$::  04 laf4p yt2+DXi $6ELt9@FHIǼDzDzDzǨDzǜtfUfIhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhzOJQJ^JaJhihN#5OJQJ^JaJhN#OJQJ^JaJhN#OJQJ^JaJhzOJQJ^Jh}LOJQJ^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^J hJhN#OJQJ^JmH sH  hJh`LVOJQJ^JmH sH +,C/)$Ifkdl$$Ifl4\ B*$:::: (04 laf4p(yt2CDXZ\^`bdfgiB$Ifxkd$$Ifl9T:  t 0<44 lap ytaHBsGH<jaa $Ifgd2kd9$$IflFj  9 . t0<    44 laytaH$If  !"9:<=>!Ͼٲϡٲsb!j3hN#OJQJU^J!jzhN#OJQJU^JhN#0JOJQJ^J!j{hN#OJQJU^J!jЌhOJQJU^Jh20JOJQJ^J!jӋh2OJQJU^Jh2OJQJ^Jjh2OJQJU^JhN#OJQJ^JjhN#OJQJU^J&<=zz $Ifgd2|kd؍$$Ifl09~+ t0<44 laytaH!"wxy[uy2ABfgh獅xxmxx\xQhN#H*OJQJ^J hJhN#OJQJ^JmH sH hN#5OJQJ^JhN#5OJQJ\^JhN#CJaJhJV%CJaJh20JOJQJ^J!jh2OJQJU^Jjh2OJQJU^Jh2OJQJ^JhN#0JOJQJ^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J[\kqoi$If 8^`gdJV%|kd$$Ifl09~+ t0<44 laytaHklu}&Rz~t~jttt & F$If & F$If h$If^hwkd$$Ifl9R:  t 0644 lap z{ $$Ifa$gkd.$$Ifl9R: t0644 la0*$Ifkd$$Ifl\ B*|8:::: (06j4 lap(yt`W23As  9r $Ifgd+:$Ifwkdȕ$$Ifl4|88   06j4 laf4p yt`WABhijaXMGA$If$If  9r $If $Ifgd2kd$$Ifl\ B*|8::::06j4 layt`WhiIJU\]`~o]#hJh2OJQJ\^JmH sH h2OJQJ\^JmH sH #hJhh1OJQJ\^JmH sH #hJhN#OJQJ\^JmH sH &hJhN#5OJQJ\^JmH sH h* OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^Jh`LV5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH  a[[U[L $Ifgdkyp$If$Ifkd3$$Ifl\ B*|8::::06j4 layt`W-'$Ifkd$$Ifl4\ B*|8:::: (06j4 laf4p(yt`W>Iv  9r $If$Ifwkd$$Ifl4|88   06j4 laf4p yt`WIJabcda[[[[$Ifkd$$Ifl\ B*|8::::06j4 layt`Wderstua[[[[$Ifkdc$$Ifl\ B*|8::::06j4 layt`Wuv^XXXX$Ifkd$$Ifl4\ B*|8::::06j4 laf4yt`W^S  9r $IfkdǛ$$Ifl4\ B*|8::::06j4 laf4yt`W||n|  9r $Ifgd2  9r $Ifwkd|$$Ifl4|88   06j4 laf4p yt`WHI^SSES  9r $Ifgd+:  9r $Ifkd8$$Ifl4\ B*|8::::06j4 laf4yt`W#(GHIJKLY_`abɺۙtbNbtA-&hJhN#5OJQJ\^JmH sH h0k5OJQJ\^J&h* h0k5OJQJ\^JmH sH #hJh0kOJQJ\^JmH sH &hJh0k5OJQJ\^JmH sH  hJh0kOJQJ^JmH sH h25OJQJ\^J&h+:h+:5OJQJ\^JmH sH h+:OJQJ\^JmH sH #hJh2OJQJ\^JmH sH &hJh25OJQJ\^JmH sH  hJh2OJQJ^JmH sH IJKL`a^SSES  9r $Ifgdh1  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4yt`Wab^S  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4yt`W|||j$ 9r 6$If`6a$  9r $IfwkdW$$Ifl4|88   06j4 laf4p yt`W{};<xyz󺬛yoaPaDahN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^Jh(OJQJ^JhN#H*OJQJ^JhN#OJQJ^Jh yt5OJQJ\^J hJh ytOJQJ^JmH sH h ytOJQJ^JmH sH &hJh yt5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH &hJhN#5OJQJ\^JmH sH hN#5OJQJ\^J^SSSA$ 9r 6$If`6a$  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4yt`W^X$IfkdȠ$$Ifl4\ B*|8::::06j4 laf4yt`W:$Ifzkd}$$Ifl9:  t 06P44 lap yt[|E :;nhh_V $Ifgd`LV $Ifgd yt$Ifkd,$$IflF9|* t06P    44 layt[|ES`sdXd>d3jh+:h+:>*B*OJQJU^JphhyY0JOJQJ^Jh+:h+:0JOJQJ^J3jʤh+:h+:>*B*OJQJU^Jph$h+:h+:>*B*OJQJ^Jph-jh+:h+:>*B*OJQJU^Jphh+:hN#OJQJ^Jh`LV0JOJQJ^J'jɣh+:h`LVOJQJU^Jh`LVOJQJ^J!jh+:hN#OJQJU^J?@AFGJKstu|}678Z[!"LtihN#5OJQJ^JjhN#5OJQJU^Jh[|EOJQJ^J!jhN#OJQJU^J!j¨hN#OJQJU^J!j hN#OJQJU^JhN#0JOJQJ^J!j hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh ytOJQJ^J"\{r $Ifgd`LV$If}kdd$$Ifl09|+ t06P44 layt[|E\]mP{{r $Ifgd[|E$If}kd$$Ifl09|+ t06P44 layt[|ELMORact 9<HӶӶӶ|o|[J hJh!OJQJ^JmH sH &hJh!5OJQJ\^JmH sH h}L5OJQJ\^Jh!5OJQJ\^J hJhN#OJQJ^JmH sH &hJhN#5OJQJ\^JmH sH hN#CJaJhN#5OJQJ\^JhN#56OJQJ\]^JhN#OJQJ^JjhN#5OJQJU^J$j(hN#5OJQJU^JPQR`{oooo{{{f $Ifgd`LV  $If$If}kdӫ$$Ifl09|+ t06P44 layt[|E `actu{nl_lVVVV $$Ifa$  & F 8gd+=nkdy$$IflF49|$ b" t06P    44 layt`W5***  9r $Ifkd5$$Ifl\ B*|8:::: (04 lap( &48WUIIII $$Ifa$gd tkd<$$Ifl4\ B*|8::::04 laf4  9r $If89:;<2$$$  9r $Ifgd tkd$$Ifl\ B*|8:::: (04 lap(yt tHJQSfg ûzp\K>hlQ5OJQJ\^J hJhlQOJQJ^JmH sH &hJhlQ5OJQJ\^JmH sH h* OJQJ^Jh* h* 5OJQJ^JhstH*OJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ^JhN#5OJQJ\^JhN#CJaJh!OJQJ^J hJh!OJQJ^JmH sH h}L5OJQJ^JmH sH #hfhf5OJQJ^JmH sH <fgQDB99 $$Ifa$  & F 8gd+=nkd$$Ifl4\ B*|8::::04 laf4yt t  9r $Ifgd}L,&$Ifkd$$Ifl\ B*|8:::: (04 lap( $$Ifa${r $Ifgdst  9r $If$Ifskd$$Ifl4|88   04 laf4p  e_T__  9r $If$Ifkda$$Ifl\ B*|8::::04 la  eZZZZ  9r $Ifkd$$Ifl\ B*|8::::04 la !AbWWWW  9r $Ifkd$$Ifl4\ B*|8::::04 laf4!@ABEX_κ|dRA hJh/NOJQJ^JmH sH #hJhN#OJQJ\^JmH sH /hJh/N5B*OJQJ\^JmH phsH #hJh/NOJQJ\^JmH sH hv5OJQJ\^Jh}LOJQJ^JmH sH  hJhvOJQJ^JmH sH &hJhv5OJQJ\^JmH sH hN#5OJQJ\^J hJhN#OJQJ^JmH sH &hJhN#5OJQJ\^JmH sH ABCDEbWWWW  9r $IfkdY$$Ifl4\ B*|8::::04 laf4bW  9r $Ifkd$$Ifl4\ B*|8::::04 laf4~sss  9r $If  9r $Ifgdstskd$$Ifl4|88   04 laf4p $=SbWWWIWW  9r $Ifgda  9r $Ifkdd$$Ifl4\ B*|8::::04 laf4"#$>STUVkq޾veQ?e-#hJhaOJQJ\^JmH sH #h] ha5OJQJ^JmH sH &hJha5OJQJ\^JmH sH  hJhaOJQJ^JmH sH h/N5OJQJ\^J/hJh/N5B*OJQJ\^JmH phsH #hJh/NOJQJ\^JmH sH  hJh/NOJQJ^JmH sH haOJQJ^JmH sH #h] hfB5OJQJ^JmH sH hfBOJQJ^JmH sH &hJh/N5OJQJ\^JmH sH STUVbWWWW  9r $Ifkd$$Ifl4\ B*|8::::04 laf4bWWWI  9r $IfgdZzI  9r $Ifkd$$Ifl4\ B*|8::::04 laf4r[I4)hd|YhkypB*OJQJ^JmH phsH #hd|YB*OJQJ^JmH phsH , *hd|Yhd|YB*OJQJ^JmH phsH &hJhd|Y5OJQJ\^JmH sH  hJhd|YOJQJ^JmH sH hd|YOJQJ^JmH sH hZzI5OJQJ\^Jh:OJQJ^JmH sH hZzIOJQJ^JmH sH &hJhZzI5OJQJ\^JmH sH  hJhZzIOJQJ^JmH sH ha5OJQJ\^JbWWWI  9r $Ifgdd|Y  9r $Ifkdh$$Ifl4\ B*|8::::04 laf4bWWWII  9r $Ifgdd|Y  9r $Ifkd$$Ifl4\ B*|8::::04 laf4/bW  9r $Ifkd$$Ifl4\ B*|8::::04 laf4/03EFGwz{Ҿ~m~c~cRc~H=hN#H*OJQJ^JhN#OJQJ^J hJhV;)OJQJ^JmH sH hV;)OJQJ^J hJh[?OJQJ^JmH sH h[?OJQJ^Jh[?5OJQJ\^Jh+:OJQJ^Jh>m5OJQJ\^J#h>mh>mOJQJ\^JmH sH &hJh>m5OJQJ\^JmH sH hN#5OJQJ\^J&hJhN#5OJQJ\^JmH sH hd|Y5OJQJ\^J/0123E  9r $Ifskdl$$Ifl4|88   04 laf4p EFGM/-! $$Ifa$gdVkd$$Ifl4\ B*|8:::: (04 laf4p(yt>mMTbfg&kd2$$Ifl\ B*9:::T (04 lap(ytV;) $$Ifa$gdVgxyz{|wiw` $IfgdV;)  9r $IfgdV $IfgdVvkdM$$Ifl49:   04 laf4p ytV;) $Ifgd[?bYKYB $IfgdV;)  9r $IfgdV $IfgdVkd$$Ifl\ B*9:::T04 laytV;)b`Z$Ifkd$$Ifl\ B*9:::T04 laytV;);yy $Ifgdst$Ifwkdz$$Ifl9R:  t 0644 lap :;<=yz{󽯽{hN{?{h{hh>mh>m0JOJQJ^J3jh>mh>m>*B*OJQJU^Jph$h>mh>m>*B*OJQJ^Jph-jh>mh>m>*B*OJQJU^JphhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^J)hsthstOJQJ^JfHq hstOJQJ^JhsthstOJQJ^JhsthN#OJQJ^J;<NHqkbbYPG $IfgdZV $Ifgdt $Ifgd|f $Ifgd>m$Ifkd#$$IflF9|P* t06    44 laLMNO|}~FGHIvwxοάάοάάxοάά^οάά3jh>mh>m>*B*OJQJU^Jph3j!h>mh>m>*B*OJQJU^Jph3jTh>mh>m>*B*OJQJU^Jph$h>mh>m>*B*OJQJ^Jphh>mh>m0JOJQJ^J-jh>mh>m>*B*OJQJU^Jph3jh>mh>m>*B*OJQJU^Jph! " # $ Q R S        F G H I    οάάοάάxοhZP?Z!j"hd|YOJQJU^Jhd|YOJQJ^Jjhd|YOJQJU^JhZzI>*B*OJQJ^Jph3jUh>mh>m>*B*OJQJU^Jph3jh>mh>m>*B*OJQJU^Jph$h>mh>m>*B*OJQJ^Jphh>mh>m0JOJQJ^J-jh>mh>m>*B*OJQJU^Jph3jh>mh>m>*B*OJQJU^Jph#  H B C D   @ iccc$Ifzkd$$Ifl09|+ t0644 la $Ifgd>m $Ifgd> $Ifgd22 @ A C D E                  ; < ? @           > ? ҳħҖħ҅ħtħcħ!jhN#OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^J!jNhN#OJQJU^JhN#0JOJQJ^J!jOhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jhd|YOJQJ^Jjhd|YOJQJU^Jhd|Y0JOJQJ^J&@ A Q  ~~$Ifzkd$$Ifl09|+ t0644 la? Q S T             ()*6ۻ~qdqYH hJhN#OJQJ^JmH sH hN#H*OJQJ^Jh'5OJQJ\^JhN#5OJQJ\^JhN#CJaJ!h'5B*OJQJ\^Jph!hN#5B*OJQJ\^Jph$j/hN#5OJQJU^Jhoo0J5OJQJ^J$jnhN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^JhN#OJQJ^J              u  & F 8gd+=nzkd$$Ifl09|+ t0644 la     $$Ifa$*:5/$  9r $If$Ifkdz$$Ifl\ B*|8:::: (04 lap(679:D\abcmnopĺuk]RGR:h'hs%,OJQJ^Jh'5OJQJ^Jhs%,5OJQJ^Jhs%,hs%,5OJQJ^Jhs%,OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^Jh?<OJQJ^JhN#OJQJ^Jh JH*OJQJ^Jhiho5OJQJ^JhoOJQJ^JhJV%OJQJ^J hJhN#OJQJ^JmH sH h'OJQJ^JmH sH #hJhN#H*OJQJ^JmH sH :dopOI>I  9r $If$Ifkd$$Ifl\ B*|8::::04 la $Ifgd' W$If`Wgd Je_T_K $Ifgd'  9r $If$Ifkd'$$Ifl\ B*|8::::04 la *+,-01232Ӂvk`Ukh=H*OJQJ^JhoH*OJQJ^Jh<)sH*OJQJ^JhJV%H*OJQJ^Jh JH*OJQJ^JhN#5OJQJ\^Jh`WOJQJ^Jh?<H*OJQJ^Jh?<OJQJ^JhyYOJQJ^J hJhN#OJQJ^JmH sH hN#H*OJQJ^JhN#6OJQJ]^JhN#OJQJ]^JhN#OJQJ^J ec]$Ifkd$$Ifl\ B*|8::::04 la  !"$%'()*,-./0$Ifwkds$$Ifl9R:  t 0644 lap 0137o<pqe $Ifgd<)s $Ifgdo & F0$Ifgd+=n $Ifgd' $If$If 2opq<[opqQX ٴٴϪ~s~eTeHhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^Jh}L5OJQJ^Jh4h<)s5OJQJ^Jh}LOJQJ^Jh'OJQJ^Jh<)sOJQJ^Jh=OJQJ^JhRehoOJQJ^JhihJV%5OJQJ^JhJV%OJQJ^JhoOJQJ^JhN#OJQJ^J$hHthN#5B*OJQJ^Jph HqkkbYPYG $Ifgd\ $Ifgdg4 $IfgdQ $Ifgd'$Ifkd$$IflF9|P* t06    44 la    ABCFGHIvɵ֦ɏ|b||H||3jYhQhQ>*B*OJQJU^Jph3jhQhQ>*B*OJQJU^Jph$hQhQ>*B*OJQJ^Jph-jhQhQ>*B*OJQJU^JphhQhQ0JOJQJ^J'jhQhQOJQJU^JhQhQOJQJ^J!jhQhQOJQJU^JhN#OJQJ^JjhN#OJQJU^Jvwx`abοάάο΂tjYtMtjChN#OJQJ^Jh)z'0JOJQJ^J!jh)z'OJQJU^Jh)z'OJQJ^Jjh)z'OJQJU^Jhg4>*B*OJQJ^Jph3jhQhQ>*B*OJQJU^Jph$hQhQ>*B*OJQJ^JphhQhQ0JOJQJ^J-jhQhQ>*B*OJQJU^Jph3j&hQhQ>*B*OJQJU^Jph'$~u $IfgdQ$Ifzkd$$Ifl09|+ t0644 la   34(),-"#5u!jhN#OJQJU^J!j hN#OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^J!j`hN#OJQJU^JhN#0JOJQJ^J!jahN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J*$%5~~$Ifzkd$$Ifl09|+ t0644 la578klmy{%&6=ABRz䧠vvvvlvbhQOJQJ^Jh}LOJQJ^J hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#CJaJhN# hN#5\hN#OJQJ^J$j~hN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J%uhf`$If  & F 8gd+=n 8^`zkd)$$Ifl09|+ t0644 laekdm$$Ifl9R: t0644 la$Iftkd$$Ifl9R:  t 0644 lap  $$Ifa$2,!  9r $If$Ifkd$$Ifl\ B*9:::T (04 lap(yt \Q  9r $Ifkd $$Ifl\ B*9:::T04 layt $If#b\Q\\  9r $If$Ifkd$$Ifl\ B*9:::T04 layt #$%&'?b\Q\\  9r $If$Ifkd$$Ifl\ B*9:::T04 layt ?@ABCPb\Q\\  9r $If$Ifkd;$$Ifl\ B*9:::T04 layt PQRz{b`S`M$If  & F 8gd+=nkd$$Ifl\ B*9:::T04 layt ekdS$$Ifl9R: t0644 la$Iftkd$$Ifl9R:  t 0644 lap  $$Ifa$2,!  9r $If$Ifkd$$Ifl\ B*9:::T (04 lap(yt ./12nop}~MζΨΗ}l}`}O!h?<hQB*OJQJ^JphhQ0JOJQJ^J!jahQOJQJU^JjhQOJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^JhN#5OJQJ\^JhN#OJQJ^JhQ5OJQJ\^JhQOJQJ^J hJhQOJQJ^JmH sH SH  9r $Ifkd$$Ifl\ B*9:::T04 layt  $Ifgd,$Ifb\Q\H $Ifgd,  9r $If$Ifkd$$Ifl\ B*9:::T04 layt b`Z$Ifkdg$$Ifl\ B*9:::T04 layt ./0x $If$Ifwkd!$$Ifl9R:  t 0644 lap 01Nqkbkb $IfgdQ$Ifkd$$IflF9|P* t06    44 laMNOLMNOPʼʄxgx\LjhN#5OJQJU^JhN#5OJQJ^J!j/hN#OJQJU^JhN#0JOJQJ^J!j0hN#OJQJU^JhV0JOJQJ^J!jhVOJQJU^JhVOJQJ^JjhVOJQJU^JhN#OJQJ^JhQ0JOJQJ^JjhN#OJQJU^J!j,hQOJQJU^JNO~~$Ifzkd$$Ifl09|+ t0644 laq~~$Ifzkd$$Ifl09|+ t0644 la345ACmnprtv    " $ ѧwlw[wlPFwh* OJQJ^Jh* H*OJQJ^J hJhlQOJQJ^JmH sH hlQH*OJQJ^JhlQOJQJ^JhN#CJaJhN#5OJQJ\^J!hN#5B*OJQJ\^JphhN#OJQJ^J$jIhN#5OJQJU^Jhoo0J5OJQJ^JjhN#5OJQJU^J$jhN#5OJQJU^JhN#5OJQJ^Jqrsvzxkxe$If  & F 8gd+=n 0^`0zkd$$Ifl09|+ t0644 la< & F$Iftkd$$Ifl9R:  t 0644 lap  $$Ifa$ekd8$$Ifl9R: t0644 la 5/!  9r $IfgdE $Ifkd$$Ifl\ B*|8:::: (04 lap( # $ % 1 Q   _Q  9r $IfgdE kd$$Ifl\ B*|8::::04 la$If$ % 1 Q        V!!!!!!!!!!!!!!/"6"|"}"""""""鳦rfhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^Jh OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^JhN#OJQJ^J hJhjLxOJQJ^JmH sH ha OJQJ^J hJhlQOJQJ^JmH sH hlQOJQJ^JhlQ5OJQJ\^J"      e_Q__  9r $IfgdE $Ifkdj$$Ifl\ B*|8::::04 la   V!!!e_Q__  9r $IfgdE $Ifkd$$Ifl\ B*|8::::04 la!!!!!!e_Q__  9r $IfgdE $Ifkd$$Ifl\ B*|8::::04 la!!!!!!e_T__  9r $If$Ifkd\$$Ifl\ B*|8::::04 la!!!!ec]$Ifkd$$Ifl\ B*|8::::04 la!!!!!!"{"xk $Ifgd  $If$Ifwkd$$Ifl9R:  t 0644 lap {"|""&####qkbbbb $Ifgdb}$IfkdQ$$IflF9|P* t06    44 la"""""$#%#&#'#T#U#V#############ؾ؅wm\wPDPwmh`LV0JOJQJ^JhN#0JOJQJ^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J3jhb}hb}>*B*OJQJU^Jph$hb}hb}>*B*OJQJ^Jphhb}0JOJQJ^J3jhb}hb}>*B*OJQJU^Jphhb}>*B*OJQJ^Jph-jhb}hb}>*B*OJQJU^Jph####E$F$G$L$M$P$Q$y$z${$$$$$$$$%%%%M%N%O%g%h%i%j%%%%%%%%0&1&2&J&}l!jr hN#OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jhb}OJQJ^J*##$i%%L&M&~~~~~$Ifzkdg$$Ifl09|+ t0644 laJ&K&L&M&&&&&&&&&&'''5'6'7'8'P'h'|'}''''''''''(¯秚~mahN#0JOJQJ^J!j%hN#OJQJU^JhN#H*OJQJ^J hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#CJaJ$j hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jhb}OJQJ^JhN#OJQJ^JjhN#OJQJU^J!M&N&^&&~~$Ifzkd_ $$Ifl09|+ t0644 la&&&&&wuo$If  & F 8gd+=nzkd $$Ifl09|+ t0644 la&&&&ekd $$Ifl9R: t0644 la$IftkdJ $$Ifl9R:  t 0644 lap &&&''' $$Ifa$'''''5/$/  9r $If$Ifkds $$Ifl\ B*|8:::: (04 lap('5'6'7'8'9'N'_T  9r $Ifkdz$$Ifl\ B*|8::::04 la$IfN'O'P'g'ec]$Ifkd $$Ifl\ B*|8::::04 lag'h'|'}'~'x $If$Ifwkd$$Ifl9R:  t 0644 lap ~''''qkk$Ifkdo$$IflF9|P* t06    44 la''l(m(~~$Ifzkd$$Ifl09|+ t0644 la((("(#(&('(O(P(Q(X(Y(~(((((((((((())ʹʮ~kZI!hRhN#5>*OJQJ\^J!hRhR5>*OJQJ\^J$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^Jm(n(~((~~$Ifzkd^$$Ifl09|+ t0644 la((()))))!)xxllll $$Ifa$gdJ 0^`0zkdj$$Ifl09|+ t0644 la))")#)$))))))))++-- . .#.$.(.6.D.E.G.H.V.a.d.e.f.g.i....///׾}s}ejhN#OJQJU^JhyYOJQJ^JhN#B*OJQJ^JphhN#H*OJQJ^JhN#6OJQJ]^JhN#5OJQJ\^JhN#hN#OJQJ^JhN#CJaJ hJhROJQJ^JmH sH hROJQJ^JhR5OJQJ\^J!hR5B*OJQJ\^Jph&!)")#)2) $IfgdJkd $$Ifl\ B*|8:::: (04 lap(ytJ#)$)%)))))))Kkd$$Ifl\ B*|8::::04 laytJ $IfgdJ  9r $IfgdJ)))))))b`TGE8  & F gd+=n  & F 8gd+=n  & F gd+=nkd$$Ifl\ B*|8::::04 laytJ))))*+",,#--llllll & F<<$If^`tkdo$$Ifl9R:  t 0644 lap $If ------- $$Ifa$gkd$$Ifl^9R: t0644 la---2,$Ifkd$$Ifl\ A*{89::: (0R:k4 lap(yt`LV---$Ifskd$$Ifl{88   0R:k4 lap yt`LV--- . . .$Ifskdj$$Ifl{88   0R:k4 lap yt`LV . .%.&.'.(.b\\\\$Ifkd$$Ifl\ A*{89:::0R:k4 layt`LV(.).5.b\$Ifkd$$Ifl\ A*{89:::0R:k4 layt`LV5.6.D.E.F.G.$Ifskd$$Ifl{88   0R:k4 lap yt`LVG.H.f.g.h.i.b\\\\$IfkdD$$Ifl\ A*{89:::0R:k4 layt`LVi.j..b\$Ifkd$$Ifl\ A*{89:::0R:k4 layt`LV......O//$Ifxkd $$Ifl9R:  t 0R:44 lap yt`LV//0p00pjaX $Ifgd`r $Ifgdsyp$Ifkdd!$$IflF9|P* t0R:    44 layt`LV///0000405060n0o0p0q00ʳwgP=$hHshHs>*B*OJQJ^Jph-jhHshHs>*B*OJQJU^Jphhsyp>*B*OJQJ^Jphhsyphsyp0JOJQJ^J3j #hsyphsyp>*B*OJQJU^Jph$hsyphsyp>*B*OJQJ^Jph-jhsyphsyp>*B*OJQJU^JphhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!j"hN#OJQJU^J0000000$1%1&1+1,1/101X1Y1Z1a1b1v1w11112222425262E2F2J2K2οεyhW!j'hN#OJQJU^J!j'hN#OJQJU^J!jX&hN#OJQJU^JhN#0JOJQJ^J!jY%hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhHshHs0JOJQJ^J-jhHshHs>*B*OJQJU^Jph3j#hHshHs>*B*OJQJU^Jph"00u13}}$If|kd$$$Ifl09|+ t0R:44 layt`LVK2222222222233'3(3)3\3]3^3j3l33333333555l_[_NhN#6OJQJ]^JhN#hN#5OJQJ\^J$j+hN#5OJQJU^Jhoo0J5OJQJ^J$j.+hN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J!j)hN#OJQJU^JhN#0JOJQJ^JjhN#OJQJU^J!j(hN#OJQJU^JhN#OJQJ^J33'33}t $Ifgd`r$If|kd*$$Ifl09|+ t0R:44 layt`LV333333rl$If ^`|kd,$$Ifl09|+ t0R:44 layt`LV3345 & F$Iftkd=-$$Ifl9R:  t 0644 lap 5555555 $$Ifa$gkd-$$Ifl^9R: t0644 la5555/$Ifkdj.$$Ifl\ A*{89::: (084 lap(555666 $Ifgd%(Z$Ifpkd/$$Ifl{88   084 lap 555666 6!6"6'65666D6E6F6H6I6J6b6v6x6{6~666667V7X7Y77鸩ԍyok]ojh:?OJQJU^Jh:?h:?OJQJ^Jh}LOJQJ^Jh`rOJQJ^Jh:?H*OJQJ^J h:?hN#OJQJ^JmH sH h:?H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#H*OJQJ^Jh%(ZH*OJQJ^Jh%(ZOJQJ^JhN#OJQJ^JhN#5OJQJ\^J6 6$6%6&6'6e____$Ifkd,0$$Ifl\ A*{89:::084 la'6(646e_$Ifkd0$$Ifl\ A*{89:::084 la465666F6G6H6{  9r $Ifgd:?$Ifpkd1$$Ifl{88   084 lap H6I6J6a6ec]$IfkdA2$$Ifl\ A*{89:::084 laa6b6v6x6y6{6|6~66677X7`8a8$Ifxkd2$$Ifl@)A  t 0A44 lap yt`r777^8_8a8b8c88888888888%9&9(9)9t9u9v9{9|9999999999:sb!jY9hN#OJQJU^J!jZ8hN#OJQJU^J!j6hN#OJQJU^JhN#0JOJQJ^J!j6hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh:?OJQJ^Jh:?0JOJQJ^Jjh:?OJQJU^J!j3h:?OJQJU^J$a8b88'9pjj$IfkdZ5$$IflFYA-}8 t0A    44 layt`r'9(99:A;B;}}}}$If|kd7$$Ifl0@-8 t0A44 layt`r:::#:$:':(:u:v:w:::::!;";#;?;@;B;;;;;;;;;;ʹʫtiVtItthoo0J5OJQJ^J$j>hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jh`r0JOJQJ^J!j;h`rOJQJU^Jh`rOJQJ^Jjh`rOJQJU^J!j;hN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!j:hN#OJQJU^JB;C;S;;;<}}}}$If|kdw=$$Ifl0@-8 t0A44 layt`r; < < <<#<4<8=Z=g=h=l=m={=}=======>>M>N>O>\>]>^>_>>>>>>öǶǫǶǫǶǶǫǝnjǝveYh`r0JOJQJ^J!jFh`rOJQJU^Jh`rOJQJ^JhN#0JOJQJ^J!j2EhN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^JhN#5OJQJ\^JhN#hN#OJQJ^JjhN#5OJQJU^J$j>hN#5OJQJU^JhN#5OJQJ^J"<<<<#<$<3<tn$If  & F gd+=n|kd?$$Ifl0@-8 t0A44 layt`r3<4<<<<8= & F$Iftkd)@$$Ifl9R:  t 0644 lap 8=9=:=@=G=U=Y= $$Ifa$gkd@$$Ifl^9R: t0644 laY=Z=i=j=k=l=5////$IfkdVA$$Ifl\ A*{89::: (084 lap(l=m=~====e____$IfkdkB$$Ifl\ A*{89:::084 la====ec]$IfkdC$$Ifl\ A*{89:::084 la======>$IfwkdC$$Ifl9R:  t 0644 lap >>^>>qkk$Ifkd|D$$IflF9|P* t06    44 la>>f? A~~$IfzkdF$$Ifl09|+ t0644 la>>>????? ?!?I?J?K?R?S?h?i????????'@(@)@8@9@=@>@@@@@@@@@@@AAAv!jKhN#OJQJU^J!jJhN#OJQJU^J!j'JhN#OJQJU^J!jFIhN#OJQJU^J!jHhN#OJQJU^JhN#0JOJQJ^J!jGhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^J+ A AAA~~$IfzkdL$$Ifl09|+ t0644 laAAAOAPAQA]A_AAAAAAAAAAAAAABBB?BABBB~BBBBBB䧣sbsVshN#0JOJQJ^J!jShN#OJQJU^JjhN#OJQJU^JhOJQJ^JhN#H*OJQJ^JhN#5OJQJ\^JhN#hN#OJQJ^J$jNhN#5OJQJU^Jhoo0J5OJQJ^J$j\MhN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J AAAAAAuo$If  & F gd+=nzkdN$$Ifl09|+ t0644 laAAAAgkd P$$Ifl^9R: t0644 la$IftkdhO$$Ifl9R:  t 0644 lap AAAAAA $$Ifa$AAAAAA5////$IfkdP$$Ifl\ A*{89::: (084 lap(AAABec]$IfkdQ$$Ifl\ A*{89:::084 laBBBB@By $Ifgd$Ifwkd^R$$Ifl9R:  t 0644 lap @BABBBqkk$IfkdS$$IflF9|P* t06    44 laBBBBBBBBBFCGCHCMCNCQCRCzC{C|CCCCCCCC%D&D'D(DVDWDXDgDhDlDmDDsb!jXhN#OJQJU^J!jWhN#OJQJU^J!jWhN#OJQJU^JhN#0JOJQJ^J!jVhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh`r0JOJQJ^J!jTh`rOJQJU^Jh`rOJQJ^Jjh`rOJQJU^J%BBC8E~~$IfzkdyU$$Ifl09|+ t0644 laDDDDDDDEEE6E7EIEJEKE~EEEEEEEEEEFFFFʹʮ~kgZZhN#5OJQJ\^JhN#$j\hN#5OJQJU^Jhoo0J5OJQJ^J$j[hN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J!jVZhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jeYhN#OJQJU^J8E9EIEE~~$IfzkdG[$$Ifl09|+ t0644 laEEEEEE~qoi$If  & F gd+=n 9r zkdS]$$Ifl09|+ t0644 laEFFFz h$If^h$Iftkd]$$Ifl9R:  t 0644 lap FFFFFFF $$Ifa$gkd^$$Ifl^9R: t0644 laFFFFF5/$/  9r $If$Ifkd _$$Ifl\ A*{89::: (084 lap(FFFFFFFFFFGQHHHHIIJIIIIJJJJJJJJJLKMKKKKKK则|k|Z|!jdhN#OJQJU^J!jchN#OJQJU^JhN#0JOJQJ^J!jAbhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JmH sH hN#6OJQJ]^JhN#CJaJhN#B*OJQJ^JphhN#5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH #FFFFFFF_kd5`$$Ifl\ A*{89:::084 la$IfFFFFFFGGec]cPcJ$If  & F 8gd+=n 9r kd`$$Ifl\ A*{89:::084 laGGGHHJKQLRLvl h$If^h & F$If & F$Iftkda$$Ifl9R:  t 0644 lap KRLtLLLLM M M MMMMMMM(M)M@MBMCMDM]M^M_MaMbMcMdMfMgMMMʸukk^kʸk^kk^h5OJQJ\^JhOJQJ^J hJhdWOJQJ^JmH sH #hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hH*OJQJ^JmH sH #hJhH*OJQJ^JmH sH  hJhOJQJ^JmH sH hOJQJ^JmH sH hN#5OJQJ\^JhN#OJQJ^J RLSLTLZLaLoLsL $$Ifa$gkd"f$$Ifl^9R: t0644 lasLtLLLL2,,,$Ifkdf$$Ifl\ A*{89::: (0R:k4 lap(ytLLLLLLL\kdg$$Ifl\ A*{89:::0R:k4 layt$IfLLMb\$Ifkdh$$Ifl\ A*{89:::0R:k4 laytMMMMMMx  9r $If$Ifvkd:i$$Ifl4{88   0R:k4 laf4p ytMM)M@MAMBMb\N\\  9r $Ifgd$Ifkdi$$Ifl\ A*{89:::0R:k4 laytBMCMDM_M`MaMb\N\\  9r $Ifgd$Ifkdj$$Ifl\ A*{89:::0R:k4 laytaMbMcMdMeMfMb\N\\  9r $Ifgd$Ifkdgk$$Ifl\ A*{89:::0R:k4 laytfMgM~Mb\$Ifkd!l$$Ifl\ A*{89:::0R:k4 layt~MMMMMMMHOw $Ifgd$Ifxkdl$$Ifl9R:  t 0R:44 lap ytMMMMMMN&NsNuNNO2OGOHOIOJOOOOOOOOOOOOPPȾȴߴՏ~rՏaUh`r0JOJQJ^J!j!oh`rOJQJU^JhN#0JOJQJ^J!j@nhN#OJQJU^JjhN#OJQJU^JhWh%(ZOJQJ^Jh 0oOJQJ^JhOJQJ^Jh`rOJQJ^JhWhWOJQJ^JhN#OJQJ^JhyYOJQJ^Jh%(ZH*OJQJ^JhN#H*OJQJ^JHOIOOPPeQpjjja $Ifgd`r$Ifkdm$$IflF9|P* t0R:    44 laytPPPPPPPPP)Q*Q+QcQdQeQfQgQQQQQQQQQ糠wm_mN_B_m_mhN#0JOJQJ^J!jshN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jhtojhtoj0JOJQJ^J3jqhtojhtoj>*B*OJQJU^Jph$htojhtoj>*B*OJQJ^Jph-jhtojhtoj>*B*OJQJU^Jphhh 0JOJQJ^J!johh OJQJU^Jhh OJQJ^Jjhh OJQJU^JeQfQRS}t $IfgdW$If|kdbr$$Ifl09|+ t0R:44 laytQQQQQRRJRKRLRRRRRRRRRRRR%S&S'S4S5S8S9SSSSSSSSSSST(Tʹʨʗʆ~viihN#5OJQJ\^JhN#CJaJh`rCJaJ!jBwhN#OJQJU^J!jQvhN#OJQJU^J!juhN#OJQJU^J!jthN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jthN#OJQJU^J'SSSSSvtn$If  & F 8gd+=n|kd3x$$Ifl09|+ t0R:44 laytSSSSgkdzy$$Ifl^9R: t0644 la$Iftkdx$$Ifl9R:  t 0644 lap SST TTT $$Ifa$TT*T+T,T5///$Ifkdz$$Ifl\ A*{89::: (084 lap((T)T9T:TNTOTUTVTfTgThTTTTTTUUUUUUUDUEUFUUUUUꪻtZKh`rht0JOJQJ^J3j~h`rht>*B*OJQJU^Jph$h`rht>*B*OJQJ^Jph-jh`rht>*B*OJQJU^JphhN#0JOJQJ^J!j}hN#OJQJU^JjhN#OJQJU^JhN#5OJQJ\^JhyYOJQJ^JhDOJQJ^JhN#OJQJ^JhN#H*OJQJ^J,TUTVTcTdTeTfT\VVVV$Ifkd{$$Ifl\ A*{89:::084 la $IfgdDfTgThTTec]$Ifkd{$$Ifl\ A*{89:::084 laTTTTT$Ifwkd|$$Ifl9R:  t 0644 lap TTUUqkb $Ifgd`r$Ifkd)}$$IflF9|P* t06    44 laUU&VV~~$Ifzkd$$Ifl09|+ t0644 laUUUUUUUU V V VVV&V'VlVmVnVVVVVVVVVV W WWAWBWCWOWQW{W}j}]}hoo0J5OJQJ^J$jhN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J!jƂhN#OJQJU^J!jhN#OJQJU^J!j,hN#OJQJU^JhN#0JOJQJ^JjhN#OJQJU^J!j-hN#OJQJU^JhN#OJQJ^J#VV WW~~$Ifzkdy$$Ifl09|+ t0644 la{W|W~WWWWWWX%XBXCXTXnXXXXXXXXXXXXXXXXXXX YYYBYKY˾ӾӾӾӕӾӊӾӕxӾnndhOOJQJ^JhZVOJQJ^J#hJhN#H*OJQJ^JmH sH hN#H*OJQJ^J hJhN#OJQJ^JmH sH hyYOJQJ^JhN#OJQJ^JnH tH hN#5OJQJ\^JhN#CJaJhN#OJQJ^JjhN#5OJQJU^J$jڄhN#5OJQJU^J$WWWWWWW~|o|i$If  & F 8gd+=n 9r zkd$$Ifl09|+ t0644 laWWWWgkdɆ$$Ifl^9R: t0644 la$Iftkd%$$Ifl9R:  t 0644 lap WWWWWW $$Ifa$WWX2,$IfkdR$$Ifl\ A*{89::: (0R:k4 lap(yt 0oXX$X$Ifskdm$$Ifl{88   0R:k4 lap yt 0o$X%X0X@XAXBX$Ifskd $$Ifl{88   0R:k4 lap yt 0oBXCXQXRXSXTXb\\\\$IfkdӉ$$Ifl\ A*{89:::0R:k4 layt 0oTXUXmXb\$Ifkd$$Ifl\ A*{89:::0R:k4 layt 0omXnXXXXXxrr$If  9r $If $IfgdDskdG$$Ifl{88   0R:k4 lap yt 0oXXXXXXb\\\\$Ifkd$$Ifl\ A*{89:::0R:k4 layt 0oXXXXXXb\Q\\  9r $If$Ifkd$$Ifl\ A*{89:::0R:k4 layt 0oXXXb\$Ifkdn$$Ifl\ A*{89:::0R:k4 layt 0oXXXXX Y$Ifskd($$Ifl{88  0R:k4 lap yt 0o Y!Y"Y#Y$YAYb\\\\$Ifkdێ$$Ifl\ A*{89:::0R:k4 layt 0oAYBYCYDYEYPYb\\\S $Ifgd-$Ifkd$$Ifl\ A*{89:::0R:k4 layt 0oKYLYMYOYPYQYiYlYnYYYYYYYYYYZZ+Z,Z-Z/ZnZZZZZZ׿qqcYLhN#5OJQJ\^Jh_OJQJ^JhuV'OJQJ^JmH sH  hJhuV'OJQJ^JmH sH huV'OJQJ^Jh(3H*OJQJ^Jh(3OJQJ^Jh)UOJQJ^Jh}OJQJ^JhN#OJQJ^JhN#OJQJ^JnH tH hczOJQJ^Jh-OJQJ^JhOH*OJQJ^JhOOJQJ^Jh`rOJQJ^JPYQYRYSYTYmYb\\\S $Ifgdcz$IfkdO$$Ifl\ A*{89:::0R:k4 layt 0omYnYYb\$Ifkd $$Ifl\ A*{89:::0R:k4 layt 0oYYYYYY$IfskdÑ$$Ifl{88  0R:k4 lap yt 0oYYYYY.Zb\\\S $IfgduV'$Ifkdv$$Ifl\ A*{89:::0R:k4 layt 0o.Z/Z0Z1Z2ZMZmZb\\\SS $Ifgd_$Ifkd0$$Ifl\ A*{89:::0R:k4 layt 0omZnZZb\$Ifkd$$Ifl\ A*{89:::0R:k4 layt 0oZZZZZZZZZZ\[[wwwwnwwee $Ifgd $IfgdO $Ifgd(3$Ifxkd$$Ifl9R:  t 0R:44 lap yt 0o Z\[[[[[[[[[[\\\\\\\]]]]˽ˬˌ|eY|F$h`rhcz>*B*OJQJ^Jphhcz0JOJQJ^J-jhcz>*B*OJQJU^Jphhcz>*B*OJQJ^Jph'jhcz>*B*OJQJU^Jphh(30JOJQJ^J!j h(3OJQJU^Jjh(3OJQJU^Jh(3OJQJ^JhOOJQJ^JhcZ+OJQJ^JhOJQJ^JhuV'huV'OJQJ^J[[\]]]pjaaX $Ifgd`r $Ifgdg4$IfkdP$$IflF9|P* t0R:    44 layt 0o]]G]H]I]]]]]]]]]^ ^^^^^^^;^<^?^N^O^P^Q^i^}^^^^^ջ袘uk`uV`khJ|OJQJ^JhN#H*OJQJ^Jh}LOJQJ^JhN#OJQJ^JnH tH hN#5OJQJ\^JhN#CJaJhN#OJQJ^Jh(3OJQJ^Jh`rhZV0JOJQJ^J3jh`rhZV>*B*OJQJU^Jph$h`rhZV>*B*OJQJ^Jph-jh`rhZV>*B*OJQJU^Jph!]]]]]]]]]}pneeee $$Ifa$  & F 8gd+=n 9r |kdP$$Ifl09|+ t0R:44 layt 0o]]]2,$Ifkd$$Ifl\ A*$:9:: (0:4 lap(ytO]]]]]^} $Ifgd}L$Ifskd$$Ifl$::  0:4 lap ytO^^^^^^b\\\\$Ifkdϛ$$Ifl\ A*$:9::0:4 laytO^^;^b\$Ifkd$$Ifl\ A*$:9::0:4 laytO;^<^=^>^?^O^$Ifskd_$$Ifl$::  0:4 lap ytOO^P^Q^h^b`Z$Ifkd$$Ifl\ A*$:9::0:4 laytOh^i^}^^^y $Ifgd}L$Ifwkdڞ$$Ifl9R:  t 0644 lap ^^^^qkk$Ifkd$$IflF9|P* t06    44 la^^^^^^^^^;_<_=_B_C_F_G_o_p_q_x_y_________ ````睍zmZ$jӤhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J!jhN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!j9hN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J ^^__~~$Ifzkd$$Ifl09|+ t0644 la___`~~$Ifzkdr$$Ifl09|+ t0644 la`````!`(`6`:`~qoffff $$Ifa$  & F 8gd+=n 9r zkd~$$Ifl09|+ t0644 la``;`E`F`I`S`T`u````aa(amanaaaaGbHbXbbbbbbέέrrbrTh[h[5OJQJ^Jh[ 0JCJOJQJ^JaJh[ 5OJQJ\^J, *hkyp5B*OJQJ\^JmH phsH , *h[ 5B*OJQJ\^JmH phsH * *h[ h[ 5B*OJQJ\^Jphh[ H*OJQJ^Jh[ OJQJ^Jh[ hN#^JhN#OJQJ^JhN#5OJQJ\^JhN#CJaJ:`;`B`C`D`E`5////$Ifkd$$Ifl\ A*{89::: (084 lap(E`F`G`I`T`U`[`b`p`eccVcMMM $$Ifa$  & F 8gd[ kd3$$Ifl\ A*{89:::084 lap`t`u`v`,&$Ifkd$$Ifl\ A*{89::: (084 lap( $$Ifa$v``aaaaaa"bSMM$Ifkd$$Ifl\ A*{89:::084 la $Ifgd[  $Ifgd]"bGbHbIbJbKbb_V $Ifgdukd$$Ifl\ A*{89:::084 la$IfbbbbbbbbeccWWWW $$Ifa$gdkdd$$Ifl\ A*{89:::084 labbbbb2))) $Ifgdkd$$Ifl\ A*{89::: (084 lap(ytbbbc&c)c*c^c_c`ccccccccccccdddKdLdMdOdPddǹҹҁugVggҹ!jhuOJQJU^JjhuOJQJU^JhN#0JOJQJ^J!j'hN#OJQJU^Jhu0JOJQJ^J!jhuOJQJU^JhuOJQJ^JjhN#OJQJU^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^Jh[OJQJ^Jh[5OJQJ\^JbbbbcYWQ$Ifkd3$$Ifl\ A*{89:::084 layt $Ifgd[cc&c(c)ccc$Ifwkd$$Ifl9R:  t 0644 lap cccMdNdqkbk $Ifgdu$Ifkdq$$IflF9|P* t06    44 laNdOddd~~$Ifzkd$$Ifl09|+ t0644 ladddddddddddddde3e4e5eAeCemenepeseeeeeeʹʮ~kcVIIhN#5OJQJ\^JhZ5OJQJ\^JhN#CJaJ$jhN#5OJQJU^Jhoo0J5OJQJ^J$j۳hN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^Jdddqe~~$Ifzkd;$$Ifl09|+ t0644 laqereseeeeeee~qoffff $$Ifa$  & F 8gd+=n 9r zkdG$$Ifl09|+ t0644 laeeeeee5////$Ifkd$$Ifl\ A*99::g (0:4 lap(eeeeeeeeccVcP$If  & F 8gd+=nkd $$Ifl\ A*99::g0:4 laeeeeee fWfZfpfqfsfffffffff$g%g&g5g7gWg`grgsggggggggׂxnaxh5OJQJ\^Jhk{OJQJ^JhOJQJ^JhHOJQJ^J hN#CJhKCJmH sH hKOJQJ^JhK5OJQJ\^JhK5OJQJ^JhKhK5OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^JhN#CJaJhZOJQJ^JhN#OJQJ^J#eee h$If^htkd̷$$Ifl9R:  t 0644 lap eeeeef f $$Ifa$gkdp$$Ifl^9R: t0644 la f ff=fZfof5////$Ifkd$$Ifl\ A*{89::: (084 lap(ofpfqfrfsffff_]WJ]A $$Ifa$  & F 8gd+=n 9r kd$$Ifl\ A*{89:::084 la$Iffffff,kdº$$Ifl\ A*{89::: (084 lap( $$Ifa$fffffffff_]UPgdK & FgdKkd׻$$Ifl\ A*{89:::084 la$Iffffff $$Ifa$gd]fffff2))) $Ifgd]kd$$Ifl\ A*{89::: (084 lap(yt]fg#g$g%g&g5g7gPKIIC gdKkd$$Ifl\ A*{89:::084 layt] $IfgdK $Ifgd]7g=gDgRgVg $$Ifa$VgWgggg5,&&$If $IfgdHkd`$$Ifl\ A*{89::: (084 lap(ggggggg_VM $Ifgdk{ $IfgdHkdu$$Ifl\ A*{89:::084 la$IfggggecZ $Ifgd kd)$$Ifl\ A*{89:::084 laggggh||| $Ifgd zkd$$Ifl9R:  t 0644 lap yt gghhChDhEhRhShThUhhhhhhhh0i1i2iuiܿꨕ{l^TC^7hK0JOJQJ^J!jhKOJQJU^JhKOJQJ^JjhKOJQJU^Jhuh0JOJQJ^J3j)huh>*B*OJQJU^Jph$huh>*B*OJQJ^Jph-jhuh>*B*OJQJU^Jphh0JOJQJ^J!jHhOJQJU^JjhOJQJU^JhOJQJ^JhH*OJQJ^JhhThhwixineeee $Ifgd kd$$IflF9|P* t06    44 layt uiviwixiyiziiiiiiiiiiijj(j)j\j]j^jjjkjljjjjjjjϲϲ瑆sf瑆S$jh5OJQJU^Jhoo0J5OJQJ^J$j=h5OJQJU^Jh5OJQJ^Jjh5OJQJU^J!jhOJQJU^Jh0JOJQJ^J!jhOJQJU^JjhOJQJU^JhKOJQJ^JhOJQJ^JjhKOJQJU^Jxiyijjxx $Ifgd }kd9$$Ifl09|+ t0644 layt jj(jjxx $Ifgd }kd$$Ifl09|+ t0644 layt jjjjj k&k'k.ksfa[$Ifgdkyp  & F 8gd+=n  & F gd+=n}kd$$Ifl09|+ t0644 layt jjjj&k'kYkZk\kZmmmmmnnnnnn ooooox`xMx$hJhN#0JOJQJ^JmH sH /jxhJhN#OJQJU^JmH sH )jhJhN#OJQJU^JmH sH h}LOJQJ^JmH sH &hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^JhkyphkypmH sH tHhN#CJaJh`LVOJQJ^JhkypOJQJ^JhN#OJQJ^J.k/k\ktllZmmrrr_ 9r h<<$If^h & F<<$If <<$IftkdO$$Ifl9R:  t 0644 lap mmm no}} 9r <<$If` <<$Ifekd$$Ifl9R: t0644 laooooo,o0o$Ifekd$$Ifl9R: t0644 lao0o*B*OJQJU^Jph$h|H!h|H!>*B*OJQJ^Jph-jh|H!h|H!>*B*OJQJU^Jphh|H!OJQJ^JhN#OJQJ^Jha}0JOJQJ^JjhN#OJQJU^Jrrrss$Ifykd$$Ifl09|+ t044 larrr)s*s-s.s^s_s`sqsrstssss|t}tIuPutuuuvvvv(w)wwwxʹʱrdrrrrP&hJhN#6OJQJ]^JmH sH h}LOJQJ^JmH sH &hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^JhkyphkypmH sH tHhN#CJaJ!jQhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhhN#OJQJU^Jsstssssytn$Ifgdkyp  & F 8gd+=nykd$$Ifl09|+ t044 lasst}tuuvv)wYyzyggggggy & F 9r <<$If 9r <<$Ifwkd$$Ifl9R:  t 0644 lap xxyyyAyByXyYyzzz{{${%{&{0{2{I{J{{{{{{{{{{ٚٚuju`juVuuLuu`uha}OJQJ^JhZOJQJ^JhyYOJQJ^JhN#H*OJQJ^JhN#OJQJ^JhN#OJQJ^JnH tH hN#5OJQJ\^J&hJhN#5OJQJ\^JmH sH $hJhN#0JOJQJ^JmH sH /jNhJhN#OJQJU^JmH sH  hJhN#OJQJ^JmH sH )jhJhN#OJQJU^JmH sH zzzzzzz $$Ifa$gkd5$$Ifl9R: t0644 lazz{71$Ifkd$$Ifl\ A*{89 : (04 lap({{&{J{s{{ $Ifgdkyp$Ifnkd$$Ifl{88  04 lap {{{{{{gaXaa $Ifgdkyp$Ifkd$$Ifl\ A*{89 :04 la{{{{{{gaXaa $Ifgdkyp$Ifkda$$Ifl\ A*{89 :04 la{{{{ | |||||>|D|E|Z|[|]|n|p|r|||||||||||||||||}}}}~ȺȰȰȰȘ߁sjhN#OJQJU^JhN#B*CJaJphhN#H*OJQJ^JhN#OJQJ^JnH tH hyYOJQJ^JhD5OJQJ^JhD5hD55OJQJ^JhD55OJQJ\^JhZOJQJ^JhN#5OJQJ\^JhN#OJQJ^Jha}OJQJ^J'{{{ |||||gaaaaaa$Ifkd-$$Ifl\ A*{89 :04 la||$|+|9|=|g[[[[ $$Ifa$gd kd$$Ifl\ A*{89 :04 la=|>|D|E|[|4..% $IfgdD5$Ifkd$$Ifl\ A*{89 : (~04 lap(~ytD5[|\|]|^|_|n|o|akd$$Ifl\ A*{89 :04 la$Ifo|p|q|r|||gaaaa$Ifkd$$Ifl\ A*{89 :04 la||||||gaaaa$Ifkd$$Ifl\ A*{89 :04 la|||ga$Ifkd\$$Ifl\ A*{89 :04 la||||||$Ifnkd($$Ifl{88  04 lap ||||||gaaaa$Ifkd$$Ifl\ A*{89 :04 la||||ge_$Ifkd$$Ifl\ A*{89 :04 la||}}}}d}}}$Ifwkdi$$Ifl9R:  t 0644 lap }}.~~~_yJKqkkkkkkbbb $Ifgda}$Ifkd$$IflF9|P* t06    44 la ~~~,~-~.~/~c~d~e~~~~~~~~~~~~CDE]^_`ʹuaM'jha}ha}OJQJU^J'jha}ha}OJQJU^J'jha}ha}OJQJU^Jha}ha}0JOJQJ^J'jha}ha}OJQJU^Jha}ha}OJQJ^J!jha}ha}OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J MNOwxyzӿӨ{k]SB]!j+h4XOJQJU^Jh4XOJQJ^Jjh4XOJQJU^Jh6>*B*OJQJ^Jph3j^ha}ha}>*B*OJQJU^Jph$ha}ha}>*B*OJQJ^Jph-jha}ha}>*B*OJQJU^Jph'jha}ha}OJQJU^Jha}ha}OJQJ^J!jha}ha}OJQJU^Jha}ha}0JOJQJ^JHIKLḾ́΁Ձցʂ˂uv˃̃̓ҳħҖħ҅ħsePs)jhN#OJQJU^JnH tH hN#OJQJ^JnH tH #jhN#OJQJU^JnH tH !jhN#OJQJU^J!jehN#OJQJU^JhN#0JOJQJ^J!jfhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh4XOJQJ^Jjh4XOJQJU^Jh4X0JOJQJ^JKL@ʂ~~~~~$Ifzkd$$Ifl09|+ t0644 la+~~~$Ifzkd$$Ifl09|+ t0644 la̓VWXdf=DTx~̼~tg_gtUtgGgthN#OJQJ^JnH tH h}LOJQJ^JhN#CJaJhN#5OJQJ\^JhN#OJQJ^J$jihN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JnH tH #jhN#OJQJU^JnH tH &hN#>*B*OJQJ^JnH phtH uo$If  & F 8gd+=nzkd$$Ifl09|+ t0644 la Tr$ h$Ifa$gd}L$Iftkd$$Ifl9R:  t 0644 lap TUVX^esw $$Ifa$ekdX$$Ifl9R: t0644 lawx~71$Ifkd$$Ifl\ A*{89 : (04 lap(~$Ifnkd $$Ifl{88  04 lap ąȅԅQTbde}†ɿޱtct!j,hN#OJQJU^JjhN#OJQJU^J#h.ah.aOJQJ\^JmH sH #h.ahvOJQJ\^JmH sH hvOJQJ\^Jh)YhvOJQJ\^JhyYOJQJ^JhN#OJQJ^JhH*OJQJ^JhN#5OJQJ\^JhN#H*OJQJ^JhOJQJ^J#gaaaa$Ifkd$$Ifl\ A*{89 :04 laga$Ifkd$$Ifl\ A*{89 :04 laąŅƅDž$IfnkdK$$Ifl{88  04 lap DžȅԅՅօׅgaaaa$Ifkd$$Ifl\ A*{89 :04 laׅ؅ga$Ifkd$$Ifl\ A*{89 :04 laRS $Ifgd.a$Ifnkd$$Ifl{88  04 lap STUabcgaaaa$Ifkd5$$Ifl\ A*{89 :04 lacde|ge_$Ifkd$$Ifl\ A*{89 :04 la|}$Ifwkd$$Ifl9R:  t 0644 lap qkkb $Ifgda}$Ifkdv$$IflF9|P* t06    44 la IJKny789>?BCklmtuܱ܅tc!j hN#OJQJU^J!jRhN#OJQJU^J!jShN#OJQJU^J!jhaOJQJU^JhaOJQJ^JjhaOJQJU^Jha0JOJQJ^J!j hN#OJQJU^JhN#OJQJ^JjhN#OJQJU^JhN#0JOJQJ^J&ӈ~t  $If$Ifzkd$$Ifl09|+ t0644 laЈш!"#/1[\^e#̡܆yhWEh:hyYOJQJ\^J#hJh5OJQJ^JmH sH  hJhOJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#CJaJ$j9 hN#5OJQJU^Jhoo0J5OJQJ^J$jf hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JjhN#OJQJU^JhN#0JOJQJ^JӈԈ_~~$Ifzkd $$Ifl09|+ t0644 la_`abceȉuo$If  & F 8gd+=nzkd $$Ifl09|+ t0644 laȉɉʉ|$If^`tkd $$Ifl9R:  t 0644 lap ʉˉ̉Ήԉۉ $$Ifa$ekd( $$Ifl9R: t0644 la711&  9r $If$Ifkd $$Ifl\ ){8D   (04 lap($%&';<^S  9r $Ifkd$$Ifl4\ ){8D  04 laf4$If#$&'23789:;>?DEHJX\_`efɸɔɃɔr`VLVAhW/H*OJQJ^JhqaOJQJ^JhW/OJQJ^J#hJhN#5OJQJ^JmH sH  hJhW/OJQJ^JmH sH  hJhqaOJQJ^JmH sH #hJhN#H*OJQJ^JmH sH #hJh5OJQJ^JmH sH  hJhOJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^JhN#5OJQJ\^Jh(hN#OJQJ\^J<=>?`d^^SJ $IfgdW/  9r $If$Ifkd$$Ifl4\ ){8D  04 laf4d^^SJ $IfgdW/  9r $If$IfkdT$$Ifl4\ ){8D  04 laf4Պ׊xz|Ӎԍ|}?AُڏۏµuuugVgJghN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhqaOJQJ^JhhW/OJQJ^JhhW/OJQJ^JhW/H*OJQJ^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^JhN#5>*CJ\aJhVOJQJ^J hJh(OJQJ^JmH sH h(OJQJ^Jh(5OJQJ\^Jdb\$Ifkd$$Ifl4\ ){8D  04 laf4Պ؊v$Ifukd$$Ifl9R:  t 044 lap vwxz{}=pjaaaaj $IfgdW/$Ifkd$$Ifl4Fx9|hn* t0    44 laf4]Ԑsmmd $IfgdF$Ifkd;$$IflFx9|hn* t0    44 la ![\]^ҐӐԐՐ֐!"#(),-U}n]QhN#0JOJQJ^J!jhN#OJQJU^Jhtojhtoj0JOJQJ^J3jhtojhtoj>*B*OJQJU^Jph$htojhtoj>*B*OJQJ^Jph-jhtojhtoj>*B*OJQJU^Jphh(0JOJQJ^J!jh(OJQJU^Jh(OJQJ^JjhN#OJQJU^JhN#OJQJ^JԐՐr!vv  $If$Ifykdw$$Ifl09|+ t044 laUVW^_pqʹʩ~k_RJRhN#CJaJhN#5OJQJ\^JhN#5>*CJ\aJ$jShN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J!"2p$Ifykd$$Ifl09|+ t044 lauo$If  & F 8gd+=nykd$$Ifl09|+ t044 laU| & F 9r $Iftkd$$Ifl9R:  t 0644 lap Гѓ   RSUw+,}~ՐyyhyZLy;L!j!hN#OJQJU^JjhN#OJQJU^JhN#B*OJQJ^Jph hN#5>*B*CJ\aJphhN#OJQJ^JhN#5OJQJ\^J$hJhN#0JOJQJ^JmH sH 8j?hJhN#B*OJQJU^JmH phsH )hJhN#B*OJQJ^JmH phsH 2jhJhN#B*OJQJU^JmH phsH  hJhN#OJQJ^JmH sH UVW]drv $$Ifa$ekd$$Ifl9R: t0644 lavw71111$Ifkd$$Ifl\ ){8D   (04 lap(gb\$If$a$kd$$Ifl\ ){8D  04 la$Ifukdj $$Ifl9R:  t 044 lap ,-.@ABCDEėŗƗ͗Η#$oܓ܂q!j&hN#OJQJU^J!j &hN#OJQJU^J!j %hN#OJQJU^JhF0JOJQJ^J!j#hFOJQJU^JhFOJQJ^J!j"hN#OJQJU^JhN#OJQJ^JjhN#OJQJU^JhN#0JOJQJ^J(BC}}}$If|kd "$$Ifl409|+ t044 laf4CD&(vv  $If$Ifykdp$$$Ifl09|+ t044 la()9o$Ifykdz'$$Ifl09|+ t044 laop1=STUxyޙߙ𨚒{q{gZghlQ5OJQJ\^JhlQOJQJ^Jh OJQJ^JhW&OJQJ^JhN#5OJQJ\^JhN#CJaJhN#>*B*CJaJphhN#OJQJ^J$j(hN#5OJQJU^Jhoo0J5OJQJ^J$j(hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J,0triiii $$Ifa$  & F 8gd+=n$a$ykd)$$Ifl09|+ t044 la 01=TU71(( $Ifgd $Ifkd2*$$Ifl\ ){8DHh  (04 lap(UVxyakd_+$$Ifl\ ){8DHh 04 la$Ifޙgaaaa$Ifkd+,$$Ifl\ ){8DHh 04 laޙߙ gaaaX $IfgdE $Ifkd,$$Ifl\ ){8DHh 04 la  1345BCPQRSkšĚ&ݾݱȚӚwfZhO0JOJQJ^J!j1hOOJQJU^JhOOJQJ^JjhOOJQJU^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^JhF5OJQJ\^JhuV'OJQJ^JhGH*OJQJ^JhGOJQJ^JhlQ5OJQJ\^JhlQOJQJ^JhlQH*OJQJ^J#  4gaaaa$Ifkd-$$Ifl\ ){8DHh 04 la45ABCQgaaaa$Ifkd.$$Ifl\ ){8DHh 04 laQRSjge_$Ifkd[/$$Ifl\ ){8DHh 04 lajk&$Ifukd'0$$Ifl9R:  t 044 lap sm``  $IfgdO$Ifkd0$$IflFx9|hn* t0    44 la\]^&')+,9CDm`SH@hN#CJaJh`WhN#CJaJhF5OJQJ\^JhN#5OJQJ\^J$j4hO5OJQJU^Jhoo0J5OJQJ^J$j4hO5OJQJU^JhO5OJQJ^JjhO5OJQJU^JhThOOJQJ^JhO0JOJQJ^J'ja2hThOOJQJU^JjhOOJQJU^JhOOJQJ^J*$Ifykdv3$$Ifl09|+ t044 la*+,-./0123456789ykd5$$Ifl09|+ t044 la9DST:b|П,7ugggYYYY & F 9r $If & F 9r $Ifwkd.6$$Ifl9R:  t 0644 lap $If  & F 8gd+=n DTab67Ytu à34ϡС@A]_klmEghȣʣO󶨶󶨶󶝶{wmh ;=OJQJ^JhN#h4h45OJQJ^JhlQOJQJ^Jh4OJQJ^JhN#H*OJQJ^JhN#B*OJQJ^JphhN#OJQJ^JhN#OJQJ^JnH tH &hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^J(789?FTX $$Ifa$gkd6$$Ifl9R: t0644 laXYt2,$Ifkda7$$Ifl\fA*{8 :: (084 lap(ytkyptu$Ifskd8$$Ifl{88  084 lap ytkypb\\\\$Ifkd=9$$Ifl\fA*{8 ::084 laytkypb\\\\$Ifkd:$$Ifl\fA*{8 ::084 laytkyp3b\$Ifkd:$$Ifl\fA*{8 ::084 laytkyp34Ck$Ifskd;$$Ifl{88  084 lap ytkypա@Ab\\\\\$IfkdH<$$Ifl\fA*{8 ::084 laytkypABT`aklb\\\\\$Ifkd=$$Ifl\fA*{8 ::084 laytkyplmnopDb\\\\$Ifkd=$$Ifl\fA*{8 ::084 laytkypDEgb\$Ifkd>$$IflZ\fA*{8 ::084 laytkypghwz$Ifskdh?$$IflZ{88  084 lap ytkypNb\\\\$Ifkd@$$IflZ\fA*{8 ::084 laytkypNOPQRb\\\\$Ifkd@$$IflZ\fA*{8 ::084 laytkypb\$IfkdA$$IflZ\fA*{8 ::084 laytkypԤ4i $IfgdW&$IfqkdsB$$Ifl{88  084 lap ytkyp4hij|}ȥɥ 468;HIZ[\_mnȦ˦ڦۦܦߦԼԼʭԢʗʌ|ʌ|Լrghkyp5CJ\aJhkypOJQJ^JhN#5B*OJQJ^JphhN#5OJQJ^JhN#H*OJQJ^JhN#OJQJ]^JhN#OJQJ^JmHnHuhN#OJQJ^JnH tH hN#OJQJ^JhN#5OJQJ\^JhW&5OJQJ^JnH tH hN#5OJQJ^JnH tH (ijkz{|d^^^^$Ifkd"C$$Ifl\ A*{89:::084 laytkyp|}~d^^^^$IfkdC$$Ifl\ A*{89:::084 laytkypȥd^$IfkdD$$Ifl\ A*{89:::084 laytkypȥɥ$IfqkdDE$$Ifl{88  084 lap ytkyp    $$Ifa$$IfqkdE$$Ifl{88  084 lap ytkyp 89:b\\SS $$Ifa$$IfkdF$$Ifl\fA*{8 ::084 laytkyp:;<\]^b\\SS $$Ifa$$IfkdjG$$Ifl\fA*{8 ::084 laytkyp^_`b\\SS $$Ifa$$Ifkd2H$$Ifl\fA*{8 ::084 laytkypb\$IfkdH$$Ifl\fA*{8 ::084 laytkypȦɦʦ $$Ifa$$IfqkdI$$Ifl{88  084 lap ytkypʦ˦ڦۦܦݦަb\\\SS $$Ifa$$IfkdqJ$$Ifl\fA*{8 ::084 laytkypަߦbUPPPPPPUgdkyp  ^`kd9K$$Ifl\fA*{8 ::084 laytkyp fɧ Fߨ-./4589Ǽǟnj||l^M^A^^hkyp0JOJQJ^J!jjMhkypOJQJU^JjhkypOJQJU^Jhkyp5B*OJQJ^Jphhkyp0JCJOJQJ^JaJ$hE hkyp0JCJOJQJ^JaJhkypOJQJ\^J"hkypB*CJ$H*OJQJ^JphhkypH*OJQJ^JhkypOJQJ^Jhkyp5OJQJ\^Jhkyp5CJ\aJhkyphkypmH sH tHhkypmH sH tHf˧}xkdL$$Ifl9R:  t 0R:44 lap yt/ $Ifgd/~neX  $Ifgd/ $Ifgd/kdL$$IflFx9|hn* t0R:    44 layt/9abcjk~ߩ()-.~«}j_WhN#CJaJhN#5CJ\aJ$jRRhkyp5OJQJU^Jhkyp5OJQJ^Jjhkyp5OJQJU^J!jPhkypOJQJU^J!jOhkypOJQJU^J!j"OhkypOJQJU^Jhkyp0JOJQJ^JjhkypOJQJU^J!jiNhkypOJQJU^JhkypOJQJ^J"zz $Ifgd/|kdQ$$Ifl09|+ t0R:44 layt/«ëݫޫtrrrh h$If^h  ^`~kdR$$Iflq09|+ t0R:44 layt/«ëݫ345UVpqܬݬ    8Cִ֪֪x֪n`U֪KhW&OJQJ^Jhy[H*OJQJ^Jhy[hy[5OJQJ^Jhy[OJQJ^JhN#OJQJ^JmH sH h-iOJQJ^JhN#5OJQJ^JnH tH hN#5OJQJ^JhN#OJQJ^J!hN#5B*OJQJ\^Jph hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#5OJQJ^JmH sH hN#OJQJ^JmH sH 3y 9r h$If^hwkdS$$Ifl9:  t 0:644 lap 345;BPT $h$If^ha$gkdMT$$Ifl9: t0:644 laTUVp5++ h$If^hkdT$$Ifl\fA*9 :g (0:4 lap(pq۬QKE; $If^$If$IfkdV$$Ifl\fA*9 :g0:4 la h$If^h h$If^h۬ܬݬ  [UUH $If^gd|H!$IfkdV$$Ifl\fA*9 :g0:4 la h$If^h  -8IJe\VI? h$If^h $If^gd|H!$If $$Ifa$kdW$$Ifl\fA*9 :g0:4 laCGHJK\]hpst%&bcdqrst   xϷܘ{nZ{KhFh|H!0JOJQJ^J'j_hFh|H!OJQJU^JhFh|H!OJQJ^J!jhFh|H!OJQJU^JhN#0JOJQJ^J!j^hN#OJQJU^JjhN#OJQJU^Jhy[OJQJ^JhFhN#5OJQJ^JhN#5OJQJ\^JhN#OJQJ^JhW&H*OJQJ^JhW&hW&5OJQJ^JJKLZ[\e[U[[$If h$If^hkdxX$$Ifl\fA*9 :g0:4 la\]^qrse[U[[$If h$If^hkdHY$$Ifl\fA*9 :g0:4 lastue[U[[$If h$If^hkdZ$$Ifl\fA*9 :g0:4 lae[U[[$If h$If^hkdZ$$Ifl\fA*9 :g0:4 lae[U[[$If h$If^hkd[$$Ifl\fA*9 :g0:4 laecY h$If^hkd\$$Ifl\fA*9 :g0:4 laҭӭԭ#$of $IfgdF$ $Ifa$gd|H! h$If^hukdX]$$Ifl9R:  t 0R:44 lap $%szpfYY x$If^xgdF h$If^hkd]$$Ifl4F,9|) t0R:    44 laf4xyz{/0167:;cdelmʷʎʄzlz[lOlzlz>lOlz!jchN#OJQJU^JhN#0JOJQJ^J!jbhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh-iOJQJ^JhFh|f0JOJQJ^J3j5ahFh|f>*B*OJQJU^Jph$hFh|f>*B*OJQJ^Jph-jhFh|f>*B*OJQJU^JphhFh|H!OJQJ^J!jhFh|H!OJQJU^J%|nn  h$If^h h$If^hykdb$$Ifl09|+ t0R:44 la#$ݱ5TXgnpu˲Ͳ12QR}罰wj`hFOJQJ^Jh (hN#^JnH tH hN#CJaJh}LOJQJ^JhN#OJQJ\^Jh}LOJQJ^JmH sH hN#OJQJ^JmH sH hF5OJQJ\^JhN#5OJQJ\^JhN#0JOJQJ^J!jWdhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J!±w $h$If^ha$ykde$$Ifl09|+ t0R:44 la ±ɱʱرܱ $h$If^ha$ܱݱ.("$If$IfkdKf$$Ifl\ 0*9|x  t(0:644 lap(5TUVWXqOF $Ifgd}Lkd\g$$Ifl\ 0*9|x t0:644 la$If $Ifgd}Lqrstu^XXXX$Ifkd h$$Ifl\ 0*9|x t0:644 la^XXXX$Ifkdh$$Ifl\ 0*9|x t0:644 la˲^XXXX$Ifkdli$$Ifl\ 0*9|x t0:644 la˲̲Ͳ128^\O\I\? h$If^hL^L  8^8`kdj$$Ifl\ 0*9|x t0:644 la8?MQR+kdj$$Ifl\fA*9 :g (0:4 lap( h$If^hR]}ijٳLkdk$$Ifl\fA*9 :g0:4 la 7$If^7$If $Ifgd,}ϳӳֳسٳڳ۳ $&7;@BRVY[ko 6ҹүҥ}rhN#5OJQJ^JhN#OJQJ^JmH sH h (hN#^JnH tH hN#5OJQJ\^JhN#OJQJ^JhyYOJQJ^Jh:~hF5OJQJ^JhFH*OJQJ^JhFOJQJ^JhF5OJQJ\^JhFOJQJ\^JhF5OJQJ^J(ٳڳ۳[RLLB h$If^h$If $Ifgd,kdl$$Ifl\fA*9 :g0:4 la 7$If^7'(e___U h$If^h$Ifkdm$$Ifl\fA*9 :g0:4 la()*+CDe[UU[$If h$If^hkdmn$$Ifl\fA*9 :g0:4 laDEFG\]e[UU[$If h$If^hkd=o$$Ifl\fA*9 :g0:4 la]^_`pqe[UL[ $Ifgd:~$If h$If^hkd p$$Ifl\fA*9 :g0:4 laqrste[UU[$If h$If^hkdp$$Ifl\fA*9 :g0:4 lae[UU[$If h$If^hkdq$$Ifl\fA*9 :g0:4 lae[UU[$If h$If^hkd}r$$Ifl\fA*9 :g0:4 laeccccccccckdMs$$Ifl\fA*9 :g0:4 la $If$  h$If^ha$ h$If^h 65/%% $If^$Ifkdt$$Ifl\fA*9 :g (0:4 lap(678op[UKK $If^$IfkdNu$$Ifl\fA*9 :g0:4 la h$If^he[QQ[ $If^ h$If^hkdv$$Ifl\fA*9 :g0:4 lae[QQ[ $If^ h$If^hkdv$$Ifl\fA*9 :g0:4 lae[QQ[ $If^ h$If^hkdw$$Ifl\fA*9 :g0:4 laecY h$If^hkdx$$Ifl\fA*9 :g0:4 laqqqqqqqqqqq H4$If`4 h$If^hukd^y$$Ifl9R:  t 0R:44 lap  N]d¶wJKL0ǽǬnbTJhFOJQJ^JjhFOJQJU^JhN#0JOJQJ^J!jzhN#OJQJU^JjhN#OJQJU^Jhy[OJQJ^J(hhhhCJOJQJ^JaJnH tH  hhhhOJQJ^JnH tH h}LOJQJ^JhhhhOJQJ^JhN#OJQJ^JhhH*OJQJ^Jhy[H*OJQJ^JhN#H*OJQJ^J "N¶g߸wJ h$If^h & F4$Ifgd] $Ifgdh $IfgdF H4$If`4 JK{|pffff h$If^hkdz$$Ifl4Fx9|hn* t0R:    44 laf4012yz{|}~ɻʻ˻лѻԻջ,-.ʲʡʲʄʲsʲb!jhN#OJQJU^J!jhN#OJQJU^J!j hN#OJQJU^JhN#0JOJQJ^J!j ~hN#OJQJU^JjhN#OJQJU^JhFOJQJ^JhN#OJQJ^JhF0JOJQJ^JjhFOJQJU^J!j{hFOJQJU^J#|}si[[J  h$If^hgd4  h$If^h h$If^hkdI}$$IflFx9|hn* t0R:    44 la  sqqgggTN$If$  h$If^ha$ h$If^hkdL$$IflFx9|hn* t0R:    44 la  !+/<=OP\fjx{|Ķόq`qTqhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#5OJQJ\^JhN#OJQJ^JmH sH hsyphsypOJQJ\^JhsyphLOJQJ\^JhsyphN#OJQJ\^JhN#OJQJ\^JhN#OJQJ^JhN#OJQJ^JmH sH h (hN#^JnH tH hN#5OJQJ^J  !=O5////$Ifkd $$Ifl\fA*9 :g (0:4 lap(OP\fghe_YLB h$If^h $h$If^ha$$If$Ifkd>$$Ifl\fA*9 :g0:4 lahijxyze[UH[ $h$If^ha$$If h$If^hkd$$Ifl\fA*9 :g0:4 laz{|ecY h$If^hkdޅ$$Ifl\fA*9 :g0:4 laq H$If`H h$If^hukd$$Ifl9R:  t 0R:44 lap Vpff]P +$If`+gdif $Ifgdif h$If^hkdT$$Ifl4Fx9|hn* t0R:    44 laf4'()TUVW  @ABIJ`ջՒziz]zzLz]z!jThN#OJQJU^JhN#0JOJQJ^J!jUhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^J3jljhifhif>*B*OJQJU^Jphhifhif0JOJQJ^J3jhifhif>*B*OJQJU^Jph$hifhif>*B*OJQJ^Jph-jhifhif>*B*OJQJU^Jph]^_si[[  h$If^h h$If^hkd$$IflFx9|hn* t0R:    44 la_`asqqqgggT$  h$If^ha$ h$If^hkd $$IflFx9|hn* t0R:    44 la`<IJ!HJKLXZsιyιoeZLeh!OJQJ^JmH sH h!OJQJ\^Jh!OJQJ^JhkOJQJ^Jh.aOJQJ\^Jh\OJQJ^JmH sH hLOJQJ^JmH sH hN#H*OJQJ^JhN#OJQJ^JmH sH hN#OJQJ\^JhLOJQJ^JhN#OJQJ^JhN#OJQJ^JmH sH h (hN#^JnH tH hN#5OJQJ\^J/kd΍$$Ifl\fA*9 :g (0:4 lap($IfJ!VPP$Ifkd$$Ifl\fA*9 :g0:4 la $IfgdL$If!IJKLXYQKKE; h$If^h$If$IfkdϏ$$Ifl\fA*9 :g0:4 la$h$If^h`a$gdkYZ[recY h$If^hkd$$Ifl\fA*9 :g0:4 larsqg H$If^H H$If`H h$If^hukdo$$Ifl9R:  t 0R:44 lap 7fpff]]TK $Ifgdk $Ifgd\ $Ifgdsyp h$If^hkd$$Ifl4Fx9|hn* t0R:    44 laf45678糠w`M3`3jhVhHs>*B*OJQJU^Jph$hVhHs>*B*OJQJ^Jph-jhVhHs>*B*OJQJU^JphhVhsyp0JOJQJ^J3jhVhsyp>*B*OJQJU^Jph$hVhsyp>*B*OJQJ^Jph-jhVhsyp>*B*OJQJU^JphhN#0JOJQJ^J!jܒhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J =>?ǰt]J0]3jVhVhk>*B*OJQJU^Jph$hVhk>*B*OJQJ^Jph-jhVhk>*B*OJQJU^JphhVh\0JOJQJ^J3jhVh\>*B*OJQJU^Jph$hVh\>*B*OJQJ^Jph-jhVh\>*B*OJQJU^Jph$hVhHs>*B*OJQJ^Jph-jhVhHs>*B*OJQJU^JphhVhHs0JOJQJ^J?defgDǰzmcUcDU8UcUchN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhVhN#OJQJ^JhV0JOJQJ^J3j#hVhV>*B*OJQJU^JphhV>*B*OJQJ^Jph-jhVhV>*B*OJQJU^Jph$hVhk>*B*OJQJ^Jph-jhVhk>*B*OJQJU^JphhVhk0JOJQJ^Jfabcj`RR  h$If^h h$If^hkd$$IflFx9|hn* t0R:    44 la $IfgdifDEFMNde}~./klmz{|}ºʢziR-jh{)h{)>*B*OJQJU^Jph!jhN#OJQJU^JhOJQJ^JhG"5OJQJ\^J hJhN#OJQJ^JmH sH hN#5OJQJ\^JhZhZmH sH hN#CJaJhZCJaJhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^Jcde}~sffa_U h$If^hgdZ  ^`kdi$$IflFx9|hn* t0R:    44 lay 9r h$If^hwkd*$$Ifl9:  t 0:644 lap  $h$If^ha$gkdӛ$$Ifl9: t0:644 la5+++ h$If^hkd]$$Ifl\fA*9 :g (0:4 lap(TJJJ h$If^hkd$$Ifl\fA*9 :g0:4 la$$If^`a$e[[[J$$If^`a$ h$If^hkd^$$Ifl\fA*9 :g0:4 lae[[[J$$If^`a$ h$If^hkd.$$Ifl\fA*9 :g0:4 laecY h$If^hkd$$Ifl\fA*9 :g0:4 la,- h$If^hukdΠ$$Ifl9R:  t 0R:44 lap -.|yp $IfgdiD h$If^h|kdt$$Ifl409|+ t0R:44 laf4}OPQVWZ[ijӼzn]nSSFhN#5OJQJ\^JhjYOJQJ^J!jahN#OJQJU^JhN#0JOJQJ^J!jbhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhG"OJQJ^Jh{)h{)0JOJQJ^J-jh{)h{)>*B*OJQJU^Jph3jh{)h{)>*B*OJQJU^Jph$h{)h{)>*B*OJQJ^Jph|n  h$If^h h$If^hykdţ$$Ifl09|+ t0R:44 lah|| h$If^hykd$$Ifl09|+ t0R:44 lahijklmnouttttt`xx$A &P#$/Ifgd+Np 7^`gd+Npykd$$Ifl09|+ t0R:44 lajov"1FMvrsMN123㐟r^r'jh+Nph+NpOJQJU^J!jh+Nph+NpOJQJU^Jh+Nph+NpOJQJ^Jh+Nph+Nph_OJQJ\h+Nph+Np5OJQJ\h+Nph+Np6OJQJ\]h+Nph+Np6OJQJ\h+Nph+NpH*OJQJ\h+Nph+NpOJQJh+Nph+NpOJQJ\h+Np5OJQJ\^Jh+Np uvq>s|\\\\\\\\\ & F;xx$A &P#$/If^`gd1kdT$$Ifl4833  t 6PA  0644 lap yt+Np NQRS`amhXhhh 7^`gd+Npgd+Nprkd$$Ifl833 t 6PA 0644 layt+Np & F;xx$A &P#$/If^`gd13OPQS`,-.STUVlµҘ†qa҆La҆)jǪh+Nph+Np5OJQJU\h+Nph+Np0J5OJQJ\)jPh+Nph+Np5OJQJU\#jh+Nph+Np5OJQJU\h+Nph+NpOJQJ^Jhyh+Np5OJQJ\^Jhyh+NpCJ^JaJh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\!jh+Nph+NpOJQJU^Jh+Nph+Np0JOJQJ^JUU::: & F;dhxx$&@#$/Ifgd1kd$$Ifl4833  t 6@ 0644 lap yt1dhxx$&@#$/Ifgd1$&@#$/Ifgd1lmn   "#678JKMNؽ}kY#jRh+Nph+NpOJQJU#jͬh+Nph+NpOJQJU#jXh+Nph+NpOJQJUh+Nph+Np0JOJQJ#j߫h+Nph+NpOJQJUjh+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+Np0J5OJQJ\#jh+Nph+Np5OJQJU\)jth+Nph+Np5OJQJU\"Ntuv5689Zp^#j&h+Nph+NpOJQJUh+Nph+Np0J5OJQJ\)jh+Nph+Np5OJQJU\#jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\#jFh+Nph+NpOJQJUh+Nph+Np0JOJQJjh+Nph+NpOJQJU#jh+Nph+NpOJQJUh+Nph+NpOJQJZ[\vwyz1245Vƴަo]#jh+Nph+NpOJQJUh+Nph+Np0J5OJQJ\)jh+Nph+Np5OJQJU\#jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\#j*h+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+Np0JOJQJjh+Nph+NpOJQJU#jh+Nph+NpOJQJUVWXijlm -./RSTUiƴƢƐ~p^p#jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\#jwh+Nph+NpOJQJU#jh+Nph+NpOJQJU#j{h+Nph+NpOJQJU#jh+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+Np0JOJQJjh+Nph+NpOJQJU#jsh+Nph+NpOJQJU#TaOJgd+Nprkd$$Ifl833 t 6@0644 layt1" & F;dhxx$&@#$/If^`gd1 & F;dhxx$&@#$/Ifgd1ijk  #$&'Fغo]#j;h+Nph+NpOJQJU#jȴh+Nph+NpOJQJUh+Nph+Np0JOJQJ#jUh+Nph+NpOJQJUjh+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+Np5OJQJ\h+Nph+Np0J5OJQJ\#jh+Nph+Np5OJQJU\)jh+Nph+Np5OJQJU\FGH\]_`!"ƴƢޔm]K#jh+Nph+NpOJQJUh+Nph+Np0J5OJQJ\)j?h+Nph+Np5OJQJU\#jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\#jȶh+Nph+NpOJQJU#j=h+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+Np0JOJQJjh+Nph+NpOJQJU#jh+Nph+NpOJQJU"#,-/0BCDWXZ[mnoشآؐ؂p#jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\#j~h+Nph+NpOJQJU#jh+Nph+NpOJQJU#jh+Nph+NpOJQJU#j1h+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+Np0JOJQJjh+Nph+NpOJQJU#9:;CDFG_`aghjkؽ}kY#jûh+Nph+NpOJQJU#jLh+Nph+NpOJQJU#jݺh+Nph+NpOJQJUh+Nph+Np0JOJQJ#jjh+Nph+NpOJQJUjh+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+Np0J5OJQJ\#jh+Nph+Np5OJQJU\)jh+Nph+Np5OJQJU\"/034TUVdeghm#jyh+Nph+NpOJQJU#jh+Nph+NpOJQJU#jh+Nph+NpOJQJU#jh+Nph+NpOJQJU#jh+Nph+NpOJQJUh+Nph+Np0JOJQJjh+Nph+NpOJQJU#j.h+Nph+NpOJQJUh+Nph+NpOJQJ*GHI_`abz{|ԕn^NNh+Nph+Np5OJQJ\^Jh+Nph+Np0J5OJQJ\)jgh+Nph+Np5OJQJU\#jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\#jֿh+Nph+NpOJQJU#jkh+Nph+NpOJQJUh+Nph+Np0JOJQJjh+Nph+NpOJQJU#jh+Nph+NpOJQJUh+Nph+NpOJQJ$<<$Ifa$gd1 <<$Ifgd101456723Fʻѻ򻃻wkcVh+Nph+NpB*H*phh+Nph+Np7h+Nph+Np>*OJQJh+Nph+NpH*OJQJ h+Nph+NpB*H*OJQJphh+Nph+Np0JOJQJh+Nph+NpOJQJjh+Nph+NpOJQJUh+Nph+NpB*OJQJph h+Nph+Np h+Nph+Np5B*OJQJphh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\, <<$Ifgd1kdu$$Ifl44\ +;:}G `(064 laf4p(yt10F~uuuuuuuuuuu $Ifgd1 ($Ifgd1wkd$$Ifl4;:  064 laf4p yt1 F`z $Ifgd1 $Ifgd1 Mi  'begz{ "$(8νްޤΖνޅsssb޽sWh+Nph+NpOJQJ h+Nph+Np>*B*OJQJph#h+Nph+Np5B*OJQJ\ph h+Nph+NpB*OJQJ\phh+Nph+Np5OJQJ\h+NpB*OJQJphh+Nph+NpOJQJ^J h+Nph+Np5B*OJQJphh+Nph+Np5OJQJ\^Jh+Nph+NpB*OJQJph h+Nph+Nph+Nph+NpB*phe^UUUUUUUU $Ifgd1kdf$$Ifl4\ +;:}G064 laf4yt1   <<$Ifgd1hkd7$$Ifl4;:064 laf4yt1 $Ifgd1  'Rbz8:6~~~~~~~~~~ss <$Ifgd1 $Ifgd1wkd$$Ifl4;:   064 laf4p yt1 246?@LMN~ɽɱskWHW7W hyhy>*B* OJQJphR|hyhyB*OJQJphJJJ&jhyhyB*OJQJUphJJJhyOJQJh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\! *h+Nph+Np5OJQJ\^Jh+Nph+NpB*OJQJphh+Nph+NpOJQJ\h+Nph+NpH*OJQJh+Nph+NpOJQJh+Nph+Np5H*OJQJ!h+Nph+Np0JB*OJQJphh+Nph+Np5OJQJ6| $Ifgd1$<$Ifa$gd1 <$Ifgd1 ?^Q <<$Ifgd1kd$$Ifl4\ +;:}G064 laf4yt1?@LM~~~~~~~~~~~ $Ifgd1wkda$$Ifl4;:   064 laf4p yt1 &'4589hi˺꜏lN(Jjh+Nph+Np0J'>*B*CJOJQJU^JaJhmH phsH ;h+Nph+Np0J'>*B*CJOJQJ^JaJhmH phsH Djh+Nph+Np0J'>*B*CJOJQJU^JaJhmH phsH h+Nph+Np0JOJQJjh+Nph+NpOJQJUh+Nph+NpOJQJmH sH  h+Nph+NpOJQJ^JmH sH h+Nph+Np5OJQJ\^Jh+Nph+NpB*OJQJphh+Nph+NpOJQJhyhyOJQJ678^ULLLLLL $Ifgd1 $Ifgd1kd$$Ifl4\ +;:}G064 laf4yt1ijsw^n FTU#ݭvjvvXjvLjvj *h+Nph+NpOJQJ#h+Nph+Np0J'5CJOJQJaJh+Nph+NpOJQJ\ h+Nph+Np0J'CJOJQJaJh+Nph+Np5OJQJh+Nph+NpOJQJh+Nph+NpOJQJmH sH ;h+Nph+Np0J'>*B*CJOJQJ^JaJhmH phsH #h+Nph+Np0JOJQJhmH sH Djh+Nph+Np0J'>*B*CJOJQJU^JaJhmH phsH YZ\]^_`abcdn{ $Ifgd1GHIJTU$% $Ifgd1#$&9:;qr'()9:YZp˺ˆ{i\{{J\{{#joh+Nph+NpOJQJUh+Nph+Np0JOJQJ#jh+Nph+NpOJQJUh+Nph+NpOJQJjh+Nph+NpOJQJUhyh+NpmH sH hy>*B* CJaJphR|hyB*CJaJphJJJ jhyB*CJUaJphJJJ h+Nph+Nph+Nph+Np5OJQJ\h+Nph+NpB*OJQJph h+Nph+Np0J'CJOJQJaJ%&89:^UULLLUU $Ifgd1 $Ifgd1kd$$Ifl4\ +;:}G064 laf4yt1;<=(TUPQ6h"$Fr $Ifgd1pqr "$246ƺƬƀrfUfAU&jh+Nph+NpOJQJU\ jh+Nph+NpOJQJU\h+Nph+NpOJQJ\h+Nph+Np6OJQJ\h+Nph+Np6OJQJ h+Nph+Nph .5OJQJ\h+Nph+Np5H*OJQJ\h+Nph+Np5OJQJ\h+Nph+NpOJQJ]h+Nph+NpOJQJh+Nph+Np0JOJQJjh+Nph+NpOJQJU#j"h+Nph+NpOJQJU6JLNvz456ɵv^K^6^+hyh+NpOJQJ(hyhy>*B* CJOJQJaJphR|%hyhyB*CJOJQJaJphJJJ.jhyhyB*CJOJQJUaJphJJJh+Nph+Np5OJQJ\!h+Nph+Np5H*OJQJ\^Jh+Nph+NpB*OJQJph h+Nph+NpB*OJQJ\ph&h+Nph+Np5B*H*OJQJ\phh+Nph+NpOJQJh+Nph+NpOJQJ\ jh+Nph+NpOJQJU\h+Nph+Np0JOJQJ\NPRTVXZ\^`bdfhjlnprtv3$$d%d&d'dIfNOPQ]^gd1 $Ifgd1678A8^UUUUULL !$Ifgd1 $Ifgd1kd$$Ifl4\ +;:}G064 laf4yt168A@AB[vbTHvv *h+Nph+NpOJQJh+Nph+Np0JOJQJ\&jh+Nph+NpOJQJU\h+Nph+NpOJQJ\ jh+Nph+NpOJQJU\h+Nph+NpOJQJ^Jh+Nph+NpOJQJ\^J!h+Nph+Np56OJQJ\^Jh+Nph+Np56OJQJ^Jh+Nph+Np5OJQJ\h+Nph+NpH*OJQJh+Nph+Np5OJQJh+Nph+NpOJQJ89<=kl@A[\i $Ifgd1 & F?$Ifgd1 $Ifgd1 ijkl $Ifgd1 <$Ifgd1 [\]ghklmY³}j}U}G8h+Nph+NpCJOJQJaJhh+Np5OJQJ\(hhy>*B* CJOJQJaJphR|%hhyB*CJOJQJaJphJJJ.jhhyB*CJOJQJUaJphJJJh+Nph+Np5OJQJ\h+Nph+Np5OJQJ\^Jh+Nph+NpB*OJQJphh+Nph+NpOJQJh+Nph+Np0JOJQJ\ jh+Nph+NpOJQJU\&jLh+Nph+NpOJQJU\lm XY^UUULLLL !$Ifgd1 $Ifgd1kd$$Ifl4\ +;:}G064 laf4yt1i7yEݦݖ݋݋|l^F.jhhRB*CJOJQJUaJphJJJh+Nph+Np5OJQJ\h+Nph+Np5OJQJ\^Jh+Nph+NpB*OJQJphh+Nph+NpOJQJh+Nph+Np5CJOJQJaJh+Nph+Np6CJOJQJaJ h+Nph+Np0JCJOJQJaJ+jh+Nph+NpCJOJQJUaJh+Nph+NpCJOJQJaJ%jh+Nph+NpCJOJQJUaJY.78HyEFG $Ifgd1 !$Ifgd1 -$If^gd1 3YPPPPPPPP $Ifgd1kd $$Ifl4\ +;:}G064 laf4gKyt1 123Z[ԿԴxj^OO?h+Nph+Np5OJQJ\^Jh+Nph+NpB*OJQJphh+Nph+Np6OJQJh+Nph+Np0JOJQJ\&jh+Nph+NpOJQJU\ jh+Nph+NpOJQJU\h+Nph+NpOJQJ\h+Nph+NpOJQJhh+NpOJQJ(hhR>*B* CJOJQJaJphR|.jhhRB*CJOJQJUaJphJJJ%hhRB*CJOJQJaJphJJJEFGHYZ]^k[\ $Ifgd1^YYLL<$<<$Ifa$gd1 <<$Ifgd1gd+NpkdY$$Ifl4\ +;:}G064 laf4yt1 !  01234b弫k\Mjh+Nph+NpOJQJUhRh+NpB*OJQJph(hRhR>*B* CJOJQJaJphR|%hRhRB*CJOJQJaJphJJJ.jhRhRB*CJOJQJUaJphJJJ h+Nph+Np5B*OJQJphh+Nph+NpB*OJQJphh+Nph+Np5OJQJh+Nph+Np5OJQJ\h+Nph+Np5OJQJ\^Jh+Nph+NpOJQJkd*$$Ifl44\=+;: `(064 laf4p(yt1$<<$Ifa$gd1 !zwkdI$$Ifl4;:   064 laf4p yt1 <<$Ifgd123vwxyz~~~~~~~~~~~~~ $Ifgd1wkd$$Ifl4;:  064 laf4p yt1bcdtuy9}~/023N\ƷƷƫƟzlƟƷ\Oh+Nph+NpCJOJQJh+Nph+Np5OJQJ\^Jh+Nph+Np0JOJQJ\&jth+Nph+NpOJQJU\ jh+Nph+NpOJQJU\h+Nph+NpOJQJ\h+Nph+Np6OJQJh+Nph+NpB*OJQJphh+Nph+NpOJQJh+Nph+Np0JOJQJjh+Nph+NpOJQJU#jh+Nph+NpOJQJU#:[\0 <$Ifgd1 $7$8$Ifgd1 $Ifgd10123N[\UL $Ifgd1kd$$Ifl4\=+;:064 laf4yt1 $Ifgd1\]#$5B豝wjYYH=Hh+Nph+NpOJQJ h+Nph+Np6B*OJQJph h+Nph+Np5B*OJQJphh+Nph+Np0JOJQJ,jh+Nph+NpB*OJQJUphh+Nph+NpB*OJQJph&jh+Nph+NpB*OJQJUphhgQh+NpB*OJQJph(hgQhgQ>*B* CJOJQJaJphR|%hgQhgQB*CJOJQJaJphJJJ.jhgQhgQB*CJOJQJUaJphJJJ%&'(45BCZ}~ $Ifgd1BCZ~45pqï՟ՀmXD&jh+Nph+NpB*OJQJUph(hRhgQ>*B* CJOJQJaJphR|%hRhgQB*CJOJQJaJphJJJ.jhRhgQB*CJOJQJUaJphJJJ h+Nph+Nph+Nph+Np5OJQJ\^J&h+Nph+Np6B*H*OJQJ]ph#h+Nph+Np6B*OJQJ]phh+Nph+NpB*OJQJph h+Nph+Np6B*OJQJphh+Nph+NpOJQJ^UUII $$Ifa$gd1 $Ifgd1kdg$$Ifl4\=+;:064 laf4yt1342\SJJJJJJ $Ifgd1 ($Ifgd1kd"$$Ifl44\=+;:064 laf4yt101qtvNPRV X Z G I X c d z ~  չti]iQiEih+Nph+Np6OJQJh+Nph+NpH*OJQJh+Nph+Np5OJQJh+Nph+NpOJQJ h+Nph+Np5B*OJQJph h+Nph+Np>*B*OJQJph#h+Nph+Np5B*OJQJ\ph h+Nph+NpB*OJQJ\phh+Nph+NpB*OJQJphh+Nph+Np0JOJQJ&jh+Nph+NpB*OJQJUph,jh+Nph+NpB*OJQJUph23456aqFfh Z   H I X d z { ~      x$Ifgd1 $Ifgd1          $ : = > e f g         5 佮䖈佢䮖wphWKh~B*CJaJphJJJ jh~B*CJUaJphJJJh+Nph+Np5 h+Nph+Np! *h+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\h+Nph+NpOJQJ\h+Nph+Np5OJQJh+Nph+NpB*OJQJphh+Nph+NpB* OJQJphh+Nph+NpH*OJQJh+Nph+Np6OJQJh+Nph+NpOJQJ h+Nph+NpB* H*OJQJph        $ : V f g j k ~        $Ifgd1      P u v ^UUUUULL $Ifgd1 ($Ifgd1kd3$$Ifl4\=+;:064 laf4yt15 6 7 N O P v w        6 7 [ a b   Ŷ{j[j[J=Jh+Nph+Np0J.OJQJ!jh+Nph+Np0J.OJQJUh+Nph+NpB*OJQJph333 h+Nph+NpB*OJQJ\ph333h~0JOJQJ&jh~B*OJQJUphh~B*OJQJph jh~B*OJQJUphh+Nph+NpB*OJQJphh+Nph+Np5h~>*B* CJaJphR| jh~B*CJUaJphJJJ&jh~B*CJUaJphJJJv   7  %&'\]xAabx $Ifgd1    D&']xABbhix67pӰӡykyy\yykykyyPyh+Nph+Np5OJQJh+Nph+Np5>*OJQJ\h+Nph+Np6OJQJ\h+Nph+NpOJQJ\h+Nph+Np5OJQJ\h+Nph+Np>*OJQJ\h+Nph+NpB*OJQJph#h+Nph+Np5B*OJQJ\ph333 h+Nph+NpB*OJQJ\ph333h+Nph+NpB*OJQJph333!jh+Nph+Np0J.OJQJUh+Nph+Np0JOJQJ6789:;<=>?@ABCDEFGHIJKL $Ifgd1Lp,>?+kdI$$Ifl4\=+;:064 laf4yt13$$d%d&d'dIfNOPQ]^gd1pq*+>?AHIQRjA|&'(`㰥yi]]N]h+Nph+Np5>*OJQJ\h+Nph+Np5OJQJh+Nph+Np5CJOJQJ\h+Nph+NpCJOJQJ\h+Nph+Np5OJQJ\h+Nph+Np5OJQJ\^Jh+Nph+NpOJQJ! *h+Nph+Np5OJQJ\^Jh+Nph+Np0JOJQJ\&jFh+Nph+NpOJQJU\h+Nph+NpOJQJ\ jh+Nph+NpOJQJU\?AIR]i$<<$Ifa$gd1 <<$Ifgd1gd+Npij, d $Ifgd1kd$$Ifl44\<+>: `(064 laf4p(yt1|'(`~:={rrrrrrrrr $Ifgd1wkdD$$Ifl4>:  064 laf4p yt1 d $Ifgd1 12389=>hj岣ƲtatLtAtatLth#q=h+NpOJQJ(h#q=h#q=>*B* CJOJQJaJphR|%h#q=h#q=B*CJOJQJaJphJJJ.jh#q=h#q=B*CJOJQJUaJphJJJ,jh+Nph+NpB*OJQJUphh+Nph+NpB*OJQJph&jh+Nph+NpB*OJQJUphh+Nph+Np0JOJQJ#jh+Nph+NpOJQJUh+Nph+NpOJQJjh+Nph+NpOJQJUl>@BDF $Ifgd1jln$%&'(^_|dQd%h#q=h#q=B*CJOJQJaJphJJJ.jh#q=h#q=B*CJOJQJUaJphJJJh+Nph#q=OJQJh+NpOJQJ#jh+Nph+NpOJQJUh#q=OJQJh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\h+Nph+Np0JOJQJ#jh+Nph+NpOJQJUjh+Nph+NpOJQJUh+Nph+NpOJQJ&'^UUUUUUUU $Ifgd1kd$$Ifl4\<+>:064 laf4yt1 _}~opstXȽqd\QE=h$=OJQJjh$=OJQJUh+Nph$=OJQJh+NpOJQJh+Nph+Np0JOJQJ#j"h+Nph+NpOJQJUjh+Nph+NpOJQJUh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\h+Nph+NpOJQJh#q=h+NpOJQJ.jh#q=h#q=B*CJOJQJUaJphJJJ(h#q=h#q=>*B* CJOJQJaJphR|'6KLYnopUkdT$$Ifl4\+9064 laf4yt1 $Ifgd1 pqrstLC $Ifgd1kd8$$Ifl4\<+>:064 laf4yt1 $Ifgd1 $Ifgd1xy:; $Ifgd1XYZuvwLMN_`aǻǡǡpapPpEh$=h+NpOJQJ h$=h$=>*B* OJQJphR|h$=h$=B*OJQJphJJJ&jh$=h$=B*OJQJUphJJJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+Np6OJQJh+Nph+Np5OJQJ\h+Nph+NpOJQJ\h+Nph+NpOJQJh$=OJQJh$=0JOJQJjh$=OJQJUj h$=OJQJU(KLMNUkdD$$Ifl4 \<+>:064 laf4yt1 $Ifgd1 NO_`   !!!!!!! !!!"!#!$!%!&!'!V!W! <$Ifgd1 $Ifgd1 $Ifgd1  !        !!!!#!$!]!^!#######嬤~naI.jh$=h$=B*CJOJQJUaJphJJJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+NphxOJQJ\h+Nph+Np>*OJQJh+Nph,xOJQJh,xOJQJh+NpOJQJ#jh+Nph+NpOJQJUh+Nph+Np0JOJQJ#j.h+Nph+NpOJQJUh+Nph+NpOJQJjh+Nph+NpOJQJUW!!!!"1"2"3"4"5"6"7"8"9"F"g"""""#####2#N## (($Ifgd1 $Ifgd1########C$UL $Ifgd1kd$$Ifl4\<+>:064 laf4yt1 $Ifgd1#$ $A$B$C$F%G%m%n%{%%%'''%'&'.'/'G'j'k'}'~'''ԿԴ~rrddrUC#jmh+Nph+NpOJQJUjh+Nph+NpOJQJUh+Nph+Np5OJQJ\h+Nph+Np5OJQJh+Nph+Np5>*OJQJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+NpOJQJh$=h+NpOJQJ(h$=h$=>*B* CJOJQJaJphR|.jh$=h$=B*CJOJQJUaJphJJJ%h$=h$=B*CJOJQJaJphJJJC$D$E$$$$$$$$$$% %B%C%D%E%F% $Ifgd1F%G%m%z%{%|%}%~%%^ULLLLLL $Ifgd1 $Ifgd1kd$$Ifl4\<+>:064 laf4yt1%%%%%%&&&&&&&&&&&&&& '''' $Ifgd1 h$If^hgd1'''&'/':'F'^YLL<<$<<$Ifa$gd1 <<$Ifgd1gd+Npkd$$Ifl4\<+>:064 laf4yt1F'G'j', <<$Ifgd1kd$$Ifl44\=+;: `(064 laf4p(yt1j'k'|'}''K(((~~~~~u $Ifgd1 $Ifgd1wkd$$Ifl4;:  064 laf4p yt1'''''J(K((((((((()))*)T)U)W)X))))))))*ض؏}k\Qhl4hl4OJQJjhl4hl4OJQJU#jh+Nph+NpOJQJU#jh+Nph+NpOJQJUh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+Np]^Jh+Nph+NpOJQJ^J)h+Nph+NpB*OJQJ^JnH phtH h+Nph+NpOJQJh+Nph+Np0JOJQJjh+Nph+NpOJQJU(((((V)W)))^ULUUUUU $Ifgd1 $Ifgd1kd>$$Ifl4\=+;:064 laf4yt1***7*8*;*<**********+9+,,+-,-/-0-5-ƴƩ{ocVIh+Nph+Np^JmH sH h+Nph+NpOJQJ^Jh+Nph+NpH*OJQJh+Nph+Np6OJQJh+Nph+NpB*OJQJph%h+Nph+NpB*OJQJmH phsH h+Nph+Np5OJQJh+Nph+NpOJQJ#jhl4hl4OJQJUhl4hl4OJQJhl4hl40JOJQJjhl4hl4OJQJU#jhl4hl4OJQJU):*;**********+:+;+u+++++,,3$$d%d&d'dIfNOPQ]^gd1 $Ifgd1 $Ifgdl4,q,r,,/-0-M-Q-j-n--------------..>.B. $Ifgd1 ($Ifgd1 $Ifgd15-=-Q-j------------.1.2.X..........ꛍoaM&jh+Nph+NpB* OJQJUphh+Nph+Np6OJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+Np6OJQJ]h+Nph+NpH*OJQJ^Jh+Nph+NpOJQJ^Jh+Nph+NpH*^JmH sH h+Nph+Nphhb6]^Jh+Nph+Np6]^Jh+Nph+NpOJQJh+Nph+Np6^JmH sH h+Nph+Np^JmH sH h+Nph+Np^JB.X.j........... $Ifgd1 & F@$If`gd1 $Ifgd1 ....J/K/L/M/^UL?LLL O$Ifgd1 $Ifgd1 $Ifgd1kd$$Ifl4\=+;:064 laf4yt1.B/C/D/G/H/I/00h0i0l0o0q0{000000000Ÿ𭡭tj_jUEh+Nph+Np5OJQJ\^Jh+Nph+Np]^Jh+Nph+Np5H*]h+Nph+Np5]h+Nph+Nph5OJQJ^Jh+Nph+Np5H*OJQJ]h+Nph+Np5OJQJ]h+Nph+NpH*OJQJh+Nph+NpOJQJh+Nph+Np0JOJQJ&jh+Nph+NpB* OJQJUph,jh+Nph+NpB* OJQJUphh+Nph+NpB* OJQJphM/N/O/////00h0{000000 $Ifgd1 <$Ifgd1 $Ifgd1000061122^RRRRGG <$Ifgd1 $7$8$Ifgd1kd$$Ifl4\=+;:064 laf4yt1000114151611111122222P3Q3۳ۧqaTC7Chl4B*CJaJphJJJ jhl4B*CJUaJphJJJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\h+Nph+NpB* OJQJphI}h+Nph+Np6OJQJ]h+Nph+NpOJQJhl4h+Np5OJQJ(hl4hl4>*B* CJOJQJaJphR|%hl4hl4B*CJOJQJaJphJJJ.jhl4hl4B*CJOJQJUaJphJJJh+Nph+Np5OJQJ2222355{r{rg <$Ifgd1 $Ifgd1 $Ifgd1{kd$$Ifl40=;:064 laf4yt1Q33333M4r4555555&5'5/505H5T5U5V555555źźŞŞźs^Ohl4h+NpB*OJQJph(hl4hl4>*B* CJOJQJaJphR|%hl4hl4B*CJOJQJaJphJJJ.jhl4hl4B*CJOJQJUaJphJJJh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJh+Nph+NpOJQJh+Nph+Np5OJQJ\h+Nph+Np6OJQJ^J jhl4B*CJUaJphJJJhl4>*B* CJaJphR|555'505;5G5rrbb$<<$Ifa$gd1 <<$Ifgd1gd+Np{kdU$$Ifl40=;:064 laf4yt1G5H5T5U5,## $Ifgd1kd$$Ifl44 \z*`9 `(0?64 laf4p(yt1U5555555 6 666<666666h7777777888 $Ifgd1 $Ifgd15555556 667888j8r8s8{8|8888899999 : :::::<:=:ְ֠֠֠yhYh+Nph+NpOJQJmHsH h+Nph+Np0JOJQJmHsHh+Nph+NpOJQJ^Jh+Nph+Np5OJQJh+Nph+Np5OJQJ\h+Nph+Np5OJQJ\^J h+Nph+Nph+Nph+Np0JOJQJ#j!h+Nph+NpOJQJUh+Nph+NpOJQJjh+Nph+NpOJQJUh+Nph+NpB*OJQJph"88828i8j8^UUUU $Ifgd1kd$$Ifl4 \z*`90?64 laf4yt1j8k8s8|888^HH//$<<$&P#$/Ifa$gd,x<<$&P#$/Ifgd,xkd$$Ifl4 \z*`90?64 laf4yt188"kdR$$Ifl44\>,=;" ` 6P(064 laf4p(yt,x888888D99hVVVVV$&P#$/Ifgd,xkd$$Ifl4=;  6P 064 laf4p yt,x<<$&P#$/Ifgd,x9999:D::;;;zhhVVhhVV$&P#$/Ifgd,x$&P#$/Ifgd,xkdw$$Ifl40=; 6P064 laf4yt,x =:B:C:D:E:::::::::;;;;=<===????????ೢ{k{kc[PChhOJQJ^Jh+Nph,xOJQJh,xOJQJh+NpOJQJh+Nph+Np5OJQJ\^Jh+Nph+NpOJQJ^Jhl4>*B* CJaJphR|hl4B*CJaJphJJJ jhl4B*CJUaJphJJJh+Nph+NpOJQJmHsHh+Nph+NpOJQJ%h+Nph+NpB*OJQJmHphsHjh+Nph+NpOJQJU h+Nph+Np0JOJQJmHsH;;;-<.</<h<i<<<<<<<;=$&P#$/Ifgd,x;=<===_=`=d>TB000$&P#$/Ifgd,x$&P#$/Ifgd,xkd=$$Ifl4V \,=;`  6P064 laf4yt,xd>>>??G?H????$&P#$/Ifgd,x ??????????TOOOOOOOOgd+Npkd^$$Ifl4\,=;   6P064 laf4yt,x ?????W@X@@@@@8A_AbAAAAAABB$&P#$/Ifgd$&P#$/Ifgd?????????1@2@U@V@W@X@Y@@@@@@BB&B'BRBSBXBYBZB宛{ibUMhOJQJhhOJQJ^J hbh#j0hhOJQJUh];hOJQJ(h];h];>*B* CJOJQJaJphR|%h];h];B*CJOJQJaJphJJJ.jh];h];B*CJOJQJUaJphJJJhh0JOJQJ#jhhOJQJUhhOJQJjhhOJQJUBB&BZB[BBVF444<$&P#$/Ifgd$&P#$/Ifgdkd$$Ifl4Z\,=;  6P064 laf4ytZB[B\BBBBBBBBBBC,C-CDDDDDDDୢtmbZRGbh+Nph,xOJQJh,xOJQJh+NpOJQJh+Nph+NpOJQJ hbhhh0JOJQJ#j1hhOJQJUjhhOJQJUhhOJQJh];h];OJQJ(h];h];>*B* CJOJQJaJphR|%h];h];B*CJOJQJaJphJJJ.jh];h];B*CJOJQJUaJphJJJh];OJQJBB.C/C0C1C2CrCsCCCCCC%D&D'DmDnDqDrDD$&P#$/IfgdDDDDDDDDDQLLLLLLLgd+Npkd$$Ifl4Z\,=;  6P064 laf4g*GytDDDDDDDDDDDDDD  $&@#$/Ifgd1gd+Np DDDDE EYEZEEEOFPFQFwFt <$Ifgd1 $Ifgd1gd+NpqkdJ$$Ifl4Z 6@064 laf4yt1 DDDDDEEEE E E;E*B* CJOJQJaJphR|%h3lh3lB*CJOJQJaJphJJJ.jh3lh3lB*CJOJQJUaJphJJJh+Nph+NpOJQJh+Nph+Np5OJQJh+Nph+Np5OJQJ\^Jh+Nph+Np5OJQJ\|J}JJ, <<$Ifgd1kd} $$Ifl44\8+>: `(064 laf4p(yt1JJJJJJJKKKKK LL-L~~~~~~~~~~~~~ $Ifgd1wkd $$Ifl4>:  064 laf4p yt1-L.L?L\LLLLLLLLLL+M,M-M.M $Ifgd1 $Ifgd1LLLLLLLL,M-M.M/M6M7M8MjMkMugO:064 laf4yt1kMMMM7O8OCODOEOzO{OOOOOOPPPPPQQȽujcXcJXAXch+Nph+Np0Jjh+Nph+NpUjh+Nph+NpU h+Nph+Nph3lh+NpmH sH h3l>*B* CJaJphR|h3lB*CJaJphJJJ jh3lB*CJUaJphJJJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+NpOJQJh3lh+NpOJQJ.jh3lh3lB*CJOJQJUaJphJJJ(h3lh3l>*B* CJOJQJaJphR|MMM&N'NiNjNNNNN O6O7O X$If^Xgd1 & FC$Ifgd1 $Ifgd1 7O8OCODOOOOOOOP{riiii^^^ <$Ifgd1 $Ifgd1 $Ifgd1 $Ifgd1{kd$$Ifl408>:064 laf4yt1 PPPPPOQQQQQQQQQQQQQQ*RnRoRRRRRRR $Ifgd1 <$Ifgd1QQ*RjRmRoRqRRRRRRR5S6SJSKSLSjSSSSSSTTT!T"T#T$T%T&T'TͿٱ٥ٔـrcWh+Nph+NpOJQJ]h+Nph+NphxOJQJ\h+Nph+Np0JOJQJ\&jh+Nph+NpOJQJU\ jh+Nph+NpOJQJU\h+Nph+Np5OJQJh+Nph+Np5OJQJ\h+Nph+Np6OJQJ\h+Nph+Np6OJQJh+Nph+NpOJQJ\h+Nph+NpOJQJ h+Nph+Nph+Nph+Np\!RR5S6SLSjSSSSSS$T%T&T'T <$If^<gd1 <$Ifgd1 $Ifgd1'T(T-T.TTT,U-U^ULL?UL t$Ifgd1 $Ifgd1 $Ifgd1kd$$Ifl4\8+>:064 laf4yt1'T(T-T.T/TvTwTTTTTT U U*U+U,UUUVW W W WWWWWXW_W`Wɼ㫜ؕ؄vjY h+Nph+Np0JOJQJmHsHh+Nph+Np5OJQJh+Nph+Np6OJQJ]!h+Nph+NpB*OJQJ^Jph h+Nph+Nph+Nph+Np0JOJQJ^J!jh+Nph+NpOJQJU^Jh+Nph+Np0JOJQJjh+Nph+NpOJQJUh+Nph+NpOJQJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^J-UHUUUUUUU\V]VVVVWW W W <$Ifgd1 $Ifgd1 W WWaWSX^UUU $Ifgd1kdg$$Ifl4\8+>:064 laf4yt1`WaWWWPXTX_X`XaXXXXXXXXXYYY Y Y!YvYwYZ泦{f[OAh+Nph+NpH*OJQJ\h+Nph+NpOJQJ\h3lh+NpOJQJ(h3lh3l>*B* CJOJQJaJphR|%h3lh3lB*CJOJQJaJphJJJ.jh3lh3lB*CJOJQJUaJphJJJh+Nph+Np0JOJQJjh+Nph+NpOJQJUh+Nph+Np5OJQJh+Nph+NpH*OJQJh+Nph+Np6OJQJh+Nph+NpOJQJh+Nph+NpOJQJmHsHSXTX_X`XXY Y Y Y Y Y Y!YxYvvvvvvvvvvvv $Ifgd1kdC$$Ifl40 90644 laf4yt1 xYYYZZ2ZKZOZhZiZZZ $Ifgd1 ZZZ-[d[[\\\\^UUUUUUUU $Ifgd1kd$$Ifl4J\8+>:`064 laf4yt1 ZZR]S]Y]h]i]]]]]]^^=_T_o_____~r`T~@'h+Nph+Np6CJOJQJaJmH sH h+Nph+NpH*OJQJ"h+Nph+Np5CJOJQJ]aJh+Nph+Np5OJQJh+Nph+NpCJOJQJaJhAsh+NpOJQJ(hAshAs>*B* CJOJQJaJphR|%hAshAsB*CJOJQJaJphJJJ.jhAshAsB*CJOJQJUaJphJJJh+Nph+NpOJQJ^Jh+Nph+NpOJQJh+Nph+Np5OJQJ\^J\\]]]Q]R]S]Y]UL $Ifgd1kd$$Ifl4y\8+>: 064 laf4yt1 $Ifgd1Y]Z]f]g]h]]]]]]]]]^H^b^^^^^^T_o_}__& & FA$If`gd1 &$Ifgd1 <$Ifgd1 $Ifgd1________``D`E`H`I`T`c`````````EaFaGaHa $Ifgd1 $Ifgd1_``B`H`I`S```````aa6a7a8aBaCaDaEaHaIaXaZaοΥγrcSEh+Nph+Np5OJQJ\h+Nph+Np5OJQJ\^Jh+Nph+NphxOJQJ\h+Nph+Np0JOJQJ\&jh+Nph+NpOJQJU\ jh+Nph+NpOJQJU\h+Nph+Np5>*OJQJh+Nph+NpOJQJ\h+Nph+NpCJOJQJaJh+Nph+NpOJQJ'h+Nph+Np6CJOJQJaJmH sH $h+Nph+NpCJOJQJaJmH sH HaIaXaYaZaaaa!b^UUUUUUU $Ifgd1kd}$$Ifl4\8+>:064 laf4yt1Za[aaaaaaa!bcrdsddddddddeeeff8f9f赪zm赪z[Lh+Nph+NpCJOJQJaJ"h+Nph+Np5CJOJQJ\aJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+Np7OJQJh+Nph+Np\h+Nph+NpOJQJ\h+Nph+NpOJQJhAsh+NpOJQJ(hAshAs>*B* CJOJQJaJphR|%hAshAsB*CJOJQJaJphJJJ.jhAshAsB*CJOJQJUaJphJJJ!bbbbbbbbb4cccccddodsddddd $Ifgd1 <$Ifgd1 $Ifgd1ddddeeOe|ee^ULLLLLL $Ifgd1 $Ifgd1kdY$$Ifl4\8+>:064 laf4yt1eeeeeefffUkd5$$Ifl4\8+>:064 laf4yt1 $Ifgd1f8f9fffggjgkgggggg h h3h4hhhhhhhhhhi $Ifgd1 &<$Ifgd19f:ffffffffffffggggg*g+gݢjWL@Lh+Nph+Np5OJQJh+Nph+NpOJQJ$h$Z=h+NpCJOJQJaJmH sH (h+h$Z=0JCJOJQJaJmH sH $h$Z=h$Z=CJOJQJaJmH sH h$Z=CJOJQJaJmH sH 'jh$Z=CJOJQJUaJmH sH  h+Nph+Np0JCJOJQJaJ+jh+Nph+NpCJOJQJUaJh+Nph+NpCJOJQJaJ%jh+Nph+NpCJOJQJUaJ+g,gfgigjgg3hiiiiiiiiijjjjjajbj۱yhP=P%h$Z=h$Z=B*CJOJQJaJphJJJ.jh$Z=h$Z=B*CJOJQJUaJphJJJ h+Nph+Np0JCJOJQJaJ+jh+Nph+NpCJOJQJUaJh+Nph+NpCJOJQJaJ%jh+Nph+NpCJOJQJUaJh+Nph+Np5OJQJ\^Jh+Nph+Np56OJQJh+Nph+NpH*OJQJh+Nph+NpOJQJh+Nph+Np5OJQJh+Nph+Np5OJQJ\iiiiiiiijUJ &<$Ifgd1kd$$Ifl4\8+>:064 laf4yt1 $Ifgd1jjjjkkmkkkkk\l]l^llllllllm-mxmym x$Ifgd1 $Ifgd1bjjjjjjjjjjkkkBkCkkklkmk>lBllll-m.mymzmmmȽӪȽӪȽxhZH#jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\h+Nph+Np5OJQJ\^Jh+Nph+NpOJQJ]h+Nph+Np6OJQJ]h+Nph+NpH*OJQJh+Nph+Np6OJQJ%h$Z=h$Z=B*CJOJQJaJphJJJh+Nph+NpOJQJh$Z=h+NpOJQJ.jh$Z=h$Z=B*CJOJQJUaJphJJJ(h$Z=h$Z=>*B* CJOJQJaJphR|ymzmmmmGnnjopRp^UUUUUUUU $Ifgd1kd$$Ifl4\8+>:064 laf4yt1 mmmmmmmpqqqqqqqqq(r)r>r?r˻򰤖yyaNa9a(hlh_ >*B* CJOJQJaJphR|%hlh_ B*CJOJQJaJphJJJ.jhlh_ B*CJOJQJUaJphJJJh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+Np>*OJQJ]h+Nph+NpOJQJ]h+Nph+NpOJQJh+Nph+Np0J5OJQJ\#jh+Nph+Np5OJQJU\)jh+Nph+Np5OJQJU\h+Nph+Np5OJQJ\RpSppppqyqqq x$Ifgd1 $Ifgd1qqqqqqqqq^UULLLUL $Ifgd1 $Ifgd1kd$$Ifl4\8+>:064 laf4yt1q@rArrrrrrrrspstsssssssst`tatbtcttt~t & FBE$If`Egd1 $Ifgd1?r@rArBrorprrrrrrrrpstssssscttttt|p|b|V|p|J|>h+Nph+NpOJQJ\h+Nph+Np6OJQJh+Nph+NpH*OJQJh+Nph+Np5OJQJ\h+Nph+Np5OJQJh+Nph+NpOJQJhlh+NpOJQJmHsHhlh+NpOJQJhlhlOJQJ(hlhl>*B* CJOJQJaJphR|.jhlhlB*CJOJQJUaJphJJJ%hlhlB*CJOJQJaJphJJJ%hlh+NpB*CJOJQJaJphJJJ~ttttuuu u!u"u#u$u%u&u'u(u)u*uDuEu[u^uuuuuuuuu $Ifgd1ttuuuuuuu*uDuuuuuuuuv(vvvvvvvvxxx㲧㲙}o}``R`}}h+Nph+Np0J5OJQJjh+Nph+NpOJQJUh+Nph+Np5OJQJ\h+Nph+Np5OJQJh+Nph+Np5OJQJ\^Jh+Nph+Np5>*OJQJh+Nph+NpOJQJh+Nph+NphxOJQJ\h+Nph+Np0JOJQJ\&j|h+Nph+NpOJQJU\h+Nph+NpOJQJ\ jh+Nph+NpOJQJU\uuuuvvv&v'v^YYPPPPP $Ifgd1gd+Npkd$$Ifl4\8+>:064 laf4yt1'v(vv*! $Ifgd1kd$$Ifl4S\LJ '3 J J  @(3ff03444 laf4p(3ffyt1vvxw & FE$Ifgd1zkd $$Ifl4L334  03444 laf4p yt1xxxyyqyz]z^z_zzz{zzz={~~~ & FE$Ifgd1 $Ifgd1kkd!$$Ifl4,L33403444 laf4yt1xxxyz\z]zz|||/|0|1||||||X}]}j}k}}}}}~~:~;~_~`~~~~~\noLM689?vw¶¶ۚ¶~h+Nph+Np6OJQJ\h+Nph+Np5OJQJ\h+Nph+Np6OJQJ]h+Nph+NpH*OJQJ\h+Nph+Np5OJQJh+Nph+NpOJQJh+Nph+NpH*OJQJ]h+Nph+NpOJQJ]h+Nph+NpOJQJ\h+Nph+NpH*OJQJ1={>{?{i{{{{{|| $Ifgd1 ||0|1|||||X}Y}[RRRRRRRR $Ifgd1kd"$$Ifl4\LJ '3 J J  03444 laf4yt1 Y}Z}[}\}]}k}}}~:~Rkd"$$Ifl4\LJ '3 J J  03444 laf4yt1 $Ifgd1 :~;~^~_~~~~~~~~~~~ $Ifgd1 ~~~~~~~~~~[RRRRRRRR $Ifgd1kd#$$Ifl4r\LJ '3 J J  03444 laf4yt1 ~~~\M789k~kd[$$$Ifl40LJ 3` 5&03444 laf4yt1 & FD$Ifgd1 $Ifgd1  3LZƒڃ+,-:;̰̰̥̾p\pNpph+Nph+Np0JOJQJ\&jn&h+Nph+NpOJQJU\ jh+Nph+NpOJQJU\h+Nph+Np5OJQJ\^Jh+NpOJQJh+Nph+NpH*OJQJh+Nph+NpOJQJh+Nph+Np6OJQJ]h+Nph+NpH*OJQJ]h+Nph+NpOJQJ]h+Nph+NpH*OJQJ\h+Nph+NpOJQJ\h+Nph+Np6OJQJ\3 $Ifgd1 ƒ[VVVVVVVgd+Npkd$$$Ifl4\LJ '3  J J  03444 laf4yt1ƒكڃ-xzkd%$$Iflp55  t 0644 lap yt1 <<$Ifgd1-.:atttt <<$Ifgd1}kd/'$$Ifl01 p5 ?( t0644 layt1   HIJZ[atUVd?HЇ߇FIghÈwk___h+Nph+NpH*OJQJh+Nph+Np5OJQJh+Nph+Np5OJQJ\^J h+Nph+Nph+Nph+NpOJQJ&j)h+Nph+NpOJQJU\&j(h+Nph+NpOJQJU\h+Nph+NpOJQJ\h+Nph+Np0JOJQJ\ jh+Nph+NpOJQJU\&j'h+Nph+NpOJQJU\%abtԅ Utttttt <<$Ifgd1}kd.*$$Ifl01 p5 ?( t0644 layt1UVd=>tggggg <<$Ifgd1 <<$Ifgd1}kd*$$Ifl01 p5 ?( t0644 layt1>?HЇtg <<$Ifgd1 <<$Ifgd1}kdz+$$Ifl01 p5 ?( t0644 layt1Їч҇އ߇|||oo (($Ifgd1gd+Np}kd ,$$Ifl01 p5 ?( t0644 layt1 gWWW$(($Ifa$gd1kd,$$Ifl00*p5*@   t0644 lapyt1+,IiˆÈ6k^^^^^^^^^ (($Ifgd1kd-$$Ifl4Fh 0*p5 @  t06    44 laf4yt1 Èň^yz͊N_ّڑGXВ )*+DEk̿螰qjjjjjjj h+Nph+Np#j8h+Nph+NpOJQJUh+Nph+Np5OJQJ\h+Nph+Np0JOJQJ#jh7h+Nph+NpOJQJUjh+Nph+NpOJQJUh+Nph+NpOJQJ^Jh+Nph+Np5OJQJ\^Jh+Nph+NpOJQJ\h+Nph+NpOJQJh+Nph+NpH*OJQJ)6789EFd^kdc.$$Ifl4Fh 0*p5 @  t06    44 laf4yt1 (($Ifgd1 CDETz͊Ί ^kd%/$$Ifl4Fh 0*p5 @  t06    44 laf4yt1 (($Ifgd1  ;lɋʋk^^^^^^^^ (($Ifgd1kd/$$Ifl4Fh 0*p5 @  t06    44 laf4yt1 Ek^^^^^ (($Ifgd1kd0$$Ifl4Fh 0*p5 @  t06    44 laf4yt1ƌ%Xk^^^^^^^ (($Ifgd1kdk1$$Ifl4Fh 0*p5 @  t06    44 laf4yt1XYh+OPk^^^^^^^^^ (($Ifgd1kd-2$$Ifl4Fh 0*p5 @  t06    44 laf4yt1 ˎ@A^kd2$$Ifl4Fh 0*p5 @  t06    44 laf4yt1 (($Ifgd1ABQzk^^^^ (($Ifgd1kd3$$Ifl4Fh 0*p5 @  t06    44 laf4yt1k^^^ (($Ifgd1kds4$$Ifl4Fh 0*p5 @  t06    44 laf4yt16Swk^^^^^^^^ (($Ifgd1kd55$$Ifl4Fh 0*p5 @  t06    44 laf4yt1 Mkff] $Ifgd1gd+Npkd5$$Ifl4Fh 0*p5 @  t06    44 laf4yt1MN_`aۑ|ssssssssf & F<$Ifgd1 $Ifgd1 $Ifgd1zkd6$$Ifl 3x3  t 0644 lap yt1 1CDtВђh_ $Ifgd1kd7$$Ifl40 3 l& t0644 laf4yt1 $Ifgd1 & F<$Ifgd1 ђҒ     FWwғ!Ajk & F>$Ifgd1 & F<$Ifgd1 & F=$Ifgd1 $Ifgd1kqrkd9$IfK$L$l0X`S064 layt1 $Ifgd1K$ $Ifgd1K$rkd9$IfK$L$l0X`S064 layt1 $Ifgd1K$rkdB:$IfK$L$l0X`S064 layt1 $Ifgd1K$rkd:$IfK$L$l0X`S064 layt1 $Ifgd1K$rkd~;$IfK$L$l0X`S064 layt1 $Ifgd1rkd<$IfK$L$l0X`S064 layt1Z[ah~yyiWRII $Ifgd|Cgd 8^`gdo 7^`gdogd+Npkd<$$Ifl40 3 l& t0644 laf4yt1ȔYZ[yҳyoybTM@2hiOJQJ^JnH tH h85OJQJ\^J hihih8OJQJ^JnH tH ho5OJQJ\^Jh^JnH tH h (ho^JnH tH hhmH sH tHh 0ohoB*CJaJph *h 0ohB*CJaJph *hhB*CJaJph *h 0oB*CJaJph *hhB*CJaJphhoCJaJ h|C5\ ho5\ h+Nph+Nphv)kdf=$$Ifl\ B*|8:::: (0j4 lap(yt $Ifgd|Cw $$Ifa$gdiskde>$$Ifl|88  0j4 lap yt $Ifgdi $Ifgdi^skd ?$$Ifl|88  0j4 lap yti/01;=ARSTU]^qrñ۠ۖۈzl_UKU>hi^5OJQJ\^Jh,OJQJ^Jhi^OJQJ^Jho5OJQJ\^JhoOJQJ^JnH tH hi^OJQJ^JnH tH h|COJQJ^JnH tH h#LWOJQJ^J hJh)OJQJ^JmH sH #hJh)H*OJQJ^JmH sH h)H*OJQJ^Jh)5OJQJ\^Jh)OJQJ^Jh)OJQJ^JnH tH hi5OJQJ\^J $Ifgd{y>skd?$$Ifl|88  0j4 lap yt-u  9r $Ifgd{y> $Ifgd{y>skdT@$$Ifl|88   0j4 lap yt-./01<bYKYY  9r $Ifgd{y> $Ifgd{y>kd@$$Ifl\ B*|8::::0j4 layt<=TbY $Ifgdi^kdA$$Ifl\ B*|8::::0j4 laytTUq $Ifgd,skd5B$$Ifl|88  0j4 lap ytqrstu $Ifgd|CskdB$$Ifl|88  0j4 lap ytru~Ɩǖ֖ז   23opq~˾˾ߓv_-jhjhj>*B*OJQJU^Jphho0JOJQJ^J!jIhoOJQJU^JjhoOJQJU^Jhi^hi^OJQJ^Jhi^hi^5OJQJ\^Jh,5OJQJ\^Jh,OJQJ^Jh#LWOJQJ^Jho5OJQJ\^Jhi^OJQJ^JhoOJQJ^J!bYYYY $Ifgd|CkdC$$Ifl\ B*|8::::0j4 laytbYPPP $Ifgd|C $Ifgd,kdD$$Ifl\ B*|8::::0j4 layt2))) $Ifgd|CkdD$$Ifl\ B*|8:::: (0j4 lap(ytƖǖȖɖʖ֖YPPP $Ifgd|CkdE$$Ifl\ B*|8::::0j4 layt $Ifgd֖זbYY $Ifgdi^kdXF$$Ifl\ B*|8::::0j4 layt wwn $Ifgd 0o $Ifgd|C $Ifgd|CvkdF$$Ifl4|88  0j4 laf4p yt    bYYYP $Ifgd $Ifgd|CkdG$$Ifl\ B*|8::::0j4 layt1bY $Ifgd|Ckd?H$$Ifl\ B*|8::::0j4 layt12HI}tkbYYbP $IfgdO $Ifgdi^ $Ifgd1ib $Ifgd#LW $Ifgdj $Ifgd|CxkdH$$Ifl9R:  t 044 lap yt|C +,-Ӽ햆l`E.-jh)h1ib>*B*OJQJU^Jph4h#LWh#LW>*B*OJQJ^JmH nH phsH tH h#LW0JOJQJ^J3j5Kh#LWh#LW>*B*OJQJU^Jphh#LW>*B*OJQJ^Jph-jh#LWh#LW>*B*OJQJU^Jphhjhj0JOJQJ^J-jhjhj>*B*OJQJU^Jph3jjJhjhj>*B*OJQJU^Jph$hjhj>*B*OJQJ^Jph!"#FGHIvֿv\M:v$h)hi^>*B*OJQJ^Jphh)h)0JOJQJ^J3jLh)h)>*B*OJQJU^Jph$h)h)>*B*OJQJ^Jph-jh)hi^>*B*OJQJU^Jph$h)h1ib>*B*OJQJ^Jphh40JOJQJ^J-jh)h1ib>*B*OJQJU^Jph3jLh)h4>*B*OJQJU^Jphh4>*B*OJQJ^Jphvwx'(GHIJοάh\I2-jh,hO>*B*OJQJU^Jph$h)h1ib>*B*OJQJ^Jphh:?0JOJQJ^J3jgNh)h)>*B*OJQJU^Jph$h)h)>*B*OJQJ^Jph-jh)h)>*B*OJQJU^Jph$h)hi^>*B*OJQJ^Jphh)h)0JOJQJ^J-jh)hi^>*B*OJQJU^Jph3jMh)h)>*B*OJQJU^JphJwxyGӼw]Q>w$h,h,>*B*OJQJ^Jphh,0JOJQJ^J3jPh,h,>*B*OJQJU^Jphh,>*B*OJQJ^Jph-jh,h,>*B*OJQJU^Jphh,heQ0JOJQJ^Jh,hO0JOJQJ^J-jh,hO>*B*OJQJU^Jph3jOh,hO>*B*OJQJU^Jph$h,hO>*B*OJQJ^Jph|}qhh $Ifgd|C|kdR$$Ifl09|+ t044 layt|C $Ifgd $Ifgd,GHIz{}~ɛʛ˛Лћԛ՛./0Xiڜθ|umeXNAhN#6OJQJ]^JhN#OJQJ^JhN#5OJQJ\^JhN#CJaJh^wCJaJ hP5\!jShoOJQJU^Jho0JOJQJ^J!jRhoOJQJU^JjhoOJQJU^JhoOJQJ^Jh,0JOJQJ^J-jh,h,>*B*OJQJU^Jph3jRQh,h,>*B*OJQJU^Jph,-zz $Ifgd|C|kdzT$$Ifl09|+ t044 layt|C-.@XYhsfd^$If  & F 8gd+=n 7^`gdDH|kdU$$Ifl09|+ t044 layt|Chirۜ!4KLzzzzz & F$If$IftkdU$$Ifl9R:  t 0644 lap ڜLNmn}ΞϞ 8HUWcdefhrtzk\H&hWahWa5OJQJ^JmHnHuh{OJQJ^JmHnHuhWaOJQJ^JmHnHuhWahWaOJQJ^JhWaH*OJQJ^JmH sH #hJhWaH*OJQJ^JmH sH #hWahWaOJQJ^JmHnHuhkOJQJ^JhEOJQJ^JhN#OJQJ^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#OJQJ^JLMNT[im$IfgkddV$$Ifl^9R: t0644 lamn}5/$IfkdV$$Ifl\ B*|8:::: (0j4 lap(}~$IfpkdW$$Ifl|88   0j4 lap ˞̞͞Ξ$If$IfpkdX$$Ifl|88   0j4 lap ΞϞޞߞe____$IfkdNY$$Ifl\ B*|8::::0j4 lae____$IfkdY$$Ifl\ B*|8::::0j4 la  e____$IfkdZ$$Ifl\ B*|8::::0j4 la  7e_$Ifkd@[$$Ifl\ B*|8::::0j4 la78VWw $IfgdWa$If$Ifskd[$$Ifl4|88  0j4 laf4p ȟɟџԟ֟ןڟ۟ ,-.<=>?BV`anpޠ߽ucXhN#H*OJQJ^J#hJhkypH*OJQJ^JmH sH hN#H*OJQJ^JmH sH #hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hkypH*OJQJ^Jh4H*OJQJ^JhN#OJQJ^JnH tH h4OJQJ^JhEOJQJ^JhN#5OJQJ\^JhWaOJQJ^JhN#OJQJ^J"şƟǟȟe____$Ifkd\$$Ifl\ B*|8::::0j4 laȟɟ֟ן؟ٟڟe_____$Ifkd?]$$Ifl\ B*|8::::0j4 laڟ۟e_____$Ifkd]$$Ifl\ B*|8::::0j4 lae_$Ifkd^$$Ifl\ B*|8::::0j4 la$Ifpkd1_$$Ifl|88   0j4 lap  ,-.>?@A~~  9r $If$Ifpkd_$$Ifl|88   0j4 lap ABUe_$Ifkd`$$Ifl\ B*|8::::0j4 laUVa~  9r $If$Ifpkd1a$$Ifl|88   0j4 lap ݠe_$Ifkda$$Ifl\ B*|8::::0j4 laݠޠߠNO{u$If $Ifgd/  9r $Ifpkdb$$Ifl|88   0j4 lap ޠ()*HM4hmnz·ͦzjVC͜$hZVhZV0JCJOJQJ^JaJ'hRNhRN0J5CJOJQJ^JaJhRN0JCJOJQJ^JaJh:?OJQJ^Jhih(35OJQJ^Jh(3OJQJ^JhN#OJQJ^J!hN#0J5CJOJQJ^JaJh/H*OJQJ^JhN#H*OJQJ^JhN#0JCJOJQJ^JaJ#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH OPQe__V_ $Ifgd:?$Ifkd1c$$Ifl\ B*|8::::0j4 la4nz{b\QHH\ $IfgdRN  9r $If$Ifkdc$$Ifl4\ B*|8::::0j4 laf4{|}b\\\\$Ifkdd$$Ifl4\ B*|8::::0j4 laf4b\S\\ $Ifgd*$Ifkd/e$$Ifl4\ B*|8::::0j4 laf4;Piwѣ٣ڣۣޣߣ!,+2lҸҫҫҡҫҖuhҸXh}L0JCJOJQJ^JaJhN#6OJQJ]^JhWaH*OJQJ^Jh(3H*OJQJ^Jh/H*OJQJ^JhN#H*OJQJ^Jh/NOJQJ^JhN#5OJQJ\^JhN#0JCJOJQJ^JaJh:?OJQJ^JhN#OJQJ^Jh/OJQJ^Jh*0JCJOJQJ^JaJh*OJQJ^Jb\S\\ $Ifgd0k$Ifkde$$Ifl4\ B*|8::::0j4 laf4b\$Ifkdf$$Ifl4\ B*|8::::0j4 laf4&| h$If^h$Ifskd3g$$Ifl4|88  0j4 laf4p &'()*:b\R\\ h$If^h$Ifkdg$$Ifl4\ B*|8::::0j4 laf4:;Ob\$Ifkdh$$Ifl4\ B*|8::::0j4 laf4OPYZ[h| h$If^h$Ifskd>i$$Ifl4|88  0j4 laf4p hijklvb\R\\ h$If^h$Ifkdi$$Ifl4\ B*|8::::0j4 laf4vwb\$Ifkdj$$Ifl4\ B*|8::::0j4 laf4"ckdk$$Ifl4|880j4 laf4$IfskdIk$$Ifl4|88  0j4 laf4p ѣӣգ֣أ٣ۣܣޣߣnukdl$$Ifl9R:  t 044 lap $Iflq !"˦̦ͦڦۦܦݦѯãіq`qTq=-jh:?hk>*B*OJQJU^JphhN#0JOJQJ^J!jnhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh{hWaOJQJ^Jh{h{OJQJ^Jh(30JOJQJ^J'j6mh@5~h(3OJQJU^Jjh(3OJQJU^Jh(3OJQJ^JhN#0JCJOJQJ^JaJ'hihN#0J5CJOJQJ^JaJ"ܦQajd[Rdd $Ifgd@> $Ifgdk$Ifkdn$$IflF9|P* t0    44 la $Ifgd:?ݦ   OPQR~էӼ햃iZI<h:?hMOJQJ^J!jh:?hMOJQJU^Jh:?h@>0JOJQJ^J3j|ph:?h@>>*B*OJQJU^Jph$h:?h@>>*B*OJQJ^Jph-jh:?h@>>*B*OJQJU^Jphh:?hk0JOJQJ^J-jh:?hk>*B*OJQJU^Jph3joh:?hk>*B*OJQJU^Jph$h:?hk>*B*OJQJ^Jphէ֧ק456_`abھڱڱsYJsh:?hF0JOJQJ^J3jsh:?hF>*B*OJQJU^Jph$h:?hF>*B*OJQJ^Jph-jh:?hF>*B*OJQJU^Jph'jrh:?hMOJQJU^Jh:?hMOJQJ^Jh:?hkOJQJ^Jh:?hM0JOJQJ^J!jh:?hMOJQJU^J'jGqh:?hMOJQJU^JaPQRgkeee$Ifykdv$$Ifl09|+ t044 la $Ifgd:? $Ifgdg4 $IfgdF IJKջՕhYI;1hd|YOJQJ^Jjhd|YOJQJU^JhM>*B*OJQJ^Jphh:?hZV0JOJQJ^J3jth:?hZV>*B*OJQJU^Jph$h:?hZV>*B*OJQJ^Jph-jh:?hZV>*B*OJQJU^Jphh:?hg40JOJQJ^J3jsh:?hg4>*B*OJQJU^Jph$h:?hg4>*B*OJQJ^Jph-jh:?hg4>*B*OJQJU^JphNOQRSҪӪԪ۪ܪ456ijmn߫@sb!jyhN#OJQJU^J!jyhN#OJQJU^J!jaxhN#OJQJU^JhN#0JOJQJ^J!jbwhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jhd|YOJQJ^Jhd|Y0JOJQJ^Jjhd|YOJQJU^J!jluhd|YOJQJU^J$@ABef%&(*,HYĭŭ"#ijѮʺ|tl_____R_h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJhniCJaJ$ji}hN#5OJQJU^Jhoo0J5OJQJ^J$j|hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jzhN#OJQJU^Jghx)$Ifykd{$$Ifl09|+ t044 la)*+HIX|omg$If  & F 8gd+=n  8gdniykd~$$Ifl09|+ t044 laXYŭ#jvvv & F $If & F$Iftkd~$$Ifl9R:  t 0644 lap ͮѮ$IfekdU$$Ifl9R: t0644 laѮҮ5/$Ifkd$$Ifl\ B*|8:::: (04 lap( $Ifpkd$$Ifl|88  04 lap  )+<>OPh|KLMZ[^_ް߰3̺ꓤve!jfhN#OJQJU^J!jghN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#CJaJ#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#OJQJ^JhN#H*OJQJ^J$  e_$Ifkd$$Ifl\ B*|8::::04 la+>?N~  9r $If$Ifpkd4$$IflF|88  04 lap NOPgec]$Ifkd$$IflF\ B*|8::::04 lagh|~ $Ifwkd$$Ifl9R:  t 0644 lap  \]qkk$Ifkd0$$IflF9|P* t06    44 la]^~~$IfzkdDž$$Ifl09|+ t0644 la345MNQR+,.01ARʹʩ~kZREhN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^Jph$jhN#5OJQJU^Jhoo0J5OJQJ^J$jGhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J/~~$Ifzkd$$Ifl09|+ t0644 la/01ABQuo$If  & F 8gd+=nzkdŋ$$Ifl09|+ t0644 laQRvlb h$If^h & F $If & F$If & F$Iftkde$$Ifl9R:  t 0644 lap EFȶ<IM[]^_~зѷӷԷ #$o۾|۾!j)hN#OJQJU^JhN#H*OJQJ^JhN#CJaJ hJhN#OJQJ^JmH sH h (hN#^JnH tH hN#0JOJQJ^J!j hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhN#5OJQJ\^J-Ķȶ$Ifekd$$Ifl9R: t0644 laȶɶ5/$Ifkds$$Ifl\ B*|8:::: (04 lap({  9r $If$Ifskdz$$Ifl4|88   04 laf4p e_$Ifkd-$$Ifl\ B*|8::::04 la ;$IfskdӐ$$Ifl4|88  04 laf4p ;<IJKLbWQQQ$If  9r $Ifkd$$Ifl4\ B*|8::::04 laf4LM[\]^eZTTZ$If  9r $Ifkd2$$Ifl\ B*|8::::04 la^_e___T  9r $If$Ifkdؒ$$Ifl\ B*|8::::04 lae___T  9r $If$Ifkd~$$Ifl\ B*|8::::04 laeca[$Ifkd$$$Ifl\ B*|8::::04 laзѷҷ$Ifwkdʔ$$Ifl9R:  t 0644 lap ҷӷ!"qkk$Ifkds$$IflF9|P* t06    44 la"#~~$Ifzkd $$Ifl09|+ t0644 laopqvwz{ҸӸIJLNOQ^rsʹʩ~kcc_QhN#OJQJ^JmH sH hN#hN#CJaJ$j՚hN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J¸ҸM~~$Ifzkdb$$Ifl09|+ t0644 laMNOQ^rssf`$If  & F gd+=n  & F 8gd+=nzkd$$Ifl09|+ t0644 la&v/kܻvllllll & F$If $$Ifa$gd!$Ifwkd $$Ifl9R:  t 0644 lap s&34opq89Sacdfgxy|ħppf\ph!OJQJ^JhyYOJQJ^J hJhN#OJQJ^JmH sH hN#H*OJQJ^JhN#OJQJ^JnH tH h (hN#^JnH tH hN#0JOJQJ^J!jɜhN#OJQJU^JjhN#OJQJU^J,hAh!5B* CJOJQJ^JaJphhN#OJQJ^JhN#5OJQJ\^J $Ifgkd$$Ifl9R: t0644 la83-$Ifkd $$Ifl\ B*|8:::: (06j4 lap(89Sx $If^`tkd*$$Ifl4|88   06j4 laf4p STcdefy  9r $If$Iftkd$$Ifl4|88   06j4 laf4p fgxyz{d^S^^  9r $If$Ifkd$$Ifl\ B*|8::::06j4 la{|d^^^^$Ifkd?$$Ifl\ B*|8::::06j4 laaVPPP$If  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4dY  9r $Ifkd$$Ifl\ B*|8::::06j4 la־׾ھ۾.23>@ABVXYZkmno{|}~͹ͨnnnnnnnnn\#hJhN#5OJQJ^JmH sH  hJhN#OJQJ^JmH sH )hJhN#5H*OJQJ\^JmH sH &hJhni5OJQJ\^JmH sH  hN#5OJQJ\^JmH sH &hJhN#H*OJQJ]^JmH sH #hJhN#OJQJ]^JmH sH hN#5OJQJ\^J&hJhN#5OJQJ\^JmH sH $׾ؾپھ  9r $Iftkd@$$Ifl4|88   06j4 laf4p ھ۾aVVVVV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf42aV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf423>?@A  9r $IftkdT$$Ifl4|88   06j4 laf4p ABVWXYaVVVV  9r $Ifkd $$Ifl4\ B*|8::::06j4 laf4YZklmnaVVVV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4no{|}~aSHHHH  9r $If  9r $IfgdAkdh$$Ifl4\ B*|8::::06j4 laf4aV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4  9r $Iftkdƨ$$Ifl4|88  06j4 laf4p ¿ʿNOPQijkMNOPwhίhJhy[OJQJmH sH &hJhy[5OJQJ\^JmH sH #hJhy[OJQJ\^JmH sH #hJhN#5OJQJ^JmH sH  hJhoOJQJ^JmH sH hyYOJQJ^JmH sH hN#5OJQJ\^J&hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH $¿aVVVV  9r $Ifkd|$$Ifl4\ B*|8::::06j4 laf4aVVVV  9r $Ifkd+$$Ifl4\ B*|8::::06j4 laf4 NOPaVVVV  9r $Ifkdڪ$$Ifl4\ B*|8::::06j4 laf4PQiaV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4ijk  9r $Iftkd8$$Ifl4|88  06j4 laf4p MNOaVVVV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4OPQaVVVV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4κ|j[j[G&hOhO5OJQJ\^JmH sH hOOJQJ\^JmH sH #hOhOOJQJ\^JmH sH hN#OJQJ^JnH tH #hJhN#H*OJQJ^JmH sH hN#5OJQJ\^J hJhN#OJQJ^JmH sH &hJhN#5OJQJ\^JmH sH ho5OJQJ\^J hJhoOJQJ^JmH sH &hJho5OJQJ\^JmH sH aV  9r $IfkdL$$Ifl4\ B*|8::::06j4 laf4  9r $Iftkd$$Ifl4|88  06j4 laf4p aVVVV  9r $Ifkd$$Ifl4\ B*|8::::06j4 laf4a[$Ifkd`$$Ifl4\ B*|8::::06j4 laf4q  9r $IfgdO  9r $Iftkd$$Ifl4|88  06j4 laf4p .0123̻~k~aWa~LAhniH*OJQJ^JhN#H*OJQJ^JhniOJQJ^Jh>OJQJ^J$h!h!5B* OJQJ^JphhN#OJQJ^J&hJhN#5OJQJ\^JmH sH #hJhN#H*OJQJ^JmH sH hN#5OJQJ\^J hJhN#OJQJ^JmH sH #hOhN#OJQJ\^JmH sH hOH*OJQJ^JmH sH #hJhOH*OJQJ^JmH sH aVVVV  9r $Ifkdű$$Ifl4\ B*|8::::06j4 laf4./01aVVVV  9r $Ifkdt$$Ifl4\ B*|8::::06j4 laf4123a[SQQQQQQ$a$gd! 9r kd#$$Ifl4\ B*|8::::06j4 laf4  wkdҳ$$Ifl9R:  t 0644 lap $If ijkMNOPQR߳ߢ߳Յyo߳^߳!jhN#OJQJU^Jh5= OJQJ^Jhni0JOJQJ^J!jhniOJQJU^JhN#0JOJQJ^J!j1hN#OJQJU^JjhN#OJQJU^Jh}LOJQJ^JhOOJQJ^JhniOJQJ^JhN#OJQJ^JhOH*OJQJ^JhN#H*OJQJ^J# gvijOYkd{$$IflF9|P* t06    44 la $Ifgdni $IfgdO$If OPQ{uu$Ifzkd$$Ifl09|+ t0644 la $Ifgd5= =>?KMwxz}ʺ|xk^kM;M#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH h (hN#^JnH tH hN#5OJQJ\^JhN#$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J{~~$IfzkdE$$Ifl09|+ t0644 la{|}uoooo$If  & F gd+=nzkdc$$Ifl09|+ t0644 laA5***  9r $Ifkd$$Ifl\ B*|8:::: (04 lap(@BCYZnopqбННÌxkaWaLahN#H*OJQJ^Jh4OJQJ^JhN#OJQJ^Jh<)5OJQJ\^J&hJh<)5OJQJ\^JmH sH  hJh<)OJQJ^JmH sH &hJhN#5OJQJ\^JmH sH #hJhN#H*OJQJ^JmH sH hN#5OJQJ\^J hJhN#OJQJ^JmH sH  hJhG;OJQJ^JmH sH hyYOJQJ^JmH sH ABC[nopWkd $$Ifl4\ B*|8::::04 laf4  9r $IfpqbWWWW  9r $Ifkd$$Ifl4\ B*|8::::04 laf4bWWWW  9r $Ifkdb$$Ifl4\ B*|8::::04 laf4b\ZZZZZT$If 9r kd$$Ifl4\ B*|8::::04 laf4$Ifwkd$$Ifl9R:  t 0644 lap qkk$Ifkdc$$IflF9|P* t06    44 lacdejkno=>@Bz瘍zmZRhN#CJaJ$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J ~~$Ifzkd$$Ifl09|+ t0644 laA~~$IfzkdR$$Ifl09|+ t0644 laABz{wuoooo$If  & F 8gd+=nzkdp$$Ifl09|+ t0644 laz{&DEFqrst-.1abe ACD\]ҭ{qh}LOJQJ^JhW&5OJQJ\^J hJhW&OJQJ^JmH sH &hJhW&5OJQJ\^JmH sH &hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^Jhni^JnH tH h (hN#^JnH tH hN#5OJQJ\^J,2,$Ifkd$$Ifl\ B*|8:::: (0R:j4 lap(ytni$Ifvkd$$Ifl4|88   0R:j4 laf4p ytni&x  9r $If$Ifvkd$$Ifl4|88   0R:j4 laf4p ytni&'Cb\$Ifkd$$Ifl\ B*|8::::0R:j4 laytniCDEFQq{r $Ifgdni  9r $If$Ifskd;$$Ifl|88  0R:j4 lap ytniqrstub\Q\\  9r $If$Ifkd$$Ifl\ B*|8::::0R:j4 laytnib\Q\\  9r $If$Ifkd$$Ifl\ B*|8::::0R:j4 laytnibW  9r $IfkdF$$Ifl\ B*|8::::0R:j4 laytni-~~~x$If  9r $Ifvkd$$Ifl4|88   0R:j4 laf4p ytni-./01a_TTTT  9r $Ifkd$$Ifl4\ B*|8::::0R:j4 laf4ytniabcde_TTTT  9r $Ifkd]$$Ifl4\ B*|8::::0R:j4 laf4ytni_Y$Ifkd$$Ifl4\ B*|8::::0R:j4 laf4ytni$Ifvkd$$Ifl4|88  0R:j4 laf4p ytnix  9r $If$Ifvkdz$$Ifl4|88  0R:j4 laf4p ytni_YNYY  9r $If$Ifkd3$$Ifl4\ B*|8::::0R:j4 laf4ytni A_M $If^`kd$$Ifl4\ B*|8::::0R:j4 laf4ytniABCDEaxo $Ifgd}L  9r $If$Ifvkd$$Ifl4|88  0R:j4 laf4p ytniabcdeqb\Q\H $IfgdH  9r $If$IfkdP$$Ifl\ B*|8::::0R:j4 laytni]bcdnpr>?AB~и읉{q`{T{qhh0JOJQJ^J!j hhOJQJU^JhhOJQJ^JjhhOJQJU^JhzyOJQJ^JhniOJQJ^Jh0&hHOJQJ^Jh0&hH5OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^JhHH*OJQJ^J hJhHOJQJ^JmH sH hHOJQJ^JhN#OJQJ^Jqrb\$Ifkd$$Ifl\ B*|8::::0R:j4 laytni@w $Ifgdni$Ifxkd$$Ifl9R:  t 0R:44 lap ytni@Apg^^ $Ifgdni $Ifgd)kdT$$IflF9|P* t0R:    44 laytniEFGؾ訚wj`jSj`H`hN#H*OJQJ^Jh (hN#^JnH tH hN#OJQJ^JhN#5OJQJ\^JhN#CJaJhhOJQJ^J!jh)z'OJQJU^Jjh)z'OJQJU^Jh)z'OJQJ^Jh)z'0JOJQJ^J3jhMh)z'>*B*OJQJU^Jphh)z'>*B*OJQJ^Jph-jhMh)z'>*B*OJQJU^Jphvtn$If  & F 8gd+=n|kd$$Ifl09|+ t0R:44 laytni! & F $Iftkd]$$Ifl9R:  t 0644 lap $Ifekd$$Ifl9R: t0644 la 5/$/  9r $If$Ifkd$$Ifl\ B*|8:::: (04 lap(  !"-.12EIWŻӣӰәӄzpfpphOJQJ^Jh^OJQJ^Jh|OJQJ^JhZzIOJQJ^JhH*OJQJ^JhOJQJ^JhN#5OJQJ\^JhN#5OJQJ^JhuSOJQJ^Jha$huS5OJQJ^JhN#OJQJ^J#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH &  !"2W_T  9r $Ifkd$$Ifl\ B*|8::::04 la$Ife_T_K $IfgdZzI  9r $If$Ifkd3$$Ifl\ B*|8::::04 lae_T_KK $Ifgd^  9r $If$Ifkd$$Ifl\ B*|8::::04 lae_T_K $Ifgd^  9r $If$Ifkd$$Ifl\ B*|8::::04 la/9  >۹ۯۉxl[Nhnih4OJQJ^J!jhnih4OJQJU^JhN#0JOJQJ^J!j*hN#OJQJU^JjhN#OJQJU^JhOJQJ^JmH sH hniOJQJ^JhOJQJ^JhN#H*OJQJ^JhN#5OJQJ\^Jh4OJQJ^JhN#OJQJ^Jh^OJQJ^J hJh^OJQJ^JmH sH eccccccccckd%$$Ifl\ B*|8::::04 la /124579Fxxx $Ifwkd$$Ifl9R:  t 0644 lap $If  WQH? $Ifgd5= $Ifgdni$Ifkdt$$IflF9|P* t06    44 la $Ifgdni $Ifgd>?@-./^_`aھz˧`˧V<3jhnih4>*B*OJQJU^Jphh4OJQJ^J3jhnih4>*B*OJQJU^Jph3jhnih4>*B*OJQJU^Jph$hnih4>*B*OJQJ^Jph-jhnih4>*B*OJQJU^Jphhnih4OJQJ^Jhnih40JOJQJ^J!jhnih4OJQJU^J'j hnih4OJQJU^J`JKLrll$Ifzkd$$Ifl09|+ t0644 la $Ifgd> $IfgdniHIKLMNǹziz]zzLz]zz!jhN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh\0JOJQJ^J!jMh\OJQJU^Jh\OJQJ^Jjh\OJQJU^J$hnih4>*B*OJQJ^Jph-jhnih4>*B*OJQJU^Jphhnih40JOJQJ^JNOP !#%(>@_ʺ|kcVIVVh (hN#^JnH tH hN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^Jph$jhN#5OJQJU^Jhoo0J5OJQJ^J$j1hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jrhN#OJQJU^J$~~$Ifzkd$$Ifl09|+ t0644 la$%&(>?@FM[_zxkxxeeee$If  & F 8gd+=n 0^`0zkd$$Ifl09|+ t0644 la _`5/$IfkdO$$Ifl\ B*|8:::: (04 lap({  9r $If$IfskdV$$Ifl4|88  04 laf4p #89  >?Eeg۱۱۠ss۱i[ihNhN5OJQJ^JhNOJQJ^J hJhuSOJQJ^JmH sH #hJhN#H*OJQJ^JmH sH h3+OJQJ^J hJh3+OJQJ^JmH sH hN#H*OJQJ^J#hJhuS6OJQJ^JmH sH hN#5OJQJ\^JhN#OJQJ^Jh8YVOJQJ^J hJhN#OJQJ^JmH sH  e_$Ifkd $$Ifl\ B*|8::::04 la #bsmm$If  9r $IfgduS  9r $Ifskd$$Ifl4|88  04 laf4p eZZTT$If  9r $Ifkdb$$Ifl\ B*|8::::04 laDeZLFF$If  9r $IfgduS  9r $Ifkd$$Ifl\ B*|8::::04 laDEfe_$Ifkd$$Ifl\ B*|8::::04 lafgh~~$If  9r $IfpkdT$$Ifl|88  04 lap b\$Ifkd$$Ifl\ B*|8::::04 laytN{{{$If  9r $Ifskd$$Ifl|88  04 lap ytN!#%&'1JKLyzʼqdYKjhN#OJQJU^JhN#H*OJQJ^JhN#5OJQJ\^J hJh$|OJQJ^JmH sH h$|OJQJ^JhyYOJQJ^J hJh3+OJQJ^JmH sH h3+OJQJ^Jh}L5OJQJ^Jh3+h3+5OJQJ^Jh3+h (h3+^JnH tH hN#OJQJ^JhNOJQJ^J hJhNOJQJ^JmH sH e_VVVV $Ifgd t 9r kd`$$Ifl\ B*|8::::04 la#2) $Ifgd}Lkd$$Ifl\ B*|8:::: (04 lap(yt t#$%&'Ir  9r $Ifgd t $Ifgd tvkd$$Ifl4|88  04 laf4p yt tIJKLMxbYKYY  9r $Ifgd t $Ifgd tkd$$Ifl\ B*|8::::04 layt txyzb`Z$Ifkdx$$Ifl\ B*|8::::04 layt tx $If$Ifwkd$$$Ifl9R:  t 0644 lap qkk$Ifkd$$IflF9|P* t06    44 laEFGLMPQyz{ VghjʹʨʗʂugʂʂʂʂʂhN#OJQJ^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^Jph!jhN#OJQJU^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J'~~$Ifzkdd$$Ifl09|+ t0644 la =VWfzna_Y$If  & F 8gd+=n  & F gd+=n 0^`0zkd$$Ifl09|+ t0644 lafghigkd$$Ifl^9R: t0644 la$Iftkd\$$Ifl9R:  t 0644 lap ijpw$If5/$Ifkd$$Ifl\ A*{89::: (0k4 lap($Ifpkd$$Ifl{88   0k4 lap e____$IfkdK$$Ifl\ A*{89:::0k4 lae____$Ifkd$$Ifl\ A*{89:::0k4 lae____$Ifkd$$Ifl\ A*{89:::0k4 lae____$Ifkdg$$Ifl\ A*{89:::0k4 lae___V $IfgdK$Ifkd$$Ifl\ A*{89:::0k4 la;Ydghwx789FGHI읮yh\yhD0JOJQJ^J!jZ hDOJQJU^JhDOJQJ^JjhDOJQJU^JhN#0JOJQJ^J!jy hN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^JhN#OJQJ^JnH tH hyYOJQJ^JhN#5OJQJ\^JhN#OJQJ^JhKOJQJ^J$ :e_$Ifkd$$Ifl\ A*{89:::0k4 la:;<=>g$Ifskd$$Ifl4{88  0k4 laf4p ghijkwe____$Ifkd6$$Ifl\ A*{89:::0k4 lawxe_$Ifkd$$Ifl\ A*{89:::0k4 la$Ifskd$$Ifl4{88  0k4 laf4p e_$IfkdQ$$Ifl\ A*{89:::0k4 la$Ifskd$$Ifl4{88  0k4 laf4p e____$Ifkd$$Ifl\ A*{89:::0k4 lae_$Ifkdl$$Ifl\ A*{89:::0k4 la$Ifukd $$Ifl9R:  t 044 lap Hsmd $IfgdD$Ifkd$$IflF9|P* t0    44 lawq$If  & F 8gd+=nykdU $$Ifl09|+ t044 la Fz{}~%&)׸כttj\h=Zhw5OJQJ^JhwOJQJ^JhN#OJQJ\^JhN#H*OJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ]^J#hJhN#H*OJQJ^JmH sH #hJhN#OJQJ]^JmH sH h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJhDOJQJ^JhN#OJQJ^J  h$If^htkd $$Ifl9R:  t 0644 lap  $Ifekd $$Ifl9R: t0644 laE5/$Ifkd $$Ifl\ B*|8:::: (04 lap(EFz{|}vpp$If  9r $If $ 9r $Ifa$pkd"$$Ifl|88   04 lap }~e_T__  9r $If$Ifkd$$Ifl\ B*|8::::04 lae\ $IfgdKkdu$$Ifl\ B*|8::::04 la$Ifpkd$$Ifl|88  04 lap 3e___V $Ifgd}L$Ifkd$$Ifl\ B*|8::::04 la)0234567PSZ\]^_`a;<=ܶܶܶܤ܅t!jehN#OJQJU^JjhN#OJQJU^J hJhN#OJQJ^JmH sH #hJhN#H*OJQJ^JmH sH h=ZhN#5OJQJ^JhN#OJQJ\^JhN#5OJQJ\^JhN#OJQJ^Jh=Zhw5OJQJ^Jh}L5OJQJ^J)34567]e___V $Ifgd}L$Ifkdn$$Ifl\ B*|8::::04 la]^_`ae___V $Ifgd}L$Ifkd$$Ifl\ B*|8::::04 lae___V $Ifgd}L$Ifkd$$Ifl\ B*|8::::04 laec]$Ifkd`$$Ifl\ B*|8::::04 law  9r $If$Ifwkd$$Ifl9R:  t 0644 lap LMqkk$Ifkd$$IflF9|P* t06    44 la=JKNO:;<HJtuwyzܺܪl`XPhqHmH sH hDmH sH hN#B*CJaJph$jhN#5OJQJU^Jhoo0J5OJQJ^J$j>hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^JhN#0JOJQJ^JMN~~$IfzkdF$$Ifl09|+ t0644 lax~~$Ifzkd$$Ifl09|+ t0644 laxyz{|}~}}}}}}pj$If  & F 8gd+=ngdDzkd$$Ifl09|+ t0644 la 589478"#jlopFGrtvϷϷϷϭϣϣϭϣhD5OJQJ\^Jh>OJQJ^JhDOJQJ^JhN#H*OJQJ^Jh (hN#^JnH tH hN#OJQJ^J#hN#B*OJQJ^JmH phsH hN#5OJQJ\^JhN#CJaJ6zi$If]^gdA$If]^wkd\$$Ifl9R:  t 0644 lap tkd$$Ifl4|88  06j4 laf4p $Ifgkd$$Ifl9R: t0644 la -kdE$$Ifl\ B*|8:::: (06j4 lap($If56789?kdO$$Ifl4\ B*|8::::06j4 laf4$If h$If^h $If^`[kd$$Ifl4\ B*|8::::06j4 laf4$If4567aOE??$If h$If^h $If^`kd$$Ifl4\ B*|8::::06j4 laf478a[Q[[ ,$If^,$Ifkd\ $$Ifl4\ B*|8::::06j4 laf4 !"a[Q[[ ,$If^,$Ifkd !$$Ifl4\ B*|8::::06j4 laf4"#$mnoa[Q[[ ,$If^,$Ifkd!$$Ifl4\ B*|8::::06j4 laf4opqa[QQQ[[ ,$If^,$Ifkdi"$$Ifl4\ B*|8::::06j4 laf4a[[$Ifkd#$$Ifl4\ B*|8::::06j4 laf4$Iftkd#$$Ifl4|88  06j4 laf4p Az ,$If^,$Iftkd}$$$Ifl4|88  06j4 laf4p a[QQQQQ[[ h$If^h$Ifkd3%$$Ifl4\ B*|8::::06j4 laf4 CDEFa[Q[[ h$If^h$Ifkd%$$Ifl4\ B*|8::::06j4 laf4FGqrstuva[QQQ[[ h$If^h$Ifkd&$$Ifl4\ B*|8::::06j4 laf4vwa[[Q[[ h$If^h$Ifkd@'$$Ifl4\ B*|8::::06j4 laf40**$Ifkd'$$Ifl4\ B*|8:::: (06j4 laf4p(QF  9r $Ifkd($$Ifl4\ B*|8::::06j4 laf4$If h$If^h'*+hijkmntκΘzm`zUzmhvH*OJQJ^JhF{ahvOJQJ^Jhv5OJQJ\^JhvOJQJ^J&hJhv5OJQJ\^JmH sH  hxZ&5OJQJ\^JmH sH  hJhvOJQJ^JmH sH &hJhN#5OJQJ\^JmH sH hN#5OJQJ\^Jh>OJQJ^JhN#OJQJ^J hJhN#OJQJ^JmH sH '()QF  9r $Ifkd)$$Ifl4\ B*|8::::06j4 laf4$If h$If^h)*+i*  9r $Ifgd 0okd]*$$Ifl4\ B*|8:::: (06j4 laf4p($IfijklmnQF  9r $Ifkdm+$$Ifl4\ B*|8::::06j4 laf4$If h$If^h*  9r $Ifkd,$$Ifl4\ B*|8:::: (06j4 laf4p($IfNkd,-$$Ifl4\ B*|8::::06j4 laf4$If ,$If^,gdv()vvv $$Ifa$gdv$Ifwkd-$$Ifl9R:  t 0644 lap ()*+ghivwxyµui_NBhD0JOJQJ^J!j0hDOJQJU^JhDOJQJ^JhN#0JOJQJ^J!j:/hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhvOJQJ^JhNhvOJQJ^JhF{ahvOJQJ^J)hN#6B*OJQJ]^JmH phsH #hN#B*OJQJ^JmH phsH hvH*OJQJ^JhN#H*OJQJ^J)*xqkk$Ifkd.$$IflF9|P* t06    44 la~t h$If^h$Ifzkd0$$Ifl09|+ t0644 laSTUac 𨗆umfYLAhN#H*OJQJ^JhN#5OJQJ\^Jh (hN#^JnH tH  h6hN#hN#CJaJ!hkyp5B*OJQJ\^Jph!h>5B*OJQJ\^Jph!hN#5B*OJQJ\^JphhN#OJQJ^J$ji2hN#5OJQJU^Jhoo0J5OJQJ^J$j1hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jzzzzzzzzzzzzz 0^`0zkd3$$Ifl09|+ t0644 la$If  & F 8gd6 0^`0  5/$Ifkd3$$Ifl\ B*|8:::: (0j4 lap(  >?u{r $Ifgd#  9r $If$Ifskd4$$Ifl4|88  0j4 laf4p <=>JSuvT]*BCFyӼӼӲӲӨӛӇziӼ hJh#OJQJ^JmH sH h{hHOJQJ^JhHOJQJ^Jh{OJQJ^Jh{h{OJQJ^Jh=OJQJ^JhyYOJQJ^JhN#5OJQJ\^Jh#OJQJ^JhN#OJQJ^J#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH %uve_T__  9r $If$Ifkdn5$$Ifl\ B*|8::::0j4 lae_$Ifkd6$$Ifl\ B*|8::::0j4 la E_} $Ifgd#$Ifskd6$$Ifl4|88  0j4 laf4p _`l~e___V $Ifgd#$Ifkdm7$$Ifl\ B*|8::::0j4 lae___V $Ifgd#$Ifkd8$$Ifl\ B*|8::::0j4 lae____$Ifkd8$$Ifl\ B*|8::::0j4 lae_V__ $IfgdH$Ifkd_9$$Ifl\ B*|8::::0j4 la*e_$Ifkd:$$Ifl\ B*|8::::0j4 la*+BCDE{  9r $If$Ifskd:$$Ifl4|88  0j4 laf4p EFye_$Ifkd^;$$Ifl\ B*|8::::0j4 layz{  9r $If$Ifskd<$$Ifl4|88  0j4 laf4p $%&'AB^_`ad۽ʝʝʋy#h.hh&H*OJQJ^JmH sH #h.h.H*OJQJ^JmH sH #hJhN#H*OJQJ^JmH sH hN#5H*OJQJ\^JhN#5OJQJ\^J hJhN#OJQJ^JmH sH hN#OJQJ^JhN#OJQJ^JjhN#OJQJU^J/e_T__  9r $If$Ifkd<$$Ifl\ B*|8::::0j4 lae_T__  9r $If$Ifkd]=$$Ifl\ B*|8::::0j4 la&'()e_T__  9r $If$Ifkd>$$Ifl\ B*|8::::0j4 la)*`abce_T__  9r $If$Ifkd>$$Ifl\ B*|8::::0j4 lacde_$IfkdO?$$Ifl\ B*|8::::0j4 la{{$If  9r $Ifskd?$$Ifl4|88  0j4 laf4p eZZTT$If  9r $Ifkd@$$Ifl\ B*|8::::0j4 laeZZTT$If  9r $IfkdNA$$Ifl\ B*|8::::0j4 lae_$IfkdA$$Ifl\ B*|8::::0j4 la{xxxxxja $Ifgdh&  9r $Ifgd2  9r $If$IfukdB$$Ifl9R:  t 044 lap z{鼯饛|pbXGb!jDh2OJQJU^Jh2OJQJ^Jjh2OJQJU^JhN#0JOJQJ^J!jChN#OJQJU^JjhN#OJQJU^JhVOJQJ^Jhh&OJQJ^JhSmhh&OJQJ^Jh.OJQJ^J hJhN#OJQJ^JmH sH #hJhN#H*OJQJ^JmH sH hN#OJQJ^JhN#5OJQJ\^J{7jdd[R $Ifgdkyp $Ifgd{$Ifkd@C$$IflF9|P* t0    44 la $IfgdD56789qrijΧΝth^TL>hN#OJQJ^JmH sH hN#CJaJhb 6OJQJ^JhN#OJQJ^JhH0JOJQJ^J!jGhHOJQJU^JhHOJQJ^JjhHOJQJU^Jh{OJQJ^Jh{0JOJQJ^J!jFhOJQJU^JhOJQJ^Jjh{OJQJU^Jh2OJQJ^Jjh2OJQJU^Jh20JOJQJ^J789aqrxke$If  & F 8gd+=n  & F gd+=nykdH$$Ifl09|+ t044 lanzz & F$If$IftkdZI$$Ifl9R:  t 0644 lap rmq !"3GHIX|obUboKbKbhqHOJQJ^Jhvs5OJQJ\^JhqH5OJQJ\^Jh-5OJQJ\^JhqHOJQJ\^JhJDOJQJ^J hJhOJQJ^JmH sH h.OJQJ^JhOJQJ^JhOJQJ\^Jh5OJQJ\^Jhh5OJQJ\^JhN#OJQJ\^JhN#OJQJ^JhN#5OJQJ\^Jnoq $$Ifa$gdt)ekdI$$Ifl9R: t0644 lapgg $Ifgdt)kdJ$$Ifl08`' 04 lapytt)|s $Ifgd  9r $Ifgdt)tkd^K$$Ifl08`'04 laytt) !"0Xss $$Ifa$gd- $$Ifa$tkdL$$Ifl08`'04 laytt)sm$IfkdL$$Ifl08`' 04 lap$IfnkdM$$Ifl8`9   04 lap yy$If  9r $Iftkd(N$$Ifl08`'04 layt-.ERVeftuYg &'34?@QV˾˾˱˧h 0o5OJQJ\^Jh 0oH*OJQJ^Jh 0oOJQJ^Jhvs5OJQJ\^JhN#5OJQJ\^JhqH5OJQJ\^JhqHOJQJ^Jh{)hqHOJQJ^J hJhqHOJQJ^JmH sH 8$IfvkdN$$IflG08`'04 laytqH-$IfnkdxO$$Ifl8`9   04 lap -.D$Iftkd!P$$Ifl08`'04 laytDEWe $IfgdqH$IfnkdP$$Ifl8`9   04 lap efgt{ $IfgdqH$IftkdpQ$$Ifl08`'04 layttuv{{ $IfgdqH$IftkdR$$Ifl08`'04 layt{{ $IfgdqH$IftkdR$$Ifl08`'04 layt{ $Ifgd4$IftkdbS$$Ifl08`'04 layt{ $Ifgd4$IftkdT$$Ifl08`'04 layt{{ $IfgdBg$IftkdT$$Ifl08`'04 layt2~~~ $$Ifa$gdtkdTU$$Ifl08`'04 layt23Xpj$IfkdU$$Ifl08$<' 04 lapytqHXYZg $Ifgd4$IfnkdV$$Ifl8`9   04 lap gh$Iftkd~W$$Ifl08`'04 layt $Ifgd$Ifnkd$X$$Ifl8`9   04 lap { $IfgdqH$IftkdX$$Ifl08`'04 layt{ $Ifgd($IftkdsY$$Ifl08`'04 layt{ $Ifgd($IftkdZ$$Ifl08`'04 layt{ $Ifgd?<$IftkdZ$$Ifl08`'04 layt{ $IfgdqH$Iftkde[$$Ifl08`'04 layt{ $Ifgd?<$Iftkd \$$Ifl08`'04 layt { $IfgdqH$Iftkd\$$Ifl08`'04 layt { $IfgdqH$IftkdW]$$Ifl08`'04 layt&{ $Ifgd($Iftkd]$$Ifl08`'04 layt&'(3{ $Ifgd($Iftkd^$$Ifl08`'04 layt345?{ $Ifgdn0$IftkdI_$$Ifl08`'04 layt?@y$Iftkd_$$Ifl08`'04 laytV !]^_lmn˾˛ˑviUv'jhhbh4OJQJU^Jhbh4OJQJ^J!jhbh4OJQJU^Jh4OJQJ^JhqHOJQJ^JhbhqH0JOJQJ^J'jghbhqHOJQJU^JhbhqHOJQJ^J!jhbhqHOJQJU^JhqH5OJQJ\^Jh 0o5OJQJ\^Jh 0oOJQJ^J!{ $IfgdqH$Iftkd`$$Ifl08`'04 layt{ $IfgdqH$Iftkd;a$$Ifl08`'04 layt{ $Ifgd($Iftkda$$Ifl08`'04 layt{ $Ifgd7,$Iftkdb$$Ifl08`'04 layt{ $IfgdqH$Iftkd-c$$Ifl08`'04 layt{ $Ifgd?<$Iftkdc$$Ifl08`'04 layt{ $Ifgd?<$Iftkdyd$$Ifl08`'04 layt{ $IfgdqH$Iftkde$$Ifl08`'04 layt{{{{{{{{{ $Ifgd?<$Iftkde$$Ifl08`'04 layt $Iftkdkf$$Ifl08`'04 layt nopqrstuvwxyz $IfgdJV%ukdg$$Ifl9R:  t 044 lap z{|}~ $IfgdJV%@Zm<i  L    $Ifgd1ib $IfgdX $Ifgd $IfgdB[9 $Ifgd" $Ifgd $Ifgdr$If $Ifgd/Y $Ifgd7, $Ifgdn0 $IfgdJV%>?@Amno/ӼfL3jkhvqxhvqx>*B*OJQJU^Jph3jDjhvqxhvqx>*B*OJQJU^Jphhvqxhvqx0JOJQJ^J3jyihvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^Jphhbh4OJQJ^J!jhbh4OJQJU^Jhbh40JOJQJ^J/01XYZ[()*klmnοάzfRά'jnhvqxhvqxOJQJU^J'jnhvqxhvqxOJQJU^J'jlhvqxhvqxOJQJU^JhvqxhvqxOJQJ^J!jhvqxhvqxOJQJU^J$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jkhvqxhvqx>*B*OJQJU^Jph:;<=ijk   g h οάάο΂kX>k/kh 0ohB[90JOJQJ^J3j.qh 0ohB[9>*B*OJQJU^Jph$h 0ohB[9>*B*OJQJ^Jph-jh 0ohB[9>*B*OJQJU^Jphhvqx>*B*OJQJ^Jph3jcphvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3johvqxhvqx>*B*OJQJU^Jphh i j           J K L M z { |    é֚֊pdJ֚:hf>*B*OJQJ^Jph3jshvqxhvqx>*B*OJQJU^JphhB[90JOJQJ^J3jrhvqxhB[9>*B*OJQJU^JphhB[9>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J3jqhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^Jph$h 0ohB[9>*B*OJQJ^Jph          ; < = j k l m           X Y Z [  ֭֭y֭_֭3jvhvqxhvqx>*B*OJQJU^Jph3juhvqxhvqx>*B*OJQJU^Jph3j-uhvqxhvqx>*B*OJQJU^Jphhvqxhvqx0JOJQJ^J3j`thvqxhvqx>*B*OJQJU^Jph-jhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph l  Z    Vzf $Ifgds$ $Ifgd5| $Ifgd$Q $IfgdN7 $Ifgd3 $Ifgdtoj $Ifgdu $IfgdV $Ifgdf $Ifgd;& $Ifgd $Ifgdk $Ifgd1ib          H I J  οάhYI<hAJIhAJIOJQJ^JhAJI>*B*OJQJ^JphhAJIhf0JOJQJ^J3jaxhAJIhf>*B*OJQJU^Jph$hAJIhf>*B*OJQJ^Jph-jhAJIhf>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jwhvqxhvqx>*B*OJQJU^Jph          ()*TUVWλΒλλxΒλλ^ΒλλD3j{hvqxhvqx>*B*OJQJU^Jph3jzhvqxhvqx>*B*OJQJU^Jph3jyhvqxhvqx>*B*OJQJU^Jphhvqxhvqx0JOJQJ^J3j.yhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^Jph4hAJIhf>*B*OJQJ^JmH nH phsH tH BCDxyz{defgǭǓy_3j~hvqxhvqx>*B*OJQJU^Jph3j}hvqxhvqx>*B*OJQJU^Jph3j/}hvqxhvqx>*B*OJQJU^Jph3jb|hvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^Jphhvqxhvqx0JOJQJ^J! !NOP"οάάοάάxοάά^οάά3j8hvqxhvqx>*B*OJQJU^Jph3jkhvqxhvqx>*B*OJQJU^Jph3jchvqxh>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph V>u\B $IfgdX} $Ifgdv $Ifgdm= $Ifgdg4 $IfgdO $IfgdoU $IfgdR $Ifgd* $Ifgdb $Ifgd.k"#$TUVW<=>?lmnοάάοάάxοάά^οάά3jhvqxhvqx>*B*OJQJU^Jph3jڄhvqxhvqx>*B*OJQJU^Jph3j hvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jhvqxh>*B*OJQJU^JphGHI-./stuvοάάοάάxοάά^οάά3jۈhvqxhvqx>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph3jAhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jthvqxhvqx>*B*OJQJU^Jph&'(οάk_L23jBhm=hm=>*B*OJQJU^Jph$hm=hm=>*B*OJQJ^Jphhm=0JOJQJ^J3juhm=hm=>*B*OJQJU^Jphhm=>*B*OJQJ^Jph-jhm=hm=>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph$%&Z[\]@ABǭڒڂh\ڒڂB\ڒ3jhm=hm=>*B*OJQJU^Jphhm=0JOJQJ^J3j܌hm=hm=>*B*OJQJU^Jphhm=>*B*OJQJ^Jph4hm=hm=>*B*OJQJ^JmH nH phsH tH 3jhm=hm=>*B*OJQJU^Jph$hm=hm=>*B*OJQJ^Jph-jhm=hm=>*B*OJQJU^Jphhm=hm=0JOJQJ^JB)*+|}~ַsdI/dI3jChX}hX}>*B*OJQJU^Jph4hX}hX}>*B*OJQJ^JmH nH phsH tH hX}hX}0JOJQJ^J3jvhX}hX}>*B*OJQJU^Jph$hX}hX}>*B*OJQJ^Jph-jhX}hX}>*B*OJQJU^Jph<hv hv >*B*CJOJQJ^JaJmH nH phsH tH ,hv hv >*B*CJOJQJ^JaJph$h 0ohv >*B*OJQJ^Jph~`;'.8,  %!! "" $Ifgd22 $IfgdZV $Ifgdt $IfgdVv $Ifgd{y> $Ifgd yt $Ifgd $IfgdiD $Ifgd{) $Ifgdg4 $IfgdX}~^_`a9:;ջՒx^3jwhvqxhvqx>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph3jݐhvqxhvqx>*B*OJQJU^Jphhvqxhvqx0JOJQJ^J3jhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^Jph;<ijk%&'(UVWջՕhY?Y3jޔhvqxhvqx>*B*OJQJU^Jphhvqxhvqx0JOJQJ^J3jhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^JphhiDhiD0JOJQJ^J3jDhiDhiD>*B*OJQJU^Jph$hiDhiD>*B*OJQJ^Jph-jhiDhiD>*B*OJQJU^Jph,-./\]^6789fghοάάοάάxοάά^οάά3jhvqxhvqx>*B*OJQJU^Jph3jEhvqxhvqx>*B*OJQJU^Jph3jxhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph* + , - Z [ \        #!$!%!&!S!T!U!~!!!!!οάάοάάxοάά^οάά3jFhvqxhvqx>*B*OJQJU^Jph3jyhvqxhvqx>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jߘhvqxhvqx>*B*OJQJU^Jph!!!"" "!"N"O"P""""""""M#N#οάάοά{hN{?{h4h40JOJQJ^J3jh4h4>*B*OJQJU^Jph$h4h4>*B*OJQJ^Jph-jh4h4>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3jhvqxhvqx>*B*OJQJU^Jph"O##?$%&&&&K'L'bykd$$Ifl09R( t044 la $Ifgdvqx $IfgdqH $Ifgd $Ifgd4 N#O#P#}#~#########=$>$?$@$$λΒλλxΒhTDh/>*B*OJQJ^Jph'jh/>*B*OJQJU^Jphhvqx>*B*OJQJ^Jph3jGhvqxhvqx>*B*OJQJU^Jphhvqxhvqx0JOJQJ^J3jzhvqxhvqx>*B*OJQJU^Jph$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^Jph4h4h4>*B*OJQJ^JmH nH phsH tH $$$%%% %%%% &&&&&=&Ը}q^G4$hvqxhvqx>*B*OJQJ^Jph-jhvqxhvqx>*B*OJQJU^Jph$hvqxh4X>*B*OJQJ^Jphh4X0JOJQJ^J-jh4X>*B*OJQJU^Jphh4X>*B*OJQJ^Jph'jh4X>*B*OJQJU^Jphh/>*B*OJQJ^Jphh/0JOJQJ^J'jh/>*B*OJQJU^Jph-jh/>*B*OJQJU^Jph=&>&?&&&&&&&&&&&&*'+','I'J'K'L'M'οάzfYL>jhqHOJQJU^JhbhqHOJQJ^JhbhX}OJQJ^J'jhvqxhvqxOJQJU^J'jhvqxhvqxOJQJU^JhvqxhvqxOJQJ^J!jhvqxhvqxOJQJU^J$hvqxhvqx>*B*OJQJ^Jphhvqxhvqx0JOJQJ^J-jhvqxhvqx>*B*OJQJU^Jph3j"hvqxhvqx>*B*OJQJU^JphM'''''''''''''''''F(J(((((U)V))))***zo\z$jhQ5OJQJU^JhQ5OJQJ^JjhQ5OJQJU^JhfGhQ5OJQJ^Jh0#hQOJQJ^JhQH*OJQJ^JhQOJQJ^J!jWhqHOJQJU^JhqH0JOJQJ^JjhqHOJQJU^J!jXhqHOJQJU^JhqHOJQJ^JL''''''F((()wj]TT $IfgdQ h$If^hgdQ $If^gdQ $IfgdJV%ykd$$Ifl09R( t044 la$If ))>*?*@*C*g*h*n*j``SQH $$Ifa$  & F 8gd+=n 0^`0kd+$$IflFb9& t0    44 laytQ$If***:*;*=*?*A*C*g*h********+.+=+K+L++++++⺩vivviv_U___JhN#H*OJQJ^Jh?5OJQJ^JhN#OJQJ^Jhvs5OJQJ\^Jhvqx5OJQJ\^J!hN#5B*OJQJ\^JphhN#CJaJhN#5OJQJ\^J!hN#5B*OJQJ\^JphhQOJQJ^J$jhQ5OJQJU^JhQ5OJQJ^JjhQ5OJQJU^Jhoo0J5OJQJ^Jn*u****+ $$Ifa$gdvqx $$Ifa$++-+71$Ifkd$$Ifl\ ){8D   (04 lap(-+.+/+0+=+L+ $Ifgdvqx$Ifnkd$$Ifl{88   04 lap L+M++ga$Ifkd$$Ifl\ ){8D  04 la++++++$Ifnkdj$$Ifl{88   04 lap ++++++gaaXX $Ifgdvqx$Ifkd$$Ifl\ ){8D  04 la+++++++++,,,-,C,D,T,U,e,f,u,v,w,x,,,,,,,,ɼzmcVLcLh,OJQJ^Jh@*5OJQJ\^Jh@*OJQJ^Jh5OJQJ\^JhOJQJ^Jh(35OJQJ\^Jh$QOJQJ^Jh(3OJQJ^Jh|f5OJQJ\^Jh|fOJQJ^Jh yt5OJQJ\^Jh ytOJQJ^JhN#5OJQJ\^Jh?5OJQJ^JhN#OJQJ^Jh?5H*OJQJ^J+++ga$IfkdѮ$$Ifl\ ){8D  04 la++++++$Ifnkd$$Ifl{88   04 lap ++++++gaaaa$Ifkd8$$Ifl\ ){8D  04 la++ ,ga$Ifkd$$Ifl\ ){8D  04 la ,,,,,,,$Ifnkd$$Ifl{88   04 lap ,,-,.,/,0,C,gaaaa$Ifkd]$$Ifl\ ){8D  04 laC,D,E,F,G,T,gaaaX $Ifgdvqx$Ifkd$$Ifl\ ){8D  04 laT,U,V,W,X,e,gaaaX $Ifgdvqx$Ifkdٳ$$Ifl\ ){8D  04 lae,f,g,h,i,w,gaaaX $Ifgdvqx$Ifkd$$Ifl\ ){8D  04 law,x,y,z,{,,gaaaa$IfkdU$$Ifl\ ){8D  04 la,,,,,,gaaaX $Ifgdvqx$Ifkd$$Ifl\ ){8D  04 la,,,,,,gaaaX $Ifgd@*$IfkdѶ$$Ifl\ ){8D  04 la,,,,,,gaaaX $Ifgdvqx$Ifkd$$Ifl\ ){8D  04 la,,,,,,,,,,-(-)----------/.ŷ{m\mPmChtojhN#OJQJ^JhN#0JOJQJ^J!j(hN#OJQJU^JjhN#OJQJU^JhN#hN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^JhoCJaJho>*B*CJaJphhN#>*B*CJaJphhu5OJQJ\^JhuOJQJ^Jh@*5OJQJ\^Jh@*OJQJ^Jh,5OJQJ\^J,,,,,,gaaaX $Ifgdvqx$IfkdM$$Ifl\ ){8D  04 la,,,,,,,,,,,,gbbbbbbbbbb$a$kd $$Ifl\ ){8D  04 la ,,,--(-*--kwkdɹ$$Ifl9R:  t 0644 lap $If$a$ 8^`gdo---./..(// 00qkkkbYYPP $Ifgd?5 $Ifgdo $Ifgdr$Ifkdr$$IflFx9|hn* t06    44 la /.0.\.].^.f.g..........&/'/(////ջ謠Ն謠viUEhI>*B*OJQJ^Jph'jhI>*B*OJQJU^JphhtojhoOJQJ^Jho>*B*OJQJ^Jph3jԼhtojhvqx>*B*OJQJU^Jphhvqx0JOJQJ^Jhtojhvqx0JOJQJ^J3j htojhvqx>*B*OJQJU^Jph$htojhvqx>*B*OJQJ^Jph-jhtojhvqx>*B*OJQJU^Jph/// 0 0 0 08090:0B0C00000000111141ԸteYe?e3j5htojhvqx>*B*OJQJU^Jphhvqx0JOJQJ^Jhtojhvqx0JOJQJ^J3jjhtojhvqx>*B*OJQJU^Jph$htojhvqx>*B*OJQJ^Jph-jhtojhvqx>*B*OJQJU^JphhI>*B*OJQJ^JphhI0JOJQJ^J'jhI>*B*OJQJU^Jph-jhI>*B*OJQJU^Jph011 2j22S33'44 5V556 $IfgdAJI$If $Ifgd|f $Ifgd yt $Ifgdg4 $IfgdeQ $IfgdO $Ifgd) $Ifgd$Q $Ifgdtoj $Ifgdu $Ifgd1ib 415161b1c1d1111111 2 2 22;2οί~kQ~B~k~khOhvqx0JOJQJ^J3jhOhvqx>*B*OJQJU^Jph$hOhvqx>*B*OJQJ^Jph-jhOhvqx>*B*OJQJU^JphhAJIhvqxOJQJ^JhAJIhAJIOJQJ^JhAJI>*B*OJQJ^Jphhtojhvqx0JOJQJ^J-jhtojhvqx>*B*OJQJU^Jph3jhtojhvqx>*B*OJQJU^Jph;2<2=2h2i2j2k22222222 333Q3R3S3T33οάάοάάxοάaN$hg4hvqx>*B*OJQJ^Jph-jhg4hvqx>*B*OJQJU^Jph3j6hOhvqx>*B*OJQJU^Jph3jihOhvqx>*B*OJQJU^Jph$hOhvqx>*B*OJQJ^JphhOhvqx0JOJQJ^J-jhOhvqx>*B*OJQJU^Jph3jhOhvqx>*B*OJQJU^Jph3333333333%4&4'4(4U4V4W444444οάhY?Y3jh,hvqx>*B*OJQJU^Jphh,hvqx0JOJQJ^J3jh,hvqx>*B*OJQJU^Jph$h,hvqx>*B*OJQJ^Jph-jh,hvqx>*B*OJQJU^Jph$hg4hvqx>*B*OJQJ^Jphhg4hvqx0JOJQJ^J-jhg4hvqx>*B*OJQJU^Jph3jhg4hvqx>*B*OJQJU^Jph444 5 5 5 5,5-5.5T5U5V5W5555555οάάοά{hN{?3?hvqx0JOJQJ^Jhtojhvqx0JOJQJ^J3j?htojhvqx>*B*OJQJU^Jph$htojhvqx>*B*OJQJ^Jph-jhtojhvqx>*B*OJQJU^Jph3j7h,h>*B*OJQJU^Jph$h,hvqx>*B*OJQJ^Jphh,hvqx0JOJQJ^J-jh,hvqx>*B*OJQJU^Jph3jjh,hvqx>*B*OJQJU^Jph5555 6 66O6P6R66666666վreXN@N/@!jyhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhtojhuOJQJ^JhAJIhAJIOJQJ^JhAJI>*B*OJQJ^Jphh,hvqx0JOJQJ^J3j h,hvqx>*B*OJQJU^Jph$h,hvqx>*B*OJQJ^Jph-jh,hvqx>*B*OJQJU^Jph$htojhvqx>*B*OJQJ^Jph-jhtojhvqx>*B*OJQJU^Jph66+7,7~~$Ifzkd$$Ifl09|+ t0644 la6666677777=7>7z7{7|7777777778$8%8&8'8R8ܻ}phpZpI hJhN#OJQJ^JmH sH h (hN#\^JnH tH hN#CJaJhN#5OJQJ\^J$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jxhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^JhN#0JOJQJ^J,7-7=77~~$Ifzkd1$$Ifl09|+ t0644 la7777777888ullll $$Ifa$  & F 8gd+=nzkdO$$Ifl09|+ t0644 la 88$87' & F $Ifgd+=nkd$$Ifl\ A*{89 : (0k4 lap($8%8&8'8S8T8  9r $If$Ifnkd$$Ifl{88   0k4 lap T8U8h8ga$Ifkd$$Ifl\ A*{89 :0k4 lah8i8j8888  9r $If$Ifnkd$$Ifl{88   0k4 lap R8i8j88888888,9P9R9k9p9q9s9999999999999Ƹ󍀍vkvvk^vSvk^SvhvsOJQJ\^Jh|QYhvsOJQJ^Jhvs5OJQJ^JhvsOJQJ^Jho5OJQJ\^Jhvs5OJQJ\^JhH5OJQJ\^J hJhHOJQJ^JmH sH hHOJQJ^JmH sH hHB*OJQJ^Jph hJhN#OJQJ^JmH sH hN#B*OJQJ^JphhN#5OJQJ\^J888888gaVaa  9r $If$Ifkd:$$Ifl\ A*{89 :0k4 la888ga$Ifkd$$Ifl\ A*{89 :0k4 la8888nkd{$$Ifl{88   0k4 lap $Ifnkd$$Ifl{88   0k4 lap 88888)9Q9s $$Ifa$gd[e $$Ifa$gdnkd$$$Ifl{88   0k4 lap $IfQ9R9\9]9q94..% $Ifgd[e$Ifkd$$Ifl\ A*{89 : (0k4 lap(ytvsq9r9s9t9u999aX $Ifgd[ekd$$Ifl\ A*{89 :0k4 la$If9999999gaaXaa $Ifgdvs$Ifkd$$Ifl\ A*{89 :0k4 la999ga$Ifkd$$Ifl\ A*{89 :0k4 la999::#:yp $Ifgdo $Ifgd] $$Ifa$$Ifnkdd$$Ifl{88   0k4 lap 99::::!:":#:$:L:V:~:::::::::::::%;';痈vi_T_J_h] OJQJ^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^J#hJhvsH*OJQJ^JmH sH h[eH*OJQJ^JmH sH  hJhvsOJQJ^JmH sH hvsH*OJQJ^JhG;hvsOJQJ\^JhvsOJQJ\^Jh>hvsOJQJ\^Jhvs5OJQJ\^JhvsOJQJ^JhvsB*OJQJ^Jph#:$:%:L:\:]:g^^UO$If $Ifgd[e $$Ifa$kd $$Ifl\ A*{89 :0k4 la]:^:}:ga$Ifkd$$Ifl\ A*{89 :0k4 la}:~:::::|nh$If  9r $Ifgd[e $$Ifa$gd] $$Ifa$nkd$$Ifl{88   0k4 lap :::ga$IfkdN$$Ifl\ A*{89 :0k4 la::::&;z $Ifgd] $Ifukd$$Ifl9R:  t 044 lap &;';u;w;;G<<p=smd[RI@ $Ifgdo $Ifgd> $Ifgdr $IfgdG" $Ifgd] $Ifkd$$IflF9|qe* t0    44 la';(;d;e;f;s;t;u;v;w;x;;;;;;;;<<<E<F<G<H<u<稕{lRl3j!hoho>*B*OJQJU^Jphhoho0JOJQJ^J3jThoho>*B*OJQJU^Jph$hoho>*B*OJQJ^Jph-jhoho>*B*OJQJU^JphhN#H*OJQJ^JhN#0JOJQJ^J!jshN#OJQJU^JhN#OJQJ^JjhN#OJQJU^Ju<v<w<<<<<===n=o=p=q=r============οάάοΈ~p~_pSp~p~BpS!j:hN#OJQJU^JhN#0JOJQJ^J!j;hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhG"OJQJ^J3jhoho>*B*OJQJU^Jph$hoho>*B*OJQJ^Jphhoho0JOJQJ^J-jhoho>*B*OJQJU^Jph3jhoho>*B*OJQJU^Jphp=q=>k>smc  $If$Ifkd$$IflF9|qe* t0    44 la==l>n>o>q>z>{>|>>>>>>>>>>-?.?/?????????????????@@ε}}oooeoooh.OJQJ^JhN#B*OJQJ^JphhN#OJQJ^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJh!.CJaJhN#5OJQJ^Jh!.h!.5OJQJ^Jh!.hN#5OJQJ^Jh[e5OJQJ^JhN#OJQJ^JjhN#OJQJU^J&k>l>m>n>{>|>>>>>>omggg$If 8^`gd!.gd!.ykd$$Ifl09|+ t044 la >>>>,&$Ifkd$$Ifl\ A*{89::: (0k4 lap( $$Ifa$>>>$Ifpkd$$Ifl{88   0k4 lap >>?,?-?.?$IfpkdR$$Ifl{88   0k4 lap .?/?^????e____$Ifkd$$Ifl\ A*{89:::0k4 la??????e____$Ifkd$$Ifl\ A*{89:::0k4 la???e_$Ifkdg$$Ifl\ A*{89:::0k4 la??????$Ifpkd$$Ifl{88   0k4 lap ?????@e____$Ifkd$$Ifl\ A*{89:::0k4 la@@@@@(@e___V $Ifgd'$Ifkd|$$Ifl\ A*{89:::0k4 la@@"@#@%@'@(@)@,@4@A@O@r@s@t@@@>A?AMA彰teXJ=3=3hN#OJQJ^JhN#5OJQJ\^JhN#OJQJ^JnH tH h(,5OJQJ\^Jhb OJQJ^JmHnHuh(,OJQJ^JmHnHu#h(,h(,OJQJ^JmHnHu h(,h(,OJQJ^JmH sH h(,OJQJ^Jh.s5OJQJ\^Jh!.h.sOJQJ^Jh!.h'H*OJQJ^Jh!.h'OJQJ^J h!.h'OJQJ^JmH sH h.sOJQJ^J(@)@*@+@,@s@e___V $Ifgd(,$Ifkd0$$Ifl\ A*{89:::0k4 las@t@@e_$Ifkd$$Ifl\ A*{89:::0k4 la@@@A$Ifpkd$$Ifl{88   0k4 lap >A?AJAKALAMAe____$IfkdE$$Ifl\ A*{89:::0k4 laMANAAe_$Ifkd$$Ifl\ A*{89:::0k4 laMANAAAAAAAAAAAAABB B BBB#B$B%BLBMBPB[B\B_BkBlBoBB󸫸ugXh[_5OJQJ^JnH tH h[_OJQJ^JnH tH hW&5OJQJ^JnH tH hW&OJQJ^JnH tH hN#5OJQJ^JnH tH hW&OJQJ^JhlQ5OJQJ\^JhlQOJQJ^JhN#H*OJQJ^JhN#OJQJ^Jh%OJQJ^JnH tH hN#OJQJ^JnH tH hN#5OJQJ\^J AAAAAA $Ifgd%$Ifpkd$$Ifl{88   0k4 lap AAAAAAe___V $Ifgd%$IfkdZ$$Ifl\ A*{89:::0k4 laAAAAAAe____$Ifkd$$Ifl\ A*{89:::0k4 laAAAAAAb\\\\$Ifkd$$IflM\ A*{89:::0k4 layt"AAAAA Be____$Ifkd|$$Ifl\ A*{89:::0k4 la B B B B BBe___V $IfgdE $Ifkd0$$Ifl\ A*{89:::0k4 laBBBBB$Be___V $Ifgd6$Ifkd$$Ifl\ A*{89:::0k4 la$B%BLBe_$Ifkd$$Ifl\ A*{89:::0k4 laLBMBNBOBPB[B$IfpkdL$$Ifl{88   0k4 lap [B\B]B^B_BkB5////$Ifkd$$Ifl\ A*{89::: (0k4 lap(kBlBmBnBoBB5////$Ifkd$$Ifl\ A*{89::: (0k4 lap(BBB5/$Ifkd#$$Ifl\ A*{89::: (0k4 lap(BBBBBB C CCC-CFCZC_CaCdCeCCCDDDDEEXEιvlaaVIhL'h'OJQJ^Jh'OJQJ\^JhN#OJQJ\^Jh.OJQJ^Jh}LOJQJ^J)h (h'B*^JmH nH phsH tH #h (h'H*^JmH nH sH tH #h (hN#H*^JmH nH sH tH )h (hN#B*^JmH nH phsH tH hN#OJQJ^JhN#5OJQJ\^JhN#OJQJ^JnH tH h[_5OJQJ\^JBBB$Ifpkd8$$Ifl{88   0k4 lap BBBBC C$Ifpkd$$Ifl{88   0k4 lap  C C CCCCe____$Ifkd$$Ifl\ A*{89:::0k4 laCCCCC-Ce____$IfkdF$$Ifl\ A*{89:::0k4 la-C.CECe_$Ifkd$$Ifl\ A*{89:::0k4 laECFCZC\C]C^C_CaCbCcCeCCDEE}}}}}}}}!$If$Ifukd$$Ifl9R:  t 044 lap XEYE`EbEEEEEFFFF2G3G4GAGBGCGDGpGqGrGGGG~kQ~B~khoh?<0JOJQJ^J3jhoh?<>*B*OJQJU^Jph$hoh?<>*B*OJQJ^Jph-jhoh?<>*B*OJQJU^JphhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^J!hL'h'B*OJQJ^JphhL'h'H*OJQJ^JhL'h'OJQJ^Jh'OJQJ^JEFFFCGG4HHf`WNE $Ifgdo $Ifgd0*T $Ifgd?<$IfkdT$$IflFx9|hn* t0    44 la <$If^<gdoGGGGG2H3H4H5HbHcHdHHHHH+IջՕhYI;1h[_OJQJ^Jjh[_OJQJU^Jh>*B*OJQJ^Jphhoh0JOJQJ^J3jhoh>*B*OJQJU^Jph$hoh>*B*OJQJ^Jph-jhoh>*B*OJQJU^Jphhoh0*T0JOJQJ^J3jhoh0*T>*B*OJQJU^Jph$hoh0*T>*B*OJQJ^Jph-jhoh0*T>*B*OJQJU^Jph+I,I-IaIbIcIdIeIfIIIIIIIIIIIIIJJJJ Kʽwm]RhN#5OJQJ^JjhN#5OJQJU^Jh%OJQJ^J!jhN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh0*Th[_OJQJ^Jh[_OJQJ^Jh[_0JOJQJ^Jjh[_OJQJU^J!jMh[_OJQJU^JHcIdIeIJJ}ww$Ifykd$$Ifl09|+ t044 la $IfgdoJJJJKvm $Ifgdo xx$If$Ifykd9$$Ifl09|+ t044 la K KKKKKKKK3KTKKKKKKKKKKKKLKLqLrLLLLLM'MZM[McMeMˬ{ӗpӗӗeӗӗӗehN#OJQJ\^JhN#5OJQJ^JhN#B*OJQJ^JphhN#OJQJ^JnH tH hN#5OJQJ\^JhN#CJaJh> CJaJhohomH sH tHhomH sH tHhoCJaJhN#OJQJ^JjhN#5OJQJU^J$jhN#5OJQJU^J#KKKKKKKK3K4K:KAKttootttmdd $$Ifa$gdo 8^`gd> ykd$$Ifl09|+ t044 la AKOKSKTKK.($Ifkd$$Ifl\ A*{89 : (04 lap( $$Ifa$KKKKnkd$$Ifl{88   04 lap $IfnkdK$$Ifl{88   04 lap KKKKKKKakd $$Ifl\ A*{89 :04 la$IfKKKKKK$Ifnkdi $$Ifl{88  04 lap KKKKKKgaaaa$Ifkd $$Ifl\ A*{89:::04 laKKLga$Ifkd $$Ifl\ A*{89:::04 laLLLJLKLqL$Ifnkdr $$Ifl{88   04 lap qLrLLLLLgaaaa$Ifkd $$Ifl\ A*{89 :04 laLLLga$Ifkd $$Ifl\ A*{89 :04 laLLLLLL$Ifnkd$$Ifl{88   04 lap LLMga$Ifkd\$$Ifl\ A*{89 :04 laMM&M'Mnkd$$Ifl{88   04 lap $Ifnkd($$Ifl{88   04 lap 'M7M8M9MZM[McMdMeMxMaV  9r $Ifkdz$$Ifl\ A*{89 :04 la$If eMxMyMMMMMMMMMMN NNNN N5N7NDNFNnNoNpN}NNNNNNNNNNNNNN˵thh)A>0JOJQJ^J!j_h)A>OJQJU^Jh)A>OJQJ^Jjh)A>OJQJU^Jh)A>5OJQJ\^Jh":h":mH sH hN#B*CJaJphh":OJQJ^Jh":5OJQJ\^JhN#OJQJ^JhN#5OJQJ\^J hJhN#OJQJ^JmH sH &xMyMMMMMgaaaa$IfkdF$$Ifl\ A*{89 :04 laMMMMMMgaaaa$Ifkd$$Ifl\ A*{89 :04 laMMMga$Ifkd$$Ifl\ A*{89 :04 laMMMMMM  9r $If$Ifnkd$$Ifl{88   04 lap MMMMN NgaaaV  9r $If$IfkdS$$Ifl\ A*{89 :04 la NNNNNNgaaaV  9r $If$Ifkd$$Ifl\ A*{89 :04 laNN N!N"N5Ngaaaa$Ifkd$$Ifl\ A*{89 :04 la5N6N7N8N9NDNgaaaa$Ifkd$$Ifl\ A*{89 :04 laDNENFNGNHNnNgaaaa$Ifkd$$Ifl\ A*{89 :04 lanNoNpNqNrN}NgaaaX $Ifgd":$IfkdO$$Ifl\ A*{89 :04 la}N~NNNNNgaaaX $Ifgd":$Ifkd$$Ifl\ A*{89 :04 laNNNNNge`W $Ifgd)gd":kd$$Ifl\ A*{89 :04 laNNNUOVO}tt $Ifgd)A> $Ifgd)xkd$$Ifl9R:  t 044 lap yt)NN$O%O&OSOTOUOVOXO[OuOO(Q*QHQIQYQhQ R RRAUBUUӷӚsisasiRiRiDijhN#OJQJU^JhN#OJQJ\^JmH sH hN#mH sH hN#OJQJ^JhN#5OJQJ\^JhN#CJaJh> CJaJh)A>OJQJ^Jh)A>h)A>OJQJ^Jh%h)A>0JOJQJ\^J6j@h%h)A>>*B*OJQJU\^Jph'h%h)A>>*B*OJQJ\^Jph0jh%h)A>>*B*OJQJU\^JphVOWOXOuOvOO~ljd$If 8^`gd> gd)A>|kd $$Ifl09|+ t044 layt)OOOOXP(Qzzz & F$If$Iftkd$$Ifl9R:  t 0644 lap (Q)Q*QHQIQXQ$If 8^`ekdR$$Ifl9R: t0644 laXQYQhQ RRSTUUzzzzzp h$If^h & F$If$Iftkd$$Ifl9R:  t 0644 lap UUUUUUUUUUUUUUUVV(V+V?VIVJVSVTVWVXVnVqVrVVVVVº}lʝlʝ^lʝlʝlʝlh.OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ\^JhN# h (hN#CJ^JaJnH tH hN#5OJQJ\^JhAmH sH h%mH sH h3pmH sH hN#mH sH hN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!j{ hN#OJQJU^J UUUUUUUUUUUUUUU $$Ifa$ekd^!$$Ifl9R: t0644 laUUU kd!$$Ifl\ +9 xx (0:4 lap($ 8$If^`a$UVV(V)V*V+V?VGVMkd#$$Ifl4\ +9` xx0:4 laf4$If  9r $If$IfGVHVIVJVTVUVVV^SM$If  9r $Ifkd#$$Ifl4\ +9  xx0:4 laf4$IfVVWVXVnVoVpVgaVPa$If  9r $If$Ifkd$$$Ifl\ +9 xx0:4 lapVqVrVVVVgaVPa$If  9r $If$Ifkd%$$Ifl\ +9 xx0:4 laVVVVVVgaVPa$If  9r $If$Ifkd&$$Ifl\ +9 xx0:4 laVVVVVVVVVVVVVVVVWW`WaWbWWWWY1Z2ZFZZZZZ[N[[ҽүҞ҇҇yobohN#5OJQJ\^JhN#OJQJ^JhN#B*OJQJ^JphhN#OJQJ\^JhN#0JOJQJ^J!j*hN#OJQJU^JjhN#OJQJU^JhN#mH sH hN#5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH #hJhN#H*OJQJ^JmH sH "VVVVVVgaVPa$If  9r $If$Ifkdh'$$Ifl\ +9 xx0:4 laVVVVVVgaVPa$If  9r $If$IfkdB($$Ifl\ +9 xx0:4 laVVVVge_$Ifkd)$$Ifl\ +9 xx0:4 laVVWWWWW0XXhNN$ & F $If^`a$ & F $If^`$Ifzkd*$$Ifl9:  t 0644 lap ytdX.YY2ZZZZN[[3\gaVaa $7$8$H$If$If}kd+$$Ifl0 9& , t0644 laytd$ & F $If^`a$ [3\6\]]L]M]N][]\]]]^]]]]]]]]'^(^)^P^Q^^_______ݾϲϨϋzϲj_Lj$jQ0hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jn/hN#OJQJU^Jh%0JOJQJ^J!j-h%OJQJU^Jh%OJQJ^JhN#0JOJQJ^J!j,hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhN#H*OJQJ^JhN#OJQJ^JmH sH 3\]]]]]{}kd<,$$Ifl0 9& , t0644 laytd$If]]]S^_{{{$If}kd.$$Ifl0 9& , t0644 laytd____ `g`t`u``||||jXI$4&`#$/If$$4&`#$/Ifa$$$4&`#$/Ifa$!$a$}kd0$$Ifl0 9& , t0644 laytd__` `f`g`t`u`````` a aa3a4aua}a~aaaaaaaǹԨǹ}r`Lǹ&h (hN#5CJ\^JaJnH tH #h (hN#5CJ^JaJnH tH hN#OJQJ\^JhJhN#5\aJmH sH hJhN#5aJmH sH hJhN#aJmH sH !hN#5B*OJQJ\^JphhN#5>*OJQJ\^JhN#5OJQJ\^JhN#OJQJ^Jh (hN#5^JaJnH tH  hN#5hN#5CJ aJ hN#````` a a3a$4&`#$/If$$4&`#$/Ifa$$$4&`#$/Ifa$3a4aua~aaaaao``QQQQ$4&`#$/If&$4&`#$/Ifkd1$$IflF"&;: 6`406    4 laaaaa bbbUbVbbbbbbbMcVcWccc$4&`#$/If$4&`#$/If^$$4&`#$/Ifa$$4&`#$/If$4&`#$/Ifa bbLbTbbbbbbbMcVccccccccccadbdedddddeee>e?e䷨zzvgYjhN#UmHnHuhN#5CJ OJQJ^JaJ hN#hN#5OJQJ^J!hN#5B*OJQJ\^Jph"hN#B*CJOJQJ\^JphhN#5CJOJQJ\^JhN#5>*OJQJ\^J'h (hN#5CJ^JmH nH sH tH hN#OJQJ\^JhN#5OJQJ\^Jh (hN#5^JnH tH !ccccccomg^^ $$Ifa$p^pkdJ2$$IflF"&;: 6`406    4 laccccc{uu$If $$Ifa$zkd2$$Ifl0:$ t0644 laccc6dad{uu$If $$Ifa$zkd|3$$Ifl0:$ t0644 laadbdeddde{uuu$If $$Ifa$zkd4$$Ifl0:$ t0644 laeee>e@eAeCeDeFeGeIeJeMeOeQe~yyyyyyyyyyyy$a$ zkd4$$Ifl0:$ t0644 la?e@eAeBeDeEeGeHeJeLeMeNeOePeReSeTeUeVeXeYeZe[e\e]e_eaebedeeefegeheiejekemenepeqeseweyeeeeeeeee̿hy%+OJQJ^Jh, hN*OJQJ^J!hN#5B*OJQJ\^JphhN#OJQJ^JnH tH hN#5OJQJ\^JhN#CJaJh%mH sH hN#mH sH jhN#UmHnHuhN#hN#5CJ aJ 2QeReTeVeYe[e]e`eaecedefehejelemeoepereseteuevewexeyeee 8^`$a$eeeeee.kd5$$Ifl\ ){8D   (04 lap( $$Ifa$eeee$Ifnkd96$$Ifl{88   04 lap $Ifeee}f~ff$If $Ifgdy%+nkd6$$Ifl{88   04 lap eefffffffffggg)gGgNg{g|ggggggggggggggŻŮܣrdPrrrr&hJh(35OJQJ\^JmH sH h(3OJQJ^JnH tH  hJh(3OJQJ^JmH sH h}LOJQJ^Jh-OJQJ\^Jh(3OJQJ\^Jhw?OJQJ\^Jhw?5OJQJ\^JhN*OJQJ^Jhw?OJQJ^Jh, hw?OJQJ^Jh(35OJQJ\^Jh(3OJQJ^Jh, h(3OJQJ^Jffffffe\VVV$If $IfgdR}kd7$$IflT\ ){8D  04 lafffe\ $Ifgd(3kd8$$IflT\ ){8D  04 lafffffggg{$ & F5$Ifa$gd]$Ifnkdc9$$Ifl{88  04 lap gg'gga$Ifkd :$$Ifl\ ){89  04 la'g(g)g{g|ggw  9r $If $Ifgd}L$Ifnkd:$$Ifl{88  04 lap gggga$Ifkd;$$Ifl\ ){8D  04 laggg  9r $Ifnkd?<$$Ifl{88   04 lap gggggg$If  9r $Ifnkd<$$Ifl{88   04 lap ggggghg\VV\$If  9r $Ifkd=$$Ifl\ ){8D  04 laggghhhhh,h-h.h/h0h;h$$Ifl\ ){8D  04 la,h-h.h/h0h;hg\VV\$If  9r $Ifkd)?$$Ifl\ ){8D  04 la;h $Ifgd{y> 8^`kdD$$Ifl\ ){8D  04 la$If  9r $If3j4jjj|s $Ifgd% $Ifgd{y>zkdE$$Ifl,99  t 0644 lap yt{y>sjjjjjjjjjjjjjjj!kNk~kkkŲʼn|tlh[Q@2@h}LOJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^JhN#5OJQJ\^JhN#hN#CJaJh-CJaJh-h-OJQJ^Jh-h-0JOJQJ^J3j4Gh-h->*B*OJQJU^Jph$h-h->*B*OJQJ^Jph-jh-h->*B*OJQJU^Jphh-OJQJ^Jjh-OJQJU^Jh-0JOJQJ^Jjjjjjj kkr`WWWW $$Ifa$ 8^`gd[e 8^`}kdH$$Ifl0 ,9UC+ t0644 layt{y>kk k71$IfkdH$$Ifl\ ){8D   (04 lap( k!k"kNkOkkr  9r $Ifgd}L  9r $If$IfnkdI$$Ifl{88   04 lap kkkga$IfkdoJ$$Ifl\ ){8D  04 lakkkkkk$Ifnkd-K$$Ifl{88   04 lap kkkkkkkkkkkklll$l2l4l5lGl\lllllllllllllllmmmmmm(m)m^m_mtmmmmmmmmmmmƻưh*so5OJQJ\^Jhr!5OJQJ\^Jhr!OJQJ^JhvVOJQJ\^JhN#OJQJ\^Jhr!OJQJ\^Jh (hN#5^JnH tH h}LOJQJ^JhN#OJQJ^JhN#5OJQJ\^J7kkkkkkgaaaX $Ifgd}L$IfkdK$$Ifl\ ){8D  04 lakkllllgSMMM$If $If^`kdL$$Ifl\ ){8D  04 lall#lga$IfkdRM$$Ifl\ ){8D  04 la#l$l2l3l4l5l$IfnkdN$$Ifl{88   04 lap 5l6lFlga$IfkdN$$Ifl\ ){8D  04 laFlGl\llll$IfnkdwO$$Ifl{88   04 lap llllllg^XXX$If $Ifgd> kd P$$Ifl\ ){8D  04 lallllllg^XXX$If $Ifgd> kdP$$Ifl\ ){8D  04 lallmmmmg^XXX$If $IfgdvVkdQ$$Ifl\ ){8D  04 lamm'mga$IfkdZR$$Ifl\ ){8D  04 la'm(m)m^m_mtm$IfnkdS$$Ifl{88   04 lap tmummga$IfkdS$$Ifl\ ){8D  04 lammmmmm$If $Ifgd> nkdT$$Ifl{88   04 lap mmmmmmmmmmmg^XXXXXXXX$If $Ifgd> kd(U$$Ifl\ ){8D  04 la mmmga$IfkdU$$Ifl\ ){8D  04 lammmnnoo $Ifgd*so$IfnkdV$$Ifl{88   04 lap mmnn'nHnnnnnoooooooooooop4p[plppppppqҷ~~~~vv~iX h (hN#CJ^JaJnH tH h65OJQJ\^JhN#CJaJhN#OJQJ^J!h_Uh*soB*OJQJ^Jphh*soh*so5OJQJ\^Jh*soh*soOJQJ\^Jh*soh*soOJQJ^Jh*soh*so5OJQJ^Jh*soOJQJ^Jh[e5OJQJ\^Jh[eOJQJ^JhN#5OJQJ\^JoooooogaXaa $Ifgd[e$IfkdMW$$Ifl\ ){8D  04 laoooooogaXaa $Ifgd[e$Ifkd X$$Ifl\ ){8D  04 laooppp p.p2pgXVMMMM $$Ifa$ 8^`kdX$$Ifl\ ){8D  04 la2p3p4p[p\p75&5 8^`kdY$$Ifl\ ){8DHh  (04 lap(\pkplp{ppwkdZ$$Ifl9R:  t 0644 lap $Ifppppppppppppppp $$Ifa$gkd][$$Ifl9R: t0644 lapppq#$Ifkd[$$Ifl\ ){8DHh  (04 lap( 8$If^`qqqqPqYqz$If  9r $If$Ifnkd]$$Ifl{88   04 lap qqXq[q\qqqqqqqqqqqrrrr$r%rsrtrrr/s0ssssssssttt%t)t*tȽ嚫؁o#hJhN#H*OJQJ^JmH sH h (hN#^JnH tH hN#0JOJQJ^J!jchN#OJQJU^JjhN#OJQJU^JhN#h6h6mH sH h6mH sH hN#CJaJhN#5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH 'YqZq[q\q]qqgaVPa$If  9r $If$Ifkd]$$Ifl\ ){8DHh 04 laqqqqqqgaVPa$If  9r $If$Ifkd^$$Ifl\ ){8DHh 04 laqqqqqqgaVPa$If  9r $If$IfkdU_$$Ifl\ ){8DHh 04 laqqqqqqgaVPa$If  9r $If$Ifkd!`$$Ifl\ ){8DHh 04 laqqrga$Ifkd`$$Ifl\ ){8DHh 04 larrrrrr  9r $If$Ifnkda$$Ifl{88   04 lap rrrrrrrrrrgZUUUUUUUgd6  ^`kdbb$$Ifl\ ){8DHh 04 la rrr r!r#r%r&rIrsrtrrrr$If ^`  & F 8gd+=n  & F gd+=n  ^`gd6 rrr/ss & F$Iftkd.c$$Ifl9R:  t 0644 lap sssss tt$Ifekd+e$$Ifl9R: t0644 lattt*t2,!  9r $If$Ifkde$$Ifl\ B*9:::T (04 lap(yt3p*t2t3t4t6t7t@tMtNtOtttutttttttttttu u unuuu4vYvZvvv˾˭˾˭˭˭˾ːrdS!jkhN#OJQJU^JjhN#OJQJU^J$h?ehHt5B*OJQJ^Jphh'{>H*OJQJ^JhN#H*OJQJ^J#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#OJQJ^Jh'{>H*OJQJ^JmH sH #hJh'{>H*OJQJ^JmH sH h'{>OJQJ^J *t5t6t7t@tOtPtttSH  9r $Ifkdf$$Ifl\ B*9:::T04 layt3p$If $Ifgd'{>ttutttttb\Q\\  9r $If$Ifkdg$$Ifl\ B*9:::T04 layt3pttttttb\Q\\  9r $If$Ifkd?h$$Ifl\ B*9:::T04 layt3pttttttb\Q\\  9r $If$Ifkdh$$Ifl\ B*9:::T04 layt3ptttttb\ZT$If 9r kdi$$Ifl\ B*9:::T04 layt3pttuuuuu u uu4vvvxkxx $IfgdHt $If$Ifwkdmj$$Ifl,99  t 0644 lap vvvvvvvvwwww w!w"whwiwjwwwwwwwwwwwww@xAxBxGxHxKxLxtxuxѯەфsb!jGqhN#OJQJU^J!jHphN#OJQJU^J!jnh'{>OJQJU^Jjh'{>OJQJU^Jh'{>0JOJQJ^J!jmh'{>OJQJU^J!jlhN#OJQJU^Jh'{>OJQJ^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J&vv!wwwlff] $Ifgd8b$Ifkdl$$Ifl4RF m,9U) t06    44 laf4wwxx~~$Ifzkdo$$Ifl0 ,9UC+ t0644 lauxvx}x~xxxxyyyyyy"y@yQyRyTysytyyyyyyyyyyzzzzzЭۏ~~q~`~``~UhN#H*OJQJ^J hJhN#OJQJ^JmH sH h (hN#^JnH tH hN#5OJQJ\^JhN#!hN#5B*OJQJ\^Jphhoo0J5OJQJ^J$jrhN#5OJQJU^JjhN#5OJQJU^JhN#5OJQJ^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!xxxy~~$Ifzkdr$$Ifl0 ,9UC+ t0644 layy y"y@yAyPyzzkic$If ^` 0^`0zkdss$$Ifl0 ,9UC+ t0644 laPyQyRy~ h$If^hwkdt$$Ifl9R:  t 0644 lap RySyTyZyayoysy$Ifgkdt$$Ifl9R: t0644 lasytyyy2,!  9r $If$IfkdFu$$Ifl\ B*9:::T (04 lap(yt3pyyyyyyyy\VK  9r $If$Ifkdav$$Ifl\ B*9:::T04 layt3p$Ifyyyyyyb\QKK$If  9r $If$Ifkdw$$Ifl\ B*9:::T04 layt3pyyyzb`Z$Ifkdw$$Ifl\ B*9:::T04 layt3pzzzzzx $If$Ifwkdx$$Ifl,99  t 0644 lap zzhzizqkk$Ifkd8y$$IflF n,9V) t06    44 lazWzXzYzfzgzjzkzzzzzzzzzzzzz{{V{W{X{d{f{{{{{{n[$j~hN#5OJQJU^Jhoo0J5OJQJ^J$j}hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jn|hN#OJQJU^J!jo{hN#OJQJU^JhN#0JOJQJ^JjhN#OJQJU^J!jyhN#OJQJU^JhN#OJQJ^Jizjz{{~~$Ifzkdz$$Ifl0 ,9VB+ t0644 la{ {{{~~$Ifzkd'}$$Ifl0 ,9VB+ t0644 la{{{{{{uo$If  & F gd+=nzkdE$$Ifl0 ,9VB+ t0644 la{{{{{/|0|2|M|P|s|t|u|v|w||||||||||||||||||кݠxgx\xQxgx\xgx\xgx\xhN#H*OJQJ^JhN#5OJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ^Jhfhf5OJQJ\^JhfhN#5OJQJ^Jh (hN#^JnH tH hXhN#OJQJ^J+hXhX0JH5B*OJQJ\^JphhXhXOJQJ^JhN#5OJQJ\^JhN#!hN#5B*OJQJ\^Jph{{0|{ h$If^hgdXwkd$$Ifl9R:  t 0644 lap 0|1|2|8|?|M|s|t| $$Ifa$gdf$Ifgkd$$Ifl9R: t0644 lat|u|v|w||5/$/  9r $If$Ifkd$$Ifl\ B*|8:::: (04 lap(|||||||_T  9r $Ifkd$$Ifl\ B*|8::::04 la$If||||||e_T_K $IfgdD  9r $If$Ifkdł$$Ifl\ B*|8::::04 la|||||}e_T__  9r $If$Ifkdk$$Ifl\ B*|8::::04 la|}} }} }$}%}D}G}H}T}U}Z}[}e}h}i}{}|}}}}}}}}}}}}}}}}&~s~t~~őzБpphkOJQJ^JhN#5OJQJ\^JhUOJQJ^JhkH*OJQJ^JhkOJQJ^Jh*5OJQJ^JhOJQJ^Jh+@OJQJ^JhN#5OJQJ^JhN#H*OJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ^Jh<)sOJQJ^J%}}} }%}E}e_Y__$If$Ifkd$$Ifl\ B*|8::::04 laE}F}G}H}[}f}e_Y_P $IfgdD$If$Ifkd$$Ifl\ B*|8::::04 laf}g}h}i}}}}e_YPG $IfgdD $IfgdKN$If$Ifkd]$$Ifl\ B*|8::::04 la}}}}}}e_Y_P $IfgdU$If$Ifkd$$Ifl\ B*|8::::04 la}}}}ec]$Ifkd$$Ifl\ B*|8::::04 la}}}}}t~xo $Ifgd}L $If$IfwkdO$$Ifl,99  t 0644 lap ~OPQ^_`aʀˀ̀̀ĶĥĂoUFoohfhf0JOJQJ^J3jhfhf>*B*OJQJU^Jph$hfhf>*B*OJQJ^Jph-jhfhf>*B*OJQJU^JphhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhkOJQJ^J#h}LOJQJ^JfHq )hkhkOJQJ^JfHq `̀F)JqkbYPGk $IfgdR $Ifgd3 $Ifgd; $IfgdHs$Ifkd$$IflF n,9V) t06    44 laDEFGtuvÁ'()*HIJKοάάοάάxοάgZFggZ'jhfhfOJQJU^JhfhfOJQJ^J!jhfhfOJQJU^J3jhfhf>*B*OJQJU^Jph3j'hfhf>*B*OJQJU^Jph$hfhf>*B*OJQJ^Jphhfhf0JOJQJ^J-jhfhf>*B*OJQJU^Jph3jZhfhf>*B*OJQJU^JphKGHIJwxyׄ؄ل:;<=Ӽ퓼y_K'jhK>*B*OJQJU^Jph3jhfhf>*B*OJQJU^Jph3jhfhf>*B*OJQJU^Jph3jIhfhf>*B*OJQJU^Jphhfhf0JOJQJ^J-jhfhf>*B*OJQJU^Jph3jHhfhf>*B*OJQJU^Jph$hfhf>*B*OJQJ^JphJI<؇هNzkd$$Ifl0 ,9VB+ t0644 la $Ifgdf $Ifgdr $Ifgd yt $Ifgd|f $Ifgd $IfgdX=΅υЅևׇŹufUH4UfU'jhfhfOJQJU^JhfhfOJQJ^J!jhfhfOJQJU^Jhfhf0JOJQJ^J3jEhfhf>*B*OJQJU^Jph$hfhf>*B*OJQJ^Jph-jhfhf>*B*OJQJU^JphhK0JOJQJ^J'jhK>*B*OJQJU^Jph-jhK>*B*OJQJU^JphhK>*B*OJQJ^Jphׇ؇هڇ%&',-01YZ[bcvw)*,.۾۾鐅reR$jzhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jh;hN#OJQJ^J!jNhN#OJQJU^JhN#0JOJQJ^J!jOhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh;h*OJQJ^Jهvwx-~zkd$$Ifl0 ,9VB+ t0644 la$If-./1[\kzzmke$If  & F gd+=n 0^`0zkd%$$Ifl0 ,9VB+ t0644 la.1[lmo‰É&'E]qrtuŠӵӋӀrarUrhN#0JOJQJ^J!jԟhN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^J hJhN#OJQJ^JmH sH hJhHmH sH hZ4OJQJ^JmH sH  hJhHOJQJ^JmH sH h (hN#^JnH tH hN#OJQJ^JhN#5OJQJ\^JhN#!hN#5B*OJQJ\^Jphklm~ h$If^hwkdŚ$$Ifl9R:  t 0644 lap mnou|$Ifgkdn$$Ifl9R: t0644 la‰5/!  9r $IfgdH$Ifkd$$Ifl\ B*9:::T (04 lap(‰Éĉ&'(CTkd $$Ifl\ B*9:::T04 la$If  9r $IfCDE\ec]$Ifkd$$Ifl\ B*9:::T04 la\]qrsx $If$Ifwkdu$$Ifl,99  t 0644 lap stŠqkb $Ifgdf$Ifkd$$IflF p,9X) t06    44 laŠÊhijopstˋ̋ջ蟕vjYjI>hN#5OJQJ^JjhN#5OJQJU^J!j!hN#OJQJU^JhN#0JOJQJ^J!j"hN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhZ4hN#OJQJ^JhZ4hN70JOJQJ^J3jhZ4hN7>*B*OJQJU^Jph$hZ4hN7>*B*OJQJ^Jph-jhZ4hN7>*B*OJQJU^Jph~~$Ifzkd$$Ifl0 ,9X@+ t0644 laˋF~~$Ifzkdڣ$$Ifl0 ,9X@+ t0644 la  BCEGJpqӌԌՌ-9=HLfgōӍԍŲݨ~q```~q```` hJhN#OJQJ^JmH sH h (hN#^JnH tH hN#hN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^JphhN#OJQJ^J$jMhN#5OJQJU^JhN#5OJQJ^Jhoo0J5OJQJ^JjhN#5OJQJU^J$jzhN#5OJQJU^J%FGHJpqzzmk^kX$If  & F gd+=n  & F 8gd+=n 0^`0zkd$$Ifl0 ,9X@+ t0644 la~ h$If^hwkd$$Ifl9R:  t 0644 lap όӌ$IfgkdA$$Ifl9R: t0644 laӌԌՌ 5/$/  9r $If$Ifkd˧$$Ifl\ B*|8:::: (04 lap( +,-9:;_T  9r $IfkdҨ$$Ifl\ B*|8::::04 la$If;<=HIJe_T__  9r $If$Ifkdx$$Ifl\ B*|8::::04 laJKLfgmtecVcPPPP$If  & F gd+=nkd$$Ifl\ B*|8::::04 laōƍ5/$/  9r $If$IfkdĪ$$Ifl\ B*|8:::: (04 lap(ƍǍȍӍԍՍ֍_T  9r $Ifkd˫$$Ifl\ B*|8::::04 la$If֍׍e_T__  9r $If$Ifkdq$$Ifl\ B*|8::::04 lae_T__  9r $If$Ifkd$$Ifl\ B*|8::::04 laec]$Ifkd$$Ifl\ B*|8::::04 la&'(x $If$Ifwkdc$$Ifl,99  t 0644 lap &')*fghuvyzŎƎǎ͎̎Ўю()efgstvгггvcVhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jBhN#OJQJU^J!jChN#OJQJU^JhN#0JOJQJ^J!j¯hN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^J ()wxqkk$Ifkd $$IflF p,9X) t06    44 laxy~~$Ifzkd$$Ifl0 ,9X@+ t0644 la(u~~$Ifzkd$$Ifl0 ,9X@+ t0644 lauvwyŏӏzxkxax[[[$If  & F   & F 8gd+=n 0^`0zkdn$$Ifl0 ,9X@+ t0644 la vy׏؏ُڏۏ-/پ~tcXM@M@hk{hk{OJQJ^Jhk{hk{OJQJhk{hk{nH tH  hk{hk{OJQJ^JmH sH hk{OJQJ^Jhk{5OJQJ\^Jhk{H*OJQJ^Jh[`OJQJ^Jh[`h[`OJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ^Jh (hN#^JnH tH hN#hN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^Jphӏ׏؏ُ/)$Ifkd$$Ifl\ B*|8:::: (04 lap($IfُڏۏKI@ $Ifgdkd$$Ifl\ B*|8::::04 la $Ifgdk{$If  9r $If-/||o|ZA$ & F7 2$If`2a$gd1$ & F6 $Ifa$gd1 & F6$Ifgd1 $Ifgdzkd$$Ifl,99  t 0644 lap ytL012?kdj$$IflF m,9U) t06    44 layt $Ifgd $Ifgd$ & F7 2$If`2a$gd1LN./023opq~ΖϖЖՖ֖ٖږ  1յȫo^!jhk{OJQJU^J!jhk{OJQJU^Jhk{0JOJQJ^J!j&hk{OJQJU^Jjhk{OJQJU^Jhk{OJQJ^J%hk{hk{0JB*OJQJ^Jphhk{hk{OJQJ^J!jhk{hk{OJQJU^Jhk{hk{OJQJhk{hk{5OJQJ^J x}kd$$Ifl0 ,9UC+ t0644 layt $Ifgd !1xx $Ifgd}kde$$Ifl0 ,9UC+ t0644 layt12nop|~ 1@AE]qs𨤗o]oSoHhN#H*OJQJ^JhgxOJQJ^J#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^Jh (hN#^JnH tH hN#5OJQJ\^JhN#hk{OJQJ^J$j޼hk{5OJQJU^Jhoo0J5OJQJ^J$j hk{5OJQJU^Jhk{5OJQJ^Jjhk{5OJQJU^Juoooo$If  & F }kd$$Ifl0 ,9UC+ t0644 layt  2,!  9r $If$Ifkd/$$Ifl\ B* 9::: (04 lap(yt3p1ABC\VK  9r $If$IfkdJ$$Ifl\ B* 9:::04 layt3p$IfCDE\b`Z$Ifkd$$Ifl\ B* 9:::04 layt3p\]qsx $If$Ifwkd$$Ifl,99  t 0644 lap 0qkk$Ifkdg$$IflF m,9U) t06    44 la !./01z{|"#HIstvqfSq$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^Jhf0JOJQJ^J!jhfOJQJU^JhfOJQJ^JhN#0JOJQJ^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J 67~~$Ifzkd$$Ifl0 ,9UC+ t0644 la78Hw~~$Ifzkd[$$Ifl0 ,9UC+ t0644 lawxyzxzrrrr$If 0^`0zkd$$Ifl0 ,9UC+ t0644 lavxyԚ@ACbcyz*1JԠtbTh}LOJQJ^JmH sH #hJhN#H*OJQJ^JmH sH hN#H*OJQJ^JhN#OJQJ^JnH tH $h?ehO5B*OJQJ^JphhN#5OJQJ\^JhN#CJaJhN#OJQJ^JmH sH  hJhN#OJQJ^JmH sH h (hN#^JnH tH hN#!hN#5B*OJQJ\^JphhN#OJQJ^J 5/$  9r $If$IfkdF$$Ifl\ B*|8:::: (04 lap(Ԛ_][RE  & F 8gd+=n & F kdM$$Ifl\ B*|8::::04 la$IfԚ՚Av & F$Ifwkd$$Ifl9R:  t 0644 lap $IfABCIP^b$Ifgkd$$Ifl9R: t0644 labcy5/$Ifkd&$$Ifl\ B*|8:::: (04 lap(yz~  9r $If$Ifpkd-$$Ifl|88  04 lap Je_T_F  9r $Ifgd}L  9r $If$Ifkd$$Ifl\ B*|8::::04 laJKLste_T__  9r $If$Ifkd$$Ifl\ B*|8::::04 laJLsܜ,-hij|!"^_`mnqrochN#0JOJQJ^J!jwhN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^Jh.OJQJ^JhN#5OJQJ\^JhN#H*OJQJ^JnH tH hN#OJQJ^JnH tH hN#B*OJQJ^Jphh}LOJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ^J#e_T_K $Ifgd}L  9r $If$Ifkd&$$Ifl\ B*|8::::04 lae_$Ifkd$$Ifl\ B*|8::::04 la~  9r $If$Ifpkdr$$Ifl|88  04 lap ,e_$Ifkd$$Ifl\ B*|8::::04 la,-hij~  9r $If$Ifpkd$$Ifl|88  04 lap ec]$Ifkdr$$Ifl\ B*|8::::04 laڝ xx $If$Ifwkd$$Ifl;99  t 0644 lap  !opqkk$Ifkd$$IflF p;9W) t06    44 lapq~~$IfzkdX$$Ifl0 ;9WP+ t0644 laĞŞȞɞ !]^_km֟ɡʹʩ~kZREhN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^Jph$j#hN#5OJQJU^Jhoo0J5OJQJ^J$jPhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^J ~~$Ifzkd$$Ifl0 ;9WP+ t0644 la֟ןuo$If  & F! 8gd+=nzkd$$Ifl0 ;9WP+ t0644 laiKȣ~~~~~ & F$Ifwkdn$$Ifl9R:  t 0644 lap ɡСȣʣVWuv56Z[\]ɥʥ쬛ߑ쬛w߬i[hdOJQJ^JmH sH h.OJQJ^JmH sH hhN#OJQJ^JhhOJQJ^JhOJQJ^J hJhN#OJQJ^JmH sH hN#6OJQJ]^JhN#H*OJQJ^JhN#OJQJ^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#OJQJ^Jh}LOJQJ^JȣɣʣУף$Ifgkd$$Ifl9R: t0644 la5/$Ifkd$$Ifl\ B*|8:::: (04 lap(Wuv~  9r $If$Ifpkd$$Ifl|88  04 lap 56[e_T__  9r $If$IfkdU$$Ifl\ B*|8::::04 la[\]e_T__  9r $If$Ifkd$$Ifl\ B*|8::::04 laʥ˥̥ͥΥϥe_QQQQ__  9r $Ifgdf$Ifkd$$Ifl\ B*|8::::04 laʥ̥ͥѥ678jkΦɸ׮נ~׸tcQcDt׈hG5OJQJ\^J#hJhGH*OJQJ^JmH sH  hJhGOJQJ^JmH sH hGOJQJ^Jh.OJQJ^JhN#5OJQJ\^Jh3ph3pmH sH hN#OJQJ^JnH tH hOJQJ^J hJhN#OJQJ^JmH sH h.OJQJ^JmH sH hN#OJQJ^J hJhfOJQJ^JmH sH hfOJQJ^JmH sH ϥХѥe_T____  9r $If$IfkdG$$Ifl\ B*|8::::04 la67e_V $Ifgd3p$Ifkd$$Ifl\ B*|8::::04 la78k~  9r $If$Ifpkd$$Ifl|88  04 lap e_Q__  9r $IfgdG$Ifkd@$$Ifl\ B*|8::::04 laͦec]$Ifkd$$Ifl\ B*|8::::04 laͦΦ)]xxx $If$Ifwkd$$Ifl9R:  t 0644 lap ]^_ڨۨܨ !"߶ǪߓfW@-jhfh>*B*OJQJU^Jphhfh{y>0JOJQJ^J3jhfh{y>>*B*OJQJU^Jph$hfh{y>>*B*OJQJ^Jph-jhfh{y>>*B*OJQJU^JphhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhGOJQJ^JhN#OJQJ^JhGH*OJQJ^JhN#H*OJQJ^J]^!qkbY $Ifgdf $Ifgd{y>$Ifkd5$$IflF9|P* t06    44 la"OPQ,-/12NӼuhUD<hN#CJaJ!hN#5B*OJQJ\^Jph$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^Jhfh0JOJQJ^J-jhfh>*B*OJQJU^Jph3jhfh>*B*OJQJU^Jph$hfh>*B*OJQJ^Jph0~~$Ifzkdf$$Ifl09|+ t0644 la012NO^zmke$If  & F! 8gd+=n 0^`0zkd$$Ifl09|+ t0644 la^_`~ & F$Ifwkd$$$Ifl9R:  t 0644 lap N_`bªJKҫӫԫګ:<[jmopϿ鿱Ͽ镍ϿϿϿtϿhN#H*OJQJ^JhN#5H*OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^JphhN#OJQJ\^Jh (hN#5^JnH tH h (hN#5\^JnH tH hN#6OJQJ]^Jh (hN#^JnH tH hN#OJQJ^JhN#5OJQJ\^J-`abho}$Ifgkd$$Ifl9R: t0644 laª5/&/ $$Ifa$$IfkdW$$Ifl\ B*|8:::: (04 lap(ª+JK\VVV$Ifkd^$$Ifl\ B*|8::::04 la $$Ifa$Ыѫҫe_Y__$If$Ifkd$$Ifl\ B*|8::::04 laҫӫԫի֫׫ثګeccccccVc  & F! 8gd+=nkd$$Ifl\ B*|8::::04 la :x & F$IfwkdP$$Ifl9R:  t 0644 lap $If:;<BIW[$Ifgkd$$Ifl9R: t0644 la[\n5/$Ifkd$$Ifl\ B*|8:::: (04 lap(nop $$Ifa$$Ifpkd$$Ifl|88  04 lap e_V__ $$Ifa$$Ifkd7$$Ifl\ B*|8::::04 lae_V__ $$Ifa$$Ifkd$$Ifl\ B*|8::::04 lae_V__ $$Ifa$$Ifkd$$Ifl\ B*|8::::04 la׬ج$&01>?@ADVqѭխubUUhG5OJQJ\^J$h (hGhG5\^JnH tH !h (hG5H*\^JnH tH h (h+5\^JnH tH h (hf5\^JnH tH h (hG5\^JnH tH hGOJQJ^JhN#5OJQJ\^Jh (hN#5\^JnH tH hN#6OJQJ]^JhN#OJQJ^JhN#H*OJQJ^J!e_V__ $$Ifa$$Ifkd)$$Ifl\ B*|8::::04 la֬e_$Ifkd$$Ifl\ B*|8::::04 la֬׬ج $$Ifa$$Ifpkdu$$Ifl|88  04 lap e_V__ $$Ifa$$Ifkd"$$Ifl\ B*|8::::04 lae_V__ $$Ifa$$Ifkd$$Ifl\ B*|8::::04 laABCe_SM_$If $$Ifa$gdf$Ifkdn$$Ifl\ B*|8::::04 laCDUe_$Ifkd$$Ifl\ B*|8::::04 laUVWnop$Ifpkd$$Ifl|88  04 lap pqe_$Ifkdg$$Ifl\ B*|8::::04 la $$Ifa$$Ifpkd $$Ifl|88  04 lap ѭҭӭe_V__ $$Ifa$$Ifkd$$Ifl\ B*|8::::04 laӭԭխe_V__ $$Ifa$$Ifkd`$$Ifl\ B*|8::::04 lae_V__ $$Ifa$$Ifkd$$Ifl\ B*|8::::04 la 56NbdefgLM^_ϷugWL9W$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhGCJOJQJ^JaJh}LCJOJQJ^JhGCJOJQJ^JhN#CJOJQJ^JaJ!hGhG5H*OJQJ\^JhGH*OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^JhN#OJQJ^JhG5OJQJ\^JhGOJQJ^Jh (hG5\^JnH tH  e_$Ifkd$$Ifl\ B*|8::::04 la   234$IfpkdR$$Ifl|88  04 lap 456Mec]$Ifkd$$Ifl\ B*|8::::04 laMNbdegMyob $If^gdd $If^ $Ifgdd$Ifwkd$$Ifl;99  t 0644 lap MN^ٯqkk$IfkdN$$IflF r;9Y) t06    44 laկ֯دگ;=\]^_`!"#$%BCDEFst⺲}}ll hN#5OJQJ\^JnH tH hN#OJQJ^JnH tH hN#6OJQJ]^Jh (hN#^JnH tH hN#5OJQJ\^JhN#CJaJhN#OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jhoo0J5OJQJ^J*ٯگwuo$If  & F! 8gd+=nzkd$$Ifl0 ;9YN+ t0644 la;~ & F$Ifwkd"$$Ifl9R:  t 0644 lap ;<=CJX\$Ifgkd$$Ifl9R: t0644 la\]^_`5/&/ $$Ifa$$IfkdU$$Ifl\ B*|8:::: (04 lap(`\VPVP$If$Ifkd\$$Ifl\ B*|8::::04 la $$Ifa$e____$Ifkd$$Ifl\ B*|8::::04 la!e____$Ifkd$$Ifl\ B*|8::::04 la!"#$%Be____$IfkdN$$Ifl\ B*|8::::04 laBCDEFse____$Ifkd$$Ifl\ B*|8::::04 lastuec]$Ifkd$$Ifl\ B*|8::::04 latu@ABGHKLtuv}~¥¥¥shUs$jx hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!j hN#OJQJU^J!j hN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#CJOJQJ^JaJhN#H*OJQJ^JhN#5OJQJ\^JhN#OJQJ^Jx $If^$Ifwkd@$$Ifl;99  t 0644 lap qkb $Ifgd6$Ifkd$$IflF p;9X) t06    44 la~~$Ifzkd$$Ifl0 ;9XO+ t0644 la~~$Ifzkd $$Ifl0 ;9XO+ t0644 la"HIh;BDEFG⺩wjZMZ?wwh65H*\^JnH tH h}L5\^JnH tH h (h5\^JnH tH h.5\^JnH tH h (hN#5\^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^JphhN#OJQJ^J$jK hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^Jhoo0J5OJQJ^J "HIOVdhzzmkeeee$If  & F! 8gd+=n 0^`0zkd $$Ifl0 ;9XO+ t0644 la hi5/$Ifkd $$Ifl\ B*|8:::: (04 lap(F}t $Ifgd6 $$Ifa$ $$Ifa$pkd $$Ifl|88  04 lap FGSԴմe\\SFF@$If -$If^-gd ;= $$Ifa$ $$Ifa$kdJ$$Ifl\ B*|8::::04 laӴԴմִ.01=Yxz{Ƶɵ45M{} }ȸȣvkգգգգah6OJQJ^Jh.OJQJ\^Jh (hN#5^JnH tH #h (hN#5CJ^JaJnH tH h.5\^JnH tH hN#OJQJ^JhN#5OJQJ^Jh (hN#5\^JnH tH hN#5OJQJ\^JhN#OJQJ\^Jh ;=h ;=OJQJ^J#h ;=h ;=OJQJ^JmHnHu$մִ./0e\\SS $$Ifa$ $$Ifa$kd$$Ifl\ B*|8::::04 la01=xyze\\SS $$Ifa$ $$Ifa$kd$$Ifl\ B*|8::::04 laz{e\\SS $$Ifa$ $$Ifa$kd<$$Ifl\ B*|8::::04 laŵƵǵȵe\\SS $$Ifa$ $$Ifa$kd$$Ifl\ B*|8::::04 laȵɵe_$Ifkd$$Ifl\ B*|8::::04 la45{}t $$Ifa$$If$If$Ifpkd.$$Ifl|88  04 lap {|}e_Y_P_ $$Ifa$$If$Ifkd$$Ifl\ B*|8::::04 la ()}e_Y_P_ $$Ifa$$If$Ifkd$$Ifl\ B*|8::::04 la}~e_YPG $Ifgdd|Y $$Ifa$$If$Ifkd'$$Ifl\ B*|8::::04 laηϷзѷ!opɿ{ncUGUh}LCJOJQJ^JaJhCJOJQJ^JaJhH*OJQJ^JhN#5OJQJ\^Jh4XOJQJ\^J#h (h4X5CJ^JaJnH tH h4XOJQJ^Jh ]OJQJ\^J#h (h ]5CJ^JaJnH tH h ]OJQJ^JhN#OJQJ^JhN#OJQJ\^JhN#5H*OJQJ\^JhfOJQJ^Jhd|YOJQJ^Jͷe_YPG $Ifgdd|Y $$Ifa$$If$Ifkd$$Ifl\ B*|8::::04 laͷηϷзѷe_YPG $Ifgdd|Y $$Ifa$$If$Ifkds$$Ifl\ B*|8::::04 lae_$Ifkd$$Ifl\ B*|8::::04 laozm $If^gd}L $Ifgd$Ifukd$$Ifl;99  t 044 lap op2smd[RI@ $Ifgd ] $Ifgdd|Y $Ifgd $Ifgdi^ $Ifgd6$Ifkde$$IflF s;9[) t0    44 lapq0123`ab޹缲~kQ~B~k~khfhf0JOJQJ^J3jhfhf>*B*OJQJU^Jph$hfhf>*B*OJQJ^Jph-jhfhf>*B*OJQJU^Jphhf0JOJQJ^J!jhfOJQJU^JhfOJQJ^JjhfOJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J޹߹οίzlbQlE9Elbhb 0JOJQJ^Jh ]0JOJQJ^J!jh ]OJQJU^Jh ]OJQJ^Jjh ]OJQJU^Jhd|Y0JOJQJ^J!j^hd|YOJQJU^Jhd|YOJQJ^Jjhd|YOJQJU^Jh@)>*B*OJQJ^Jphhfhf0JOJQJ^J-jhfhf>*B*OJQJU^Jph3jhfhf>*B*OJQJU^JphCDExy{|ռټ$%(NT[\_}rg\}Oh%& 5OJQJ\^JhkOJQJ\^Jh0kOJQJ\^Jh.OJQJ\^Jhk5OJQJ\^JhN#OJQJ\^Jh (hN#^JnH tH !hN#5B*OJQJ\^JphhN#5OJQJ\^JhN#OJQJ^Jh4X0JOJQJ^J!j$h4XOJQJU^Jh4XOJQJ^Jjh4XOJQJU^Jz{|}ssmmmm$If 0^`0ykd$$Ifl0 ;9[L+ t044 la $Ifgd4X 5////$Ifkd> $$Ifl\ B*|8:::: (04 lap(ռe____$IfkdE!$$Ifl\ B*|8::::04 laռּ׼ؼټe____$Ifkd!$$Ifl\ B*|8::::04 lae____$Ifkd"$$Ifl\ B*|8::::04 la$e____$Ifkd7#$$Ifl\ B*|8::::04 la$%&'([e___V $Ifgd0k$Ifkd#$$Ifl\ B*|8::::04 la[\]^_xe___V $Ifgd0k$Ifkd$$$Ifl\ B*|8::::04 la_xy{ֽڽٿڿ,KLNOyz} K̿ݵݿ݉ݿ݉ݿtgY݉݉hN#B*OJQJ^JphhN#6OJQJ]^JhN#OJQJ]^JhG*OJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ^JnH tH h (hN#^JnH tH hW&OJQJ^JhN#5OJQJ\^Jh[ehN#^JhN#CJaJhN#OJQJ^Jh%& 5OJQJ\^Jh%& OJQJ\^J xy{ecWJD$If  & F" 8gd[e  & F! gd+=nkd)%$$Ifl\ B*|8::::04 la]1~~~~ & F$Ifwkd%$$Ifl9R:  t 0644 lap ǿտٿ$Ifgkdx&$$Ifl9R: t0644 laٿڿ5/$Ifkd'$$Ifl\ B*|8:::: (04 lap($Ifpkd ($$Ifl|88  04 lap +$Ifpkd($$Ifl|88  04 lap +,KLMN~  9r $If$Ifpkdc)$$Ifl|88  04 lap NOyz{|e_T__  9r $If$Ifkd*$$Ifl\ B*|8::::04 la|}e_$Ifkd*$$Ifl\ B*|8::::04 la$Ifpkd\+$$Ifl|88  04 lap  Ke_T__  9r $If$Ifkd ,$$Ifl\ B*|8::::04 lae_Q__  9r $Ifgd[e$Ifkd,$$Ifl\ B*|8::::04 la'(,679:;=Yp%}odoXN@}hN#OJQJ^JnH tH h tOJQJ^Jh th t5mH sH h}L5OJQJ^Jh th t5OJQJ^JhN#5OJQJ\^JhG;OJQJ^J hJh[eOJQJ^JmH sH h[eOJQJ^JmH sH h3pOJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^J hJh%OJQJ^JmH sH #hJhN#OJQJ]^JmH sH ()*e_Q__  9r $Ifgd[e$IfkdU-$$Ifl\ B*|8::::04 la*+,789:;<e_QQQQ__  9r $Ifgd[e$Ifkd-$$Ifl\ B*|8::::04 la<=Ye_$Ifkd.$$Ifl\ B*|8::::04 laYZp{  9r $Ifgd[e$IfpkdG/$$Ifl|88  04 lap e\ $Ifgd}Lkd/$$Ifl\ B*|8::::04 la $Ifgd tskd0$$Ifl|88  04 lap yt tMG$IfkdM1$$Ifl\ B*|8::::04 lap(yt t$%(`kd2$$Ifl|8804 la$Ifpkd$2$$Ifl|88  04 lap %;<FGHI}www$If $d$Ifa$pkd_3$$Ifl|88  04 lap $If%;o  KLMZ[^_ʽʳ|k|_||N|_||!j:hN#OJQJU^JhN#0JOJQJ^J!j#9hN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^JhN#5OJQJ\^J hJhW&OJQJ^JmH sH hW&OJQJ^Jh}L5OJQJ\^JhW&5OJQJ\^JhW&h (hW&^JnH tH hN#OJQJ^JhN#OJQJ^JnH tH IJjklme\VVV$If d$Ifkd 4$$Ifl\ B*|8::::04 lamnou|ecZZZZ $IfgdVkd4$$Ifl\ B*|8::::04 la2) $IfgdVkdX5$$Ifl\ B*|8:::: (04 lap(ytVu  9r $IfgdV $IfgdVskde6$$Ifl|88  04 lap ytVb``Z$Ifkd7$$Ifl\ B*|8::::04 laytV   x $If$Ifwkd7$$Ifl9R:  t 0644 lap  \]qkk$Ifkdm8$$IflF9|P* t06    44 la]^~~$Ifzkd:$$Ifl09|+ t0644 la JKLXZʺ|kZI8!h%5B*OJQJ\^Jph!h3p5B*OJQJ\^Jph!hd5B*OJQJ\^Jph!hN#5B*OJQJ\^Jph$j=hN#5OJQJU^Jhoo0J5OJQJ^J$j<hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!j;hN#OJQJU^J ~~$Ifzkd\<$$Ifl09|+ t0644 lazzzzzzzzzzz 0^`0zkdz>$$Ifl09|+ t0644 la $If  & F" 8gd+=nFGRScdelmxy  ƶƞƶƔƔƔ~ƶƞtdjhHOJQJU^JhHOJQJ^JhN#H*OJQJ^JhN#OJQJ]^Jh KOJQJ^JhN#6OJQJ]^JhN#OJQJ^JjhN#OJQJU^JhN#OJQJ^JhN#OJQJ^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJ&5/$Ifkd?$$Ifl\ B*|8:::: (04 lap(Gztt$If d$IfgdH d$Ifpkd!@$$Ifl|88  04 lap  Z[\e_Q__  9r $IfgdH$Ifkd@$$Ifl\ B*|8::::04 la'()34?CHIJYZ\]t̡o[I8 hJh OJQJ^JmH sH #hJhHH*OJQJ^JmH sH &hJhH6OJQJ]^JmH sH  hJhHOJQJ^JmH sH h OJQJ^JhN#5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH hHOJQJ]^JmH sH hHOJQJ]^JhHOJQJ^JmH sH hHOJQJ^JjhHOJQJU^JhHOJQJ^J\]te_T__  9r $If$IfkdtA$$Ifl\ B*|8::::04 lae_$IfkdB$$Ifl\ B*|8::::04 laEFGtwxy1EKννΛ΅ννzljhN#OJQJU^JhN#H*OJQJ^JhN#OJQJ]^JhN#OJQJ^JjhN#OJQJU^J#hJhN#H*OJQJ^JmH sH  hJhN#OJQJ^JmH sH hN#OJQJ^JhN#5OJQJ\^JhN#OJQJ^JnH tH h 5OJQJ\^J&~  9r $If$IfpkdB$$Ifl|88  04 lap Ee_$IfkdmC$$Ifl\ B*|8::::04 laEFGxy~xx$If  9r $If$IfpkdD$$Ifl|88  04 lap e\QKK$If  9r $If d$IfkdD$$Ifl\ B*|8::::04 lae_$IfkdfE$$Ifl\ B*|8::::04 la~  9r $If$Ifpkd F$$Ifl|88  04 lap 0ec]$IfkdF$$Ifl\ B*|8::::04 la01EGIKmxxx $If$Ifwkd_G$$Ifl9R:  t 0644 lap $%&qkkk$IfkdH$$IflF9|P* t06    44 la"#%&'(stuz{~!#MNPRʯʞʎpcP$jjMhN#5OJQJU^Jhoo0J5OJQJ^J$jLhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!j>KhN#OJQJU^J!j?JhN#OJQJU^Jhh OJQJ^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jHhN#OJQJU^J&'~~$IfzkdI$$Ifl09|+ t0644 laQ~~$IfzkdK$$Ifl09|+ t0644 laQRSrszmke$If  & F" 8gd+=n 0^`0zkdN$$Ifl09|+ t0644 laRSr(+,BCDFpq}DEsٴ٥ٚϏϴمwϴhٴϴhN#5OJQJ^JnH tH hN#OJQJ^JmH sH h.OJQJ^JhN#H*OJQJ^JhN#OJQJ]^JhN#OJQJ]^JmH sH hN#OJQJ^JnH tH h (hN#^JnH tH hN#OJQJ^JhN#5OJQJ\^JhN#CJaJ!hN#5B*OJQJ\^Jph(~ & F$IfwkdN$$Ifl9R:  t 0644 lap $Ifgkd^O$$Ifl9R: t0644 la5/$IfkdO$$Ifl\ B*|8:::: (04 lap($IfpkdP$$Ifl|88  04 lap ()*+e_YYY$If$IfkdQ$$Ifl\ B*|8::::04 la+,BCDEe____$IfkdBR$$Ifl\ B*|8::::04 laEFpe_$IfkdR$$Ifl\ B*|8::::04 lapq$IfpkdS$$Ifl|88  04 lap e____$Ifkd;T$$Ifl\ B*|8::::04 lae__Y_$If$IfkdT$$Ifl\ B*|8::::04 lae_$IfkdU$$Ifl\ B*|8::::04 la$Ifpkd-V$$Ifl|88  04 lap De_$IfkdV$$Ifl\ B*|8::::04 laDEopqr$IfpkdW$$Ifl|88  04 lap rse_$Ifkd-X$$Ifl\ B*|8::::04 la$IfpkdX$$Ifl|88  04 lap 01mno|}  zljhOJQJU^J!jQ_hN#OJQJU^J!jR^hN#OJQJU^JhN#0JOJQJ^J!j\hN#OJQJU^JjhN#OJQJU^JhuSOJQJ^JhN#5OJQJ\^JhN#6OJQJ]^JhN#H*OJQJ^JhN#OJQJ^J*e____$IfkdY$$Ifl\ B*|8::::04 lae\VVV$If $IfgduSkd&Z$$Ifl\ B*|8::::04 laec]$IfkdZ$$Ifl\ B*|8::::04 la/x $If$Ifwkdr[$$Ifl9R:  t 0644 lap /0~qkk$Ifkd\$$IflF9|P* t06    44 la~u~ $Ifgd$Ifzkd]$$Ifl09|+ t0644 lacde!#$%56Fp_NF9hN#5OJQJ\^JhN#CJaJ!hbC5B*OJQJ\^Jph!hN#5B*OJQJ\^Jph$jbbhN#5OJQJU^Jhoo0J5OJQJ^J$jahN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^Jh0JOJQJ^JjhOJQJU^J'j `h<hOJQJU^JhOJQJ^J"~~$Ifzkd`$$Ifl09|+ t0644 la"#$%*56Evic$If  & F# 8gd+=n  & F" gd+=nzkd c$$Ifl09|+ t0644 laEFr & F$Iftkdc$$Ifl9R:  t 0644 lap Frt%&;TU23\  ,./01345679:;<>?@δΌh3ph3pmH sH hN#OJQJ]^J#h (hN#CJ]^JaJnH tH h (hN#5]^JnH tH hcOJQJ^Jh (hN#5^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#OJQJ^J7rstz$IfgkdQd$$Ifl^9R: t0644 la5/$Ifkdd$$Ifl\ A*{89::: (04 lap($If$Ifpkde$$Ifl{88   04 lap e____$Ifkdf$$Ifl\ A*{89:::04 la #$%e____$IfkdPg$$Ifl\ A*{89:::04 la%&;RSTe_YYY$If$Ifkdh$$Ifl\ A*{89:::04 laTUeYSSSS$If  n$Ifkdh$$Ifl\ A*{89:::04 lae__YY$If$Ifkdli$$Ifl\ A*{89:::04 la012eWQQQ$If .$If^.`kd j$$Ifl\ A*{89:::04 la23I\e__YYY$If$Ifkdj$$Ifl\ A*{89:::04 lae____$Ifkdk$$Ifl\ A*{89:::04 la   e____$Ifkde_Y__$If$Ifkdo$$Ifl\ A*{89:::04 la>?@ABCe_Y__$If$Ifkdo$$Ifl\ A*{89:::04 la@ACDEGHJKLMOqrs}-/0Hiklڦtgh)huSOJQJ^Jh (huS5]^JnH tH huS5OJQJ\^JhuSOJQJ^JhuSOJQJ]^Jh (huS5^JnH tH h (hN#5]^JnH tH hbCOJQJ]^JhN#OJQJ]^JhN#5OJQJ\^JhN#OJQJ^Jh (hN#5^JnH tH $CDEFGHIJe___Y__$If$Ifkdp$$Ifl\ A*{89:::04 laJKLMNOe_Y__$If$Ifkd6q$$Ifl\ A*{89:::04 laOPre_$Ifkdq$$Ifl\ A*{89:::04 lars$If$Ifpkdr$$Ifl{88  04 lap -./e__YY$If$IfkdKs$$Ifl\ A*{89:::04 la/0Hijke_VPP$If $Ifgd3$Ifkds$$Ifl\ A*{89:::04 lakle_VPP$If $Ifgd3$Ifkdt$$Ifl\ A*{89:::04 lae_V__ $Ifgd3$Ifkdgu$$Ifl\ A*{89:::04 la3=>xz{|FGHMNQRz槚{o^o!jh|hN#OJQJU^JhN#0JOJQJ^J!jzhN#OJQJU^JjhN#OJQJU^JhN#5OJQJ\^JhN#OJQJ^Jh (huS5\^JnH tH huSOJQJ^Jh)huSOJQJ^Jh (huS5^JnH tH huS5OJQJ\^Jh (huS^JnH tH !e\VVV$If $Ifgd)kdv$$Ifl\ A*{89:::04 lae_$Ifkdv$$Ifl\ A*{89:::04 la34={{$If$If^`pkdw$$Ifl{88  04 lap =>PxyzeWWQQ$If$If^`kd0x$$Ifl\ A*{89:::04 laz{|ec]$Ifkdx$$Ifl\ A*{89:::04 la$Ifwkdy$$Ifl9R:  t 06>44 lap {{$If}kdAz$$Ifl0$:|, t0644 laytbC~~$Ifzkd{$$Ifl09|+ t06>44 laz{| !#(UVfgi/3Kabʺ|tggZgJgh (hN#5\^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJ$jhN#5OJQJU^Jhoo0J5OJQJ^J$j~hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jg}hN#OJQJU^J$~~$Ifzkd ~$$Ifl09|+ t06>44 la$%&(UVeuo$If  & F$ 8gd+=nzkd>$$Ifl09|+ t06>44 laefg & F$Iftkdހ$$Ifl9R:  t 0644 lap ghiov$Ifgkd$$Ifl^9R: t0644 la5////$Ifkd $$Ifl\ A*{89::: (04 lap(/01e_Q__$If^`$Ifkd $$Ifl\ A*{89:::04 la123Jec]$Ifkdԃ$$Ifl\ A*{89:::04 laJK_`$Ifwkd$$Ifl9R:  t 06>44 lap `a{{$If}kd1$$Ifl0$:|, t0644 laytbCb 123:;`a{n[ShN#CJaJ$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jWhN#OJQJU^J!jXhN#OJQJU^JhN#0JOJQJ^JjhN#OJQJU^J!jׅhN#OJQJU^JhN#OJQJ^JNO~~$Ifzkd$$Ifl09|+ t06>44 laOP`~~$Ifzkd$$Ifl09|+ t06>44 lauo$If  & F$ 8gd+=nzkd.$$Ifl09|+ t06>44 la>Ep:zzzzzzzzz$If & F$Iftkd΋$$Ifl9R:  t 0644 lap ./bczy}egh鰜vhjhN#OJQJU^J)hJhN#B*OJQJ^JmH phsH  hJhN#OJQJ^JmH sH 'h (hN#5B*\^JnH phtH h (hN#5\^JnH tH !h (hN#5\]^JnH tH hN#6OJQJ^Jh (hN#^JnH tH hN#OJQJ^JhN#5OJQJ\^J($Ifekdr$$Ifl9R: t0644 la5/$Ifkd$$Ifl\ B*|8:::: (04 lap($Ifpkd$$Ifl|88   04 lap e_$Ifkd$$Ifl\ B*|8::::04 la,-.$IfpkdQ$$Ifl|88   04 lap ./0`abe____$Ifkd$$Ifl\ B*|8::::04 labcde____$Ifkd$$Ifl\ B*|8::::04 lae_$IfkdJ$$Ifl\ B*|8::::04 lav ,,$If^,`$Ifpkd$$Ifl|88   04 lap 2yz{eWD>>$If $If^`$If^`kd$$Ifl\ B*|8::::04 la{|}e_I__ ,,$If^`,$IfkdC$$Ifl\ B*|8::::04 lae_L__ ,$If^,`$Ifkd$$Ifl\ B*|8::::04 lae_$Ifkd$$Ifl\ B*|8::::04 laenhh$If ,,$If^`,  9r $Ifpkd5$$Ifl|88   04 lap ec]$Ifkd$$Ifl\ B*|8::::04 laf$Ifwkd$$Ifl\::  t 0:644 lap fg~u~ $Ifgd|H!$Ifzkd1$$Ifl0\:|L, t0:644 laefglmpqʳwm\K!jhN#OJQJU^J!jhN#OJQJU^Jh|H!OJQJ^Jh|H!h|H!0JOJQJ^J3jh|H!h|H!>*B*OJQJU^Jph$h|H!h|H!>*B*OJQJ^Jph-jh|H!h|H!>*B*OJQJU^JphhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!jїhN#OJQJU^J~~$Ifzkd}$$Ifl0\:|L, t0:644 laC~~$Ifzkd՛$$Ifl0\:|L, t0:644 la?@BEdv   %<𨛎xm\m\\ hJhN#OJQJ^JmH sH hN#OJQJ\^JhN#OJQJ]^JhN#H*OJQJ^JhN#5OJQJ\^Jh (hN#^JnH tH hN#OJQJ^J$jHhN#5OJQJU^Jhoo0J5OJQJ^J$juhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JCDEKR`d||||$Ifzkd$$Ifl0\:|L, t0:644 ladeu2,$Ifkd$$Ifl\fB*|8 :: (0j4 lap(ytbCuv~  9r $If$Ifpkd$$Ifl|88   0j4 lap  b\R\\G  9r $If $If$Ifkdi$$Ifl\fB*|8 ::0j4 laytbC$b\$Ifkd1$$Ifl\fB*|8 ::0j4 laytbC$%@c}}}r  9r $If$If  9r $Ifpkd$$Ifl|88   0j4 lap <?@bc !56789:[\fg*+SźҙүүҺ҅үү{҅үh3pOJQJ^J&hJhN#5OJQJ\^JmH sH hH*OJQJ^JhN#OJQJ\^JhN#H*OJQJ^JhN#OJQJ]^JhN#5OJQJ\^JhN#OJQJ^J hJhN#OJQJ^JmH sH #hJhN#H*OJQJ^JmH sH 0bYOII>  9r $If$If $If $Ifgdkd$$Ifl\fB*|8 ::0j4 laytbCb\$Ifkdn$$Ifl\fB*|8 ::0j4 laytbC!789~  9r $If$Ifpkd6$$Ifl|88   0j4 lap 9:\bW  9r $Ifkd$$Ifl\fB*|8 ::0j4 laytbC\]h|q  9r $If $IfgdbC$Ifpkd$$Ifl|88  0j4 lap b\O\\D  9r $If $IfgdbC$IfkdX$$Ifl\fB*|8 ::0j4 laytbCbW  9r $Ifkd $$Ifl\fB*|8 ::0j4 laytbCTUVt  9r $If$If  $Ifpkd$$Ifl|88  0j4 lap SUVWo;l123@ABCwxyثؚثsgثVث!jhN#OJQJU^JhbC0JOJQJ^J!jhbCOJQJU^JhbCOJQJ^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^J&hJhN#5OJQJ\^JmH sH hN#H*OJQJ^JhN#OJQJ^J hJhN#OJQJ^JmH sH hN#5OJQJ\^J!VWnb\$Ifkd$$Ifl\fB*|8 ::0j4 laytbCnoxx  9r $If$Ifukd]$$Ifl9R:  t 044 lap Bpjj$Ifkd$$IflFf90P* t0    44 laytbCH}}$If|kdx$$Ifl0f9+ t044 laytbC+,-45HI/0_ax12?o^M h (hlCJ^JaJnH tH !h (hN#5\]^JnH tH !h (hN#5H*\^JnH tH h (hN#5\^JnH tH hN#5OJQJ\^Jh (hN#^JnH tH hN#CJaJh[eCJaJ!jӮhN#OJQJU^JhN#0JOJQJ^JjhN#OJQJU^J!jhN#OJQJU^JhN#OJQJ^J+/ylffff$If  & F$ 8gd+=n  8gd[e|kdү$$Ifl0f9+ t044 laytbC/0bx6(($If^`kdu$$Ifl\ B*|8:::: (064 lap(xy12`RRB$ f$Ifa$gdl$If^`kdz$$Ifl\ B*|8::::064 la$If?AbcrsuvΫߡsbTsTshN#OJQJ^JmH sH !h (hN#5H*\^JnH tH !h (hN#5\]^JnH tH h (hN#5\^JnH tH hN#5OJQJ\^JhN#OJQJ^Jh (hl0J^JnH tH 'jh (hlU^JnH tH !jh (hlU^JnH tH &h (hl5>*CJ^JaJnH tH h (hl^JnH tH `RR$If^`kd$$Ifl\ B*|8::::064 la$IfrstufXXRRR$If$If^`kd$$Ifl\ B*|8::::064 lauvfXXRRR$If$If^`kdE$$Ifl\ B*|8::::064 lafXXRRR$If$If^`kd$$Ifl\ B*|8::::064 la 02456BCDFGHIKLwx0_`ȻȻȻȻ~q~gYgH!jh<)sOJQJU^Jjh<)sOJQJU^Jh<)sOJQJ^Jh (hN#^JnH tH hN#5OJQJ^Jh[eh[emH sH h[emH sH hN#5\]^JnH tH !h (hN#5\]^JnH tH hN#5OJQJ\^JhN#OJQJ^JhN#OJQJ^JmH sH h (hN#5\^JnH tH h (hT H5\^JnH tH 01234fXRRRR$If$If^`kd$$Ifl\ B*|8::::064 la456789:;<=fXOOOOOOO $Ifgd[e$If^`kd1$$Ifl\ B*|8::::064 la =>?@ABCDEFGWkdն$$Ifl\ B*|8::::064 la$If $Ifgd[e GHIJKLwOkd$$Ifl\ B*|8::::064 layt3p$If$If^`wx~$Ifrkd?$$Ifl|88  064 lap yt3p06000$Ifkd$$Ifl\fB*|8 :: (064 lap()*+,;JKMey{HIѽѽѽххwfwZwhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^JhN#5OJQJ\^JhN#OJQJ^JmH sH hN#CJaJh3OJQJ^JhtojOJQJ^JhyuOJQJ^JhN#OJQJ^Jh<)sOJQJ^Jh<)s0JOJQJ^Jjh<)sOJQJU^J0*+WN $Ifgdyukd$$Ifl\fB*|8 ::064 la$If $Ifgd<)s+,-./:f``W` $Ifgdyu$Ifkd$$Ifl\fB*|8 ::064 la:;<=>If``W` $Ifgdyu$Ifkdh$$Ifl\fB*|8 ::064 laIJKLMdfdbb\$Ifkd$$Ifl\fB*|8 ::064 ladey{$Ifwkd̽$$Ifl9R:  t 0644 lap Gqkkk$Ifkdu$$IflF9|P* t06    44 laGH ?j qkbYYPGG $Ifgd8b $Ifgd3 $Ifgdtoj $Ifgdl$Ifkd+$$IflF9|P* t06    44 la   &>?@mno᫛qWqqq=qq3jZh8bh8b>*B*OJQJU^Jph3jh8bh8b>*B*OJQJU^Jph-jh8bh8b>*B*OJQJU^Jph$h8bh8b>*B*OJQJ^JphhB[9>*B*OJQJ^Jph$hB[9h8b>*B*OJQJ^Jphh8bh8b0JOJQJ^J'jh8bh8bOJQJU^Jh8bh8bOJQJ^J!jh8bh8bOJQJU^J+,-hijk   VWX]^ѽޮޤ{oeWeFW:WhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^Jh8b0JOJQJ^J!jh8bOJQJU^Jh8bOJQJ^Jjh8bOJQJU^JhlOJQJ^Jh8bh8b0JOJQJ^J'j'h8bh8bOJQJU^Jh8bh8bOJQJ^J!jh8bh8bOJQJU^J h3h8b>*B*OJQJph  ~~$Ifzkd$$Ifl09|+ t0644 la^ab01356<LMt}l[SL?hN#5OJQJ\^J hdhN#hN#CJaJ!h[e5B*OJQJ\^Jph!hd5B*OJQJ\^Jph$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^J4~t h$If^h$Ifzkd_$$Ifl09|+ t0644 la456789:;<MNszzzzzzzmke$If  & F$ 8gd+=n 0^`0zkd}$$Ifl09|+ t0644 la stz$Ifpkd$$Ifl|88  04 lap t#$%')*Vijlm&'AD~ܶ~vhh (hN#5^JnH tH hN#CJaJ-h (hN#0J5\]^JmH nH sH tH h (hN#5H*^JnH tH !h (hN#5\]^JnH tH h (hN#5\^JnH tH hN#OJQJ]^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^Jh (hN#^JnH tH '5////$Ifkd$$Ifl\ B*|8:::: (04 lap(e_V__ $$Ifa$$Ifkd$$Ifli\ B*|8::::04 la'()e_Y__$If$Ifkdw$$Ifli\ B*|8::::04 la)*Vjkle_Y__$If$Ifkd$$Ifli\ B*|8::::04 lalme____$Ifkd$$Ifli\ B*|8::::04 laec]$Ifkdi$$Ifli\ B*|8::::04 la "&$Ifpkd$$Ifl|88  04 lap &'E~5//)$If$Ifkd$$Ifl\ B*|8:::: (04 lap(#$_kd$$Ifli\ B*|8::::04 la$If6ABRVnghi쵪͕}j\K\!jhN#OJQJU^JjhN#OJQJU^J$hJhN#0JOJQJ^JmH sH /j^hJhN#OJQJU^JmH sH )jhJhN#OJQJU^JmH sH hlH*OJQJ^JhN#H*OJQJ^JhN#5OJQJ\^J hJhN#OJQJ^JmH sH hs OJQJ^JmH sH hN#OJQJ^Jhs OJQJ^J$%6BSTe_T__  9r $If$Ifkdi$$Ifli\ B*|8::::04 laTUVmec]$Ifkd$$Ifli\ B*|8::::04 lamn:$Ifwkd$$Ifl9R:  t 0644 lap :4\VV$Ifkd)$$IflF9|P* t06    44 la  9r $If & F$Ifinors#$%23EFܺܪldWhN#5OJQJ\^JhN#CJaJ$jhN#5OJQJU^Jhoo0J5OJQJ^J$j@hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^JhN#0JOJQJ^J45E~t h$If^h$Ifzkd$$Ifl09|+ t0644 lausmmmm$If  & F$ 8gd+=nzkd$$Ifl09|+ t0644 la9:ikl#$CDbd} <=?BCMܴܩܒܴ撈~sdhL\h0J5OJQJ]^JhH*OJQJ^JhlOJQJ^JhOJQJ^JhN#0J5OJQJ]^JhN#CJaJhN#5OJQJ^Jh.OJQJ^Jh (hN#5^JnH tH h (hN#5]^JnH tH hN#OJQJ^JhN#5OJQJ\^Jh (hN#^JnH tH $5/& $$Ifa$$Ifkd^$$Ifl\ B*|8:::: (04 lap(9:VijkYkde$$Ifl\ B*|8::::04 la$If$Ifkle____$Ifkd $$Ifl\ B*|8::::04 lae_V__ $$Ifa$$Ifkd$$Ifl\ B*|8::::04 la#$*1?CeVNLFFFF$If & F$gd+=n 8^`kdW$$Ifl\ B*|8::::04 laCDc5/$Ifkd$$Ifl\ B*|8:::: (04 lap(cd}$Ifpkd$$Ifl|88  04 lap  @ABe_V__ $Ifgdl$Ifkd$$Ifl\ B*|8::::04 laBCRhije\VVV$If $IfgdL\hkdW$$Ifl\ B*|8::::04 laMQRjkl}~STUm+ο{{{{p{fYL{hp%hL\hOJQJ^Jhp%hp%OJQJ^JhL\hOJQJ^JhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^JhN#5OJQJ^Jh ~5OJQJ\^Jhp%H*OJQJ^Jh ~OJQJ^Jh ~0J5OJQJ]^Jh.s5OJQJ\^Jh.sOJQJ^Jh.s0J5OJQJ]^JhL\hH*OJQJ^Jjkle\SMM$If $Ifgdp% $IfgdL\hkd$$Ifl\ B*|8::::04 lae_$Ifkd$$Ifl\ B*|8::::04 la$IfpkdI$$Ifl|88  04 lap QRSe____$Ifkd$$Ifl\ B*|8::::04 laSTUlec]$Ifkd$$Ifl\ B*|8::::04 lalm+y $Ifgdp%$IfwkdB$$Ifl9R:  t 0644 lap JKqkk$Ifkd$$IflF9|P* t06    44 la9:;HILM89:FHrsuw瘍zmZRhN#CJaJ$jMhN#5OJQJU^Jhoo0J5OJQJ^J$jzhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!j!hN#OJQJU^J!j"hN#OJQJU^JhN#0JOJQJ^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J KL~~$Ifzkd$$Ifl09|+ t0644 lav~t h$If^h$Ifzkd$$Ifl09|+ t0644 lavwusmmmm$If 8^`zkd$$Ifl09|+ t0644 lakz}+.UVuvABCf  VWZ[mܛܛuܛhlhlmH sH hlOJQJ^J hJhN#OJQJ^JmH sH hN#OJQJ^JnH tH hN#CJaJhN#OJQJ]^Jh (hN#5\^JnH tH h (hN#5]^JnH tH hN#5OJQJ\^Jh (hN#^JnH tH hN#OJQJ^J-   5////$Ifkd$$Ifl\ B*|8:::: (04 lap(  +ABCe____$Ifkd$$Ifl\ B*|8::::04 laCDkz{|e_Y__$If$IfkdE$$Ifl\ B*|8::::04 la|}eWQQQ$If,$If^`,kd$$Ifl\ B*|8::::04 la+,-eWQQQ$If,$If^`,kd$$Ifl\ B*|8::::04 la-.UV\cqueVTNNNN$If 8^`kd7$$Ifl\ B*|8::::04 lauv5/$Ifkd$$Ifl\ B*|8:::: (04 lap(~  9r $If$Ifpkd$$Ifl|88  04 lap e__T__  9r $If$Ifkdu$$Ifl\ B*|8::::04 laABe_V $Ifgdl$Ifkd $$Ifl\ B*|8::::04 laBCfyyy  O $If$If$Ifpkd$$Ifl|88  04 lap e___UUU  O $If$IfkdR$$Ifl\ B*|8::::04 la    e___UUU  O $If$Ifkd$$Ifl\ B*|8::::04 la  WXYZe\RRR  O $If $Ifgd[ekd$$Ifl\ B*|8::::04 laZ[{e_$Ifkd$$Ifl\ B*|8::::04 lamnz{| ! 7 8 ; < [ ^ _ s v w            ' + ƹve hl5OJQJ\^JnH tH hl5OJQJ^JnH tH hlOJQJ^JnH tH hlOJQJ]^JhlOJQJ^J hJhlOJQJ^JmH sH hl5OJQJ\^Jh (hl^JnH tH hN#5OJQJ\^JhN#OJQJ\^JnH tH  hN#5OJQJ\^JnH tH "{| $Ifgdpkd$$Ifl|88  04 lap 2'!$If  9r $IfkdQ$$Ifl\ B*|8:::: (04 lap(ytl   _kdP$$Ifl\ B*|8::::04 la$If ! " 8 9 : e____$Ifkd$$Ifl\ B*|8::::04 la: ; < [ \ ] e____$Ifkd$$Ifl\ B*|8::::04 la] ^ _ s t u e_V__ $Ifgdl$Ifkd$$Ifl\ B*|8::::04 lau v w    eZTTT$If  9r $Ifkd$$Ifl\ B*|8::::04 la   e_$IfkdH$$Ifl\ B*|8::::04 la      $Ifpkd$$Ifl|88  04 lap    e_$Ifkd$$Ifl\ B*|8::::04 la   ( ) * ~~~$If  9r $Ifpkd%$$Ifl|88  04 lap * + 6 7 8 9 eZTTT$If  9r $Ifkd$$Ifl\ B*|8::::04 la+ 5 6 : l p               a b c d f v w x y   ԵԣԒvdZMZhN#5OJQJ\^JhN#OJQJ^J#hJh?OJQJ]^JmH sH h?OJQJ]^JmH sH h?5OJQJ\^J hJh?OJQJ^JmH sH #hJhlOJQJ]^JmH sH !h (hl5\]^JnH tH hlOJQJ^JnH tH hl5OJQJ\^J hJhlOJQJ^JmH sH h":OJQJ^JmH sH 9 : l m n o e_YYY$If$Ifkd\$$Ifl\ B*|8::::04 lao p    5*$$$If  9r $Ifkd$$Ifl\ B*|8:::: (04 lap(       ZTT$Ifkd$$Ifl\ B*|8::::04 la  9r $If      eZTTF,$If^`,$If  9r $Ifkd$$Ifl\ B*|8::::04 la     b eZTTZ$If  9r $Ifkd$$Ifl\ B*|8::::04 lab c d e f w eZTTZ$If  9r $Ifkd$$Ifl\ B*|8::::04 law x y  ec]$IfkdM$$Ifl\ B*|8::::04 la     $Ifwkd$$Ifl9R:  t 0644 lap            D E F K L O P x y z           ܿܿܿꍂobhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!jDhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhN#H*OJQJ^J    qkk$Ifkd$$IflF9|P* t06    44 la    ~~$Ifzkd%$$Ifl09|+ t0644 la   " ~~$Ifzkd}$$Ifl09|+ t0644 la  ! # C D c d s t ~              *678;MOYd˾ӒӾӒӒӣӂwӣlwӒӣZ#hJhN#OJQJ]^JmH sH hhOJQJ]^JhN#OJQJ]^Jh (hN#5]^JnH tH  hJhN#OJQJ^JmH sH hN#OJQJ^JnH tH h (hN#^JnH tH hN#5OJQJ\^JhN#CJaJhN#OJQJ^JjhN#5OJQJU^J$jhN#5OJQJU^J#" # $ C D J Q _ c usmmmm$If  & F% 8gd+=nzkd$$Ifl09|+ t0644 lac d s 5/$Ifkd; $$Ifl\ B*|8:::: (04 lap(s t ~    ~  9r $If$IfpkdB $$Ifl|88   04 lap       e_T__  9r $If$Ifkd $$Ifl\ B*|8::::04 la      e_T__  9r $If$Ifkd $$Ifl\ B*|8::::04 la   e_$Ifkd; $$Ifl\ B*|8::::04 la      $Ifpkd $$Ifl|88  04 lap       e_YYY$If$Ifkd $$Ifl\ B*|8::::04 la   e____$Ifkd4$$Ifl\ B*|8::::04 la  e_$Ifkd$$Ifl\ B*|8::::04 la789:{uu$If  9r $If $Ifgdhpkd$$Ifl|88  04 lap :;Me_$Ifkd-$$Ifl\ B*|8::::04 laMNOdef~  9r $If$Ifpkd$$Ifl|88  04 lap fge_$Ifkd$$Ifl\ B*|8::::04 ladgVWXefijyhXjhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#0JOJQJ^J!j$hN#OJQJU^JjhN#OJQJU^JhN#H*OJQJ^JhN#5OJQJ\^Jh (hN#5^JnH tH h (hN#^JnH tH hN#OJQJ^JnH tH hN#OJQJ^J $If$Ifpkd&$$Ifl|88  04 lap e____$Ifkd$$Ifl\ B*|8::::04 lae____$Ifkdy$$Ifl\ B*|8::::04 laec]$Ifkd$$Ifl\ B*|8::::04 la$Ifwkd$$Ifl9R:  t 0644 lap ghqkk$Ifkdn$$IflF9|P* t06    44 lahi~~$Ifzkd$$Ifl09|+ t0644 la~~$Ifzkd]$$Ifl09|+ t0644 laUVWce67=]^`azѧum^uhN#5OJQJ^JnH tH hN#CJaJ hJhN#OJQJ^JmH sH hN#OJQJ^JnH tH h (hN#^JnH tH  hN#CJhN#OJQJ^J$jhN#5OJQJU^Jhoo0J5OJQJ^JjhN#5OJQJU^J$jhN#5OJQJU^JhN#5OJQJ^Jztttt$If & F'gd+=nzkd{$$Ifl09|+ t0644 la5/$Ifkd$$Ifl\ B*|8:::: (04 lap(~  9r $If$Ifpkd"$$Ifl|88   04 lap $eccccVcPP$If  & F& 8gd+=nkd$$Ifl\ B*|8::::04 la $267^/)$Ifkdu$$Ifl\ B*|8:::: (04 lap($If^_`abx~  9r $If$Ifpkd|$$Ifl|88   04 lap xyzeccc]]]]$Ifkd) $$Ifl\ B*|8::::04 la5////$Ifkd $$Ifl\ B*|8:::: (04 lap(,.2NOQRXac{|}~(ְְֻ֐~sf\H\&huShuS5CJ H*OJQJ^JaJ huSOJQJ^JhuS5OJQJ\^JhN#5OJQJ^J hN#5\hdWOJQJ\^JhdWOJQJ^JhOJQJ\^JhUOJQJ\^JhlOJQJ\^JhN#OJQJ\^Jh:~0JOJQJ^JmH sH hN#OJQJ^JhuS0JOJQJ^JmH sH hN#0JOJQJ^JmH sH .e___V $Ifgd:~$Ifkd!$$Ifl\ B*|8::::04 la./012Oe____$Ifkd|"$$Ifl\ B*|8::::04 laOPQbc|e____$Ifkd"#$$Ifl\ B*|8::::04 la|}~e____$Ifkd#$$Ifl\ B*|8::::04 laecaX $Ifgd3kdn$$$Ifl\ B*|8::::04 la'||| $Ifgd3zkd%$$Ifl9R:  t 0644 lap yt3'(vne\e $Ifgd> $Ifgd3kd%$$IflF9|P* t06    44 layt3()efgtuvw-./4589abc糠weTC!j)huSOJQJU^J!j(huSOJQJU^J"h>>*B*CJOJQJaJphhlh>0JOJQJ^J3j`'hlh>>*B*OJQJU^Jph$hlh>>*B*OJQJ^Jph-jhlh>>*B*OJQJU^JphhuS0JOJQJ^J!j&huSOJQJU^JhuSOJQJ^JjhuSOJQJU^J~xx $Ifgd3}kd-($$Ifl09|+ t0644 layt3cjk   ̡̃reQrBrehlhl0JOJQJ^J'j,hlhlOJQJU^JhlhlOJQJ^J!jhlhlOJQJU^Jhl5OJQJ^J$j,huS5OJQJU^Jhoo0J5OJQJ^J$j1+huS5OJQJU^JhuS5OJQJ^JjhuS5OJQJU^JhuSOJQJ^JjhuSOJQJU^JhuS0JOJQJ^Jxob d $Ifgdl $Ifgdl $Ifgd3}kd*$$Ifl09|+ t0644 layt3 qqqq,$If^`,}kd.$$Ifl09|+ t0644 layt3   LMNxyz  OPQQRSjklΫΫΫΫΫΫΫΫΫΫΫΫ{$hZ9hW&5B*OJQJ^Jphp0hW&OJQJ^J$hN#0J5OJQJ\^JmH sH *h (hN#0J5\^JmH nH sH tH hN#5OJQJ\^Jh (hN#5\^JnH tH hW&5OJQJ^Jhl5OJQJ^JhN#5OJQJ^J/   KL7))),$If^`,kd,/$$Ifl\ A*{89::: (04 lap(LMNOwxyZkd.0$$Ifl\ A*{89:::04 la,$If^`,yz{hZZZZ,$If^`,kd0$$Ifl\ A*{89:::04 la hZZZZ,$If^`,kdp1$$Ifl\ A*{89:::04 la   NO7))),$If^`,kd2$$Ifl\ A*{89::: (04 lap(OPQRZkd!3$$Ifl\ A*{89:::04 la,$If^`,hZZZZ,$If^`,kd3$$Ifl\ A*{89:::04 lahZZZZ,$If^`,kdq4$$Ifl\ A*{89:::04 laPQ7))),$If^`,kd 5$$Ifl\ A*{89::: (04 lap(QRSY_ekZkd"6$$Ifl\ A*{89:::04 la,$If^`,klm7))),$If^`,kd6$$Ifl\ A*{89::: (04 lap(Zkd7$$Ifl\ A*{89:::04 la,$If^`,hbbbb$Ifkdt8$$Ifl\ A*{89:::04 la:;ChffffZUffgd-E  & F& gd+=nkd9$$Ifl\ A*{89:::04 la nv12ðÁn[QI5' *h-Eh-E5B*OJQJ^JphhN#CJaJhN#OJQJ^J$hZ9hq5B*OJQJ^Jph_Iz$hZ9hq5B*OJQJ^Jphp0(hZ9hZ90J5B*OJQJ^JphT3j9hZ9hZ95B*OJQJU^JphT$hZ9hZ95B*OJQJ^JphT-jhZ9hq5B*OJQJU^JphT$hZ9hZ95B*OJQJ^Jphp0$hZ9h <5B*OJQJ^Jphp09:;BCDcdƼ||n]|]|]|U|Jh5= H*OJQJ^Jh5= CJaJ hJh5= OJQJ^JmH sH h5= B*OJQJ^Jphh5= 5OJQJ\^Jh (h5= ^JnH tH h5= OJQJ^Jh5= hN#5OJQJ^Jh5= h5= 5OJQJ^Jh-EOJQJ^J'h-Eh-E5OJQJ^JmH sH tH' *h-Eh-E5B*OJQJ^Jph! *h5B*OJQJ^JphCDJQ_c $Ifgd{y>gd5= cd2) $Ifgd5= kd:$$Ifl\ A*{89::: (04 lap(yt{y>z $Ifgd5= $Ifgd{y>skd;$$Ifl{88   04 lap yt{y>bY $Ifgd{y>kd<$$Ifl\ A*{89:::04 layt{y>u  9r $Ifgd{y> $Ifgd{y>skdQ=$$Ifl{88   04 lap yt{y>bYYYK  9r $Ifgd{y> $Ifgd{y>kd>$$Ifl\ A*{89:::04 layt{y>bYYYK  9r $Ifgd{y> $Ifgd{y>kd>$$Ifl\ A*{89:::04 layt{y>b]T $Ifgd{y>gd5= kdx?$$Ifl\ A*{89:::04 layt{y>Q||s $Ifgd-E $Ifgd{y>zkd2@$$Ifl9R:  t 0644 lap yt{y>OPQRS"#$+,ջ蟕vjYjHj!jDh5= OJQJU^J!jCh5= OJQJU^Jh5= 0JOJQJ^J!jjBh5= OJQJU^Jjh5= OJQJU^Jh5= OJQJ^Jh5= h5= OJQJ^Jh5= h5= 0JOJQJ^J3j@h5= h5= >*B*OJQJU^Jph$h5= h5= >*B*OJQJ^Jph-jh5= h5= >*B*OJQJU^JphQRnee $Ifgd{y>kdA$$IflF9|P* t06    44 layt{y>?@xx $Ifgd{y>}kdKC$$Ifl09|+ t0644 layt{y>@AQxx $Ifgd{y>}kdE$$Ifl09|+ t0644 layt{y>,QR*?`abcmnqz{~ۨxjYYY hJhN#OJQJ^JmH sH hN#B*OJQJ^Jphh (hN#^JnH tH hN#5OJQJ\^JhN#hN#CJaJhN#OJQJ^J$j"Gh5= 5OJQJU^Jhoo0J5OJQJ^J$jOFh5= 5OJQJU^Jh5= 5OJQJ^Jjh5= 5OJQJU^Jh5= OJQJ^J" sd^^^^$If ^`  & F& gd+=n}kdG$$Ifl09|+ t0644 layt{y> )5/$IfkdsH$$Ifl\ A*{89::: (04 lap()*+,-?$IfpkdI$$Ifl{88   04 lap ?@_e_$Ifkd5J$$Ifl\ A*{89:::04 la_`abcm~  9r $If$IfpkdJ$$Ifl{88   04 lap mnopqze___T  9r $If$IfkdK$$Ifl\ A*{89:::04 laz{|}~e___T  9r $If$IfkdJL$$Ifl\ A*{89:::04 laec]$IfkdL$$Ifl\ A*{89:::04 la$IfwkdM$$Ifl9R:  t 0644 lap  TUV[\_`  . ܿܿܿꍂobhoo0J5OJQJ^J$jRhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jQhN#OJQJU^J!jPhN#OJQJU^JhN#0JOJQJ^J!jOhN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhN#H*OJQJ^Jqkk$Ifkd[N$$IflF9|P* t06    44 la~~$IfzkdO$$Ifl09|+ t0644 la2 ~~$IfzkdJR$$Ifl09|+ t0644 la. / 1 6 W h j              ,!-!.!;!!$Ifgkd[$$Ifl| t06+44 la>!?!!!~~$Ifzkd\$$Ifl09|+ t0644 la!!!i"~~$Ifzkd^$$Ifl09|+ t0644 la!+","-"9";"e"f"h"j"l"n""""""""""""""####2#F#ѧtjj`RhN#>*B*CJaJphh OJQJ^JhOJQJ^J!hN#5B*OJQJ\^JphhN#5OJQJ\^JhN#!hN#5B*OJQJ\^JphhN#OJQJ^J$jJ`hN#5OJQJU^Jhoo0J5OJQJ^JjhN#5OJQJU^J$jw_hN#5OJQJU^JhN#5OJQJ^Ji"j"k"l"n""""zzxixc$If ^` 0^`0zkd`$$Ifl09|+ t0644 la""""ekd9b$$Ifl9R: t0644 la$Iftkda$$Ifl9R:  t 0644 lap """""" $$Ifa$"""71$Ifkdb$$Ifl\ ){8D   (04 lap(""""""$Ifnkdc$$Ifl{88   04 lap """"###gaXXaa $Ifgd $Ifkdd$$Ifl\ ){8D  04 la###1#gb\$If$a$kdDe$$Ifl\ ){8D  04 la1#2#F#G#H#$Ifwkdf$$Ifl9R:  t 0644 lap F#G#I#J###############$$$"$#$H$I$$$$$$$ܿܿܿꍂobhoo0J5OJQJ^J$j:khN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jihN#OJQJU^J!jhhN#OJQJU^JhN#0JOJQJ^J!jaghN#OJQJU^JjhN#OJQJU^JhN#OJQJ^JhN#H*OJQJ^JH#I###qkk$Ifkdf$$IflF9|P* t06    44 la##6$7$~~$IfzkdBh$$Ifl09|+ t0644 la7$8$H$$~~$Ifzkdj$$Ifl09|+ t0644 la$$$$$$$ %E%%%%%%%%%%%%%%&&&5&6&C&]&_&`&n&o&&&&&&&&'' 'W'X'd'e'u'v''''''''ƸӭӞӖӌhvOJQJ^JhN#OJQJh}LOJQJ^J hN#5hN#5OJQJ^Jh.OJQJ^JhN#hN#5OJQJ\^JhN#OJQJ^JjhN#5OJQJU^J$j lhN#5OJQJU^J7$$$$$$ %sm$If ^`zkdl$$Ifl09|+ t0644 la % %F%G%ekdm$$Ifl9R: t0644 la$IftkdXm$$Ifl9R:  t 0644 lap G%H%J%P%W%e%i% $$Ifa$i%j%%71$Ifkdn$$Ifl\ A*{89 : (084 lap(%%%%%%$Ifnkdo$$Ifl{88   084 lap %%%%%%gaaaa$IfkdWp$$Ifl\ ){8D  084 la%%%%%%gaaaa$Ifkdq$$Ifl\ ){8D  084 la%%%%%%gaaaa$Ifkdq$$Ifl\ ){8D  084 la%%%%%%gaaaa$Ifkdr$$Ifl\ ){8D  084 la%%%ga$IfkdOs$$Ifl\ ){8D  084 la%% &&&&$Ifnkd t$$Ifl{88   084 lap &&&&&'&gaaaa$Ifkdt$$Ifl\ ){8D  084 la'&(&)&*&+&4&gaaaa$Ifkdtu$$Ifl\ ){8D  084 la4&5&6&7&8&B&gaaaa$Ifkd2v$$Ifl\ ){8D  084 laB&C&^&ga$Ifkdv$$Ifl\ ){8D  084 la^&_&`&a&b&m&$Ifnkdw$$Ifl{88  084 lap m&n&o&p&q&&gaaaa$IfkdWx$$Ifl\ ){8D  084 la&&&&&V'gaaaX $Ifgd}L$Ifkdy$$Ifl\ ){8D  084 laV'W'X'Y'Z'c'gaaaa$Ifkdy$$Ifl\ ){8D  084 lac'd'e'f'g't'gaaaa$Ifkdz$$Ifl\ ){8D  084 lat'u'v'w'x''gaaaa$IfkdO{$$Ifl\ ){8D  084 la''''''gaaaa$Ifkd |$$Ifl\ ){8D  084 la''''''gaaaa$Ifkd|$$Ifl\ ){8D  084 la''''''''geeeVeP$If ^`kd}$$Ifl\ ){8D  084 la'''|$If^`tkdG~$$Ifl9R:  t 0644 lap ''''''((( (!(,(.(/(0(;(=(>(?(K(M(N(O(Z(\(](^(i(j((((((((((())))))|phN#0JOJQJ^J!j҇hN#OJQJU^JjhN#OJQJU^JhN#5>*CJ\aJ"hN#OJQJ^JmH nH sH tH  hJhN#OJQJ^JmH sH  hN#5OJQJ\^JnH tH hN#OJQJ^JnH tH hN#OJQJ^JhN#5OJQJ\^J,''''''' $$Ifa$ekd~$$Ifl9R: t0644 la''(71$Ifkdp$$Ifl\ ){8D   (04 lap(((( (!(,({  9r $If$Ifskd$$Ifl4{88  04 laf4p ,(-(.(/(0(;(b\\\\$IfkdB$$Ifl4\ ){8D  04 laf4;(<(=(>(?(K(b\\\\$Ifkd $$Ifl4\ ){8D  04 laf4K(L(M(N(O(Z(b\\\\$Ifkd҂$$Ifl4\ ){8D  04 laf4Z([(\(](^(i(b\\\\$Ifkd$$Ifl4\ ){8D  04 laf4i(j((b\$Ifkdb$$Ifl4\ ){8D  04 laf4(((((($Ifskd*$$Ifl4{88  04 laf4p ((((b`Z$Ifkd݅$$Ifl4\ ){8D  04 laf4((((fkdK$$Ifl| t0+44 la$Ifukd$$Ifl9R:  t 044 lap ()))))v  $Ifykd$$Ifl09|+ t044 la$If))e)f)g)l)m)p)q))))))))*****?*@*B*D*G*u*v*穞~k_[T hN#5\hN#hN#5>*CJ\aJ$jxhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jOhN#OJQJU^JhN#0JOJQJ^J!jPhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^J)))C*$Ifykd$$Ifl09|+ t044 laC*D*E*G*v*w*}****rpgggg $$Ifa$ ^`gddykd#$$Ifl09|+ t044 la ***71$Ifkd$$Ifl\ ){8D   (0k4 lap(******$Ifnkdߎ$$Ifl{88   0k4 lap v*****************+++%+,+++,,,,,,,b,c,d,i,j,m,n,,,,,,,߽߯鞯遯p!jȖhN#OJQJU^J!jɕhN#OJQJU^JhN#0JOJQJ^J!jKhN#OJQJU^JjhN#OJQJU^Jh}LOJQJ^JhW/H*OJQJ^JhW/5OJQJ\^JhW/OJQJ^JhN#OJQJ^JhN#5OJQJ\^J+******gaaaa$Ifkd$$Ifl\ ){8D  0k4 la******gaaaa$IfkdF$$Ifl\ ){8D  0k4 la***ga$Ifkd$$Ifl\ ){8D  0k4 la***$Ifnkd‘$$Ifl{88   0k4 lap **++fkd$$Ifl| t0+44 la$Ifukdk$$Ifl9R:  t 044 lap +++2++++,,Nkd$$IflF9|I) t0    44 la & F- p=h$If^hgd+=n $IfgdW/$If,,,,v  $If$Ifykd,$$Ifl09|+ t044 la,,,A-$Ifykd$$Ifl09|+ t044 la,,-----=->-@-B-E----------..>.?.@.𨚖xdVEV!jhN#OJQJU^JjhN#OJQJU^J&hJhN#5OJQJ\^JmH sH  hJhN#OJQJ^JmH sH hN#5OJQJ\^JhN#hN#>*B*CJaJphhN#OJQJ^J$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JA-B-C-E----rpj$If ^`$a$ykd$$Ifl09|+ t044 la---  9r $Iftkd9$$Ifl9R:  t 0644 lap ------- $$Ifa$ekdݚ$$Ifl9R: t0644 la---4.$Ifkdb$$Ifl\ )$:DHh  (04 lap(ytd------$Ifqkd$$Ifl$::   04 lap ytd------b\\\\$IfkdD$$Ifl\ )$:DHh 04 laytd----db\$Ifkd$$Ifl\ )$:DHh 04 laytd--..fkd$$Ifl| t0+44 la$Ifukd$$Ifl9R:  t 044 lap @.M.N.Q.R.............//=/>/?/K/M/w/x/z/|/}////ܺܪl_[_hN#hN#5OJQJ\^J$jhN#5OJQJU^Jhoo0J5OJQJ^J$jhN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^J!jhN#OJQJU^J!jhN#OJQJU^JhN#OJQJ^JjhN#OJQJU^JhN#0JOJQJ^J.O.P.Q...v  $Ifykd$$Ifl09|+ t044 la$If../{/$IfykdO$$Ifl09|+ t044 la{/|/}///////ulllf$If $$Ifa$ ^`ykdj$$Ifl09|+ t044 la///////00*04050L0N0g0q0r0~00000000000000000桓ˈz桓mcmVhk5OJQJ\^JhHOJQJ^JhH5OJQJ\^JhN#OJQJ^JmH sH hN#H*OJQJ^Jh$hN#OJQJ\^Jh$h$OJQJ\^J&hJhN#5OJQJ\^JmH sH hN#CJaJhN#OJQJ^J hJhN#OJQJ^JmH sH hN#5OJQJ\^Jh (hN#^JnH tH !/////<666$Ifkd$$Ifl\ ){8DHh  (04 lap(///////0a__P_J$If 8^`kd4$$Ifl\ ){8DHh 04 la  9r $If000  9r $Iftkd$$Ifl9R:  t 0644 lap 0 0 000%0)0 $$Ifa$ekd$$Ifl9R: t0644 la)0*05060g0q0<6660$If$Ifkd)$$Ifl\ ){8D   (04 lap(q0r00000lffff$IfkdH$$Ifl\ ){8D  04 la000000lfff[  9r $If$Ifkd$$Ifl\ ){8D  04 la000000lffff$Ifkdī$$Ifl\ ){8D  04 la000000lffff$Ifkd$$Ifl\ ){8D  04 la000000lffff$Ifkd@$$Ifl\ ){8D  04 la000000lffff$Ifkd$$Ifl\ ){8D  04 la00000 1lfff] $Ifgd}L$Ifkd$$Ifl\ ){8D  04 la001 1 11,1-1.1F1Z1[1\1HIJOPST|ҷthWh!jͳhN#OJQJU^JhN#0JOJQJ^J!jOhN#OJQJU^JjhN#OJQJU^JUhN#H*OJQJ^JhN#OJQJ^JhN#5OJQJ\^J!hN#5B*OJQJ\^Jphh0kOJQJ^Jh0k5OJQJ\^Jhk5OJQJ\^Jh}LOJQJ^JhkOJQJ^J 1 1111,1lffff$Ifkdz$$Ifl\ ){8D  04 la,1-1.1E1ljd$Ifkd8$$Ifl\ ){8D  04 laE1F1Z1\1$Ifukd$$Ifl9R:  t 044 lap GP to receive clear information regarding the choice of therapy and the steps that should be taken if treatment is deemed successful or not within a specified time frame  HYPERLINK "http://www.nice.nhs.uk/page.aspx?o=ourguidance" NICE guidance HYPERLINK "http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm" MTRAC /  HYPERLINK "http://www.prodigy.nhs.uk/" Prodigy / other guidance PCT informationHYPERLINK "http://www.ppa.org.uk/edt/August_2007/mindex.htm"Drug Tariff  HYPERLINK "http://www.drugtariff.co.uk/"  APPENDIX The following drugs are not considered appropriate for initiation. HOWEVER if patients are stable on these medications there is no requirement to change them to an alternative. BNF CategoryDrug2.2.2 Loop diureticsTorasemide2.5.5.2 Angiotensin Receptor BlockersEprosartan, Telmisartan Olmesartan2.6.1 NitratesIsosorbide dinitrate (oral)2.6.2 Calcium channel blockersLacidipine LercanidipineNicardipine2.8 Anticoagulants and protamineDalteparinTinzaparinLepiridin4.1 Hypnotics and anxiolyticsClomethiazole (chlormethiazole)Nitrazepam4.3Escitalopram4.7.1 Non-opioid analgesicsCo-dydramol4.7.2 Opioid analgesics Dipipanone hydrochlorideBuprenorphine patches (Transtec)4.8.1 Control of epilepsy Ethosuximide Clobazam4.9.1 Dopaminergic drugs used in parkinsonismPergolideCabergoline Bromocriptine6.1.1.1 Short Acting InsulinsInhaled Insulin (Exubera ) as part of Extended Transition Programme in Secondary Care only 6.1.2.3VildagliptinSaxagliptin6.3.2 GlucocorticoidsCortisone6.4.2 Male sex hormonesSustanon preparations 7.3.1 Combined hormonal contraceptivesNuvaRing Qlaira Yasmin Logynon 7.4.2 Drugs for urinary frequency, enuresis and incontinencePropiverine Solifenacin11.6Bimatoprost dropsGanfort 12.2.1Fluticasone propionate (Flixonase and Nasofan )     The Interface Formulary for Adults Autumn/Winter 2013 (November to February 2014) Patient identified as potentially malnourished or at risk of malnutrition using Community Nutritional Screening Tool Give food boosting dietary advice and outline Food Boosters leaflet* to the patient. Leaflets are available from the Nutrition Support Service, Freshfields: (01564) 732803 and available on the SCT intranet from January 2009 NO IMPROVEMENT with Food Boosting Measures alone Review at 4 weeks or before if appropriate. Record: Weight (if possible)/visual assessment Assess dietary changes made Still losing weight/ not eating better. Reinforce food boosting dietary advice Reassess underlying problems and treat where possible Introduce sip feeds 1-2 per day in addition to food Reassess after 4 weeks IMPROVEMENT on Sip Feeds IMPROVEMENT with Food Boosting Measures alone Weight stable or increasing/ appetite improved. Reinforce food boosting dietary advice Monitor compliance with sip feeds if used Reassess after 4 weeks Weight stable or increasing/ appetite improved. Reinforce food boosting dietary advice Monitor regularly NO IMPROVEMENT on Sip Feeds When aim of therapy is achieved e.g. agreed weight reached/ eating returned to normal: Withdraw sip feeds gradually under supervision Weigh or record visual assessment every month for at least 3 months If problems recur, start at the beginning of flow chart Weight/ eating continues to deteriorate: Contact dietician for advice or make formal referral if necessary smm$Ifkd$$IflFx9|hn* t0    44 lav  $If$Ifykd0$$Ifl09|+ t044 la|}~"#%,56NRCQR`am|ʺ|ʯʯoʯddddddddhN#OJQJ\^JhN#5>*OJQJ^J$jhN#5OJQJU^Jhoo0J5OJQJ^J$j"hN#5OJQJU^JhN#5OJQJ^JjhN#5OJQJU^JhN#OJQJ^JhN#0JOJQJ^JjhN#OJQJU^J!j̴hN#OJQJU^J'&$Ifykd$$Ifl09|+ t044 la&'(*+56~~$Ifykd$$Ifl09|+ t044 la jdd$Ifkd=$$Ifl04;:#  t̙̙0644 lap̙̙CP~~$Ifzkd$$Ifl04;:# t0644 laPQR_~~$Ifzkd$$Ifl04;:# t0644 la_`al~~$Ifzkd($$Ifl04;:# t0644 lalm|~~$Ifzkd$$Ifl04;:# t0644 la~~$IfzkdL$$Ifl04;:# t0644 la~~$Ifzkd޻$$Ifl04;:# t0644 la~~$Ifzkdp$$Ifl04;:# t0644 la~~$Ifzkd$$Ifl04;:# t0644 la~~$Ifzkd$$Ifl04;:# t0644 la)FGfu!"/89grs$%&0ïxtj]h2lh0kOJQJ^Jh0kOJQJ^Jh0kh OJQJ^Jh OJQJ\^Jh. OJQJ^JhN#OJQJ^JmH sH h&!'OJQJ^JhGOJQJ^JhOJQJ^Jh.OJQJ^JhN#OJQJ\^JmH sH hN#OJQJ^JmH sH hN#OJQJ^JhN#OJQJ\^J$(~~$Ifzkd&$$Ifl04;:# t0644 la()Gg~x$If$Ifzkd$$Ifl04;:# t0644 laghitxr$If $If|kdJ$$Ifla04;:# t0644 latuyzt$If $Ifzkd$$Ifl04;:# t0644 lazt$If $Ifzkdr$$Ifl04;:# t0644 lazt$If $Ifzkd$$Ifl04;:# t0644 la~~$Ifzkd$$Ifl04;:# t0644 la!"/8~~~~$Ifzkd($$Ifl04;:# t0644 la89gq~~$Ifzkd$$Ifl04;:# t0644 laqrs~~$IfzkdL$$Ifl04;:# t0644 la~~$Ifzkd$$Ifl04;:# t0644 la ~~$Ifzkdp$$Ifl04;:# t0644 la #~~$Ifzkd$$Ifl04;:# t0644 la#$%1~~$Ifzkd$$Ifl04;:# t0644 la012HSjk%&1ݱpcSHhDOJQJ\^Jh (hD5\^JnH tH h (hN#^JnH tH h (hN#5\^JnH tH h3+OJQJ^J#h (h3+5^JmH nH sH tH (h (h3+OJQJ^JmH nH sH tH h (h3+5\^JnH tH h (hN#\^JnH tH h (hN#5^JnH tH hN#OJQJ^JhN#OJQJ\^Jh0kOJQJ^Jh0k12HR~~$Ifzkd&$$Ifl04;:# t0644 laRSkmg$If $If^`gd zkd$$Ifl04;:# t0644 lapj$If $If^`zkdJ$$Ifl04;:# t0644 lapj$If $If^`zkd$$Ifl04;:# t0644 lapj$If $If^`zkdn$$Ifl04;:# t0644 lapj$If $If^`zkd$$Ifl04;:# t0644 la$pj$If $If^`zkd$$Ifl04;:# t0644 la$%&2mg$If $If^`gdGzkd$$$Ifl04;:# t0644 la12378IKLVW^ɻyn`VLBL:6:6h((jh((Uh%& OJQJ^JhN#OJQJ^Jh<)OJQJ^Jhh<)OJQJ\^Jh<)OJQJ\^Jh (h<)5\^JnH tH hOJQJ^JhhOJQJ\^Jh (h5\^JnH tH hGOJQJ^JhjhGOJQJ\^Jh (hG5^JnH tH h (hG5\^JnH tH hDOJQJ^JhjhDOJQJ\^J238Jmg$If $If^`gdGzkd$$Ifl04;:# t0644 laJKLVmg$If $If^`gdGzkdH$$Ifl04;:# t0644 laVW^mg$If $If^`gdGzkd$$Ifl04;:# t0644 laCv  9gd9}zkdl$$Ifl04;:# t0644 la ABCDEM[NO!:koqܢܗܢܢܢܢܗܢܢܓhN#OJQJ^Jh.1th/OJQJ\^Jh/OJQJ^Jh/5B*\phh/5B*ph h/5huh/mH sH hgh/mH sH h/hmh/mH sH h/mH sH h((jh((U(CDE 1L$ & F(Eƀfa$gd+=n$a$$ a$ $ a$1NOwYV & F+ hhLEƀf^h`Lgd+=nL$ & F(Eƀfa$gd+=n !:;iQOOOOOM(V & F+ hhLEƀf^h`Lgd+=nV & F+ hhLEƀf^h`Lgd+=nijk5OV & F* hhLEƀf^h`Lgd+=nV & F* hhLEƀf^h`Lgd+=n 5]opqQOOJOOO$a$V & F* hhLEƀf^h`Lgd+=nV & F* hhLEƀf^h`Lgd+=nYQV & F) hhLEƀf^h`Lgd+=nV & F) hhLEƀf^h`Lgd+=nYV & F) hhLEƀf^h`Lgd+=n8091F0:pO*A }.!"n#7$7% nfC6*ʊzEk$PNG  IHDRcPYsRGB pHYs+tEXtSoftwareMicrosoft Office5qeqIDATx^\Wy6j%zlK{Åb!!@H#|!! !B )&܄d˒-YV{ߝ3{gvj% ̽{^NNE ,fr^53= IwXDF#"YDlL,#ĵlɭ(o-ʗn%_䗜\3 eas4W3C[cr9%1;~ߣqr$ p$IVp#y+kDr|2rW(HQhQ%@ yIA/ibi~o{t$$ݏC2Q >(Y`f%H \A4+[yxux6Tr0/ eE%)Jn_*,+پl0.P69r+sXys?_>eFe3/{#\@z6A.d+$ ys⑘!: %#!p cc Ā(%rpyr%//_ʀ$J,WJK%},..9 LCh-/KWM-Tɴ @?}._E:.|,ge i|#B@,p  `(,amV!m_Q@#v aMk{! g9GdPz?(Yy2F{l:| IQr,YoI*>uq)h[ `s"0"C@aVblTO Z08l"Y/ sX|ɑ2pERE%@Y!`>dswx0-ș1 (/C=òk@˩QNl*/nX"D0/ m,e[#'[>W- x Ǘ(NU z N"DP&7" B C)Ȣ!: d~Fqi JXP1<2X[X([R6T M3^3>V6uıAKߵ> kM:vy6$QS@iejR`Q)#1ȡVq]hJOɴJ%!3å3M )qEdj˳]t@&RrF~X{]X(+ugeq@VCi{y}Z11}&P8*{J~yK^ ? RA*]fnrhoMȟP,ˮlU^!N_:ecUIN蟂+:R,4ӿ/@_,9(즋B2$t ,:+C5v*&)ӯ%k1r0!Zl1c]}:r xgS=6hV3Nd~ f ypT~], 'F䯶43\3oc؀5p F!'͟BԔ5,eiϚ} ol` G@4^Z6 7񓢫F: xrK@;z//0" ͽMĩ^hKfUl)?(e ={H}y}|-ci*ZB;l&lEY&;[WGegɫr5!n򧗬#PqXPV`LJ}#@HGbHreU"Oe^uK!n>Җbg"n#c&2q bzX4_O| ]k*5p3y*|p ZxXί:&n]˭/Z v]]M;io6OcAN>ٟN^ ;dж+xb8 L| j3N@>*9 &kpօZKS9o SKo05iͮW Zd='q*zBi7$"gJ yk/A{6, RTfjtfhV9=9Ȁ@K3 XRwQ_wPN@X0,D'[ʮ&9s 5|cEPlܰHx.*yi Bd&Klvd[(,}xOp@2j]ע`sBSnDj zѦzݨ"j0 u1D8!(xU36C9kW<@0YFjÝ]ߝṪiG 248 8ЛN`6aL1 rQqF@DXyRu+֟5}`}:w|&F?yzkH}D"u[]e+%yHo>.ӈGA}-uXcHyz AI2Ɠ s9b؜At4DBJW(,6-:pJeEJxHCGZ)=r -|oJ. c {}Ll?V:߳@X("2!rX|`"Cᨴ4H[Wlؤ43*U\lsmՃqS?=Ҧ9갶7w.dE5eziOcWI ZBփv=0i괔2eh(KZz,~xv?Z_`!n( xa$(UT`G-,3 sRFcDX,_\!!DRw ,6ҏ1,>D.D=r1f?i3RD~ ) Nܨp;Ǹ'VyI\S*?~XNQPL]XLv>,Y[ INQG~.S/ 8*D.FBoi a}+o{^j4shg2i(/6\N ) OtVM[)^^,|SKlƱq] BT(ŀ f]U*ލL{~ * 9>uR$`)C8֡ɨ Y9n5g6J3:7>XTR3q` r &tf`HvkQWqBaT9Ud^C>lJ&<׾q} z#>W[{%gϻmRt\x+i95(Qt?s/qf>9hT`!Poj$9s8ۆCr"ۇ='l/]rY1&نʲ3%O2My(}P@&‰cr=E5ruIf-mC'uFSY?K9`yM_63)x @Zao),+SQFeI=o؇a+zMVdޒ;b@ZJ8d<3Lȭ~g.=NʘP5'm2қL^z PĠ"¹X 1$9=r7ۛ/u _@% V˄5H=cbiXPuwaMYʔ7ٔIezȵ`@P /?F3l | i0Ƈi*fbR6acrS #u%N$1 [44gO0S/ EJKsv*ɥ xAMkps`9\e1?b)beߨࣾ3xS!GLSѰf.)&]bO!&'buV8} 1^wZޣ?,W̲ڼ>@? )2y^>%rjgQ>\{7_^X%  %Ry%nď> qFz;|E32d 1(b0NwuPLF5#4&@1S!sʲ\i-dgDXH-yH$d@DɗfLY}CWƋ$ {=QW`*~tGȋHқ I1: @] 2jG$)g7~';`rlTSJvB{t6zecU\]aAmB? /ƻm帶P]#\~ҟLW <t%^|l; %poƥe))'_t@@ $fn拮n7:޶ǰp5[x nrr+>Pvz.yp&au7@ ( z!_]$QLj 5&RH Oncׅ}t542-hp3qIQmRz|o<"xAiP0.F%Ǥ TӁsZ*mg2qY.aBw^4@&od'hB_d̅⠒rQ;=O6֘d ҙkGWn$qx (\*͏+̶>ɿ2ī-'I~<p@͕<%\lxp3M!F>8.F<-Evyzåy&LB͙ ]*t ~J*9 cQw_  :-cRƲ֗r%6,i# G'xOt X-> `EUe+;}ЮRyTgB3z2xa4KN{G'\('!LD b%ێT[lyۏHN,n(2. qQ!㪍KR<@lBM6rN>᝗䡣xΒ J"H"k5{j-{ /d-Xb뒒XP-U>KLj:inX'"AH;@JB ?&~lD"2=p¦U@ekDPP~5n՟7N] 3G,|i5i0n*,2$)X"*iQԂj:湟 na{g|xb^SpgbIGP"(u]BiX, Jc?̔(蹖A>8+n+{w^2cpQ6@Hś6\FއW?xQ>~9Շ6#g4v()VJ&L,vYĀPnX`#_dulB`q٨`5\0nrVO Ex0)9J'Nb#ȡ<=z!^Ob~n@OӡlBSsh5X[r9،pP@e:!`ǍwxX:dA̫O/N.,~*9@1 =˅evpơ&c_y{OSRȹ_S* 6,.㠑Ts[ݲRjGT1legRc|;KMJ/N"Ȃd(٥6w_7wˡ t|e 0XQlnn=D:U`BN ű4 JWgG'(&BD* V1 tBD(L Q 7RA.}.6,Sax- &>'F B^8_1Z)3VL@b P D4%CeǑKAG$P7AP@!>! *Xjr@Iڵn!+ uhA]%j:dB|o@eRy*KQ =ԬڊY =>(i+4`!RxDl,(✿k-J_IOY+F dP/VIߔU;z=kOa]XaK. Xq{ȲPhהTO5 JcA<=q k~x 4)`=TI7@R>I0ƧGf&~tE@~&V?>$5ȶ{+zZϩ!!3do#ʱ! (L@嚥pʓnX4t,_r4/4@uWZw] ѶWu,еXG: >V+t/ZQ+ ŵЊݜC]XG`*몓K%ȉl0`@LĄXfo(2Et5:etFe]Qͫ6=\|C )R bfɈl@EVy+z lΌi@ :a2֤vlJc/vR8<ΊGk悺2uU n-@ex˩Q8!}|w! @j/ 1+Uɟ^u1UcM;&֢ MY`B77 y sT@" >E|s18+D@$5R(d D*\B(&*@ 3Ɗ&+Ju+Fyy`R ^DK\7~J %_B>w3׾Wqn&VM ̚T |&*MgC]<oIʒLqgЧ" Kޕ@F" MKǓ)M+P(ﯿ_erܼi s`t`ی'p<!|W(*hŖ.A(R(7A_1ty,;ԛ^D.ێ5R;#r([ :{e/**kٌ{wTe$v=jlQ$GŒBP"D-uH-V JHϞH0TTʕC֪_Z͚+薗UgvÔ$]`[uX5Vv2a&Ō-B&]b߭2 J},YEtx BȆYTبo^j'a3z£n3bXFYDě|Szm`s1OPjېԢg7#0Z~)B\e@LI:B2E0dJ!|嵨K*HUp@ee<Wc5wjD?A78=u_ڀۘ(J$~r^w[c+JЧjzK8]3b%sc.Z *CV>2״ 9kC_G$:}b$ QWJLp(YgyH{S$+Te7gS՝,'~1ff*9+ _dFxX)8gk?F;gl'@n`26>Ej\-kV=jy"i^c8tlG2Ϊ MJǺԀ//߰KК؟ 莏rHHM͊(ަG`Y<\{"㩊f75޹:M8 z{}RnӾuۧ"5Vt:I%s)C/&Ò[!$mI|nfYđwKEIy(@:%KGm,jfXwrP9;2 zG EnF#]\G2(`AI&.wqv|AGГ[/QZ 䲌P"IFJQ\{՜'H?;Vdꩨ `Z"8@>"2M2M/w 5 s08, {4惊P +8洠iX,d70캚. sSYE\%-#+e'V)iU,5}%\Y,=$;[}[P2N"bk+Y Jon4ך [,vI`9`wA)?>$ayW60;`ѻٛrN)=Nc[@8ݞq%ٟ3m(DҪ1Nj*D-vd)Z3q9(r!J!?&EUNi@/PgB=@ gtNmˤmlfȱGee)}(”e/IF8 Wz-k~,˶c` XmJsz]\TL] -K/CsVu<˥%\yg yFuZNȰ.G:y3zU"6 uCHsq^@-0m]C3dL "p qR/nru F*<-M=)BnBcХ*ZfI/Q=5P~n kDɟ7~75bg/ãsIus.d;T׍K;=8$V%י1kBu;R+'ϓqn8McI3";@ϵ-LꈹR^O*30YCj4E?jFh՚e@ iO?^C.@ T썧=I|I^q'qBF` _,+\d/ t<*XC K/!HCaDM{? OICnr$̋>N51R J\+&*Huvɼ<"d<hcL!7˱ռ`H"4lF6fj~!Ufx,UHU#Mz7Z4򑔥#3^8L%Bq-cpO5!H c@Uʳuy[t&tD6I9/(\YW¢S`|Ej5u(!Ckg"cKvݮp~9EEzr^%zYn(rI=iKn9\$)e Vsi'+sJY{.,1c `4 ; YQdڹĹQ9㌃^+0'?gZd+‟+؇OK+6E5#>YC;l2?'fal p\bw}ްR#\ &}03<`r +;*tL/[t+!5q"lK1K%/q__Q\s+ tutIO lJ6lr2fI+8R-àxkI͘YHo14كK~<ۘIw&33*z. KCI&Qv{[R&DD,f]gw? 68,7"rZ; =<灗 %Rv:Ғ,k='-FrvʮplPO6_߹)#ahj*>̶v㖀DxZ ~8H%u9?0ff6J>dߟg{=aVgW_Or'jyo5"Ct۩]hw""5hϼ%i)iA&2f}2W[]g z#+&(3|..z'M|s?~l[NWCg=Ƚ <{(S[{)tzjӯVcMז^ G>~d:X;fԞ;$̏KZPXGÃJ!gW ?]AGT. Ȁ?@+(@@bD}tz#28*dy19 'gW 5prqSţ 𡣋 ~^m*y J˗5FurmBui{xUV!=k:x6 HqvD޽!4G{>aФPiɱjge$u>-.m o}Fj_q5wB^=ȷz"sK`}M׏RRWL[ OSb2#cg>6Aj*2ܜj4qȂmF3{XW٧MA$QCQnhSPJRr'0w^>|ܰ)M19XW >.˫Yx+m|,dv8PqNT޸EYY8 瑺<>PX^YC8߽l|RcΔgsupzN&5|CՑi@ |c0V/Rv3mu u13{`@ImdХ$4}h~C8ٕ*]]pXopEr8͚:cP&j{zx_'wgZ(P`b7+5 >~&R2*k3y?EBpw=׍@PMKo'z.F!ziII%ltaœ,@ٚ} gHYHuVHޘ_1hB=PVˑaT EWBʴE;ۆ;|U09H *NU쭁16Z Ϝ~5^LC&M1Pj'{蛼'!w"rW'=<"h@>gRw^|W14%_ZLgI,na.S<TM|v0ۣtN4wȀr7 _^\ &Yj~9^(93{dr<\ֱX.%I,/X+.3`,](3b>=R`(R|{6}6I5y㽧y,& TF=h IXqVݼUu7Vo1) E8$d݇6!b?>uNʽkeg{R/CniB;7ȑA(H#E{}ǡXb8A+Ly(n-q!C?̇}yэW7*Btwm{C7/ - ]Ƒ˨ blOvKQ/!9Ë,"\\P.8ц1X{icKuxfIY^s"Wb|$&VoAO>vр0㿩s9z%R0u/r?9&pKsx n3.{.x)CT~\zE6n/ז/P:U°'qxe|^7)=@9L-NNtG"Wmmy\y5uX~$^ıdePzu:ԆCd.Z p8 S:L ?CG!\}@5<<Pg4u1{}pn%>W12O)G l539 =iө<!?[W y'/|\^,Z$G"/WcX"P@I@ug4$YzEO [N\ jOȅ!J0mN5m}UCl&@rz$Y.HAyEk^gDLwvG}HO=/ǎ5K HM=!?x90'/q澩,@Y%p3-(A`ˆXu{rD^39D j gO޳P@@'9>^K OMQ9\Qӭ/@')G_({^Og>ac߀/5/Fڐ`h \S@҇{@j -ǽg;T7mװ G&)h_:aܛ +6SAXPy w5ԛY')3ɽ ֨SI9+a4Du½u?vVXsQ97,m|ӎnN\xU]ѯˎ̿@(qP}q \`hXۈЅz^F˺^m^ vMjد7S9A=-cIQ*]_nyiA_~C1@QXq}:;,[*Ʌp6H{Xv,fŤGÅتvn lawFvˏVJ8 4|\+V|GԶ>%ؘm)]P4bx 8"\)i,_zur vK/³ qoN |b9/U$H;*+Qh[ubN1<1Tˁ>9pCN[#-=5roG6Xwo>o&xP#OGV{(ȗGq}_{LijB[ dHZ=և7x}3>Ҋ";oy}glNְc=Y}r9l9GdyErN{z8k0j P1=R Mq܁ x0-h4>fRysXys?,;4ګq8MqyO1@8^X<gY]g=rJxÂ=s~<ɧ}$" _ĻvGHW,7]qm(5Ȓ^,/8wk+ '}-ʺ~ }/HW{6_|B_F>ze`>55ٮ\Q'w\ l-"&f(%0=} ndy۷wDZy :ٗ:ᦽBiNgnR#ӎuYȾ/d9Ĩ[AoCK4宒?b0 `՗/*_c^j7;+|by5GwIÕ}N7q ڂ "#r fe pQlilg yU!<~}Q?]^zʭe*;xZ>|fYs\V }_i)i$tBKX0Er ؈ݐx>MOQMo Tp>y HI5E,#XQ@ ;]>[)G@v8:u @Fpy(dm{ `]vg!9AεQ`^O@Ye .}#|Y˾`kVLaٗ@6\Fh(}02'pҙc1UOLvR>ﰼ#P @s&؆<*xZ }ͧC "||!M11ןݸ\y߷GW_z|JmKpbKΗ؈Co ? dP[\$]r=$uDWP 7 3_DsmWk6,)Rt&02"[\yxp,+Y޾ePr-OˊNO?(?y]G+63/ɍW(G`LgcDNv SnߺV>}=G@~i!~Pa1 P9x*η@(_yM^ P& ] K+)Mzd5ؤJ(*{d_[bZxQ=Lo[;%XZ?bO㬁"QF|-0i4a#J#jΞ${rFl|.'IcɃ1 l%p=Q|AjC ;j]OQp^}dl2~5=>ޗ˩@pMjgBx1R&怷P?)&[[OA!|s-3#g"Kll e{ kVG 9Tu6Qt89%SɳHWT.=|BN SqxJ8;N҇@0VbRXa1 $u.x&$̒<^n T?#okEf  N`,QC t"@Ԯee'AykэC(4!*e 0DuXKGy| o1%J!pXD !tBLգe|_D'vb<ƚ{@7~fs<c"6o9#zAOAs)Xjt{tSTa} D0xph/+UA9,E7LX}jǢ=X-_.sr׆^D Ƥ߽ 9^w;t`{j.g̫'TsZ>v?Ū$B5_Tea&'KnöhHy)n"Gae{@^wj*NmL\>+'wI=0;Ù䦵urÆj} 6z)rs`A^7@ByT+NE`_YS'0xX㊊u9瘊q)} lح;~^<"r7b(rm h [#7Dj .wAiDkR~-cA|lcĎ$ox<;_6\6sxH#?|:cI<}Zm _RK,`qDnI,G֮,VW>Oљb3[ ?+b :b{QCpdkjwly$Ungf9h\\m =p*-}Ƨi1>@w hSrwO9İ"Q)@zdf-*5/I5#G@V:۰L|:V  \"" Zbk i_GӯFe/>|7-O`}_k T؝4"%NSuaQ/XZ[ʯ=Wn_>]OA.U)<B~ܳ{?~ =%Ӑ~3P7l>篁x N!N'ֻ^9!L:cZrݟ=rBn#7]?֡ &Dip-Ox%əbw.o' j)*E"R豐 0B0) gfЅLRB`leL)|)`S!RF}Z'R0^9`.I[{{|%T\5lx҇Dʜ"=EYwΓp,:PYW+.t| )!~Tx:"}M=W~ P A _(I0%Z?~|`n1y7PޝE[\/Ӭw)|@/oLVAyȠwGVVKxI~u_|~?pium޷5cŸ~?5[{ZcjTvZw?3[5f#ں߳=z|U}>!/n͟'~;Ƒlb. 1r4 G@Q녞E)? /BA\A WW?屮& tB i g>DD eGChfB:2,,5ܵZy/o0* b4F D-=}ؘBP5pP3=\2??t(Ȼ/&58l,b0To0_*"aL}Ox>C\)xQ}^W+;&-߄/5_{5cJm+"( {HW}ocYE\\/7W {̓mx^uE(7b<?.YR%{눵8[ :[J57Bwv~v>#ϧm$K>1m4bao0VJs8Yzޚkϳdi\jWמaQ}-\"4@ٵX>>ON\2b"= 2g/$T|oy/@j8#e=5T#^' 7F%V(p )5ڕ]bBV^=_l5;Ν:Ps|vEk=#?Y}= {\6k+}Ytq87%ǵ︽mv֔Rpti8>G=ެ*@͜T޻Vq۷SyEBCGBttJCﺻnm&up$/ ԭτkޒ8]Ŕ=u$(\p_mj¦58l ^$6ƫL2w hLt UgAMyb +#G]-_m ~X .͡^1l:!`3wtaaS^VN/CӷTC!P[MTݚh0q\QZ5+a3.'Y=eT y8HR!4YW9|*Pz]'VV$_i/-Enn}BۯŜw^-JT}p*,ѓr`5M#ߏ˰D`>~9gq7dj+o*5b~-%Bgc=o:3 1NoR}mT/ߏﴧc)Libn /_}}fֲtwq*hd]l;[59vfH20^ϗ;/zVK^kS`8K9lǠ_P3=ȫQQ=PsشqHJ'L|c4f pI$ Q}<qa'RP@`zp4#r()9)&4/G!ਭBXr`! ӼF>K $ȿٸVD? ਉhR8u㊓y~[0&k7pga] $^x7o%hYw ΗozB! sk2 ۩?/jR\ڃ8ƛwyakBCqAA#|`b6)%K(+0Zhfg"2 G]D 6 J\ {"8(&ۅz@0K?LhD<"d;҉(rOBw߽"drya^'_YR-m'@FӔ;}64Jb <CΓ2jj\>{j*@){bf:;o)WS󯵟cwj"|fez E~ڰK6lFYdu9JJ,;ϙ:e]&CGJ(g (ZHO7PLA֙^^쀁0dMBUvxB,-zyX0^CJ:'.<6̨&h5@}:h0:aH5 "tckc(O=Ͻ00u8<-8B~xJaRnf^QgM1"${&.tx/\DaM0Ō7!:GZύ]ȼO@B΁T] .MOu>÷`0R3qp #б d)7}ML h_to#Ct(ҸqxY#@$-{!+{ NZ Gp9F@*$-LpCa$_ VƆ%P1H%Nj;a- 0}︂l=^7L$8n)8p?H~dA?0wT"޸߶0Gٝ_^r&'" (@du~I"]Wy1:ΌL!.Lb |j`;P ӲN5[!; 4w5ϫ&R~eUZ6 _&Kvw$+|@s&Oʻ!hѩRwpcHPf nU\Y`ȹ>4D'7~,ls? &о~I*Al[ovodnV+pp%v.Q"40)8`'R2fzRǤ/Nb[FI BYn$BS.5櫝WD$ZwmXUUxN8"A'AwT~o/4 @ \&H"Դh<ܯ|DIV!n*GZ9g@"Bk%^-9pv}1D Y_q ߟgW ,X5쾑ig%J<[lŗIl#Qw>,[u@14|Hbl{*V r!`Dc/;`;S}]g&PGFx3Hr'aMFY/5w-l˅8+ӬT*r̎ N-?Nquvw ڟ X?cN՘o79|Ʊ|.c @?tO <>Su/hg ,t--T{W`_W08+3Hz9IENDB`Fe@RAfy`c^lJFIFC     C  Tc" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?((((>/Z}g~4W$:?-jzqСw|II&::~_L3(K&f]On/.')"H7Ue?j+0+Ú̱@mk7֨y5 mW3,oQ !T{`,ui7Gþ3յ 6u7~ iֻSW7-Sw,wyۖ?QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEVgi>Vp[Z^Gr}I ̠Bߟ({v%7_6K:+[꺫"G>\CM&u,UOgp|y-' lѴOmw'α¤]$%X2ͳ O DҼ=m2qO\Iu{|ϖrƑ۩J,pT ?.5߄^;U$II gmV*U?ث෍O['%Ev4_i2mwm-Jn85r5ֿH3wDMe(^W.巖\SoyB '$~wn] 7t=<+kXVx&V&!wvO$k+YePb?+/ž8W45Kl"]ڄv /#?: kY-|Wi6,.SpGoDH[UB$><|S@(=+GzL>W2u@9T"33j3u>ҟsbƏ~Q_?xF~$agPT;mޝ4Đi}Z4A}PA._Q5cj+w{G%u߅_40A!WEVv(aEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP8 -~> q>;ٿNZ}@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@xtNVi鬰ZF%.."G+B3*0_x@ykzf=\0[B$B$5ֿo(/d/s^7฿@RkKM^+#l#nZ[Q?`?"i?B/z7 7^Hl0Y-?|NZ?f+[xcߊmmc}smv&NŅHÚJ_'"/sJx¶~6zx\-bY>֊sRڮN` ~:6K&5Ԣ[ۘ5~BHPC\a%R|WI ~%kVky@KٴH͑gCU W?@\O뿷nj>&Í'5I5H*is3G LeQN+# IWw9Y%6 *0I9&9{om!~~<5%4#gUƤI$a;}GQ ]Z[[x̗7$%9$_R-g&ljK~!|\=(rre0~? ;Nÿ ]>v,$ B!Ptuc 7ga{Iԩ}ӯcLs]S᦯ucŐxFe]>)~ǏxVlw,3 ?Ieǁ?rUo <~co|\#n5.Xd-t=zTtk +h[YEʪY7V{Uͱ*8,7x?/ۯՠa3]bԮ_2W1_A6ja/ [!x[wR&"M~QҒIwp}w'KySk4_m R1̐u_&7G ?*j1]EYS܏|Oiix#짠Y\gKimsyo'sCg&e>[$yQԭɑ_xQG${<S5k,32l˽&Qcr9nm+O[~?qO⦙yOt[2ܭgʃ-o%|iJns>:շj _ |b[on ݏbc,H$Ò@C!~V񒒺=|6+(((((((((((((((((((((((((((((((((((((((((((((((?N'o7_(((((((((((((((((((((((((((({ğC^"^h[x_Ż 0[(s\0F۴~9?o|,x/|;]WT/7݅6ib'&9FϘd^%GtOߵխcl ww4tI6 9 kKgB{^׍|Ac;KLIu rN?%+?~(:>;оGI#,6~l#a]>"6~ǿSEEcܛ`LriM.ߦ ۧRU3`=m9tN˜u9Q[JL1s"2{ #@࿉,>~jJS#N2FJrAUh';Ohe鶑Yımj#E $K+U1w5n<7N au-}ko- Rv"Ysdᇝw~'}C xMkxz+69mٺr-ESw?I?$Od}6Zj.ge,k$>pV6 $̥s&>^U{V>kx\_y/$p_JQ'Ї׷nwR3j[-ǝqAw4 ?A4;];Mac`*(?4P"RQa |׫NFT6,dB{`U9etx4Kɯ&|7 ꖑiڕ.Du$2A__W UBhain>\ީP/8oXCx_,SlCiU0U=րEyaT|> /Kvl$xLj2Jsڼw ~Rk dږ{G.;c*4衎Q4=Q@Q@PH$ +sUa4>b׭IdcOIQt"mSV3%ġ#ff ( jK[W+Ri0M+2HTbH@Q@Q@Q@Sfx* ۩QEQEQEs?2|,>~5Nυ 3ukz h$$(2#?>:ޤݭ:4ʹ2Fq,J1;,.F>((((((((((((((((((((((((> q>;ٿNZ}_ ||v' ( ( ( ( ( (>'~ |R}~5>{=nbybrP 2{E~Y1?hߨԕυUgyF-ZOx|}ZP-I/qlKK~_O|}_H"&_TWWBYl?7eD-{"E':oOsq49;w08_U~,_w\WQ'V8 8Zsgt/_WJPi?qu~^wF~՟dXxߎBMg4d H|NOWW?&Hk,0UQitv?6d|?PIΚM'{ni}7ۿ/oj_ OC.qzn^_m_ҿm~WGdl>ö9Z>-cW,~&)NnWQZIoe7di94+Rud!Q0#gcS૏dkki,;gTGd*dCc?~ؕ/_Fd yvUcxS/pE2I][[Z;s,WV{(&Iiw^ߴ1~:|~ γo$lmO$lbF\u58?*? ?kĿI 5߉xO ^6m}~9|-1s+ʸ7Գ|νJjW|*BOs.UQRmr;8ǯsp+3^g/ßᾝo/FXJl/D%xUr;WCE{G~O!~dx}nO(κ^dq;sp>g<FYF*ujs$ԓKXG[ۯ]ÎxC:B.VӋM]YiRzZn^_H/?m(&;bF B?_ŭhZѼ4lMˀ8$ιV5/ڧI_I}L׎|',EVRQwvM;$ 3~^?O1AZKsӮ`/xT@99'l|CKZ^8t?XGU5:NV1މ_O5kZ?;a^͆eՕg+,R taT]qx~QNTjF鶞}RJi8 ^8FJE4^ͷ{ȷ4 +aQK1` /V_ Xa_pGu׳&/C>'בwJv23|'4~ǟ|%_]xw^v6C*X\eYH`{ q^7!8d:Wk[;8npw4x59TD__U'OՏ=xt-?R%Y76q1*1x>s Gyߍ>kZ/'!d:x5cE498c|?7>|Xlv`+yqێ3kʲ^ 'G7N&3ejV>8ϸU| NP)4REy'>s G'<_"5Mwk? WVz/o/3f߷vvgȯҏ.73 !ՃtM'qENu2* 'l,3N#U5Q'o "r4mȪ9+ffϒxxYtۉ&UIf߼sWWa)j '*jOoz-Z^|0W2ZWŠ+ou%qWgilx}lLiVN4J}kコQ_}QEQEQEWIO$ie:-+ cEe}gݳ´ ͪS/(D-W#Mt+}C-<Τ+ΒɄƌF. 濌O?bߍ&@o[Ȯ|9)s4rZ2?7.2Q$@?{ O,Qk1ajΑl:=^d@呇_O*C_OZjS~=_͎MӠuinԆE`T6 _ ƐI Ös^8y IH$g_>_>K/uQsk-[]Œ7$H<A ? iW,4MG^n,좂}N P;XP2NW'~G ~.,n_Hr1̄3(ɕ A6ݴ%MF1NE; 82)+[ Q+xft+\:>󶷫J)ߞT:rNlMeN6>s<ԋX:ߞQ?|3kV|ok5ar2t7_z SD8un1W*5Qv8)0F u'T'N㤟r_AӮMʹrE Uz(U.:#[^:tgmO=Y|:HtG+/_"i.+;wGTU?+V_O_i.*9~1bO9T*̏ΦOR*OLrԿgg#"_.,RO@ >K ^*xLDv<@/M:MwG:Ө+>#Gg*Ϊi?k>"X*}%EnYӪ:5r?ySG<η]!/[<3"s~.> [m|SG$>9Q(V8ȯR|q!|k%>\kcCV=Məv?n#>Y __՟oړὁ_xj5S7#u]譨by&yYb|Ku˳?z+7 w'-?u?Ŀ0e0kaiD^66z]f[Xg23OzW}oJ?jφ^1~'E,o[FyZ(df͖\אKQZ~^: Y  ~<^ZGgO'h4Ori<5]Xow}[t\ &2q+̏?ŚWᎲ5_ +ϣ߳3+Z _EO7dwo7xZ9AqvLk6z?ؿ,c%~)|~ךo|Y8jV Xj ck 2#;q%eXW+ b*'??85 |C]/K_ qZ`[;k]^ 6GB W E;Y>7AoO<:hןjFivc9<Y: lOj uZZ.,-TΖVU@|şjਿHc _ h`^hږy53|RnqcJ?g `6g(4]@cvV JEZoJ?h/?|e6_äZnƯLbw Lw,m Ag r:|eH𧅴Oqͪk l,y,B$_}R?w ~̷$GkwmM.-iPl8<__D%h&_M|)x~]ƚBI~qF#J\F_!Avm@?s[_Ĉ~iX\]\{=S^af{uHWJ/}gyiEiQoXgicWj_?JKg<_֯Q[B ׿Z5~oj i߳<|EvjE؅IxQO ^?SV񅔶L1Yݐ$P)i|bW!L~?oo_}>/Dfy1*dLDq1q_a)OI\g|C|\G_Z;g\g/,#EP"G|^#UԼ Afdk\ƿ8P;_y?O ~#16sZ5\B$XWSj`j G,bci|7wŷzR4qЋh㝁^{m9G <{kak -k< mR<ԐjGW&?Sl._/ӴiPΏ^wȲ*LȰFVČ q\_&hZ:skj60A`I84NxM o#|Z b6%;پMVA]~K?$H_`~yWmqڀ?_؟ eEcHߺed%4WτOWP-|/xţRwkUhC{v5PNz~??^:6G@a ɊU<2A1yw]]?dOgXe5J|BZu"$G;xF`Y@<w'_ӵ4?м{n.E82A+,F\?WGGj7O&MsW{ei[QbBc|{|3o?U[[ity"|-:&Fw+p"(c[/nnvP+l?q_7R:!50ޯ m܂8L6 ovƁW=p(QEQEQEQEQEQEQEQESf$B|cZ~=Nu4} Fp1__œ!VT{>[7~k>+x ROik4nuE6_ooO,o?qVDW̿* >#fW@IWe g|EQ g|EQ2,?6e ? 'E6_woO,o?ooO,o?/ #fW@IWe fDQ gDQ2,?6e ? 'E6__g_,owoO,o?/ #fW@IWe gDQ g|EQ2,?6e ? 'E6_woO,o?ooO,o?/ #fW@IWe gDQ g|EQ2,?6e ? 'E6__g_,oooO,o?/ #fW@IWe fDRۇbjψxR?T?2LOR?wa5=2X/:D)R?9)"[ӗZSC#q~տ82,_O&_/}㏉'a\Kqq-ŽW 0˖-Nc!r5ԒV?J+OEſQ _䏒݄)k?J+OEſQ?1Oo|YyC:??k/MBmk{iu-m Fق@ݑ3Nkپ ?n_𯋼AxR+ +v7')܅ v_o%2:>cf%"pY+MC2WdmÆ>Q!7i+]a_r?w#F+BorO?%m'x*'ȟG-k?!c4[Iuî: ?:_~??OOi|G񾹢)_Ds)Vpexpc)8ë֭C9YWxFx|K^ϿE(WXM{?kc|T5Nq!R ؋8f8zW&A5ixǖK 5tC$wc3WROƷ%S/q?-LڍljuyBXi>if?S$)?:zv)x fk>=Q:ipbHUdjXsk=l-j;6kcMH;TI28p`JH1\OƓy4(O>eC$YmFRpo2NkIjF-{Ҷj܉Ommd.gĹm+ NRMrFnN]Z7LxgkI7b9/= Mm.KOu]#,jI޺Z3gWN45qUw[OhrņCzF6_?NGE_4,Wa/%"g0xSᏈQ i  W5:nod~q~_')6OkN/FSr".yІhJHF;O_oZ=5?xJ n'M[~\6"EHO#lf2e*5KuxpϹ(AaG T/7 qxNo Y-SP>%Yg<]f80bG(g/O|+n>~m1#=ؓ޿?ο&xP~:η3z|CFhM]G$Jc#FGs 㟊zoe|8oF%OM8>QWfUCFUgU/.O(O­E'A5+{wߘcUy‡fxWm+|𔡭tkMmؼzv~b->Ũ|O>4H- #R_}ϝ+TL֞&~G7!KO/YZF o7OzOּt?Eu?p/>6xFY[pe_Jsf?7Va>gu(oZ+TQE}yqS~ζ/gsAXܤ 8 sWtV2?;3 բ2¿"qm5#2}RuYmく|j)k.Qo ij̲#z:ӫNi}ֽ=׆n-WJRl@2u\`R,1~-&J iu-m6>Yz#~lxX!; ^i[]FOݑL?)%Ϳ?kY[yAM`,*UwEBjc2O.9p}7W<͏Ƽqn&*|pg5ϙxDZK9_^|xsPWfo{A3!(^%7H.~ S\֊'GK77m&ӯI &hb+ď<ُL? 8j3#Hw/ਚ?/sm}NHЮ\-ſ'xg&xV3by$'%d`OZ fz5T3·U~GEQ^_{?m_-i:&1ki_HEp?}\-~_oJ|ߎt6wc' >e GzI?_F[ ž%;#;ˁ3GֿI~%> >kۇ^u-}LtEyt3E Kqw"~߲m)K}jhա,?OBS,!Ccq_X[Gei 14 `- um%1D*H푊#f'_M-/d~NV.ʸZ#MO*z^ K.Gio ,6*>TaU爬c1@S/*f{i/Wi-X[SLr, b@2X<$ c~|:h k߳g3ZwSw׉<*Bi#G$&5ҶgO4|C}٫cW=NZj!h]ʭ 5?-J,k??i|wL_-gWNRmBVh,x_5C د'k;/SgxDXQCxi!S"dS1E'vJ~ 58W_:/<7g4~'f$ܚ9?eOC'%-tW@Ԓ[M_wI:(HL.AVVp{Bx??g#~k>%xƙmjn.5+}m 7c\zi'9cO=+x'Ɨ H=gCE {rK3E |:{9k=NM.NU{ @o ? |/oxkzd:~Z1ġcwp[:?#SR:,Q?%G|`W (kE-_o gĿ thZxF+;GW֛\ӼA =6v|A`?oN'qOxak;,ڔ.͒ld&j٧Yl~ V?/Ʊ$۴{.c7 إok'ïᲀ@B*r$9?'W1hu5B~t縊dᢛ1J@$d{_C ' /_߱Wm7J +-6YnQe1l@(ȼ* #x;~ѿJ''oE~F&ӥae ߞa0O/rq%xaWL<7F%%YdXĎK4οMKſkT['fS]b9Dd7F댕p>m35/كjGrvS_B5g-,9?x#x;K]B#XGump^)VW2 ?x? e 7uP6?7? C@~xxW00Qq 9ifTܠcguC+e"M_=K+O|-6=Z>im$Q* RjO-3:lOEy̻ dvO2{Lm~\eO ^x;l'iZ/ i1C=O50m>W{@Q@Q@Q@Q@Q@Q@Q@Q@ C.<YjgP_˷?x-qZksJy7 d ~ξ,K&⯱iM=Ɇ,cyc>XJc E'ᦁ->ladkϸIQ WxTiӓR4vvWRϒ+q4ՊiBOUuwh;b7:Mg&kOLfe C~˾Nh1i;B:kkyR5Czuy /-^g_x]\&M +<=%p'9^t%hS/(Qŵ#hTJq2eG.~޿ #% ^)R5ۃD8?Z|[+afhNͫݤor=l/Z W`*my~)wI>t kAjA_et$Nk$H, ~~ w#HOI,FA|Eh$=CWpc2{a8yiV$-}|NpL^e4isKݺ]<ؑ@c;M?b ;Lٿ_$#h~ʰ???†33V(V^ݻw?Y`5 ՝Z)d_/ xmO4YW|4 * fdG`*S;ןSYirY؞I=M6)/ MgNM#?n'LDž,5B/MKN,`#9Wd@ _ſo?!43_m ~3][2/)*U$8:6G.#NjQJR&~Ug|kae?H|;{ dzc޿_x<]>յVm:"M#=~r>(¹|xI˹NeVM q׎΃tIs=$(F⒲rmޑKͣ77{ i63OcψjKo߳uS \xzN3UC +c A_ ?l|4<:g?| jo uj.BʹM,qk*7cσ'㎉jOJ֗fy$l R2Þk?PoZP/e~#v?V$5g/<[(K.g_To~UaaT)'8rʕ̺6ow(g]5}o_$ SK)_g3W^((O (>@3)fO9k|gSr((( +) mWWU;|&5XנYmL*Aсw@$?i*Gy;Pi0Rw~  1sfX L>U?32Uf]/ew-}lƖ37Ȣ'iI%vZn|;E}7nkO٧oƙxSÚb1iEoyP3G#>d[Ὣ+g8z?̰kQ2du8kN(?<3gk][F^i `!:|͜o?d5߇H( cㅩFS+]m}/YKNiI7{$里OJ#N?C/?)Tk/ mq=BdW;?͗¿ὑ^-Ige)qq5?SkÿW!_Y ZcEDp7;6Qɯ1ys4:TS?~d_VjN:ߞ]}l;QEVǧbQ'E@I)}_$Wz銧N)"r?6ipc ?!ɷw9kbz~g ރTqtJ[10{ orzt\Lavn52˱ pXTI+y=Ks6Jŏi_6Z+O'/F{k)t^)>'K%v|lb60YV%NJ6vkhi=YN?#z8/Cegz^xq[Ǹj@;eXx;(J6i1zsgП'/K 7_@v1č?geԮ ,21Qf>j_FU` OOݕݜ." ey,ΰ\ 413ssJ\A#v]eC^Ͱ 8SV%dyO?ߵ>&XusxcM~o l~4TE %冶,vqN1kg\ |:>xgㆯ[m-[Sq;ddo%=#gTfkQK>g:%:%tN۹Kv<_I?*~?|(oGx\?/7dZ+wrqO7^JRВn"f$UGsTW{5tE񷆘\F]NyFeN׋]tֽ~?h;1Ԣ7;*8دom{o(Zacn?>,5MlM֎-Ma$UWܬU[`xOAr'ūW25>0\g+^vcZԪ5,^庵cƜ5|KT/Z\O[Yߕ/ni .j;;geeԫ!~<'ʻW{bD:F Ju/۷Շs-JHK AmtE9 2ǵ1^zc'cR8ZHv&mmA_ 8,<yҖ^2KFߣ= mkC>Џ_io"p]K_Z3gWN?N"g>Z|mfQZiyr4ő)ԫӎ>-%t{׽\n?c;o??YK oM_?5MM,I2;sz2 a灩ΣZ䏈𿆳bi'Wմ=oJѵDv 񞌎X~ E~pNEՙ]'bK>7 ɪaWWnwz+Fx?n+]WƂBVF .#@Iʧ9?Q+JD_)] ; 1_wq1Ji$FQM4S/*#FYu<#P(J J2mMM~Cq_-/xP$7zͭ&eh܌o޼URq?OE twgzU" x;kS|Gٿ񗎮ŚoDyo(N,A#v 3/ eʕf՜-nmùNe ~'6̒jܩA;pѾͷ?b(/4!#' EUc kh7[=c`Mcę0t%~JjҌlֽUc~qm,\q"wxGQE|EPEPY5Qei)hikZӯ೿V?Hoي<$|MMx+[ەMM4% v Kn<?+ go?ν♾9|:t[a0,+]*;_ο¯)1>#7#5_j6.6SHowo"-̉EI?n'C LzdԶƾPN;v ׇg#|W T1q ĪG@_jOC4]|dwg|Z5f9lY y 20>=iO쑣jWE_֡F.a&#޿z-gG$zL_?ਟ|l.]'N!-{}ûZ>kq>._i _=KQcWLҔlS{vF9y0GG^;b2VQZgFqH8.:{Μ&E+\Xs(*~8?WC"zkqh]aO)#K^n?j`Ğ=U~.$/zG?ܹ#hGN|LmQ_t~~|B^ψzk7]VRokڼm65m7]@Vcr4peW#O!G ; Wc7jr{fң//[W&Ӽ+@jWZA-$8UP=I"~t 4 K=q;TJ'H?Go[?_lm-5xi$#cO5 }>M)UVӵpJW_G⾟_sW*_eӋ+H`A HoowMflj/x|+?yysePp6MyMMK?~5 j{A2n1]Hʌά1'#kWd<챹}+ɿ_?c~ƾvj|Hu]v~NmeVu$ 367> !I=ͧ]'/*O]3?k᧊Q"i:kHWƌY:'88?oMo d(GtKP2I8PTKJiCt5v (,p"(3=IW7 >!|?64xFkNd<ǰyF1_v ˤk6E>WN+>؝]}o);z]v/5CkWomcݻfyU߇?H3V/?a] J7"V2W̸:?igc OΞyO/|k59K;o'3E?iݻ'c|-߳'MK|?|="xK-7öZdysqU2@} e_ڧ5s7^"],]q>^/n~EJĞڞem!Hh~{]/H3}OIa}j6 fh<$q+fUtatl=Ax4, r#xo+6? @N[mۃshHZ~-zxǶ#qFN ~ ?ߵq?_ hx9l-^V6wQI*+-:Af*@PiA+Q<̷]0jz(CWReA(j}K 8 :`QEUԵF ub777 ~ TT6:6J~b((((((((?ʿoZFQ3ǟW\/y 6?.OvLqXƾ9H+(xĺG<1x>Ea5gˆ$.*Shھ ^.{Kh-fC7P؂ |a~>~%w m8,ג<|t:|3[,؅s_,}U=yp,4j ~EGƾ0u5qRX+KF~\ G=jO1[KS#5O|aoU}_u>'½|,7'^a䩓l`~_bW~_WÚh?iwu{A o&X|1 dy3 41X)IfZ-3pX#a0* ✛Ishof5Ofѷ?Z&QOfѷ?Z&W8o}UaS?Sg;a k.o a*$O[PGZ.3GO߆d]b^FgcXI&k0ͫ:TMJȲ쌛lZ?-ω,>Y5y? $k'a ,tU\0^M ]s,Wϙo=Jn$wNG@ߵg~7~:g˽V%G:}틸-kiu(s¿I(-"i/?- K1嬗$կ8/j~ עi7Ѵu#l<"][=.3'i.KS/9fM5u]j咊_o:9?v|Twѿt~Y>k%iZl^*|Mϊ4(珴r'A'q粍(Ofz6^Guļ= V?iI}j_v|:(Cw(g]5}o_$ SKL%p?( (?OoӖ__8 -~(((ˏ8׈t~=jQMkQF [za3c)+Q_־|zwƃ}(,274~\*P}+è8cכ\>V?|M*\iӗ<~w>_x?/>wSԎcBm?z׏ltڇy}@Zkijj#nP f ;Ow }3c^aaU iJWmr~-'s<[KEƢQO-}k?G{$9Mfr>1Z5]/CӦF ;Kh̗WS,qĀd3S_ ?੗Ɲ߱?I$KꚆ"L#]߁9^;j ƽo\/4ǸF݊D%>s_&o|A,mY*4d-{~ %]zɷoMd?Yl.* ||B2Ej8| |W;^~h|kw 6?!a*SrI3߇;$aS嬾]%|%ˉ-.mX(ܯ C+>°%|]wFkjA"-K?5#q/~׸A\/ ij"ɶ5HRY0[b68WA_r?w#{+gTpSFCzE_:i;=//O?}}O?}}؟yj ~k^v~XUfu]\Rd6qھw?m+x3%Vre库~s?v ~(xĢ: ٿcvz>WB[^Ԛ nf#FU]OP@: 6 2WNcEIʜ&~?4C8eRҊwX>x?VnWvý.UG ޺x0Э|Q=rSoY_\,H`}A-/rѿg_L0?%&;̡UU[M+.hsi|9X\(ƃRMg˪:>#|aOLoz[;n5ZUlu Q|_:sMl &Ð> E`T_o r? ~6IkZ>~ŖH#)*=G_̯/'}WK%xOuBWD;ݾǼe*R{G%jK3 um29dGPE>ȁE-lWkG\]% IbQTIbHI5l5⹳y1s݅d߲Bdm2:=GiT~ʾ ך($rsN+ & ċ/=aUUnVW6q#<\nY:J1i&|~'iڣf7.'? zNd/4Gְ`:;ST?d[D6E_ْ%~Z?"?=^g`lE OWM.[1"Uyz_=v9WJqN#$&+7`zJIٻ2q?o-G^0'Z|ql'u[.3ԛȑ8Kn3|WK-?i_&2Zx{Ƴ\1d`Hp\ F_;6C/xE4[ͩ[~GxfK/Ͱn˙]\oٮQE~f~QEq_?iO{+VNI;m2G+:w(#)ԢK-a6#fѳKw7o# '_x7*xS!f|Oʷn@!7aHjg 1`տ`/޺*jgگ!P3~fO|A|kxϳ2D~]-  I }7eŚw18旨{h4jM)+4\=E3^??>k/ú֖Ϗ2}y\WyI);Q>.]ύM{þ)׮$yq ph(>,/+G~QEX yIM[>#jg-]99^"ŸN2hkhc}x^_'VY31;|ԕ1iىS;G\${ή[޷B)'-֏S+ί[x0s\ *Abk,EE<{.~oOvd|_OA4?tA\|U^RWKGEWЁE~>xljُ×iXd%Hש~sf 9xN4EDGם)[ީiq^CV~io1_ 2o|-?/ !ʋ$rG9 | |a᷋,5TMe {)\:8"|5 j>jRZj67)'E*GN"j[ٯ=le*+ $OM{3ǿ|G{X?F4@ҹ)ugeǙwE+ -{.3SZ}eǛƩkNGެT./g-i37fζy'Yz} ~BQɳ^ :ILLJk*{MR5O *5$Al~5|K7Vo->и u5xs;Ü_ºSMN#;J2%Nreҕg[)u$wf(P?Zν(;eu04~A_yo[Eͣ_7%_,?UGa~Ua֙|PmuY)4j$ø*H?Zg4']זS/c}[(f<I!1=U'*~>+xOO[oc#¨|)VzgUéNڮ'ڽh7 ᰿ |Ki<f /}?lp=r֍k!w?Z{?  4mS:Å&fбqۛ.{Z6o ~?j?xYDp9}̀$,ͺVCq=~_?_ڗѾFMOſ]JK5ʠf GlcP_hΉ JXf{M|o_W&@G/ E g#_;VԮcl<)'ͭ+m; I&r+(# [.|D_ׂgNm+Xu !F'A_{//_Ky"W vusu#T=$ mx6 :>oGjb?.;G ڴ T1@__W;4įه◄4 T[ ^N1,L[P>iB`8r 㟆d/KLڏn`/Oh\цޭ 7^smK^,qxK&Ԭ|ylA*62{Zfֶ]H(Or}w>+qWϕo e؁L@¨rk vl)ŝV6ݺxgއ=VG1,J$ Q__ZǞ>YEfmO⦗]o;?e77=N}A>>Ǐ}u]oXV4'[4|!LZ?x]y5 _]%i #`zG _~v~i7`Z(}by"6E|K7dOM={pM?J-6;yL$(̲3dq?;A"^G¶Z_Sj[ũ\KjA".@o.{k~ػzjǾ+|QGq|(b-쥖#LcgU;IT+k~ػzK?_ T?$yX 5bO\r#UєT$>,|TZ/&Ѽ7&}K[.[BsI_ R6t7w|Nug,{ƌIo}@#~PWcoW:_piɷuhA Owwaϓ *8c!hvZw|4[Ru'}MdeG> wkϋ|QӰȎKV?C 5~?w><>-"&Y 8g ;d{x_~:7JOIV5בZ'!C+mkh/n߆z'/ŕ„%Y{$2(f$g? OX|g7X UgdQ PpJ=5{oӝUH?hF>=xĚhcL47w kP#.ᓃk0cUM?^uχu줚1`#.<8-Ji_vg]Jhbho؛w^:|3Ǧx[\u͝5$|!P^E_H?moۯ_S-Bj2C)\LS{#Mfҭu6*̓ n#9!TUg I*IF?dsx;hY :$ma@O5Dj~ɿtI'cmox'y,DI|8şO&.gͧNj|]s\'"CE10(nHK''|3A[D~3xcN#wi1W[!9 Eq?W/~?O,{UbJ#]H#ȁP@П"gM * 5o[4iU#-n8-h*&o]G:zK}<_ƭ\3[s\K*-_;k>mlXF"^لke}2Yej~@o߁WكE%ƺ|CC(<7b*ۣb@O͌Ĥ^O|fi>ç^v^-mO(qa;F 9 N ~ƺh^4t$<_4dmffX-C3gi%3n_?ࡿQ:4|Eա9;^iIa$?~_uZۖ<7M[ZF`60kˁ,ಿK::RTmψ5m9h7R+$NGV 87+T9+F 0<=nSZX55"sݚMğS_q4|^խ~_%灭u<[]A7Y.y;Uo;/4<:|W>N[H7^H ƀ5h(((((((lv?kW?p*]y#Ƴak_So֧~ 3|@sm=ep%l{ѫ}~xd/U9OzJz^L-A۩'ÌbֳNomi7ٓ 6MOT^ Kv>e'ꢼ κ"մ*6n<E0Q$grqwHj /|>9r_0;~9:~?'y0‹;*H[ꢿR^<5E+GJ(;OW)4yTg7'?j>k5]TD$E0' oEWA޿L+?o_OڗIkQKKtrY=2>kO8|Ti^~Kk[Gi/#«||:Ҧ5M-{r˟-~d|>𕇀<xK%[X۠DkCUԭ4m2WG4QT$32K1̫bzԜW+-aV)/|JW:|l+SS"o$nf`Z@"@ۏ_Ɵy]I8|R"XS; [0[7G"DnXkfgbrIWlpx8(Jk3,kFMTrrvi{ %}kox[TOh=Ν1gD#}?oO Mp?Ҵ!?NQ`?>+񍿏xRl֝rSx;~{s rg5Ln_{K?XWJl:J0x`A ּ7 Xko웡|eN MlbҠ쮥o#k+Lnc*a+N ꝏ7 i⨻¤TW~g;c.[ƞmH$ѭW%lgF{U?RU !lfU_i!.K9Y _5G#6^-m'k_H)YV[.dKޟ!t|;px3O.)_g3תJ (肊(> q>;ٿNZ}_ ||v' ( ( (8OWwuT־P2ž՞,y1DOGFǐr 9g5iسwc~,%qo&:;KC3~Z6Œ+khbD}$3I*28*P`AB4 VZM&ik1fLSp(_i5wOE}n>9 2Eմ;i ɏvvqcү&a?ڹic@[?t4w쩵/?2/F;BK>qGHE31UFI>Wg#ğ 3/Q>ѮhVzvˁlBW@Kmќtw`$/~|vZ,BRԚQG9Ii,Uךr2sLc:pӚNɨgii;Ku!O((Jھտ gO;>gtj7eNNU = ^Ow7W]TO[פUI 0JTi5ںX77իUNE 4|U6QEF'& I.ǹf@]vkn~J쯁q9Z2t>[-%p;JWZ ˖Mٿy^Ggu⏀~4NđjIj0Fꓪ! 8 >ea+ )W"dcOX) S4:5(-)9i! 1\oSҿ຿I(2W\&'<u2Lqn瓹=&=;Q1V#+*&.ex'HN:]r=ƨ{W)x_><9IҢV{Qx .4ǩ NbY&jsi~0CQj+>}k߿k_(S|eBkYI&{UF+A~?7>YCwq,ӈ+R\v:WOgceՄ1$df+WݣW.{ş*/Ě-Kĸ3'PH?~t#,F1WxNx_Tp6fr__'?g 8'>[?k aQ[aڣL$==c 0~:ᶧ?Fo.d93xRy\XPYỌ̄ @lNJѣx?' f[ƶsZkϜΪSH׷ qWp _#pՊF''> oO@0W[#3` W g48A\kG^R4SQE}"( rf+mvt|Lvu zͷF_VLvOg_Bj #_tO;6Zfp3,FY?tm+v{"dd )w#?k UxQc 罃AyT_MyjMU7Uzc~ek?`loنox/Fq˨^TynnlrYT:Ơ}_YRA^YAS[%m_a_guů(|6 ixIA,T=%?3l,}%/| TH!&vvQFK ?ğWRjBTutd*bcPXt O_>"x)'S~}k_n=ֽx6VV=NJ"D$R $_ߴ]$58|o<mbιONG.h`$b/( |6qO[)n9wKx.BXS:gᯆ>3|./-Ώ J qR,Xe\+cp8> ~UǣZ|f״?B?OJ&c:'u$F?శ"_i3qrBK.#8/6 /[ c,xNm2'%l*5Z6|&l|10_8_ܯ*O9UP|zy/ xSP%n<_ms2,eݺm8 =dk/ۇD:^υe#cua&ωb ~> )? /dz>bZXaY1ܛW/NCgE_ehڄ{qʰ8eu!2@5@+,↑ +KkߋZI+{stc n|75+i_5m2!"\~U#?:63;EBO4o xsľ7-}-VCq3S+j/ .8_m?S:K~Ho4Vn=_i)OoWEi^ F/YWU牒QX_wYn8^U=(O w_f?Kgӵ QOtiD$Y pff;zN]_Pii7-^"0eoku+H-"h $ H 50.4}_ZWIfyk|dx1̘@{?t'ͣ^8#_xg]/@$գn%l2+s w jfyiz7'=~kI5,̮ y g tF>?d|+lLEiW>3ڎle Žr~wbY ߇.mRG/-g+?_oxK >o{sxUy쥆0#Cgӭ}.7j?)o?tK]&AjVQ' mOji_ٳ˧m_ү7!xN5]tVvі{XXn@w ~߷~xNÞ 5HofTS`(+f)PHԌA8> >IU85 20C"p_Olq~_4ώ4/?;~;5yRU'2EscsD( D\(_)G1-椪؎I~42~ j>`?hU Tx{5סOIyGo+IsWq8/=R 7 31Cw=a}eyKe4#ͦBwHuڿ"O7< sO^h5_dt/fC%CI3RydXg&}_Us D?QxwƗ{~4ˌkc~?Sï3ZNxkƗEdn*pq xJ~ GMi_}5K6 ,C~_V͞\ZxyccS>¿-ໟo#e_d'?4"z Uj(3 x_>5Դ;Z,c|3隇|Ue}&z VhS ;?X߱[Y7no zU=,㨯?߇@+ڷ*4+\xaXH}6M႗W\ t._WOg׍_@mK ܘ&6ܘ)t$i/෈.-x?rmuO xF{}Ae|uT2z3uֿx}U͆m equoO%|NOM_xදe3O񟈮,o.RE䛻Ɔ ;9'߄?-ϋ%E֙`Xqu#1[*?noZsixbkYfK&~NRO&?oƏ Z9tOYijPI" $!9hx+m/-WG>$8_rN-s"$1i`W%7YݿQEQEQEQEQEQEQEQE?W5 \֯&U|#i'_AT?q)/&}~Xa㏫=7gg]JSK4ߟ;o)Ù-|%hq* Ͽ#WS`+hR TQ+3~*/5jۇn"c)ȱ㱓NN, +Hӊ_(~H}?g Ηmg[qhIG"<[;Sv!kWP%Ƴ.Ќc$,1')M`߱7}-om?Y#v0a?7־xw36Gqs{U$Jj,+?8JRn?ᗽk'(l+ÿO~|gǕp|1=gκŲce^__<=l+lm,` G ࿴x Ӝo|[^&jKծU|06ž<#KԐb=Ie?6?Um4{iXtд7Q_5UzSQ+ų<+}Khɫ:S7ʿn_c#Ӽ#x,8"HQctֿo?6OY-/f$@Ҽ%{!jOI~.G~3c§:oQ gm}~2\K=B?i1홣}b| Y<4]ψ֮I,&GU7-*IVQ{I<[kJPo_W}[_}~( B xaEl16k?L ?޾ٯɯ9+iͭ:m{=Lΐq!8,#.wn%~&??sOYGE Rj?|@d>Omu7LCB)qT?_POrƟD'e߆zsi~+>>~埓zo֬ph>vTh_C^&<3TEM=m}[ŒgRw([޳M5[dMr~;/e4 Ys^C{|[֭IicCg Vo@UAkοJN4Ӌi?7o8zU*MvUZWy2x/@5ԷVDNZ…F/4MNrq+(SOUz I .{B8g,fN4U~Dd8*TI/$Kv%vύo:N|I}eq!C4vǤ_|U_u5o\{BOv=Tpt~8o'C^+WM?8;gYME$W;px3O.?W?R?[OIAEW}QEN'o7_?OoӖ__EPEPEP_r]|,g r=KS1FO&>U+ %d>I/ch '+2~X_qm9$e/×peX_o'5 WћWQc?<*/³k?y*CF11co>؈VWe/6-W(۔cS'-Hؼk;d?T~@U(wgZJ*+?n/3_Oo$N@bWf[#?_,/%mQ_m;7+|;ͽ}_3~ښھ4Vg!h+Bor|\~%޿ <3/^,-q6$`x`ycO0r-ݾ1p+ IE$LG |KSB:2KpX!r7sQ_[S[U֟Z~M"֟Z~M"5:e)[D%y;N)h/3_Ɵt9K{6m>^qr PaЊGG%?M5+ ("&YաH%Iqq}yx_E4ׂ;uގ@=vxg&*r)T5RzR^ik8]V6p٩>z67?$⿉#o&M*O7/<6ZøyP$H$? &ĻOCYoT?d3'৊u+;G:V dA]U@5$giae>I쯢k>':b327|z?௿LjeڿZ oռ=zF==G#2Zs -yᶗ0p豋o dgZms۰v& ')gƏZz5ɂpC 놎AH=GBE~i{p|H[7bi3xw6O<0:s?4jEp6ت~j}wqiu}bI4{mִ4Sٺn[QhS)?9/۳w%zm牤{K b Hay_ ;n^ 7cO ߥzO7#Ǐ hVAu-uzaшGgbF4ymkٻoNǗ58rO\׽vkr~_j @*vi8;Y-I |o>Zj/yt+M6;#,AʂpNľγ|GEԕ;%m=خ灿ࠟ{+ڿQKn% #PA Eۧ6l'Ow:]GmY %*F,ĐIooٷ%O{\;? xTe FUl$ p*SO2nVm+n-N&֧NTnwz-#i_Oh}qе ꨍn_i]eq\QB?/~6xNXt:tbmx<(9L>6]-&>|R~l.m UpWw=@W;q"OP10O5\_`2:U$m//[ޓ.WX'fcyF"Mhv+_6~_4,ӿ?W'x;Uƿ77fo9<(RT^X|S?Fo5>7LlXgV"bDp:$`3̣8b#*BM=l)E;yXr'|9熗))K2J[qϧ_.-|~ǃtV;tIŨ"~c'ݫ-?ٯ[gjWڗ vUlaP+G+Q7*P\n6#p=REF_&*r)T5RzH\߆%5 xR|1}>Y#\Bꭷ#>ȳLC/re}+]^#QkھdO+G[Xkgc~ |)?kzfxNԴ~T@`Ac9m!L3~ .~hE{4 3k6ֹxUcv:`!جD^Xm܀O<)H?/'aό?cΖז[?_-rT@3]K3ɲ[yZپ:G^K+}۟|w㯏uFCy1xDŠU^ʠv>1]~eׁXZ "SwoV~[srzrWv61]Fl91^)+;W1`w9ǥfGֽ3{5p׻zWm#|?iڧ:vOl& ̾k=}iݞJ#g _O .m71#'P}{EaciXæB#%ע@*ZҲ*j(tI}E~7/_/㏇kzX~(bO1M2>SL{kténv.>|m_o)ƿ3_ f{wj^" v}>-: `u.ie {kKqn>x??_#|Lk_ ˽c[֯Y iK1$ѷ7QyחQŸߕTVW7Ld ?1REb[ȠRpi~%9TDᕆUK@^VҬGǢ2?%A$NXeYNAQPz_Cc3J'45R#(*tzB(cg4=Q@T6ڎ{#g )C@QH$Hdª1a{  C `@E2#=DG hTvyWQ̙8a (n>) f.Ohj)2Aw?G?O !kO/Yn (.HE}AE?@o.[ [l)ݼFy&ᄳN5S|[Mx˦״zC&{?a_x?W;?b" <_ڟ?kw~+|]JLR#rC"s+?/O;/W;?b{^u+;Zn{aewC/O;/oϏE{Mtӡl?|P0g|ݨ J{?a_x?W;?b_ p٪i5ugױx K2KĩVuNsW~x |&4/Mv_?_i=<x?MDZW};M_̰Cƛ2vZ!9({?a_x0͡c)JJD)jƛv? }< ~gjW_\?%Ϊ4l#M.pXb9v'k!9({?a_xYem;ZNt vmB ҩuucmZBælʏe"/[Yhq$9Wx(K7r7VFP5C s=Q~¿a72$_ vi?4ΌxEG]G$RM~C+@쏧4䧌dU?8gP_-1d+)Wg+A1GC s=W ZrXY|cԞS-H\~N PLw~pLT8^_.a14RWͶ[-JNv]E'`+=p(?OoӖ__8 -~(((*obA*mihO%xLMs\$-Դ)|NӴd#z<<w⾩x/S],;KN_EWy߶@ %|M j&%>%G O5lNrf^폣(h̕E o b]f2>o0~ƾݹCź`r?kjkLUn+_~ (XТ(((((((x^M`!Yeo#sp@(5Žt1—`2}9EQEQEQEQEQEQEQEQEWO,Mx퍠i4HMnފnW> j/Ym/_f"IG%dyӠq[u :V#tȆx54l它MY\<+Fkq5OF `ŕ8ӭAo s;XpU}{F h2Y:Zzhl34O'~k4L b1mVtt7߲ߢ#ƌ: >e~Ɩ_w!n1A@N}]!FX=McĿa{?Ά%֮e+%QHڇ¿11[ܦVͽ_͟UɲY.3j!U6ѷ6|EZ8r̿TWѿN,?6~Ҫ6Ϗʸq;M{խw,2IbC+ vC eiWOSC e/X]>ϣOS*i/10RRߜfOlo2u8p~i`QZQvO %\&TjJ.׮)5(y#jqǂZp*#CY+ɭ]⽪nEd] 5W~ΝJg7tNz=.I%}y׻L>¿!o]/_Ώ]+* "ȁ1۬*T3ֽ\_%x3k݇z~:ׂg xE_|wx&.%}U$({ 5x>5H"uP<ևHY% wwݍ}7wAG>i^1'["5bzgYҼ?ടc#cl(x1e4ӾcO+ m'X^_fTR[ͺ܈3; *A c||1mW77 ve`8Bn/pOǿx?a,#Ga;[g)&HFŘu 9H?hGWşx]:u K3W7 U%ܘ`O_kT/&->Zhg!:`\X]KB-rx? k2ⶡiweoFkq$Qިg.;gE~oU5?4P%gO~5xċ-v Mt[Wk~6e2іp#"K?oEi|[ּxpef핒0Z :F#%r~[}/r-ZNjt+RGp<)s!ĺ8t㦈X6q@/?e?ۃ~+k> WԼ=2\ť\]8$VVMWBso|IyxO;A7U״}6O [5 \A y[9uI?P?x{NPWDsh'@ա|c ox-lMI\g|R?य़Eߋov𗈎G5wHl":!\)ˡcVu?_ 'x{Úz-$k/s424rK6q,T F ~o #<_Ƌo^(f MN=BT|MpP(2:@֏ ? /}OT񆟧 zu(?]M0[i 0"-Й@Iƀ=[^?hO кy'L-<-uA4Vo !FD eUK ~߳U@a״h>ocnG >SEʤ2,;oF^9WTO"k8FwVFR=O߲㿃ijGU׆%-(W+:v ?mqZ?OOO> xR:'Wtj>V GIc- yƿ j?:/^&׀/A׮,g b56 ڟߴi}e/kDf/Ri[I`<'f ^|H :4ۏ j2Z*.CkEȨͻwʫVw?hkc8-TǨK\[]\!4lq"2OB?d iWştĨ̓y?s+cիOl^:8qI>jϰ a%^gᯆI4l󮮝J Ey[Bp~_W|xgω|=x{Vz%˓[3m 29#kG<ׂCCus^uQk,ñDVE7Z+N?NZ$'ŭe( Y$5[~~K_(rx}5 oLQmkxda墖B9c+;'15x$3@c]̨0Z>,|F/mwm3ZLvI+$m"yJA۝EQ@M'Yh;>-w̸еxCO:8Õ,F8$@_{O|a_xnh^"".2e6 DMʤ3$L_CtM/Z_xD{&?4igP0JҾ=<l&;cx@{Vl5[h[A1HuO!45S?k?h{/>+=ׇ"{>*kyy ȑ*JP/?l/_Z_dl`$W?x\%Ne Z@ϖ6ῊPo_a`zVSBԭ%\5!`z.TBkWCO-)/IM*EKꮈШ/5 J|+<)|axk {P-Lm%KGSDrK&|U<5 >) vei\,m<־.)?x4>HuCWt9~̿/kAQI]]4/" fr5S!~_ o8$Qj'M^_P7q~"ctwít('((((((((((((((((((((((((> q>;ٿNZ}_ ||v' ( ( 7~_t(G|-~(.: { 3_,#a#p-!'I܊yzֿ/n?W>W:M*ou}\LM\?QTUy5TSn#)CU8BydɄN\v~Gg BgEk}ZOj7{wu)yfqowf嘶I'I^^i.GkiRkZDl*1W/B>0Wsz$Q3jWʤIAj/,Bo|:.ic ];I-մnlqȪ2I8GYiiW?h_XB]^xXRH0k.O{ ҿE|\;8;^ˋ>: j+s;[kQ_N|oi_ >.ösi7ckYH i}ם\It:Ҋ*%I<{6#QK.IK3F{k,G?khƓ7z^]6wӴr"Ѻ2A^Dῇ[D y)^%sY~Eog[:ߊ l-Lr3Pf>xC&x:^!Zk:"P)bXx ѿ`K/.M|Lsi|ct)eY TR/^MlIh&ݯ4]5m%d%>m,l%X #+)__R3 Q_T[ឋkx;Zo7O$ h~\:Td\.F!T9" 8?~`ߌS?OO+/KNֹi^46klaxYF88Œ_'WwAeO|x<#C:RMO}yPH2[9?a.s; X_w!?Vڗ楨v". Y_=3?;LJ|'7í77KoJsuz܎F"&8E+8;ïb!O_4 7:C w$.;9"Jg0|N_:LjmxC>gͦ>cs|I4_n| uX-S7l<ყisꗛ}9sm߀O_ߴ'j6^ӯln45H#Ӓ Oj -/ |hms@RG;L ~ ֻ; $yxuH :.Cs4ɍXp 3 }iDe'ޟoӼu1^X"1 N0灊p? W㏅i <U߇wzNyXp)u@K(,_9؟῍}slK)2\A"xH#5Qh\?O^!+=Hw=o? aPM.P[ LP>$> Rg?_??xkkd_hzyd\).Vh2Q@{^>1$)o|Cke6@/[6r*=#?:wV".eYOoMAih1_%Qv&_x.:~~?gCO3P:|9ZWԵ[Hb u!C{=8B -;I# a/5w#Uמ?nׂMk8d3."c;C)W>|ޗ6|EW%ܚ@[FiD̐p $E}:gBϟڻ/RÄգ_M]go ;R|`H#_<~u+qwpҸQ$ 'N7$Y=}gܿo%AO`{J)mm@4pUA#?g?.=A|lg}gJ)?L;x?tZI!h-YKH|5v?a?ҾJ%}~OT#>R*>km|XE<j2xn}5㷆+Vks唔uCm|ڗ ȇ5kg\s_ޙ9t>:E}J´:sk_şP|qx#_?е:|Đ8܋sa[ uqxO⷏< 7ƺZ]\@RCTi~.O~0vW Ȏ2ܲPpǒ_l7GX~ɾ?^G{v7i32H%F8Fq?q׏?߳7hKzT6Mo0rpUl0ho ndhPxLo8.7lKZR TZt7k|'G7=1sYgkGe>G]-gEtS WbfzNLtT p1\Ã]. WcQ⎑!^b[xG2LCeg> |7>*Ch \ 7Wՙb}Io'ŏX/&}{l-.mNg9[O)-Bq@?8;Ԟ"IVz%y۱Y.g吔9+[?S>2|W:OlѬy0 3H?UG .G_~'|mu:O(z$IQ^=a<_|ܥL Lh[d<|bNh4adܟWf֋E~>y,Q4~|Zv~?/ej׎׶i(B\c1봸zo-.o"I5c`UԌu濜=M$W ?߶7G ]nO-EƓ$?"3WpQg<ثokgz=o"ϩG~]յugoGu>k:OxsSuɲE>[Ӓ;3⏀UƺhƋ-g0E,lU#WW_ۮ؟*"Gi/ sgۥߖY$Vw&ݩcE4jкZqFcfZU_sz$ P5ꍌxn05~v:ֶ֦ï_|/oۍ[^t:2#U'xHhݤESI+}Q5Orn?Kⶖ,oc]8u(o {e"i:tk|?*Կ&?R׏i qFͶc[`|>3?O˟- }AU~4e-~R6أAw .27+¿((E`|!G 5 +OׇڽipW;Xgk2!q_?c8k mR?f>%^l58CAdki7̭\_B-?E;_-x\ [E $*87;2,jXWU!?'|+CI-7L:`SWx?C+h__' M?Mu}w6!;ݾ~A'_'MT/C{ v =?ꨠ7) Z>? |y?7v|HoMBOAW$wII?h>?c_ؓVs~/%Y,/<4lmtƘHaRIbȜ<qN)gQ]'O|eى-. c84$[73x@'t~¿' |݅[<=Yi7E.d_4}'Gc,ZDNiX@6%oKഇĖ:i:̺ J# Lj l@<{l<_x|Hb 2jW m H;&o+lBHN`wh /΅HcG೭b[$" I'5cQ@?C?pů(i)\?b}wU[4Xg1b'IޫڿNۇRҤRE[ U,43'N !?[%O>*~_WIOG"| {vlֱ>-F\#?7Mg|Dz <|1~7"5wF{'XQ[۫ZM>e1Fݸ䞵6?_UPO~#; n귚z,V^FJ? ?J?o_ǀS]?i.h}.(aAݝTR+( G^|| O·O5 sXE+i%rUA&*K'C%ivm%A.-Ks&! *1 8<-8i  e/n]' VIa7Fe*[ 8>$F)~৚7,~:&M2ϳ@F{PEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP8 -~> q>;ٿNZ}@Q@Q@yϋc7#񏎿fOί'}j|x1$Vq4M6# l6**5tyG0wAF{=? ў/O5WOg?Ko쌫G(?~?ჿb3߅Af^?3?? _WWo ~w~ '2095UU hzN&nV衄oi7+ǛK?eo*gY$]OVwDUgep3q\;FP5WE<3WKd$s2sOV"~nNjù`4o5G;FP5Ulf?_G&M@?MAүF 72F|3o׳GmAa5??2;;H(@E`@j0%ǯ$#OEmK^.}O[ 76w4SF$r3 r5Q^v秱~˟|;=|i𦚶%&Bgwc1>o>+xOQ<+r+Z< xI#"σ?w?mE|(g,_[^xTm^q)ehv%@s4|xg__&?Zǀ/WmV pʉ>|YUmrstP߷IQ4KiCLW|d$O 2wK!]1zQn~ i>j f/Tֻ}e&uzd&}̒8QɯR9~ u<=bMyeOF + 2RQ%,~|OѾ+xkFbO=;0u}?C0ekk[%*@*YXPFբ8/cba?gG՗|#ƫiWF #WE`]YHGkF?~:m;x-|w]]C*=Ar,8h0c׼o^XaXBM}SE|u0c(ͷ_uw}FLjtMnMt}w)P@f E+~û[?u;Y-߉o;Ia% H\j(jo+s i0+ڊ0hfPBO VH%P 8$Noǟ5-W:T>N7,?ioP‰f&#N{Wۑ@1G=wρd֮~ 5k_j0% 圛S^E|i;GO&1J廖si:I,$nV ;]=|# ~ <0w?.i-}4 ^tҷH[޳e??GMGK?f?!Mq.ɩyiOs$6dvf?P1m>ɧx#5!浑 >dF_O Y4NJl|'Uoe3],̓q"wu7 e⯌jwMkXxZ;MNiZinIMFf(GwWooi~_mmO jE+4<Ds+"ᐃGBA(? Vi{wUŝue(%n®E}EQEQEQEW eD~ .[k?O j2a\7~u)Ƥe9:4VW? >)<]K-5-6#xO \_~fz~l-tϊmDX,(C) #@Y?5 /i:tڎE5pA_)agAџg+$rTWeѯ]Wj|º-2Lrt9Nbb::.^J s\~ss]txoSң3npLc{nkjP0 VPێj~LFTdj}ּ*&屲{eNMcjW䚂UㆬG<65+w?O@יN!$xwG0?vU8ng'%{u~_G_/qꗗhB|3| _eQk lv26ًt}(cp(((((((((OootU "uC[‘訠ҟEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEN'o7_?OoӖ__EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP_ M0>gmM])x|^Z8 ?_YԥNf\f ú8E.Wi#g*os^18[P\ႜ4랜9w-NxO{H/Hxve w|Yqqwػ^o蠴=RtT^b~5YIZ/y~?O3~ da/Ruk~yi`cpG/Oƿ Ks߈^Դ=^]隽G ?RX_G5;GAJFv:ZִFqҵ9-^%l5uN HcT8>K{`7U.X}T[ul[w:9 洧.E@ج]BdޣՓ}kԡg-J]Z.x<5FE.eZI+ bO@+دP~x~xRB{Cki l=36|X |Di1_g|φ|A|@[cFM~vwccAԻ9$W]C,|W%chi~~q=Ÿ_oI7>  N2KX ?iaeY~S *R~~.-ُ7]B(dP(((((((((((((((((((((((((((((((((((((((((((((?OoӖ__8 -~(((((((((((((((((((((((((((((((((=)~οǯZ/!D+o=6"?h?6ᖷ41-x~lVt"/C_W'/?~zoO#Z* 3=BQuĻ!}{WN:QIyOF=5 QQKVAEUQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ |p:: GikV}qA=i"B̈όR@'c4QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE!eh@(J*?HnsdzspZwGR:}h.O٨bz.o?/bz.oGszѹ}jԿlO~s#Q*S{Z #N D8M@QLN(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((- p3QI&(/D :{YZ%/z+ ZٟR`P/ָPj,Z~6/֣mn-zjO ɩ!* Hc$ ZOz.T5Z뻿+]Sy,W-7cfj6xPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP%l~VMXP}FW=j3w=VF q\p/PF{}n<-_J3 H?Z͸yֹFLʺ$T<[?O?j2o>'<9)Oz,vvxɀ[O6pRR֝]x͇j6/?ZRiL;d+~f:2Qdg~),q~6z5qI:_+Z;,) :5mY͸uSGZ8 Xޥ𚰽Ҁ ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (":xtZ.jn7C%=) TP?g Q@ξjF(ǵ!S (_ڏj(W: <P{RߥMEE҈}jJ(J#E EpAEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE٠Fw OKlNJFIF,,,Photoshop 3.08BIM,,8ICC_PROFILE(ADBEmntrRGB XYZ acspAPPLnone-ADBE cprt2desc0dwtptbkptrTRCgTRCbTRCrXYZgXYZbXYZtextCopyright 1999 Adobe Systems Incorporateddesc Apple RGBXYZ QXYZ curvcurvcurvXYZ yARXYZ V/XYZ &"pAdobed      u!"1A2# QBa$3Rqb%C&4r 5'S6DTsEF7Gc(UVWdte)8fu*9:HIJXYZghijvwxyzm!1"AQ2aqB#Rb3 $Cr4%ScD&5T6Ed' sFtUeuV7)(GWf8vgwHXhx9IYiy*:JZjz ?ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~cXI8a3,JB*3UVU.B$@I't vzWf%2I%CnՂ39*ĮɰP=Zң3}=anW%XMR V4:̷|`~hixa27+݉Q{ge9oz]C|XҟiW?4s|:UTJGD0R4|Ay?/sEh5F3>GCI;(p##r wm)˘c@N,AܐBQ>af=9.o/v(jǚAo4zສ|{Qo^׽u~%r[daփ/*ƴY,$IQ+Z}ٴI4H4Ӂ sk˻xZHWRC#)ZT%FF7TUcf؃odUXzZh@ ԩ#鎽{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺Mnqo׶fߤ\u@IX`KO,8X/teכ %o("yocVc#?閩lw(GcPBp!>u #E?Ӭϸdzg 7"_XaqNõQ]aBAѿ7w|?"ރ3+!{?/|uwH] .OٚR?pl?Gu  )_Q䨦.Q&oPZId,v0Vt|b[&?%|kLt@ 1ώxwG夆2ǯk#+fBb B:mtKifzA54:>]m5/mE(nk:5zvgL£{~oĢq>d2[>XIc{#k Yv+KAJR~&;W!:AB{{^,m([[qf<`<5vK)< ~UEETR 8Gȧˬs:9,}$\Eq:؀JF%;zm_/{ߺUWugŹ; hRStSnROasUPZi)#={}-glZ@Oh|5(=e?tMMoژgd=#M)9QeQvSߕU{ճ{.Wa㌒D-IBb%Ζ[}d6;NtfR3nL2 Toen]\ "XGE [Ԛ:uLuo᪣5)FURǐH<n;۰xٕRT`3=wHcUҪM EA_m| ׸6R >SB u*)bp7ݬo(u\SB00A N۷<F=kS-k`{ IϾqlSwS=G nv#(% @J$M_#6)48A(lS,'QVB},x=6jkaʅlouVjhTχ#54JSy{vk;K<2۹Ii /۸nIľCF=nxv7XvW_L 9Mu%ֲp Q<-l{J1SøO`bsGg>f۵6az%tF03_;cb=㯬: 47HD5!e{6yy_]S`G3y 8Q>zxQreAy_R2LE8:6pEUK<54`ettaudu%YHH>q r5~]B1GX`AyrYۦu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{?,>6|a~__uu3Bgܙ%V? +a+KO3rE>\q?u!/wZ3Cc69GϪ& cϲ~˩yeo;u:L KF\-%^mO۟Lira:(ijIO=Q|?'WGwM<#t*8j&˘I,ʼR{Lk5OgrXWfU G̈mZI,,MIn^]ٛ C3ZCX5Y΢\_ ySk>iio x(?׺u{{^׺u~[?kbh@}SUJZ 8CMSQ%y_uf=ymym-/$EO/#* 1qOX/>g`WsvCCU!d/Z*:O)ii+EIӫU* }3ǯ߼?tof\n h ]!|ЋՌ{X=3)M[ҝ;ÍhYӣh?Tb'4Ljt/"NۄC"a?јƧ![sN`cdabaCʍE%aHp용UUTVVTOWYW;U;I$HIwv$I$or1w%ff$$ԒNI'$=vZR8* U(P:9׽u~{ߺ^׽u~{ߺCY|9zƊ9|db[jXD8$܏b^;mŸ#ddozsw\ϪWy۬4)Nh$LbeGLl{/YglMr ?{]jn0(j}4@T>7\jhlE ¿KR yuj=;>&vK㷝^"+)~ҷbc RK4}+}9g";CA0$IpA /μ["?h( 'fOy ܛ#tmP=&olVSRH 4TR,LlA vxg9aU'Y27pd4h"xdR 2*җzu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺jgpc;3 =#ʈi(`^Ijj8`,ʠrHiǥV63s%o,0HI, =QPW9=Օu܎etU#R _qd _xۏ~γop\nj%Ak§mPV;}+ֶ(g'bV +%.Unw=CKZRALr170O0?ju{wn˸6f\zw9ùs9]ß5v[9w7y*jIݙimmPqj8E4QUPP<t}+׺u{{^׺u{{^G6oln߻3 0E]mmT=5<( I,0ͅϽ'yI漏 {xYGh 318ЯH+ɼ;cnݰ<=#MjiQ^t7A#Op _:{ϽEvk&Ȳ5Spn_Dh+5{Xsd1x9Vǩw;m+4xWP:Tg&?{L>Z}-WgC.[Ǎ R;{T.>_v+dz{{.3N$;I#%ܖf$$o6 ;KX(a"(*GjU@UP5{Mν{{^׺u{{^׺u{{^׺]hv7Tfru[8CduE*xb rF A:عp噼}ky1VFBiH 2p89ܟs-!BLthAں+wjLWwm|qa9,qS^h! $ɮMoVcȔ)4!>m(˛zmSR!}Wv$q2W5>+\&(n$cv`wk؝"BtIs͒gȣ[O\zc4biZ-Xn:ur\Msj7:` ZUU!2ƃ4x˽c^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺI]_Zl=ٷ66m_;~TUI/jas`.HM8mWuo5(-yeau̿RgOufvgÝ/tJ8{K|V3j5(<#-sVc7g]/[7bym1)= N $#aO W~P|[2O]ɺw::1z/P->69bG1O+]Ž]+r53qhֱ2$5"{\>fYKE"g?JЌNjVZW)O+Hd${_kv3iPVܟjdF*hj2 %]p[{>5qf(5 +#Ki帻g>YgsyY` C H* HD*S2]}{#K<ͮIPwnǓ 6RpĂ*OIff%f%%!쫣ν{{^׺u{{^׺u{{^׺u{{^׺>??Giwš)=eѤ HPԴƅRt-<k3 LȾ"i9ͺ}=e@<:t꼟ywoS:`R S j.uhm;vnߵL&/y&F $:6,B%Bdi?]w1{nϳ폥:WpD␣͜$2Zns] **vΤP 褁6Y*@-3id>lV̳=]#V5?(E7ݺzu{{^׺u{{^׺u{{^׺ *mߝ#vl- Ly_0VOjM]4"4q;oゥr- {g586Q0/´iw \o/7`|[jvC=5WʮiqԁPVVIB/۽Mlq5)Lk4 iޡٶţ?|0&;hr)Pj T=i[${Cpvdd~9AEANdEtE'Lh 4UI,jIǶmRi!WvŞf\TASJ  { t=׺u{{^׺u{{^׺u{{^׺u{{^׺u/3E&?h]*z{4_jqRf".CM B~vx•,\f445encv~VZ[ 鿴 ƪc)2֕)ja+^O?|r?õj0*dM1iُ]g>dLg`5*L,gk:)CG;uܹdo_Y湸S|I(~F$ZР>Elʸilc<>޼>v۔2C{I@)H>D#nCXjλ׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽uy?wZ|!۽Tg5x+$BefSuL~jzo:/ު?cv< ?AlSr?SŃH{cb:\v;K?CCB8(QFQU_>3NY݉ffcRMI$rNOIn[+rvQ͡reyztcDP^ir aVHVIVZ夷ײ,PBvz$ $ycopkbindXxo2NTU؅E_ka.͋]#u-4|$IBa+rݿt܍̚RZOq5 G.Ex>cn%` jǨJi\Nq_S^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ]2e%YNe> 2:679NRIq mW3i[y@8BIgsr2{λA@$&P)bX歿mm'֪)# X=:aX_ k֖W(덡ȢE)Ԅ%vf괾Z>ӎg=^i9z=CF_;p|I9;s[rgtk3uf&d\QY_]*n.| 9U& rdk()3N-452V$pm.ZVutT1:)=u몶7K6ݥ}ט(wL!-ED S][PTUT=娩YfF'`SwMM{iifNౢDUE@ 43T==ޘz,n#WTl0BFEFz4>:C}v!["봂CiXU9դ5=gm쟽}Y_/kf:]1Wۯn{{^׺u{{^׺u{{^׺u^ޝfnmKQ17y ^jܬPAJlLtnkwY KHin f$*(;˯g[1]VLu +dXt( :|p+OPiV9:?v_oѱe'_MuL?m;?y$Cd4\Do׼?-mo—T6%y5}ۅы7ڭ|L)y:{׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^ҏkݽi{WqĖ1v VBl4I8_fnwY,@tUo<. qh>oZ+!=X:>ˮŕTeЁOn_nF6㻑b5?8.m*UxOq_RKՀu'-+ *ۋkk4װѷM wGk sR?~]cG5xk6==_\u|Ӯo­iY R:Jd L-;}[.{y.x5EF~„|7OoRw6 Y[F).>UU]uxqb-wm}.>)j4Q1.I$iٶ ]?4I!9tvi&`1df00(1ٿA{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺?ͯcslTgrvq6 lb*&ryX6B5rJ:KuH=c&umbhȔ=Gdgȫhuٻ7c;;vwM糒%{pF,T("T"D@LqX"B(}IgVga A bbzij%cI? dޑ͢ĹxxW;V>>x"}%{OJu{@ը !>?:ۛ+::ZϜLT9#Rdp$iО>GeǽaA?K?w붽{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~oS~KVXD90\:j6~کU*#]6o0&j( "VWoI[坒j|K$mToP2T4aU\`bѰc|ߤCniDZh&t"}S R81Ѥ@OPO~}Om6Ձ.p|i)(U\uu?ӻUl]Z鲿S.mpJT#V3֟չ:̖J#I]WHO<9YBK,1gv%$Ii{i$fgf,ij31$I5$䞻ookJQ@UUU{{^׺u{{^׺u{{^׺u{{^׺uSUAKK5U3-=55:$Qwv *I$/0DI$$RYV.*,Up$?F}һx{&c 2Q*kh'&b%Z'KAa,Q[[ >ZeOP:}u-Ү<*H[IGҜ8 W,T Zf1ln nA\OR&S Oou+}pU(#,)f=bo9xZI?{cp[5ίj ;-MC*rKZ.9E.?d? YI{ϻ)S3c톧cb8/c|-%5ڜ|vڻ3g흿0CTT4aa Xl8}̶;u(A"E zߥ7q)$f'ν{{^{+6:;iX9DRʲU$O5܊1J:@:육!gsqX`Ek*>@vɖ:M˙0=>zﱥ%e 6biZ,V$zO7o2[j\΃>3?.],)z'7< I@qfNXV"=te =1ǘ[^@|I~ҫЁAg2f`wI6mElߒ(Ԏ}|s +;i$ wv$Y4`=K"Fz ouh]3pG=vŜٛ 2 5Ds@Z)GºA\λG>-ym{n%%PU yvg6ۅ*2=EEz2#ҟ؟n{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{UT454tTtUYYTQEI$r#DH,h:qA$Ikv|FLKڶEUG$=%$'6'y_TZ7??p3_X^b4xlc 8gD_ ݩC33bYfnI'IN2]{^`9q=q~?ϭƞAPiTv?*.mts38_S]`OZx¦3Qm[wxV JkS_?r$U?n';>dm*ˁS{뭽{ߺ^׽u~{ߺ^׽u~{ߺ^׽u7 Y'.%GI>{{/w>`©~&ق: 5l&??[3d_Fk+4>Vy: ߮|>2&P XV+XQciC^HDN`{[?oɷ; #TҚkUE=ݽeۗVJ[x? Ři'ͽ@v~~ǺkCEo2 h( k r3r7y7;,Z  Il{}lM[kC1,AEg^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽tCvo|MU9 9)f~OOnu!Y<#7T E{eЛ hWX}#*dA_gleSXŋƊS}ϼ^sV1긐GGX~G-QM>0eO!ҋ:I_6ޝKM#o_Tre%|\^sFb(޶*4'򌴟T}a;x3Z-mv5>zҪB>`oo^8"zclS d$M!%"ɐ%Eg'IB#v;{|STqS.|1ŷ_Y¦H3()U {^׺ 7t7]yzvTrꚸ޳E #arah⿣%fHPJJ#ס.ysecs:~,ctR\ݻoF^Zҵk<}y:yG"Mt|h枯tRQ_| tbܨٯa39GE?x2N˙b[hlWG5H'XЉjzCa>ߛrSe h Gco>pv&aFa)KxU?tUwBDܝiMC8W?(@[&w{w-pd5}-_&ma <6hglUaJ< z؛ΰ10TƦ sx`nn`H^{E]k2֪ItS_hdj{XVU@g;mkFI Pw#U#chX<IN^nHP]qn䴱<,||vW,wҳY3v\՘ͣ?jWnaqQ. 0|@7{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u7L_snl;p^dFje(K310D I't]Ti$" ,hMjG?&sC3~39wt= =.]A<(c=<|XGv>\蟱(&EQ*-*Z|O ySY9׽u~l 48BB8w L~5 FO˒nCJ]kRCh|O|譫ita>5R/ܐ2_D.)K7Ր}^rO_|.M/1JfXٽk? ׭kۮ~{ߺ^׽u~{ߺ^׽u~{ߺGw|_>Ff (tNE<O*D*"Q wQO DՍ08}Ή.^n Ђ"~)D[ oGWu鎻ٽS֛~kl=Ѓ .Ťi Yd-$ҳ+4vH_3<ۜ=ܯ<NU@U:WX6:1bTRy*)y吪E Q;@۞tFF*I'*IZZK*A4Hqww!UUEIf$I4ig>\v*+)zs`6#q2jQ5Ȕ%` U"S;I}=sw:@XXKd5!0'h9Tb{HԪxK0T j}d^׽u~{ߺ^׽u~{ߺ^׽u~{ߺJ^S헶wՂip{b!Y(cYŀO$_kݮxAi r#7ب>oݗ/@n ~)n%yTp=YJ'ߕ-EWogyw|FmX<%h́r\Ea=Y;!|+u` DnS͠(Qm3/uvEn^H6'G lRFJTWTFFY3ʟuN\شAB|V" >O#*q˜9T[RPaQssCeJpRdZRv/\uXasv: ZX 20@y%f$nIO$Oz]{^׺u{{^׺u{ܖC_GU2xPH $RUtapA~׺w1YK$$SBVBX+ dԫdu"2 8|IE+̩v8_#4BEK !`ɑ{kjKw;׃ݡ.s;` *]R$ >}έ%uK KIi^'̴>Idk}OU׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺oX VK;Paj r|RXথ6zeaK $ȆBA$2I>C休bY*"ƀ*I$z2ʬSuem~i: EQdkɋECFRy1RMʋ` ?(?I'*ɸȿj# zAvgc~;{^׺uAxN{OobҢvCxo܇Kk'\\jmy0xW;:}j+)F013Y $煽uֵn ־.z Gm>Tt{^׺u{{^׺u{{^Cߛm썛{wi62NԔF9yEEމz.7{^_T)'i (R|~ξ_A ݝ߼i˴:SK9PڞxWsQY$}Gz}&WMUnqۆִ <#X׫#ny'O ,U=ٚǿ v9Tqz?Pafx?w@<>HE<`zᥧ<]zgO;npԻTN>{W\dk^׽u~{ߺ^׽u~{ߺ^׽u&jhe` 31 ${#JTI*I8Ğ$ rTI $Ձow!F^ svɉFChq^Q֐B~Ódoż&|Ҝp:c/{HTMy Qp[Ԑ-2iN3BI۹{1Kׁ\⤞\ACk8T6J62nK} A[{c!\Ӭ ̛v h6K˿4}<#Sl]sԽcXd_v*Gi@J"EcoT3ǖby-Co_i,I>g-uo7Ѯ&ytC}@QЅ^Wvo(?MՀ&*3P#1 ]ZW?@ so=lo{>Ou2oEZ:;kpi|{Xcy)m 3A魵+{! E<qKT'ݎ)HG!q?y[\[$W{6>аDKyq\oo0o_q 4}Dz;wyNʆ0eO]ehG8Ny8)s7k6<,(>!=<5ȐsHrgv*=ؚ@kYܤUânMۺw{ewnnl_=U=\r_`,sG9q{٤S; F)H´@:˗,m᷏Ƒ.<@*~g='5׺u{{^׺u{{^׺u{{^,3MM4UDO tu!єVV {zKIXу*A A5#I̥V@ (Aut aaWvJF}RDEڠ ɠVyԙ,rr5̋rn*7@":Sx`*j޶HْMźJON'>c=A]b7^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~chiᖢXi療"BI&r} eR $IR/*>B 9a轹nmˌnH TS!4rr}H9Pm.nS|8q].ﺠ7-b?Fq%Je^׽u~{ߺ[z"lT TfbHd1㲃E"厽\!/pU9/\NfxӲ2>~ususc'_ lf o`Q>L+(ԲWluR0ҔfJ` *9JPe!{=ҋ fґTXcUFG}bYvBnR+ RIʕqR22\w)kBl['^,5544KI,һ;$I+/eybHjK3xI$ee v,qƀ*$hUT P`N{c={ߺ^׽u~{ߺ^׽u~ 9ü@dtYn8cieԴ2AN *rx{]tćRXfӨl{JK!< z߯kV=Ou(~ETt쫥{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~eiY`U b22A~7$ԄJߩ~F<<E<CzŞ{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^Z tGEgw|4VݯE<H*NH l{Y$r4HGlϿ^gOG{}ǺЁd~{{^׺u{ ԟ6UD d䮦I!'%1y)ێx6G>6Ǣ? e}esl~-o0}ξp!>WU8yc*.tЋ 1('Hz}'}`[j^+ssUYu~{ߺ^׽u~{ߺ^׽uho~}m}?FSڐ)LhBqS%]R4Zk+~߹bK{l]=n !3;Xmmm`j::HR"8@UE ݀_6Wnsr,H#gI3ĒNI5o;/svS͜*LP@%"Ay$evo;k-ۈIUQSH'[n6kVc^,i(p '#[+{qjLS]+,HhRTj*eɡ~sV.=V?FFǢ!YYi-TOd~^ԺIoc@ `I!&IH{gwיb/`eWgd(d~Ci)pd*f,D?zOu|Wl^[kSnx!.0O\^Vlt: 66x=4&`(޽{{^׺u{{{(6ۙ۹2q I=umCaY *l9<{]w;oiH;}:,7>^{ᶂ1Y&D$y W/wf9tڗDn{h OjlY6cNݷ3oRFJKrqԳA Zmː8UŖQ z2|j:ꆷuҪ)i߻TF2Ew/ ajazMpN2ȍQ|:}sw%tujZ\CP+3ÆtoA{ߺH={wav#)h!/ϧ)cUTF<.[k[XkƐ $H%,4ft'Kyokš{DAv/Q58ޠe{xꆞ@T#d^p{V:7ok } l%qI XrWyͿ]oiG+ }BF깻/o%s_)@_\x*vnhiT[5}NnwMEg\~:#b<ÿӓعGHzPĜI58A @[^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺKN7{*&9>䧨n.؆oqwOjwmgsl"5G"]} A j{>smMp̺O+qWS:2QEA㤻mwm aMTK- jy"d{ EGDZ~;rit"zzT25~ruب <$.3ZT{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^Pg> [9`i;|nhi)!fs}X=A@vv'e ^!:u{{^׺u{{^oNts|+krc[O9ˍoK|Z9O?뎟ADϼ:iQ/lFdumow]WMCjY[x6[X"ۡG2z)чVh- h5GA˔uc_ގaQrmI #LT"%5****'jGbK;Y$I7y$iĒI$MI$xK@TUP@ 8u:^׽u~=m;so.I-I dERS>hO8=X9qmq!V$-JEtyvp"t'S8"cW#q|Lȕ-s,SV9 ̱KG DR㬍>K~a0~ԂyH*=5k 9x,yBjd5EnjVwD^N||?OrDVa/]W(Vְ ~;W%Cmv[bYU1=s̸{YGZ8,qD^Ob{ߺE~NuI )7n{aEp *, O$a*EXTI7R_'{ [{:o{K. jv"zٽj=` g#FG:a>T4m4_}Jܬn/2)u-!\AW{yfkcUnoxW[GqS3yfݝ X=co3U9fկ姖VM3<>otW=į431T㬜}8bAE$XGT?!_u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^ѐ^3UGX̴P ބ+ДO7+SdX̍#x&A$Rꮌ_ϼZ72$MXPGAO_M%4r#*G"82'^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺMYla2p 2|o/bF!c}8V H$ҋKY/H!Vy$eDEgv!B8MG +9'[ :gRlޞFH,qnxEb!R%$EGpgfdxc8~>[{ʷi{+m@跒+h$q1NTg^Gimvٸj-~ l5tSPPԔ$5E&ÒMϽPu%;ײ44ҹ,]ُ1$u[)K;[QeN)biȹ!#BlbxPI=piqB$Ɗն]nᰲTUI*Ip8u_O;wyn~ʊ,[n57 L *g.%IV]>r/_p+xp;h'HFwcLg~Z1˶D:^jxדՠ:8{I[u0~{ߺBwTjhu.[>Zj\G%Vjڷ1PSTWk.q][1Q5w4D\|N+>}ٽ7pѦz3z#Vjf_䗍.9J,:w>㺖.?Z8|QVz#uh'ԀcM^Υ?"< Rxy4H[e)_GZz e8_:|at?lM}5 Ϛ-.}杊]nqS gą|i lyhrׇs ?ϐ?AIVlA )BA# $u]{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^?ȶW'Eo ?%,]y]TԵX}RӃkMiU'v͌ÐwJRl$3$ҒkdF}齦qfOԌEbyN5M-M{gX׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^ֹ(}'OwU};]yhQoXt1(r`TD[>u>C{\.%UPv*Ë(pUOZ:n{{^׺u{{^׺uW@-JS딾ݹX]a΢d%/pcn.Ǐ_PuOwJ_D/۝d^׽u~{ߺ^jzy炖 jfZzjjugI"(,@I z&RI.*%TN>x`}%[Qm܁vPWK[" Uϯ|~-5Nշۖ(jKs囆P\%#Pj'k>^h%lLmtn,EN'1<}J?+Ox9Byf[S凊q4hXu_۔6`~qr*?A=k^:{{sR{|Z4xM%C\)vQ㦦BFd.9wr4 ] n%?%-A¬x*6by|;W#5u ITҺTa37 0$|nQRIZ;w>q4H^yy!c+ssj~݈_I THz$rWCnj>jӓ(zλ.MIfݏhP,T3M1EQQ%J,ǟyl\n|[ļ#-|ɠ65$z/4svm}OwpeFU(*Kfzu{{^׺u{{^׺u{,;mmXY/GOR&ԏ{#ݹgm߅/-')Ftga^myh支qA&kǼa_"I?U7ՏSHkoۭQ˻Pvֶ\qxyk^f3?)AA=_A`Tk/""PG}ݕ ַVXnGPEx1muY)5k\?b=叴g{y1&~X3SKH_:xKth.Ǖ0T0i k_OmSAHp nt&G{bnQTz 4j T d>n${vJxR!Jֲ(D>خh./`&A =j|H! _ ~Jm#Mՙjt'MNݫ7X`jR qslPp5=&l`. XMOͳR,R#x䍃 FAK)U]J:0  4 'Tj`MLx]E)LU 0d#S"Y-W?I_tbܭ4nq-' 2)kAE0OO\'xh#OkG5?^5DN(暩јC{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^f}OmP-YﶩQ xrt-eE3T CQ0S#ٶɵ>r/jPq?$>>rDnm+A*VC 7bͿ7Z;rqn YWW+M4 *v!Q@TPUdeZƱF(uj-AP $䜜Ku{{^׺u{{^׺S\q_!췼z)OWR+v5ct=:z4ox̿X ~m=}@}?r*nu{ߺ^׽u~{ߺ[|~>O6OeWįK=wۅI` վ;C*4Wz}`^SeFeJ9rCB=c'߮t[>Z3xdSd)lWn]h(>3T2L|[<,ɧ;"zҹb8 cԯ짵>ĺ e|!Gݻ7;znܭNosF= QWU+M4`jw6UTYTA̷NdiI,O8`c]e86(+{xc_#Bx'$z69~X9i6/馬jtiZU<~okJH~J:suݭv+w+x#i(}Yܪ [;co,ja]5<٩Օr*hqѸQB*'*J8n>7nCn"Vԓ5]MC#ge ETܣDtI)LTT ORTN؏gu&llB]W!OZejoOmqk[o*#\v5go1'2 k}w6B]1s5UiХC?{^׺u{{^׺u{{^׺u{{^׺u{{^׺+#:tp A=Ք8*E9#ՊGAN莘>Wܝ_U.+:*8#}?=?%-ldE gOɺsAiF!UU7?}労6VۂN!.~C!?.5;jAEs2;]UR+4<"8kzJr {FbcF[IBkN֑X"c.E+)hF$|>]u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^цݵ}X,("J ]o:=M,|/#9`֮H RQ O^-ZM( TT1c:\%-} D5tUYGWN)TV>CO**ӡ&»K!$T\[hm +>-@*T5x~:ݟۿ)s~ơFTƹPU}z^{{^׺u{{^׺u{}U=g?rJF{+JΟA$1 rxWrħQm7Ao{F|ŀ?ۋS.Ҫ9 Y׽u~{ߺ^СҝAzm[jmNt jd'e b<ZA7 }Վ^V>{n$<7"tGǍ3ƬZ+X"Ʒ/!Q?^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^9bxxP,Ree<e ij)G x A?B3MSPKM_REN9ffo{9-oi$ZNĊTh`,xNg ]*I_#$ETlݻvuCD"M1?URߜP_ Sa_þSOcN{Qw [[JkzzV5ʔi~-Vy$sjsêMo#EXEEqBnxִoッ.t[fAjmgZvwz"BiI1pGS/{s]}m37U&+ נQϯ{^׺u{{^׺u{{^׺u{^wvˬ,a?nB!De2O\e(WZ|ݤG^?>gy[8&>=H>ج`Z%Dq @ PA ./v{ߺ] A Ӡ[zs=WW5:>±eSTɼ)?wESn-0!mr~L2yU3z9wݮdJ -Tpƈ}$A?S2ZӨoRf)J>*hcS嘏sbN_ܯv9\"_[ͼVB8{忽eE,WYMDO*8_~@m-F#߸o6ժ_8@. RVIL"c>𻟿>O%6۴ )f Jա-1MxTgQ'['4gA?)!27H{Otlݛs;"YI%!MT8ٔ;~N*,#ΓB@WPTpzƱ׺??eϿuG[/^}ur>/6_{Vן~{_M^|_ղlߺ^g#Se>׺x*~Ȋ'pd$UXۆoMO?s .yӌvV# R3ĐTȟC$_<ğz\?$`.j~j}T~@uW~T~{ߺ^ѻ)7t|AUPnl-(mQȆt%:E1҉keƜ<}vV,Ǣ佐ǂ Ri5X|=}:v&ڝe]\-ٛn](Hi(( JjX#Q\ܱ1$`S}}{Fi'W5i%˻$:V{E={ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽tTEX}C6c)bQ%,4Ah4[~um;vE+^ŠE])~X6jH$rW=㈩f󋤑BO=SM,̚ᨧetu?BA>q "etaUe! Gӝf^׺jఛ\^⳸ŧfi᪁ {+6;.aw x.aqG(扇 2H-+Q=C"2D?oE/|D]2s]nͨ05 QD~ GIe6#{uAMvEe05 m!#CLN\ҲΗvڜ?Bfl ]{ہtŢ啱u)fY\(>v?1mqV 6W:|j xAAìo7kY".!IzpD}thuE.ۑ> t>J9 z%nHx+g˿Wj3^ؒh4E@ vr@dw-s*lrs E3LGAw^׽u~{ߺ^׽us˗ٙΣTNknyZ&._މ%rI@kyb Ǭ[}E{ :I>5\w`C=%c~bqlOM{{^׺u{{^׺u{{^׺u{{^׺u7=lL/~Q{}nf8 fdu@E8ٍ~|+\?ߺ^d]R׺&(/~׿4C>WyԸuɧ_uM>Pϕ_.{OS:r.XcrylZD"*y%r%$*($~l]{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{mv.u4׺/}d]3)~Xǿu{:w'|Y]U=u/'3GC{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~W?AlęLu7rWlRSW{u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~4m-œ`Rdr\Ay$v * {^~L2}ӹ[Cjmtf~pVzL9SVF LO~V7{;s5.*toߙ$td,,Y Hk{?ɭ5Y<^ؐ5nÌ$}M  ߺB)BWaȘO<^q珧>׺3 dov@n)0㦑~WtL'z1TE6Ԇ(dધǃ6Qȣ30ENtye}o>gwn̬Ud欜oS~iDUGؠu=leGQ˜lH%%zu{{^׺u{{^׺u{E|5,@gf,ĕԨ -` 9tƇNnƝ>3ջu}|?V.HUFsrV)1Qʶ66z Z/_Fp+fD9(_϶E5˪z'{^׺u|?~4|8Oڟ&rXT 1./@&nWl5lr,1j/q?7\}ז;#IOlۓv1q1?^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^=!m tҘ+U~VKD,UDEuInJ$eHFݮ`tJ^ϷezZ &6B甕nR~76mEđ譡R:4ѭ>;ncoo4婅%^kEpXϼ䟿;r1iF0L{y%.OIN Y5[ݩFN2XO B?^?r=k Y}8'Ff\ j/z5&>3Rڿr5}&˞.r4HgC2W"DAӡp}{պu 5IDQOb2:VV2aK)"V2XA 㑢`J5#WOa3iGEv&şr>{Iı}Gv, ,cE6TsY\ZQ.KOҼP"U@)B!_zbEoX^R^<&Oll+KGQ!#j8_b;^Wr+U_ N *!h~YɞR׺cmdnhkġ "N>x!;/*~%EU] jYO#%$Fپi_ 6˻,I$zܟ$"I#u<[?9& T8(mEliг{^׺u=7PvWKi1~oE[X9%T,D2e`nOQȳ(t!  p=qJ AP0AϮ~zu{{^׺u{{^׺u{{^׺u{{^͎Z|\!{}u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^ֶkʻ|ڗ O~YlęLgucߺ^֝;>,|׺C{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u_ʮ0uړC)7JVR)I/ի6ύ?/]h05mKJ9C p3.4^׺~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~t̨ʨYI<u!ݻvNJh:kd :Wk`b!6j@E$d*K#Cq7./Z֘rYlv9_-kD4t$ lA]5+b]s~"]el-殬{U)$:cT@=׺u~{ߺ@v{σ 5wEH7!j:!{u~}Xd޻inh*l"VeVg@YV[LCqYxvnRb T YSr鶢ouߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^5noWpgU֙9T$ (װa{RM/Y1ٻZn˔3 5,+b/!>,\^C׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^nfp\Z!l6zA 4a_Nݑ}==m/"+B_9 2 P5.G_63!L93)"E 8zeu)Vv{{^׺u{{^׺u{{^n;j߈;,;Aet fu,$<5lTp*0:~.d=|$" {h (®/n*S4K}2qHƀ(qtQB~꽴:7qZsPVaQ_}{ߺ^Ջ+O0:+q٨^wXۘɢi̠^t:/") _y֝cw޳۽7pl9-y2Wj Zq48]6?E 8a4#(*@X{ZKYYݙؒI$I5$=K׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u]׻Kvxѩuzf+iehj"ti?khޠY ,?*t Ք0>B|oݝ-072u t†R*40<:GŸOݫvSj&sʸb)`?J:"GM^׽u~{ߺ^׽u9H&đM eaee Џn;86de )*Gzшؿ,;`a6wp(G1-Fcyȟ{~~ )-*֡딙GT s6' 쭇SC)`f6lhౡt5SɵLGIl/,\͵TۜKpIGIjpVQ::{MGŵw!S WVfƮyx>M+B;m+5#jz e2~{tt Yih0URU̒FՇA+$WEe`ANy-]dH*J(A_z~⮇>LKu6% svE 8{msCfMgAr{^ޕ=# cyC'9g hGPVZkgz^=ô~cb'a+A 9%e09D=Q>,"izqL6 ٘NnrIvN zo_a5ͺ#y6J|6e^35O-,[Dp R >XܹBw[[;H%kESBTiCCCIm{)oH]dCHH7.:u]櫘͘.]ݙڻf||k7'ܛw|6䓩YnōOM^׺u{{^׺u{{^׺u{{^׺u{{^׺u{>rxwal}5nlX#aQ{?!Tzy[Lpù֒O׺Lff:FF+C)"*l[Hu^׺u{{^׺JM6jyw~ڻV#I2+K^hpu+쮑E޽7$8HMτ,MW\x}}t'a=F gvXpDX^ߺ^׽u~kkƿ쫷pՙ+&IO{^=u~iӹ?{>9=t?!:~ ׺u{{^ ;C6lM&Sfre,?Hj"#׺MR:㥣=.# !Q+K5'ЭG[GWM_ERJz9X_I"G^>{>׺u{{^׺u{5ݽ3sp$9*ee6`b7IߺX=ҙEV1i1;S)$cp?ߺB+#(ee7ApA׺ߺ^׽u~{ߺ^;r'_mvv:<ܹ:*OߺHؾD~Hᇽ:rYqQEl+fbl~ ?F _sdTES K ӟu{{^׺u{Ki@*^ۛbP5HGemx>F|{$4I6n'?{/65o=@juPU/{~H۟׿u{{^׺u{{^׺u{{^׺u{{^׺G~$){gP\\ +u R ~m1»ZI?{^Pf142>F+v*x!b>e ߺN>׺u{{^׺u{{^׺/޲u_MrUMaA,&SbT9i$ҭJHCEǺTEӽ]~}mm~ ikK%,jUJc"Pa{篶Vlvu ǭ |$aꖢwPJKK+jaߺ^׽u~{ߺEDwMn=$nM;\Ddљ tH$hЏuqjel5TP1K4DZ9a' Y7PA{^lq۝7]?f T@,%t ߺBu{{^׺Fn^̛͖~콦7.RߤU?,}; 9Ibsa2Auk~lm.{SvFY: @ K4׺U^׺u{{^׺u wtܫj ۽aF*y*PVzpVǿuT;GzuVhZ=JX #ɷ6ӟ~^׺u{.S}M> ͗??OMUDMߺI.茕DtxJMܘidcuǓ׺i)xjA$쮎J׺{{^׺u{{^׺u{+g˻~:Y7BJrA @ߏ_:gBW{^Knm)Zl Fx**O$ ׺{׽u~{ߺ^׽tg;6K{WJ]$zO~7PD]IMC0y@}H~ pEUI<5TӠ vWGSdu%YOo~f׽u~{ߺ^׽u~{ߺ^׽tꍣPԛlU+p汴R *jb`)6-Nu2~j=ɆFYЩKWK]O ]M=e%B u7Sdt%YO~H׽u~{ߺ^׽u~%7>&({jm%]QM4t^Zhu|4ztJ(sUTW>׺L3PHQ L,"X]},}t{{^׺u{{^׺u{{^5em:j]52y*++$HsywJmۥ@?Wo~Ii4gՕ=>bSz>Q1ғgvlXx,FJֽt{!捱=#&v8+Se?NlVʷ 3jav H]Qf#y\ܛ_,a5aӪt+^Kxl-8ӈ[1ޯ>j9LwS$0B=µ6[卭9\’$SRz2az=9qinLUP` :[#4*r=S+vm{+I<^oJ%E}*f5De?hlSlVUՑ>JOD ŧyuܶ1ovxi dN}|Uݿ(w]ֵ>SMz`dH? $OTG ^E /m1l7Q։s8V1\8<'+_W -N讙m_%*1V:zl>U[rnmԵ؜Vf)LzyUd&rBjUfTzݞo~rլm{Ao A~#FY!uX.i*N9nm6%&W[H͠:jj|A?~ /~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^f5o'={/e_ӟFCߺ[>^׺u{{^׺u{`,wgPvj`غtGmԴ-%%=ZEkU(P4T{ߚ]۷7bm!!_t1E1Q,T5C"%@}׺7jxMݵTeq*StT22:Fpꬤuu~$]m7[smc%l(Q׺{{^[_5e]?KM'u_6WL&3ߺV1{{^NU_O~ma ^f׽t w{6m2-MQYuJ=$Dl- C{u@}{=Y[&VhvШhū띖Ԙͮsuͅک~袖b3KK" YW-$}t"~|Q]Yhbb%|z?T7}}tmΐۿs5@qhS"!+ X-㨅ԋ]Hu/vC7lv%]Y?e,H-=M CXR4Tՙ^׺uxߐc1a樨((&f(`,LqC Q֪GhQULmٙܙ^62-IL $)p52Ou~WĘJZ4ث:SȬNe UYIl.LAq)=׺l/ItJ30jj?^!~6w[QϓޝUpUUZVSD[x^Q|^S 핣E(zv-d3T|POT<^a?(6}.R{";QYIXeZ2rr{G{{^׺|E,,Z >CٔP.q)+؟uO~}o`3=a^FJ]x>*:ܩ!/;f}׺.[';^Z׻x4*:)L:Ĺ iDH<u:τ_*i媛eQ!O[,T~QTvIIxRd\Ut> ^# Gu+)ɒ쏑RI[*Qc:(0;f jD1fԼus L1TSE=DK4ete%YYH b9׺{{^9wv{o/fT]W(gGb8ZI8՝OTO7&۝/=g]lztîrШIߙZ*9+gRʖ.UE~?_{!=5[뽇es$j#eOg0ECkqXY`YXd*ˬʵ*cbFx<{^5_wjYl-{S窜 m>׺6U{=MJu/pd&;GR-04^h׽t w{u.߹%fBvJWWBYA XV(G]J{/XlWYl.5/ܢ*fv^ }׺/;#;Jݑכw<:Iޔŋyk J$fR&S~  >T饫w$D(fl MY,x*~_~ݯ;iVo -/,'ou &QԐARA^~42uݛ`(;3-96U9j8QbUE:n/W=A_Ci2X܅,u h'U4r"0ee%YH }u/ߺ^y2뼶'EmLݻf{fQڕX)yV7(XdF"{tY?wjv~}=w> m%d207*YQ2$RX؟~;b N[)+5BP JODx FFq sBCu[N#uvŸ$u)1׺|3Ce:cwKM b6FP$|}EUAD>׺ fvWOt W H19E`CEQ+q{|ĠۛڛnUdE>J{Z%uI6dubi{o8XTJz<2XLղRrRH+?Uz^4-$AB\_Ɖ&7 (M'ߺJ|'o<a V.FR:v?>׺s[z?OMp`nZ7+աC鞝Xd+$fǂEu7 {{;Ϲv~Nx!R9T X䲖C${uzꮌy{^~{ߺZw~w{bq]^7q 1YAU0""ETӷ s')gsU_yLR|-1ܳBo$r{uJ=w?& qYGWuU T5FR`IsD@^FN:n(BJIGt<i7P}toN(an&GK[){jb"9׺5{voN-vX~ۮܴ#˸ԳD-2I,%S#H0Ο~PܹzֵsNhqyrMme;r53,vsP@o~?(71t*F:Kyt楚O%j}W tӻ*|شR/PoJ\t L+&=r u:{kdyG?,>.jҖy4R"5{u??wɟ+48-^:M嵒B7% ^ѫ崬{tiu~3wvG{q v6^Razl<&zIaYui%Tnݿ)zoǹekhmܼyj_$NEqfPG[ ^׺{GvgNlߙAbUk䞢yii!43 gvH}׺aո화ꭐ\I34y9+r8L`)RzDҭv#!O8BoϿu!X3d|ͽU"QP:ҧ((JAu:F tq11TE&f^,ș)ir}us|F-i5;"4؊u_UAXEXOH錯u;Rx*uVbWF%^:pE"G X^vVCD&C-F8H$u-jVge=׺?׺u̬wkf|esTIW6N6hji9fIVx${^~4wxg@9ܽ;E^*Qdx&xٕԩ}u׿u{{^|_׿s^޹zWmtΪJ HqEB$|C,1RMPr뫬LjE6|c"-G'W_MTrNe#6GƮjHr;7[RR5%WXiW?ߺJx*Fm<(a#/[S*c!'~{?{ws󝣺7_g(jBqQȤ78N!u<]}uq'kmMV—S⫤*đ㪤#׺t^W;sn6['cv8yijDT@,N>`y^;3޽-Olq9^ۘܦ/%Ϙx'ZƊhfJ${^>`||ױu%&z5zZ E[7#ߺFg쮲PmخO_HM-e{X佌rݠvbM[{;"zssz-XANB-M l K$С,VX}׺(?߸{oz|`iv6¾ԾsfuH!"O{^u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺD|@/WbwT%!KV`UbO>f<$jVwb$}wAo T_S܆yI''7j3OlLuz֣Gz*em^;#IUcꤢ s^9cu*2 GVA몱Jt!ee )#us{^׺u{{^׺u{{^dOhTlTq7:傥,4_E^Ǜw ~ڧM}>u/%LTf)$4ܻ.7+GPџUC%Xz'?ip2lM#4kēd q=jug{^w3`-vrI*&BT=x(=K'Wـ+12MB1'/~tKj}gnc]I,{$5de8WtGtFMu~{ߺ^׽u~{ߺ^׽u~{ߺ\7Y#fI r?CRAAdG:F[\]x)d ajkP :;wh>rh<@e ;h!_>\0^ψh ؕe||815QA(ڗktVrU Ҿ &*^YkoLjenLk QB)7 A=/,vΖh[L(9(K U(^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽uY[ffq{^> WkQϾ׺u{{^׺u{{^5e&B gE)bJI"1VR EuWo;ptҢZZ50s'sr%xKNU4{yF[ߙ/!V򳶐mIY/膣LBIQ'uߺ^ֽPzddi2-UxhG%JKEG##'ա+/[YJjSLc=4CL_AHœ{4HE8"",~r37uT\ɕteC QS3$1)#Tq~jݝŻ{߱s]gf،TlZ} ;Z `mhW76I{OVaݡޘHs{% d,񰾗l;5U0#?k{b(( 8`5bPUPUP,u{^n;c04ugcf 鞊IxʵmPm3G"]}u{tNu+S.9^1!Im"UR&LŭeWw;anzTiUW\cv&KHL#JvII>Xu{p~y|̪;{#!χ#:eEJM JK !m?YcM> _;Q TDci|r2YTqȞ)u;SE8l^aPb0EMM  *'aɹ7'ߺO׺7:FMx59[TRJ˧(VRT(׺tכb-su,l}AAMMM<?=u/n?!;/rS`)|nҷW>% OHƑucX ::x)))aZzjZTX4Q#DQE8ߺYtw$)=HP?j ,% tֵ=ӻà{/wR%\0)} }Bb(CuZ)Uc6S}KU'_uM!Jn.}uQFQYU{^{^׺sr$jt)mL?e|.34tSdc~8Y1e)Uފ oXNWC ,{6Evn=4RbGO rWF]>׺Q^zdܬ[mbF'TU+5-B:&T<{sbN|kݴXk]as@4-L]{}QJ-DWt#^,5uQwK6gꪘq+M_JGjqZW#{{^׺u{{^׺dC3?~Voߺ[%{^׺e  ytDt T`;SjidI⡣S2$c׺6Ta0%IzLW\3d?jHaE1 i׺~{ߺDe+(Xwkb1>P4 LmtWGQo5fo,VD{h)O b3xLZZiAVM qee{nt]v+sm*rZuRQJ,,O~ ׺u{{^׺u$I .I{^Ow}Ѻ2gjbؖ&^ߺ[)|ڱm?=OL*Tfq3FTUn.D*nnOFߺ^׽u~{ߺ^׽u~{ߺ^sxnۃynj6&lV ]-ƹQ.Uy#ߺZ|]q,Eڇkmcɂ1™:33WJ/Vi.\># :Qe6]䔚x "@:hv5*9u ::x)))aZzjZTX4Q#DQE8ߺYtvgSupmbml^;FM+f[TRN?OI{s\|RgOQU&ӪәqDl,sDe(}׺7ov79O|dޣ KֵhZIq:k ZVzeP% j'Wu{{^͎-un.vMגJ,blDx[DrV4$ gab#:{ujڝ3h=ȲCDxrU:SDᢎ0idQW UEuj0ߌ{~w6*g* rqz`Sܛײ+U; ?lll:cafO!xQB!E^b mݭm.Oa᎞5UXijI>׺{yW{idv^R$R,T5Yj<וp#{utu~W;Gyub_cKM]!9 BtunѭVlKVfEd}J&rygښuf$ug$}tsu~jk7?3nW{^O4]7&j,fFʢf %.$@P>Ho, b$YWX)ZNBŏ @I׺u6PL&OߺUg:#fu'u{hܝŌzcsV:ddZEKӤZhT1׺z\hpF&?vdmƺZQSSWY !g9HpJ/OC 4OOT,0A DDUTUU{^/uꭃfi,EB7 deU+i*$lRTuɮul'<̪YiWҳ,RA0A&tQ׺ܹ_g1(1n \e.if~qauߺPry\F7!s.\d.V(#id ~HE<~}ui&w; vI{3.DA:ii#S*CP䛓' ŔRd{k?# |k$0@X_3%@#Q׽tKX=_ W3`r,{$ktj (%{NJ7Ikn~8"jٹ䬥w%Ck Ip˩H=Y({C6Oacbj8i hLH$\M!ߺK~ߜJ=jZ/cu@?;f'r׺u<Cn|؎tmĻhj $CIe}un۸Gsͼa@I%gXMLxP4O~^[GXf:Z*; 0h*r*8Z]!L{uc׺u~՟ 03ߦ.6$qeh %&kk7wǮlMvBḏUFI$V]N$utU$d㖫nek_T,:+c{;׽uF͓fR]{=moZZN`3P1 %&eQ9"pW7f\GfwF ?0ǔ䕍gYJ9>׺0׺uLO{~*6tw#,GG{ߺEGu/mߺZu}}GHl݉B䨘`!I?^|UϺ>_dWdSn 2׺֯ CzyS˛3TH,nWWK%&%wiL׺7ʧΘT;␝1TӼ4sL3A%X^}u~#T~(}<-IjUT+P",`}jV@ߺZ_o^lFk>gu=~FG`OY_[;kHYv FUouR[;`x2Z`!S#X 2MHS3M(i[{-{{^h| ޚR` :u{{^׺u{{^׺u{{^׺u{{^׺d3cGuA ]\5ڼu}32ARRH]IRA>ߺJ؟OW~{$v'>ߺ^I=ϥw׿Gb{?]_u؟OW~{$v'>ߺWyAn_)2e%c]5y gb^ǽu~ԻS?{Ÿɍޒ%zWғgeԼRGS֭[pueu:ae+iX]=LVej@#uwwX&y;fcGlkL*"v7Jη70gvԝ1b-q#0YWdЕNuOP姓ߺTG. OβTU.0#.<<ѷפBG+M2cHKp^t[>]mGR|yێz\BeJܤCIH@H>kMԝy=sgwn1/RNͮ7ZZTfug 6 i( #50O1嘖bI'ߺO׺u{wQ>c:TPҦKGw}>JViAkнUԝםO;Ae5oDmhf?6$[ߺ[i+22VSpAG{uߺVe+&e?{׽uN?k'udv}t3{^gOgc^'0ΖFYZh\9Xٽ׺φ3OVUl } uԒPP4dS,AH)+u[D****UQ`{u~{ߺU˺z{v="iq5M] X]ZIiG5׺rMvؐK򑖲*.= y*l{{^Qs+Ω}?Jtldf棠 TR,hJC.EjL:\GߺVw{{^׺ {jSoݣU3)X5UCPDǿu!Y`)XCfVR #Aߺ[2c5fWN"&*xRQebYGI#ϿuuV+}[:R6m9f$/S_q}u[zN{Qf6pL/IRѸ>ZbY M׺ٸ{u~{ߺUz=Y;oUn2ˏǪc_ j):i<,-&{'~F'ȝ7U.֩I:Z96Ą s}u}׺B;u'IWaC"G]͇y,Td*cS_Q#.>׺ՃhcomLzn:l-$LZbNwMr3sWm62a6",U Ҕ[S.TUL^i[R;1^k{{^׺~E?:wz\1~CjOl|ADrX,wϿuv{&/7%>\SgyPlBOxdSWe?_~mыQ汘:aQPCpYbp#R8?}u?ߺ^׽u~{ߺ^s4&I^/v.ou5~׺+ߺ^5o(]g{w^w&Z*]mUlȴ`٢䪌o{u~{ߺ^֮57'pbSVHm?O^[׽u~{ߺ^׽u~{ߺ^׽uU??umCE>I F& Hl>W.SihzVےe GKQQḦAAkG[2{^׺u{gO;өo]b2t Uke`Vz `5(IxXF{T*+sSVӵVs,U@4I_APIVLߺ[iuF݅B;lf䧎ybSSOniy<}t ^͎,t__5t9FBt (r#{iiPj#DPQ~{ߺMYE6*oQWS e, _~i{~ }񇯭Nd3o,e|rW*\}׽u~kq#T\T2uLb1H=thFYv?pbHo c%5UQ-6[\ Nz$/G7?I Aa{&W=twҪ(N9zs<֫P&Ȍuߺ^׽u^_;)o}MڋM*dUThjY2) cή=׺I|_oʭ6{@bM[5Dymœ5e*|% jCYo{ue:xDUۛ"&i'UVYbتT[~~ߜJ=jZ/cu@?;f'r׺uvF_voQT5 dYYi9!h#VOopx>׺nX=%GpzTz#mFV#fтBĕʤ4CߺW{{^׺u/nehRm֔oRyZQ_)F*.~{^:7:{cQkpCQꚂ[`s= uӧ YRzjVx2:ʲA׺{5l0z _~SIڟ#ve)% 4˩%j!&"bH^e~{ߺ^׽u'ڴ_FjH]MIb֒cZZeߺVMrt&LYUjċ1<`[(~uuߺ^֠}3~uO&ΎeHt?^_2^VG(G h fblIٝմ3(*&&My5 ܖUnN :Q@^a׽u~VGڴ~_ G9aM]OUKXpC9lEdia& 'ue׽uwٻEPaz&*-WQ-02_H#4ѓ)w<_ulܝӒS흹;cPJ6lG$v ׺~{ߺ^׽uw ^R%&J%x!e< WE$ʊ4Sƣa҇hPb֨uu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺4-ED3DEݘUUM^|?ܗ_"AeadWA<`80P<-%1ʁ2JT4ZmE Lr}FmT 59?3) ?G͟RO- uu4S L vI rщ#rYS }]' o?ƽџ/?yFkoo-M0mn4=%ul SIWKR|t_xFW[:p q!E <,}^ϺG۬ᇚ?//QC[mp$:̴Aƥ*E٧C.{{^׺u{{^׺u3N#n?SP^?vG}}]?*?u?zOuy4^_S:#7z;ϵ-w7D+ʹ~J▥@)Iۻ 5q *y H v|}jāqϤg2Eyd>!wW*>l|΢2]V-)kaygx1ݒZ{Y A?zӬwƾr]HI׷PpV"<_L*JJZ Zjjz:*:tE(BGq q \]fbY,MI$rI=H׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^EBZюERuN#CQZ*h^:8Ɗ]̳C1E^^׺uc\ʭDҙiGS_(?OU>XPz3t~R.ԘZh`Cbmj͍k՚^׺u{{^׺u~;JԘ|ik %uUH* Woއ|جί][ D5MOF#AM ΄TKX 7{^? Yo^QDž,[uy([׺<-~{?ŖuމxDU{v=^ I(TDPly׺ڻ3nT%f[u0jf G>׺}uߺVe+&e?{׽uN?k'udv}t3{^ꊿ▧iÅU8) i BcH_{})/[77ks`!,&z KM:WXo׺/y([׺<-~{?Ŗu?x_ߺAlt}tllExaӪ@a+RH}}uFm-㴷U;UgsPn$OԯEUJ0Gu ׽uuI^eo|g^]1ɰ( ,UYS77>׺1׺u{mw_uGu _{ug\;}`wu&ILx5e_l6{j׽u~{ߺ^׽u~WD2b~:b {#1!^Ā`#~~T­{&ݝ(ڴ9 UO4oY%觊iԙU4@q{g2Jvw-Kg'M ~{{{^׺u{{^e$_duY˗ʻcڗ7~l{{^.3)U1Rp)qŗuQ=R6W{{^׺uc_UԸO{^̿ew$̧c=uc׺u{{^׺u#'O|'5/FK~Gu)`X&)bqfVRC)A#ߺ[XYѵZ8z bG i7b}׺u~{ߺ^׽u~{ߺ^׽u~k7͉gx4Qt䝀joPOԅPMTJ .b^m#s*:(H-.]#RǕ׺~{ߺ^׽u~jsió~Rv2!t@#Rrt9𩪑Oۏ~\Wrg~/aJt7~_n &P#Y)[ 6'{{jO[76;t{ߺU1WRiՅ٬7|lf l{{^׺u5S?:DnǥOWM{^I׽u~PVٿq^׺0S=duo׺u5e G+u_ |ޣm4Y:܅OHŊӫJ"m~~{ߺ^@6zKYьAeꪊh֟-fnEߺW{{^׺ dl3ߺZ^qo~{ߺU(&b'{__WG3^׺ٓߺ^e0b{Weƶ'7|[~;ΒumㅉAs{Qfc#.Քհ?vISߺJ~{ߺ^׽uGo}D՝I2d٣OR[Sij9އDzߺ@OD 9|u@5N.U24zyʪᕕU/ug?X塂64]7s"R,BSn5j>w`c۽r,~, U(5}tai` i\54βFUԕa ^?u{{^Q?R{e'1?u׽u.7ݹ9fBIч+sJ ǿuxmŝT#o Owd,jyk$6,M G{ߺ^׽u~bj(秩Pte<2<{Al;gm= 1+忴k_Lfgq\0- 3 m%3Y4׺_3?ͮG6e"2RHKk Y6VfU,O ^u~{ߺ^ֽ N/r~׺9ʏdbMocui~׺uLO{~*6tw#,GG{ߺEGu/mߺZt~.,uuph\bjHHkY^m~{ߺ^׽tFv׺U9kd=uu{>wv]ӽ_qnvi[VUP{-/{ A{.ȶ^GTjiJfV?sR`Hc^x׽u~{ߺUv3쾡TbFCmXd)" ޠ%n}:ߩtO/ jߺ[{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{q?!o y>vuD+mLAO@'SQNA A2-55Tts[yQ1S[߯{^wL7M˷f]}͸&ק9yK5f%嶐C~=h1CM6נJ 8<cλ/Y&~tq?`ު!_27fG'wu%N_hVq|`Ff񉨋_ERƕs'YHJBD7{=RM^&tN(k:wTxIXAx = ׮Td>u{{^׺u{{^;sBH,TݪW1{@0b *Bk)OA4\Iuqe8>.XWObJGU @4 ~=թ}ÏpvtbGnIG$wѧ[t~%~-NJgf嫍Mq*TS A__.1]>ZUʅe AW'UiIɅ4CBNJ[\׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺uS$heՅYM+bp}Xe(2*A ^~[|IaK_}iA$"i VԠaٍx\1}iٱ?{#rKm0I52FMwgZHvN<1d+b LZ+>cO{n*B鷽rCE/T!ӑ>xν{{^׺u{{^׺u{{^׺u{{^͎Z|\!{}u~{ߺ^׽u~{ߺ^׽u~%7}swmݷ|N^HEc~M3(ǪIQA,=uwT}߲"Pw^eb(TGDbY*Hĕ2<[{7n}_1ˏSKRաld keIXuۛ 8}϶4|W: ,|׺C{~?tu +m4X(-RreWo 9u7GUgi0U4[{!3"zԥa,T"6?׏~?(?Wz׿~Pίe/{h^ϼ_ߺ^A:x׿u u{/>ׯ~{G_}^׺؋L|5VCCUr3-"ƢF.ybXs^wu7=Z~lSɳb??~׺u{mw_uGu _{uc`ܐ@l&?*\׺m-4siQ-?kd!my; $k>Ny^Ƚu~{ߺ^׽u~{ߺUi?Mu$VGߺT]/wKvڌ8yRix$9S{^h^ϼ_ߺ^A:x׿u u{/>ׯ~{G_}^׺6^um{^~&utqnm2%>aQJ ~87_ǿu_u{{^׺u{h?M?1f._*j\juWu{jP7;wߺFJǻݿ֌uߺ^׽u~kkƿ쫷pՙ+&IO{^=u~{ߺ^׽u~{ߺZ|Oם{HajћE]'~uQs^u|q>\nz %-d)K!mh ׺~{ߺ^׽u~{ߺ^|/{w{lmEĜvjzcTh qN%1 Qu_}؛obomϼR,zjJ?deO B_JtPYguaE^`:| Ԅ7mTd <6uh_6UJA*gk0C~{^ƽu~{ߺ^׽u$O Dm4U`5h\~B}Ն*e+(~Ȳ-qo .\՘{^͎Z?T2/~la{{^׺uu2bᛋ=t׽u~PVٿq^׺0S=duo׺u5e G+u%-o׺6^׺u{m{gQoFgv~_'u{{^3=~jk{Žu~W?AlęLu}^uG{^fO~{ߺ^`OݛWVHm紝hr,HMZUC3(TߺUÿ稜zjHq֞||o)ۆ0ӭ͈P5u7ddz>RfIOnRY)?G>׺-SS}A{&-Em;/fOpG^t~ѲWҙ+;MKee,D N~_?KwfﭓI6A(e1uRVYr!"xٕз{{^5mJ#IM_AY SVQVƒ,n4rFєث~Wk-duVn?Ej1eͽO6Ep'MϿuVViٻd5<^ j4}׺(I:{PӍSi!Dv8/'u͟{+Ccϴ+Mo.߭E2"ʤ( X 0#~Zgih8)|E8['EN?KMrFSJuuUy*:L>:GY"Pf98N@quoᗗQ{^c~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u/+C>/|{:|g) T[OcQOYHh^OPzr >5>I;R׺\d=iG~Ɛ&PN(pȢDZ9Pr#̥bYԣ (G%4n* Sf|S(q;Gv5+p[}2+;q"VHuI+nxqS꧇Ϩ+zڛhl(ħ|u`~)S)h&ZL}mقr]sZKDuugQSM9~?' W;OCB~X|6,s5Nx<>qc{:{{^׺u{{^׺4_/KLᑢT`V+MCRޅg`.JK?0ο?a>X.$ܰGHi>\z߻7^*R{fsg(iTij1Ʀ9uJР@l:LggϽ^nQFp' br )'<+PFΓNzۦ {xA)33y 5Pbi'@K*=8Xr}ǘtgnmk"8"L覙 I1؛Sl썥] 0QR¼銞T{_+q]}v,I<ұI,;3~g]׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺX) hf42̬ᕁ8>,K2pXe` A`ǯuM_-(Tec umAaV텖F䪯l?#N>g&*Eu.8itɑS㢩}v6Z]Nc@͌ܚ5|дrY#^.ߕ,?Go얍2Y:b4lY)tRCX,u|~׺u{snԟ{+xv'qA(U=9úܒZU\tv.#̆k(1+I (Q䩕A ׺~{ߺ^׽trޅ댷dz,OGg:tX(aF"~b=k]n.nף.; je_txcI{^}uWWlˑm;kҎۧP+HčA~ηuݔk;S"7m8E>YKVAru1׽u~{ߺ^SEE%Wvu45L$]y8e`AߺC>/nw _KfhbtN$tYaKF2GߺN>׺WoR?SI{2WM2Ռ{^׺ӧrşWoߺ[X|rzC;_tt>׺uG_͓lMxg1N~mbfP*Jl}zE^Lx3ð~'nl%:(`}-[{׽u~{ߺPr M-)}׺ʉQO]C5HF AH ^Auq^׺u{{^6\nܔmK EU&;畧Iz䞡ja׺%{78NhrqRm*xaj/<+0+$Ҭ6{x3&sAE ?7bZQmp6J0@=uU?wm6O-["CGiK#[uH+u'u{{^׺uɏLG ^eqc2x*KE<ʆKHAߺBX-م=r}3/e=Eu"8Ͽu{{^׺u{h?M?1f._*j\juWu{jP7;wߺFJǻݿ֌uߺ^׽u~kkƿ쫷pՙ+&IO{^=u~{ߺ^׽u~{ߺTq:\^ٽ͎o۫6~1LRHtѯ'3t .S9Y[b3+iR3'gYiGjB{^b~{ߺ^׽u~{ߺIhMV̜⧍(R@Hrʠ@֣v[2Ųpn*ᨰY*y5&߷,U׺_[K?[N@5,%7UOh6#{a{}6ӗ  4{`Njz9=M:l}ъSvluQ|};dJ>±͖ {^߽u~{ߺ^׽u=M؟#{uQL30L*T%u?R$ǿuwmIŝQU ̮OuRDՏKLi)"mWSuu7=lL/~eA//Z׺u{{^L~m_/'ߺK/~{ߺ^5o(]g{?]`FOߺV{{^S_Ptߺ[ |QR!{e{{^׺I9Z1׺>fk{^׺u>9?֦o>,|~׺[ߺ^s4&I^Qy׿ud)j*%&y`;I~駧?_U{3ߺ^׽ts']Ʋ2%>v*Ax$u2HO*{3]_-uG]M;͆SIK$"f&hhK?u߀[keMlJɉ)!DdDSL^e/~1n Ӷv$Y ո[fzGn૧ew$2F!HقF:s׮+moݗrmNRr˸y$*maߺ^׽t]Iwjo-=RaxE!5q'VIԬnR#{u>Ht{;PL}E*3u2;ɣSDhSu-մ+޻]Szm=CY5锒KGEW *#}}׺~ߜJ=jZ/cu@?;f'r׺uw(~Cܟg d\]2+ukߺW;F+f]ۗ#cswO9S_JߺGߺ^׽u~538nBbp8RSR!6?=uT͸=bU<^z$~mejO36\-O_T8R"<528{^a6O=Imw/u_7 %OY}us׺u{{^^e'Ay?~G2k&׺~{ߺZGMSsϿ?:;#q#{#˗{s~9B?&m~m{{^׺uP?ޓߺT_ʿ?s[u}׽u >FbZ V$z&%Iz:~S7-.KeE6Ħ'=ߐ[-+Á{{{^׺u  ]cG>Xjۛ3u䤎ıCE+؀BT)0!1eT^׺ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~|?Rݸm2czKX xk9LVGpUJE2O)g܇h-N`KoZy ?zֻؗ^׽umɻʌ^}i)6_~mr[&4-OԲ.YyFƹCQAE*P?v`plemn\E6ui}mceƥm;Ss1 C!&RZDrG{׺u{{^׺u{{^׺u{{^׺/{G> IKOUf.8ܬ>)itisEi)"ZI(Fʼn^y{{^׺-+zOwn߼ _BwdSjjx.,G̷^Y~n p' 6)mƳJ6+#~m˅c&2 F6~Da{?~kkƿ쫷pՙ+&IO{^=u~iӹ?{>9=t?!:~ ׺!?g;G9zXc$"= %6MG4tR !|b&}9T&.Ld ¢4,(~mOel]]>C#`O4N$lXpA{^gu{{^껿vRuJTu:cݬП݇dt蹉uP z~׸SNgoH%$ue'UU?Ng^h~{ߺZw_^ěݭ_uddu~{ߺ^6{;jj׺ӣߺ[un/p`ߺUɺ:.=ሤzTdq]NتX2A s{韂HT'NڝymEO}Sy$ 0H׺ڃgX'Cd<59cpG{~{ߺ^L4l͵3{(6~W*qgR}׺(Sޟ!`Sz Q5ՑA6O4ߋu%e{OS XV2PjzĊO=u4bzVtƲ3Q1!e?Zzy[{^kN'xn|#¿ƱꙜtLIDWQ8> HrE'{sߺ^׽t wobz7wbbOg?3):tiHVI-d>׺gj6_tM>K=EvBQYĖync'ߺ[o=> ݣ(bGOFhĒKI$ߺJ~{ߺ^׽u~{ߺU(&b'{\UԹ^d~{ߺTտvo!w7uwu?~[u{{^׺WoR?SI{2WM2Ռ{^׺u{{^׺u^\'xuvlX#PU- bCBu|"$+~j6VM[\N&)t!X^ˮH8x]x#ߺWs?9Zz~TB ¶z ` , JCՃ{^׺u{{^? ;']o2 Qؙ em;+%= $Th-{{;:9%[rh& 2z%("AUB^hUETEUEP,=u߿uu*3}M|,͈A qx sq:|V:vzR{ySB 4‚Tw"DH>}u7%rl/)GC_F$S2 "'RU2~M׽u~/E=9R4mF_4^bm&_ ,ŢߺZuf nۜ FtfgJt hM3}4w6~m/dm=pX}۸{jQ׺Q^͎Z?T2/~la{{^׺uu2bᛋ=t׽u~PVٿq^׺0S=duo׺u5e G+u%-o׺6^׺u{m{gQoFgv~_'u{{^3=~jk{Žu~W?AlęLu}^uG{^fO~CPe(+%CUdhH`A?>׺u7&ʣGͿGROGQ%<$3ߺ[Rrz3, MG2?g#F! UW (Yu~{ߺ^_](2n ߏ~RÞɡ꿑i2KGɶ20X-f%BK<,D{=u~{ߺ^)6\&/?]_)j%GFTWߺI=GZu u6Ħ@Zy9*DtXqsൽ׺?~ߜJ=jZ/cu@?;f'r׺uuT$1AD|c\XJ]䲁d^Gӝ.թEF(0UP]\xHYC¨ev ~׺u{{^?/l~W/ϳY(y(i(%4fI U?;vFzI*pܛ@@5BlB H< qk^j/~{ߺTk?`'׺Y(/?e{^׺u{z?#,_ts?ɮĚ{^u~j17OΟߺ[>TlFXďߺCu?̏%._ue (}uWu{{^׺#_gC| zO~S?*o2׺ߺ^4o6|F顏jnRDY*4of}/}>?JtodUm\(뱚 uC7#e=NF!Qgm4>lh"IȡЂpAG^뗿u{{GhoJ 6 $d-UK(.V4v_u\^ÿ7i8jɜT#ɥFz*QZgH ߺFhPb֨uu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺K8~~lbL^Sd2gFG<4F,u )*2k?]v>o_~u׽u~{ߺ[h?uT˗Z|59O{50>xIWRM+kSP0 hH ]c~0?sŤdCxs?`ޣ7]5 {gd7 F>>n?Yb]Fi{\}4k+95zI$MO7׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^ՙ-b~y؜~ৈGM=4̧f؃_-{{K7]x/,2_AO>kҞ{{^׺u{{^׺u{{^׺u{jO[76;t{ߺUcmߛʶ\~۹*dP)Ь0#eU6^~(s&_=uqɗO~{g9eߺ^=g<׿~(s&_=uqɗO~;`~aܹ6oLlZ X*H!BJI"@R@mKǬkUQy]xczȊC-C!׺>x[|oب2@¢( JUuYí)%%^B<5y*B2M$@ͥLGFߺ^ Y;c ٴhQ[cQI."6V,?--7bzVOuuu~M[>tm\LFJK: E4M 1׺3ziߘ%q÷VתLnJ5S=3 DڄIaшW֋{qLn 7U QOMQC<2.FO~k߿j(5YU1VehK3}\B.BxqǕ4΀dOuGu=uk]3gWːFcu@D1 lԠ#כmn$HbjQJY4RhK5vB<$QFG*IߺUGV+]]v_aȆy17Y[ 93$,q{ -}#da|Hi*\$X$PD:"N=׺7Ec><6`ne{/!j 5c)A ±$,р׽u@7CwK^2Yz n膉 \>^wW H P@|a׺$|ܿ8J9ڡSQ:Ӑk!5 $N3Fʲ/W՟":kie*QR.R?TPc Ln_ߺCWuGo~roV_=N RX9eCpO Du1[xީ3ѮnaJM2CCLU<%1UEUGVS0fMރ1jVXR9fSφ&%9o~[u{mv.u4׺/}d]3)~Xǿu{:w'|Y]U=u/'3GC{ߺX*ii( PQt`UԐAAֲ0~0f:Y [%VFyS':k(u ϕ#^lmƫ(izӴbg:9O, kpG.`a%^E+^vluhPGe<׺&}zoXޫԢW"2RQFa"z9Hk۽{Ӱ2ybDtH1ènZI吼HW{UW`$UYJI@1v1f֐L }׺?׺u7=Z~lSɳb??~׺u{mw_uGu _{uURVTQA U%\KUMP9# {k>fP|y|UoS*6Y($c)L Yu{Y%fꧩy(͐¼^Gʕ4O!-%32apu7WԽEo^oLЉKP7/\{^OZᥦ T2"; ?${^|]?̮3'YԒ؁&K! Bx w$hq {u@{?{3yWݛ~*u-,3OKM8]"Qʢl?NuoQ3 þ2#TJH5@D](_1{K{{^lp|ظjy  dM+{RW "vGb*}O+o}Q%5;-&Cx )[E! 8xO۔\E,>l ԟ'Gi6NĶRu]:,.mtjI.ld <,{ߺE>QoLQUM=:/h,$0 H>׺WgtRULwbm$Oh'AQ]2 q Zkf'z uSQu ZH C`!2SY_ .]Wu{{^׺u{{^e$_duY˗ʻcڗ7~l{{^.3рRo'{~׽u~{ߺZ1*j\'i=uf_ɲfSq1׺~{ߺ^׽u~{ߺ^׽tEf|;|gBaWhӭc )$Nof(ɏ{zs8];\fb=ȬI[IQhe ׺wv]CftKvbjS"rpcF<\2gXfp^uwUo푰0sUVZzH*W[=SèjvdF^fBs&KynfM2d+fݣ])ًK$O~{ߺQ(2TVS=mR,KRHF^9A-{hc|U|u3*ztWI>ٝiYHqJS >&sQ I/u߇;2O^4==udI]212}H*([Z3H.KE'W}E w^щM J-l@*(%7L!׺d8ciH ! .l.I~3=A|hG6]DUNeiIEb5 sߺZy﯐[{oj1A@ŒF%rYup6C+;p&VbqӪdkӣ$EV{{^͎Z?T2/~la{{^׺uu2bᛋ=t׽u~PVٿq^׺0S=duo׺u5e G+u%-o׺6^׺u{m{gQoFgv~_'u{{^3=~jk{Žu~W?AlęLu}^uG{^fO~{ߺT?>9]{mP)H% ՔCb8& }YY X{)c}j6b8 ģBբ]tʆY*{v{dl۶f>HĂoVը?G1&̭fS`׺RTSQA-UeD.j]c I>ԃt"(Ȟ:䡡Eky5NvJyH}׺׿wxwbvI˺QttihiPݼq<3yu'ܟFY|LtFˍH *79*&>׺=׺)9{Դ_^~)Iw$O{=u~$7۝7ݴKۣ̕9k4sD:'RXr8GuqЛ`WO,]D")CTlFXďߺCu?̏%._ue (}uWu{{^׺#_gC| zO~S?*o2׺ߺ^k]}~oJGV@'<4CifU& 褆Sֲ#>4[l6壚lWT{֒7*.i5K!C/]X=:|T8LC]@AGD)K$uo4JE3-Xk1TȊZJɋ.׺Ix9_If6*҉k+)u6)׺^}lvA+s E:kEHdo>&ZzݜF*A{tm~K|jfbk^~eZɀb wfǫdʲ,ie1eT^׺ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽uh) zT8ԻUI=l MUٽ\gj߹XDLlE|B^Rd/PuoS}L ~*?`YotOu~{ߺ^dn]k%^R-pҼt5S%E%]4ѐOO~,;yX~^]XP^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^z4^/tQ@fl=.1+dq1ա?W'XyV/>Lq2:Ǐ_+k-0*4f;%O'}p{Tٺҧn|_Ejubf&HICotSL}~Ć9Uݸ"H|Gׯ~{G_}^׺6^um{^k˷]rݠqY̓ASWAQ1D#~O׺l ??͇uC"3'ؽC3fDSF&8j/V!H"D^sEo-қ'}{lf6QU>)#S^hPk'W0FY/uߺ^׽u~Tg??HiwKIQvNQ++hh\:(`u񿲩c6~[oÙRd ,HId${׽t[hv^ܛo/^ HexI׺NWYW&,[Gt&N"PV-f2*|>۾MK&.ƘWCtjV mp"06 Q>ɦlvRX3 A=tbɫj/]``js{'~ud]?ZBޗ9#{~6㞧7}81*STqȌHmP^{^׺u؜^{fyl>ZL~Oe TK!>׺WTn_٪:h'sQ'^n]"nJrGt$j*m!v4E:wS=| 55UF@7?ouzC&슘$ zX+16 X[k{^J_~Joڈag Gt52E޶kEg^9- 7wydq{7G"lbaHdj'Hɕ6&8 ȵ(}uj$qj@}u{^׺ߘ? Ϻ;svȡSܮ7KI&K#mS81UAXKhX}t#{^׺Ǵ;ke6^Q-%n:0NDe p9#etau`}uJw/mfiaۂhhx:@lrt`R,xڊOH$ڶ*i E׺LK0bgNPfH^^zO?%"5+>sc%?['!"LS( ^1,돎Qs 瓅c.T}/!w@X6uWu{{^=]%-}-M u5=mm;VQբH$X2IYXAߺUauۧr;zڦ H(uëK%*216RW'X>X z"@#{_mڛ~7&19w\^UA7X)8ʎ z}FD.Еtb@WC <coA7O෧zǿu{cO$Ks*㘨UIJuaWY=(j DjkOmͽun?_tn;yo~*&ZdC,t%MTMTOHY" T?u;ߺ^׽tK~utvۻ; fI-RXqzW+#+Z쿐I{^0a;}6o!LfB:|1JJ{^=u~{ߺ^ֹ?(?Wz?U[_\kq;vXJ%( Pl#~(u~{ߺUCrwmה{z MTjUC8XVfGߺBo=t]Mt䱕XZR*ԛYU]Ճ{^׺^^#7m㶋wgcf6r!US#1bu/MߺVwT?]펒Ŷ48%Z(8̷6~=t={^׺u J.ϵY:խ( UCL q^9!3?v&ܽGfYж&*ԕdTRㅹ~Zgu{{^:{mb&VvІz }uBon/D(*+ʮ>Mߺ[{^׺'7:_{MSl6;* xlTbdP5J׺6ʚXM "Jv:|(,ǭU!ĜH~$]g쏴}OӧǣǧF4h|N!'MVҕ'pt9O g6 uK?rR"6ΒVf!h aUp]mݹibPA bh&I>׺w׽t w #FQ8y lZZYp*B'TW=]]Nď{q4yb,_Jdi=׺(9.V?uwf`jDrp1i5$2r ^2GF6?f&SQ԰&JȽ=t;u<zfc-1k6tɓc{-+Zյg_yw݋DSA[Sl%#ijboS;Wwu ߺ^ {wkt?buҎmŹqԸB^*J) 6~}uT=?_/Yo}ŎqථeG, yI qv 8ߺW{{^׺ {WvNL>o3e>9Z*yjSf[̧{Yo[V%J>H0`aNHV4X 9tsuo;eV5]DUXX*/7a^uq:ibvfv/j*; GH6{֟a@A: #6_Klq.=&O !6EuOOޱ扛^Y`1Tl(:h<](2.>)ͮIY1^{^׺u^ vci0U4[wncrMJVR%@@׺Q|I|?Xz&_-7Wo{׽u~{ߺU!wtrmEj0PɔJi~ $6F:tΖ7{C;]o ؔ|kz j 9:o$-^^׺x.Oٽߺ48͜Y}]ir+*2ǿuעg`tXĔvH%TSӤrPlmϿu~">{Gv&؎]ܘTub2)"O6>owsS  MI-NqMl?>׺~{ߺ^׽tX`V}"qer8ʚHSxJ)%+ DqqߺU~O|u` Y(,t>I.׺_~{ߺ^ڻkza+vbw&#:$cYCXYC}u\rO_[qD\bQ'ԁuSנU\ iQ^)юr5:f#M!qVb}f.}׺U5zeGzyd]FUS,$O-#I{0=C%7^VSvfjj-閨%A0Ӥ0Z1kE: JkvzeuZo(5EDdQMUj9ӣ2յ7f"Iak{ľ׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{ y򓰌N6'=, 9:cD_?UOT_WQH+ƞ4)kB~{ߺ^׽u~󟳿ɭ l:O]frmʧO9=_ar"tWmib|*jGo=3;{&YP1h(! #I)ؖ)bnP kW1SCuڽt/TSSGY5TP5U-J+$n^9WGRC)H"2c!AhAi& 7mgLL3 dzRS,GW9?|JZ15o|韰^p>ڨրEzY@j6*Ϭ׺u{{^׺[&|TBo%Fz֥ۢU UdumŇ?Kܘ[X<;qUsi ^aQ쒧U?]װX׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽tǹ;vsyWj$l9Q񹉃 >k-=[Yc7ǪHgΫ{mL{c7sLh߻ qso}}5peVc0lr7[) bScuf&?~*:KXY:aiUcLW9j*/Cˏ ӧtyGb.@ -O?Dl6] {3lm ݴs&*b*)*],"x6!n7u s=ڽwx0K]2!84 Q#2_MλgxupUZȗ&)!&ϗ~nR֝*EwnOlZҤ&6]&⮫׽u~{ߺ^׽u~{ߺ^׽u~# uJLcn/I=\n_}vaKoGc!o[{w^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^zU)GlSnj,ӏDTۜ%h)ij") >X~RbRm%}œi#=fh>*w*Y)ٛup)cV@$4{XJzJ(掠9O'EK/?6QAquG1Ѣ9#4'Ib .H pG{ ;6'uN._io,[c]+=<)i$eq m B$IʊYYu)Wa}&2)>tw6/h_RÃ+ *Y|_߿p.cۦ(:lih4#GQfT4: v}w{f7?Pn]=Оɢ$`?q h On={ߺ^׽u~lG m~Hs;kڬ SWjpRluEAT_B0OXa5m|\Bj,n5>;~[{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u5ޔp11I =utz$)\M^  ~YB.^+1#7?/˪$zYљ]X2G 9~"mXq&^>9pc{uU4nCg1ꐒ^jhmn`Or2xzzuߺOh{ r/$׍EXq%d}zή>{.}樋VmmĩJ*64xgP-$q^>yH#%ZpAh ,u GDeo-ՎZi9I`x}.0^K}.6}H ⌎0A#"1-ֺu{{^׺u{{^׺u> <-a2-S?egnGm;/`l},{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^꯿Dڢj̷Y&Y0% mBe ׺}٘x8ٷ5Ί*,9KtwV^eN>-ES!, uE[D慑N<,Cu~{ߺDζr4%l/fU/$mj*hbb*&b@{oY!]75UA ճq0ļ8[LqGut ʭHgܻX NSuE8ÈC׺2׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{}|]SG>8UH4dDQQ9j56a]WqcЃ] z|N{ߺ^׽u~{ߺ^׽u''kmvvô?jbd:(Y6Dr\ $eI$chPsq?D?oQo8rӱv1@? ?=Gz|/_3njU%/szyJj,AEU)R"Uii>8qRA"z8p'SOs}u=RAljIC4c֏{cδ`~K-.p`Ijz[K) `oz6ߥ+h1EaE@( WJ'YMIYv`}J Tt]Q!1-NmK)zlmYbŚ1 Q jafBrI*ԱVVck* Z (ѣr,n$e A\{ d[\#,NQ#+U A'Q{ߺ^׽u~{ߺ^׽u~?J;jT;RgULu 9:n3S峀x#Suqч^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^D9dE(A>ߺTkiO'>OWHɸ2,,xD0UC:_7konOE?_=%|Za@xee<~//Mࡊ r %?UnWMҥ HcϿu'۶3UT2➊%QKou:F&SO-[|~ᬆ=׻=TvX%Ux&]mcX{C4Uh-d-[IFUY*kXT&8c[ua׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^C_翗 >ι{̏qrbi:u{{^׺u{{^jnɱw>޻79ifw.xI!C:TVRY!57R >$XTB=RHe(AɏoI:}UL}.#lE"*!ݸEb 뼔<CQWo;QdQ?ϭ!Ncf7Cg Mwdl?~HlөpaaL.:;ɺX[4|zgMTEdf7uIs>~}k_wy?#i_B]-fljnh$SI*}Z:`eik1 z5IDuoN@ې<+ŸHo9w&|.M+S>UwO1MD]qϯ{^׺zHv&>峲d $"-=Dw QGW 45h]pUזq*(GGAMrapÁdqQU]NIؿ3zz֥oG{KlFOǨi%VdYۯ?wEp DMi] +N:0׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{r3ʥ%U H uЀX~׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺OQ4'rSV7H{3gBXXLS:c]s#oniE7?'u5~{ߺ^׽u~{ߺ^׽te!Dlⷆc*vk1U8̜Dq$N#xj-_FcqA#?-=APx5>D|?$497ym Q;o='&N5I!UJY ·[}dˁ#ȏ|7=Mc #e#X8{GZ8p!lwZI5,MW?{%S+G4keps&>??y9}J˛#?O@z.{{^,K<54KOSO*OQtt!ԆWV z 0ꮂ@U "=}|O=K"6'pW$7i"(ޕGK+oE}ϰ>Au&ginpsg}45+7pOΗS @Rm22#unIM-w e<[#. 0@&&cƕ1/I%GN׺u{{^׺u{VUSREKUP6͍>ڵ#-p5;㊞0׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^ꜿ=aOb6iڤS7vFuQϑuZʆeRXiaQBTp$|=M{ߺ^׽u~{ߺ^׽u~{ߺVb-/;ދ56Ql0I㢕ҝ7Q;fhXʷmw8aoC~GElC(އ.}KyޝiN3zua KsbX5Tf $3Dᢚed%F1G Ў{g1 |KڪZZZjz*wE)bJI(`H 5V9&  B yi_˶:SQ{ )INſT6PHSHd?q~(L?ǝ:I ϶m ģDP?0X%@u={ߺ^Sa|ϸZ)י-$d~2>S5's]Zpm.?(jr~"?p?% ~[K{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^qwFmy1 UG Urnc`È =$,rKyRX6T#ork|dnU 璞`?I0'Eqa^l}Mk9~8%΋u{{^οg|Þ;xVWVtcda~bR{3}-3m7[4EEr@cY\fw2Y|6f#-'f6hh] WV M* 8 skuI4.G"ee`H*4 u?n&Sn sT2cT",RVSk2n2 0o 4YOn,1<3DGpAM zx@_":3/{ /V|I_3mBJBʓk% *"؍\7HcƇPY)M]UA@~{ߺ^׽u~{ߺ^קrXleSjzn؇mu>'EZd~0׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^곿]~nj7Fdw1 uBL&r bgmQq^yy_B?n?ʃܭ׽u~{ߺ^׽u~{ߺ^׽u~l7̃;7SU7"=uuU;9UiEk]E#EC<3Z߶_1?އ=(^xQy}*}q~_CQ1yJ88ܖ:TtYa fhf*C) :"=C4=0+hn-8ʹ7^.\6A$52"xU6WU`ں*j~պl1HMD4eapEA:{| {9ॏ#}W-OZyar$Q pZ <<ƛ9Gz'"zVU{i^ŌIQ[Wױ7S^ `Iuo_ai:eV4b&Sk_ʖ6eoVC:b1$2۱0kOǸϬ6׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u+` os/ldM4-};@F  ?rScvϽpW9{p.NR:׺u{{^b_Na lUGnlu;1S#XSV^*.=:E.1C_,I,ɻԿkIV$.ouoVlڤ, n̅%r+jpYǒ&e[KK_;w{ 5 -.4{[REQ%FٖŽ:y(ֵu9S`%H'H xۓ7ow[tuk!EԎ:5;Ian׽u~{ߺ^׽t#̦a@&D7k[rye|]nuBE+^5`T~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽tV>sl ~_l46ÿv*+vVC1XHYUpXZUsFގ0n/s c[ܽA~{ߺ^׽u~{ߺ^׽u~{ߺ^_>:޻j|Uu^<3*ʉ42uFy"KO a|JD3yH|}xcnpy?_^h=uG?rl؅h6HGTjJ0+()zK>jMOz3) jHS1$XI,ir.e.sXkcuox~αIvQVjrmOZn1뚽{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^֜gǶ~qQ±auf8sp5^yŽ܋1OH?:?[:Ө qTkS[ xskݸcQVzhj ˞?XmD:$vQa%%2&cݭ;׶Wh1"TjFeMYz$AǾTu~{ߺ^׽t9gިżirv*+mV6~_pv)5kJkJҝY2Gþ]׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^y}=[ELweycO5:q^ktÂC _~{`n^sߺ^?sX׺8/?e׿~!/u ~7?Y}up_?{n񳲷fc57OSy8dǞe $ bA^9럗;kvP~/A=E/NrZSB|ju3Y {^{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺utFn]3ndٜG4h,xM 3R}tY;~*n,#oO2ܝ>Iq婪 ?$t5꺝Vf{s{{^׺u{{^׺u{{^׺un.v'-[V;QY,tюtsw <{^ ?sX׺8/?e׿~!/u ~7?Y}up_?{ÂC _~{`n^[~f|lن'?n31g'qO"kItgu~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~Oz7!vh!vZ n#wՎDr~Ͽuu>o*ޯ P>~.TT~_/o^:WC7u=J?J?ŶhկѫKi^S|^e][?*$e`C#dh)8s{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~$k;z?}Te I4p!RC=DU[$lE@_?sX׺8/?e׿~!/u ~7?Y}up_?{=%d裕f#y + GF7g&*Fػk H4jA#-~4V^e{{^׺u{{^׺uoc|ԻcawF6*+qszTӶZ!"`#ߺB7Uw\wnެ}a ~jMW_Z+"H|Y ZIL5q6B]V{3ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~Nc;4ӱq %%X!&K ?sS,hr>/.褕6Womc;SEW6`!9G EC ׺Aù>׿uWu|Ǽzzm|MV8弿(O*BtuUhiva᫳.E2WapZ"\ߺCu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺qFB/=Vlmt#\3J#R14[ISvGY~r#vdvPGF6j)WGa&dE >ɹ5 5M`Nsonn֟]k,>oΝ*獋ͳR{iOP??_B4tH^7PApAG~E0zk{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^XP>jm~$.ɘh(bqxYJ ` ġY(}_#[ vjȠMӭvss{^׺u{{^O] ٻCz,۳rj(|u31' |eHdS (H7mMvO,e<V:X{A'& OB0/eI=S?ܝhtmm]tR%1$TiQd{%n<ѯ9}DTHq-px 9U^;:g{^׺u{usr"V3-qjOXrkײ`v_޾YMJK{g< #+f.E[wY׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^?]4Ϯ;-dP%CH¢ $OL@Y굍ߺDw_ߺ^]<>?x׿~W't7Ǿ*'gahh**pG[KYJVf,ieGΖ kߏOO`=m1)w]5]U="$58HfVD4$ )FCw_ߺ^]<>?x׿~W't`~,|#ymL^?mmܕUNV :%SXay^̢ʦ׹~d3cGu\˗ʻcڗ7~l{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺>U6w#,I{fSg/RM֓ߺ[q^׺u{{^׺u{{^׺u{l.J׺N ;> QSGGSQ 22SB5C6 <}ti~W'un_~{w_ߺ^]<>?x׿~W'un_~Duu[S[w%US+tIqVjW(xߺW{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^'6sߺK/s,׺~S?r}ɯ~#6sߺW{{^׺u{{^׺u{{^׺u{{^׺u{{^׺.*{)+{\%q)$"R23Ԗ}ߺDg =[/rwpT+h_] "moHH~Zu{{^׺u{{^Q?R{b)iPN) ]`.l؎O׺;ܿ+~׺7/_u x|/~?W{r OU^;? >Qi*9)C#z< >cUV{^3;dgyͧp%b=m4lˮ6hH-{wk7V[}UH3)U Z؅-9b:#U1׺~{ߺ^׽u~{ߺ^ֶkʻ|ڗ O~Xz_?۾׺/~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺI vYml9-0y2kC =D(I#~PGo =S_%pYHdf215W@"ii%ijE^uRv_o 77)glz&h) 4Ҡc${ٟʯCSwقe4 SUAEKͺ=׺GRMoP6q0[Ou{{w+tyҞ,"(o1ߏu{u s;pR?*|O 6M0=2}t~01-Uܵ͡`;{ٜR\/L,`㔵@[e!{u|[gs`7vZ;I))e`2:){~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^uf?66XX s[ J6wU*&)(##  LZN?YB >]>̺9׺u{{^׺u{{^׺u{ N[+3,C !afh* ]C)  uP*9ȳc>r!sXϗ;>5^.R$XQwN4?:vcb$cx>g9pmD+~GGʻ1`oQAl=C>CtO%|UfX#QsGlXAá]}~ԃǸߋ3< HxxхIG}TsS'n<3jY*'f,mITT5A23$S,IfUA.ަxN|uYy(蘂bj*m0^_#un[O;{654Rb,Q`GYBHާfbOu׺u{:`w&֫hfy-MJU HZZB..6douOsi lϙjVѧ!Fj)(W*=׺1˻_[>)_`o܀=S+53{rR ;E1(fou׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~|R}8vI@!D`nE~smڨ7/+$4Ȁr >Vķ),Gh^Fm gHE>LOZ{4׺u{{^׺u{{^׺u{{^U=嵻`'=Ka*)j~"`Ti$k*aPE7,K:p c/8}ƺ.טhS饃rC1p!e\D Kjqږ2p}!>^m%LL{[O1W쏠E~q)qs#TmۅubdH9t8QTR;!ӽ\l~%9VG=y]۫sKPX\`8kJ\0*RH"7JN=KK'uUKPDR8$hPy)M8tIsۄޟ˸@UA,B h2IB~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^[븾G(w.C0뫰Tiԑ tu>\%5暝$ICHeD1}x%i4< 8l'lIAPIP *J 'U \PknnxQA,3:j c~,E/G_j1u|^,QqnF?HJs\;׺u{{^׺u{?槞iԴ՝=r-䩠lOJ뤈F|qzx~?r/MWimW?k'xk5eq]5|ڬL1MSK+5jG+ 82|vK5 隋}9)J$1r&b1i(kT E׺Evw[d2`; ceSa2I!%:T4y)6ߺK~{ߺP:RW__*C H8-$2-Ԑ=t^0>2mڛ%[Y06MA:/6ċtAcJiilG+Z_u$|3URCՅA#{w޴6vۻpCmWB IPM?^G{{^׺u{{^׺u{{^׺u{{^G%ϑd(xTS_8!~yeeD=t^s01mʆwNʖd4d77U'7~ur-36du.sˍFf6dKxoue%e&Bu)cauxBH#}u#ߺ^׽t|lFYēߺZ^ěݭ'ucuo]qۻKr_+if,K@{^UGQ-,˷^H[K$< )"qXߺJ}~:|'s6+Z*#ȊWw%xUOS,sA4k,3Dр*~d׽u~{ߺ^׽u~TcwzV\UԹ^d~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺI]׾Nģѡ ܵHjcߋ-$.}tVAP6ڒH͙zf&eu˯tNIyᥛI)<-Q&׺0tTRT WY#u?FGBUPHԏ~{ߺ^׽u#GGXK(x>UrٳKM]T zLmjd&*FA^)K{\ܻy$UO1`OY8as{h#1MSV2@:e4q~U@>׺W{^׺uO3k9}tQ0_*{37/Z7M3h9uy^׺u{o q_RjryidwHGucgGNΞ]Eua|~_Tnx:ymװ3>.jE%t%,2㢻^ן!, qeQ^>S 1i⦎ TsB^ߺ^׽u~{ߺX*j櫬3-EMKqK; Ԓt0~2mwFʒ[CwɪpUW">׺o{j'WM_wu.gwc=łMmzvM$ {~{ߺ^eKo<uS??kߺ[2{^׺u{{^׺uo%-׺omŀ/oߺ[{^׺u{{^׺l]ENش j X_?~ gpsM8!#olXN:Y" Yij.ij}׺~׽u~{ߺ^9Ҵӛb >vmt^-J:<|3Ia׺_W)UUQ #Gu]%֝45~̉`!JZ%/~k{ߺ^)炖jj̳NEٝ؅UQ$~{g ,f`Dغ^<:?U 0׺H/_.ʣ`9hI~}t+n¨e9D8 /޹zhE7?C{^Y׽u~{ߺ^׽uI#9&D(,(&Z*nAz%"Ju3S9S %:^kn{^eg\ԚZ3J &><|cާ!=W48}YMEA 9mEjI+l $>|>^?ZjOww~ĐJ!3օǽJ{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺB?Pc/f-ٓיط8jZ;<QAnmѝihwjR Q)&YKʧTT#hOuc;;p%^Y]WYC$!&RQJ^ھ(11{z LlC#I\H0 U!Q4QyuoE~w{1姢o B]{Rl>׺σWʞe*`1Z$z N@ٕȿ#ߺ[4^׺u{j5=גPVUHRH_ybP"![Yoɼd\\fU<%Qv"{u~4vT[tz~ڬʘd 22K227T#޻pnuhL>ݥXdH1qቍfI8.^i~RHtS5y]Vj)f9 ~ ɷ5׺qFۢ=C?,휝 D94MD’7?N ׺ ;뚃Y% nֻ*?JJ~>PW>Fm? {{lgf1JJ-ɷ%Mf.PRNZpJT%=׺ώۃ=7l^Xe=KS3++fC+)rXx#ߺ[Y^Wd?'uOI7ZO~]qtUOYuje4Ih`7JoPʲ0^0{g Y`if'6EݩboԴddH 5EqK-2 O+!sG6f?s^td\xH,ÐǥU ՔMf16 p@^ˡ>Rv%NUv܉3 /,c*$yBDžʥ騀,<׺7i^a;g'4qCYMHR@"z^6IROBu{{^׺u{l.J׺#?˗ʻcڗ7~l{{^׺u{{^׺,+z{0dR TT~ιT#t8k7K{uLc36\SNUS^̬ !?~GuKKCi.Դ[nXETT BK *F/%{O{{^KUSEMMMOQQ;8wwbQTI .xַ4Xe;ױ[rsK)I$Vʥ!i+iY_~ ro̽}r metXZ.?& ֑G{)j*%&y`;I~S_K QOMGJEꈒi'ub0U*;I}P$aRw^ꮱn 8^Y΂'X7I7yQ$~<7SZPKcJMTmk2=׺Eσ_'|Ku/-~Ξ*@,ƖY+EI9vb`ɐ$غ #0]&E : Fߺ[ Ta~K1A{ }ӳZMec,k]j I$a)&^{^׺/#>Hl_7Ǻd9H6R*gP5io$`y^({x_r}YlI6-y)P xVȤ_RҸbtK ^g[9tdY)(*Hߕ_$UDG(Ч\*1rUSMx4X.J)ck@}tV2>MSzycq-^2@6N&&"fF=ulV'>J# $,qSCHH VU.^u~Qdԟfr^e`TߺW1{gn_/5{ofs{^u~W>m;tE0 ^ hZQEJ.fdFf^ꈷcvynzzw>u> V8'}:`GSĀt{mE@u{jx_GE3\̲VDA.Т"zt+i+_Z5+o=t>S6.~CL$93>KP O*yX=׺_4ȺO⦤55xxXN*B\2yiX/^Xô~~{ߺZ`ݰC ]HeUQU T8ߺVտ$vǟ}Ew|W_CMjbd_+Zuj*]aR^;'>A|ˌmŹڦsQ]OU% 2'^fULY@'T{T(ֲ}" Z&ea{x~WߺL[WMG>F~qS!Yu].J[ tQC/ $Y nAOEhm՛fvˌ4dZ7lWB.=u7Ÿ|+J;%>^JFr'GT]TK#EGߺZ|vO. wlE62"yC[{v5O[ړ%UyWO@-P=Dw MSS|VbMi%zlxe61m# O׿~[<uPnz7c*i|?tNקu{^}u~{ߺ^׽tS~s(hmֳ{o>,|~׺[ߺ^׽u~{ߺ^ 5-_pu"QϿ*o*#a I]."OS{C?hVF"ZI?ǎ>^umŸ&w0(U8 {^i]G-31aI-ed((aI=D0TE? P_]9UMm %& c^0x%4j=D&Y4r5啞iͮXy$v?Ir& ZI˱7,t{b9ʝOGl)X)4ReW .M_~X򴮭&{!W#FoM'^=u8e~GPAEzYuΔ`.mѹ/{nHĊ5;=,˸X׺{7w;5f"O2G)iqXkS-7X#p{u_ǟCz{"X~'PhӼI}CLTpCz$ryԕrF^X ߺJSj}hVy)z0 oTKI ؋\>̶:v-&_z`ZqP8܅;\jeV1b uto;/)M}_^U~y%ӥ zBT}£^=u~ܛ36WwSǏeitlTq(yy I$V8݇ZwZ^HGv 9HWhu~vL-Tbz\q}%%5/D  >Q$O"|X1O *x`^ 쏊!z+z?I 9A'Gkݞ5ZRm׺y%D Ve0#餗,Dխ 9Y`j ed3]=;Oz؛:`+QG7UtTg"2H ׺*7*)~+wE,SO< |:YHapm{^ꐾg3u_*z~1Lh &t`19fVr"~^WɿNن2f'l)V9tƖ37$^_c]YWuP!{e^ѽ\u{{^׺urvÕgcvmT}PoLPhMꟋܐI^OWÍ[k.M"IA@UMkgTpO-FV{{^׺u{{^׺ ۯp|wqn̄sg*u./#M4sVN&>E\5f+*a4TduR`nnG^jO~WG?z,n&Ju>Wԫ$b{1{ߵ{vU[wnRQZZK9S&CM%B}}tbOhҼmM4BXQRL׷Vij{FE<uo?)6])% Zi6ue.Fae 颊Q_/~7W@\nt&咫enLWim"M$lH28džSHĉFuGmK&)<5(3ck![ḃB$i׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^Z{l|ݿeDT=br&<ಾ/dR"ц]Z+e*ʿ֞nzt:F=G?0H=WtlmڽؽivVb}:{i2SΗH牚9 p0=O)yy/n^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^нcfwH,읇\&CYAY 454+QR#훋tB*kH1J5+qygu?1u?{ Zo0ufKUYnKozMO6cGD{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u?=wmLURNVMÓ!?Al^Q*%"0 '6 6a_:O{ycc=$:UERuhTe~N;;i2J8:OCUTҤ0E<de##E:2aQtNڦ&ͱDJKy,ymVe?72X~ۮHm|_{kJ kS8QT:OY*"("F(m&n(~#>Kw+F5IuZ%boٛ3kgS7IjYcb96#`7 5n(H }-יl,dYm"Ixce6z Q9MqQA+ 35wMaBH{/s2ON[W&HcYu TN :]WN;ym]ITn]IgHNx5bĞ_"rlWUݽ+DҪ($I^lEGO`$q(DQ ;H"H"P,h(U:G^׺u{{^׺u{{^׺u{{^׺u{{^꓿_|=#jlo{^2U?PGwwߺW{{^׺u7=lL/~Q~텑Id6Cl(2tQUL" 3_R~[?,]/NyӂteizHVe {UTUDUTU ߺ]^/^-{s3NiFt<8|_쏕ۻ-9 n׃*[s u fV8.y\K/Wԟ?*63;ͻwqH-iK TI^Gp0ƑE0UTYUTXX׺-_,O7}?ͻ2*e%:;,pZ(y,EʧߺZbӶ.6dw^y 1zڹ <ǀYBv!Tǟ>**ܝYFpoJawA@i(5&LtEFߺ^S)]j6al+F0TUdHRG12}׺ևwϱjNqSjnXP9vT)-⩉<:Ap^'G^jjKy^tlljl&J,e!jVvqNΦt vե^2%X׺U9kd=uu{{^׺O2k&>׺#_Gʃ^_E{=tAu:)M ⶦ2jARCO07J@{^W}4_7`nE@A`.tƁp^=׺MmTSPnR{XZEˮj(--I$S1{tp=u~6>'pAݔT)*9MM ĴXј *uNFNO2̞!=U<&CU4Ju/Cf^׺>U6w#,I{[6{nnmg5uƯbx67t~|Y|yjf+3sH*7bgc2RZQ%dȑa;I[0xmV? ӊLn' AOkHUnIrI'}t{TմUUtHE,R)I#7^7RC)H {s~|jtOcˡ=yؑ[BriJS`BOBڜ/gn;o.(zU]1.Gah]A \*U`,ߗPO~mTA0L"ceu5t !{X)V^i.߻_6nߛ7"=(P,nJ x)VXɺH{u|8J; $W#Og(iQ^<2:RHd_usǜ̠T?qAq2qFZ**`bB ܴ(+ЛWk`6Nmҋ$PġT\ݝ;/#wff$t{e&*t|{yЦKGE0KzOR8&*Tu\~5/66 #}Ή)5WVe[IY!e>l=Szwkm۴[L0 URfkUPuO~{ߺU6s: ;v#3cc3Pz,' `Li4k "i읫nif$ՔJJ WNY (JȶtVm7+xmT}sasؚjRxXH ׷>{(0{oQI􎞚&V"(區~jոh3hșҎ1AU%eI;-~[o=wo)1M[hM[{\c͔JjfS94u~ږƢ@}׺:1۳5P\]{C;ACTt8֑S#jBjV{Bez5lͥ v 5-8knI}tֶkʻ|ڗ O~Xz_?۾׺/~kп?b/'{r݃xnRJ)<&ҵ9|BSSBY0Fj #{6gؿu.GMԨzuEtOq Brk׺2׺uw|v6^7|eoJ ETerUA[kɑ)@S,Sy'r}׺ {gmv^\~h)1+Q GB.qI$muv{^{gha} = 6%.Aqzz葁Q]CIy1ӘeIoթ^׺,?+;maA* }UzzMbqz(ۏ{OɎIJW姉J @0S+RXـ~=u߿u A,A^ ;ofaTRfK/4$0$RHe*U}׺Z*nǫ]U3 DujԹ<QplW{GKElu'u~='4=2̓$kf82~:Je#.j>G*&K>)(be@BkCI*&ut:3hwF7Wݰ1ah.dHՅr:GRC`!HUE~V;?Ob{7OvVA|NI⧨SzŦ_\^~ꏑ[ID{}HcsL9(,e׺u{y#_EQKVNlA 4ƥ~jOV Sw4 *G3?[4ԉ+oA{>4ZtGxR7ېli5 U34Hǟh,{t:{^׺u{55SUP:zhZy,NE, (&uYɸ3WgYL\jy RH{mm<ٳ˕,IoPz@ѝ׽u~{ߺ^׽u~{ߺ^tIc5. I>ߺZxUˍɾ;kSIp)cT? RᬞY*%uqQ̞Xu{qY wCei^%DA<2 /HAߺZ|?ٖڸ1(|[g$<4URM׺_?}lAMU]ӾsPRxn#^y C{C{{^~Emܕlu;swº>S@(VF -1:%<ֻ|˦uWFzy$Q)R%I(uIhvVV7&0K]AQ F?SQ+5YߺBu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u?%=pvR{Sw)40(M-Lr^fޛm:1t)dm7D#O(zwCwƾ{ےNaǮHҪe/M_A;D Y&P^ OW P`Rw$){{{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺBCl|f퍛#vQrpb\ ed,LDJGn- 88c/(Ŗ8QUN6-,i?qtK^Ggcc_81+#rivtܭ3뻚 Qc&[[Q73ȟ?c}l7?Ycm7pB[gntڋۮ9mhh *`6%ⶓǑ#G9Ԋj7fݯl -4E3(xSO.!;׽u~{ߺ^׽u~{ߺ^_?lcetm_6OeKj)v:R1_HP׍1w:ޮۚ;> L*GC#!>~-Im MW| ?:<@([5x'jZeJIJ:0  Aw?sIj!gl+QRq`|RTJP>g۴L[MJ܆N)4ξapð۞~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~RwkM~_ʧyn^u~{ߺ^f5o'={U=u׭SnIɼz%K_"r9=׺NGI:**:e Pā#4[*"P8=u'ߺ^׽uJͧlkQ/d1y]7裖Iթj,^n}@{^rnv^JdzrhtpSsϫ5{^uS͏eS[#ߺT~gwz%73 j,2BIH1/#ZȊxߺ[auGYm{NCۘ5 UMmFb9TUQЉ{{^^mT.nCBi:?da$=,G4,/{j]yEl}Cl})(UGsbL3C8^׺u{E;[$`|m-L9?\S^:꺃z)dn(e*^c6J ZUو66uGI$HPA  #}t@o[,?n~T*o2׺ߺ^׽u~U\5_WuY~eA//Z׺Yvϻ2nJWRRjC*_~FV]MO{xV&8[m%YDt3`"]}׺~{ߺ^׽uL_cMxez7Lۚ3HUDA$SP ߺU3mP^l~*;_q$֪(+Q#$8${':^PǕtd&|G[$96R{^Z׽u~W6teHh^fSύtSka\ -J)ęܹ=uk?ʿo;b98%1Ս5!, K~Zu{{^9XLDs>Fd CF{^NI(+jfdi$hܣ$T6~m9Y31YY\X`2CRLłCۋ8П{엲yas^Qy׿ud׽u~{ߺ^׽u~ߜJ=jZ/cu~2cXPEXbڼR+齍ױõYA~{nϒ{^{w|k?ߺ^kۿ_׺GnϞXvGMqu#rWFbtx!Z}Ϩ[^_ɔWVEԴQi_Ie`>׺!4 3˹hk==f3\Q48.#n/fic>lcvGObhac1()X$$qFT~N֠}3~ujSg~@nz|el_Kɦ̈42`ZTWM{{^׺WoR?SI{U?O[6Gt{wߺVe{z?#,_tV={M{xoxj64?_H#O↖;^=u~{ߺDGQUݓO.?qak(bFNXw_^^޼ڲoLNɻ~7k`TCK<{^oL}*(aE(({׺u{H JS-tzȓzPqsuJ{<NIi m"/k4<^{^;#r7WMۼ1Qz28^uOLu^䒅2_lAHMV;$l%LRor/{ߺ^׽uXb:cQ<-uGnUSӓhfgQҏ׺uAz:sjbP*Rέ6RB=;{5D|s{{+>FljaQ,{pC94$YRS!̗VPߺ[6^׺u{{^Nl$nɼr!!G #ߺZ^m*n xb0ƿED*t(^׺u{{^׺u{{^xs`o.jdYPڊ)2ȩ)1;V+Z{!W"Ee!cD*c5^ E>׺&b*zx a *U?ߺY}u~{ߺTWj$ެIjmSSSZG5| 0+2u?NyW3TȂl^ߞH.׵"Vy{^uVsd]M_d}uG[Ol差ۻ?fFn&*H" EMn51Vu鮧]';o((J+M]|&UJ rtĖDP=׺}u~k{&tw?`R͉MJG_U-j4\6ʷi֋zwV^Z{AE)R^Vx G^@>Gu;ߺ^׽u~QLz]؛?T *-aO!*fDRyBĒm4+Ed 5;s{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺.#~%ks%"_᩺iǼclNV]5M<_rZ6ةyWg5k=j#rwoڵIUOwN;t5QFQFe2ơl?8?gChIi:Շg!=?A[4Eۋxk,:T$M aC s"<~Fk3׺u{{^׺u{{^׺u{{^^~폌ݱ{wSaN.Wo S bSTᡬiਁ)Qź]!G5ݤwјB<_KO;:s5 ÉSb )w3K[Tz|)jOUWnKP!c~$ٟͣ'}xGA{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u~_)l;S+gmCJ`Socfeo졞h\uc r^]0'[\M4lGCִ^{^~嵞eaOtXlYrM?HߓüL۟7ٷ O?e :m?' 0ꫥ-VH*Up'JC:<܂A"'e~a@'_=ߺ||J,J>~]fE={ߺ^׽u~{ߺ^׽u~Ldk *ő( ehdB9bC+)X Ǻ VAAEԶ2$n# d@ ?'Jq;)SLDKqqiV5lq(P#3"NTXS0G1f(>F|ݻX*/ (NZP6: { :ϐi3vM5\̭>_sɬI?AIAW/?xo^n;r73y?b RFE]%]Rj5'Dl*frU_.y!cKGMNLHX^Cfav1[?q3EtZXQ4N{q@s:u~{{^׺u{{^׺u{{^׺u{{^׺u{Nm{TB/C9m~_u{{^׺d3cGu\ˮ ]}$чzn ~&yu'-^{/e_ӟFCߺ[>^׺u{k&j#{51eT^׺ߺZ|>ownNkJ,ES2đ6f=um+oÇQDۯ}esS9'$I^½u~{ߺ^6?8h.K2*-`ěA^__Pkߺ[e{^Wd?'u:*|ku:u89rTѸʱ?ߺ[w{^׺u{a#"v׺T=+o~m-{{^׺u{{^˾ҷpGuߺ[%{^׺u{{^׺u{{^y[d!%$lxj`rSM2=M>j=+ }yh9RdqZ؁'O#$vLũj> 6{Ͱ\[%ַbTpI׺ ߏU쪜m/lU ijj28X8#?_~X9oo/G^m7{Ö^<u[{v<׺Hv ڃ%;hd\Dhř+ylI[ `r;;3-f-Md!XKM2M U,lmߺ[4UQ e`X׺3?ͮF/ucߺTܿ_kkߺH73͡{^Vܿ';"djmU IXğzCvy 裖%?,5M]}LiC:V;׺2_m7{Ö^<u[{v<׺9oo/G^6]fܴ[qc%%GUO3]U8Xmp}׺,˷=&vxxX8ȔZhqXuuOYe'?2'ue=ޢl'i'drH-a~B6ѽ׽u~{ߺZ2vDUDMUU ߺ[L|rzC;_tt>׺t@o[,?n~T?1̞׺u{{^׺u{GKEluQBH"5ՑQH+jչJnoO?~{Sp^қv׺T*\lM»kDT@#ķ<m"o^}u~kͻOt[M㥍I+S"#`opIx|T-,5AE>ۢdSQInx&P$^48iv~~@mBlVVR)I܋7ugbtǍ6Kwe6d2&Ul8k{ޝǽ2~S=e4A1¾iB$vyݽ׺)wڛ[~׺~U\5_WuY~Ѷ?)}MLFh+Bu%B_;&#&]Ѵ8)Tk/0X!u_c׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^Scpucz,/) u J:2#=duJ't|9<;ڧ6YNjG>0kr(iݧ0co&ƀdqZ|vg2}bj?StG5Tm̭Gf!d25qE3ω+h( 9|`uau>l~ػî7%brT$5|0T(>1ȲHA?BgKH#~ӽ{ߺ^׽u~{ߺ^׽u~{ߺ^Йӝٿ7fNo,읃L87 5< :0h)j"gd $ K(pA鋛dC2_uP?[.'x YlZ˽:9i@$;WiY5TEƹ +NU3QVoOP03ZL{[7? Ik{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺ ;F^S_N I( V U[PRҢOy"ĜX??q=[=S$H]M'ԑC;cuko?s sTLRZ8DjR,t)0ċ8ZZKpPrzt{cW˟A^|P>t[׽ugͮ_y&]8IYvj+ XW R8 M00fGx 2i :aޤfiX>f쵧 k@T?! ܓrgnSm{|';us4?gm'~>T{u{ߺ^׽u~{ߺ^׽u~{ߺGolߐsI=T{ m.Cj\pBSkmSXe1ly1{?_a#w_fy,l楽b5@0@ޯ n,>'p`l&wg q$4Q$Ⱦh]]pT>gC*„`)׺u{{^׺u{{^׺u{{^׺u{{^׺u{Nm{TB/C9m~_u{{^׺d3cGu\˗ʻcڗ7~l{{^׺uǻ_֌gu_r?۾׺~TcwzVeU?PGwwߺW{{^׺(&FhwZ)cqbX^h?tz.jdD:H4Oc,lO׺}u~{ߺ^׽urMGoD?dg&E2Ro{> SKI(wt#Ims' Cǿu[d[ߺU_ʿ?s[u}׽u~{ߺUi?Mu$VGߺDkhPb֨uux@=O!bn8ku(tcXp`hYߺW5*b=RԋK?2>׺=׺u{{^|5Qc]e}$\$'ߺZ|rL_w>׺+ߺ@ʿ&eI=uJOI{^n?~{ߺ^׽tL/nz|/uJiߺ[K{^׺u{{^׺2奔{3쫶?s^׺u{{^׺u{{^׺)dD%&"_13~Y# ~.yߺTjxiHtl+\ǿu׽u~{ߺ^׽u~P'VAecq 9AJA̙YC} (u$}@e{^x%'ԮʜUD <]z4dDe`G鵏u_5O_g>9}ujt|s^?!?׿~Be?;{T˦wߺ^ =L9uK%/C3#KGVQ*H~uO3k9}tQ0_*{37/Z7M3h9uy^׺REX6=ǹ *JfѬmt`~GߺF+s=7gUU Wcx 4:N"YH:~/~Be?;{T˦wߺ^ =L9u S{.ώs~{/]3c׺>7/N=?W`B!IKV5 U2c$I* I>\wuOYe'?2'uNږv~/~{ߺ^׽ud߿ze?:~m- ^feKo<uS??kߺ[2{^׺u{{^׺uo%-׺omŀ/oߺ[{^׺u{{^׺u{{^P>t׺[C{{^׺WoR?SI{U?O[6Gt{wߺVe{z?#,_ts?ɮĚ{^u~{ߺDk(o\?oI{NieCҿyGZf׺u{{^S_Ptߺ[|7__2{^{^~^0͗DLcw7aU"TIRw Ӹ%D$JH\*uQymUTUښZk¾Vj [{g?m 5Y~n̆r oJcam>׺2sK9˻Thvj oŏCW$wKǒ}=-9PQN o#ߺ@ 鞭鿍S{' PUS1V<յ";>Y_If"Ś_e]KM_uJMdݶ?ߺTOO&b.?~ma{{^׺u.gSS-F~ i S<+UzR߄uIMwOvj30m5F},j(e.~u>+ACTGWQ_AW),3"MFݸwV8LV{t<4&.,K;*Iu 7hWey$f$~O~q;hbe]M6ř!?$%ѭ$bI${_u{{^׺u{QNy:m3z1kQdj:@~]?Wqe[#ۦ `&}|)K+~B4U%8{^Ľu~{ߺ^׽u~{ߺZ|Ӑ={sw,vnICiU i()ִZ״I:Eku]&_anǛf?jz1a9}ujt|s^|\_]?u^`6?ՙYkp |^pԐџTd FOV{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^Ng|V'[o~=`p~bC#gr)'R*L3C#F7{Ȗ͏]Tkd ҽI5E)ݟs>\܅JcGg/SN-)sC79~~gtFA ҡq9c ?v_Q&#)3I{V%ng]{=^'*?0oE2t]k8 g?OT0?{<\cwDNT0!OWXz!SM;}{*'fU1l4?.^}@+vJ?=CW׽t +fNuoG4TC5DOQARY養eIluFOȑқklTN}T=k>7{ƭ.ikɼ6k$YmKFU,cK w*UV4X !OоǞn _'h9<OAd7oǪLc tk۲CG<;3q#j"[^am?Cn-ᷤ+HsdvT9lvjJYӇ# PQX~G`z@H On{{^׺u{{^׺u};ߪ7잶9vNj ŵ7^ݝh+i<32UnՑM$fRPsBQeaB:$&o獱|uX- A3CILiH i+qa+AP[y֕1njA\I2V)_#?= u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~k=~WYvg-߲;w_5ͤNѷ>UTO>s={TG%O| {ߺ^ȃ622q7kCB/%%,Ty  z`Ԩ4W5?͇:Oefvb.%_?W}::ak ܻSl@弦<;T14kc5L>_\Km me)5'Qxb()´bޱ/{^׺u{{^׺u{{^׺|v?Onߏ[ չ ʞ,s%$.nθ:d!.zŬpZN<1=u%ѲO׏][)Q<Ȭ#ƀQz`N˯{^׺u{{^׺u{{^׺u{{^׺u{{^׺u;?gu/Se y}u׺u{{^͎s._*j\juWu{{^׺I9Z1׺/ʧyn^uS͏eS[#ߺETB/C9m~_u{{^V>]_0DazTz5 <9X`z|hJA{\ naA)يY!dόQeGߺ^׽u~"y{"S٭KO$HnY~j!,ٌ%2>wy乲䑾}Moy]tvf/lSpMW1^u*Gday&eSP*]nxGuN@ƫG?^g~{ߺ^׽uM͟uB 齑\ꯊRRQscR/qmCOEhPb֨uug2m8nq =qu e5Jة'RG ȂѣT=N쾧V~"SE hO":i)[U7uߺ^׽u~VJz|Nmu)+yK/jA<[6^9B?&m~m{_gx2$׺o?r'$i=uu{{^׺&?>ߺTkʇ{u~{ߺ^׽u~TcwzV\UԹ^d~{ߺ^׽u~{ߺ^׽u~SX1uvLB=4(t«>JezhJڄ"u]>9f>Gm&QQE0^<-e̦8G%@ruo^Ox|Nh1pXc^uQCGTy-Zgous|O83-f1ݛ|>8LЛVxA!][{v>};hdɏL2. Fᣑ~ XϪ9*}t?hToޏ퍣GO,6.ޱid}<1#,~{S6~jnmhZmi3JGQD`rx>׺ogqiUOMW T@=qH~_~<{^׺u{ z/w?WSu:3TSp}yjiZ/ Z*15 ^|bj]g*v_ ^C*U5Wq5NGZZW{l^H}9#U׫}VAW9_kۋt $frᐝ,`F  rǺW{{^׺u7{Y͟۸g#(vX)i!y&e]Gl*YA6׺)|S44TTJA [t3; anY^^'6sߺK/s,׺~S?r}ɯ~#6sߺW{aumiv~֧hZ:|RtH~JW_ TjFOV7>Ɇ ̕r\r5$ y>4?Oe{{{^׺u^MO;rG05yhtMYVd)HR zLT1:4Q_{׮^wُ}wFR)&=L)fj]=4JFHn}׺2׺?gxL\׺J=9jZd=tlu~{ߺ^֠}3~u/'3GC{ߺD/eL/+Σ~l{{^׺u{{^׺)9{Դ_^YT?~n-{{^׺u{{^׺u{@#f&)^io_O]gkߺC7u{{^[_5e]?KM'ucT=o/L~Yuh_RtT&k{K׽u~3dsݽ'u;Jiߺ[K{^׺u{M~FB&m~leˋ{Y?z5KLfE[,m<Y)d@>׺'vN_XB-7 .y2D25Dn(Ec{Ov}ؘzzfZxgE5J[=UlfXBD({{^׺/]MDl\kHkTlrc ?ߺU쫶?s^׺)9{Դ_^~)Iw$O{=u~{ߺ^׽u??x㨩>nnF !*!D3#ߺWk$||.*uwj_.&[f5o_iX^ ϻPCE莵P 45U\LHS?!{*'۴n]WKu1ȑTO :3.1P3d>۸v7mmT",^.08s<^IdgVēңߺ^׽uE_͆NjHaO]<7X23G {ޖ@?ߛ{tRw_'{Z5]u5U3WRu׺u{ZeivWwLD\Lq e׺?ݽ)wݝBykFO#%Z:$t~86uu{{^׺ [Ϥ0t7<{_.V<- ӄX1uDP9i Vp΁׺Au_`}s_qZ9&#;J<4Yze54j HUF7ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^֌ߍY ~Tbm{ tTĤ42nA>x,jz~6<F-l[A+[IcUY.9)1&w~6Ήzj悤băPlź7kz[jJR탕S8$G3/4KE* #Ka]JSo%9Ph\~'?Nu~ߐ>-|Нaې%3RQwv*\8*óYlk]-L/ڛ{mMcf_p=,dJHּ')7f.a{LX6Av٧55K,?Q{TU=GiUt-终q:,v7!ּ&?;dXٴ&YSrt x՘m[;rS$|tt5gm ۘ0XaAEGB.pf1GB,o pv[cnD X̍+TQVLOe=A] #fGIwν{{^׺u{{^ܾ+pmKda3xy奫gjzydX^7Ue`ze (r>}U8 A zG,?/>+|8͵pkܵ*Lfa4d%V)rh 1X޶mYaN%|:͕gœO_>ζ ׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺA7{w.;Oml 6n%`UL-9 47eMD-SgjײIō>S WnlVh!cOą3[Owwwgu͑ݛrTLıDiܘc%=W)y/n|c6c.vZ\!erWm+1.3?0P|U v?i&)Q$R,.1j#V?kojSڭ^IbTk~{ߺ^׽u~{ߺ^׽u~{ߺV7fp*+r̈0p{ Gkx mYq"ihjpҐmiWu~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^'6zGߌew!6uߺ^׽u~VoVzٿ^׺e]KM_uJ׽u~{ߺU/]g?F3ߺETB/C9m~_uo̻o=+{^*(]g#ͻ{׽u~SQ骖f"ZU^"+$d2rYGuG]65G- e&kEC_ :RITJL6>lt A\~׺u{g_!pTjOOG`~ڎ'Z~={MU:K*P*A5Q۟ vMUOzhꤐ66ig>#6!{^f~{f}WQ1y J p) U{^]upb;cz㲙B/J`[hҴ}yu؆hjaX)"Y+)*A_~{ߺX X&*jjhz$qƀIsǿupw{ዙc N+jdUeY°>׺?/ jߺ[{^HvKü4mW}!KI."tEFZ{:yAguG}9Ή-4j0f1Zv>q⬤sH1 #cI(u]dea DIi#5Tt38#b}׺[{^׺Nnݶnߘ We2ͦ8[H$qgcYTu7.?&wpJzKI0]pc,IUPd: $12$cߺI_Pkߺ[e{^Wd?'uOI7ZO~m{{^׺uCO4_<3{^io~{ߺ^׽u~{ߺU7]7=tF/v.ou5~׺+ߺ^׽u~{ߺ^׽u~'1I1STF\vf0Pd#75UH&FOu {]iFjZ %W:QrXuwYbv.[`2[p*i|JDQ4܍KvnRPŤ.<UA5-T1TTTSΡ7]de$A=u~ߟ G3uV}*ˍ >Wi)Ks%8+wx&sӛz{L}er*)k*Itƕ7׺ߺZ隞}㷢j]}۲EMX" d5դ-?;aUQIQ~ƪ3͋2)+գ^׺u;|m޵ٻ})QXǢ䨞Bă,=uao,i(35N`ARU3ia.2C{~7tG^Gm9nÞ>DKIR% |l *F^_lI6T6VcUZ]5K+zV]G{^km[nwfSŕiMXfPX^̌#){~{ߺ^k2ؽJQOwg]OJl$L I*oV!{_nà0[Joֺ->-X@A 9O/do>׺ߺTk?`'׺Y(/?e{^M{^`?׺~S'Y̽}Xmt u1V`"Ԡ{t]?W~u/m\[;-L g)SHR2׺u{{^zP>ܭJ/X3ӰhY!\1S }3KQ Q^ETW-Nk{!J“D m EA$q2Uu׺~jO&e.O~_%-o׺6^׺u{{^P>t׺[C{엲yas^먞WXɜ3 Rm"G$~l{{^׺u{{^׺)9{Դ_^YT?~n-{{^׺u{{^׺u{@#f&)^io_O]gkߺC7u{{^[_5e]?KM'ucT=o/L~Yuh_RtT&k{K׽u~3dsݽ'u;Jiߺ[K{^׺u{M~FB&m~leˋ{UTQӴ:QA ʨdkn{GSMrΑP *I!U# f XV$$m={{^׺ub=ڣ{Z:ՐḁCrUY)xo4RȌʤt쫶?s^׺)9{Դ_^~)Iw$O{=u~{ߺ^׽uY=m?3[9' LiA~3;qs{;kw&U0@v@ƹTbd"T0zHŏ^1PvoIGP'u)ح2ѼrM-B>l\'nE `3vkXD@&68^.M׺:^׺u{{^׺u{:n']n64Ҋii*i+afDA:X3ֻ֪Dy\Բ2⨄؁F,p=׺?3tf咗0ԫ9X,Q4}Yhe>Q*V}{{^׺uhHqww \O>׺,=Wי}5Y\k'$uDkiaOGw;)3u]Tᩙ3K*>) _{uP_ͪIW!yJ AxK5 @6 7*^+]ǍJHW\PوJZׁVܖi<Ol {{^׺m1[{26\S%\8`2K, I?{X>Ow+tf QRK8*džnB3${Rw_'{Z5]u5U3WRu׺u{HjM5ؽюoPqw,+)LX\ۗy6 J ~g׳k֏lvTTS ,@r +S0RG[^׺u{{/{Pgkm֭f10c7R2YO%A0$]fZV ʛg>3GTi^WkUxrG($JHd׺/~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺUw~"π]x\Hv>ƎXbel܊zGH֩⤭u( Z  -}h|9=4=OM@?roѳnT_ Ԁ+ԕ_/yw~{ߺ^Ѕ}ڝ/PvFIav(7jh''ꅊ`A#[w$_u ?avsI$/Q!Ǯ*>G_oSξL?x/]nxcۛQH Y-/غgVN0xwn/nDyc_|6~7mxݯ _jد(ywأv.C7)Xye #!n$5Oȑ[KhڢvCꤏuF#1˯Jo]R5J|[CK0V ,AZ?fNx=7VǡEm}X{ߺ^׽u~{ߺ[&/PFʏiT`!#3>%R*\^ϖBCo%E3\m;zug gQ1Yxc?NwR1TYE[F,3C*XB$r#VRU $uLZ׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺Ջ;wm߈{/&DoNzf*2auQNS!4TZ^$^M)q8>c_|ʛT':I=<܊Qkֺ}@}{ߺ^׽u'#;tJ)WԺVnH[z(Ofm(CrM)bk%\ҙ3'n:u{{^׺u{{^׺u{{^׺u{{^׺u{{^꓿_|=#jlo{^2U?PGwwߺW{{^׺u7=lL/~W?ߺ[%{^׺u{m{w!6uߺU7]7=tYO.3{^׺uemcnmό'K OޛzeWy]!RM43^e?pΓkSMywL0)P'Q)1ӆ qb$~O~7f14NSJ^k>'%I(OSC4l?*SߺZwN'77^gbh>LW!V@X q,D^ƾ0~Ibڛ)*4q0dW1Ҡ<))HFeounLn8kuZ #P@Ӭ8 ."m%dnx#2:Y$U%͓ǿ+K\L>NJgƓ<d}t㹿&͆IU;c•2"H([,u[3Tn,^75M|띙“H5EmY@f@ BWߺG?|;]形^=l1054uYU^E&2WX{uY_z6uɳeO~k7ҟ9znv׺ۏߺ^׽u~? d۟ޟ {5ieCҿyGZf׺u{{^׺uo̻o=+{^'۝s#ۑSVWC=4e#(-yT{nVXΈUMc:VW{{^=NڝŰ^*?g -,zDӯ0P $ip̭֭;{\|nN4e!C!o7uSqrcdϒ7{]+v?Ho^Wro%v21ciBA<{FJKе&?vKe2:>:i+ fHdu#:cFkbv^QBm$ Pf1?Pt0 f@ ~VUJQS##t)S 9 ;C?E^ꋾY|ݟ$qai궧Xb* 5\pG n%8$+HuG#f/&Z}*e֮OC|Y*KS^=ubߺZ|Y6.izwd=2Y33Ɋ1{#EZHMlRu35;kl.[B 8$"2$夥)֒@#OEKSKkQU*cd́4-+^,dA> M3;+`ch9W㡉x'$*O'{S?z[A֕IڻȡqH%VA~y- TKW7%^Kv]ےii$IGMEEMm#[ePI{~d?zw$,t*c)4[ PӲP8ߺG[ߺTk?`'׺Y(/?e{^M{^`?׺~!/vklM׻p[5ĐTH!gD"AD[.ZwHoN=h)o#B)t%aki#xduO"]GcqǏv6:6#/LT <!M{][֑k6k m)IDk3R,u0đ {^6^[;[q0~EJ @/0$<ƌÃ{71b2[+! mtOJѷ"eZu$ /'rGVOVonsʣShi 2d'2SïScdDF^i^u:kFm*.LUU;4.B"@^J֩+?f[r|QR!{e{{^׺uLO{9=t?!:~ ׺&_?fث*݋a4-4@Ikݍ[};&WMs%-)IfY$=)`X uۿ?>+gY.=<+UawF*w6n" Yn.K,[9[{{mWo7c1FsMK_N}49i5EI[t/^׺u{{^Q?R{f|X]Ruu{{^׺u{{^׺uLO{9=t?!:~ ׺u{mv.u4׺Sd3dG}uf^׺ףI2^OߺG3Q̚_Iwu/ߺ^׽tFv׺T=+o~m-{{^׺u5e G+u%./7u~]y)ۿnTᖨ& jI@ߺZo]:wgN͉ܛc'&3'G(#LVXd_L:H}׺sjWn׺Vt'\d{׼vNʪn+Esi>"IAr%zh@iY pA ,E,D"UP=uߺ^׽u~{ߺ^׽u~}TSm۴6h$n

+zQUQ=Lqco׺&zuG_Pq[8yGמum¾1zixܤbvM$6}tuc.jݩuNjpJ̌g9:!aɧ#uN!7t_dchu}k?Tʪo#"(VJ( {OvwC+]3-5y<@_WH*+EYt*=1ƱĖHu~%_ޝ`iV5]H9xyna,BGZmɸu7F߫n}L>)Y {xr. I 2G=u@1M;2q±d!Hb,=J_٧ϨTw(Ne>hiv4~QC-A񁨾Ӡ/:ks~ݏ{O[STgd7^Nc`RP@"MŽuM_%~fvW*]obVe!1 Uj Z_$VA$, ʑ=׺'EWߏ]WsyyE4"|n)$ I;Jʧ;qBOL~N~6oSy,ޘ1:*G%]$4 D@iVT Ԯx{迒]o"=?\Fz:l^jiVGI1 v]uH^5]u5U3WRu׺u{綺m'^nnqJN*cKPIKYij$PMN3֭ӛۢwOboZ )k3ⲑ 2 }Q8h "2u)o#T(X3TQK35P,ǖ\էm]FgZO#$9Z51S2T@܏L\qϿun=J{:XfQ4/"G3Nnc׺?̢)loG#y.έJY#p*G++SoetNo^ ^ԒTV*3՚FEE}dnK!X #>m5=w`~дXMLu3o$vb)ivߺK~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^̫|.<{' 9_L#N-|uTEh$t{o߻r5/ғԕKZgֽ`"RQn+l<)Nc$RvmRR| `b M[ACS2ȍw_j; :'QK+)n=t-\WRW͂x]G='߻z==]dHnPe䮉yUu*Dude nnmmT0:vwKk,s!Q$,Gч^9i"x' 2:0*+) ,Gߺ4@(O_3WUg NY6]?z.*ZƯ:`'+}ᑩNZoTz&:5T?rLvVQO v?uSQBv}4?l9"OgV*DVT->̘4uK} eKߑ8Jwi!d|w8yt`leDSl*gx~x>} Fouo^Yzy*+kgz[5!!EE@sd1,`ܗgݏjO3Γu~{ߺ^jom:aTL[wJL?JC5?Y#y?='Z@0½bj%|2d&3[QTi&OoMz_"gj KM2@2}OJ^"uξ{{^׺u{{^׺u{{^iC];~Œ FyGp9#אˠh`-Lq`~C=Xڝik߿׈sIn{{^׺u{{^׺u{{^׺u{{^׺u{{^׺ɼ_Wm=˵ %jn#V J7(mZ6^%.f iIif!Yi`OJSf-#{.׽u~{ߺE+_K0[jX,+~ɪZ1J6~^]BV^X {V kᚲjd)礆;+ ]~Z߿u{{^׺#5.nx{m$ ]k#TUENnog.f iIif!Yi`OJSf-#{.,u+3{Qsj "KOUoϿuO wջ6~wU[NMkL4 ]bsKxP1mLYwu{{^׺Ev]l;m ˷koh%BSTGsX$[5T?ʿpUUe:Gx1,{SzU>82\`cSCu{{^#vX]E-._ov~=䶰ҕX$$_uc}UPB Trh<`d%MSkǛ{t^Z d?baTH^5da*H?{y [Tz)$=SM+#ײn|tx"ߺVtl>cedi#{Jm qVIbOTDx$jHeYQ$]%u|.R=CJR~)#ߺE+g}wc)ؖ9zEFqI zT>@}ui׺u{?~:vU^W%$[;aJsr-7llһLұ'ߺD36ۚk%aௐ/6H2x,?'@~s)]OVtw^w1Cqz|- MQʠ$}}t~cK,^N4$nefVe _%xXLw׺DG"Vbh.չZR :%f6Ut^_鲟#2 ZlEoEFNx7?6^׺ ;dOTvUdѮ5 ~GƯ'K\RmߺU)?mmw]o`uMWMJr~Y"D] "Q\Ͽuߺ^׽u~&3o䱘 Ǘ,FO'9eHʺT{u];G;`v.g|/ig+[C99L^Z(w~\Ou{{^׺u{YO>1V jgl2snRD«A;j ɸߟ~Ww5q?_^]?{Qwnou EW׺5q?_^]?{QwnouW_a\o~߸}_IDr^iad)%% 'ur>׺3?1>/ɌmAUddkM3WV(320`ȣ{OfGcVx{o+AKVU_)ߺM$ Wȭս{^׺u{#Ρvڟ͵5Z1#/PVxzIkRS*zZd{?mն{c0ob2tC<,_UřXu%X$unxg5Ug52#Ȯ5 : >m׿uoQ/qE)|HfV9e`s B_ߺUٟMLov~H~"d|cSd%XUs =tZj$|n73fjL|2>׺Q폄_)7UBAG[>*;A~Yx$`?#{_}PnNngJ.2;Xa@xhhة^٨((qT4x]&7ACġ"U(E *u^׺h`0 ۻAf)Z)DAVo6OV/U|x-{v=kڗLFYQyn}׺9>׺uýcsSO05w #P&V]!E ׺~IGy|aIǶw/>żoѧWkۋt|tC~mQ_'їKq흿5Cj7=0,w>3}{jg>I5xj }4 IߺV!{{^-ΘAiLU3*hj qrT2PuM;UU][0ija&7*y$6AMso>Lߓz=4H/q'zO7{^;̥@-\6F?U+ߺF?qnJZz $hVQbV4v&(}^'{/gm)zfElFDWTk8^i׽uL{S_+}7xnCE9׺gΘ؝ie2W=%e~+45 HI:rߺCOu{{^׺;w?7&v|~-3J&E}4u*ċ ^Ӭ}a#SKYٛ eH|wUm$\ǿu׺[EGd)i+餢E) K*ȌU0/ɛtv&aaXC _D?:DW{o:U%:흱$-k&fķgh_ߺVKGh|vK?& M=bUg|U|v]ucߺ^׽u~{ߺ@ȞwLoy]Տ+x*jeX *y#s{*ckNxȈr"\׺O~{ߺ^׽u~{ߺ^׽u~QW;M]q >k?YOZ%MD"\bE^zil>덍lͅutZ2͎$>EG;Yu*.ߺK~{ߺ^R| |Vc4kZg/च;3Jُ^Ǐ~o7/ްm՚gr]U!paXg6`(zce+{k{k~Ev6f=YZ'2OW+8zYP=W7t<0>5l=ӵ7Vsniv#GKMɮxXoq{{{^׺.)w9/n1X|bW~k(렪pSߺU˓z6bwyr8ÑQc4墎=Wq^׺u{XO|^Qn JӒEG!QYsx]<m,˨9զG_d6]f+hr9=LMmv3݋EHf҃׺tS>K|>oTq WPR+|bG +O_NZ5RIU/|S"uN}~J캪{ظشY=YS5W=%PUfPxt7̧(b*pBGA{^y~GXWmIX r[A<2G<{cT zjp:dʛyϿu*g*:dzpnNw UJ(环O.}׺|_F7VyYvVֱ݃/S=$GziU9$}-{'0u^Wucण>6|)$)JH\^:glZ^onݴ[r>ybetD-R=us׺u{{^׺uhxͫE[Fl**ODQMG+璆єLQBՒB֖EnVUԿP$H5{^׺u{{^׺u{{^׺ {?:߹p #jcw69K=*SK# h)SK)z\2{?K\aKLdmnU2t0J@ۀCNؖUxܬuf^ jHꚩAI16^ʟ?ݙ{#t^ai+sc0O EJ՛$,p@^򪧦wn!l$il1"G%BO94mkMu{cֻvi=zХK+;,9嘟~+u~{ߺUs~lNWom ',py1yIeR7먆i`C{uT/=Q2mCWeWG.sDqL B@w&?ؒ׺v'=\TwOv,Y:=mWWQؓex뢺z_QҿO~?<.jB!J DHC=BD}< b.o~<>J=6sj*w!GUM>ɮpyXoa{;s훜ʹk6`MiKS=$)aƢ^Xm՞^׺u{:7{lpB^\NZr\f ^:T˥DH/uõlmښΧ{ &+),xvي q/@l=׺)y?'15-IU{YWOn&y?_ub|ԊZNQJ~1O{^uWWIY^.$bLYľq/Op}׺辶][IRfeP@B456Pũ1F~ ׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^?@ٹM-!ܿ>6Ǯ!Of=*?LE&5?m&#sH)5{&'SK{ZYFU|/X?׽u~{ߺ^׽u~{ߺ^ғio-߰s;bɲ>-Ǵ 9aloҔUVP"E.$7T||3N**ڢEv~ͻKI摔eH/*X`>ӸԈ,,W2u'Qԛ{Ϳm 2(m8r~eWaԙG9{l*F܍.bYeQBXvP<ܽ<ʽX=DpCUK4540E=E;HGGRUԂ$AS5/u{5tA M-L-OSMPWGF]I A {^Wv*:V'ku3FI^L6Fio_Mdz7[F km9\NoJ=uA9691 [—%G^@ټRھ|SG:w貅 ӃMOz^RoP^׽u~{ߺ[x&w:v!Q.Ea:ڻQTi1|;a_ @{ Gxnrܝin>$͞{{^׺u{{^׺u{WtnuNȵ.ܰ`i'e.12VW̪ClurMc.G6_ަ IOл2-ew2ZIC]*i];gzduvͦjMvE)!e<2J痑,}^HҾYرI_C˖mvK H#S% >liV?1JP~=F]{ߺ^׽u~{ߺ^׽u~{ߺ^׽te?_K"{h& kkujNV)=Hq~ ybyXGRƺwAw dM?joW_kuZ2R#; vZY0C+j&^}0&в'{]LҀ8j%m\TnhCW)i᫣15=M3Ȍ.)B l`/0Y~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺE_~\oz,M}\ >gc-Wi"SaLaʬX\_\%< zEX z s6rz% H;3O-F:֏rzr_Y n?# ~b"j!)K>g(#?ьQ!PLVc~8R`m.dE]Rb竗%3L mG!]ɸ>ϼ0q=ᤖ2*Aں)ԁn40n֓DX Ϋ|ćƼ[;$O:DUIڣ&,,` \peޗ0^<O@qrΆXa }5iZ*n#--O5?h?phMzyZaL+u $*lW8{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^rY#WslJS{ٵLs;iWһvĭZcrǪ&J>ƕU4urȿUt+$n]u#V u]Sجn'we]wB(k𙹖&LUdtWZf(׺=H"$!}u{^̎|mtU۽SUOWWHHb5*oROuݽӿ݇V5))iQro$;{u}oJDucރ~c!Iq#IRXdP{^^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^?|ksg۸k!*,EḺ1@{^S񶪊JˬYQ1l4K*T9P~VSymONl}~zh vP 9j&ұ32E|tuGlw/sZmՒŻ2ʧ.AXEbU EM"7[uu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{o??-ٰ04Gz}Ў3T7A& G&G17ڨ.d<|>L?Ozǟ@?q=ym{uOԁ>˯vOl>KqIM-L4SA* $nV=8R A Gzi#hXR B9#>:u{{^׺u{{^׺u{{^׺u{ר~P|SOGo1o9ŕSHuk"*Z݉.:-٭7?"򫢱l;Iq4@9W*կ(uRRn=ዤdXh{mм5QCo7in]DxO.CJkMoĒEp+=+fXV +j>QfƲ~(?**ԓ`fXfʔ)?ޤ=l8wC oE?QKL^6@(v:[rGwP<t?}7 'hSd~mN~fIu9[{"C&#jn|=VA.͍J}<`>BcۿXmHC6/%F# teu׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^g*wlv91vrpQ(RoENk9%` @$l|{̓kdCQjp bϢx3ʑ cJ4׳wۄd6< ;ᩧ=2fZ3bm礠C$&yOo+9 ĭ[DHp=U?ìy{e;Jׁ@ 􉐿"?S׹'n͚5ym5SPK#X51 m`"#P:忑GcVwbO̚?;BmÚH̉S\FA?+ J9ӚͶmj iVI[OMƚ$mRHi$fv%|79.H|ٍO<;l,b KxWLqE(>g=(9 >>-tRrY()FiʤqEvbTHRƃ$S҉$XM$CO-GǾhNڡ_Sb =4,Gꥸֈ1eCev[?w9~s576n28vSqˢO^׽u~{ߺ^_%n5İ_)%Ϳn=(7SϱUҏ>zڷqK(W'RɞďYz_νSou3e~{ߺ^׽u~{ߺ^׽tc&p?+;dtG՞5+ JVLFKrZ Rs]ݦo,(&<OԝW^smUY]ĠWY qPTFE]ovNmfc!mM[醒'wkgbY85={8x~- 92h,fM/{/c]q؛H\N}vK"X ~A{^߮7=s+V]4sT!="x{^o~AvtGvI+/62)<V6w{zUd+q{Z>YK$$VBpޥX_uߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^oܛo+v3o O3HuغZtiZiTbrl=ug./PV\GN, 0$ ?{;`,%M۽m2WRj;=RM- $~EwIl4eA1gef!Y(ZYʪ($H s{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺[{F]KH:Ϲs{@7,5Us s,L)!}毬t0L$(O/r7ONR/c҇b-֬>{^׺u{{^׺u{{^׺u{{^׺u{{^׺uUwcP(J\6Y\vr#^M>9~po ĘW*?#Їoj## D䒤|Ǻ3Һaf\u8E;c R@@[e&.v<>מl_ MFˏo,pG0$?1?=XZ¯{,}7wUw1)Y87v^K=;rj.d_@51&6q91J~/zP|.QgH|뚊Lh0[NBj&Y-d, %IERC7^b )Kڤ~icg!f*m1y~=^}_ʷC` c{p@jڌAś(=M,TJ>\V*K]Tė䟻i|@hX?'G&#*ŴǕH_S)k}ݺjloþ-[19 faP4L }5d.[[1‚#͉3I'ۮuJgsƴ8((mν{ҮŚ^|J*buSVKmMO{֭mڶ֌$a~urwzZOrH+յ?Q:箩~'lژuUXdeg[1J'&#^P~Oqچ_᧧Pm7L+1?k píL}b^׽u~{ߺ^׽u~?).} #q+ϸqW=ƝdZ…Q?+ܙH_ex6gZ:_^׽u~{ߺ^׽u~{ߺ[)/aAn棃14aqbwVղ<ȤѫS޳qB3y>}va[b"|IFkմ u{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^jz^ji䷒ WF . 0\}@>׺IAC@4TI#ji#H@6Կ~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^U=-";0q>ݳQwF)0I饳z9:Yk)!Sf.2\BtlOz1Q lyuG*q>Ȏ 2:m|[>MoϏ:|'jdIBM-M K?~][oR^׽u~"cl.UDz7_?ʳ{HJč+/y-h@HޔVbiqI4#R`2hDv >' .4_<!y(15 &.JͽK~M&Q~Qs?[-?x҂hPsO}hˊRI bAd5b8fR*p.Vs,M+;A7^׽uh7]95TZ^ L&3 fV-~/MTmnK1G):t?j7}̵!$~*1MC=f/@_N_zW}wV5*7D%>,~.YTV2F 7` VǏdn`!9/'=@v8U68q8r~ݻy=6w-2EݢTQisKTbAEQAsIoLu(W'RɞďYz_νSou3e~{ߺ^׽u~{ߺ^'wj'{&ޡG6.G;aKG&Ki"HT[EԐfʧӬyuùG]omѕhx5?o ;p6uؾ{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{qO >6c&/3"#GWʃF?;*)RsG ב^3%UN}G^r2sD .bBm-CJ.۹sOt;{s|Vx OOWC_E;VQA Y!6Օ Y]e`XdEA":+wJ3#*H =3{szu{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^7nm._qZPaXi+*!I'g<*"ۖUK T2p:v$qJh?W_ݐc'uS3ؐ=^먁1j]O,2Hejq#^}{~T@0s5j^^X?ui%-#4Ʃ)_ʛt+GpF+u>*]1ti1AEƴ`6Fj'H;9x55XQl@Y6FkR$sB~J8('|x MTxC)ZZ^='ͽA[80~N:y%ZŵE_/aAc'X˷qwiu Ys*㡢GEA s4QG~tNlݽY<\ݽsPఔ)pIOY+x 4(RIҤ,wx6 YonLPw?!=I4 <ϥ^6qF |Ϡ y6ΓA*˝T&W1P)A,*YO0R%^uqzfj#k86%vVv xz({ t!M?#|+3s}%(d&7T4 Z|h/EFlÊh,ʻG8yT.3ݮrwp5`b $7.Uhêc,"׺u{{^׺u{?=7E7_`nx/Gu4ukU >%+SMMjK} -N}EroCiNҩ~_O07F?c[r_\׺u{{^׺uw?tmؑy2Nr[rMIMHC,+"1O=LӇV0,Hxi4QO>%=~u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u/_(~\gu-FSC)Upl:ٻ'%qd?OLSUԽϐ)LPUR|Uao~T2lX|שMzymdaB}m gGOer훰ZL>CqWիE8,0ƖAn{6YP/ثEO{)mܰ,`Hp5H'jpMpF/B>{߿0:|gN6ecﳵ*X_%RG1IXU+r,Vf}jE$yzg V**#ҷjh}MC#en6u7Yaܴ1,sJz%ceWCQR]Sp|G>#^nd푈W )/7boU{nj4gb &J*6]QEJSzC5̏+,X8`yta.{{^׺u{;,|LHMظMX>Lfޜ :1!I4ϼr7۵nN$~ qXǜ))}ݐ~_ՙi#) _l_Ц{}WSU ޾qaeVSML߽|h:ᩔ9DZ|jٍ oA?o!SǟQg|ZxӌqgOHHKrX׽u~{ߺ^׽u~{ߺ^_ x[{|hCvwcm}E %Y/ -D/1g ?~:{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺41TE,OC43(dt`U <iֈ_>jeg bgeP{w+gcMnf~.{W|*>@~RrO@~{ߺ^׽u~{ߺ^׽u'^^ִ`S:Xf3o'm{Y"k\G5?Y "oa|lu]jᓺ(\NY)ըjG& W~?pmfg;GqP'xu~{ߺ^׽uګ;*";0UU$rI>M:کcApO[n):nQl(N۹V}B uǛ߾o/%Z<'}^>vm[U?irMtP{B#2w^g^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^?zeݝkػs&Um}۶3)䦮AVsfFWF+z$Ybb2{Hx&PtaP„~T;rv񽲙={3U2uNtYqRuЙZ8.i$.J6VX鲟>hCn#\w|8A8Ag2Mlj^V> Ϩ @W=SQw^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^Ԛ**̕e&;IS_6iEQ gY,@L$ pY` $$OV2>O6f@ݶ*X*ȘʨuQHx$, ڶ0:~]IF#?id>yuK?ǭh3+{xn^=3ϱ35AS["X&??w~gB?Q!@!`,,\7'K2lC?3X㩨`X"V r9WY2)Q모;u6^C婉SF; h(GO?2I,{^!8.ڛH̴jU*7c)lq_ȧB?#؇`=˚dyf< U_Elâmly}5MC1o*~}gYTZ{糵PrꨚԂ![4ԓx> # *ҫu sETa.߳USE:Y˪Ho$~H8Y$\~-&Ьr<@̒iY1Yg>4p(eaL}{ެ+uos)?W;ײ!h =MOϢec{^׺u{{^׺u{#zwdm[f˦+Gu.*:8KQXģ-j[JY *h<=h}uI#ԟEQROo'[O6LbJl%9@r 'QfӡĞ\qΛ<\(P|$ܱvppQVo9$?B0CﰿGiv^^\tNf%3[Dzz#hRR$WP$RS\} ~<=U=>C׬Pk~ ~ uI ʯr 7ػ{{^׺u{{^׺u{{^iO&>xUmY> 䦠%ŬMZXߓncxoԈE#dEycl[ ֥_Ϸ,?,:A%>+>=VܢEH&xYT؀ھ=˾ߠ7"_iyޠ{LO!仼h@Ϫ<;zu{{^׺H-])/k:5 +tWlFl2)tҳF\HzPFv9T!E>cc Ӯu~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^Yݝ'"xtslVlF۹u% JfVjjY'#DV /&YbY`s {kG !AYiӶm37O*QCJph @*Ȕx)rj2^ZT8>DǸ>\5 djqp?&=z:u{{^׺u{{^׺u{{^׺upx,ew{/TX&jʩ$i[=IV.*H=;t8UAf'Rz_w|8.~unߐ5?ݥINe(u+&-`,}vaaXOR^ьN1FzW%w69n)D'cXk/WïS )}"U"!iQcؾV>q$栧_/$OZt4G&-^~xJ,Vg*řٍxti$hQG:6NTyqieoFUvOF7B{ ͺU-0Ko.欧s̵UREc{Ugc6 7ۂF~PI1su&uv ,@Uy9]Z+1|ynhDgh (6j]*q"J%?N>^Y bب ג9h|PaeCGڤ꯳9Vf_'de2j{5D@f&ǹ;4DUG(~]E.dO̚gk{^׺u{{^׺u{{^׺sP|?:/cDmKCZaxcX)G`%?˿o[Kf5 yAoU?<։9y?e:c>ǯ{^׺uY+i2mKnX: bu\ePR R&Si$ckck濧?K}:!Pb0?3DE+-茬)@f* v( *>qW]Xw{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{?Fx}[̦ 㨦JG]JzyeDu X_ͶJ Cd0pFH7=yQdX`BA_9roy6!r{u夏a3Iy$& ưQeRL9V(y3 5#Qpެ=G q}Ldu8I)|po* s;.׺u{{^׺u{{^׺zSO 3IQ|B541 4E0YoVPFp?=֦}w[>7jUK#pgQI 3ok6IIieViQs@П'Wfw]**O̒ztm׽t٘a63c0x\SSB3Q{y.G*b~@OM2[y*bM{6WEiԅuL _NX[1}[+W3/;S~H7E}EZRI @ƣP8:lcV0E*O U͉?>]yޟĻI[ذ`8Qgu~{ߺ^׽u~{ߺ^׽u~{ߺ^׽uu?f޴"?ug]^&?g:M-㞨GH8sY7̧0B”`yUJhr_ЅIHIJT<|Pdm[΋ʯgI߲ptivRsy.?JJS(qONTkXωU'Y8臙yX{QWG? s%5Oנڞ:u{{^׺u{{^׺u{? q?+Iݟ3 tXlnJYC[Sbr}WGc^h|-Jm'{ u-{`}Om0}\%TҮ*8rl~"pq75![(AcnC i/b{^׺a*Z6g)$Y޹̲6p]>K5lReZ+%du688a"$`* =ń׮uߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽tdܝwW6.IOsSEYC]K(QO2n] [Ih,LQYI=ݤW43"n 0 C}F߉h|i2͖*5v 5`_\5R-WHھlr#_ )ˁ#{ kͱZ[l-$̺\*Z:u{{^׺z}wA}!ҽN)`]oR%:fiJ*'^}-[cGU٨]iif*|Aպ'GVn>} *;pSE3FlYmR GSONŇ:T =lHҿk q̉4Fz'ոģ|ENl.LlL'-9QWu}$`qwŭ'bk ԒL*-= ?:3-g|\؛pQ*twƙk([+zC{<DLtS2zvm6=Hفk3W SY3RN.OCE>1*G¨OaFbI'9'ʠAE u{ߺI=v?]a=v.gvAy2sm] )&s"FbzIy܆K$ZFT_SW޴ɝaQ4t"KjLL<$}dv]-lp%HuuTFEuٽ5(2jk_8`O×FG[W䄿TgQ>{U;u<`0~ު{ϸ'[{3yO䯞+IF\RQkyd孿ðJ Y557Ğ~]JkPQ~*yO^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽to>|L/1?uowlIu@F f $f-#)9nkJKxZy^.}1Ď2ۭV5M'G_/7[-:fmz\8pEC+arnH$K#4sn$rݏpݰl-PơQG}OrsW+bYBMerRTM!X݈UPYhK&$I"¥܅U&*I'Z83_y?*^z7Wb$jeJWqU1)U(,ơ{fT]= OEg_qyչ-%a^d#թZ Ay׽u~{ߺ^׽u~{ߺ^׽u~{ߺ[& />xLLέј؞fS!sS뾓a$PS@>ڀ>r|9I⛵kĂ[Pɨp mFSG=>3ʟs,X@?Ks(5z0l۪@EG4r:%zzIIU_UMCCMQY[YPttK,0H4G!UTĀ'ޙO:v8՝݂,hM']6ϖqBKe4t4CrFn֩Eazxǭ-_OR>s4<ͱimp ~%pi s&bP*Ѱ)~׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u#G/ݫy޻%zEhhkdvI{v|Z&>oCm1IAJR5fTT6S<$| )E?>=7nz6Z(8?51o鮡[3jit$COR"?"90v{6u#HU.:o}[)) Ŀh[=V7m7*)1Ըi!P+|BLJ9@ Bҫ3l^F'qNԵI0ly=FP%(R霻W깷^/.r,|뮪ոY` 'rݎo"8PpHcQ u]~$|N:oט#O9 _+hXJ Qx"?!YZ3L8y>m9JfI)!$i зbw {8~֎d=qRq,VH3![LM'T,㮁R)KG=@C:{Z->xo/?u{{^׺u{{^׺u{{^׺rmo ztuu|?>]ǥ]=}»y:.A[5k:zu3x+rߺU.RYȲ-LC y.X@1|{p|ѼJ}pv (Akc599}9ٝ1=sC/7vfM4Z]bw+OGG7y8ݼo3Q|@q':,H}m乸PaݍyִnOǮ'~8YS4c2b8(Ei*E6FTInGJ*s5KuHk?ͩw Gn>5+#+n43¡Dj̦=ˎ{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺U9,}3G!*CH8$2Ƌsb"`*I? 2z,JYd@'#V ee11ɍٓ˸jD`Ș4.QϱW0Tlg)@:A -jw#L_JD>}z}n*UZ<) 9Z҃&{FsC{sw%Ǩsޢ >Ećoڣcw]뎧▯lJ0% oaFk (Wn~nו Ȫx?9 S:1_])%%-2'  AikeݫiVBGX܂nәʸ@ 9(t{E׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ\WHFI$q%I'T+ۿW-{0xv%DݷDuVJ`pKs?NEF.By.}/YtS/t࿦}KU_KCi\$ 7-&ɥp-S:Wd jȏvC˩_̎OryyNÄ!.  dUYFJBGy̒4Ye;,I$OqT(yu+bI$I$Oz}W{^׺u{{^׺u{{^׺u{g@mWCбtm@a<@ZMG`C'Ϭ͋ڛ?RcY$$7I#е!F:0~u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^qϗꭿKv~ U>5bA#SDI0U>GڋEE9B*G3pΑUPxhKݽݝͼr~ޛrnJ|B7,XsRRE>-au(`(C.- QUh&EC3D}L}$U h@L )5C/^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~_w5~#wqXmEP鍭_Yqj#pQѺځH>jj}1 }Kն=RE?#0{xi/h}]{T6C_!=Ow+ϼ=%,-R]ZFՂT99JX1_!P)飚r#f&(>>Jd4s$fsDI4QҤ B{C0ٍۻF_M.>gz wbu;<5XFF(~d=a.sܶs_%Q0#{{^׺u{{^׺u{{^׺u':*9j;xVK,8,{}fWm,|}<{+LG{v/R1g/'쇘w(-iUiw?d>d>{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{^cʶ;MNFDoRU{kiљ5D=,Q_ր@_1,%jձܜOӔL 17wt7m|y5;V_f -'ިzZAq$dG ׍Ȭ5yw9\L 2QQC,{.`o*Xz 0O:}O׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽uhWVK`T] rQ˹khFVX4[C)],wh`"%h橆DA9魘cR 6\xXxx2#11~ARcqx(uk" āR8B( rYfbK3RI9$RO8%PPpˤ߻C^M3ga,Ee $9Ej#$Q#p,ƀ3ױmHRǀX$g|6x /YS>EK sHJʤʘZRBJ ,Lf-h]-#.r}y~>y^q2)U3VM1 zajBs/{^׺u{{^׺u{{^׺u{YUT1 >׀['y_޽ݷRox꣣6f* CK,S%Jw'hrGnN~Hn^7+Kf(FbaE v>]K{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺAlWwѬݵp{l]1B4:uT5J zy"A 8ss -N.l&xde5V_#fZ.YP0}A*~jAo䱿Sdn 9D9Z cOV}(HK{^F:m` rѓ5'*:.mRT['r8,7z; m<=M5e4bTST$sC ]]C$neDaUt`2qo%VGSFWRЂ3׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~߅>ڣ|T6vŖ+dd-hVSTV't{϶܁`neJ[xk$E(s(#JAV5M-0_/"GOHo:c=e*m5qu?,@I<]E]L3#}{ޮyK˷2K+jf?(P0u^n8J >drI$hiX&y`;Ie@W=iԿ()y0hfZmb(0BYf?55:*rC?2zɮKז]=4(AG7OW)+Ա׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^i~Ra-j|6G .F%1x&S3r𷱇)RkWq_ 76iM7 Qd'?־%sج_wNFiN֯cw4wQ^UeDh.;YboyWxv;I8xY-5OC(q=s7wudSh(ΗT%ꚷ6+7]mMŋ:I)jj2G#RG5D6ʼl>EIf[ S#FJCza{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽t5}.-;zksy|챔1FhC0avg%y9\iR_^5E5 $U&/r3]%՛%t,@?$e)F2Ӂ_7-J"rr*c䵂C 7||glqtE_ObImr,rێw jo(GB.q̩*?>;}d ~աQIVDkS-a[H Dc3]9#d쮻{d,,> ^4B?V!;^F%ݙ$4pܖcēSge,hTE ץoU׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ@s|v/C.[!h(rP诤 ChrM&Lr6n<'I HSTjSF7D.s ~)(aܿXQ#G&5ߍhx:<_MF:\-*r EՀ _.}^F{lsC*]Bޙ^o+o pMLjU`O*L֍3-2=~$麱-ٹRGS xw dLlgLJX_;0ajp#}~=z l1 6upB>G 4K,$#M41gwbY,M<(NTƧ$=c׽u~{ߺ^׽u~{ߺ^j쪪YUQrIԟ~Wfj,*g eQ؍2SK I)%5Xʷ[_s oNxסQI@B6"]b;tS$Y0n)A֠I__k U&(±_iϩ=5ˌ??A,ߛPWIvn6;k ح(( 8q͔_yV9,OI$ޥ[XE ,hTғ}(׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{TմWIUASKT$r# 2:8*؂#2I #ЎEA ~jWZ\nZ%y5iͅGswwi S=\F)w#uo~lXp hPZFzFvv PSE$ Xs~[?3Snᕏע__3STK_NRƺ/^}zu{{^׺u{{^׺ڻWroɄC {qb`Xj,qEYOEوPHK}} \:jYݍTq$[VT n5~m!{q7} `PcC&GPG`&PQS?FnDQC#dxD|#!K>r\4ԃ$qП<98 oo}.uȽe8V+2(IK4vWea'/MNO>_iF~| Vv/ MG:~@N9۞їϚ2Uuu24HYi\3I$rqJ@ 8:vF,K31f&|g{^׺u{{^׺MMQYQUULԴ$;HE݈ I 4ʥI$s5N͵5?B1 ѦS]Y\Y)/A50 },̎GC7/GOV*MO_yV=fQ ^X bb.U^Nȿ=J7JmXN7o?ORn8&D\kw\I) xb(XUB/wY_(:vNL9z# r` |6:~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~{ߺ^׽u~t@`UeafS A׺*=kWtDl:Yg) ۟$ 3U<8A 6?r](4`z:#mMŬEUV?;'t|iv?]YEmX+Y#=;G_t% 5bحy'ɴʃXB|ۯS>}Yi5U|MYK%e_@ܡ}[ n`o3%~j@-ڦH&BɔoY~6{bV]tm@'~TzH6v9su>]o,4}7Z/ǟE_rlj~w=͵*rPUPɩI *)Ro V(d63M}Oh>t{^׺2>#|=]{SEMe' OT 5ɑ뿝QU{3CF)"l kvO!50'tI̛ )`AT!Ͽ+{wۂtoMᔓ/\#,h <P(cEQ6ۥUu6;\1y$b 0c7E׽u~{ߺB&엎>K'(V%fkҢrZE7~=-V:f$tagn<24w9 <}ˑ^䣯&?>:Y{(D }`S/|-f}9sO?m]ljwɨECpԁlgNÂ*^Ik[w1 ?wWr\5iOkE ASv_qWV_uKV)%dkdW1OM Nč)Tseu(Ic$] ]؋v;#bX^oHģt!G\qCYw|,+m͓ML-yDurt77^Q"/>1HC^Uj:>/FЪd$k˫򹌭r(>u(Nc_{k6$qۣ>/l -*R賵D4K3xf,J&{A.<7zZra45?-|b8ccHaQE ,,T 82k럿u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^׺u{{^@=agzLIHNa/gx{_W7Ν;ff>N$d2$fz&Qc]Q{-T@"RDRQAQ齝~~z`dm>Ⲋp/,|ťAg.W˿e'lPp9]k_W ur.mM˳~Jޏnǿ_2gnrr 8  謬'?/$vUA`櫀Vo< |aeq|T!h9~LlB]U%y@wthf8`7V4V,0[0t]e]CI#qxk0f1˭ eg Da#?vή8kJ?̺>~ SԌM F1ħ1N➚0Al!;3ЌYIb3LF=J`XG&YģNᱝc[(uWS>&+D^<V;eq# 2Fw$1>CzʚI;bgu0X@inD6Q jl#?B=csvJG$Ŀ1Y-9qDzʅ @(UbF}~@+r7á A Hw֢A#]C QLE? e2tކ(j0;}4H-iM9vR~s~fG>I%:҈nkDѫAgS:(&S7:ȸ2(}曍pzjrQ\3uT3Q"4YPZ uК0rN-;KQ H1(B& 4FRr}L'HG$VSZkTe~jq3i5in}O!ckc IvŒ(UpV|mU,SflyPfq@K2N@V ^GOmI"*/>3Jى %N|OC'2_CTNL*rTʛJ=dY⋱O97) 0v9LPFv ȟN+6hQq#:wT.Z2`ԧˢxh2 Ѣ~t* J>oDV8B.#clA:G!ߛ6ˁ;>"Fs|Ap`"~*4ZE**ncF_OeG,Q|Uq Џ8mUi2ٺ3;pa (cBFГ?H!zyg.Ds7s0lEM'iIzLO?$<7@U}wBWsBٵSPU8@sALK,tZQC!?WS9gZn܉Y$wxU$4[HGt=Оx`khC76QV],eAh][g׈uGkE4O&lF~7{)4zΣ%i/La4n.jq&8nD<@q0ݷ+X7L3;Δ5h*"i[hÀCyqnmq7z7Ewx2y Ejdm൸D[v %~PLH9%zāPnϒnPvf'I=4Z0F.rH;ouq#j -#އm4ƂS(=녶Vea#}|=+,F4׎.a7z.s9 -z<u)ބkDymG׎<9|E^9i$4!Xkz*ƮG]ԥQ٥S΁w;8~.+gm18sW۾B^N H=g#u_}h2.d @`XA3UOmYњcqpS\c/*Fҷ5i S^!G;3-Mх&z ~uj4EOj~ z?"1Ciy] oVNncGс1t@G^xOp.tDkb>Ɩ|/ۚiH%/&#'WFox,x6a 4Yo sx'擅FF}Z/x7ѧXӀpxƜËH=1NdHm33cB}oaO>`38֪Zc5 `9 W<-f?A?5s\v ^_+• gCB9 Į.bV{3&U`׹q¿qg1zMyU.cS[hGA[~\;N`ڱ0LE[[5u\O.ٮ$݈F?{8m>/&bĦb:Dn MV$Ycӆ-4|Ɲr6}X7c]K؊#D(Ag>w2uZmh ;wS`ḏv7]*.¨_~Wp+keS `9Rd揍3F| mE{LCJ$trH_ꂌK^y0Ag" W" b#s&ji#M؅#7%M[t8 sG閷`BS2'\89s_d Y{$=c k}4EF[KCuTU&s qk(Obp['1Yͽ!Tx9]UQTn@}׋0$-~ѓɋ1( !ḰRsQj>No0eqܰ/-jc1;bBGLFsi V%"c5FZ:)wp"^$33D\14un{m5gAgH_(sc]m 6} ɏBI;a2nFꊧ)ƱH,b7}瘃4ŎO"gHwBK..EY"WgVDup= P>7g[tp:u*0۪pzp ۹7G~1f%xZsR]3+/Trq A?#xLC#t^"kX7J?,ST&'d7Ӯɇ]T'᧩ d,z_ v="˜up|Qx5Q Ey,P Y9%s\a-no8̠E_:-x eQIooFW&X2BCC3Zw-*RR(zCj`5;Gsp-ܟFLp#$R~] :HCt>A|'j<:sh.\F'O5'.{WNL+~1rӠY?ʈr2s^ '!BwuUh<>8)}[4/l//B8~=mT#zIa5D)wnce '8dGz*.?E&sGemAA?0ef]+34\)37e] o<%d/eB?#d8EQLִЏW2XH-m6<Ep=ʽh)U,jPym. jkKX6-Ga$F{.~+^b!ױWpK(_?ZHg*d?k97*O/C(g/L98xlm(r}(9 s^ChT pe/` M"7b 7R"a TQ1NAyNC匛L <2{O!GS m\Z` ""Lg}yߟia:*Ek.ЉJ pcHH&NZQ ~k,(jI.%q9Ƃ%X2~2NCոI,\߰3B_˵#ƞHIk$+>&6:ƹtUGbm@%HY1:MhL=@o$mceyY#8]l<C4x-:"r5EFi!%e*eClQd.l >H^A&Kg=49<;&4Y\s8_e Q6%G1Od5e_ T]9wʠ 3~g AKAl*֓W~Sh ymWm"ԣ$x9R _ᔬKޢQvY%`lĬH'dG0EY t >k3CΖ77Nr5N1H1&~mU^&Yn.x%'o:_B/[3YL9Ha y!U mtj$pCga;JP Cq^# /xoU!Ҕ\rJ鿆vWC_D}Ig}"̇%ULUxɵwL`NvGߣc{ֳ&0NTk'}4B!<0 \ׅxގDy8pE\;5j{W| %,kUcnWCABӋ ?ODY h׏OD"4qp?=,X‡`,NIm"*<48N]'ۂ>=^ ~uPLgs蟡F)ĢZG߶+q |eY7 EN7}剈ܷٻx>5!v+ XQۿAٿ^~fwJ2vբ?k>Fux> Bj2jw|BY*t*[~MpB7pgSW| KL6=7H?!o$:`^EO"z˷<4K{ rhI?HjOƙ㐱9lM:ڏep-A\y>'+>Bޚ0%]ZC9I}C35[$zIe`yb]e?MUKg!.GRGQ 23Ph98~8C9fS.pUM  J_yH^:R =xqjg_GºQ_M\gW nG,%Mj4 c8Gz~ř "r]QlUY濾ц<'zs05E2C'P]v3|$0EY }%a<* M'zq9WA{s ΜEQZHڏ&w+},tЙ ^=+ȉ0G'y@cvv i(j>MNzO +P]/D04cRN\Vcuʷns?nmCcG xI>{S1B;]e#+x#ƕpX:g@{5d{m={f_GCC.]:;Z)I>.s 鬃"7/87*8`QbJr[.IL s7 SG4Ơ/2) -6cθ_v<3G;uBunדBk%؇xWkټc4sK9%<9sF>`g{ Ў䎅^B:"3xKiu(~&&x1BSA&nڤK3Tʬ3cn!x7N{mlݥ8.vﭤM:`n893SI)_T\lrO_-c9#jeQSV+F A?4j%Y\x UzZ:3c~Ne$OVΧ]>a79WD]_aclk_SD۴i  \RV!xY!mNLWD3(ߛbL5{voObCs *(spNE>+/;FV)fG{{[+3tcu|"~c8)>> CGKy偓þ346tt#$uFAj+a:v!'R)>v=8I\M,KIiPPFvrt߁DNF[ &SlTr-?` 00H 7?OT95,L4o>z@3 M&f$r#rL34seNedlFY0 =-{}ww.w~޻ޙ 7.ְ^&S͓YrAوt2%wp1x uyG~OoL{ ^) SO@S^4i,E9FrJ_"*[NlG$wi93[]Ȱٜw-9(WZjV1P(},W>zȶý;Ory/pq-YK?Ƕ3UvEZvЛ Fʖw )<;];]2&)НpqБ%~l6ޗSQB[g VNCԁ;XGаN@|H*2&}vcu1ZŪSNVEvvB7AE0( CAp^~hYGut3 !R~7L9S#XhFRD;[I+9y&~K?i0y lG*DuX )[neF#W[8F?S|=~&T7q)~&nl˺L+@קP{qohwZ˩GȮMAXPڔZvnߠ#s]=mACrجUxYGe1@G=¿.쑕a(f'qCb~MxF-ԪId¾2C9L 6:ϲ:?vYmju-׶Vo[֢ #0 SDQ!f !C{$$~'^ᱼ~S_y}g\sss?% cPGl{Օv7 u)l:4%x\H2乸wJQa, XD.VjBBYE29p~z Gg # > m\%(yd`mIdR &,2yB/jZ W {BWA%lyE679w*O9kPlMz]=->*<}a̰f8c<4ƓREp7q7[y̰5]N^[C4sAUdhr {[z}oM02d8*0oUa: &KXԀѺkJcS7BU+ ߨ limB'3ٰ7Fxw\^̯ g>p_E8dT(4ΐ2$bgN a, xmI!|n?hY ?N(V&G{\+f0JqIq*EMpcZ"3cJYCH l cZfV>YhL_Ρ9\ .g>F*}vK\#vVw6=m#sYfhKcM0qoh1lNgL𻾇[7mEjfsH'ߎַ2ld$9\κ:E ۏUɃUӡM( )佒3[g[>V *s5wȺPU)^#WӝSN)5{gL,{9+JI~!z6G3{(WlW6Âm,1ڑST6F ?eyHP SUCu ت}^,Z@YU ͕ӰnEY$]_ gnd\OE? R=)|4$7ͼlyi#l3ށ2gs2]84`8 *-=#NӸtG֠ }~gm:J> mzu$Pe I9q*LbyLx yjG.ahU )[[|YQ"F jѨ.Zحwބ{_W3~:fҴuN7R`\nߘ\XlSbؑճ;'t>6։J؇S4pm! qnm̶a=rdQw[ d2Zκ_yy|! 8]ڙ:FH'\θ0wXx(6ud2=~,^(fxLg6xI\ HsZU]ƄZfw'q1Ig^cq29BYn!+`th@Wqi]1BPP9 U5LtV=44md3 pf&9uq.l4i 7W3I -XGԨ&ݪԹ!`BJ]Ύg"c4[?pI̺Wr =TӖ=epFS:'Yc;Úy9 [ 6Tœ||Jmd8+2NӸz _L0%@",Ù𦏬i&nWl_ftΡWXpߢT2cj9?~SjŲ22.λwkW}ȇ-xWi٘HUS7}lEhD_(cJuNni/˯/qǛ zuľ%ÿyL7 jsDAVKl[w> Z N6E Sxb 2>Iýwgm _NW%]/v< u)mx>@{ \9S2ҳVm|լn!xC(W9 m~_CVʴ6`^Yxbꡕ3?܊Sɔ>X~,cTԔ9G[xm᭡VJ2I2%Fk7™3TAL}o3L3Z`GGw(Ѭq[iҀnZ=2d!eƼ^iJX3im;u,.JjUBأCu"f0|./Pؽ"z*eŭ5jg8ϣm3bL֬\κe Z8f4y)*#[TvJW4aZбE;YM|i>&MrXH[ LBacɞק> k7l7+Eѳ&)5n]ܟdX{ jU{v2è5L*jLK۵5lvmUhЯaZ1g {vV7I'6ΚO޼1[*fSsBW\98r:uYiǸ~&K1S_M.izqk\3%lC Uƭ҇AOcs*F~ʤMYA;٣[_CZ"o\6A;nsKnZ6^6/wkG[/hH+]?lAF5xrzVOEdYs{7oКj;4:΍ZmHajuZ3}S7d1#sh۵' n9JܵJޥŝ~ҞI߷4^FQT,jFLC_35lqscա1kRtt])΃?xB~7hy畻1"аjp3K1mRQAKV뭐nGEF4q3~Ӭ})#GkZޢ7^Xs {Oh٘sk+wW߷"qnj,-KN1 K3S >>Evx\+)) 3tk4=vܩCe?] g${;`J(gsXwdz^3{ϒh8'}*_[Ux [\/wƹm~HI%hj61va1|Dp6# 3ƴzR?=E{Ϯ~iE;:nLKׯ g,uV^3'YR&{+v{}{(Jѐ<1'ظ5q aW9^_F>m췋B-{^K3zulQ7n^A5˨jDx,wC_jGy:n.Ѧn*t.HbV jejI_';pOU#ngd' uwߦn*rxckNH ڹG)wiiGðQ[?3g2Lb7mМ؟-^4ޠddl+G hńMh}keطܻUˠ3}IV#?lImQĻֈ?A~׹ VdP"UrS_M<'h:??ֺt*>Y ?(2&m_2Y9llE|D;#ܹN֏Q_HzU4T:ޫ]&sыjq67eB95NRT2uSA6{}E1~~mS{>~9X0۸wd ZVG11nxRP-XG{>Sdoe-}MK);~kk[Ǡj[zpCְxR7FhP۱UqKCV:жv.ޡmۗ %kXZڍ^l0$9k,L>SjFإY[{Z~L?VΒPl U4bwInq"[ݞVbld(vݥ]^^~ځ}Z߿[1 -dxc4uT͑yt8(L== gJ5Ҩaㆼgp{tR}~a\XaMy9oF!nDNEuc؛ݯ~Sɛѭݶ,oEf_{/n3֊vVҁg%.d='J]]MԪ~q;'a =WJDVnv[ufO7?Gʙׄ`ɴ%{lwMGӹ$_RcTܣf7jۨ}$i|>h46/=I]8XRmTV.{M>ʁHq#_VT;}G4Vcí|a,-3QL@| gT:_83EggFjW[9onקO]ezlwS"̂x=Կ?pr~&q萺*=3t[3<؅O}ZNMU슞-i-LwG#9swФ໵6 ωڅ]ƿ 5_xli62M?{ {3+eh!A߾薤Ft3Ƶ_0b☜+~Rs&'y`&2 mQ_cњc)ùP>`4s nVKwj4¢NbZ\&UB8ƪ$zVw] S^}ڼ* +^ ߥyS{XaAIy[ܾgП57':o;kw k0n[ <80Csvv@4]/#c|n~f}Ez<ءjZ5I2K4ZEgԧΫyW{Ѿ۰,uk^W(ȹbNQG#&Uy 7aoٝ6;EwsVwG[;$rNB3 ̺wRHjӐ?jBtp œr>3Yc;vD |Fzv؃f)75kJQv꓏*ae?=ofv#g"9)MZ)uHg^CppHqǠπ93tl -_47e-jXȷ]̅ɛLXK@Z'w8{ ڬ5r>qۼ/6}.i+&֜,m!dn|ጁ7sqnٜCzcKB .N>jJZzeѰ͑M}-瑱hCfjJPn>~\o`} lhd("U8;mMmgؐ41NU )'eӶ4>~ ۏ4"΅}Y3F? [4&(1Ee}s+g4#rm"KZǼsqOUiӴ.t>Gдw_$ 5g8gܾޯ?̙luvhD#;|%u54ey/ ߸}7PӺ>34 `ܤK9N1#מGGXZ)Jjjg5yM{ZӺV_o/3Xw Y5S8h}&Y\ )mיͫ9/S gӒV7kY[9W9ůaqi2nU뛥COi]xgGt&7*uvBs1xΠm~q~}yd tlBo]ž<9XWy:z:<:iF Ѥ +m^s` b-\:Ho QK~O{Ff&TqCTt཈cxQ$4EAv3t~0w:GuzrTpe=wj]/wd0[f}U0дH+3S*Ү͚as_)_1_ކɲG\owN~Ŝ-KyṝWk65éW4Ψ O3wȳ: *l<˪懗IVzڻt)u`YeV&wiS+ӗU&ş̂)_IKPZzBnTQTc[7>O hty, Y1*v^nwm3a "j;Z!mhfmL:ζܹq5psi ]3ϳ0 V͟b3ff_}ظ dOe |l)ۚHkV=!?5K&Xn1iA4/G/>Z=2ӳ 8Qiz |`feۧloQ1*/SrqF3A%*qV!lssW5ZVkttaq*d;O^j摽>#VV.),yqTQ mpFp8`K9{QGjgS3p^-uJGƺgU8O|}..NGqdf~СC|Xni5o}aȎiזuJ8s2ZƳS33ܹ}Նlpv_%?5pǝ羆|cWZ^sO`/\v>YX2:qfzo.~_exÌas6 H1V~Rs7گ,sZ6f ~V9l2մXgjVEQaebk>5j~^4ӋM7y]wX pC5JomhmWϞ˘U:k}zC(+`aX0! ̡3[ַ$kS^Tc;l,vY365]8/vcb7kw_nnmq-Ol~5M_ַB\c53bb٨_*~7֦?.mM׶~"RU]_irZ|Lo1ٰ>~5ߟ\W{KW<2|57+SevF8qfcwUc5-C.G6TWW κ0ws.a0X~8bm1do.Wi/\X_w;Kd0>y~YF9Q_cb_]ܾzӿo{i6FΪ|sRq WSi̯&iqزe?_ 41 h=xM(ϗ;8Y;cr@9+^L<U\JFU쿺y6Ͽ{wb}g\䗏_xtJ].&q#{m+Gn1߽^ͼ~1>ww5\W٘iq(0}9,{WS8r]J]|]*'2 d @@2 d @@2 d @@2 d @@2 d @@2 d @@2 dJ>gt'_+:QnsHdP–XGFR$7)*5spF0q#Uqto_|3ҩ|74≷Gp?N%|;83}|xWq÷-/ǹ'q:i'?Ҋ;œIc11rQ\(Ǿ'TuhiO$ͣ}:&![x\cLQW,W2~ٺ] geWk5 lw] nьhrȽ~Q!ktqnDsݬwir5'~ ~\#C<7il5CMmpf=zP3_Fψ55^>E6zG i8ߩ|?wiJ;4mlNA?4CK_W[QlrIn;Z- GMRtPߧ9Ҵu43]=$_曯n,+_v|?X3HS[~_K޾K+BoԺjiZZ}:hVK+҉Z:غA)]ji5;ZꇎҮ*wfn}NR\Zm-%gmSL۴74Zmnwwvmj@'\K|K_97iV f Cѡ7+*Zml-hJY[]mozܤ%ia{~ Vy-ovC^Iwia;ݦ]nUL[;Z-Wg})>kݡ/hkip=~RձOĨǵ7:q\S&۪*/ux3JU>*e/!~\Rƈ(eC:n%  N 4w;ZzP~M}ѿա!O)H-7J>{K=p?z*[?ؐ{ZA~S_!STok~oiIZ?i mE8qVY9nF|+TenxVxDk|=p7oNІٚ ,\n&?@|RQQAUĩoWr.9bDfuN &rv1Օ;icmie>~/MvV3&81zt{ϕ|UO1mP>gST'+uG*I'TDҊ8eɇ5=*LV=ڿyxVĐhJl͌W@z ,/Y1r3;[Ըּ7(oEcUFDoˆ`*C6jFchmnt8Ƶ|hG.Qg@p#Ƴz[sn[JKYUNPb״\D:gg_{gUu( ~fj?E#[\J{|;.RTѪZ.[ɯPڛ}zx 7Ky .pjU4FMwWP×')bSwu%?;rY5쿋 ׊3|ѱüy cxrY=5&egPwv O0 Ίϱss^TxZ@]EZg哃F=3U`$q&cmP]>ʸFQyBuU$Q=U[JN=xle^59E}|EICQ|BeSJ5Up]N>Mwadʿ*0h- ּ?A"Aq2IZjհ[|pO%R{#q5!_6)AʸgJVԎS廑CavcX]a%|ZԯfxZ9rO߹nYgz}4 p87*h`qA\*p^ϙC:2ݤx>y裁 xs%ikX gC0q<}6:{d1g8. W'S_{%T>]s_,`Cb}ζۚ#lX;;6pJWj/GޥةOY\BaEug#gԄ5ξ]߿_F &۞kOX; \08;Il =3#tצv9Rݚʞ7xim#V 2ZFw3N1!lq&_kBzTKYZ4_yaoD̏*fNjUCeҦS{E,":ɕHgLMgk-R_WҘveџzƭb@G%xLQi)ʯf񛨁땆zڭr-n׮'͎\DWTǼѐ'z8Hg<EWJx}jVS&V9DY}뜯Fl"R b, q|cU[X5]/mZ5Y,Zè]rnTd?!]ȇ}9 bJr۞|Hk:z"Wp>̗^YĮ f<Ǟ_~c |bv6g56)VBT gLm=;qk]~89^KBw4~ .8h]n MU/W|. Pq?IJY9UKAtkqR#gwpE*uɸRtgV Y^><ҘYo}ܩe#*ޯ$ %'@Ǟ},Ã/oLTxDjsK99]Ƶ jn 7I51[V;?xN+vV ?,;Tk&ep+M ZD*G#̽8YkbfرG߆<{>}8}:Q5t9{RnXymN'JN~j5bL_~<Ⱬ3[O ݗSZp6v795d*tWmL[U9X0faLy+ppWmklÙ2 ֬(g^,6m飘Ikw_bm[D0VqZLzCy9]*ĆȕE~>Pkkۉ-N~e[ Y-ߘ =8سoʞ,x <.+2}v'Ѥ2LHqg}Db<' l5<λyg&w!wk)[*ru:ߏ3۲ 4mI pξ/c δm7b4zP27[9^dinByS<=5uEN;. ]ؿa(X]-F^0CTU<0٫NU/nсi=q O߬*V0 > [V|.wLE7>.TS=V߮ mZF`k S*Z+,g=w+tH{<37^+:)l lto6bBY3[˗ W讼b|m؀puyc)q+حrRR[AS_{ttnd91ay5vj/z\n,_|˭7zLbڄi3i /‰kF8g.72KOǩDEeru,%R9IJSrb*PkY.apIU0uZ̭'Jد~]}8Kf]p|#z_hShL EX.\fvK?zm}sX# LĚ/i0Vd:ٯiw_X8V&Ùa+)ymuNpi9ښV)|a&bgXRyosʋyw9~5s%ꮐpf"&j= ֤WxVQ12 t14V8Of8iAEkw wc=e/,qW;+'ꋁ}ֳm\_m} Jdg4ytg0zojY[8-z=6q?,˴lH{ ߇>srE`.p쮕 JuTul'=kY$&mF߬ɌgzmգMf. <-{Wc(dpBP[ OGff )/T,U~&H-ǭ .x2&['ql71+sf>A6;T0u/2B(k.`\ ku@$q)kƘ" B:7eVd+p-.|͘T:Ҍ?ڂ M'ctַAuDH*f'kJK{fᐮ \Fgp}M6- |(}V:5\'V1ӕNg(bbyvL/W&) jy.\<Ǹƙ!̷!7>1AM^~31C 7'z Z;Ʋiԟ*/?Ѣ7zS^{RP.Mᄄ#{Ja|[ư>G@OeLd=k؜追Mᓿe#Ok'<?pV2 {h 쯛8yJ L[WhZ57_pyƘo18=֙߁M!g>ig{76778i;9vgN[OÖX7x]J[!ϰX4/tSvP&koӓy=[D8B {du*I`֜2RY8'v>:ɼKKk~7'\[Yay߆ܪer&:@X=&G7qZYq:Ovt~GyCn-myXplN> >0:FbN:@?`c#as[{xv̽ 4#QPWܤ?թ@N@Gvr~s.0 3?{)"|po=Y;El?:vgkʘa=z<#z|eϺ{yyA F$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apytl$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt%$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l: t0>655*57&apyt<)$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt-i$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyth$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt-i$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apyt\U$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apyt3$$If!vh55a7#v#va7:V l t0>655a7apyt$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apytW ?$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l t0>655*57&apytRM$$If!vh55*57&#v#v*#v7&:V l ``` t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh55*57&#v#v*#v7&:V l  t0>655*57&apytF=$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ !$$If!vh595:5:5g#v9#v:#vg:V l (0595:5g/ 4p($$If!vh5:#v::V l   05:/ 4p $$If!vh595:5:5g#v9#v:#vg:V l0595:5g/ 4$$If!vh5:#v::V l   05:/ 4p $$If!vh595:5:5g#v9#v:#vg:V l0595:5g/ 4$$If!vh595:5:5g#v9#v:#vg:V l0595:5g/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.nice.org.uk/nicemedia/pdf/CG017quickrefguide.pdfyX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.prodigy.nhs.uk/dyspepsia_proven_du_gu_or_nsaid_associated_ulcerDyK yK http://www.prodigy.nhs.uk/dyspepsia_proven_gastro_oesophageal_reflux_diseaseDyK yK ~http://www.prodigy.nhs.uk/dyspepsia_proven_non_ulcer_dyspepsiaDyK yK http://www.prodigy.nhs.uk/dyspepsia_symptoms_uninvestigated_by_endoscopyDyK yK http://www.prodigy.nhs.uk/nonsteroidal_anti_inflammatory_drugs_nsaids$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK hhttp://www.ppa.org.uk/ppa/edt_intro.htmyX;H,]ą'cDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ +$$If!vh595 55:#v9#v #v#v::V l (0595 55:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK fhttp://www.prodigy.nhs.uk/irritable_bowel_syndrome$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htm$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh595 5 5#v9#v #v #v:V l0595 5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=CG017yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.prodigy.nhs.uk/dyspepsia_proven_du_gu_or_nsaid_associated_ulcerDyK yK http://www.prodigy.nhs.uk/dyspepsia_proven_gastro_oesophageal_reflux_diseaseDyK yK ~http://www.prodigy.nhs.uk/dyspepsia_proven_non_ulcer_dyspepsiaDyK yK http://www.prodigy.nhs.uk/dyspepsia_symptoms_uninvestigated_by_endoscopyDyK yK http://www.prodigy.nhs.uk/nonsteroidal_anti_inflammatory_drugs_nsaids$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:#v::V l  t 065:/ p $$If!vh5:#v::V l t065:/ +$$If!vh595 55U#v9#v #v#vU:V l (0595 55U/ 4p($$If!vh595 55U#v9#v #v#vU:V l0595 55U/ 4$$If!vh595 55U#v9#v #v#vU:V l0595 55U/ 4$$If!vh595 55U#v9#v #v#vU:V l0595 55U/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l4;0+++5D5 5/ 4f4L$$If!vh5D55855 5#vD#v#v8#v#v #v:V l40++++5D55855 5/ / / / / 4f4L$$If!vh5D55855 5#vD#v#v8#v#v #v:V l4,0++++5D55855 5/ / / / / 4f4L$$If!vh5D55855 5#vD#v#v8#v#v #v:V l4,0++++5D55855 5/ / / / / 4f4G$$If!vh5D55855 5#vD#v#v8#v#v #v:V l4Y0+++5D55855 5/ / / / / 4f4G$$If!vh5D55855 5#vD#v#v8#v#v #v:V l40+++5D55855 5/ / / / / 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l40+5D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l40+5D5 5/ 4f4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|55P*#v|#v#vP*:V l t05|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA040yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA140yX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/12104/42745/42745.PDFyX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA187yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA199yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK fhttp://www.prodigy.nhs.uk/irritable_bowel_syndromeDyK yK http://www.prodigy.nhs.uk/diverticular_disease_and_diverticulitis$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/  $$If!vh5D5 5 5#vD#v #v:V l (06k5D5 5/ 4p($$If!vh58#v8:V l   06k58/ 4p $$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh58#v8:V l   06k58/ 4p $$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh58#v8:V l   06k58/ 4p $$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4yt4$$If!vh595 55:#v9#v #v#v::V l (06k595 55:/ 4p(yt8$$If!vh58#v8:V l   06k58/ 4p $$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh58#v8:V l   06k58/ 4p $$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4yt$$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4yt$$If!vh595:5:5:#v9#v::V l  (06k595:/ 4p(yt8$$If!vh58#v8:V l  06k58/ 4p yt8$$If!vh5D5 5 5#vD#v #v:V l06k5D5 5/ 4p(yt$$If!vh5R:#vR::V l  t 065R:/ p yt$$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ ytDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ ytDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Nhttp://www.prodigy.nhs.uk/constipationDyK yK \http://guidance.nice.org.uk/TA211yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ ytDyK yK :http://www.drugtariff.co.uk//DyK yK mailto:carolevans2@nhs.net?subject=Request%20for%20document:%20Laxative%20guidanceyX;H,]ą'cDyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htm$$If!vh5|5+#v|#v+:V l t065|5+/ yt$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ +$$If!vh5D5H5h 5#vD#vH#vh #v:V l (05D5H5h 5/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|55P*#v|#v#vP*:V l t05|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Nhttp://www.prodigy.nhs.uk/anal_fissure$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4!$$If!vh5f5 5 5#vf#v #v:V l (05f5 5/ 4p($$If!vh5f5 5 5#vf#v #v:V l05f5 5/ 4$$If!vh5f5 5 5#vf#v #v:V l05f5 5/ 4$$If!vh5f5 5 5#vf#v #v:V l05f5 5/ 4$$If!vh5f5 5 5#vf#v #v:V l05f5 5/ 4$$If!vh5f5 5 5#vf#v #v:V l05f5 5/ 4$$If!vh5R:#vR::V l  t 05R:/ p yt $$If!vh5|55P*#v|#v#vP*:V l t05|55P*/ ytOeDyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ yt $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (0595:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK thttp://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Phttp://www.prodigy.nhs.uk/heart_failureDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascularDyK yK zhttp://www.npc.co.uk/MeReC_Briefings/2001/briefing_no_15.pdf$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK http://www.nice.org.uk/guidance/index.jsp?action=download&o=29136DyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:#v::V l  t 065/ p yt[|E$$If!vh5:#v::V l t065/ yt[|E$$If=!vh5555#v#v:V l (0t65/ 4a=p(yt[|ET$$If=!vh5k:#vk::V l   0t65/ 4a=p yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5k:#vk::V l   0t65/ 4a=p yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5k:#vk::V l   0t65/ 4a=p yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET#$$If=!vh5555#v#v:V l4 (0t65/ 4a=f4p(yt[|ET$$If=!vh5555#v#v:V l40t65/ 4a=f4yt[|ET$$If=!vh5k:#vk::V l   0t65/ 4a=p yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5k:#vk::V l   0t65/ 4a=p yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5k:#vk::V l   0t65/ 4a=p yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5k:#vk::V l4  0t65/ 4a=f4p yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5555#v#v:V l0t65/ 4a=yt[|ET$$If=!vh5k:#vk::V l  t 0t65/ a=p yt[|ET$$If=!vh555 *#v#v#v *:V l t0t6555/ a=yt[|ETDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdfyX;H,]ą'cDyK yK Phttp://www.nice.org.uk/CG48yX;H,]ą'c$$If=!vh55T#v#vT:V l t0t65 5 / a=yt[|ETDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Nhttp://www.prodigy.nhs.uk/hypertensionDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular$$If=!vh55T#v#vT:V l t0t65 5 / a=yt[|ETDyK yK :http://www.drugtariff.co.uk/$$If=!vh55T#v#vT:V l t0t65 5 / a=yt[|ET$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l405:/ /  4f4$$If!vh5:5:5:5:#v::V l405:/ /  4f4$$If!vh5:5:5:5:#v::V l405:/ /  4f4$$If!vh5:5:5:5:#v::V l405:/ /  4f4$$If!vh5:5:5:5:#v::V l405:/ /  4f4$$If!vh5:5:5:5:#v::V l405:/ /  4f4$$If!vh5:5:5:5:#v::V l405:/ /  4f4$$If!vh5:5:5:5:#v::V l405:/ / 4f4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA197yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK FyC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsDyK yK http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdfyX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascularDyK yK Nhttp://www.prodigy.nhs.uk/hypertension$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5#v:#v:V l (05:5/ 4p(yt2$$If!vh5:#v::V l  05:/ 4p yt2$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt2$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt2$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt2$$If!vh5:#v::V lF  05:/ 4p yt2$$If!vh5:5:5:5#v:#v:V lF05:5/ 4yt2$$If!vh5:5:5:5#v:#v:V lF05:5/ 4yt2$$If!vh5:5:5:5#v:#v:V l4 (~05:5/ 4f4p(~yt2$$If!vh5:#v::V l4  05:/ 4f4p yt2$$If!vh5:5:5:5#v:#v:V l405:5/ 4f4yt2$$If!vh5:#v::V l4   05:/ 4f4p yt2$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt2$$If!vh5:#v::V l4   05:/ 4f4p yt2$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt2$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt2$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt2$$If!vh5:#v::V l4   05:/ 4f4p yt2$$If!vh5:5:5:5#v:#v:V l405:5/ 4f4yt2$$If!vh5:5:5:5#v:#v:V l405:5/ 4f4yt2$$If!vh5:5:5:5#v:#v:V l405:5/ 4f4yt2$$If!vh5:#v::V l4  05:/ 4f4p yt2$$If!vh5:5:5:5#v:#v:V l4 (05:5/ 4f4p(yt2$$If!vh5:#v::V l4  05:/ 4f4p yt2$$If!vh5:5:5:5#v:#v:V l4 (05:5/ 4f4p(yt2$$If!vh5:#v::V l4  05:/ 4f4p yt2$$If!vh5:5:5:5#v:#v:V l4 (05:5/ 4f4p(yt2$$If!vh5T:#vT::V l  t 0<5T:/ p ytaH$$If!vh5 55.#v #v#v.:V l t0<5 55./ ytaHDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdfyX;H,]ą'cDyK FyC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versions$$If!vh5~5+#v~#v+:V l t0<5~5+/ ytaHDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Nhttp://www.prodigy.nhs.uk/hypertensionDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascularDyK yK ~http://www.npc.nhs.uk/MeReC_Bulletins/2002Volumes/vol13no6.pdf$$If!vh5~5+#v~#v+:V l t0<5~5+/ ytaH$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (06j5:/ 4p(yt`W$$If!vh58#v8:V l4   06j58/ 4f4p yt`W$$If!vh5:5:5:5:#v::V l06j5:/ 4yt`W$$If!vh5:5:5:5:#v::V l06j5:/ 4yt`W$$If!vh5:5:5:5:#v::V l4 (06j5:/ 4f4p(yt`W$$If!vh58#v8:V l4   06j58/ 4f4p yt`W$$If!vh5:5:5:5:#v::V l06j5:/ 4yt`W$$If!vh5:5:5:5:#v::V l06j5:/ 4yt`W$$If!vh5:5:5:5:#v::V l406j5:/ 4f4yt`W$$If!vh5:5:5:5:#v::V l406j5:/ 4f4yt`W$$If!vh58#v8:V l4   06j58/ 4f4p yt`W$$If!vh5:5:5:5:#v::V l406j5:/ 4f4yt`W$$If!vh5:5:5:5:#v::V l406j5:/ 4f4yt`W$$If!vh5:5:5:5:#v::V l406j5:/ 4f4yt`W$$If!vh58#v8:V l4   06j58/ 4f4p yt`W$$If!vh5:5:5:5:#v::V l406j5:/ 4f4yt`W$$If!vh5:5:5:5:#v::V l406j5:/ 4f4yt`W$$If!vh5:#v::V l  t 06P5:/ p yt[|E$$If!vh5|55*#v|#v#v*:V l t06P5|55*/ yt[|EDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdfyX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA223yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA267yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t06P5|5+/ yt[|EDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Nhttp://www.prodigy.nhs.uk/hypertensionDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular$$If!vh5|5+#v|#v+:V l t06P5|5+/ yt[|EDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t06P5|5+/ yt[|E$$If!vh5|5$ 5b"#v|#v$ #vb":V l t06P5|5$ 5b"/ yt`W$$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l405:/ 4f4 $$If!vh5:5:5:5:#v::V l (05:/ 4p(yt t$$If!vh5:5:5:5:#v::V l405:/ 4f4yt t$$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l4   058/ 4f4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh58#v8:V l4   058/ 4f4p $$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh58#v8:V l4   058/ 4f4p $$If!vh5:5:5:5:#v::V l4 (05:/ 4f4p(yt>m$$If!vh5:5:5:5T#v:#vT:V l (05:5T/ 4p(ytV;)$$If!vh5:#v::V l4   05:/ 4f4p ytV;)$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4ytV;)$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4ytV;)$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA157yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA170yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA230yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA245yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA249yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA256yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA261yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA275yX;H,]ą'cDyK yK http://publications.nice.org.uk/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism-ta287yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK \http://www.prodigy.nhs.uk/atrial_fibrillationDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascularDyK yK http://www.npc.nhs.uk/MeReC_Bulletins/2001Volumes/pdfs/vol12no5.pdf$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA047yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA80yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA182yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA210yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA236yX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/12949/47924/47924.pdfyX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK http://www.prodigy.nhs.uk/aspirin_for_prevention_of_cardiovascular_eventsDyK yK http://www.prodigy.nhs.uk/transient_ischaemic_attack_not_in_atrial_fibrillationDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5T#v:#vT:V l (05:5T/ 4p(yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5T#v:#vT:V l (05:5T/ 4p(yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA52yX;H,]ą'cDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA084yX;H,]ą'cDyK yK http://publications.nice.org.uk/alteplase-for-treating-acute-ischaemic-stroke-review-of-technology-appraisal-guidance-122-ta264yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmMDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA94yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA132yX;H,]ą'cDyK yK vhttp://www.nice.org.uk/nicemedia/pdf/CG48QuickRefGuide.pdf$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascularDyK yK Thttp://www.prodigy.nhs.uk/hyperlipidaemiaDyK yK |http://www.npc.nhs.uk/MeReC_Briefings/2002/briefing_no_19.pdfDyK yK |http://www.npc.nhs.uk/MeReC_Briefings/2004/briefing_no_28.pdf$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidancee$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm%DyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/  $$If!vh5:5:5:5:#v::V l (05:/ 4p(ytJ$$If!vh5:5:5:5:#v::V l05:/ 4ytJ$$If!vh5:5:5:5:#v::V l05:/ 4ytJ$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (0R:k595:/ 4p(yt`LV$$If!vh58#v8:V l   0R:k58/ 4p yt`LV$$If!vh58#v8:V l   0R:k58/ 4p yt`LV$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt`LV$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt`LV$$If!vh58#v8:V l   0R:k58/ 4p yt`LV$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt`LV$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt`LV$$If!vh5R:#vR::V l  t 0R:5R:/ p yt`LV$$If!vh5|55P*#v|#v#vP*:V l t0R:5|55P*/ yt`LVDyK yK http://www.nice.nhs.uk/guidance/index.jsp?action=byTopic&o=7308&set=trueDyK yK Zhttp://guidance.nice.org.uk/TA10yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA38yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t0R:5|5+/ yt`LVDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK phttp://www.sign.ac.uk/guidelines/fulltext/63/index.htmlDyK yK Bhttp://www.prodigy.nhs.uk/asthmaDyK yK http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseDyK yK http://www.npc.co.uk/MeReC_Briefings/2006/copb_briefing_no_33.pdf$$If!vh5|5+#v|#v+:V l t0R:5|5+/ yt`LVDyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t0R:5|5+/ yt`LV$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh58#v8:V l   0858/ 4p $$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh58#v8:V l   0858/ 4p $$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh5)A#v)A:V l  t 0A5)A/ p yt`rDyK yK Hhttp://www.nelm.nhs.uk/en/NeLM-Area/News/2012---October/08/Systematic-review-and-meta-analysis-questions-safety-of-tiotropium-Respimat-inhaler-in-COPD/yX;H,]ą'c$$If!vh5-55}8#v-#v#v}8:V l t0A5-55}8/ yt`rDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Rhttp://www.nice.org.uk/page.aspx?o=cg012$$If!vh5-58#v-#v8:V l t0A5-58/ yt`rDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseDyK yK http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdfDyK yK http://www.keele.ac.uk/media/keeleuniversity/fachealth/fachealthsop/mtrac/documents/summary/Glycopyrronium SUM final (1).pdfyX;H,]ą'c$$If!vh5-58#v-#v8:V l t0A5-58/ yt`rDyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5-58#v-#v8:V l t0A5-58/ yt`r$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.org.uk/page.aspx?o=cg012yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK phttp://www.sign.ac.uk/guidelines/fulltext/63/index.htmlDyK yK Bhttp://www.prodigy.nhs.uk/asthmaDyK yK http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseDyK yK http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.org.uk/page.aspx?o=cg012yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK phttp://www.sign.ac.uk/guidelines/fulltext/63/index.htmlDyK yK Bhttp://www.prodigy.nhs.uk/asthmaDyK yK http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseDyK yK http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh5R:#vR::V l  t 065R:/ p WDyK yK http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007455&ssTargetNodeId=368WDyK yK http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007451&ssTargetNodeId=3683DyK yK http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2025447$$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (0R:k595:/ 4p(yt$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt$$If!vh58#v8:V l4   0R:k58/ 4f4p yt$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt$$If!vh5R:#vR::V l  t 0R:5R:/ p yt$$If!vh5|55P*#v|#v#vP*:V l t0R:5|55P*/ ytDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.org.uk/page.aspx?o=cg012yX;H,]ą'cDyK yK (http://publications.nice.org.uk/inhaled-corticosteroids-for-the-treatment-of-chronic-asthma-in-children-under-the-age-of-12-years-ta131yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA138yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t0R:5|5+/ ytDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK phttp://www.sign.ac.uk/guidelines/fulltext/63/index.htmlDyK yK Bhttp://www.prodigy.nhs.uk/asthmaDyK yK http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseDyK yK http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf$$If!vh5|5+#v|#v+:V l t0R:5|5+/ yt$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA244yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK phttp://www.sign.ac.uk/guidelines/fulltext/63/index.htmlDyK yK Bhttp://www.prodigy.nhs.uk/asthma$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (0R:k595:/ 4p(yt 0o$$If!vh58#v8:V l   0R:k58/ 4p yt 0o$$If!vh58#v8:V l   0R:k58/ 4p yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh58#v8:V l   0R:k58/ 4p yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh58#v8:V l  0R:k58/ 4p yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh58#v8:V l  0R:k58/ 4p yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh595:5:5:#v9#v::V l0R:k595:/ 4yt 0o$$If!vh5R:#vR::V l  t 0R:5R:/ p yt 0o$$If!vh5|55P*#v|#v#vP*:V l t0R:5|55P*/ yt 0oDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK (http://publications.nice.org.uk/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-ta278yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA246yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t0R:5|5+/ yt 0o'$$If!vh595:5:5#v9#v:#v:V l (0:595:5/ 4p(ytO$$If!vh5:#v::V l  0:5:/ 4p ytO$$If!vh595:5:5#v9#v:#v:V l0:595:5/ 4ytO$$If!vh595:5:5#v9#v:#v:V l0:595:5/ 4ytO$$If!vh5:#v::V l  0:5:/ 4p ytO$$If!vh595:5:5#v9#v:#v:V l0:595:5/ 4ytO$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l (08595:/ 4p(yt$$If!vh595:5:5:#v9#v::V l08595:/ 4yt$$If!vh5R:#vR::V l  t 065R:/ p DyK yK jhttp://www.nice.org.uk/page.aspx?o=cg012yX;H,]ą'c$$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.org.uk/page.aspx?o=cg012yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ !$$If!vh595:5:5g#v9#v:#vg:V l (0:595:5g/ 4p($$If!vh595:5:5g#v9#v:#vg:V l0:595:5g/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l (08595:/ 4p(yt]$$If!vh595:5:5:#v9#v::V l08595:/ 4yt]$$If!vh595:5:5:#v9#v::V l (08595:/ 4p($$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh595:5:5:#v9#v::V l08595:/ 4$$If!vh5R:#vR::V l  t 065R:/ p yt $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ yt DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA266yX;H,]ą'cCDyK yK http://publications.nice.org.uk/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis-ta282yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ yt DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ yt DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ yt $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/  DyK yK http://www.cks.library.nhs.uk/patient_information_leaflet/insomnia/prevention$$If!vh5R:#vR::V l t065R:/ $$If!vh595:5:5:#v9#v::V l (0k595:4p($$If!vh58#v8:V l   0k584p $$If!vh595:5:5:#v9#v::V l0k595:4$$If!vh595:5:5:#v9#v::V l0k595:4$$If!vh595:5:5:#v9#v::V l0k595:4$$If!vh595:5:5:#v9#v::V l0k595:4$$If!vh58#v8:V l   0k584p $$If!vh595:5:5:#v9#v::V l0k595:4$$If!vh595:5:5:#v9#v::V l0k595:4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|55O*#v|#v#vO*:V l t05|55O*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA051yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA77yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK xhttp://www.prodigy.nhs.uk/hypnotic_or_anxiolytic_dependenceDyK yK Fhttp://www.prodigy.nhs.uk/insomnia$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p DyK yK vhttp://guidance.nice.org.uk/cg42/niceguidance/word/English$$If!vh5R:#vR::V l t065R:/ +$$If!vh595 55:#v9#v #v#v::V l (0595 55:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 41$$If!vh595 55:#v9#v #v#v::V l (~0595 55:/ 4p(~ytD5$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=CG001yX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/10990/30191/30191.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/11786/43610/43610.pdyX;H,]ą'cDyK yK http://guidance.nice.org.uk/cg42/niceguidance/word/EnglishyX;H,]ą'cDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA066yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA213yX;H,]ą'cDyK yK *http://publications.nice.org.uk/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder-ta292yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Phttp://www.prodigy.nhs.uk/schizophrenia$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK http://nww.pctnet.wmids.nhs.uk/z_internet_hob/schz_guidelines/default.htmDyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ +$$If!vh595 55:#v9#v #v#v::V l (0595 55:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK thttp://guidance.nice.org.uk/topic/behaviouralyX;H,]ą'cDyK yK Phttp://www.nice.org.uk/CG96yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Jhttp://www.prodigy.nhs.uk/depression$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l4 t05|5h5n*/ f4$$If!vh5|5h5n*#v|#vh#vn*:V l t05|5h5n*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA098yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA139yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.prodigy.nhs.uk/attention_deficit_disorder_methylphenidate_nice_guidance$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p DyK yK Xhttp://www.bnf.org/bnf/bnf/current/3381.htm$$If!vh5R:#vR::V l t065R:/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5R:#vR::V l  t 05R:/ p DyK yK http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf$$If!vh5|5+#v|#v+:V l4 t05|5+/ f4DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK nhttp://guidance.nice.org.uk/CG43/?c=296726yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Dhttp://www.prodigy.nhs.uk/obesity$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ +$$If!vh5D5H5h 5#vD#vH#vh #v:V l (05D5H5h 5/ 4p($$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l t05|5h5n*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.birminghamcancer.nhs.uk/viewdoc.ashx?id=AvuZW0tU2WZREqlW%2FRuzLg%3D%3D$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ '$$If!vh55 5:5:#v#v #v::V l (0855 5:/ 4p(ytkyp$$If!vh58#v8:V l  0858/ 4p ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh58#v8:V l  0858/ 4p ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V lZ0855 5:/ 4ytkyp$$If!vh58#v8:V lZ  0858/ 4p ytkyp$$If!vh55 5:5:#v#v #v::V lZ0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V lZ0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V lZ0855 5:/ 4ytkyp$$If!vh58#v8:V l  0858/ 4p ytkyp$$If!vh595:5:5:#v9#v::V l08595:/ 4ytkyp$$If!vh595:5:5:#v9#v::V l08595:/ 4ytkyp$$If!vh595:5:5:#v9#v::V l08595:/ 4ytkyp$$If!vh58#v8:V l  0858/ 4p ytkyp$$If!vh58#v8:V l  0858/ 4p ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh58#v8:V l  0858/ 4p ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh55 5:5:#v#v #v::V l0855 5:/ 4ytkyp$$If!vh5R:#vR::V l  t 0R:5R:/ p yt/$$If!vh5|5h5n*#v|#vh#vn*:V l t0R:5|5h5n*/ yt/DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK bhttp://www.prodigy.nhs.uk/guidance/by_alphabet/pDyK yK Fhttp://www.prodigy.nhs.uk/migraineDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/musculoskeletal$$If!vh5|5+#v|#v+:V l t0R:5|5+/ yt/DyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V lq t0R:5|5+/ yt/$$If!vh5:#v::V l  t 0:65:/ p $$If!vh5:#v::V l t0:65:/ /$$If!vh55 5:5g#v#v #v:#vg:V l (0:55 5:5g/ 4p($$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh5R:#vR::V l  t 0R:5R:/ p $$If!vh5|55)#v|#v#v):V l4 t0R:5|55)/ f4DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK ,http://publications.nice.org.uk/the-epilepsies-the-diagnosis-and-management-of-the-epilepsies-in-adults-and-children-in-primary-and-cg137yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA232yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t0R:5|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/WDyK yK http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007475&ssTargetNodeId=368$$If!vh5|5+#v|#v+:V l t0R:5|5+/ $$If!vh5|555x#v|#v#vx:V l  t(0:65|55xp($$If!vh5|555x#v|#v#vx:V l t0:65|55x$$If!vh5|555x#v|#v#vx:V l t0:65|55x$$If!vh5|555x#v|#v#vx:V l t0:65|55x$$If!vh5|555x#v|#v#vx:V l t0:65|55x$$If!vh5|555x#v|#v#vx:V l t0:65|55x/$$If!vh55 5:5g#v#v #v:#vg:V l (0:55 5:5g/ 4p($$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4/$$If!vh55 5:5g#v#v #v:#vg:V l (0:55 5:5g/ 4p($$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh5R:#vR::V l  t 0R:5R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l4 t0R:5|5h5n*/ /  f4DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK ,http://publications.nice.org.uk/the-epilepsies-the-diagnosis-and-management-of-the-epilepsies-in-adults-and-children-in-primary-and-cg137yX;H,]ą'c$$If!vh5|5h5n*#v|#vh#vn*:V l t0R:5|5h5n*/ /  DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/3DyK yK http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2030729WDyK yK http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007453&ssTargetNodeId=368$$If!vh5|5h5n*#v|#vh#vn*:V l t0R:5|5h5n*/ / /$$If!vh55 5:5g#v#v #v:#vg:V l (0:55 5:5g/ 4p($$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh5R:#vR::V l  t 0R:5R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l4 t0R:5|5h5n*/ /  f4DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA20yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA260yX;H,]ą'c$$If!vh5|5h5n*#v|#vh#vn*:V l t0R:5|5h5n*/ /  DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5h5n*#v|#vh#vn*:V l t0R:5|5h5n*/ / /$$If!vh55 5:5g#v#v #v:#vg:V l (0:55 5:5g/ 4p($$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh5R:#vR::V l  t 0R:5R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l4 t0R:5|5h5n*/ /  f4DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA20yX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/11925/41664/41664.pdfyX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA114yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA115yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA123yX;H,]ą'c$$If!vh5|5h5n*#v|#vh#vn*:V l t0R:5|5h5n*/ /  DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5h5n*#v|#vh#vn*:V l t0R:5|5h5n*/ / $$If!vh5:#v::V l  t 0:65:/ p $$If!vh5:#v::V l t0:65:/ /$$If!vh55 5:5g#v#v #v:#vg:V l (0:55 5:5g/ 4p($$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh55 5:5g#v#v #v:#vg:V l0:55 5:5g/ 4$$If!vh5R:#vR::V l  t 0R:5R:/ p $$If!vh5|5+#v|#v+:V l4 t0R:5|5+/ f4DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA217yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t0R:5|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t0R:5|5+/ $$If!vh5|5+#v|#v+:V l t0R:5|5+/ $$If!vh53#v3:V l4  t 6PA  0653/ p yt+NpDyK yK jhttp://www.rcgp.org.uk/TARGETantibioticsyX;H,]ą'c$$If!vh53#v3:V l t 6PA 0653/ yt+Np$$If!vh53#v3:V l4  t 6@ 0653/ p yt1wDyK  MeningitisDyK &Emergency_treatment_for_CAP_in_adultskDyK URTIyDyK  Common_colduDyK  InfluenzaDyK Acute_sore_throatiDyK AOMDyK Acute_Otitis_ExternauDyK  SinusitiskDyK LRTIDyK Acute_bronchitisDyK Acute_exac_COPDiDyK CAPiDyK UTIwDyK  Uncomp_UTIDyK Acute_prostatitisDyK UTI_preg_and_men{DyK  UTI_childrenDyK Acute_pyelonephwDyK  Recurr_UTIgDyK GIsDyK  H_pylorisDyK  H_pyloriDyK GastroenteritisDyK GastroenteritisDyK Infectious_diarrhoeawDyK  Threadworm}DyK Genital_tractuDyK  ChlamydiagDyK VCgDyK BVDyK TrichomoniasisiDyK PIDDyK Skin_soft_tissuesDyK  ImpetigooDyK EczemawDyK  CellulitiskDyK MRSAmDyK _MRSAwDyK  Leg_UlcerswDyK  Leg_UlcersDyK ConjunctivitisqDyK ScabiesyDyK  Fungal_nailyDyK  Fungal_skinkDyK AcneDyK Chickenpox_and_shinglesoDyK DENTAL$$If!vh53#v3:V l t 6@0653/ yt13$$If!vh5z 555#vz #v#v:V l44 `(065}5G5/ 4f4p(yt1$$If!vh5:#v::V l4  065/ 4f4p yt1$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4yt1$$If!vh5:#v::V l4065/ 4f4yt1$$If!vh5:#v::V l4   065/ 4f4p yt1$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4yt1$$If!vh5:#v::V l4   065/ 4f4p yt1$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4yt1DyK yK \http://guidance.nice.org.uk/TA158yX;H,]ą'c$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4yt1DyK yK rhttp://www.sign.ac.uk/guidelines/fulltext/117/index.htmlDyK yK Bhttp://guidance.nice.org.uk/CG69oDyK CentoruDyK  APPENDIX1$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4yt1uDyK  APPENDIX1uDyK  APPENDIX1$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4yt1wDyK  Cellulitis$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4gKyt1uDyK  APPENDIX1$$If!vh5z 555#vz #v#v:V l4065}5G5/ 4f4yt1$$If!vh5555#v#v:V l44 `(065/ 4f4p(yt1$$If!vh5:#v::V l4   065/ 4f4p yt1$$If!vh5:#v::V l4  065/ 4f4p yt1DyK yK Bhttp://guidance.nice.org.uk/CG69uDyK  APPENDIX1$$If!vh5555#v#v:V l4065/ 4f4yt1DyK yK Rhttp://www.nice.org.uk/CG101yX;H,]ą'c$$If!vh5555#v#v:V l4065/ 4f4yt1$$If!vh5555#v#v:V l44065/ / 4f4yt1EDyK yK http://www.brit-thoracic.org.uk/Portals/0/Clinical Information/Pneumonia/Guidelines/CAPGuideline-full.pdf$$If!vh5555#v#v:V l4065/ / 4f4yt1 DyK yK http://cks.nice.org.uk/cough-acute-with-chest-signs-in-childrenyX;H,]ą'cADyK  yK http://cks.nice.org.uk/cough-acute-with-chest-signs-in-childrenyX;H,]ą'c!scenariorecommendation:6DyK  yK ~http://www.cks.nhs.uk/cough_acute_with_chest_signs_in_children-300872$$If!vh5555#v#v:V l4065/ 4f4yt1>$$If!vh5555#v#v#v#v:V l44 `(06555/ 4f4p(yt1$$If!vh5:#v::V l4  065/ 4f4p yt1DyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947404720DyK yK xhttp://www.hpa.org.uk/infections/topics_az/esbl/default.htmDyK yK |http://nww.solihullccg.nhs.uk/index.php/infectionyX;H,]ą'c$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1DyK yK @http://www.bashh.org/guidelines$$If!vh55e55Y#v#ve#v#vY:V l4065555/ 4f4yt1$$If!vh5555#v#v#v#v:V l406555/ / 4f4yt1DyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/11949474047209DyK  yK http://cks.nice.org.uk/urinary-tract-infection-lower-womenyX;H,]ą'c!scenariorecommendation:13$$If!vh5555#v#v#v#v:V l4 06555/ / 4f4yt1DyK yK vhttp://www.nice.org.uk/nicemedia/pdf/CG54quickrefguide.pdfDyK yK xhttp://www.nice.org.uk/nicemedia/live/11010/30524/30524.pdf$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5555#v#v:V l44 `(065/ 4f4p(yt1$$If!vh5:#v::V l4  065/ 4f4p yt1DyK yK `http://cks.nice.org.uk/candida-oralyX;H,]ą'c$$If!vh5555#v#v:V l4065/ 4f4yt1DyK yK xhttp://www.nice.org.uk/nicemedia/pdf/CG017quickrefguide.pdfDyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947419406DyK yK http://cks.nice.org.uk/dyspepsia-unidentified-causeyX;H,]ą'c+DyK  yK http://cks.nice.org.uk/dyspepsia-proven-peptic-ulceryX;H,]ą'c!scenariorecommendation:3$$If!vh5555#v#v:V l4065/ 4f4yt1EDyK yK http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ClostridiumDifficile/Guidelines/yX;H,]ą'c$$If!vh5555#v#v:V l4065/ 4f4yt1$$If!vh55+#v#v+:V l40655/ 4f4yt1$$If!vh55+#v#v+:V l40655/ 4f4yt1$$If!vh5s5s5s5s#vs:V l44  `(0?65/ 4f4p(yt1DyK yK Vhttp://bnfc.org/bnfc/bnfc/current/4057.htm$$If!vh5s5s5s5s#vs:V l4 0?65/ 4f4yt1$$If!vh5s5s5s5s#vs:V l4 0?65/ 4f4yt1T$$If!vh5555#v#v#v#v:V l44 ` 6P(0655"55/ 4f4p(yt,x$$If!vh5;#v;:V l4  6P 065/ 4f4p yt,x$$If!vh55,#v#v,:V l4 6P0655/ 4f4yt,x$$If!vh55k55#v#vk#v#v:V l4V 6P06+55 55/ / / /  4f4yt,x$$If!vh55k55#v#vk#v#v:V l4 6P06+55 55/ / / /  4f4yt,xDyK yK @http://www.bashh.org/guidelinesDyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846$$If!vh55k55#v#vk#v#v:V l4Z 6P0655 55/ / / /  4f4ytDyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846.$$If!vh55k55#v#vk#v#v:V l4Z 6P0655 55/ / / / / 4f4g*Gyt$$If!vh5#v:V l4Z 6@065/ / 4f4yt1DyK yK dhttp://cks.nice.org.uk/trichomoniasisyX;H,]ą'cDyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846$$If!vh5/5*5/5,#v/#v*#v/#v,:V l407655"55/ 4f4yt1DyK yK ~http://cks.nice.org.uk/pelvic-inflammatory-diseaseyX;H,]ą'c$$If!vh5/5*5/5,#v/#v*#v/#v,:V l407655"55/ 4f4gGyt1>$$If!vh5555#v#v#v#v:V l44 `(06555/ 4f4p(yt1$$If!vh5:#v::V l4  065/ 4f4p yt1uDyK  APPENDIX1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh55,#v#v,:V l40655/ 4f4yt1DyK yK http://nww.solihullccg.nhs.uk/index.php/clinical-pathways-solis/cat_view/4-solis/53-clinical-pathways/92-iv-therapy-and-cellulitisyX;H,]ą'cuDyK  APPENDIX1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5S5,#vS#v,:V l40655f4yt1 $$If!vh5555#v#v#v#v:V l4J06+555/ / / / 4f4yt1$$If!vh5555#v#v#v#v:V l4y06+555/ / / / / 4f4yt1uDyK  APPENDIX1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1DyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1DyK yK xhttp://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1DyK  yK bhttp://cks.nice.org.uk/acne-vulgarisyX;H,]ą'c!prescribinginfosub:21$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1uDyK  APPENDIX1$$If!vh5555#v#v#v#v:V l406555/ 4f4yt1$$If!vh5 5J 5J 5 #v #vJ #v :V l4S @(3ff0345 5J 5 af4p(3ffyt1$$If!vh534#v34:V l4  034534af4p yt1$$If!vh534#v34:V l4,034534af4yt1$$If!vh5 5J 5J 5 #v #vJ #v :V l40345 5J 5 af4yt1$$If!vh5 5J 5J 5 #v #vJ #v :V l40345 5J 5 / af4yt1$$If!vh5 5J 5J 5 #v #vJ #v :V l4r0345 5J 5 af4yt1$$If!vh5 55&#v #v5&:V l4034+5 55&af4yt1$$If!vh5 5J 5J 5 #v #vJ #v :V l4034+5 5J 5 af4yt1$$If!vh55#v5:V l  t 0655/ p yt1DyK yK Phttp://www.ppa.org.uk/ppa/edt_intro.htm$$If!vh5 5?(#v #v?(:V l t065 5?(/ yt1 DyK yK http://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListName/Page/1197637041219DyK yK 0http://www.bnf.org/bnf/DyK yK >http://bnfc.org/bnfc/index.htm$$If!vh5 5?(#v #v?(:V l t065 5?(/ yt1$$If!vh5 5?(#v #v?(:V l t065 5?(/ yt1$$If!vh5 5?(#v #v?(:V l t065 5?(/ yt1$$If!vh5 5?(#v #v?(:V l t065 5?(/ yt1$$If!vh5*5@ #v*#v@ :V l  t065*5@ / pyt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5 55@ #v #v#v@ :V l4 t065 55@ / f4yt1$$If!vh5x3#vx3:V l  t 065x3/ p yt1yDyK  Sore_throat$$If!vh5 5l&#v #vl&:V l4 t065 5l&/ f4yt1yDyK  Sore_throat$IfK$L$q!vh5S5#vS#v:V l065S54yt1$IfK$L$q!vh5S5#vS#v:V l065S54yt1$IfK$L$q!vh5S5#vS#v:V l065S54yt1$IfK$L$q!vh5S5#vS#v:V l065S54yt1$IfK$L$q!vh5S5#vS#v:V l065S54yt1$IfK$L$q!vh5S5#vS#v:V l065S54yt1$$If!vh5 5l&#v #vl&:V l4 t065 5l&/ f4yt1$$If!vh5:5:5:5:#v::V l (0j5:4p(yt$$If!vh58#v8:V l  0j584p yt$$If!vh58#v8:V l  0j584p yti$$If!vh58#v8:V l  0j584p yt$$If!vh58#v8:V l   0j584p yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh58#v8:V l  0j584p yt$$If!vh58#v8:V l  0j584p yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh5:5:5:5:#v::V l (0j5:4p(yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh58#v8:V l4  0j584f4p yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh5:5:5:5:#v::V l0j5:4yt$$If!vh5R:#vR::V l  t 05R:/ p yt|CDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA75yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA96yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA106yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA153yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA154yX;H,]ą'cQDyK yK http://publications.nice.org.uk/tenofovir-disoproxil-for-the-treatment-of-chronic-hepatitis-b-ta173yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA200yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA252yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA253yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ yt|CDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ yt|C$$If!vh5|5+#v|#v+:V l t05|5+/ yt|C$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh5:5:5:5:#v::V l (0j5:/ 4p($$If!vh58#v8:V l   0j58/ 4p $$If!vh58#v8:V l   0j58/ 4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l   0j58/ 4p $$If!vh58#v8:V l   0j58/ 4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l   0j58/ 4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l   0j58/ 4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh5:5:5:5:#v::V l40j5:/ 4f4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh58#v8:V l40j58/ 4f4$$If!vh5R:#vR::V l  t 05R:/ p DyK yK vhttp://www.nice.org.uk/nicemedia/pdf/CG87QuickRefGuide.pdf$$If!vh5|55P*#v|#v#vP*:V l t05|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA53yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA60yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/CG66yX;H,]ą'cDyK yK http://publications.nice.org.uk/type-2-diabetes-cg87yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA151yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA203yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA248yX;H,]ą'cYDyK yK http://publications.nice.org.uk/dapagliflozin-in-combination-therapy-for-treating-type-2-diabetes-ta288yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK nhttp://www.npc.nhs.uk/MeReC_Briefings/briefing2003.htmDyK yK |http://www.npc.nhs.uk/MeReC_Briefings/2003/briefing_no_26.pdfDyK yK http://www.prodigy.nhs.uk/guidance/by_clinical_specialty/endocrine_and_metabolic$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V lF  058/ 4p $$If!vh5:5:5:5:#v::V lF05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK Thttp://www.prodigy.nhs.uk/hyperthyroidismDyK yK Rhttp://www.prodigy.nhs.uk/hypothyroidism$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p DyK yK thttp://www.bnf.org/bnf/bnf/current/100138.htmyX;H,]ą'c$$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l4   058/ 4f4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l4  058/ 4f4p $$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p DyK yK \http://www.bnf.org/bnf/bnf/current/100039.htm$$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (06j5:/ 4p($$If!vh58#v8:V l4   06j58/ 4f4p $$If!vh58#v8:V l4   06j58/ 4f4p $$If!vh5:5:5:5:#v::V l06j5:/ 4$$If!vh5:5:5:5:#v::V l06j5:/ 4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l06j5:/ 4$$If!vh58#v8:V l4   06j58/ 4f4p $$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh58#v8:V l4   06j58/ 4f4p $$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh58#v8:V l4  06j58/ 4f4p $$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh58#v8:V l4  06j58/ 4f4p $$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh58#v8:V l4  06j58/ 4f4p $$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh58#v8:V l4  06j58/ 4f4p $$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA087yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5:5:5:5:#v::V l405:/ 4f4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/  $$If!vh5:5:5:5:#v::V l (0R:j5:/ 4p(ytni$$If!vh58#v8:V l4   0R:j58/ 4f4p ytni$$If!vh58#v8:V l4   0R:j58/ 4f4p ytni$$If!vh5:5:5:5:#v::V l0R:j5:/ 4ytni$$If!vh58#v8:V l  0R:j58/ 4p ytni$$If!vh5:5:5:5:#v::V l0R:j5:/ 4ytni$$If!vh5:5:5:5:#v::V l0R:j5:/ 4ytni$$If!vh5:5:5:5:#v::V l0R:j5:/ 4ytni$$If!vh58#v8:V l4   0R:j58/ 4f4p ytni$$If!vh5:5:5:5:#v::V l40R:j5:/ 4f4ytni$$If!vh5:5:5:5:#v::V l40R:j5:/ 4f4ytni$$If!vh5:5:5:5:#v::V l40R:j5:/ 4f4ytni$$If!vh58#v8:V l4  0R:j58/ 4f4p ytni$$If!vh58#v8:V l4  0R:j58/ 4f4p ytni$$If!vh5:5:5:5:#v::V l40R:j5:/ 4f4ytni$$If!vh5:5:5:5:#v::V l40R:j5:/ 4f4ytni$$If!vh58#v8:V l4  0R:j58/ 4f4p ytni$$If!vh5:5:5:5:#v::V l0R:j5:/ 4ytni$$If!vh5:5:5:5:#v::V l0R:j5:/ 4ytni$$If!vh5R:#vR::V l  t 0R:5R:/ p ytni$$If!vh5|55P*#v|#v#vP*:V l t0R:5|55P*/ ytniDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA64yX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/12992/48724/48724.pdfyX;H,]ą'c$$If!vh5|5+#v|#v+:V l t0R:5|5+/ ytni$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA087yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA160yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA204yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA265yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA161yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.prodigy.nhs.uk/osteoporosis_treatment_and_prevention_of_fragility_fractures$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l4  058/ 4f4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l4  058/ 4f4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4ytN$$If!vh58#v8:V l  058/ 4p ytN$$If!vh5:5:5:5:#v::V l05:/ 4 $$If!vh5:5:5:5:#v::V l (05:/ 4p(yt t$$If!vh58#v8:V l4  058/ 4f4p yt t$$If!vh5:5:5:5:#v::V l05:/ 4yt t$$If!vh5:5:5:5:#v::V l05:/ 4yt t$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (0k595:/ 4p($$If!vh58#v8:V l   0k58/ 4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh58#v8:V l4  0k58/ 4f4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh58#v8:V l4  0k58/ 4f4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh58#v8:V l4  0k58/ 4f4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|55P*#v|#v#vP*:V l t05|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://publications.nice.org.uk/induction-of-labour-cg70yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh58#v8:V l4  06j58/ 4f4p $$If!vh5:5:5:5:#v::V l (06j5:/ 4p($$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh58#v8:V l4  06j58/ 4f4p $$If!vh58#v8:V l4  06j58/ 4f4p $$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l4 (06j5:/ 4f4p($$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l4 (06j5:/ 4f4p($$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5:5:5:5:#v::V l4 (06j5:/ 4f4p($$If!vh5:5:5:5:#v::V l406j5:/ 4f4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=CG030yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (0j5:/ 4p($$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh58#v8:V l4  0j58/ 4f4p $$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5:5:5:5:#v::V l0j5:/ 4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|55P*#v|#v#vP*:V l t05|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://webarchive.nationalarchives.gov.uk/20130107105354/http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012086.pdfyX;H,]ą'cDyK FC:\Documents and Settings\emis2000\Local Settings\Temporary Internet Files\Content.IE5\IYFS8QJU\NICE TA 290 - overactive bladder - MirabegronDyK yK http://publications.nice.org.uk/urinary-incontinence-cg171yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh55`'#v#v`':V l 055`'/ 4pytt)$$If!vh55`'#v#v`':V l055`'/ 4ytt)$$If!vh55`'#v#v`':V l055`'/ 4ytt)$$If!vh55`'#v#v`':V l 055`'/ 4p$$If!vh5`9#v`9:V l   05`9/ 4p $$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V lG055`'/ 4ytqH$$If!vh5`9#v`9:V l   05`9/ 4p $$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh5`9#v`9:V l   05`9/ 4p $$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh5$5<'#v$#v<':V l 05$5<'/ 4pytqH$$If!vh5`9#v`9:V l   05`9/ 4p $$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh5`9#v`9:V l   05`9/ 4p $$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh55`'#v#v`':V l055`'/ 4yt$$If!vh5R:#vR::V l  t 05R:/ p DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA23yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA25yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA29yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA34yX;H,]ą'c]DyK yK http://publications.nice.org.uk/guidance-on-the-use-of-paclitaxel-in-the-treatment-of-ovarian-cancer-ta55yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA61yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA70yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA86yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA91yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA99yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA100yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA101yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA107yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA108yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA109yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA116yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA118yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA119yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA121yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA124yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA129yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA135yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA145yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA162yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA169yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA172yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA176yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA178yX;H,]ą'cDyK FyC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsDyK yK \http://guidance.nice.org.uk/TA181yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA183yX;H,]ą'cDyK FyC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsDyK yK \http://guidance.nice.org.uk/TA185yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA189yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA190yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA191yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA192yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA196yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA208yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA209yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA189yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA190yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA191yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA192yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA193yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA208yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA209yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA212yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA214yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA215yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA216yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA218yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA219yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA222yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA227yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA228yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA241yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA242yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA243yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA250yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA251yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA255yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA257yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA258yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA263yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA268yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA269yX;H,]ą'cDyK yK ,http://publications.nice.org.uk/crizotinib-for-previously-treated-non-small-cell-lung-cancer-associated-with-an-anaplastic-lymphoma-ta296yX;H,]ą'cqDyK yK http://publications.nice.org.uk/everolimus-in-combination-with-exemestane-for-treating-advanced-her2-negative-ta295yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA26yX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/11778/43308/43308.pdfyX;H,]ą'cDyK yK \http://guidance.nice.org.uk/CG131yX;H,]ą'c$$If!vh55R(#v#vR(:V l t055R(/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh55R(#v#vR(:V l t055R(/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh555&#v#v#v&:V l t0555&/ ytQ$$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l t065|5h5n*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA32yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA85yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA65yX;H,]ą'cDyK yK Zhttp://guidance.nice.org.uk/TA99yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA106yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA127yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA137yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA171yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA174yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA193yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA200yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA202yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA226yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA228yX;H,]ą'cDyK FyC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsDyK yK \http://guidance.nice.org.uk/TA243yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA254yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ +$$If!vh595 55:#v9#v #v#v::V l (0k595 55:/ 4p($$If!vh58#v8:V l   0k58/ 4p $$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh58#v8:V l   0k58/ 4p $$If!vh58#v8:V l   0k58/ 4p 1$$If!vh595 55:#v9#v #v#v::V l (0k595 55:/ 4p(ytvs$$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh595 55:#v9#v #v#v::V l0k595 55:/ 4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|5q5e*#v|#vq#ve*:V l t05|5q5e*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA112yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA239yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA259yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA272yX;H,]ą'c$$If!vh5|5q5e*#v|#vq#ve*:V l t05|5q5e*/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh595:5:5:#v9#v::V l (0k595:/ 4p($$If!vh58#v8:V l   0k58/ 4p $$If!vh58#v8:V l   0k58/ 4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V lM0k595:/ 4yt"$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh595:5:5:#v9#v::V l (0k595:/ 4p($$If!vh595:5:5:#v9#v::V l (0k595:/ 4p($$If!vh595:5:5:#v9#v::V l (0k595:/ 4p($$If!vh58#v8:V l   0k58/ 4p $$If!vh58#v8:V l   0k58/ 4p $$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh595:5:5:#v9#v::V l0k595:/ 4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l t05|5h5n*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA48yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA142yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA221yX;H,]ą'cDyK yK &http://publications.nice.org.uk/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-ta293yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ +$$If!vh595 55:#v9#v #v#v::V l (0595 55:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh58#v8:V l   058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh58#v8:V l   058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh5R:#vR::V l  t 05R:/ p yt)DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA74yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t05|5+/ yt)$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5R:#vR::V l  t 065R:/ p DyK yK rhttp://www.solihull-pct.nhs.uk/foi/policies_clinical.asp$$If!vh5R:#vR::V l t065R:/ $$If!vh5 5x5x5#v #vx#v:V l (0:5 5x5/ 4p($$If!vh5 5x5x5#v #vx#v:V l40:+5 5x5/ / / / 4f4$$If!vh5 5x5x5#v #vx#v:V l40:+5 5x5/ / / 4f4$$If!vh5 5x5x5#v #vx#v:V l0:5 5x5/ / / 4$$If!vh5 5x5x5#v #vx#v:V l0:5 5x5/ / / 4$$If!vh5 5x5x5#v #vx#v:V l0:5 5x5/ / / 4$$If!vh5 5x5x5#v #vx#v:V l0:5 5x5/ / / 4$$If!vh5 5x5x5#v #vx#v:V l0:5 5x5/ / / 4$$If!vh5 5x5x5#v #vx#v:V l0:5 5x5/ / / / 4$$If!vh5:#v::V l  t 065:/ p ytdDyK yK rhttp://www.solihull-pct.nhs.uk/foi/policies_clinical.asp$$If!vh5& 5,#v& #v,:V l t065& 5,/ ytd$$If!vh5& 5,#v& #v,:V l t065& 5,/ ytdDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.nice.org.uk/guidance/index.jsp?action=byID&o=10978yX;H,]ą'c$$If!vh5& 5,#v& #v,:V l t065& 5,/ ytdDyK yK rhttp://www.solihull-pct.nhs.uk/foi/policies_clinical.aspDyK yK :http://www.drugtariff.co.uk/$$If!vh5& 5,#v& #v,:V l t065& 5,/ ytd$$If!vh555#v#v:V l 6`40654$$If!vh555#v#v:V l 6`40654$$If!vh5t52!#vt#v2!:V l t065$$If!vh5t52!#vt#v2!:V l t065$$If!vh5t52!#vt#v2!:V l t065$$If!vh5t52!#vt#v2!:V l t065$$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh58#v8:V l   058/  / 4p $$If!vh58#v8:V l   058/ / 4p $$If!vh5D5 5 5#vD#v #v:V lT05D5 5/ / / / / 4$$If!vh5D5 5 5#vD#v #v:V lT05D5 5/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595 5 5#v9#v #v #v:V l0595 5 5/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/  / 4p $$If!vh58#v8:V l   058/ / 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V le05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V le05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V le05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh59#v9:V l  t 0659/ p yt{y>DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA117yX;H,]ą'c$$If!vh5U5C+#vU#vC+:V l t065U5C+/ yt{y>$$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4+$$If!vh5D5H5h 5#vD#vH#vh #v:V l (05D5H5h 5/ 4p($$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ +$$If!vh5D5H5h 5#vD#vH#vh #v:V l (05D5H5h 5/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5R:#vR::V l  t 065R:/ p YDyK yK http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2025040&ssTargetNodeId=221$$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5T#v:#vT:V l (05:5T/ 4p(yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh59#v9:V l  t 0659/ p DyK yK http://www.npc.co.uk/MeReC_Extra/2008/pdfs/MeReC_Extra_No30.pdf$$If!vh5U55)#vU#v#v):V l4R t065U55)/ f4DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/12131/43329/43329.pdfyX;H,]ą'c$$If!vh5U5C+#vU#vC+:V l t065U5C+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5U5C+#vU#vC+:V l t065U5C+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htm$$If!vh5U5C+#vU#vC+:V l t065U5C+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5T#v:#vT:V l (05:5T/ 4p(yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4yt3p$$If!vh59#v9:V l  t 0659/ p $$If!vh5V55)#vV#v#v):V l t065V55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5V5B+#vV#vB+:V l t065V5B+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5V5B+#vV#vB+:V l t065V5B+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5V5B+#vV#vB+:V l t065V5B+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh59#v9:V l  t 0659/ p $$If!vh5V55)#vV#v#v):V l t065V55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA35yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA130yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA143yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA186yX;H,]ą'cDyK yK http://publications.nice.org.uk/adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-ta195yX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13110/50424/50424.pdfyX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA220yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA233yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA225yX;H,]ą'cDyK yK $http://publications.nice.org.uk/abatacept-for-treating-rheumatoid-arthritis-after-the-failure-of-conventional-disease-modifying-ta280yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA238yX;H,]ą'cDyK yK ,http://publications.nice.org.uk/tocilizumab-for-the-treatment-of-rheumatoid-arthritis-rapid-review-of-technology-appraisal-guidance-ta247yX;H,]ą'c$$If!vh5V5B+#vV#vB+:V l t065V5B+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5V5B+#vV#vB+:V l t065V5B+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5V5B+#vV#vB+:V l t065V5B+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5T#v:#vT:V l (05:5T/ 4p($$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4$$If!vh5:5:5:5T#v:#vT:V l05:5T/ 4$$If!vh59#v9:V l  t 0659/ p $$If!vh5X55)#vX#v#v):V l t065X55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA164yX;H,]ą'c$$If!vh5X5@+#vX#v@+:V l t065X5@+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5X5@+#vX#v@+:V l t065X5@+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5X5@+#vX#v@+:V l t065X5@+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh59#v9:V l  t 0659/ p $$If!vh5X55)#vX#v#v):V l t065X55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5X5@+#vX#v@+:V l t065X5@+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5X5@+#vX#v@+:V l t065X5@+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htm$$If!vh5X5@+#vX#v@+:V l t065X5@+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh59#v9:V l  t 0659/ p yt$$If!vh5U55)#vU#v#v):V l t065U55)/ ytDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5U5C+#vU#vC+:V l t065U5C+/ ytDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5U5C+#vU#vC+:V l t065U5C+/ ytDyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5U5C+#vU#vC+:V l t065U5C+/ yt$$If!vh5:5:5:5#v:#v:V l (05:5/ 4p(yt3p$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt3p$$If!vh5:5:5:5#v:#v:V l05:5/ 4yt3p$$If!vh59#v9:V l  t 0659/ p $$If!vh5U55)#vU#v#v):V l t065U55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11926yX;H,]ą'c$$If!vh5U5C+#vU#vC+:V l t065U5C+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5U5C+#vU#vC+:V l t065U5C+/ DyK yK :http://www.drugtariff.co.uk/$$If!vh5U5C+#vU#vC+:V l t065U5C+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh59#v9:V l  t 0659/ p $$If!vh5W55)#vW#v#v):V l t065W55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5W5P+#vW#vP+:V l t065W5P+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5W5P+#vW#vP+:V l t065W5P+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5W5P+#vW#vP+:V l t065W5P+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA229yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA271yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh59#v9:V l  t 0659/ p $$If!vh5Y55)#vY#v#v):V l t065Y55)/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5Y5N+#vY#vN+:V l t065Y5N+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh59#v9:V l  t 0659/ p $$If!vh5X55)#vX#v#v):V l t065X55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5X5O+#vX#vO+:V l t065X5O+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5X5O+#vX#vO+:V l t065X5O+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5X5O+#vX#vO+:V l t065X5O+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh59#v9:V l  t 059/ p $$If!vh5[55)#v[#v#v):V l t05[55)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA68yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA155yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA274yX;H,]ą'cDyK yK http://publications.nice.org.uk/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-ta283yX;H,]ą'c5DyK yK http://publications.nice.org.uk/ocriplasmin-for-treating-vitreomacular-traction-ta297yX;H,]ą'c}DyK yK http://publications.nice.org.uk/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration-ta294yX;H,]ą'c$$If!vh5[5L+#v[#vL+:V l t05[5L+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh58#v8:V l  058/ 4p $$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p yt t$$If!vh5:5:5:5:#v::V l05:/ 4p(yt t$$If!vh58#v8:V l  058/ 4p $$If!vh58#v8:V l058/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4 $$If!vh5:5:5:5:#v::V l (05:/ 4p(ytV$$If!vh58#v8:V l  058/ 4p ytV$$If!vh5:5:5:5:#v::V l05:/ 4ytV$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK thttp://www.mhra.gov.uk/NewsCentre/Pressreleases/CON044014$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (0595:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ / 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh5R:#vR::V l  t 06>5R:/ p $$If!vh5|5,#v|#v,:V l t065|5,/ ytbCDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t06>5|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t06>5|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t06>5|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l^ t065R:/ $$If!vh595:5:5:#v9#v::V l (0595:/ 4p($$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh5R:#vR::V l  t 06>5R:/ p $$If!vh5|5,#v|#v,:V l t065|5,/ ytbCDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t06>5|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t06>5|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t06>5|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:#v::V l  t 0:65:/ p $$If!vh5|5L,#v|#vL,:V l t0:65|5L,/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA81yX;H,]ą'c$$If!vh5|5L,#v|#vL,:V l t0:65|5L,/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5L,#v|#vL,:V l t0:65|5L,/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5L,#v|#vL,:V l t0:65|5L,/ '$$If!vh55 5:5:#v#v #v::V l (0j55 5:/ 4p(ytbC$$If!vh58#v8:V l   0j58/ 4p $$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh58#v8:V l   0j58/ 4p $$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh58#v8:V l   0j58/ 4p $$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh58#v8:V l  0j58/ 4p $$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh58#v8:V l  0j58/ 4p $$If!vh55 5:5:#v#v #v::V l0j55 5:/ 4ytbC$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5505P*#v#v0#vP*:V l t05505P*/ ytbCDyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK jhttp://www.nice.nhs.uk/page.aspx?o=TA081yX;H,]ą'c$$If!vh55+#v#v+:V l t055+/ ytbCDyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/DyK yK http://www.cks.library.nhs.uk/eczema_atopic/in_depth/management_issues$$If!vh55+#v#v+:V l t055+/ ytbC$$If!vh5:5:5:5:#v::V l (065:/ 4p($$If!vh5:5:5:5:#v::V l065:/ 4DyK yK nhttp://www.nice.org.uk/nicemedia/pdf/TA177Guidance.pdf$$If!vh5:5:5:5:#v::V l065:/ 4$$If!vh5:5:5:5:#v::V l065:/ 4$$If!vh5:5:5:5:#v::V l065:/ 4$$If!vh5:5:5:5:#v::V l065:/ 4$$If!vh5:5:5:5:#v::V l065:/ 4$$If!vh5:5:5:5:#v::V l065:/ 4$$If!vh5:5:5:5:#v::V l065:/ / 4$$If!vh5:5:5:5:#v::V l065:/  / 4yt3p$$If!vh58#v8:V l  0658/ 4p yt3p$$If!vh55 5:5:#v#v #v::V l (0655 5:4p(DyK yK http://guidance.nice.org.uk/TA180/QuickRefGuide/pdf/EnglishyX;H,]ą'c$$If!vh55 5:5:#v#v #v::V l0655 5:4$$If!vh55 5:5:#v#v #v::V l0655 5:4$$If!vh55 5:5:#v#v #v::V l0655 5:4$$If!vh55 5:5:#v#v #v::V l0655 5:4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK Zhttp://guidance.nice.org.uk/TA82yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA134yX;H,]ą'cDyK yK \http://guidance.nice.org.uk/TA146yX;H,]ą'cDyK yK nhttp://www.nice.org.uk/nicemedia/pdf/TA177Guidance.pdfDyK yK http://www.nice.org.uk/nicemedia/live/12235/45464/45464.pdfyX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh5:5:5:5:#v::V li05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p DyK yK Zhttp://www.bnf.org/bnf/bnf/current/19966.htm$$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/ DyK yK http://www.cks.library.nhs.uk/Acne_vulgaris/In_depth/Background_information$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l (05:4p($$If!vh58#v8:V l  0584p $$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh58#v8:V l  0584p $$If!vh5:5:5:5:#v::V l (05:4p(ytl$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:4$$If!vh58#v8:V l  0584p $$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l (05:4p($$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5:5:5:5:#v::V l05:4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh58#v8:V l  058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l (05:/ 4p($$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5:5:5:5:#v::V l05:/ 4$$If!vh5R:#vR::V l  t 065R:/ p yt3$$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ yt3DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidanceDyK yK \http://guidance.nice.org.uk/TA260yX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ yt3DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ yt3DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/DyK yK fhttp://www.solihull.nhs.uk/getmedia/56316432-acb7-4a5c-8a2c-4f2742c70970/Procedures-of-Low-Clinical-Value-Policy-v1.2-Solihull-GP-version11052011(Matt-Formatted).aspxyX;H,]ą'c$$If!vh5|5+#v|#v+:V l t065|5+/ yt3$$If!vh595:5:5:#v9#v::V l (0595:4p($$If!vh595:5:5:#v9#v::V l0595:4$$If!vh595:5:5:#v9#v::V l0595:4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l (0595:4p($$If!vh595:5:5:#v9#v::V l0595:4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l (0595:4p($$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l (0595:4p($$If!vh595:5:5:#v9#v::V l0595:4$$If!vh595:5:5:#v9#v::V l0595:4$$If!vh595:5:5:#v9#v::V l0595:4DyK yK http://www.bad.org.uk/Portals/_Bad/Specials/BAD Specials Booklet.pdfyX;H,]ą'c$$If!vh595:5:5:#v9#v::V l (0595:/ 4p(yt{y>$$If!vh58#v8:V l   058/ 4p yt{y>$$If!vh595:5:5:#v9#v::V l0595:/ 4yt{y>$$If!vh58#v8:V l   058/ 4p yt{y>$$If!vh595:5:5:#v9#v::V l0595:/ 4yt{y>$$If!vh595:5:5:#v9#v::V l0595:/ 4yt{y>$$If!vh595:5:5:#v9#v::V l0595:/ 4yt{y>$$If!vh5R:#vR::V l  t 065R:/ p yt{y>DyK yK \http://guidance.nice.org.uk/TA156yX;H,]ą'c$$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ yt{y>DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ yt{y>DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ yt{y>DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ yt{y>$$If!vh595:5:5:#v9#v::V l (0595:/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh58#v8:V l   058/ 4p $$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh595:5:5:#v9#v::V l0595:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ +$$If!vh595 55:#v9#v #v#v::V l (0595 55:/ 4p($$If!vh58#v8:V l  058/ 4p $$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh595 55:#v9#v #v#v::V l0595 55:/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|#v|:V l t06+5|/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh58#v8:V l   058/ 4p $$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5|55P*#v|#v#vP*:V l t065|55P*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t065|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ +$$If!vh595 55:#v9#v #v#v::V l (08595 55:/ 4p($$If!vh58#v8:V l   0858/ 4p $$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh58#v8:V l   0858/ 4p $$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh58#v8:V l  0858/ 4p $$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l085D5 5/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh58#v8:V l4  058/ 4f4p $$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh58#v8:V l4  058/ 4f4p $$If!vh5D5 5 5#vD#v #v:V l405D5 5/ 4f4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|#v|:V l t0+5|/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5D5 5 5#vD#v #v:V l (0k5D5 5/ 4p($$If!vh58#v8:V l   0k58/ 4p $$If!vh5D5 5 5#vD#v #v:V l0k5D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l0k5D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l0k5D5 5/ 4$$If!vh58#v8:V l   0k58/ 4p $$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|#v|:V l t0+5|/ $$If!vh5|55I)#v|#v#vI):V l t05|55I)/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ 1$$If!vh5D5H5h 5#vD#vH#vh #v:V l (05D5H5h 5/ 4p(ytd$$If!vh5:#v::V l   05:/ 4p ytd$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4ytd$$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4ytd$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|#v|:V l t0+5|/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ +$$If!vh5D5H5h 5#vD#vH#vh #v:V l (05D5H5h 5/ 4p($$If!vh5D5H5h 5#vD#vH#vh #v:V l05D5H5h 5/ 4$$If!vh5R:#vR::V l  t 065R:/ p $$If!vh5R:#vR::V l t065R:/ $$If!vh5D5 5 5#vD#v #v:V l (05D5 5/ 4p($$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5D5 5 5#vD#v #v:V l05D5 5/ 4$$If!vh5R:#vR::V l  t 05R:/ p $$If!vh5|5h5n*#v|#vh#vn*:V l t05|5h5n*/ DyK yK ^http://www.nice.nhs.uk/page.aspx?o=ourguidance$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK |http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmDyK yK 6http://www.prodigy.nhs.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ DyK yK bhttp://www.ppa.org.uk/edt/August_2007/mindex.htmDyK yK :http://www.drugtariff.co.uk/$$If!vh5|5+#v|#v+:V l t05|5+/ $$If!vh55##v#v#:V l  t̙̙0655#p̙̙$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V la t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#$$If!vh55##v#v#:V l t0655#^J hH2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ NormalCJ_HaJmH sH tH |`| 5 Heading 1*$ 7u@&^`u%5;CJ$OJQJ\aJ$mH sH tHt`t 6 Heading 2&$ 8u@&^`u"5CJ OJQJ\aJ mH sH tHl`l 7 Heading 3&$ u@&^`u5OJQJ\mH sH tHR`R 8 Heading 4$@&5CJ OJQJ\mHsHtHT`T 9 Heading 5$$@&a$5OJQJ\mH sH tHN`N : Heading 6$@&5OJQJ\mH sH tHl`l ; Heading 7&$ H@&^`5OJQJ\mH sH tH^`^ < Heading 8$0@&^`05OJQJ\mHsHtHt `t = Heading 9+ 0p0<@&^0`CJOJQJaJmH sH tHDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List 83@8 List 3OJQJmH sH Y  > Document Map2 & F he-DM ^e`"5CJOJQJ\aJmHsHtHR>`R ?Title$a$%5>*CJOJQJ\aJmH sH tH6U`!6 Hyperlink >*B*phZC 2Z @Body Text IndentB*OJQJmH phsH tHL"@L Caption"5CJOJQJ\^JaJmH sH 82@R8 List 2OJQJmH sH D`bD +Header  9r OJQJmHsHXJ`rX ASubtitle$a$%5>*CJOJQJ\aJmH sH tHb/@b List h^h`"5CJOJQJ\^JaJmH sH ROR listing ^CJOJQJaJmH sH ^^@^ Normal (Web)dPxd\$OJPJQJ^JmH sH &O& drugref*W`* `Strong5\.). Page NumberD `D *Footer  9r OJQJmHsHNg`N HTML TypewriterCJOJ PJQJ ^J aJFV F FollowedHyperlink >*B* phHB`H B Body Text!$a$OJQJmHsHtHP "P C Balloon Text"CJOJ QJ aJmHsHtHB' 1B Comment ReferenceCJaJP`BP D Comment Text$CJOJQJaJmH sH tH@j AB@ EComment Subject%5\HP`bH , Body Text 2&7$8$CJaJmHsHFoqF CMcnultyB*CJOJQJ^JaJphVQ`V F Body Text 3(#5B*OJQJ\mH phsH tHD DKH0Revision)CJ_HaJmH sH tH B/B + Footer CharCJOJQJaJtH B/B DH Header CharCJOJQJaJtH D/D &DHBody Text 2 Char CJaJtH j@j DH List Paragraph-d^m$CJOJPJQJaJmH sH (o( DHcref2phjj DH Table Grid7:V/0/** caw20dPXOX YZ! Instructions1#6B*OJQJ]aJmH phsH > "> 3. Footnote Text2CJaJH/1H 2.Footnote Text Char mH sH tH @& A@ .Footnote ReferenceH*Z/QZ PHeading 1 Char%5;CJ$OJQJ\^JaJ$mH sH V/aV PHeading 2 Char"5CJ OJQJ\^JaJ mH sH V/qV PHeading 3 Char"5CJOJQJ\^JaJmH sH N/N PHeading 4 Char5CJ OJQJ\^JaJV/V PHeading 5 Char"5CJOJQJ\^JaJmH sH R/R PHeading 6 Char5CJOJQJ\aJmH sH V/V PHeading 7 Char"5CJOJQJ\^JaJmH sH N/N PHeading 8 Char5CJOJQJ\^JaJP/P PHeading 9 CharCJOJQJ^JaJmH sH n/n PDocument Map Char35CJOJQJ\aJfHmHq sHtHR/R P Title Char%5>*CJOJQJ\^JaJmH sH h/h PBody Text Indent Char%B*CJOJQJ^JaJmH phsH X/X P Subtitle Char%5>*CJOJQJ\^JaJmH sH H/!H !PBody Text CharCJOJQJ^JaJN/1N "PBalloon Text CharCJOJ QJ ^J aJN/AN $PComment Text CharOJQJ^JmH sH Z/QZ %PComment Subject Char5OJQJ\^JmH sH d/ad (PBody Text 3 Char+5B*CJOJQJ\^JaJmH phsH .X`q. [@Emphasis6]DoD Xnormal_0020table__charZoZ -Default I7$8$H$%B*CJPJ_HaJmH phsH tH PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] x] &,JN(     x] &,JN ( \ YY  f#(*3.04O7.::;<j>?A\BDCFiG"JBKMO[R:UWD[aABDFKMPQ(TU{WKYZ]^`bdeguijogqrx{~̓#UoD9«Cx}0`?D}j3lNZViF"i#p66[b\B 5  pj_X#'*5-.0Q35=:?ZBDGdJLkMQ'T`WZ_Za9f+gbjm?rtxÈrvJGڜޠlݦէ@3osz]>N)=rV/h    "B~;!N#$=&M'*+,/./41;23456R89';u<=@MABXEG+I KeMNUV[_a?eegdisjkmq*tvuxz{|~K=ׇ.Šv1vJɡʥ"Ntp޹_%RF@zb<S?^tiMm+   d(c,. !F#$')v*,@./0|01!"$(29GNPUZ_cehkoruy}!%'*26=GLMOQYgmps   $)*-3:?BFNPQSUY\`bcegtz} !%-27FHLP\^agtuvy $%&(37:<=>?ABCDEFHLPTVY\]`cehkortwy|~!(23457;EPU`bcefgnuy #*.BILQ]hjmu   ! " % 4 B G O U Y ] c h r x ~    " ) 0 2 6 C Q W b g l v | } ~  ! $ + 4 9 = B I Q R T X b g j t |     8 E J S \ ` m | iln>] H?7AAjBBDDEEFFKGgHI6KKULLRMMNOOOP4QQiR/TTGUPVVWWX"XC[[\]^bb c>cVccc-eeefg(mDmXmnoo$ppppqqsyssuuZvvWwwwwxyzz{DG1mʅ;qP݇Aۈވ=GzьbBő/#jʔ Un?Cؗ0Qgϙ9˚h{Oq)?Xآ/ϤRO:Sb3fܪvoѱ %hIJ<^x !ZkӴ!;U =JgŻHa2Nn|_tA'L\u4c&H[:?Yqda*QkR*U6V(`>^(gx+CB<kzAIduIa:\P`8< AS/EMg;@   : 0$#?P0Nq   !!!!{"#M&&&&''N'g'~''m((!)#)))---- .(.5.G.i../03335556'646H6a6a8'9B;<3<8=Y=l===>> AAAAAAB@BB8EEEFFFFGRLsLLLMMBMaMfM~MHOeQSSST,TfTTTUVWWWWX$XBXTXmXXXXX YAYPYmYYY.ZmZZ[]]]^^;^O^h^^^_`:`E`p`v`"bbbbccNddqeeeee foffffff7gVgggghxijj.kmo0o;ooooop4pTplpprssszz{{{{|=|[|o|||||||}KTw~DžׅSc|ӈ_ȉʉ<vԐ!UvC(0Uޙ 4Qj*97Xt3AlDgNi|ȥ :^ʦަ3Tp۬ J\s$±ܱq˲8Rٳ(D]q6J| Ohz_!Yrfc-huF 6?%8lY02  v L?ipNW!#C$F%%'F'j'(),B..M/025G5U58j8889;;=d>??BBDDDwFXGFJOJ|JJ-L.MM7OPR'T-U WSXxYZ\Y]_Ha!bdefijymRpqq~tu'vvx={|Y}:~~~ƒ-aU>Ї6 XAMђkh-<Tq֖ 1-hLm}Ξ 7ȟڟAUݠO{&:Ohvag)XѮ Ng ]/Qȶ;L^ҷ"M8Sf{ھ2AYnPiO1 O{ApA&Cq-aAaq@ $_Df#Ixfi:gwE}3]Mx7"oFv)i) u_*Ey)c{7n-Det2Xg &3?z "L')n*+-+L+++++++ ,,,C,T,e,w,,,,,,,-06,778$8T8h88888Q9q9999#:]:}:::&;p=k>>>>.?????@(@s@@>AMAAAAAA BB$BLB[BkBBBB CC-CECEHJKAKKKKKKLqLLLLM'MxMMMMM NN5NDNnN}NNNVOO(QXQUUUGVVVpVVVVVVX3\]_`3aacccadeQeeeefffg'gggggh,h;h^hbiiii j3jjk kkkkkl#l5lFllllm'mtmmmmmooo2p\pppqYqqqqqrrrrst*tttttttvwxyPyRysyyyyzziz{{{0|t||||}E}f}}}}Jه-km‰C\sFӌ ;Jƍ֍(xuӏُ C\7wԚAbyJ, pȣ[ϥ7ͦ]0^`ªҫ:[n֬CUpӭ 4MMٯ;\`!BshFմ0zȵ{}ͷoռ$[xٿ+N|*<Y%Im ]\E0&Q+EpDr/"Er%T2 .39>CJOr/k=z$eg1J`O.b{fCdu$9\Vn/xu4=Gw0+:IdG 4s)l&$Tm:4kCcBjSlKv C|-uB Z{ : ] u     * 9 o    b w     " c s        :Mfh$^x.O|' Ly OQkCcQ@)?_mz2 g l        >!!i""""""#1#H##7$$ %G%i%%%%%%%%&'&4&B&^&m&&V'c't'''''''(,(;(K(Z(i((((()C********+,,A--------..{///00)0q0000000 1,1E1&P_l(gt8q #1R$2JVC1i5Y #%&')*+,-./01345678:;<=>?@ABCDEFHIJKLMOQRSTVWXY[\]^`abdfgijlmnpqstvwxz{|~      "#$&()+,-./01345789:;<>?@ABCDEFHIJKNPRSTUVWXZ[\]^_`abcdefhijklnoqrtuvwxyz{|}~   !"#%&'(+,./012456789;<=>@ACDEGHIJKLMORTVWXZ[]^_adfhijklmnopqrsuvwxy{|~     "#$&'()*+,./01345689:;<=>?@ABCDEGIJKMNOQRSTUVWXYZ[]_`bcdefhijklmnopqrswxz{|}~     !"#')*+,-./01245689;@GIJKMNOQRSUWXZ[^_abdfgijlmnpqsuvxz{}      "#$%&')*+,-./01689:<=>?@ABCDFGHIJKLMNOQRSTVWXYZ[\]^_adhijklmopqrstvwxz{|}~     !"$%&'()+,-/0123456789:;<=>?@ACDEFGHJKMNOPRSTUVWXYZ[\^_`abcdefgiklnopqrstvwxyz{|}~                        # $ & ' ( ) * + , - . / 0 1 2 3 5 6 7 8 9 : ; < = > ? @ A C D E F H I J K L M N P Q R S T V W X Z [ \ ^ _ ` a b d e f g i j k l m n o p q s t u v w y z { | }                         ! # $ % & ' ( * + , - . / 1 3 4 5 7 8 9 : ; < = > ? @ A B D E F G H I J K L M N O P R S T U V X Y Z [ \ ] ^ _ ` a c d e f h i j k m n o p q r s t u w x y z {                           " # % & ' ( ) * , - . / 0 1 2 3 5 6 7 8 : ; < > ? @ A C D E F G H J K L M N O P S U V W Y Z [ \ ] ^ _ ` a c d e f h i k l m n o p q r s u v w x y z { } ~                        ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 9 : ; < = > ? @ A B C D F G H I K L M N O P Q R T U V W X Y Z [ ] ^ _ a b c d e f g h i j k l n o p z { } ~   9P!vaaaq%r*rr tt4tuuyłǂ9<Ńك3QUDŽ˄:< ,anoɊflp-bopBƑ?EIs{ e}ϓJfjϔ$%QR V\`():egܠޠ'Yn֡ءLPѢ٢/QTã֣ EFwëǫHPd%QRoϭ, Y_c߳=JKwxݹLZ\Խ׽$*.X`tľ>Bȿۿ*78de Vx{ HK48:;|(+x~BUqBbfP[5GTU!_mocimQtxR`cik#MUi3&'Sac%'V!P+!jpto,ano \ ^      ! P      : ` c       Y s w    d }    ERS HVX'\^%(u{ GHU.\^%)S[o'@B #yX)1Xz$$$$%G%I%w%%%%&&2&:&O&&&&''#'r'''''(6(C(D(p(q(1,,7-;-y-----.N.T.X....../O/i/k//0t0000002'35373m333333#4+4A4444555e5s5w5555)66676c6d67X7f7h7777 8&8*8T8\8r888909@9E99999:#:X:e:f:::">>>>w??%@@@"D`DnDpDDDDoEEEFyjyky{{{{#|]|_||||}}}E}M}a}}}}}~ ~5~6~uÄ46e/7I‡+W}̋΋jptHǐՐא6tƑӑԑ ;CW^W<JLQS =EY٥$bps RVװ߰bs³гӳ-/^"cY=?n&ESUٻܻ)/3]e (,.Fim#&Ncf4ORi  0BEiz}+-Cfj 58^tw03G[`9@Calo .=@[cf!8:Tf  ghC^x{ `Hcn;U<Zeq%@KT'+\_^v #RZ`e+\^ ;LO          H   ? GiQ|7_cko A\$ x  }""""#0#&1'6'8'd'j'l''''',(,---Y-}----N/z//////'0T01(2.212d2~2222444444495`5778999_:::l<<<#===#A>AIAVAAAA2BRB7DDDEEEEF.FJJJDN_NjNNNNQ&R9RaSSSST;TVW@ȼ<JL@Bq >,*78de*8<={A@~mFYDRT;= Wxc')WCEs<>lB}!O!PNP 80;=l(UW/1`@(acCEf'%Z\?Bq9;j79h@<>m)+ZI|~hjo q     y {    A m o     f h     a c    &`bPS=?nDQR~ri)LN| GIxNP "Q1hj M O p    !!!P!!!"$"("R"Z"""""""j&&&&&"'$'S''''"($(S((()) )5)=)82v2222223u3w3333o444444)515#6O6P69*:8:::h::@@@\BBBRHHHHHI%IkIIJJJwUUUUU"Vr^^/_aaabTbbbdbbbbc4c7ccccccdRd_d]eeeeeff.f6f\ffffffUkkkkk ll>llllmm4mjmlmmnnn-o/o^oooooop}ppqqqq=r?rrssisossssss3t@tAtmtntuuvv4v\v_vvvvvvwLwYwZwwwlyyyy zzz=zEzkzzz~4quFNt%cqsق܂)/3]ed 5=cۈ܈ߑbd6CDpqߘ%37$12^_/su"WY_aĤQ"*PȮɮWejWdes÷DL`ָ(56bc+9=*78deAGKu}&X\ IVW7u;AEow)L)+oJM:GHtu0[^ gu?}>|)7;(56bc\-5[k $qw{KLNt#R28<fn  9GK8 E F r s 2 p ~       1 o | }       ) / 3 ] e      JX\ IVW GUY GTUDCK$J(XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Ob$C6*ʊzEk$ f:\R$RAfy`c^lm@DR$w OKlN "$zLIHig@H 0(   'B (  V  # "? V  # "?  V  # "? V  # "?  V   # "?  V   # "?  V   # "?  V   #  "? V   #  "? \B  S D"?\B  S D"? \B  S D"?\B  S D"?\B  S D"?\B @ S D"? \B  S D"? V  # "? V  # "? \B @ S D"?\B  S D"?\B @ S D"?\B  S D"?V  # "?    c dA. image001S`TS`T#" `?> $ A:?B. "NHS Pharmacy_Landscape_greenPicture 0NHS Pharmacy_Landscape_green.jpghS`ThS`T#" `? & c A8. Aperture Device + StraplineR`TR`T#" `? ' C FA. S`TS`T#" `?B S  ?PPPPPPPPPPPPPPPPPPPPPPP('%,@&kg&@4.X<@$-t@81tPDP`tL84tt % 4t tt%tt--t$ t !\4t\ t  tP !t t@ tDt  t+-+ttD%1t  u t+i+t  !]4tkText1 _Toc13662606 Section01 _Hlt182706287 _Hlt182706301 _Hlt182706302 _Hlt182706309 _Hlt182706310 _Hlt182706316 _Hlt182706317 _Hlt182706322 _Hlt182706323 _Toc13662607 _Toc13662608 _Hlt175720245 _Hlt175720246 _Toc13662609 _Toc13662611 _Hlt162252703 _Hlt162252704 _Toc13662612 _Toc13662613 _Toc13662614 _Toc13662615 _Hlt182707247 _Hlt182707248 _Hlt140981983 _Hlt140981984 _Hlt140982085 _Hlt140982121 _Hlt182707440 _Hlt182707322 _Hlt140982296 _Hlt182709008 _Hlt182709009 _Hlt164144721 _Hlt164144722 _Hlt182709019 _Hlt182709020 _Hlt140982584 _Hlt140982585 _Hlt140982610 _Hlt140982763 _Hlt182710775 _Hlt182710776 _Hlt182710780 _Hlt182710781 _Hlt140998309 _Hlt140998310 _Hlt351561840 _Hlt351561841 _Hlt351570054 _Hlt351570049 _Hlt215386289 _Hlt215386276 _Toc13662616 _Hlt186862142 _Hlt186862143 _Hlt186862304 _Hlt186862305 _Hlt186862314 _Hlt186862386 _Hlt186862319 _Hlt186862612 _Hlt186862613 _Hlt186862577 _Hlt186862578 _Hlt186863789 _Hlt186863790 _Hlt164151470 _Hlt164151471 _Hlt163468862 _Hlt163468863 _Hlt141000036 _Hlt164152298 _Hlt164152299 _Hlt372815974 _Hlt274806842 _Hlt274806843 _Hlt274665299 _Hlt351474872 _Hlt274726956 _Hlt274726957 _Hlt275425421 _Hlt275425422 _Hlt351474879 _Hlt274806850 _Hlt351474907 _Hlt351469960 _Hlt274806869 _Hlt351474918 _Hlt372814339 _Hlt372814340 _Hlt274806875 _Hlt351474991 _Hlt351474998 _Hlt274806911 _Hlt351475142 _Hlt351475160 _Hlt351475298 _Hlt351470135 _Hlt274806890 _Hlt351475451 _Hlt274727086 _Hlt351475456 _Hlt349655044 _Hlt274806905 _Hlt351475461 _Hlt351475469 _Hlt274806918 _Hlt274806924 _Hlt351475477 _Hlt274806930 _Hlt351470247 _Hlt351475483 _Hlt351470214 _Hlt351475489 _Hlt274806940 _Hlt351475494 _Hlt274806959 _Hlt274806974 _Hlt351475501 _Hlt274807056 _Hlt351475509 _Hlt351475602 _Hlt274807046 _Hlt351475610 _Hlt274806991 _Hlt274807002 _Hlt351475618 _Hlt351475623 _Hlt274807008 _Hlt274807015 _Hlt351475629 _Hlt182280555 _Hlt351475637 _Hlt370207257 _Hlt351475642 _Hlt351473750 _Hlt351475649 _Hlt351475655 _Hlt351475662 _Hlt351475751 _Hlt351475763 _Hlt351475769 _Hlt351475777 _Hlt351475837 _Hlt351475910 _Hlt351475848 _Hlt351476000 _Hlt351476013 _Hlt351476023 _Hlt351476028 _Hlt351476035 _Hlt351476041 _Hlt351469974 _Hlt372814360 _Hlt351476047 _Hlt351474260 _Hlt351476052 _Hlt351474310 _Hlt351476058 _Hlt351476065 _Hlt351474500 _Hlt351476070 _Hlt351476077 _Hlt351476082 _Hlt351476091 _Hlt351476099 _Hlt355692753 _Hlt355692754 _Hlt351476108 _Hlt351476116 Meningitis _Hlt352061363 _Hlt352061364hypersensitivity%Emergency_treatment_for_CAP_in_adultsURTI Common_cold _Hlt372816198 _Hlt372816199 Sore_throat InfluenzaAcute_sore_throat _Hlt275158673 _Hlt275158674 _Hlt352062106 _Hlt352062107 _Hlt275158684 _Hlt275158685 _Hlt352062081 _Hlt182372660 _Hlt182372661 _Hlt352062276 _Hlt352062277 _Hlt182372731 _Hlt352067850 _Hlt275158712 _Hlt275158713 _Hlt352067129 _Hlt352062490 _Hlt275158728 _Hlt352062508 _Hlt274658711 _Hlt274658712AOMAcute_Otitis_Externa _Hlt352062840 _Hlt352062841 SinusitisLRTIAcute_bronchitis _Hlt352062961Acute_exac_COPD _Hlt352063361 _Hlt352063362CAP _Hlt275160206 _Hlt275160207 _Hlt352063544 _Hlt352063545UTI Uncomp_UTI _Hlt352063869 _Hlt352063870 _Hlt182035947 _Hlt352063766 _Hlt352063767Acute_prostatitisUTI_preg_and_men UTI_children _Hlt182372357 _Hlt182372358 _Hlt182036574 _Hlt182036575 _Hlt352065323 _Hlt352065324 _Hlt360532161 _Hlt352065311 _Hlt352065312Acute_pyeloneph Recurr_UTIGI _Hlt372816074 _Hlt372816075 _Hlt365973427H_pylori _Hlt182370127 _Hlt182370128 _Hlt182280827 _Hlt182370029 _Hlt182370030 _Hlt275421945 _Hlt275421946#Clinical_Prediction_Rules_for_GABHSGastroenteritisInfectious_diarrhoea Threadworm _Hlt182282210 _Hlt182282211 _Hlt275422275 _Hlt275422276 _Hlt347223937 _Hlt347223938 _Hlt352065866 _Hlt352065867 Genital_tract Chlamydia _Hlt372815064VC _Hlt275422393 _Hlt275422394 _Hlt275422302 _Hlt275422303 _Hlt271905891 _Hlt271905892 _Hlt275422352 _Hlt275422353BV _Hlt275422385 _Hlt275422386TrichomoniasisPIDSkin_soft_tissueImpetigoEczema CellulitisPaediatric_dosesMRSA_MRSA Leg_Ulcers _Hlt350251221 _Hlt350251222 _Hlt352066677 _Hlt352066678BitesConjunctivitisScabies Fungal_nail _Hlt275423108 _Hlt275423109 _Hlt352066901 Fungal_skinAcne _Hlt355690199 _Hlt355690200 _Hlt372817923Chickenpox_and_shinglesDENTAL_GoBack _Hlt275423402 _Hlt275423403 _Hlt182124121 _Hlt182124122 _Hlt352067075 _Hlt352067076 _Hlt275423413 _Hlt275423414 _Hlt274658539 _Hlt275423419 _Hlt275423420 _Hlt350253624 _Hlt350253625 _Hlt275423431 _Hlt275423432 _Hlt350253584 _Hlt350253585 _Hlt352067244 APPENDIX1Centor _Hlt352067894 _5_Infections _Hlt351569935 _Hlt350797250 _Hlt350797247 _Hlt350797248 _Hlt351569989 _Hlt351569990 _Hlt351569992 _Hlt351039662 _Hlt351039663 _Hlt351635240 _Hlt351635241 _Hlt214783855 _Hlt215994514 _Hlt214776593 _Hlt350767793 _Hlt350767794 _Hlt351544029 _Hlt351544030 _Hlt351544084 _Hlt351544085 _Hlt351568936 _Hlt351568937 _Hlt163545074 _Hlt163545075 _Hlt351546304 _Hlt351546305 _Hlt164590149 _Hlt164590150 _Hlt308692297 _Hlt308692298F0}}<__YL1~ȵt++6U- - T V $$''y'''---->>ccccDh###   !TV```Q]<DEGqz::stw QX*lq%(P>ggi5^2_    88ggmmI__N:wP\]] v O O      ooTT^ssp"####+#+#,#,#%&', - -------:/*0*01177W:`<PAPAPA3DDDEE{JqNQBSSSSVZZZ[^PcfJqJqLqLqNqNqqqq2r2r2r2rsrsr|r|rrtv~~W[99@IIccPP//<<  (@@@@@@ @ @ @ @@@@@@@@@@@@ @!@"@#@$@%@&@'@(@)@*@+@,@-@.@/@0@1@2@3@4@5@6@78@9@:@;@<@=@>@?@@@A@B@C@D@E@F@G@H@I@J@K@L@M@N@O@P@Q@R@S@T@U@V@W@X@Y@Z@[@\@]@^@_@`@a@b@c@d@e@f@g@h@i@j@k@l@m@o@n@p@q@r@s@t@u@v@w@x@y@z@{@|@}@~@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ @ @   @@@@@@@@@@@!" #$@%@&@'@()*+,@-@.@/01@2@3@4567@8@9@:@;@<@=@>@?@@@A@B@C@D@E@F@G@H@IJK@LM@N@O@P@Q@R@S@T@U@V@W@X@Y@Z@[@\@]@^@_@`@a@b@c@d@e@f@g@h@i@j@y0~~=ֆȌ``hYaյ,,7V. . U W $$''z'''---->>ccccEh$$$!"UWaaaR^=EFHr{;;tuxRY+mr&)Q?hhj6_3`    8BhhnnI``N:wP]^^  v P P      ooUU_tt p"####,#,#-#-#%&',--------N/+0+01177W:`<PATA3D3DDDEE{JqNQBSSSSVZZZ[^efKqKqMqMqOqOqqqq3r3r3r3rtrtr}r}rrtv~~W\::@IIccQQ00==  (hpkw3 9  JQam *3)1MU JPpyDM X!d!!!""P#Y#u####w$~$%%%%&&'!'''((-(8(T(U(q(|(k)u)**T+]+..00002233t445555 666666[8c879?9N9W999j:q:;;<<<<<<*=1====== >N>W>>>>?U?_?`?i???@@AAAArB{BBBBBICPCQCZC\CeCCC DDjDsDEE F+FFFGGEIKIJ J|JJ KK/L:LM MMMMMMM NN_NkNNNOOP!PPPQRPRWRSSRS]SiStSSTUUUUhWrWWWWWpXyXXXXXXXXX/Y:YkYuYYYfZqZ[ [![*[s[z[[[\\l]v]]]]]T^_^__aalabbcc9dGd~ddddddeezeeeeeeff.g4g6gAggggg.h8hkSkxkkkkllmmnnyoo#q*qTr[rXv_vxxxxFyMy{{"{){Y{d{g{m{{{{{||$}+}}} )V]ˡաBL(3BGz̨רai%./4ުNT<G JUHS R]'IP%/ *CQ/:yU^en%s}~\f    Q\/9S\!#+#++,',---'-AA2C;CCCCC~HHSJ^JGMUMN$N-N7N{NNNNNOO#OOOOOPPQQ"U,UUUUU$W.W[[[[[[^"^__efqf|ffKqVqqqDuPuv!vzz~~x~(?FJT9Cnxȫҫ ^e&ͺֺлٻ`f_j9B Y\>A48HS266@SYJRCFSY#1!/^g% /   [ a     ?HHV */09CM!"!!!##I$T$!&+&2'6'''++++_,a,,,,,<.A.H.T./+/D/M///r11e2s2555556S8\8)<0<<<'>/> CCCCDDDDWF`FFFFFIIII&J)JKKBSNSTT(U3UVVXXXXZZZZ\\]]]]^^^^`'`aaccnnnnoorrssstBtGttt!u%u^xbxyy&}*}v}z}M~W~v~|~~~cjɂЂ@IJTy enņENOYɇ͇5?hp!.r|GP\e) cr4>%',GN ,5_h 9DBK }'7@CL^hx$6A'jqENepu~1;LU&/MXgpNUXair#* ")MV)wV_p|)X a c n   % . C L N W           6 ? A J   - 6   +6ZfuV` fk:C48^gR[^h3 =   !!##Y%d%}'''(((((M+Y+\+c+o+t+,,----w0y01111"3)3W3[333~4444449999+R5RV!VWWWW"X0X=XDXKXRXg(g4gAghhshhhhhiijjSjZjjjjjblllllXmdmemjmnn4n=n^nfnnoooootp}pq(q2r=rrrRv\v{){7{={{{J}P}~~ʂق ǍӍyђݒ\fpw ĠϠ֢LWڤ˥kҬܬ¯$+,7hr)?J7AyYe  &3:nx<H [c ( ^i$    K!S!X!^!!!%","4"4"6"6"7"7"9":"<"="?"@"""##(.1 Ua.9~00::<<??@AGGGHSSXXE`M```ddmm_hIQG]+-))[ \.6"ħ ft;F),~W$)y">#$$$2'7'e'k'''N8R8<<<<<"====> >">$>v>w>>>>>??Q?@\@@@BCCCDDBKoKpKKKKKK|LLDMGMIOOOOO[P\PPP QQQQQBS_SSSmVoVW=WZZ^^llnn~ssgtotɁˁӁՁ݁Sf))--J=K>KbKcKK6TTw[[edrd}}~~b~m~tɃN"*oq~+K jnIwx69"4"4"6"6"7"7"9":"<"="?"@"""A(J((333333333333333333333333333333333333333333333333333333333333333333333333333XX22d2e2~2495:5`5S;d ;# EP -,svcdKA L fr;V\ucml JQYMI~lsA=^" 1;-rlGj*#u!g ! B\o&X? L~1hsp4<6fTE($U *@ #>]v>[>G@?3?&mP@AB C;x>$    ^CEDECEJ|F (d+G;HH.Is9h3J659JhbpJJOWJ~KCKRL+M~MM^M"MlNaG=NInHN 5hNi"PQ AP{gP`LS6oXTys^T T TdRUJOWwY!0Z [s [hbpJ@\M^jd^~*`pra-E E s > > W a h U %& . yP v * . {} 4?o1DHOe'/)A>x^>{y>'{>:??W ?[?BBfB(ClC DJDiD[|E+6FuFT HHIPHaHqHhIIAJIZzIJqK K}LtMKNOSOeQgQlQRStMSwSYT0*T|}T!BUoU`qUyUV:V`LV8YV W0W#LW`WdWD|WjY/Y|QYyYd|Y%(Z=Z[ \ ]-] ^i^_dc_y`|`.FaWaqab1ibe[egeief?gfif|fgh)hL\hlh-i5Qiniyitoj.k0km+=nKo 0ojooo*so3p+Np]hpkypsyp6;q.Gqr`r<)sAsHsvst.1tHtst ytVvjLxvqxyxzyzzczz5|$|b}R}a}e} ~. [u_ (4D5H%MN^wz'7M$24@)DRkm"!a(3>@S W'NuShxzD4Qk*M4X@'8":|C$Qao] Jqlv?XXo$/bCq(wX}%(pn0O@*.R?5]1d*MkW&-2/ 7ERNJ|\pO*.a|q?BMR!3F -8LY(/68b&<+@q%V-:~~ (*F^"4} l)O["*ltk{G}K5>Zy[w?cge.s<\_<HWd1|u7 5,x} t)2T*N*b Gh7,IUfj< DJ[`ip,KJ!M\U3JPloY)6h),T2Bf~^U tyuAH 4m=!6;y9GY?_$G;Ekl4 JUi /FcKomOG4[_N6m-#8ZVcx7$4[%bc(,kv]sR3KHi|P vRMRvVS`b)$= G"# p%23Y )U_Z{^DUBglqw,*#BaRe+TVfufqHQgt4"6" N (@ FormularyCustom Popup 12565610Custom Popup 12565609 Custom Popup 1256560991.@Formulary contents.@ Find drugCtrl+F@ @@ @ % NCustom Popup 12565610 Custom Popup 1256561091.@Formulary Contents.@  Fit to Window@@ @@ @UVW_`((((CCC}C(h@h^h`h@hjh@hh@hhh@hh@hh4@hhl@hh,@h1@Unknownprofile Knight Bethcarole G* Times New Roman5Symbol3. * ArialA. Arial NarrowI. ??Arial Unicode MS7.{ @Calibri7ArialMTA Arial-BoldMT7.  Verdana?= * Courier New5. *aTahoma;WingdingsA BCambria Math"1hgDD7x4   2qXZ ?N#E! xx"The Interface Formulary For Adultscarole4PCS Windows Logon password = pc E                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D Oh+'0 <H h t  $The Interface Formulary For AdultscaroleNormal8PCS Windows Logon password = pc2Microsoft Office Word@F#@xw>@|0@|0D՜.+,D՜.+,t0 hp  (Eastern Birmingham Primary Care Trust  #The Interface Formulary For Adults TitleP 8@ _PID_HLINKSA A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu /http://www.nice.nhs.uk/page.aspx?o=ourguidance A} http://www.drugtariff.co.uk/9 z 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"cw http://www.prodigy.nhs.uk/ t >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmuq /http://www.nice.nhs.uk/page.aspx?o=ourguidance An http://www.drugtariff.co.uk/9 k 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"ch http://www.prodigy.nhs.uk/ e >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmub /http://www.nice.nhs.uk/page.aspx?o=ourguidance A_ http://www.drugtariff.co.uk/9 \ 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"cY http://www.prodigy.nhs.uk/ V >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmuS /http://www.nice.nhs.uk/page.aspx?o=ourguidance AP http://www.drugtariff.co.uk/9 M 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"cJ http://www.prodigy.nhs.uk/ G >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmuD /http://www.nice.nhs.uk/page.aspx?o=ourguidance AA http://www.drugtariff.co.uk/9 > 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c; http://www.prodigy.nhs.uk/ 8 >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu5 /http://www.nice.nhs.uk/page.aspx?o=ourguidance A2 http://www.drugtariff.co.uk/9 / 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c, http://www.prodigy.nhs.uk/ ) >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu& /http://www.nice.nhs.uk/page.aspx?o=ourguidance A# http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu /http://www.nice.nhs.uk/page.aspx?o=ourguidanceB "http://guidance.nice.org.uk/TA1566^ Ehttp://www.bad.org.uk/Portals/_Bad/Specials/BAD Specials Booklet.pdf ! http://www.solihull.nhs.uk/getmedia/56316432-acb7-4a5c-8a2c-4f2742c70970/Procedures-of-Low-Clinical-Value-Policy-v1.2-Solihull-GP-version11052011(Matt-Formatted).aspx A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA "http://guidance.nice.org.uk/TA260u /http://www.nice.nhs.uk/page.aspx?o=ourguidance A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu /http://www.nice.nhs.uk/page.aspx?o=ourguidance A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu /http://www.nice.nhs.uk/page.aspx?o=ourguidance A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu /http://www.nice.nhs.uk/page.aspx?o=ourguidance A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm(  Lhttp://www.cks.library.nhs.uk/Acne_vulgaris/In_depth/Background_information"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm^ -http://www.bnf.org/bnf/bnf/current/19966.htm A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmk$ <http://www.nice.org.uk/nicemedia/live/12235/45464/45464.pdfz2 7http://www.nice.org.uk/nicemedia/pdf/TA177Guidance.pdfB "http://guidance.nice.org.uk/TA146B "http://guidance.nice.org.uk/TA134K !http://guidance.nice.org.uk/TA82u /http://www.nice.nhs.uk/page.aspx?o=ourguidancer' <http://guidance.nice.org.uk/TA180/QuickRefGuide/pdf/Englishz2 7http://www.nice.org.uk/nicemedia/pdf/TA177Guidance.pdf6 Ghttp://www.cks.library.nhs.uk/eczema_atopic/in_depth/management_issues"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmU  )http://www.nice.nhs.uk/page.aspx?o=TA081u /http://www.nice.nhs.uk/page.aspx?o=ourguidance A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/ ~ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmK{ !http://guidance.nice.org.uk/TA81ux /http://www.nice.nhs.uk/page.aspx?o=ourguidance Au http://www.drugtariff.co.uk/9 r 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"co http://www.prodigy.nhs.uk/ l >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmui /http://www.nice.nhs.uk/page.aspx?o=ourguidance Af http://www.drugtariff.co.uk/9 c 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c` http://www.prodigy.nhs.uk/ ] >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmuZ /http://www.nice.nhs.uk/page.aspx?o=ourguidance AW http://www.drugtariff.co.uk/9 T 1http://www.ppa.org.uk/edt/August_2007/mindex.htmQ :http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON044014"cN http://www.prodigy.nhs.uk/ K >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmuH /http://www.nice.nhs.uk/page.aspx?o=ourguidance AE http://www.drugtariff.co.uk/9 B 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c? http://www.prodigy.nhs.uk/ < >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu9 /http://www.nice.nhs.uk/page.aspx?o=ourguidance A6 http://www.drugtariff.co.uk/9 3 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c0 http://www.prodigy.nhs.uk/ - >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu* /http://www.nice.nhs.uk/page.aspx?o=ourguidance\' zhttp://publications.nice.org.uk/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration-ta294ND$ Vhttp://publications.nice.org.uk/ocriplasmin-for-treating-vitreomacular-traction-ta297**! http://publications.nice.org.uk/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-ta283A "http://guidance.nice.org.uk/TA274B "http://guidance.nice.org.uk/TA155E !http://guidance.nice.org.uk/TA68u /http://www.nice.nhs.uk/page.aspx?o=ourguidance A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c http://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu /http://www.nice.nhs.uk/page.aspx?o=ourguidance A http://www.drugtariff.co.uk/9  1http://www.ppa.org.uk/edt/August_2007/mindex.htm Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htmA"http://guidance.nice.org.uk/TA271A"http://guidance.nice.org.uk/TA229u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmF>http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11926u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance3=http://www.bssh.ac.uk/education/guidelines/dd_guidelines.pdf9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmB"http://guidance.nice.org.uk/TA164u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmMBhttp://publications.nice.org.uk/tocilizumab-for-the-treatment-of-rheumatoid-arthritis-rapid-review-of-technology-appraisal-guidance-ta247A"http://guidance.nice.org.uk/TA238Yhttp://publications.nice.org.uk/abatacept-for-treating-rheumatoid-arthritis-after-the-failure-of-conventional-disease-modifying-ta280A"http://guidance.nice.org.uk/TA225A"http://guidance.nice.org.uk/TA233A"http://guidance.nice.org.uk/TA220m'<http://www.nice.org.uk/nicemedia/live/13110/50424/50424.pdfy6http://publications.nice.org.uk/adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-ta195B|"http://guidance.nice.org.uk/TA186By"http://guidance.nice.org.uk/TA143Bv"http://guidance.nice.org.uk/TA130@s!http://guidance.nice.org.uk/TA35up/http://www.nice.nhs.uk/page.aspx?o=ourguidance Amhttp://www.drugtariff.co.uk/9 j1http://www.ppa.org.uk/edt/August_2007/mindex.htm"cghttp://www.prodigy.nhs.uk/ d>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmua/http://www.nice.nhs.uk/page.aspx?o=ourguidance9 ^1http://www.ppa.org.uk/edt/August_2007/mindex.htm"c[http://www.prodigy.nhs.uk/ X>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.html$U<http://www.nice.org.uk/nicemedia/live/12131/43329/43329.pdfafR;http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdfuO/http://www.nice.nhs.uk/page.aspx?o=ourguidanceU-L@http://www.npc.co.uk/MeReC_Extra/2008/pdfs/MeReC_Extra_No30.pdf+|Ithttp://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2025040&ssTargetNodeId=221BF"http://guidance.nice.org.uk/TA117uC/http://www.nice.nhs.uk/page.aspx?o=ourguidance A@http://www.drugtariff.co.uk/+=9http://www.solihull-pct.nhs.uk/foi/policies_clinical.aspF:>http://www.nice.org.uk/guidance/index.jsp?action=byID&o=10978u7/http://www.nice.nhs.uk/page.aspx?o=ourguidance+49http://www.solihull-pct.nhs.uk/foi/policies_clinical.asp+19http://www.solihull-pct.nhs.uk/foi/policies_clinical.aspD.!http://guidance.nice.org.uk/TA74u+/http://www.nice.nhs.uk/page.aspx?o=ourguidance A(http://www.drugtariff.co.uk/"c%http://www.prodigy.nhs.uk/ ">http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm|"http://publications.nice.org.uk/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-ta293A"http://guidance.nice.org.uk/TA221B"http://guidance.nice.org.uk/TA142G!http://guidance.nice.org.uk/TA48u/http://www.nice.nhs.uk/page.aspx?o=ourguidance"chttp://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA "http://guidance.nice.org.uk/TA272A"http://guidance.nice.org.uk/TA259A"http://guidance.nice.org.uk/TA239B"http://guidance.nice.org.uk/TA112u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA"http://guidance.nice.org.uk/TA254A"http://guidance.nice.org.uk/TA243@MyC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsA"http://guidance.nice.org.uk/TA228A"http://guidance.nice.org.uk/TA226A"http://guidance.nice.org.uk/TA202A"http://guidance.nice.org.uk/TA200B"http://guidance.nice.org.uk/TA193B"http://guidance.nice.org.uk/TA174B"http://guidance.nice.org.uk/TA171B"http://guidance.nice.org.uk/TA137B"http://guidance.nice.org.uk/TA127B"http://guidance.nice.org.uk/TA106J!http://guidance.nice.org.uk/TA99E!http://guidance.nice.org.uk/TA65K!http://guidance.nice.org.uk/TA85@!http://guidance.nice.org.uk/TA32u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmU"http://guidance.nice.org.uk/CG131c#<http://www.nice.org.uk/nicemedia/live/11778/43308/43308.pdfA!http://guidance.nice.org.uk/TA26;5thttp://publications.nice.org.uk/everolimus-in-combination-with-exemestane-for-treating-advanced-her2-negative-ta295Qhttp://publications.nice.org.uk/crizotinib-for-previously-treated-non-small-cell-lung-cancer-associated-with-an-anaplastic-lymphoma-ta296A"http://guidance.nice.org.uk/TA269A"http://guidance.nice.org.uk/TA268A"http://guidance.nice.org.uk/TA263A"http://guidance.nice.org.uk/TA258A"http://guidance.nice.org.uk/TA257A"http://guidance.nice.org.uk/TA255A"http://guidance.nice.org.uk/TA251A"http://guidance.nice.org.uk/TA250A"http://guidance.nice.org.uk/TA243A"http://guidance.nice.org.uk/TA242A"http://guidance.nice.org.uk/TA241A}"http://guidance.nice.org.uk/TA228Az"http://guidance.nice.org.uk/TA227Aw"http://guidance.nice.org.uk/TA222At"http://guidance.nice.org.uk/TA219Aq"http://guidance.nice.org.uk/TA218An"http://guidance.nice.org.uk/TA216Ak"http://guidance.nice.org.uk/TA215Ah"http://guidance.nice.org.uk/TA214Ae"http://guidance.nice.org.uk/TA212Ab"http://guidance.nice.org.uk/TA209A_"http://guidance.nice.org.uk/TA208B\"http://guidance.nice.org.uk/TA193BY"http://guidance.nice.org.uk/TA192BV"http://guidance.nice.org.uk/TA191BS"http://guidance.nice.org.uk/TA190BP"http://guidance.nice.org.uk/TA189AM"http://guidance.nice.org.uk/TA209AJ"http://guidance.nice.org.uk/TA208BG"http://guidance.nice.org.uk/TA196BD"http://guidance.nice.org.uk/TA192BA"http://guidance.nice.org.uk/TA191B>"http://guidance.nice.org.uk/TA190B;"http://guidance.nice.org.uk/TA189B8"http://guidance.nice.org.uk/TA185@M5yC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsB2"http://guidance.nice.org.uk/TA183B/"http://guidance.nice.org.uk/TA181@M,yC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsB)"http://guidance.nice.org.uk/TA178B&"http://guidance.nice.org.uk/TA176B#"http://guidance.nice.org.uk/TA172B "http://guidance.nice.org.uk/TA169B"http://guidance.nice.org.uk/TA162B"http://guidance.nice.org.uk/TA145B"http://guidance.nice.org.uk/TA135B"http://guidance.nice.org.uk/TA129B"http://guidance.nice.org.uk/TA124B"http://guidance.nice.org.uk/TA121B "http://guidance.nice.org.uk/TA119B"http://guidance.nice.org.uk/TA118B"http://guidance.nice.org.uk/TA116B"http://guidance.nice.org.uk/TA109B"http://guidance.nice.org.uk/TA108B"http://guidance.nice.org.uk/TA107B"http://guidance.nice.org.uk/TA101B"http://guidance.nice.org.uk/TA100J!http://guidance.nice.org.uk/TA99J!http://guidance.nice.org.uk/TA91K!http://guidance.nice.org.uk/TA86D!http://guidance.nice.org.uk/TA70E!http://guidance.nice.org.uk/TA61jhttp://publications.nice.org.uk/guidance-on-the-use-of-paclitaxel-in-the-treatment-of-ovarian-cancer-ta55@!http://guidance.nice.org.uk/TA34A!http://guidance.nice.org.uk/TA29A!http://guidance.nice.org.uk/TA25A!http://guidance.nice.org.uk/TA23u/http://www.nice.nhs.uk/page.aspx?o=ourguidanceu/http://www.nice.nhs.uk/page.aspx?o=ourguidance}v;http://publications.nice.org.uk/urinary-incontinence-cg171nC:\Documents and Settings\emis2000\Local Settings\Temporary Internet Files\Content.IE5\IYFS8QJU\NICE TA 290 - overactive bladder - Mirabegron`"http://webarchive.nationalarchives.gov.uk/20130107105354/http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012086.pdfu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htmX)http://www.nice.nhs.uk/page.aspx?o=CG030u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance 9http://publications.nice.org.uk/induction-of-labour-cg70u/http://www.nice.nhs.uk/page.aspx?o=ourguidance"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htmXWhttp://www.prodigy.nhs.uk/osteoporosis_treatment_and_prevention_of_fragility_fractures"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmB"http://guidance.nice.org.uk/TA161A"http://guidance.nice.org.uk/TA265A"http://guidance.nice.org.uk/TA204B"http://guidance.nice.org.uk/TA160U ~)http://www.nice.nhs.uk/page.aspx?o=TA087u{/http://www.nice.nhs.uk/page.aspx?o=ourguidanceg.x<http://www.nice.org.uk/nicemedia/live/12992/48724/48724.pdfEu!http://guidance.nice.org.uk/TA64ur/http://www.nice.nhs.uk/page.aspx?o=ourguidance Aohttp://www.drugtariff.co.uk/9 l1http://www.ppa.org.uk/edt/August_2007/mindex.htm"cihttp://www.prodigy.nhs.uk/ f>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmuc/http://www.nice.nhs.uk/page.aspx?o=ourguidance A`http://www.drugtariff.co.uk/9 ]1http://www.ppa.org.uk/edt/August_2007/mindex.htm"cZhttp://www.prodigy.nhs.uk/ W>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmU T)http://www.nice.nhs.uk/page.aspx?o=TA087uQ/http://www.nice.nhs.uk/page.aspx?o=ourguidanceZON.http://www.bnf.org/bnf/bnf/current/100039.htm AKhttp://www.drugtariff.co.uk/9 H1http://www.ppa.org.uk/edt/August_2007/mindex.htm"cEhttp://www.prodigy.nhs.uk/ B>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu?/http://www.nice.nhs.uk/page.aspx?o=ourguidanceZO<.http://www.bnf.org/bnf/bnf/current/100138.htm A9http://www.drugtariff.co.uk/9 61http://www.ppa.org.uk/edt/August_2007/mindex.htmO3)http://www.prodigy.nhs.uk/hypothyroidismR 0*http://www.prodigy.nhs.uk/hyperthyroidism"c-http://www.prodigy.nhs.uk/ *>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu'/http://www.nice.nhs.uk/page.aspx?o=ourguidance A$http://www.drugtariff.co.uk/9 !1http://www.ppa.org.uk/edt/August_2007/mindex.htm}<Qhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/endocrine_and_metabolicl@>http://www.npc.nhs.uk/MeReC_Briefings/2003/briefing_no_26.pdft7http://www.npc.nhs.uk/MeReC_Briefings/briefing2003.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm*lhhttp://publications.nice.org.uk/dapagliflozin-in-combination-therapy-for-treating-type-2-diabetes-ta288A "http://guidance.nice.org.uk/TA248A "http://guidance.nice.org.uk/TA203B"http://guidance.nice.org.uk/TA151\5http://publications.nice.org.uk/type-2-diabetes-cg87R!http://guidance.nice.org.uk/CG66E!http://guidance.nice.org.uk/TA60F!http://guidance.nice.org.uk/TA53u/http://www.nice.nhs.uk/page.aspx?o=ourguidancec|;http://www.nice.org.uk/nicemedia/pdf/CG87QuickRefGuide.pdf"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA"http://guidance.nice.org.uk/TA253A"http://guidance.nice.org.uk/TA252A"http://guidance.nice.org.uk/TA2007%dhttp://publications.nice.org.uk/tenofovir-disoproxil-for-the-treatment-of-chronic-hepatitis-b-ta173B"http://guidance.nice.org.uk/TA154B"http://guidance.nice.org.uk/TA153B"http://guidance.nice.org.uk/TA106J!http://guidance.nice.org.uk/TA96D!http://guidance.nice.org.uk/TA75u/http://www.nice.nhs.uk/page.aspx?o=ourguidanceYm Sore_throatYm Sore_throatv!http://bnfc.org/bnfc/index.htm##http://www.bnf.org/bnf/#5Lhttp://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListName/Page/1197637041219#J(http://www.ppa.org.uk/ppa/edt_intro.htmY*http://www.sdcep.org.uk/index.aspx?o=2334  APPENDIX1x7 http://cks.nice.org.uk/shingles O"http://cks.nice.org.uk/chickenpoxtp%http://cks.nice.org.uk/acne-vulgaris!prescribinginfosub:21ig3http://cks.nice.org.uk/fungal-skin-infection-scalp 2http://cks.nice.org.uk/fungal-skin-infection-foot}v<http://cks.nice.org.uk/fungal-skin-infection-body-and-groinoD<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726V -http://cks.nice.org.uk/fungal-nail-infectionoD<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726v'http://cks.nice.org.uk/scabiesyy0http://cks.nice.org.uk/conjunctivitis-infective  APPENDIX1JM.http://cks.nice.org.uk/bites-human-and-animalt-(http://cks.nice.org.uk/leg-ulcer-venousbG<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947348323dN<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1242630044068nK<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947336805nK<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947336805  APPENDIX1>S|http://nww.solihullccg.nhs.uk/index.php/clinical-pathways-solis/cat_view/4-solis/53-clinical-pathways/92-iv-therapy-and-cellulitisdoy(http://cks.nice.org.uk/cellulitis-acutev%http://cks.nice.org.uk/eczema-atopic s APPENDIX1s%p http://cks.nice.org.uk/impetigo5|m3http://cks.nice.org.uk/pelvic-inflammatory-disease>pj0http://www.rcog.org.uk/womens-health/guidelines9=g http://www.bashh.org/guidelinesmFd<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846Qa&http://cks.nice.org.uk/trichomoniasis9=^ http://www.bashh.org/guidelinesmF[<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/119494740884671X+http://cks.nice.org.uk/bacterial-vaginosis9=U http://www.bashh.org/guidelinesmFR<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846B O.http://cks.nice.org.uk/candida-female-genital9=L http://www.bashh.org/guidelinesz=I7http://cks.nice.org.uk/chlamydia-uncomplicated-genital`KF<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/11949474174679=C http://www.bashh.org/guidelinesKC@9http://www.sign.ac.uk/guidelines/fulltext/109/index.htmlq>=+http://bnfc.org/bnfc/bnfc/current/4057.htmM:"http://cks.nice.org.uk/threadwormWA7Fhttp://cks.nice.org.uk/diarrhoea-prevention-and-advice-for-travellersc-4'http://cks.nice.org.uk/gastroenteritisG 1^http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ClostridiumDifficile/Guidelines/VL.5http://cks.nice.org.uk/dyspepsia-proven-peptic-ulcer!scenariorecommendation:39~+4http://cks.nice.org.uk/dyspepsia-unidentified-cause`C(<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/11949474194061q%<http://www.nice.org.uk/nicemedia/pdf/CG017quickrefguide.pdf,$"$http://cks.nice.org.uk/candida-oralxb,http://cks.nice.org.uk/pyelonephritis-acutel%<http://www.nice.org.uk/nicemedia/live/11010/30524/30524.pdf`q;http://www.nice.org.uk/nicemedia/pdf/CG54quickrefguide.pdf&*8http://cks.nice.org.uk/urinary-tract-infection-childrenM;http://cks.nice.org.uk/urinary-tract-infection-lower-women!scenariorecommendation:13bL<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947404720HF )http://cks.nice.org.uk/prostatitis-acute9=  http://www.bashh.org/guidelines_2http://nww.solihullccg.nhs.uk/index.php/infectionK9http://cks.nice.org.uk/urinary-tract-infection-lower-men}<;http://cks.nice.org.uk/urinary-tract-infection-lower-women2K<http://www.hpa.org.uk/infections/topics_az/esbl/default.htmbL<http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/11949474047207m?http://www.cks.nhs.uk/cough_acute_with_chest_signs_in_children-300872)lhttp://www.cks.nhs.uk/cough_acute_with_chest_signs_in_children/management/detailed_answers/self_care_adviceu5@http://cks.nice.org.uk/cough-acute-with-chest-signs-in-children!scenariorecommendation:6+w@http://cks.nice.org.uk/cough-acute-with-chest-signs-in-children]jhttp://www.brit-thoracic.org.uk/Portals/0/Clinical Information/Pneumonia/Guidelines/CAPGuideline-full.pdfS.http://cks.nice.org.uk/chest-infections-adultY\http://www.nice.org.uk/CG101KJ=http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease  APPENDIX1R !http://guidance.nice.org.uk/CG69S.http://cks.nice.org.uk/chest-infections-adult  APPENDIX1F!http://cks.nice.org.uk/sinusitiszb Cellulitis&http://cks.nice.org.uk/otitis-externa  APPENDIX1  APPENDIX1[*http://cks.nice.org.uk/otitis-media-acute  APPENDIX1bcCentorR !http://guidance.nice.org.uk/CG69EB9http://www.sign.ac.uk/guidelines/fulltext/117/index.htmlE)http://cks.nice.org.uk/sore-throat-acuteB"http://guidance.nice.org.uk/TA158F?Zhttp://www.hpa.org.uk/infections/topics_az/influenza/seasonal/pdfs/Treatmentflowchart.pdfqh#http://cks.nice.org.uk/common-coldShLhttp://www.hpa.org.uk/cdph/issues/CDPHVol5/no3/Meningococcal_Guidelines.pdfz <http://www.hpa.org.uk/infections/topics_az/meningo/menu.htmk}DENTALd{Chickenpox_and_shinglesAcne]d Fungal_skinWy Fungal_nail{dScabiesrnConjunctivitiso@ Leg_Ulcerso@ Leg_Ulcers-_MRSAMRSAzb CellulitisrgEczema } Impetigo,0zSkin_soft_tissuepiwPID~xtTrichomoniasisbvqBVvcnVCk Chlamydia#hGenital_tractbke Threadworm9bInfectious_diarrhoeaqq_Gastroenteritisqq\Gastroenteritis Y H_pylori V H_pylorigiSGIH~P Recurr_UTInCMAcute_pyeloneph3J UTI_children8GUTI_preg_and_men(DAcute_prostatitisPmA Uncomp_UTIut>UTIca;CAPE@8Acute_exac_COPD;5Acute_bronchitis2LRTI/ Sinusitis29,Acute_Otitis_Externaao)AOM(%&Acute_sore_throat# InfluenzaQc  Common_coldURTI= &Emergency_treatment_for_CAP_in_adultsml MeningitisF)http://www.rcgp.org.uk/TARGETantibiotics"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA "http://guidance.nice.org.uk/TA217u/http://www.nice.nhs.uk/page.aspx?o=ourguidance"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmB"http://guidance.nice.org.uk/TA123B"http://guidance.nice.org.uk/TA115B"http://guidance.nice.org.uk/TA114`&<http://www.nice.org.uk/nicemedia/live/11925/41664/41664.pdfA!http://guidance.nice.org.uk/TA20u/http://www.nice.nhs.uk/page.aspx?o=ourguidance"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA"http://guidance.nice.org.uk/TA260A!http://guidance.nice.org.uk/TA20u/http://www.nice.nhs.uk/page.aspx?o=ourguidance.pshttp://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007453&ssTargetNodeId=368Sahttp://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2030729"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmNhttp://publications.nice.org.uk/the-epilepsies-the-diagnosis-and-management-of-the-epilepsies-in-adults-and-children-in-primary-and-cg137u/http://www.nice.nhs.uk/page.aspx?o=ourguidance(rshttp://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007475&ssTargetNodeId=368"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA"http://guidance.nice.org.uk/TA232Nhttp://publications.nice.org.uk/the-epilepsies-the-diagnosis-and-management-of-the-epilepsies-in-adults-and-children-in-primary-and-cg137u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/d8Ihttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/musculoskeletal't#http://www.prodigy.nhs.uk/migraineB&1http://www.prodigy.nhs.uk/guidance/by_alphabet/p"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm Rhttp://www.birminghamcancer.nhs.uk/viewdoc.ashx?id=AvuZW0tU2WZREqlW%2FRuzLg%3D%3Du/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htmA"http://www.prodigy.nhs.uk/obesity"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm*9+http://guidance.nice.org.uk/CG43/?c=296726u/http://www.nice.nhs.uk/page.aspx?o=ourguidanceFhttp://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdfav,http://www.bnf.org/bnf/bnf/current/3381.htm Ahttp://www.drugtariff.co.uk/9 ~1http://www.ppa.org.uk/edt/August_2007/mindex.htm<L{Shttp://www.prodigy.nhs.uk/attention_deficit_disorder_methylphenidate_nice_guidance"cxhttp://www.prodigy.nhs.uk/ u>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmBr"http://guidance.nice.org.uk/TA139To)http://www.nice.nhs.uk/page.aspx?o=TA098ul/http://www.nice.nhs.uk/page.aspx?o=ourguidance Aihttp://www.drugtariff.co.uk/9 f1http://www.ppa.org.uk/edt/August_2007/mindex.htmOc%http://www.prodigy.nhs.uk/depression"c`http://www.prodigy.nhs.uk/ ]>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmieZhttp://www.nice.org.uk/CG96W.http://guidance.nice.org.uk/topic/behaviouraluT/http://www.nice.nhs.uk/page.aspx?o=ourguidance AQhttp://www.drugtariff.co.uk/9 N1http://www.ppa.org.uk/edt/August_2007/mindex.htm{KJhttp://nww.pctnet.wmids.nhs.uk/z_internet_hob/schz_guidelines/default.htm/bH(http://www.prodigy.nhs.uk/schizophrenia"cEhttp://www.prodigy.nhs.uk/ B>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmLB?http://publications.nice.org.uk/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder-ta292A<"http://guidance.nice.org.uk/TA213[ 9)http://www.nice.nhs.uk/page.aspx?o=TA0662$6;http://guidance.nice.org.uk/cg42/niceguidance/word/Englishm,3;http://www.nice.org.uk/nicemedia/live/11786/43610/43610.pde,0<http://www.nice.org.uk/nicemedia/live/10990/30191/30191.pdf[-)http://www.nice.nhs.uk/page.aspx?o=CG001u*/http://www.nice.nhs.uk/page.aspx?o=ourguidance2$';http://guidance.nice.org.uk/cg42/niceguidance/word/English<m$#http://www.prodigy.nhs.uk/insomnia"S!<http://www.prodigy.nhs.uk/hypnotic_or_anxiolytic_dependence"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmD!http://guidance.nice.org.uk/TA77X )http://www.nice.nhs.uk/page.aspx?o=TA051u/http://www.nice.nhs.uk/page.aspx?o=ourguidanceVWNhttp://www.cks.library.nhs.uk/patient_information_leaflet/insomnia/prevention A http://www.drugtariff.co.uk/#J (http://www.ppa.org.uk/ppa/edt_intro.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmEY]http://publications.nice.org.uk/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis-ta282A"http://guidance.nice.org.uk/TA266u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmO)http://www.nice.org.uk/page.aspx?o=cg012u/http://www.nice.nhs.uk/page.aspx?o=ourguidanceO)http://www.nice.org.uk/page.aspx?o=cg012 Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidanceA"http://guidance.nice.org.uk/TA246o4http://publications.nice.org.uk/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-ta278u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htmZ!http://www.prodigy.nhs.uk/asthma{"8http://www.sign.ac.uk/guidelines/fulltext/63/index.html"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmA"http://guidance.nice.org.uk/TA244u/http://www.nice.nhs.uk/page.aspx?o=ourguidance/`@http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf"H@http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseZ!http://www.prodigy.nhs.uk/asthma{"8http://www.sign.ac.uk/guidelines/fulltext/63/index.html"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmB"http://guidance.nice.org.uk/TA138s/http://publications.nice.org.uk/inhaled-corticosteroids-for-the-treatment-of-chronic-asthma-in-children-under-the-age-of-12-years-ta131O)http://www.nice.org.uk/page.aspx?o=cg012u/http://www.nice.nhs.uk/page.aspx?o=ourguidancePahttp://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2025447,pshttp://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007451&ssTargetNodeId=368(pshttp://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON007455&ssTargetNodeId=368 Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htm/`@http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf"H@http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseZ!http://www.prodigy.nhs.uk/asthma{"|8http://www.sign.ac.uk/guidelines/fulltext/63/index.html"cyhttp://www.prodigy.nhs.uk/ v>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmOs)http://www.nice.org.uk/page.aspx?o=cg012up/http://www.nice.nhs.uk/page.aspx?o=ourguidance Amhttp://www.drugtariff.co.uk/#Jj(http://www.ppa.org.uk/ppa/edt_intro.htm/`g@http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf"Hd@http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseZa!http://www.prodigy.nhs.uk/asthma{"^8http://www.sign.ac.uk/guidelines/fulltext/63/index.html"c[http://www.prodigy.nhs.uk/ X>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmOU)http://www.nice.org.uk/page.aspx?o=cg012uR/http://www.nice.nhs.uk/page.aspx?o=ourguidance AOhttp://www.drugtariff.co.uk/#JL(http://www.ppa.org.uk/ppa/edt_intro.htmS I}http://www.keele.ac.uk/media/keeleuniversity/fachealth/fachealthsop/mtrac/documents/summary/Glycopyrronium SUM final (1).pdf/`F@http://www.npc.nhs.uk/MeReC_Bulletins/2006Volumes/Vol16_No5.pdf"HC@http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_disease"c@http://www.prodigy.nhs.uk/ =>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmO:)http://www.nice.org.uk/page.aspx?o=cg012u7/http://www.nice.nhs.uk/page.aspx?o=ourguidancezk4http://www.nelm.nhs.uk/en/NeLM-Area/News/2012---October/08/Systematic-review-and-meta-analysis-questions-safety-of-tiotropium-Respimat-inhaler-in-COPD/ A1http://www.drugtariff.co.uk/#J.(http://www.ppa.org.uk/ppa/edt_intro.htmsf+Bhttp://www.npc.co.uk/MeReC_Briefings/2006/copb_briefing_no_33.pdf"H(@http://www.prodigy.nhs.uk/chronic_obstructive_pulmonary_diseaseZ%!http://www.prodigy.nhs.uk/asthma{""8http://www.sign.ac.uk/guidelines/fulltext/63/index.html"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm@!http://guidance.nice.org.uk/TA38B!http://guidance.nice.org.uk/TA10@Ihttp://www.nice.nhs.uk/guidance/index.jsp?action=byTopic&o=7308&set=true Ahttp://www.drugtariff.co.uk/#J (http://www.ppa.org.uk/ppa/edt_intro.htm"c http://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/bG>http://www.npc.nhs.uk/MeReC_Briefings/2004/briefing_no_28.pdfcB>http://www.npc.nhs.uk/MeReC_Briefings/2002/briefing_no_19.pdfD *http://www.prodigy.nhs.uk/hyperlipidaemiaJHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmlp;http://www.nice.org.uk/nicemedia/pdf/CG48QuickRefGuide.pdfB"http://guidance.nice.org.uk/TA132J!http://guidance.nice.org.uk/TA94u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm/:http://publications.nice.org.uk/alteplase-for-treating-acute-ischaemic-stroke-review-of-technology-appraisal-guidance-122-ta264U)http://www.nice.nhs.uk/page.aspx?o=TA084F!http://guidance.nice.org.uk/TA52u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htmJHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascularVPhttp://www.prodigy.nhs.uk/transient_ischaemic_attack_not_in_atrial_fibrillationG Jhttp://www.prodigy.nhs.uk/aspirin_for_prevention_of_cardiovascular_events >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.html#<http://www.nice.org.uk/nicemedia/live/12949/47924/47924.pdfA"http://guidance.nice.org.uk/TA236A"http://guidance.nice.org.uk/TA210B"http://guidance.nice.org.uk/TA182K!http://guidance.nice.org.uk/TA80Y )http://www.nice.nhs.uk/page.aspx?o=TA047u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htmdYDhttp://www.npc.nhs.uk/MeReC_Bulletins/2001Volumes/pdfs/vol12no5.pdfJHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascularp.http://www.prodigy.nhs.uk/atrial_fibrillation"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmNhttp://publications.nice.org.uk/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism-ta287A"http://guidance.nice.org.uk/TA275A"http://guidance.nice.org.uk/TA261A}"http://guidance.nice.org.uk/TA256Az"http://guidance.nice.org.uk/TA249Aw"http://guidance.nice.org.uk/TA245At"http://guidance.nice.org.uk/TA230Bq"http://guidance.nice.org.uk/TA170Bn"http://guidance.nice.org.uk/TA157uk/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahhttp://www.drugtariff.co.uk/JeHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular1bb'http://www.prodigy.nhs.uk/hypertension"c_http://www.prodigy.nhs.uk/ \>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmAY"http://guidance.nice.org.uk/TA267AV"http://guidance.nice.org.uk/TA2233rS<http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdfuP/http://www.nice.nhs.uk/page.aspx?o=ourguidance$PM?http://www.npc.nhs.uk/MeReC_Bulletins/2002Volumes/vol13no6.pdfJJHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular1bG'http://www.prodigy.nhs.uk/hypertension"cDhttp://www.prodigy.nhs.uk/ A>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm@M>yC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsO;:http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdfu8/http://www.nice.nhs.uk/page.aspx?o=ourguidance A5http://www.drugtariff.co.uk/#J2(http://www.ppa.org.uk/ppa/edt_intro.htm1b/'http://www.prodigy.nhs.uk/hypertensionJ,Hhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular )>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm"c&http://www.prodigy.nhs.uk/ #>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmO :http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf@MyC:\Documents and Settings\evanca\Local Settings\Temp\Temporary Internet Files\Content.Outlook\HQ4L708A\previous versionsu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htmJHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular"chttp://www.prodigy.nhs.uk/  >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmB"http://guidance.nice.org.uk/TA197u/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/JHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular1b'http://www.prodigy.nhs.uk/hypertension"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmihhttp://www.nice.org.uk/CG483r<http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdfO:http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdfu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/ZBhttp://www.nice.org.uk/guidance/index.jsp?action=download&o=29136*=http://www.npc.co.uk/MeReC_Briefings/2001/briefing_no_15.pdfJHhttp://www.prodigy.nhs.uk/guidance/by_clinical_specialty/cardiovascular%T(http://www.prodigy.nhs.uk/heart_failure"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmO:http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdfu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/9 1http://www.ppa.org.uk/edt/August_2007/mindex.htm Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htmd'http://www.prodigy.nhs.uk/anal_fissure"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance#J(http://www.ppa.org.uk/ppa/edt_intro.htm!Smailto:carolevans2@nhs.net?subject=Request%20for%20document:%20Laxative%20guidance Ahttp://www.drugtariff.co.uk/A"http://guidance.nice.org.uk/TA2110p'http://www.prodigy.nhs.uk/constipation"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu/http://www.nice.nhs.uk/page.aspx?o=ourguidance Ahttp://www.drugtariff.co.uk/#J(http://www.ppa.org.uk/ppa/edt_intro.htmr Bhttp://www.prodigy.nhs.uk/diverticular_disease_and_diverticulitis1h3http://www.prodigy.nhs.uk/irritable_bowel_syndrome"chttp://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmB"http://guidance.nice.org.uk/TA199B"http://guidance.nice.org.uk/TA187i'<http://www.nice.org.uk/nicemedia/live/12104/42745/42745.PDFB"http://guidance.nice.org.uk/TA140Y ~)http://www.nice.nhs.uk/page.aspx?o=TA040u{/http://www.nice.nhs.uk/page.aspx?o=ourguidance Axhttp://www.drugtariff.co.uk/#Ju(http://www.ppa.org.uk/ppa/edt_intro.htm"crhttp://www.prodigy.nhs.uk/ o>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmul/http://www.nice.nhs.uk/page.aspx?o=ourguidance Aihttp://www.drugtariff.co.uk/#Jf(http://www.ppa.org.uk/ppa/edt_intro.htm~&cFhttp://www.prodigy.nhs.uk/nonsteroidal_anti_inflammatory_drugs_nsaidsS`Ihttp://www.prodigy.nhs.uk/dyspepsia_symptoms_uninvestigated_by_endoscopyB]?http://www.prodigy.nhs.uk/dyspepsia_proven_non_ulcer_dyspepsiaX&ZMhttp://www.prodigy.nhs.uk/dyspepsia_proven_gastro_oesophageal_reflux_disease|WKhttp://www.prodigy.nhs.uk/dyspepsia_proven_du_gu_or_nsaid_associated_ulcer"cThttp://www.prodigy.nhs.uk/ Q>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmZN)http://www.nice.nhs.uk/page.aspx?o=CG017uK/http://www.nice.nhs.uk/page.aspx?o=ourguidance9 H1http://www.ppa.org.uk/edt/August_2007/mindex.htm#JE(http://www.ppa.org.uk/ppa/edt_intro.htm1hB3http://www.prodigy.nhs.uk/irritable_bowel_syndrome"c?http://www.prodigy.nhs.uk/ <>http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htmu9/http://www.nice.nhs.uk/page.aspx?o=ourguidance A6http://www.drugtariff.co.uk/#J3(http://www.ppa.org.uk/ppa/edt_intro.htm~&0Fhttp://www.prodigy.nhs.uk/nonsteroidal_anti_inflammatory_drugs_nsaidsS-Ihttp://www.prodigy.nhs.uk/dyspepsia_symptoms_uninvestigated_by_endoscopyB*?http://www.prodigy.nhs.uk/dyspepsia_proven_non_ulcer_dyspepsiaX&'Mhttp://www.prodigy.nhs.uk/dyspepsia_proven_gastro_oesophageal_reflux_disease|$Khttp://www.prodigy.nhs.uk/dyspepsia_proven_du_gu_or_nsaid_associated_ulcer"c!http://www.prodigy.nhs.uk/ >http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/prdrecm.htm1q<http://www.nice.org.uk/nicemedia/pdf/CG017quickrefguide.pdfu/http://www.nice.nhs.uk/page.aspx?o=ourguidance9w(http://summaries.cochrane.org/lexicon/9 research;o(http://summaries.cochrane.org/lexicon/9risk9w(http://summaries.cochrane.org/lexicon/9bias3 =http://www.bssh.ac.uk/education/guidelines/dd_guidelines.pdfo 'mailto:formulary@heartofengland.nhs.ukP2mailto:Carolevans2@nhs.netdmailto:Rakhi.aggarwal@nhs.netN-mailto:Kate.arnold@nhs.net  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~        !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry Fp0Data &1Table|WordDocument &J SummaryInformation(DocumentSummaryInformation8MsoDataStore>0k00JRHS4YUOOT2KHQ==2>0k0Item  PropertiesUCompObj y   F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q